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3. Summary and Achievements of the Submitted Research Work:
This thesis comprises a selection of papers, based on my work on the 
pathophysiological roles, pharmacological inhibition and cellular regulation of the 
cardiac sarcolemmal sodium/hydrogen exchanger (also referred to as the Na+/H+ 
exchanger, or NHE), which have been published in the biomedical literature during 
the period 1991-2002.1 am the senior and corresponding author on each of these 
papers, and I have been principally responsible for the design, execution and/or 
supervision, analysis and interpretation of the studies described in them, with the 
invaluable support of the various students and fellows who worked in my laboratory 
over the relevant period.
My interest in the sarcolemmal NHE was initially triggered by the possibility 
that its activity may be a critical determinant of cardiac susceptibility to severe 
ventricular arrhythmias, particularly during reperfusion following a brief period of 
ischaemia. In the late 1980s, the prevailing view was that the rapid washout during 
reperfusion of IT1' ions that accumulated extracellularly during the preceding 
ischaemia would create a trans-sarcolemmal H+ gradient (higher concentration (i.e. 
lower pH) inside than outside the myocardial cells), thereby leading to increased 
sarcolemmal NHE activity and consequently intracellular Na+ and Ca2+ overload, 
with arrhythmogenic consequences. To study the relative contribution of putative 
arrhythmogenic processes (such as H+ washout) during ischaemia and reperfusion, I 
developed a technique that allowed the independent perfusion of left and right 
coronary arteries in isolated hearts, through the use of a novel dual-lumen aortic 
cannula.1 This technique enabled, for the first time, the selective manipulation of the 
rate of washout of metabolites (such as H+ ions) from the extracellular space within 
the involved zone, in isolated hearts subjected to regional ischaemia. Using this 
model, we were the first to show that limiting the rate at which extracellular pH is 
restored during reperfusion, by transient acidic reperfusion of the ischaemic zone, 
suppresses the occurrence of ventricular fibrillation (VF) and promotes spontaneous 
reversion to normal sinus rhythm in isolated rat and rabbit hearts subjected to 
regional ischaemia.2 Subsequently, we were able to show, in the same model, that the 
anti-fibrillatory effect of transient acidic reperfusion was mediated by the high H+ 
concentration, rather than the low HCO3' concentration, of the initial reperfusion
12
medium. Furthermore, we demonstrated that at least 2 min of acidic reperfusion was 
required for sustained protection against VF, which was accompanied by enhanced 
recovery of sarcolemmal Na+/K+ ATPase activity.4 These findings led us to suggest 
that the ability of transient acidic reperfusion to suppress VF was meditated largely 
through the inhibition of sarcolemmal NHE activity, with a possible contribution 
from enhanced recovery of sarcolemmal Na+/K+ ATPase activity. In 1994, we were 
the first academic laboratory to use a novel, selective inhibitor of the sarcolemmal 
NHE, 3-methylsulphonyl-4-piperidinobenzoyl guanidine (HOE-694), to determine 
the role of the exchanger in reperfusion-induced arrhythmogenesis. This work 
revealed that the selective intracoronary infusion of HOE-694 into the ischaemic and 
reperfused zone of isolated rat hearts, through the use of the dual perfusion model, 
was as effective as transient acidic reperfusion in suppressing reperfusion-induced 
VF.5 Having shown that interventions that inhibited sarcolemmal NHE activity (i.e. 
acidic reperfusion and HOE-694) suppressed reperfusion-induced VF, we then tested 
whether the reciprocal relationship also applied, that is whether stimuli that increased 
sarcolemmal NHE activity produced a pro-arrhythmic effect. In this work, we were 
able to show that ai-adrenergic agonists, which had been associated with increased 
sarcolemmal NHE activity, did indeed increase the incidence of reperfusion-induced 
VF when infused selectively into the involved zone of isolated rat hearts, through 
mechanisms that were likely to involve stimulation of the ociA-adrenoceptor subtype 
and thereby sarcolemmal NHE activity.6 Taken together, this body of work 
established the role of H+ washout and increased NHE activity in reperfusion- 
induced arrhythmogenesis, and instigated our publication of a review in 1996, which 
summarised our findings in this area as well as pertinent work by others.7
Our work on the role of the sarcolemmal NHE in arrhythmogenesis, 
summarised above, as well as data emerging from other laboratories, made us query 
a broader role for exchanger activity in mediating myocardial injury during 
ischaemia and reperfusion. On the basis of the experience we had gained with the 
then novel NHE inhibitor HOE-694 in our arrhythmia work,5 we then tested whether 
this compound would affect the contractile dysfunction that arises from global 
ischaemia and reperfusion in isolated rat hearts and, specifically, whether any benefit 
would arise from NHE inhibition only during early reperfusion. To our surprise, and 
against the prevalent dogma of the time, the administration of HOE-694 at
13
reperfusion afforded no benefit when used in the presence of a physiological buffer 
(HCO3'); in contrast, when given from before the onset of ischaemia, the NHE 
inhibitor produced a significant improvement in the post-ischaemic recovery of left 
ventricular contractile function.8 Thus, it appeared that, while NHE activity during 
reperfusion after a short period (< 10  min) of regional ischaemia was an important 
determinant of the severity of reperfusion-induced arrhythmias, such activity during 
reperfusion after longer periods (> 20  min) of global ischaemia did not play a key role 
in determining the recovery of contractile function. Instead, our data suggested that, 
in the latter setting, NHE activity during the prolonged ischaemic period was the 
more important factor, necessitating the pre-ischaemic administration of the NHE 
inhibitor to preserve myocardium and improve the recovery of contractile function 
during reperfusion. We next explored the inter-relationship between NHE activity 
and ischaemic preconditioning, a powerful cardioprotective intervention which has 
been shown to slow the progression of myocardial injury during ischaemia, again in 
rat hearts subjected to prolonged global ischaemia and subsequent reperfusion. This 
work led us to conclude that NHE inhibition and ischaemic preconditioning afforded 
comparable and additive cardioprotective benefit (as reflected by improved 
contractile function and reduced enzyme leakage) and suggested that increased NHE 
activity may be a detrimental “side effect”, rather than a protective mechanism (as 
had been suggested by others), of ischaemic preconditioning.9 This work inspired 
several subsequent studies in other laboratories, including some in large animal in 
vivo models, with essentially similar findings; one such publication was 
accompanied by an editorial which I was invited to write and which provided a 
critical assessment of the available evidence in the pertinent area.10 In related work, 
we also evaluated the efficacy of NHE inhibition as an adjunct or additive to 
hypothermic cardioplegic arrest, which is used commonly for intra-operative 
myocardial protection during cardiac surgery. In this study, we used a structural 
congener of HOE-694,4-isopropyl-3-methylsulphonylbenzoyl guanidine (HOE-642, 
now known by the proprietary name cariporide), which exhibited greater potency and 
selectivity as an inhibitor of the sarcolemmal NHE. The data provided by this study 
allowed us to conclude that the use of cariporide as an adjunct or additive to 
cardioplegia afforded significant protective benefit on ischaemic and reperfused 
myocardium (again, as reflected by improved functional recovery and reduced 
enzyme leakage), under not only normothermic but also moderately and severly
14
hypothermic conditions.11 Intriguingly, the efficacy of the adjunctive use of 
cariporide (i.e. the inhibitor given at the time of reperfusion after cardioplegic arrest) 
appeared to be enhanced in hearts subjected to cardioplegic arrest under conditions 
of moderate or severe hypothermia. Our more recent work suggests that this may be 
related to the effects of episodes of hypothermia and rewarming on sarcolemmal 
NHE activity and may have clinical relevance (see later). My views on the rationale 
behind the potential therapeutic application of pharmacological NHE inhibitors and 
their likely mechanisms of action during myocardial ischaemia and reperfusion have 
been described in recent invited reviews. ’
The apparent involvement of the sarcolemmal NHE in myocardial injury 
during ischaemia and reperfusion, as well as other emerging evidence that the 
sarcolemmal NHE may also modulate myocardial contractile and growth responses 
to neurohormonal and mechanical stimuli, revealed the need to explore and 
understand the cellular and molecular mechanisms that regulate exchanger activity. 
To facilitate such work, I established a new technique in my laboratory, which 
enabled the measurement of intracellular pH in single cardiac ventricular myocytes 
by microepifluorescence, using a pH-sensitive intracellular dye. In initial studies that 
employed this technique, we determined the effects on sarcolemmal NHE activity of 
thrombin, a multifunctional protease which, in addition to its established roles in 
thrombus formation and blood coagulation, induces a variety of cellular responses 
through a family of thrombin receptors. This work provided the first evidence that 
adult rat ventricular myocytes express a functional thrombin receptor (now known as 
protease-activated receptor 1, or PARI), whose stimulation produces increased 
activity of the sarcolemmal NHE, through a mechanism mediated via protein kinase 
C (PKC) .14 This finding led us to explore the regulation of sarcolemmal NHE 
activity through a variety of other G protein-coupled receptors which are stimulated 
by endogenous neurohormonal mediators of pathophysiological significance. Our 
work on the regulation of the sarcolemmal NHE by angiotensin II revealed that this 
peptide hormone exerted a stimulatory effect on sarcolemmal NHE activity via the 
ATi receptor subtype, through intracellular signalling mechanisms that required the 
activation of PKC and the extracellular signal-regulated kinase (ERK) pathway.15 
Intriguingly, the positive effect of ATi receptor stimulation on sarcolemmal NHE 
activity was counteracted by AT2 receptor stimulation, through a mechanism that did
15
not involve direct inhibition of the exchanger or attenuation of ERK activation.15 
Following on from our earlier work on the pro-arrhythmic effects of selective ocia- 
adrenoceptor stimulation within ischaemic and reperfused myocardium,6 we also 
investigated the potential involvement of the various cloned ai-adrenoceptor (ai- 
AR) subtypes (ocia-, ocib- and ocm-AR) in the regulation of sarcolemmal NHE 
activity in adult rat ventricular myocytes. Our analysis of EC50 and IC50 values 
obtained for a variety of 0C1-AR agonists and antagonists in ventricular myocytes, in 
relation to the relative affinities of these agents for recombinant rat (Xi-AR subtypes, 
revealed that ai-adrenergic stimulation of sarcolemmal NHE activity was likely to be 
mediated selectively by the c*ia-AR subtype.16 In view of the fact that the ocia-AR is 
the predominant ai-AR subtype expressed in human myocardium, we have since 
continued to spend considerable effort to delineate the molecular mechanisms that 
mediate sarcolemmal NHE stimulation via this receptor. Our more recent data have 
shown that, like the angiotensin II AT 1 receptor-mediated response, (Xia-AR- 
mediated stimulation of the sarcolemmal NHE in adult rat ventricular myocytes 
requires activation of the ERK pathway and that the ERK-mediated effect is likely to 
occur via activation of the 90 kDa ribosomal S6 kinase (p90rsk), a putative NHE 
kinase.17 This work has also shown that otiA-AR-mediated stimulation of 
sarcolemmal NHE activity also requires PKC activation, but that PKC-mediated
17regulation occurs through an ERK-independent pathway. Having demonstrated that 
stimulation of a variety of G protein-coupled receptors that signal via Gq proteins 
(e.g. PARI, ATi and cxia-AR) invariably increases sarcolemmal NHE activity, 
commonly through the activation of ERK and PKC signalling pathways, we have 
also recently investigated the effects of stimulation of receptors that signal via other 
G proteins. This work has revealed that stimulation of a Gj protein-coupled receptor, 
the adenosine Ai receptor, does not affect sarcolemmal NHE activity alone, but 
opposes ociA-AR-mediated stimulation of the exchanger, thus suggesting the
1 ftexistence of a novel inhibitory receptor crosstalk mechanism. Our current work is 
aimed at identifying the molecular mechanisms that underlie such crosstalk, focusing 
on the role of proteins of the “regulators of G protein signalling (RGS)” family and 
altered activation of ERK and PKC.
Our work described above, and complementary studies by others, have
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indicated that the ERK pathway is a key mediator of sarcolemmal NHE stimulation 
through a variety Gq protein-coupled receptors and that such stimulation is likely to 
occur through the downstream activation of p90rsk, which in turn phosphorylates the 
NHE regulatory domain. However, the molecular mechanism(s) through which 
sarcolemmal NHE activity is regulated by PKC, which our work has suggested also 
plays a key role but does not directly phosphorylate the NHE regulatory domain, are 
unclear. We have explored the possibility that a recently discovered kinase, protein 
kinase D (PKD), may be involved in PKC-mediated regulation of sarcolemmal NHE 
activity. Our work has shown that PKD (which is also known as PKCp) is indeed 
expressed in myocardium, where its activity is increased by ai-A R stimulation and 
PKC activation.19 In the absence of specific pharmacological modulators of PKD 
activity, in order to explore the functional role of PKD in regulating NHE activity we 
have adapted our microepifluorescence technique for the selective measurement of 
NHE activity in cells transfected with plasmids containing different PKD cDNA 
constructs. In this work, we transfected COS-7 and A-10 cells (which are easier to 
transfect than cardiac ventricular myocytes) with wild-type PKD or a kinase-inactive 
mutant (which acts in dominant-negative fashion to inhibit endogenous PKD), 
together with green fluorescent protein (GFP) to allow identification of transfected 
cells for measurement of NHE activity. Contrary to our initial expectation, this work 
suggested that PKD may be an inhibitory, rather than a stimulatory, regulator of 
NHE activity. This raises the intriguing possibility that PKC activation may lead to 
the activation of both NHE-inhibitory (e.g. PKD) and NHE-stimulatory (unknown) 
downstream signalling moieties, potentially through distinct PKC isoforms, and that 
the overall outcome may depend on the specific cellular context. Currently, we are 
extending this work to investigate the roles of different PKC isoforms in the 
regulation of sarcolemmal NHE activity, through the use of membrane-permeant, 
PKC isoform-specific agonist and antagonist peptides, as well as myocytes from the 
hearts of knock-out mice with targeted disruption of genes encoding selected PKC 
isoforms. Additionally, we are testing the applicability of our findings in COS-7 and 
A-10 cells20 to the myocardium, through the use of adenovirus-mediated gene 
transfer to modulate PKD expression and function in rat ventricular myocytes.
As part of our effort aimed at the determination of the cellular and molecular 
mechanisms that regulate the sarcolemmal NHE, we have also investigated the roles
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of other factors such as age, temperature and oxidative stress. For example, our work
has shown that the sarcolemmal NHE is subject to developmental regulation, with a
progressive decline in the postnatal period in both expression (at the mRNA level)
01and activity. With regard to the effects of temperature, we have shown that 
moderate hypothermia (as may be encountered by the myocardium during cardiac 
surgery) produces a significant, but partial, inhibition of sarcolemmal NHE activity, 
but does not affect the NHE-inhibitory potency of cariporide. The latter observation 
may be of therapeutic significance, since cariporide is being tested in current clinical 
trials for potential application for cardioprotection in high-risk patients undergoing 
coronary artery bypass surgery, during which hypothermic arrest is commonly 
employed. We have recently extended this work to investigate the effects of different 
degrees of hypothermia followed by rewarming on sarcolemmal NHE activity and 
NHE-regulatory signalling pathways. This work suggests that, while hypothermia 
itself undoubtedly inhibits sarcolemmal NHE activity, episodes of hypothermia 
followed by rewarming may lead to a significant increase in such activity, which is 
likely to be of relevance to myocardial protection during cardiac surgery and 
transplantation (manuscript currently under review). Most recently, we have shown 
that oxidative stress (induced by exogenous hydrogen peroxide) increases 
sarcolemmal NHE activity through a variety of signalling mechanisms, some of 
which (e.g. the ERX/p90rsk and PKC pathways) resemble those utilised by Gq 
protein-coupled receptors to produce a similar response. The various mechanisms 
through which sarcolemmal NHE activity may be regulated and the potential 
pathophysiological significance of such regulation have been reviewed in several 
articles which I have been invited to write in recent years.24'26
A considerable amount of information has emerged in recent years, from 
work in our laboratory and many others, on the pathophysiological roles of the 
sarcolemmal NHE, the therapeutic potential of its inhibitors and the cellular and 
molecular mechanisms that regulate its expression and activity. Nevertheless, 
notwithstanding recent clinical trials with NHE inhibitors, this information has been 
obtained almost exclusively from work utilising hearts and cardiac myocytes from a 
variety of animal species, and its relevance to humans is unconfirmed. Recently, we 
have begun to address this issue, by determining, for the first time, sarcolemmal 
NHE activity in human ventricular myocytes.27 This work has revealed that, in
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human ventricular myocardium, sarcolemmal NHE activity arises from the NHE1 
isoform and is indeed inhibited for cariporide, accurately reflecting previous findings 
from animal studies; intriguingly, our work with human myocytes (obtained from 
explanted recipient and unused donor hearts) has also suggested that hearts with end- 
stage heart failure may exhibit increased sarcolemmal NHE activity, through altered 
post-translational regulation of the exchanger.27 Taken together with recent animal 
studies, this work is consistent with an additional pathophysiological role for NHE 
activity in heart failure, and may indicate a novel therapeutic application for NHE 
inhibitors.
As outlined above, my interest in the sarcolemmal NHE arose initially from 
its putative role in mediating myocardial injury and dysfunction during ischaemia 
and reperfusion. Progress in this field has been rapid, such that several clinical trials 
have recently been completed with NHE inhibitors in patients at risk of such injury 
and dysfunction, while others are currently underway. As we have reviewed very 
recently, the findings of the clinical trials that have been completed to date have 
been mixed, but wholly consistent with the relevant scientific knowledge base. 
Ongoing clinical trials will establish whether NHE inhibitors will find therapeutic 
utility as cardioprotective agents in the clinical setting. In the meantime, on the basis 
of the strong evidence that NHE activity contributes not only to myocardial injury 
during ischaemia and reperfusion but also to the regulation of myocardial 
contractility, growth, hypertrophy and failure, our efforts continue towards the 
delineation of the cellular and molecular mechanisms that regulate NHE expression 
and activity in the heart, as well as the determination of the functional consequences 
of spontaneous or induced changes in these parameters.
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A v k i r a n , M e t i n , a n d  M i c h a e l  J. C u r t i s . Independent 
dual perfusion of left and right coronary arteries in isolated rat 
hearts. Am. J. Physiol 261 (Heart Circ. Physiol. 30): H2082- 
H2090,1991.—A novel dual lumen aortic cannula was designed 
and constructed to permit independent perfusion of left and 
right coronary beds in isolated rat hearts without necessitating 
the cannulation of individual arteries. Stability of the dual­
perfusion preparation was shown to be similar to that of the 
conventional Langendorff preparation, in terms of coronary 
flow, heart rate, and high-energy phosphate content The in­
dependence of left and right perfusion beds was confirmed by 
unilateral infusion of disulfine blue dye and spectrophotometric 
detection of the dye in ventricular homogenates. Transient 
cessation of flow to the left coronary bed resulted in severe 
ventricular arrhythmias upon reperfusion, as in conventional 
models of regional ischemia and reperfusion. The dual-perfu- 
sion model is technically undemanding, reproducible, inexpen­
sive, and can be used in several species. It enables studies with 
1) regional low flow ischemia, 2) regional zero-flow ischemia 
without coronary ligation (with attendant damage to vascula­
ture), 3) selective application of drugs or interventions to the 
ischemic-reperfused zone, and 4) selective application of com­
ponents of ischemia and reperfusion to a site anatomically 
relevant to ischemic heart disease.
\
models; regional ischemia; reperfusion; arrhythmias
m y o c a rd ial  isc h e m ia  and subsequent reperfusion lead 
to an impairment of cellular metabolic and ionic homeo­
stasis, which is associated with contractile dysfunction 
and the development of ventricular arrhythmias. Isolated 
Langendorff-perfused hearts from small mammals are 
commonly used to study the pathophysiology of ischemia 
and reperfusion by regional or global manipulation. Cur­
rent models, however, have several limitations. Global 
ischemia does not adequately mimic the condition of 
regional ischemia in the human, although it is relevant 
as a model of cardiac arrest during surgery. Although 
regional ischemia can be readily induced in small mam­
malian hearts by coronary artery ligation, there are prob­
lems associated with this technique. First, coronary li­
gation is an all or none process, and the degree of flow 
reduction cannot be regulated (thus low flow regional 
ischemia cannot be modeled). Second, coronary ligation 
H2082
itself may cause vascular damage and may disrupt venous 
and lymphatic drainage.
Limitations of current models extend to their use in 
assessment of the pathophysiological role of individual 
components of ischemia and reperfusion (defined as met­
abolic or ionic factors whose homeostasis is impaired). 
Although global manipulation of components may be 
satisfactory for the assessment of their effects on myo­
cardial metabolism and contractile function, it is not so 
within the context of arrhythmogenesis where regional 
heterogeneities may play a critical role (5, 6). A large 
number of components have been implicated as arrhyth­
mogenic factors. During ischemia, such components in­
clude catecholamines (22-24), thromboxane A2 (3), aden­
osine 3',5'-cyclic monophosphate (cAMP) (20), lipid me­
tabolites (4), platelet-activating factor (25), calcium (11), 
potassium (14,15, 17,19), and protons (15,17). During 
reperfusion, components include oxygen free radicals (9, 
28), cAMP (21), and intracellular calcium (18). Although 
several studies have been carried out with the local 
infusion of components of ischemia into selected coro­
nary arteries of large mammalian hearts such as those of 
the dog and the pig, both in vivo and in vitro (11, 17, 
19), comprehensive studies have not been possible be­
cause of cost and technical limitations. In species such 
as the dog, the issue is further complicated by the diffi­
culty in regulating the extracellular concentration of the 
substance under investigation (e.g., 19) owing to signifi­
cant collateral communication between adjacent coro­
nary beds (16). Studies with isolated hearts of smaller 
mammals such as the rat and the rabbit, which have 
negligible collateral flow, have been limited almost exclu­
sively to the use of global interventions (e.g., 1, 13, 29), 
since manipulation of regional flow has hitherto not been 
possible.
The unavailability of a technique that permits manip­
ulation of regional flow in isolated small mammalian 
hearts has also limited the utility of such hearts in studies 
of the mechanism and site of action of putative thera­
peutic agents. Thus, in studies employing regional ische­
mia and reperfusion, selective regional application of 
agents to the involved zone has not been possible, neces­
sitating the use of global application.
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FIG. 1. Schematic diagrams depicting design of 
dual-perfusion cannula (A), and correct position 
of cannula in ascending aorta of an isolated heart 
(B).  Each hemicylinder receives an independent 
supply of perfusate from distal end. Orifices near 
proxim al end are located to appose left and right 
coronary ostia when cannula is in position in as­
cending aorta. For details of availability of cannula, 
contact author.
In view of the above, a recent attempt was made to 
develop a model using the isolated rabbit heart in which 
adjacent coronary beds could be perfused independently 
(5). However, the model has several potential disadvan­
tages: 1) it is technically complex, since it requires can- 
nulation of the left coronary artery, 2) constant pressure 
perfusion is precluded owing to the necessarily small 
bore (and hence high resistance) of the cannula, 3) its 
utility for arrhythmia studies is limited by an intrinsi­
cally low susceptibility to ischemia-induced and reper­
fusion-induced arrhythmias (cf. 6 and 26), and 4) rabbit 
costs are high in comparison with smaller species.
The objective of the present study was to overcome 
the disadvantages of the rabbit dual-perfusion model. 
We opted to use the rat heart, which is relatively inex­
pensive versus the rabbit yet has a similar paucity of 
collateral anastomoses (16). To achieve our objective we 
developed a novel dual lumen aortic cannula, which 
permits independent perfusion of left and right coronary 
arteries via their ostia without the necessity of intracor­
onary cannulation. This paper describes and character­
izes the new model.
M ATERIALS AND METHODS 
Design of Aortic Cannula
A fundamental problem in developing a rat dual-per- 
fiision model is how to achieve an independent supply of 
perfusate to left and right coronary arteries. The inser­
tion of cannulas into individual coronary arteries can be 
ruled out, since the cannulas would, by necessity, have a 
very narrow bore that would not permit constant pres­
sure perfusion at physiological pressures (60-90 mmHg) 
or constant flow perfusion at flow rates (8-12 ml • min-1 • 
g_1) sufficient to provide adequate oxygenation with crys­
talloid solutions. We therefore adopted an alternative 
approach and designed an aortic cannula that would 
enable the perfusion of left and right coronary arteries 
via their ostia, without the necessity of intracoronary 
cannulation.
The coronary anatomy of the rat heart has been de­
scribed in detail by Halpem (10). The two ventricles and
the septum are supplied by right and left coronary arter­
ies arising from the ascending aorta. The septal artery is 
usually presented as the first branch of either the left or 
the right coronary artery. In the majority of hearts, single 
main left and right trunks arise from single ostia (2). 
Occasionally the septal artery, the circumflex artery, or 
the conus artery present as separate arteries originating 
from the aorta with their own ostium. The aortic cannula 
was designed to accommodate these possible variations 
in coronary anatomy.
The design of the cannula is depicted in Fig. 1. The 
standard cannula consists of stainless steel tubing of 3.33 
mm external diameter. This cannula size fits snugly into 
the ascending aorta of a heart from a 220- to 280-g rat, 
stretching the aorta taut and forming a tight seal between 
the cannula and the aorta. The cylindrical interior of the 
cannula is lined with custom-made medical grade poly­
urethane and divided into two equal hemicylinders by a 
central septum. Each hemicylinder receives an indepen­
dent supply of solution from the proximal end. The distal 
end is sealed, and two bore holes are made through the 
stainless steel and polyurethane near the distal end to 
allow exit of solution from each hemicylinder. These 
holes are located to appose the right and left coronary 
ostia when the cannula is inserted into position in the 
aorta. The openings are sufficiently large (—1.0—1.2 mm 
in diam) enough to span either an individual ostium (in 
the case of single left and right ostia) or pairs of ostia 
(in the event that coronary arteries arise from a pair of 
adjacent ostia, as is sometimes the case). The physical 
characteristics of the dual-perfusion cannula are such 
that flow through each hemicylinder of the cannula 
exceeds 50 ml/min with a pressure head of 100 cmH20  
(75 mmHg) and, within the range of flow rates normally 
encountered in individual coronary beds (3-8 ml/min), 
the pressure drop across each hemicylinder is <5 mmHg 
(Fig. 2).
Perfusion Apparatus
Each hemicylinder was supplied with an oxygenated 
perfusion solution from a temperature-regulated reser­
voir (37°C) at a constant pressure of 100 cmH20  (Fig.
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FIG. 2. Characterization of pressure gradient across individual hemi- 
cylinder of dual-perfusion cannula in absence of a heart. Pressure was 
simultaneously recorded proximal to poin t of entry and distal to  point 
of exit of perfusion fluid, a t different flow rates. Perfusion fluid was 
supplied from a reservoir 100 cm above cannula. Shaded area represents 
range of flow rates normally encountered in individual coronary beds; 
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FIG. 3. Perfusion apparatus used in conjunction with dual-perfusion 
cannula. Perfusion of either coronary bed can be switched from con­
s tan t pressure to constant flow a t required flow rate through use of a 
roller pump. Randomized concentration-response studies can be per­
formed through use of multiple reservoirs, as illustrated. Disulfine blue 
dye can be administered unilaterally to  enable delineation o f left and 
righ t coronary beds.
3). The flow through each hemicylinder was continuously 
monitored using two in-line flowmeters (Meterate, Jen- 
cons Scientific, Leighton Buzzard, UK, detection range 
0.25-12.00 ml/min). Before use the flowmeters were cal­
ibrated at 37°C, using a precision roller pump (Gilson 
Minipuls 3). A central reservoir held buffer containing 
disulfine blue dye (0.016% wt/vol), which could be in­
fused through either side of the cannula to delineate the 
two perfusion beds. The heart was housed in a tempera­
ture-regulated chamber and maintained at 37°C. To 
maintain sinus rate, the right atrium and sinoatrial node 
were continuously superfused with oxygenated perfusion 
medium (37°C) at a constant flow rate of 5 ml/min (7).
Perfusion Medium
All hearts were perfused with Krebs-Henseleit solu­
tion, modified to the following composition (in mmol/1): 
118.5 NaCl, 25.0 NaHC03, 3.2 KCi, 1.2 MgS04, 1.2 
KH2P 0 4, 1.4 CaCl2, and 11.0 glucose. The solution (pH 
7.4 at 37°C) was continously gassed with carbogen (95% 
0 2-5% C 02).
Perfusion Protocol
Male Wistar rats (Bantin and Kingman) were anes­
thetized with diethylether after which 50 U of heparin 
sodium was injected into the left femoral vein. The chest 
was opened and the heart excised and immersed in 
perfusion medium at 4°C. Within 30 s of excision, a dual­
perfusion cannula was inserted into the ascending aorta 
(in exactly the same way that a conventional Langen- 
dorff cannula is inserted) and secured in position with a 
braided silk suture. Coronary perfusion was then begun 
at a perfusion pressure of 100 cmH20 , and coronary ostia 
were aligned with the cannula orifices, using in-line 
monitoring of left and right coronary flows as a guide. 
The aorta was rotated on the cannula until flow in each 
perfusion bed reached a maximum, a procedure that 
could be accomplished within 20 s after insertion of the 
cannula. The pulmonary artery was cut near its origin, 
and a stainless steel needle was inserted into the left 
ventricle via the apex to enable adequate drainage of 
coronary and thebesian venous effluent. The heart was 
then subjected to one of the following protocols.
Stability of preparation. A protocol was designed to 
test the hemodynamic and metabolic stability of the 
dual-perfusion preparation relative to the Langendorff 
preparation. To enable such an assessment, some hearts 
were cannulated with a standard single-lumen aortic 
cannula of equivalent diameter (3.33 mm OD) and per­
fused in the Langendorff mode with perfusion solution 
supplied from the two reservoirs used for dual perfusion.
Hearts (n = 8 per group) were subjected to 60 min of 
perfusion in the dual perfusion or the Langendorff mode 
with continuous monitoring of heart rate and coronary 
flow. At the end of the perfusion period the hearts were 
rapidly frozen using a pair of stainless steel clamps 
precooled in liquid nitrogen. The hearts were then stored 
in liquid nitrogen for subsequent analysis of tissue ATP 
and creatine phosphate (CrP) content.
Independence of right and left coronary artery perfu­
sion. This protocol was designed to test the adequacy of 
the seal formed between the aorta and the dual-perfusion 
cannula by assessment of the extent of cross-flow be­
tween the two orifices of the cannula at this level.
Hearts {n =  8) were perfused in the dual-perfusion 
mode with oxygenated bicarbonate buffer for 15 min 
during which period heart rate and coronary flow were 
monitored. The perfusion fluid supplied to one coronary 
bed was then switched for 1 min to a similar solution 
containing 0.016% wt/vol disulfine blue dye. Four hearts 
received dye to the right coronary bed and the other four 
to the left. The heart was then removed from the perfu­
sion apparatus, the atria and mediastinal tissue were 
removed, and the dyed ventricular tissue was carefully
2 6
DUAL PERFUSION OF CORONARY ARTERIES IN RAT HEART
dissected away from the remainder. The dyed and non­
dyed sections of tissue, corresponding to the ventricular 
masses supplied by the left and right coronary beds, were 
then lightly blotted and weighed Samples of ~140 mg 
were then dissected from the left and right ventricular 
free walls for spectrophotometric detection of the pres­
ence of blue dye (see below).
Left-right coronary collateral communication during 
coronary occlusion in the rat heart provides to the is­
chemic zone <10% of normal flow (16). We, therefore, 
expected to detect dye in the nominally dye-free bed at 
a concentration significantly <10% of that in the dye- 
perfused bed (since hydrostatic pressure in the nominally 
dye-free bed must exceed that in an ischemic zone after 
coronary occlusion). Any value exceeding this would 
indicate an inadequate seal between the dual-perfusion 
cannula and the aorta. To test the sensitivity of the dye- 
detection method and to provide a calibration for 10% 
cross-flow, an additional heart received a 1:10 dilution of 
dye (0.0016% wt/vol) simultaneously into each perfusion 
bed for 1 min. Left and right ventricular free wall samples 
of similar size (—140 mg) obtained from this heart were 
then processed and underwent spectrophotometric dye 
detection in an identical fashion to the other samples.
Effects of transient regional ischemia and reperfusion. 
This protocol was designed to test the arrhythmogenic 
effect of transient cessation of flow in the left coronary 
bed and to compare the pattern of reperfusion-induced 
arrhythmogenesis with that previously reported in con­
ventional models of regional ischemia and reperfusion.
Hearts (n — 12) were perfused in the dual-perfusion 
mode with oxygenated bicarbonate buffer for 15 min 
after which flow to the left coronary bed was stopped 
while the right coronary bed continued to be perfused at 
constant pressure. After 10 min of ischemia, the left 
coronary bed was reperfused at constant pressure for 5 
min, during which arrhythmias were assessed. At the end 
of each experiment, the perfusion fluid supplied to the 
left coronary bed was switched for 1 min to a solution 
containing 0.016% wt/vol disulfine blue dye after which 
the heart was removed from the perfusion apparatus. 
The atria and mediastinal tissue were removed and the 
dyed tissue, representing the ventricular myocardium 
subjected to ischemia and reperfusion, was carefully dis­
sected away from the remainder. The dyed and nondyed 
sections of tissue were then lightly blotted and weighed. 
Ischemic zone size was expressed as a percentage of total 
ventricular weight.
Measured Variables
Coronary flow, heart rate, and electrogram. Coronary 
flow was measured using the in-line flowmeters, and 
heart rate was determined from a unipolar electrogram. 
The electrogram was obtained using a silver electrode 
inserted into the left ventricular free wall and a reference 
electrode connected to the aorta via the stainless steel 
casing of the aortic cannula. The electrogram signal was 
amplified (Gould Universal Amplifier), continuously 
monitored on a digital storage oscilloscope (Gould type 
1421), and recorded on an ink-jet recorder (Gould 2200S).
Tissue ATP and CrP content. Frozen ventricular tissue
H2085
samples were lyophilized (Edwards Modulyo Freeze 
Dryer) before assay in duplicate. ATP and CrP were 
extracted into perchloric acid and quantified using a 
spectrophotometric hexokinase/glucose-6-phosphate de­
hydrogenase assay, as described by Hearse (12). Analysis 
of samples was performed in a blinded manner.
Tissue disulfine blue dye content. First, the maximum 
absorbance wavelength of disulfine blue dye (650 nm) 
was determined from scanning wavelength spectra of 
several concentrations of the dye in deionized water, 
using a Pye Unicam SP8-100 UV spectrophotometer. 
Ventricular samples were then homogenized in 3 ml of 
deionized water and centrifuged at 3,000 rpm for 10 min. 
Scanning spectra of the supernatants were obtained by 
recording their absorbance between the wavelengths of 
800 and 500 nm. Blanks were prepared from ventricular 
homogenates from hearts not perfused with dye. The 
presence of a discernible absorption peak at 650 nm was 
taken to indicate the presence of disulfine blue dye. The 
peaks observed in nominally dye-free samples were quan­
tified in relation to the size of the peak obtained from 
the appropriate sample receiving a 1:10 dilution of the 
dye. In this manner we obtained a semiquantitative 
assessment of the extent of cross-flow.
Arrhythmias. The electrogram was analyzed for the 
incidence and duration of ventricular tachycardia (VT) 
and ventricular fibrillation (VF) in accordance with the 
Lambeth Conventions (27). VT was defined as four or 
more consecutive premature beats of ventricular origin, 
and VF was defined as a signal in which individual QRS 
deflections could no longer be distinguished from one 
another and for which rate could not be determined.
RESULTS
Stability of Preparation
The hearts used for Langendorff perfusion or dual 
perfusion in this protocol were obtained from two groups 
of rats (n = 8 per group) with mean body weights of 266 
± 10 and 262 ±  9 g, respectively.
Figure 4 shows the temporal changes in coronary flow 
and heart rate in the two groups of hearts perfused for 
60 min in the Langendorff or the dual-perfiision mode. 
Total coronary flow profiles were similar in the two 
groups, declining slightly during the first 15 min of 
perfusion and remaining stable thereafter. There was no 
significant difference between the groups at any time 
point. Heart rate profiles in each group were also similar 
with no significant difference between groups at any time 
point.
Tissue high-energy phosphate (ATP and CrP) con­
tents after 60 min of aerobic perfusion were similar in 
the two groups. Tissue ATP was 19.2 ± 0.2 and 19.5 ± 
0.3 fimol/g dry wt, and tissue CrP was 22.0 ± 1.1 and 
19.3 ± 0.9 fixaol/g dry wt in the Langendorff and dual­
perfusion groups, respectively.
Independence of Right and Left 
Coronary Artery Perfusion
The hearts perfused in the dual-perfusion mode for 
this protocol were obtained from rats (n = 8) with a
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FIG. 4. Profiles of total coronary flow (top) and heart rate (bottom ) 
during 60 min of perfusion in Langendorff or dual-perfusion modes (n 
=  8 per group). There were no significant differences in either variable 
between the groups a t any time point.
mean body weight of 231 ± 2 g. Mean total ventricular 
wet weight was 0.83 ±  0.02 g, and mean heart rate at the 
end of 15 min aerobic perfusion was 315 ±  17 beats/min. 
Despite the variability in the size of the left and right 
coronary artery beds (due to variable septal artery ori­
gin), the mean coronary flows normalized for the wet 
weight of each bed were similar at 11.4 ±  1.6 ml-min-1- 
g-1 in the left coronary bed and 12.2 ±  1.0 ml-min-1-g_1 
in the right coronary bed.
Figure 5 shows the typical delineation of the two 
coronary beds after unilateral perfusion with disulfine
—T"
60
blue dye. The outline of the border between the two 
coronary beds was identical regardless of the site of dye 
infusion, confirming the presence of two discrete perfu­
sion beds. Figure 6 shows the absorption spectra obtained 
from left and right ventricular free wall homogenates. 
Large absorption peaks were observed at a wavelength 
of 650 nm in samples perfused unilaterally with disulfine 
blue dye. Only very small absorption peaks were detect­
able at 650 nm in contralateral samples (not perfused 
with dye), and these were significantly smaller than the 
peaks obtained in the corresponding samples that re­
ceived a 1:10 dilution of dye.
Unilateral perfusion with disulfine blue dye permitted 
determination of whether the interventricular septal ar­
tery arose from the left or right coronary artery. Left 
dominance was found in 50% of hearts. In these hearts 
the mean weights of ventricle supplied by the left and 
right coronary artery beds, as a percentage of total ven­
tricular weight, were 71 ±  5 and 29 ±  5%, respectively. 
In the remaining 50% of hearts that exhibited right 
dominance, the corresponding values were 46 ± 3 and 54 
±3% , respectively.
Reproducibility of Preparation
To date, a total of 153 hearts with a mean total 
ventricular wet weight of 0.85 ±  0.01 g have been perfused 
in various experimental protocols, using the dual-perfu­
sion cannula. Of these hearts, 33% (51/153) displayed 
left dominance and 58% (88/153) displayed right domi­
nance. In the remaining 9% (14/153) the interventricular 
septum was supplied by both left and right coronary 
arteries. The left and right coronary beds supplied 72 ±  
1 and 28 ±  1% of the ventricular weight, respectively, in 
hearts with left dominance (n = 51), and 52 ±  1 and 48 
±  1% of the ventricular weight, respectively, in hearts 
with right dominance (n = 88). These values are very 
similar to those obtained from the much smaller (n = 4) 
population samples described above. The left and right 
coronary beds supplied 57 ±  3 and 43 ±  3% of the 
ventricular weight, respectively, in those hearts that did 
not display a clear septal dominance (n = 14). The mean 
coronary flows normalized for tissue wet weight were
B
FIG. 5. Typical delineation of left 
and right coronaiy beds by unilateral 
infusion of disulfine blue dye. Same 
heart is shown during dye infusion into 
left coronary bed (A), after w ashout of 
dye (B ), and during dye infusion into 
right coronary bed (C). Right coronary 
ostial orifice of dual-perfusion cannula 
is also visible (by right atrial appendage).
28
DUAL PERFUSION OF CORONARY ARTERIES IN RAT HEART H2087
V V
LV sample (mg) 126 
Heart No. 1


























j  v- I
Wavelength 4M 650 450 650 850 4X3 650 850 450 6K) 850 4K) sk i 850 450 650 850 450 650 850 450 650 850
ran ran ran nm nm nm nm nm
FIG. 6. Scanning absorption spectra (500-800 nm) obtained from homogenates of left ventricular (LV, top) and 
righ t ventricular (RV, bottom) free wall samples from 9 hearts. Hearts 1-4  received disulfine blue dye only to left 
coronary bed and hearts 5 -8  only to right coronary bed. Heart 9 received a 1:10 dilution of dye in both coronary beds. 
Left and right ventricular samples were, by design, of sim ilar weight.
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11.9 ±  0.2 ml-min_1-g_1 in the left coronary bed and 12.3 
±  0.3 ml-min-1-g_1 in the right coronary bed (n -  153). 
These values are also very similar to those obtained from 
the sample of eight hearts described above.
Effects of Transient Regional Ischemia and Reperfusion
The hearts used in this protocol (n = 12) were obtained 
from rats with a mean body weight of 236 ±  3 g. Mean
total ventricular wet weight was 0.70 ±  0.02 g and mean 
size of the left coronary bed, representing the ischemic 
zone, was 54 ± 3% of total ventricular weight. Mean 
values for heart rate and coronary flow in the left and 
right coronary beds, measured at the end of the initial 
15-min period of aerobic perfusion, were 326 ±  6 beats/ 
min, 11.6 ±  0.6 ml • min-1 • g-1, and 10.2 ±  0.7 ml ■ min*1 • 
g~\ respectively. Heart rate and flow in the right coro­
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nary bed remained stable during the period of regional 
ischemia and were 334 ± 1 1  beats/min and 10.1 ±  0.8 
ml • min-1 • g-1, respectively, 1 min before the onset of 
reperfusion. Heart rate could not be measured during 
reperfusion because of severe ventricular arrhythmias. 
Coronary flow increased to 24.4 ±  2.5 ml • min-1 • g_1 in 
the reperfused zone 1 min after the onset of reperfusion, 
indicating reactive hyperemia. Reduced extravascular 
compression, due to loss of coordinated contractile activ­
ity (see below), probably contributed to the increased 
flow, since flow also increased in the adjacent bed during 
reperfusion, albeit to a lesser extent (16.4 ±  1.5 ml- 
min_1-g-1 at 1 min).
All hearts were in sinus rhythm immediately before 
reperfusion. Upon reperfusion, all hearts developed VT 
within a few beats. In 1 heart VT reverted to normal 
sinus rhythm, while in the remaining 11 hearts it degen­
erated into VF (Fig. 7). In 10 hearts, VF was sustained 
until the end of the 5-min reperfusion period (Fig. 7).
D I S C U S S IO N
We have developed and characterized a dual-perfusion 
model for small mammalian hearts. The model utilizes a 
novel aortic cannula that permits independent perfusion 
of left and right coronary arteries, yet is no more tech­
nically demanding than the conventional Langendorff 
model. The model has potential utility in the study of 
regional myocardial ischemia beyond the scope of the 
Langendorff model.
The Need for New Models
Despite intensive research, progress in the develop­
ment of new therapies for ischemic heart disease has 
yielded only limited clinical success, and the disease 
remains a major cause of mortality. The development of 
new animal models, which in addition to adequately 
mimicking the human disease also function as reliable 
bioassays, may accelerate progress in this area (8).
A bioassay must possess certain attributes in order for 
it to have utility; low cost, ease of use, and reproducibil­
ity. If we define the primary objectives of any model for 
the study of regional ischemia and reperfusion as being 
1 ) the determination of the relative contribution of com­
ponents of ischemia and reperfusion to cardiac dysfunc­
tion, and 2) the assessment of the extent and mechanism 
of action of putative therapeutic interventions, then the 
potential utility of the dual-perfusion model relative to
conventional models is self-evident. The potential limits 
of the model are primarily related to the unusual char­
acteristics of rat cardiac electrophysiology. However, de­
spite these characteristics, the consequences of ischemia 
and reperfusion do not appear to be anomalous in the 
rat heart in that contractile dysfunction, arrhythmias, 
and infarction all occur (8). Nevertheless, the dimensions 
of the new cannula can be adapted to enable its use with 
other small mammalian hearts.
Advantages and Utility of Dual-Perfusion Model
The described model offers several advantages over 
conventional models by enabling the independent per­
fusion of left and right coronary arteries in isolated 
hearts of small mammals. Such procedures have hitherto 
been restricted to hearts from larger, more expensive 
animals (5,17). The use of the rat heart makes the model 
relatively inexpensive, the only extra source of cost com­
pared with the conventional Langendorff preparation 
being the dual-perfusion cannula. The novel design of 
the aortic cannula overcomes the need to cannulate 
individual coronary arteries, making the model compa­
rable to the Langendorff preparation in its ease of use. 
The model is also highly reproducible, as illustrated by 
its characterization. Low standard errors for all variables 
(coronary flow, heart rate, tissue ATP and CrP contents, 
size of perfusion beds) and the absence of any significant 
difference in hemodynamic or metabolic stability from 
conventional Langendorff hearts indicate that the model 
is sufficiently stable and reproducible for use in bioassay.
Reperfusion after transient regional ischemia, induced 
by cessation of flow to the left coronary bed, resulted in 
the almost instantaneous induction of VT, which rapidly 
degenerated into VF in 11 of 12 hearts. This pattern of 
reperfusion-induced arrhythmogenesis is almost identi­
cal to that previously reported in isolated rat hearts 
subjected to transient regional ischemia of identical du­
ration by proximal ligation of the left main coronary 
artery (29). This confirms the validity of the dual-per­
fusion preparation and illustrates its usefulness in the 
study of reperfusion-induced arrhythmogenesis. The in­
cidence of sustained VF was higher in the present study 
compared with that reported previously (29); this can be 
explained by the greater mean occluded zone size in our 
study, since occluded zone size has been shown to be a 
determinant of the incidence of reperfusion-induced sus­
tained ventricular fibrillation in the isolated rat heart 
(7).
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QC 8 0f reperfusion. H orizontal bars, individ-
2] 9 ual hearts with reperfusion initiated a t
I  10 time O', open bars, normal sinus rhythm ;
11 hatched bars, VT; filled bars, VF. All
12 —  hearts were in sinus rhythm  immediately
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The utility of the new model is enhanced by its wide 
scope of application. Possible applications include 1) 
studies of the consequences of regional low-flow (as 
opposed to zero-flow) ischemia at any chosen percentage 
of basal flow, by switching perfusion of the selected 
coronary bed from the constant pressure mode to the 
constant flow mode (Fig. 3); 2 ) studies of the conse­
quences of regional zero-flow ischemia without the ne­
cessity of coronary artery ligation (with attendant dam­
age to the vasculature); 3) assessment of the effectiveness 
and site of action (ischemic vs. nonischemic region) of 
drugs by their selective administration, with scope for 
randomized concentration-response studies through the 
use of multiple reservoirs (Fig. 3); 4) studies with inter­
ventions selectively applied to the reperfused zone at the 
onset of reperfusion; and 5) assessment of the effects of 
individual components of ischemia and reperfusion by 
their regional application, with selection of the site of 
administration (left or right coronary bed) and the size 
of the perfusion bed (hearts with left or right dominance).
Concluding Comments
The dual-perfusion preparation described in this study 
provides an inexpensive, technically undemanding and 
reproducible model for use in studies of aspects of re­
gional myocardial ischemia and reperfusion, and their 
modification. The new model has many potential appli­
cations, and its use should assist identification of the 
relative importance of different factors in the develop­
ment of ischemia and reperfusion-induced cardiac dys­
function, including arrhythmias, and the evaluation of 
putative therapeutic interventions.
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A Role for Washout of Extracellular Protons?
Me tin Avkiran and Chikao Ibuki
Rapid washout of extracellular H+ accumulated during preceding ischemia (i.e., the abrupt restoration of 
extracellular pH) has been implicated as an arrhythmogenic factor during reperfusion. Therefore, we 
hypothesized that by limiting the rate at which extracellular pH was restored during early reperfusion it 
should be possible to protect against reperfusion-induced arrhythmias. To test this, we used isolated rat 
hearts (n=12 per group) and a novel dual coronary perfusion cannula that permitted the induction of 
regional ischemia (10 minutes) and the selective reperfusion (8 minutes) of the ischemic zone with 
modified solutions. We examined the antiarrhythmic efficacy of 1) acidic (pH 6.6) reperfusion with 
stepwise restoration of extracellular pH to 7.4 (stepped pH) and 2) transient (2-minute) acidic (pH 7.1, 
6.8, 6.6, or 6.4) reperfusion with subsequent abrupt restoration of extracellular pH to 7.4. Hearts in two 
contemporary control groups were reperfused with solution at pH 7.4 throughout In all groups, 100% of 
hearts exhibited ventricular tachycardia (VT) on reperfusion. VT degenerated into ventricular fibrillation 
(VF) in 100% of hearts in the control group but in only 42% of hearts in the stepped-pH group (/><0.05). 
In the groups subjected to transient acidic reperfusion, there was a pH-dependent prolongation of VT 
cycle length (measured at 15 seconds of reperfiision), which was 47.1 ±3.9 ,51.1±5.5,56.0±1.9, 60.4±2.8 
(p<0.05), and 68.8±5.0 (p<0.05) msec in the pH 7.4 (control), 7.1, 6.8,6.6, and 6.4 groups, respectively. 
In these groups, VT degenerated into VF in 92%, 92%, 83%, 42% (p<0.05), and 33% (p<0.05) of hearts, 
respectively. In conclusion, limiting the rate at which extracellular pH is restored during early reperfusion 
does not affect the rapid induction of VT but Inhibits the degeneration of VT into VF and promotes 
spontaneous reversion to normal sinus rhythm. This is consistent with a major arrhythmogenic role, 
during uncontrolled reperfusion, for the rapid washout of extracellular H+. (Circulation Research 
1992;71:1429-1440) '
K e y  W o r d s  •  r e g io n a l is c h e m ia  •  r e p e r fu s io n -in d u c e d  a r r h y th m ia s  •  v e n tr ic u la r  f ib r illa t io n  •  
p r o to n s  •  d u a l c o r o n a r y  p e r fu s io n  •  r a ts
Reperfusion of myocardium subjected to a tran­sient period of ischemia rapidly induces severe ventricular arrhythmias (for review, see Man­ning and Hearse1). Although the precise mechanisms 
have not been elucidated, several factors have already 
been implicated in reperfusion arrhythmogenesis,1 in­
cluding the generation of free oxygen radicals,2-4 the 
rapid washout of K+ from the extracellular space,3 and 
the accumulation of Ca2+ in the intracellular space.6 
However, as recently pointed out,7 the fundamental 
question of whether the arrhythmogenic process is 
initiated by the washout of substances (e.g., K*) accu­
mulated during ischemia or by the resupply of sub­
stances (e.g., oxygen) absent during ischemia remains to 
be resolved. Yamada and colleagues8 have reported 
that, whereas reestablishment of flow and readmission
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of oxygen were independent determinants of reperfu- 
sion-induced arrhythmias, the latter was not a prereq­
uisite for arrhythmogenesis (since anoxic reperfusion 
did not significantly alter the incidence of reperfusion- 
induced ventricular fibrillation), indicating that multiple 
mechanisms may be involved. In this context, the recent 
study by Curtis3 on the effects of regional infusion and 
washout of high [K+] solutions in the isolated rabbit 
heart suggests that the rapid washout of extracellular K+ 
could be a significant arrhythmogenic factor.
Protons (H+) also accumulate in the extracellular 
space during ischemia,9 and their rapid washout may be 
another factor. Lazdunski and colleagues10 suggested in 
1985 that the rapid washout of extracellular H+ on 
reperfusion may create an intracellular to extracellular 
H+ gradient, resulting in an influx of Na+ via the 
Na+-H+ exchanger. Such an influx of Na+, in the face of 
Na+,K+-ATPase inhibition caused by the preceding 
ischemia, could result in an increase in intracellular 
[Na+], which in turn would favor an increase in intra­
cellular [Ca2+] via the Na+-Ca2+ exchanger.10 Increase 
in intracellular [Ca2+] on reperfusion, which can be 
ameliorated by inhibition of Na+-H+ exchange with 
amiloride11 or by acidic reperfusion,12 has been demon­
strated in the isolated rat heart. Such an increase in 
intracellular [Ca2+] has been proposed as a potential 
culprit for reperfusion arrhythmogenesis.6 Indeed, the
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FIGURE 1. D iagram s illustrating the p erfu s io n  apparatus a n d  the correct position  o f  the dual-perfusion cannula in d ie  aorta  o f  
an  isolated heart (inset). A  d ivided lining to the lum en o f  the cannula  perm its  each hem icylinder to deliver an  independent supply  
o f  perfusa te . T he  orifices near the proxim a l end  are designed to  be opposite the le ft a n d  right coronary ostia when the cannu la  is 
in position. Regional ischem ia was induced  by stopping flo w  to  the  le ft coronary bed. D uring reperfusion, the le ft coronary bed was 
p erfu sed  a t the preischem ic flo w  rate via a roller pum p, with p erfu s io n  so lution fro m  one o f  a bank  o f  fo u r  reservoirs. A t  the end  
o f  each experim ent, disulfine blue dye  was in fu sed  into one  coronary artery to delineate the le ft a n d  right coronary beds, thus  
enabling the size o f  the ischem ic zone  to be quantified.
recent study by Dennis and colleagues,13 who used 
solutions containing various buffer concentrations and 
amiloride analogues to modify the activity of the 
Na+-H+ exchanger, provided support for an arrhyth­
mogenic role for Na+-H+ exchange-mediated mecha­
nisms during reperfusion.
We hypothesized that, if the rapid washout of extra­
cellular H+ (i.e., the abrupt restoration of extracellular 
pH) were a major arrhythmogenic factor during reper­
fusion, then limiting the rate of washout of extracellular 
H+ (i.e., the rate of restoration of extracellular pH) 
during early reperfusion should afford protection. To 
test this, we used isolated rat hearts and a recently 
developed dual perfusion cannula14 that permits the 
induction of regional ischemia and the selective reper­
fusion of the ischemic zone with modified solutions. We 
examined the antiarrhythmic efficacy of 1) acidic (pH 
6.6) reperfusion with stepwise restoration of extracellu­
lar pH to 7.4 by sequential perfusion with solutions of 
increasing pH and 2) transient acidic (pH 7.1, 6.8, 6.6, 
or 6.4) reperfusion followed by an abrupt restoration of 
extracellular pH to 7.4.
Materials and Methods
Dual Coronary Perfusion of Isolated Rat Hearts
Independent dual perfusion of left and right coronary 
arteries in isolated rat hearts was performed as de­
scribed in detail by Avkiran and Curtis.14 In brief, male 
Wistar rats (Bantin and Kingman, Ltd., N. Humberside, 
UK) were anesthetized by inhalation of diethyl ether, 
and then 50 units sodium heparin was injected into the 
left femoral vein. The chest was opened, and the heart 
was excised and immersed in perfusion medium at 4°C. 
Within 30 seconds of excision, a dual perfusion cannula 
was inserted into the ascending aorta (Figure 1) and 
secured in position with a braided silk suture. The
pulmonary artery was cut near its origin, and a stainless- 
steel needle was inserted into the left ventricle through 
the apex to allow adequate drainage of coronary and 
thebesian venous effluent. Perfusion of both coronary 
beds was then initiated at a perfusion pressure equiva­
lent to 100 cm H20 . Alignment of the coronary ostia 
with the orifices of the cannula was achieved using 
in-line monitoring of left and right coronary flow as a 
guide, the aorta being rotated on the cannula until flow 
in each perfusion bed reached a maximum.
Perfusion Apparatus
Each coronary bed was initially supplied with oxygen­
ated perfusion solution from a temperature-regulated 
reservoir (37°C) at constant pressure (Figure 1). The 
flow to each bed was continuously monitored using two 
in-line flowmeters (Meterate, Jencons Scientific Ltd., 
Leighton Buzzard, UK) with a detection range of 0.25-
12.00 ml/min. When required, the left coronary bed 
could be perfused at constant flow, via a roller pump 
(Gilson Minipuls 3), with perfusion solution from any 
one of a bank of reservoirs. A central reservoir held 
perfusion solution containing disulfine blue dye 
(0.016% [wt/vol]), which could be infused unilaterally to 
delineate the two perfusion beds. The heart was housed 
in a temperature-regulated chamber and maintained at 
37°C. Because the atria in the rat are supplied by 
extracardiac arteries,15 the right atrium was continu­
ously superfused with oxygenated perfusion medium 
(37°C) at a constant flow rate of 10 ml/min to maintain 
sinus rate.14
Perfusion Solutions
All solutions were continuously gassed with 95% 
Or-5% C 02 and filtered (pore size, 5 pm) before use. 
The standard perfusion solution had a pH of 7.4 and
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FIGURE 2. Protocols for stepwise restoration of extracellular 
pH  (panel A) and transient acidic perfusion followed by 
abrupt restoration of extracellular pH (panel B) during 
selective reperfusion (8 minutes) of die left coronary bed after 
10 minutes of zero-flow ischemia (n=12 per group). The left 
coronary bed was perfused at the preischemic flow rate, via a 
roller pump, throughout reperfusion.
was of the following composition (mmol/1): N ad  118.5, 
NaHCOj 25.0, KQ 3.2, MgS04 1.2, KH2P 04 1.2, CaCl2
1.4, and glucose 11.0. Solutions at pH 7.1, 6.8, 6.6, and
6.4 were obtained by reducing the concentration of 
NaHC03 to 12.5, 63, 4.0, and 2.5 mmol/1, respectively. 
The concentration of sodium and the osmolarity were 
kept constant in the solutions by substitution of 
NaHC03 with N ad  as necessary.
Experimental Protocols
After 15 minutes of perfusion of both coronary beds 
with the standard perfusion solution (pH 7.4) at con­
stant pressure, regional ischemia was induced by clamp­
ing the perfusion line supplying the left coronary bed. 
The right coronary bed continued to receive the stan­
dard perfusion solution at constant pressure throughout 
the experiment. Regional ischemia was maintained for 
10 minutes (the duration that results in a maximum 
incidence of reperfusion-induced ventricular fibrillation 
in the isolated rat heart1); then the heart was randomly 
assigned to one of the study groups (n=12 per group), 
and the left coronary bed was reperfused at constant 
flow (100% of its preischemic flow rate) via the roller 
pump according to the following protocols.
Stepwise restoration of extracellular pH. This protocol 
(Figure 2A) was designed to test the effects of stepwise 
restoration of extracellular pH in the reperfused zone 
on the severity of reperfusion-induced arrhythmias. 
During 8 minutes of reperfusion, the left coronary bed 
received either the standard perfusion solution at pH
7.4 throughout (control group) or solution at pH 6.6 for 
the first 2 minutes of reperfusion, pH 6.8 from 2 to 4 
minutes, pH 7.1 from 4 to 6 minutes, and finally pH 7.4 
from 6 to 8 minutes.
Transient acidic reperfusion. This protocol (Figure 2B) 
was designed to test the antiarrhythmic efficacy of 
transient acidic reperfusion and to determine the pH-
response characteristics of any such effect. In the con­
trol group, the left coronary bed received the standard 
perfusion solution at pH 7.4 throughout 8 m in u te s  of 
reperfusion, as above. In four transient acidic reperfu­
sion groups, the left coronary bed received the solution 
at pH 7.1, 6.8, 6.6, or 6.4 for the first 2 minutes of 
reperfusion, followed by the standard solution at pH 7.4 
from 2 to 8 minutes.
Measured Variables
Arrhythmias. Arrhythmias were diagnosed from a 
unipolar electrocardiogram (ECG), which was obtained 
using a silver electrode inserted into the free wall of the 
left ventricle and a reference electrode connected to the 
aorta. The ECG was continuously monitored on a 
digital storage oscilloscope (model 1421, Gould Elec­
tronics Ltd., Ilford, UK) and recorded on an ink-jet 
recorder (model 2200S, Gould). Chart speed was set at 
50 mm/sec a few seconds before reperfusion so as to 
obtain a permanent high-speed recording of the changes 
in the ECG during early reperfusion. The ECG was 
retrospectively analyzed, in a blinded manner, for the 
incidence, time to onset, and duration of ventricular 
tachycardia (VT) and ventricular fibrillation (VF). All 
analyses were carried out in accordance with the Lam­
beth Conventions.16 VT was defined as four or more 
consecutive premature beats of ventricular origin, and 
VF was defined as a signal in which individual QRS 
deflections could no longer be distinguished from one 
another and for which the rate could not be determined.
VT cycle length. In hearts subjected to transient acidic 
reperfusion and contemporary controls, average VT cycle 
length was determined during reperfusion with the solu­
tion at pH 7.4, 7.1, 6.8, 6.6, or 6.4. VT cycle length was 
determined after 15 seconds of reperfusion, because at 
this time a significant number of hearts (n=6-12) were in 
VT in each study group. VT cycle length was calculated 
from the number of QRS deflections over a 2-second 
interval using the ECG tracing.
Coronary flow and heart rate Throughout the exper­
imental protocol, coronary flow was monitored by the 
in-line flowmeters, and heart rate was determined from 
the ECG.
Size of ischemic zone. At the end of each experiment, 
the left coronary bed was perfused for 3 minutes with a 
solution containing 0.016% disulfine blue dye at 100 cm 
HzO perfusion pressure. The heart was then removed 
from the perfusion apparatus, the atria and mediastinal 
tissue were removed, and dye-stained tissue, represent­
ing ventricular myocardium subjected to ischemia and 
reperfusion, was carefully dissected away from the 
remainder. The stained and unstained tissues were 
lightly blotted and weighed. The size of the ischemic 
zone, expressed as a percentage of total ventricular 
weight, was calculated from the following equation: 
(weight of stained tissue/total ventricular weight) x 100.
Exclusion Criteria
Exclusion criteria for the present study, selected to 
minimize variations in heart rate and size of the isch­
emic zone (due to atypical coronary anatomy) among 
the hearts, were based on our previous experience14-17 
with the model. These criteria demanded that hearts 
were excluded if 1) heart rate was less than 280 or more 
than 420 beats per minute during the preischemic
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period, or 2) the size of the ischemic zone was found to 
be greater than 70% of total ventricular weight after the 
end of the experiment Hearts were also excluded if 
there was cross flow between the right and left coronary 
ostia. To verify whether significant cross flow occurred, 
the perfusion line to one bed was clamped for 10 
seconds at the beginning of each experiment. If flow to 
the contralateral bed increased by more than 10% of the 
preceding flow in the occluded bed, the heart was 
excluded from the study (because in the rat heart 
collateral flow alone could not have been responsible 
for such an increase18). In addition, hearts that exhib­
ited ventricular arrhythmias during the final 3 seconds 
of ischemia before reperfusion were not included in the 
analysis of reperfusion-induced arrhythmias, because in 
those hearts it would have been impossible to differen­
tiate arrhythmias induced by reperfusion from those 
induced by ischemia. Of 116 hearts entered into the 
study, four were excluded on the basis of heart rate, 10 
were excluded on the basis of the size of the ischemic 
zone, nine were excluded because of cross flow, and 
nine were excluded because of arrhythmias during the 
final 3 seconds of ischemia.
Data Analysis
The general approach to statistical analysis adopted 
the guidelines described by Wallenstein and col­
leagues.19 Gaussian-distributed variables were ex­
pressed as mean±SEM and were subjected to analysis 
of variance. If a difference among mean values was 
established with one-way analysis of variance, compar­
ison with controls was performed using Dunnett’s test 
Binomially distributed variables, such as the incidence 
of VT or VF, were compared using the x2 test for a 2xn  
table, followed by a sequence of 2x2 x2 tests with 




The objective of the present study was to assess the 
effects of interventions applied after ischemia on the 
incidence and severity of reperfusion-induced arrhyth­
mias. However, arrhythmias were also quantified in the 
preceding period of ischemia (during which time the 
composition of the perfusate was identical in all study 
groups) to confirm that all groups were, in fact, identical 
before the onset of reperfusion.
Stepwise restoration of extracellular pH. The incidence 
of VT during the 10-minute period of ischemia preced­
ing reperfusion was similar in both the control (92%) and 
the stepped-pH (100%) groups, and all episodes of VT 
were nonsustained. None of the hearts in either group 
exhibited ischemia-induced VF. There was no significant 
difference between the control and stepped-pH groups in 
the mean time to onset of ischemia-induced VT (520±13 
and 531 ±13 seconds, respectively) or in the mean total 
duration of nonsinus rhythm (consisting of ventricular 
premature beats and VT) during the 10-minute period of 
ischemia (25 ±6 and 24±5 seconds, respectively).
Transient acidic reperfusion. The incidences of VT 
during the 10-minute period of ischemia preceding 
reperfusion were 92%, 83%, 75%, 50%, and 67% in the 
control, pH 7.1, pH 6.8, pH 6.6, and pH 6.4 groups,
respectively (p=NS). Again, all episodes of VT were 
nonsustained, and none of the hearts in the five study 
groups exhibited ischemia-induced VF. There were no 
significant differences between control, pH 7.1, pH 6.8, 
pH 6.6, and pH 6.4 groups in the mean time to onset of 
ischemia-induced VT (534±12, 470±23, 536±15, 
487±15, and 536±16 seconds, respectively). The mean 
total duration of nonsinus rhythm (consisting of ventric­
ular premature beats and VT) during the 10-minute 
period of ischemia was less than 35 seconds in all 
groups.
Reperfusion-Induced Arrhythmias
Reperfusion of the ischemic region resulted in the 
rapid (within a few beats) induction of VT (Figure 3A) 
regardless of the pH of the reperfusion solution. Reper­
fusion-induced VT was generally polymorphic in nature 
(Figure 3A), and episodes of reperfusion-induced VT 
were uninterrupted (see Figures 4 and 5) until either 
spontaneous reversion to normal sinus rhythm or de­
generation into VF, as illustrated in Figures 3B and 3Q  
respectively.
Stepwise restoration of extracellular pH. Figure 4 shows 
the time course of reperfusion-induced arrhythmias in 
control hearts in which the left coronary bed was 
reperfused with solution at pH 7.4 throughout and in 
hearts in which the left coronary bed was subjected to a 
stepwise restoration of extracellular pH (stepped pH) 
by sequential perfusion with solutions at pH 6.6,6.8,7.1, 
and 7.4 during the reperfusion period. All hearts in both 
groups developed VT within the first 3 seconds of 
reperfusion. In all hearts in the control group, VT 
degenerated into VF within the first 30 seconds of 
reperfusion. In contrast, only 42% of hearts in the 
stepped-pH group exhibited VF during reperfusion 
(p<0.05). Among hearts that exhibited VF, the mean 
time to onset of VF was significantly prolonged from 
14±2 seconds in the control group (n=12) to 90±23 
seconds in the stepped-pH group (n—5). By the end of 
reperfusion, 92% of hearts in the stepped-pH group 
were in normal sinus rhythm compared with only 8% of 
hearts in the control group (p<0.05).
Transient acidic reperfusion. Figure 5 shows the time 
course of reperfusion-induced arrhythmias in control 
hearts in which the left coronary bed was reperfused 
with solution at pH 7.4 throughout and in hearts in 
which the left coronary bed was subjected to transient 
(2-minute) acidic reperfusion with the solution at pH
7.1, 6.8, 6.6, or 6.4. There was a 100% incidence of VT 
in all five groups. In the control group, VT degenerated 
into VF within the first 30 seconds of reperfusion in 
92% of the hearts; in the remaining heart, VT converted 
to sinus rhythm within 2 minutes of reperfusion. Tran­
sient acidic reperfusion resulted in a pH-dependent 
reduction in the incidence of VF (Figure 6), with 92%, 
83%, 42% (p<0.05), and 33% (p<0.05) of hearts 
exhibiting VF in the pH 7.1, 6.8, 6.6, and 6.4 groups, 
respectively. Among hearts that exhibited VF during 
reperfusion, the mean time to onset was significantly 
prolonged (Figure 6) from 14±1 seconds in the control 
group (n = ll)  to 55±22 seconds in the pH 6.8 group 
(n=10), 64±24 seconds in the pH 6.6 group (n=5), and 
190±42 seconds in the pH 6.4 group (/z=4). The mean 
time to onset of VF was not significantly different from 
the control value in the pH 7.1 group (18±2 seconds). In
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FIGURE 3. Representative electrocardiographic tracings illustrating the rapid induction and polymorphic nature o f reperfusion- 
induced VT  (panel A), spontaneous reversion o f reperfusion-induced VT to normal sinus rhythm (panel B), and degeneration of 
reperfusion-induced VT into VF (panel C). Arrows indicate the moments o f initiation/degeneration of arrhythmia or reversion to 
normal sinus rhythm. Chart speeds are shown on the horizontal lines above each panel.
control, pH 7.1, pH 6.8, pH 6.6, and pH 6.4 groups, 8%, 
25%, 58% (/?<0.05), 83% (p<0.05), and 67% (p<0.05) 
of hearts, respectively, were in normal sinus rhythm by 
the end of the reperfusion period.
V T  Cycle Length 
VT cycle length was measured in control hearts and 
those subjected to transient acidic reperfusion to deter­
mine whether it was affected by the pH of the initial 
reperfusion solution. As illustrated in Figure 7, acidic 
reperfusion resulted in a pH-dependent prolongation of 
VT cycle length at 15 seconds of reperfusion. VT cycle 
length at this time point was significantly greater in the 
two groups reperfused with solution at pH 6.6 or 6.4 
than in the control group reperfused with solution at pH
7.4. Mean VT cycle length at 15 seconds of reperfusion 
was also calculated for two subpopulations of hearts in 
which VT subsequently either reverted to normal sinus 
rhythm (n=20) or degenerated into VF (n=30). Mean 
VT cycle length was 67.5±3.2 msec in the former and 
52.1 ±1.8 msec in the latter subpopulations (p<0.05).
Coronary Flow, Heart Rate, and Size 
o f  Ischemic Zone 
Stepwise restoration o f extracellular pH. Preischemic 
flow was similar in control and stepped-pH groups in
both right (14.1 ±0.7 and 12.9±0.7 ml/min per gram, 
respectively) and left (10.9±0.5 and 10.8±0.7 ml/min 
per gram, respectively) coronary beds. During regional 
ischemia induced by cessation of flow to the left coro­
nary bed, flow in the right coronary bed did not change 
significantly (12.9±0.5 and 13.0±0.7 ml/min per gram 
after 9 minutes of ischemia in control and stepped-pH 
groups, respectively). During the first minute of reper­
fusion of the left coronary bed (at 100% of preischemic 
flow), flow in the right coronary bed increased in both 
control (19.5±0.7 ml/min per gram) and stepped-pH 
(16.5±0.8 ml/min per gram) groups. This increase in 
right coronary flow was maintained throughout reper­
fusion in the control group, with a flow of 17.6±0.9 
ml/min per gram recorded after 7 minutes of reperfu­
sion. In contrast, right coronary flow in the stepped-pH 
group reverted to the prereperfusion value within 3 
minutes of reperfusion (11.6±0.8 ml/min per gram).
The preischemic heart rate was similar in control and 
stepped-pH groups (323±7 and 324±6 beats per 
minute, respectively). Regional ischemia had no effect 
on heart rate, which was 320±11 beats per minute in the 
control group and 328±8 beats per minute in the 
stepped-pH group after 9 minutes of ischemia. Sinus 
heart rate could not be measured during early reper-
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FIGURE 4. Time course o f reperfusion-induced ventricular tachycardia and ventricular fibrillation in individual hearts in the 
control group and in the group in which the left coronary bed underwent stepwise restoration o f extracellular pH  (stepped-pH 
group). All hearts (n=12 per group) were subjected to 10 minutes of regional ischemia. Reperfusion began at time zero at the 
preischemic flow rate and was continued for 8 minutes. All hearts were in sinus rhythm at the moment of reperfusion. Open bars 
represent normal sinus rhythm, hatched bars represent ventricular tachycardia, and filled bars represent ventricular fibrillation. The 
hearts in each group are arranged in the order in which the experiments were carried out (the study was randomized).
fusion because of the almost immediate onset of VT 
and VF.
The size of the ischemic zone was similar in control 
and stepped-pH groups at 56±2% and 57±3% of the 
total ventricular weight, respectively.
Transient acidic reperfusion. Preischemic flow was 
similar in control, pH 7.1, pH 6.8, pH 6.6, and pH 6.4 
groups in both right (11.3±0.5, 12.9±0.8, 13.3±1.6, 
13.4±0.6, and 12.6±0.9 ml/min per gram, respectively) 
and left (11.2±1.2, 10.2±0.7, 9.7±0.5, 10.7±0.6, and
9.9 ±0.8 ml/min per gram, respectively) coronary beds. 
The time course of the changes in right coronary flow 
during regional ischemia and reperfusion are illustrated 
in Figure 8. During the first minute of reperfusion of the 
left coronary bed, flow in the right coronary bed in­
creased in all groups. This increase was maintained 
throughout reperfusion in the control and pH 7.1 
groups. In contrast, right coronary flow returned toward 
prereperfusion values within 3 minutes of reperfusion in 
the pH 6.8, pH 6.6, and pH 6.4 groups.
The preischemic heart rate was similar in control, pH
7.1, pH 6.8, pH 6.6, and pH 6.4 groups, at 323±10, 
334±10,326±12, 330±8, and 325±10 beats per minute, 
respectively. Regional ischemia had no effect on heart 
rate, and the corresponding values after 9 minutes of 
ischemia were 335±8, 333±10, 326±9, 320±12, and 
327±7 beats per minute, respectively. Sinus heart rate 
could again not be measured during early reperfusion 
because of the almost immediate onset of VT and VF.
The size of the ischemic zone was also similar in the 
control, pH 7.1, pH 6.8, pH 6.6, and pH 6.4 groups at
55±3%, 53±2%, 53±3%, 55±3%, and 51 ±2% of total 
ventricular weight, respectively.
Discussion
The results of the present study indicate that acidic 
reperfusion of the ischemic rat myocardium does not 
affect the incidence of reperfusion-induced VT but 
inhibits the degeneration of VT into VF and promotes 
spontaneous reversion to normal sinus rhythm. Within 
the pH range of 7.4-6.4, the protective effect appeared 
to be pH dependent, with the most significant protec­
tion obtained by initial reperfusion with solution at pH 
6.6 or 6.4. In these two groups, VT cycle length during 
early reperfusion was significantly prolonged relative to 
the control group. The protection afforded by acidic 
reperfusion was not associated with changes in antece­
dent variables such as heart rate, the size of the 
ischemic/reperfused zone, and the rate of reflow, be­
cause there were no differences between the groups in 
the former two variables and reperfusion of the left 
coronary bed was performed at 100% of preischemic 
flow in all cases.
Interestingly, initial acidic reperfusion with solution 
at pH 6.6 was equally protective regardless of whether 
the subsequent restoration of extracellular pH to 7.4 
occurred in an abrupt or a stepwise manner. Thus, 
although the results of the present study support a 
profibrillatory role for the rapid restoration of extracel­
lular pH, they also suggest that this effect is evident only 
when such restoration occurs within the first 2 minutes 
of reperfusion.
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F ig u r e  5. Time course o f reperfusion-induced ventricular tachycardia and ventricular fibrillation in individual hearts in the 
control group and in the groups in which the left coronary bed underwent transient acidic reperfusion with solution at pH 7.1, 6.8, 
6.6, or 6.4. All hearts (n=12 per group) were subjected to 10 minutes o f regional ischemia. Reperfusion began at time zero at the 
preischemic flow rate and was continued for 8 minutes. All hearts were in sinus rhythm at the moment o f reperfusion. Open bars 
represent normal sinus rhythm, hatched bars represent ventricular tachycardia, and filled bars represent ventricular fibrillation. The 
hearts in each group are arranged in the order in which the experiments were carried out (the study was randomized).
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FIGURE 6. Bar graphs showing the incidence o f reperfusion- 
induced ventricular fibrillation (VF) (n=12 per group, panel
A) and mean time to onset of VF among those hearts that 
exhibited reperfusion-induced VF (n=4—l l  per group, panel
B) in the control group and in the groups in which the left 
coronary bed underwent transient acidic reperfusion with 
solution at pH 7.1, 6.8, 6.6, or 6.4. *p<0.05 compared with 
the control group.
Possible Mechanisms o f  the Protective Effect 
o f  Acidic Reperfusion 
Role o f Na*-H* exchange. As noted earlier, the rapid 
washout during reperfusion of H+, accumulated in the 
extracellular space during the preceding period of isch­
emia,9 has been thought to result in Na+ influx via 
Na+-H+ exchange and consequently an increase in 
intracellular [Ca2+] via Na+-Ca exchange.10 Increased 
intracellular [Ca2+] (“Ca2+ overload”) on reperfusion 
has been implicated as a causal factor in several mani­
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FIGURE 7. Bar graph showing the mean ventricular tachy­
cardia (VT) cycle length at 15 seconds o f reperfusion (in those 
hearts that were in VT at that time, n=6-12 per group) in the 
control group and in the groups in which the left coronary bed 
underwent transient acidic reperfusion with solution at pH  
7.1, 6.8, 6.6, or 6.4. *p<0.05 compared with the control 
group.
and Bolli20). These include myocardial stunning21-22 and 
ventricular arrhythmias,6 the latter possibly occurring 
via the induction of oscillatory release of Ca2+ from the 
sarcoplasmic reticulum and the subsequent activation of 
the Ca2+-induced transient inward current.6-23 However, 
beat-to-beat measurements of calcium transients by Lee 
et al24 and Kihara et al25 in isolated hearts (using indo 
1 or aequorin, respectively) have not shown an in­
crease in intracellular [Ca2+] during reperfusion. In­
stead, intracellular [Ca2+] was shown to increase dur-
c r s 9 r y s t  
| ischemia || reperfusion
F ig u r e  8. Bar graphs showing the right coronary flow rate 
before regional ischemia (C), during regional ischemia in­
duced by cessation of flow in the left coronary bed, and during 
reperfusion of the left coronary bed at the preischemic flow 
rate in the control group and in the groups in which the left 
coronary bed underwent transient acidic reperfusion with 
solution at pH 7.1, 6.8, 6.6, or 6.4. *p<0.05 compared with 
the value after 9 minutes of ischemia (n=12 per group).
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ing ischemia but normalize on reperfusion. Although 
this appears to contradict a major role for Ca2+ 
overload in reperfusion-induced cardiac dysfunction, 
it should be noted that such dysfunction would not be 
expected to occur after the short durations of ischemia 
(up to 3 minutes) used in the studies of Lee et al24 and 
Kihara et al.25 Indeed, a more recent study by Kihara 
and Morgan,26 in a model identical to that used in 
their earlier study,25 has shown that reperfusion after 
20 minutes of ischemia results in a further increase in 
intracellular [Ca24] and that this is associated with 
transition into VF.
Other recent studies have supported a role for 
Na+-H+ exchange-mediated mechanisms in postreper- 
fusion Ca2+ overload and contractile dysfunction. Thus, 
inhibition of Na+-H+ exchange by amiloride or its 
analogues has been shown to attenuate reperfusion- 
induced Ca2+ overload11 and to improve functional 
recovery.11-27’28 Within the context of the present discus­
sion, amiloride analogues have also been shown to 
inhibit reperfusion-induced arrhythmias in both rat13 
and guinea pig29 hearts. Although acidic reperfusion has 
previously been shown to attenuate reperfusion- 
induced Ca24 overload12 and to improve postischemic 
recovery of function,30"33 the present study is the first to 
report the antifibrillatory efficacy of selective acidic 
reperfusion of the ischemic zone after a period of 
regional ischemia.
Vaughan-Jones and Wu34 have shown, in sheep Pur- 
kinje fibers, that H+ extrusion and Na+ influx via 
Na4-H4 exchange during recovery from any given intra­
cellular add load is inhibited by lowering extracellular 
pH. Assuming that in a preparation perfused with 
C02/HC03--buffered solution, as in the present study, 
intracellular pH would be reduced to approximately 6.6 
after 10 minutes of ischemia,35 certain estimates may be 
made on the basis of the findings of Vaughan-Jones and 
Wu.34 Thus, at an extracellular pH of 6.4-6.6 (i.e., the 
pH of the acidic solutions shown to exhibit the most 
significant antiarrhythmic efficacy in the present study), 
H+ extrusion and Na+ influx via Na4-H4 exchange 
would be expected to be inhibited to approximately 
20-25% of that at an extracellular pH of 7.4. Similar 
estimates may also be obtained on the basis of the 
reported sensitivity of the Na+-H+ exchanger to extra­
cellular pH in isolated rat myocytes.36
It should also be noted that Na+-Ca2+ exchange has 
been shown37 to be inhibited by low intracellular pH, 
with 50% inhibition at pH 6.7. Inhibition of Na+-H+ 
exchange by addic reperfusion would be expected not 
only to inhibit Na4 influx but also to maintain intracel­
lular addosis for a longer period during reperfusion, 
which may directly inhibit Na4-Ca24 exchange. Al­
though Na+-Ca2+ exchange largely mediates Ca2+ efflux 
under normal conditions, its reversal potential is readily 
attainable even under physiological conditions and is 
significantly affected by small changes in intracellular 
[Na4].38 Therefore, under conditions of increased intra­
cellular [Na4] and membrane depolarization, as may be 
prevalent during the early moments of reperfusion, 
Na4-Ca24 exchange may primarily mediate Ca2+ in­
flux,39-40 and its inhibition by maintained , intracellular 
addosis during early reperfusion may contribute to an 
attenuation of Ca24 overload.
In light of these observations, it is feasible to propose 
that the protective effect of addic reperfusion reported 
in the present study may result from an attenuation of 
Ca24 overload via Na4-Ca24 exchange that is due to 
reduced Na4 influx and maintained intracellular addo­
sis by inhibition of Na4-H4 exchange. If, however, the 
rapid washout of extracellular H4 and the subsequent 
influx of Na4 (with concomitant recovery from intracel­
lular addosis) is a major arrhythmogenic factor during 
reperfusion, two questions remain to be answered: 1) 
Why did addic reperfusion suppress the inddence of 
reperfusion-induced VF but not that of reperfusion- 
induced VT? 2) Why did the abrupt change to pH 7.4 
after transient (2-minute) acidic (pH 6.6 or 6.4) reper­
fusion seldom initiate de novo arrhythmias in those 
hearts that were in normal sinus rhythm at that time?
In relation to the first question, the recent studies of 
Kihara and Morgan26 in the intact ferret heart have 
shown that spontaneous transitions to VF do not occur 
unless a state of Ca24 overload is present and that 
diastolic Ca24 oscillations temporally precede such tran­
sitions. Kihara and Morgan concluded that impaired 
Ca24 homeostasis might be a crudal factor for the 
initiation of VF. In support of this, the recent studies of 
Thandroyen and colleagues41 in isolated spontaneously 
beating ventricular myocytes have led them to suggest 
that increased intracellular [Ca24] may be a causal 
factor in the degeneration of VT into VF. Therefore, it 
is possible that acidic reperfusion may preferentially 
inhibit the transition to VF by inhibition of Ca24 
overload and consequent Ca24 oscillations.
The answer to the second question is likely to be 
found in the extent of inhibition of sarcolemmal 
Na4,K4-ATPase activity by ischemia and the rate of its 
recovery during reperfusion. Components of ischemia 
such as acidosis, depletion of ATP, and accumulation of 
inorganic phosphate are known to inhibit Na4,K4- 
ATPase activity 42 as can free oxygen radicals.43 It has 
been proposed that, during the early moments of un­
controlled reperfusion, any Na4 entering the myocyte 
via Na4-H4 exchange cannot be extruded by Na4,K4- 
ATPase and exits via Na4-Ca24 exchange, with a con­
comitant rise in intracellular Ca24.44 Indeed, a recent 
study45 in isolated rabbit myocytes has shown that, 
during recovery from intracellular acidosis in the pres­
ence of partial inhibition of Na4 ,K+-ATPase, a large 
increase in intracellular Ca24 occurs and that this can be 
inhibited by inhibition of Na4-H4 exchange with an 
amiloride analogue. Other recent studies using pharma­
cological inhibition of Na4 ,K4-ATPase support a key 
role for the activity of this enzyme during reperfusion in 
determining not only the severity of postischemic con­
tractile dysfunction46 but also the incidence of reperfu- 
sion-induced VF.47 The period of acidic reperfusion 
with oxygenated perfusate used in the present study 
may allow sufficient recovery of Na4,K4-ATPase activ­
ity to enable the Na4 entering via Na4-H4 exchange 
during the subsequent abrupt return to pH 7.4 to be 
extruded by Na4 ,K+-ATPase rather than via Na4-Ca24 
exchange. Although Na4 ,K4-ATPase is inhibited by low 
pH, in the presence of optimal ATP and inorganic 
phosphate concentrations it retains approximately 82% 
of its maximal activity even at pH 6.5.42 Therefore, it is 
reasonable to propose that the absence of additional 
arrhythmias on switching the perfusion solution from
41
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pH 6.6 or 6.4 to pH 7.4 after 2 minutes of reperfusion 
may reflect significant recovery of Na+ ,K+-ATPase ac­
tivity by that time.
Role of prolongation ofVT cycle length. In the present 
study, the pH of the initial reperfusion solution did not 
influence the rapid induction of VT but had a significant 
effect on VT cycle length; this was prolonged with 
decreasing pH such that it was significantly greater at 
pH 6.6 and 6.4 than at pH 7.4. As noted earlier, the 
greatest reductions in the incidence of degeneration 
from VT into VF were also observed in the two groups 
initially reperfused with pH 6.6 or 6.4 solution. This may 
suggest a triggering role for rapid VT in the initiation of 
VF, which is suppressed by prolongation of VT cycle 
length. Indeed, in support of an important role for VT 
cycle length in determining vulnerability to VF, VT 
cycle length during early reperfusion was found to be 
significantly shorter in hearts in which VT subsequently 
degenerated into VF than in those in which VT subse­
quently reverted to normal sinus rhythm.
It is known48 that acidosis causes reductions in the 
maximum rate of rise of the action potential and 
conduction velocity and may also prolong action poten­
tial duration. Such effects-on action potential morphol­
ogy and propagation probably underlie the prolonga­
tion of VT cycle length by acidic reperfusion observed 
in the present study. In addition to imposing a further 
burden on the metabolic deficit from antecedent isch­
emia, rapid VT during early reperfusion may also result 
in a further increase in intracellular [Ca2+], thereby 
increasing the probability of degeneration into VF.41 
Therefore, it follows that slower VT during reperfusion 
with acidic solutions may allow enhanced metabolic and 
electrophysiological recovery and that this mechanism 
may contribute, at least in part, to the antifibrillatory 
efficacy of acidic reperfusion.
Role of differences in coronary flow. Although there 
were no significant differences between the groups in 
left coronary flow rate at any point during the experi­
mental protocol, there were differences in the profiles of 
right coronary flow rate during reperfusion of the left 
coronary bed at 100% of its preischemic flow rate 
(Figure 8). However, the intergroup differences in right 
coronary flow rate are unlikely to be causally related to 
the differences in the severity of reperfusion-induced 
arrhythmias. Rather, the differences in right coronary 
flow rate probably reflect the differences in the severity 
and duration of reperfusion-induced arrhythmias (Fig­
ure 5). Severe ventricular arrhythmias result in reduced 
extravascular compression (due to loss of coordinated 
contractile activity), which in turn may result in in­
creased flow in the zone not subjected to ischemia and 
reperfusion.14 Thus, although the right coronary flow 
rate was significantly elevated in all groups during the 
first minute of reperfusion, during which all hearts 
exhibited episodes of VT or VF (or both), by 3 minutes 
of reperfusion, flow had returned toward the prereper­
fusion value in those groups (pH 6.8, 6.6, and 6.4) in 
which a significant proportion of the hearts had reverted 
to normal sinus rhythm.
Other possible mechanisms. There are a number of 
other possible mechanisms by which the acidic reperfu­
sion procedure used in the present study may suppress 
reperfusion-induced VF. The acidic solutions used were 
obtained by lowering the HC03“ concentration of the
standard perfusion solution. It has recently been shown 
that recovery from an intracellular acid load in cardiac 
myocytes is mediated not only by Na+-H+ exchange but 
also by Na+-HC03~ cotransport49 a process that may 
also result in an elevated intracellular [Na+] in the 
presence of inhibited Na+,K+-ATPase activity. There­
fore, the protective effect observed in the present study 
may have been a property of the low [HC03_] rather 
than the high [H+] of the acidic reperfusion solution. 
However, our recent studies50 that showed acidic reper­
fusion to be equally protective in the absence of HC03“ 
would argue strongly against such a possibility. These 
studies also showed that reperfusion with solution at pH
7.4 was equally arrhythmogenic in the presence of either 
25 mmol/1 HC03~ (gassed with 5% C02) or 5 mmol/1 
HEPES as buffer, despite a much reduced buffering 
capacity in the latter case. Therefore, it is unlikely that 
the protective effect of acidic reperfusion (with low 
[HC03_] solutions) observed in the present study was 
due to the reduced buffering capacity of the reperfusion 
solutions.
Acidosis inhibits a number of membrane currents, 
including the slow inward Ca2+ current51 and the in­
wardly rectifying potassium current ( I r j ) . 52 The inhibi­
tion of the calcium current by acidic reperfusion, how­
ever, is unlikely to account for the antifibrillatory effect 
observed in the present study, because pharmacological 
inhibition of this current, when applied only during 
reperfusion, has been shown to be ineffective against 
reperfusion-induced arrhythmias.53’54 In contrast, inhi­
bition of the potassium current may well play a role in 
the protective effect of acidic reperfusion, because 
selective inhibition of this current by a novel pharma­
cological agent has recently been shown to abolish 
reperfusion-induced VF in the isolated rat heart.55 
Acidosis also inhibits the release of Ca2+ from the 
sarcoplasmic reticulum.56 As discussed earlier, oscilla­
tory release of Ca2+ from the sarcoplasmic reticulum 
has been implicated in reperfusion-induced arrhythmo­
genesis, and the inhibition of this process by acidic 
reperfusion may be expected to afford protection. In 
this context, it is worth noting that ryanodine, which 
also inhibits the release of Ca from the sarcoplasmic 
reticulum, has been shown to prevent the degeneration 
of VT into VF during reperfusion of the regionally 
ischemic rat heart.57
Relevance to the Mechanism of 
Reperfusion-induced Arrhythmias
Whereas the results of the present study indicate the 
rapid washout of extracellular H+ to be an important 
arrhythmogenic factor during early reperfusion, they do 
not preclude a significant role for other factors in reper­
fusion-induced arrhythmogenesis. Indeed, whereas 
acidic reperfusion significantly inhibited reperfusion-in­
duced VF, the incidence of reperfusion-induced VT 
remained at 100%, thus supporting the argument that 
multiple factors are involved. The recent study by Curtis5 
has demonstrated that the rapid washout of extracellular 
K+, in the absence of ischemia and reperfusion, is 
sufficient to produce ventricular arrhythmias. In addi­
tion, studies with free oxygen radical-generating and 
-scavenging systems3’4 suggest a causal role for free 
radicals in reperfusion-induced arrhythmias. In support 
of this, a burst of free radical production during early
42
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reperfusion has been demonstrated,2 and other studies 
have shown that reactive oxygen intermediates are suffi­
cient to generate ventricular arrhythmias in the absence 
of ischemia and reperfusion58-59 ahd to exacerbate reper­
fusion-induced arrhythmias.60
It is indeed possible that the induction of oxidant stress 
and the rapid washout of extracellular H+ on reperfusion 
may act in a synergistic manner to disrupt Ca2+ homeo­
stasis,61 with arrhythmogenic consequences. In this con­
text, oxidant stress has been shown to inhibit Na+,K+- 
ATPase activity,43 stimulate sarcolemmal Na+-Ca2+ 
exchange,62 and increase the open probability of the 
sarcoplasmic reticular Ca2+ release channel.63 In addition, 
the recent studies of Shattock and Matsuura64-65 have 
shown that reactive oxygen intermediates can induce 
arrhythmogenic oscillations in membrane potential, indic­
ative of intracellular Ca2+ overload, in both isolated ven­
tricular muscles64 and isolated myocytes.65
Limitations of the Study 
Although the present study supports a major role for 
the rapid washout of H+ in reperfusion arrhythmogen­
esis, it does not permit the delineation of the precise 
mechanism(s) by which maintained extracellular acido­
sis during early reperfusion exerts its protective effect. 
As discussed above, several possible mechanisms may 
be involved, and the role of each must be methodically 
examined before novel therapeutic approaches can be 
formulated. In addition, although the model used in the 
present study offers many advantages over conventional 
models14-17 and enables the use of groups of adequate 
size (because of the low cost of the preparation), the use 
of the rat heart (which has unusual electrophysiological 
characteristics, such as a short action potential duration 
and a high heart rate) may limit the applicability of the 
present findings to other species. While acknowledging 
this, it should be noted that the response of the rat heart 
to ischemia and reperfusion and to many protective 
interventions resembles that of other mammalian spe­
cies.66 Indeed, in preliminary studies using isolated 
rabbit hearts with dual coronary perfusion, we have 
made observations similar to those reported here in that 
transient acidic (pH 6.6) reperfusion of the ischemic 
bed did not significantly reduce the incidence of reper­
fusion-induced VT (six of eight versus eight of eight in 
control hearts) but reduced the incidence of reperfu­
sion-induced VF from eight of eight in control hearts to 
only one of eight (authors’ unpublished observations).
Concluding Comments 
The present study has shown that the selective reper­
fusion with acidic solutions of the ischemic rat myocar­
dium, after 10 minutes of regional ischemia, does not 
affect the rapid induction of VT but significantly sup­
presses the degeneration of VT into VF and promotes 
spontaneous reversion to normal sinus rhythm. This 
protective effect is observed in the absence of inter- 
group differences in the size of the ischemic zone, the 
rate of reflow, and oxygen tension of the perfusate. 
These findings are consistent with a major arrhyth­
mogenic role, during uncontrolled reperfusion, for the 
rapid washout of extracellular H+.
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Mechanisms of antifibrillatory effect of acidic 
reperfusion: role of perfusate bicarbonate concentration
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Ibuki, Chikao, David J. Hearse, and Metin Avkiran. 
Mechanisms of antifibrillatoiy effect of acidic reperfusion: role 
of perfusate bicarbonate concentration. Am. J. Physiol 264 
{Heart Circ. Physiol 33): H783-H790,: 1993.—Transient (2 
min) acidic (pH 6.6) reperfusion with low [HCOj] solution sup­
presses reperfusion-induced ventricular fibrillation (VF) in the 
isolated rat heart. Using this preparation, we tested whether the 
effect was mediated by the high [H+] or the low [HCOj] of 
perfusate. Left and right coronary beds were independently per­
fused with HCOj-containing (25.0 mmol/1) solution at pH 7.4. 
Regional ischemia was then induced by stopping flow to the left 
coronary bed for 10 min. Hearts were subsequently assigned to 
four groups (n = 12 hearts/group), and the left coronary bed was; 
reperfused with either HCOj-containing (25.0 or 4.0 mmol/1) or. 
HCOj-free (5.0 mmol/1 HEPES) solution, at pH 7.4 throughout' 
(control reperfusion) or at pH 6.6 for the first 2 min and at pH
7.4 from 2 to 5 min (acidic reperfusion). Regardless of the 
buffer, controls exhibited a high (92 and 100%) incidence of VF; 
this was reduced to 42% in both of the acidic reperfusion groups. 
(P < 0.05). There were no intergroup differences in heart rate,' 
coronary flow, or size of ischemic zone. Thus high [H+], rather 
than low [HCOj], appears to mediate the antifibrillatory effect 
of transient acidic reperfusion.
regional ischemia; dual coronary perfusion; reperfusion arrhyth­
mias; ventricular fibrillation; protons; buffering capacity
r e p e r f u s i o n  OF m y o c a r d iu m  subjected to a  transient 
period of regional ischemia can result in the rapid gen­
eration of severe ventricular arrhythmias (for review, see 
Ref. 25). Putative arrhythmogenic factors during reper­
fusion include the rapid washout of K+ from the extra­
cellular space (7), the generation of oxygen-derived free 
radicals (4. 38), and the accumulation of intracellular 
Ca2+ (31). Irrespective of the identity of the metabolic 
or ionic trigger, the fundamental question that remains 
to be resolved is whether the arrhythmogenic process is 
initiated by the washout of components accumulated 
during ischemia (e.g., K+) or by the resupply of compo­
nents depleted during ischemia (e.g., oxygen) (30). In 
this context, Yamada and colleagues demonstrated that 
the readmission of oxygen was not a  prerequisite for 
arrhythmogenesis (39), whereas a cycle of elevation and 
rapid normalization of extracellular K+ was sufficient to 
induce arrhythmias even in the absence of ischemia and 
reperfusion (7).
In addition to K+, protons (H+) also accumulate in 
the extracellular space during ischemia (16), and their 
rapid washout has been proposed to result in Na+ influx 
via Na+-H+ exchange with a subsequent increase in 
intracellular [Ca2+] via Na+-Ca2+ exchange (23). Post­
ischemic washout of extracellular H+ has been impli­
cated as a contributory factor, to several sequelae of re­
perfusion, including myocardial stunning (17, 27) and 
arrhythmias (10). In support of the latter, our recent 
studies (2,18) employing'acidic reperfusion have shown 
that limitation of the rate at which extracellular pH is 
restored during early reperfusion can reduce the inci- 
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dence . of reperfusion-induced - ventricular fibrillation 
(VF). The protective effect of acidic reperfusion was pH 
dependent over the range of 7.1-6.4, with;maximum 
-protection at pH 6.4 (18).:|.
; The acidic solutions employed in Jour .'Studies were;' 
prepared by reducing the bicarbonate (HCOj) content of 
a standard perfusion solution (metabolic acidosis), and ; 
as such the antifibrillatory effect might be attributable? 
to the reduction of [HCOj] rather than the elevation of i 
[H+] in the reperfusion solution. In addition, to the po- / 
tential antiarrhythmic effect of .reduced extracellular 
 ^buffering capacity (10), low [HCOj] may also limit.Na+
- influx during reperfusion by a mechanism independent 
of Na+-H+ exchange. Liu et al. (24), using cultured chick 
heart cells, have shown that in C02'HCOg-buffered me­
dia, recovery from intracellular acidosis is partly medi­
ated by a Cl“-HCOj exchange process, which is accom­
panied by Na+ influx. Observations consistent with this 
concept have also been made in sheep Purkinje fibers 
(9). Na+-dependent Cl“-HCOj exchange has been 
shown to be inhibited not only by the removal of extra­
cellular HCOj but also by the .application of stilbene 
derivatives (24). It is interesting to note that the stil­
bene derivatives 4-acetamido-4'-isothiocyanostilbene- 
2,2'-disulfonic acid (SITS) and 4,4'-diisothio-cyanostil- 
bene-2,2'-disufonic acid (DIDS) have both been shown 
to inhibit reperfusion-induced arrhythmias (5, 13), 
which might support a role for Cl”-HCOj exchange iq 
reperfusion arrhythmogenesis.
With the above observations in mind, the present 
study was designed to establish the relative contribu­
tions of perfusate [H+], [HCOj], and buffering capacity 
to the antifibrillatory effect of acidic reperfusion.
METHODS
Animals and Perfusion Technique
The investigation was performed in accordance with'the 
Home Office Guidance on the Operation of the Animals (Sci­
entific Procedures) Act 1986, published by Her Majesty’s Sta­
tionery Office (London, UK). Male Wistar rats (220-280 g body 
wt, Bantin and Kingman) were anesthetized with diethyl ether, 
and heparin sodium (200IU) was injected intravenously. Thirty 
seconds later, the heart was excised and immersed in perfusion 
solution at 4° C to induce rapid cardiac arrest. The aorta was 
then cannulated with a dual perfusion cannula, and right and 
left coronary arteries were perfused independently at constant 
perfusion pressure (100 cmH20), as described by Avkiran and 
Curtis (1) (Fig. 1). Each coronary bed was perfused with oxy­
genated perfusion solution from a temperature-regulated reser­
voir (37° C), and flow to each bed was continuously monitored 
using in-line flowmeters. Solution perfusing the left coronary 
bed could be changed, as required, by switching the inflow line 
between five reservoirs while still maintaining a constant per- 
_ fusion pressure. The heart was housed in a temperature-regu­
lated chamber kept at 37*C throughout the experiment. To 
maintain a stable sinus rate, the right atrium was continuously
1 the American Physiological Society H783
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reservoirs containing solutions lor 
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Fig. 1. Schematic illustration of perfu­
sion apparatus. Regional ischemia was 
induced by stopping flow to  left coronary 
bed. Subsequently, left coronary bed was 
selectively reperfused w ith one of 4 reper­
fusion solutions. R ight coronary bed was 
perfused with standard  perfusion solu­
tion  throughout experimental protocol. 
Inset, details of dual perfusion cannula.
superfused (5 ml/min) with oxygenated perfusion solution at 
37°C; this was necessary because the sinus node of the rat heart 
is not perfused by its coronary arteries (14).
Experimental Protocol
After 15 min of perfusion of both coronary beds with stan­
dard perfusion solution, regional ischemia was induced by halt­
ing perfusion of the left coronary bed. The right coronary bed 
continued to be perfused with standard perfusion solution at 
constant pressure throughout the experiment. Regional ische­
mia was maintained for 10 min, a duration that has been shown 
(15) to result in maximum vulnerability to reperfusion-induced 
VF in the isolated rat heart. At the end of the ischemic period, 
the hearts (n =  12 hearts/group) were randomly assigned to 
one of the four study groups (Fig. 2). The left coronary beds were 
then selectively reperfused with HCOj-containing or HCOj- 
free solutions at either pH 6.6 or 7.4, according to the protocol 
shown in Fig. 2 and as described below.
HCOj-containing groups. In these two groups of hearts, the 
left coronary bed was reperfused, with C02-HC0j-buffered so-
A
CONTROL REPERFUSION_______________________________________________________
I - PH 7.4
ACIDIC REPERFUSION




SH 6.6 pH 7.4
0 1 2 3 4 5
Duration ot reperfusion (min)
Fig. 2. Reperfusion protocols in 4 study groups (n  ■  12 hearts/group). 
After 10 min of regional ischemia (induced by stopping flow to  left 
coronary bed) ischemic bed was selectively reperfused for 5 min w ith 
H COj-containing solution (A) or HCOj-free solution (B).  W ithin each 
subset, one group o f hearts received acidic (pH 6.6) solution for the first 
2 min of reperfusion.
lution. In the control reperfusion group, the left coronary bed 
received the standard solution at pH 7.4 throughout 5 min of 
reperfusion. In the acidic reperfusion group, the left coronary 
bed received solution at pH 6.6 for the first 2 min of reperfusion 
followed by the standard solution at pH 7.4 from 2 to 5 min of 
reperfusion.
HCOj-free groups. In two further groups, the left coronary 
bed was reperfused with HCOj-free solution, which contained
5.0 mmol/1 of N- 2-hydroxyethylpiperazine-N1 -2 -ethanesulfonic 
acid (HEPES) as buffer. Again, in the control reperfusion group 
the left coronary bed received solution at pH 7.4 throughout 5 
min of reperfusion, whereas in the acidic reperfusion group the 
left coronary bed received solution at pH 6.6 for the first 2 min 
and solution at pH 7.4 from 2 to 5 min of reperfusion.
Composition of Perfusion Solutions
Standard perfusion solution contained (in mmol/1) 118.5 
NaCl, 25.0 NaHC03, 3.2 KC1, 1.2 MgS04, 1.2 KH2P 04, 1.4 
CaCl2, and 11.1 glucose. This solution was oxygenated and 
maintained at pH 7.4 by continuous gassing with 95% 0 2-5% 
C02. Acidic (pH 6.6) HCOj-containing solution was prepared 
by lowering the NaHC03 concentration to 4.0 mmol/1 while 
maintaining the same gassing mixture (95% 0 2-5% C02).
HCOj-free solutions had an identical composition to the 
HCOj-containing solutions except that NaHC03 was substi­
tuted by HEPES (5.0 mmol/1). HCOj-free solutions were gassed 
with 100% 0 2, and the pH was adjusted to either pH 7.4 or 6.6 
by the addition of small quantities of NaOH. [Na+] was kept 
constant (143 ±  2 mmol/1) in all solutions by modifying the 
NaCl content, as necessary. Before use, all solutions were fil­
tered through a membrane with 5-/xm pore size and [Na+], pH, 
and Po2 were measured (Nova Biomedical Statprofile).
Assessment of Buffering Capacity
To assess the relative buffering capacities of the HCOj- 
containing and HCOj-free control reperfusion solutions (pH 
7.4), titration curves were constructed as follows. The two so­
lutions were prepared as described previously and allowed to 
equilibrate with the appropriate gassing mixtures (95% Oj-5% 
C02 for the HCOj-containing solution and 100% 0 2 for the 
HCOj-free HEPES solution). To 1,000 ml of each solution,
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cumulative amounts of HC1 (1.0 mol/1 in 1-ml increments) were 
then added, and the pH of the solution was measured (Coming 
140 pH meter with Ag/AgCl glass combination electrode) at 
each stage.
Measured Variables
Arrhythmias. The presence of arrhythmias was determined 
from a unipolar electrogram, which was recorded using a silver 
electrode attached to the apex of the heart and a reference 
electrode connected to the aortic cannula. The electrogram was 
continuously monitored on a digital storage oscilloscope (Gould 
type 1421)- at 100 mm/s sweep speed to enable arrhythmia di­
agnosis. The electrogram was also recorded on an ink-jet re­
corder (Gould 2200S) at a chart speed of 2 mm/s. From a few 
seconds before reperfusion, the recorder chart speed was in­
creased to 50 mm/s to obtain a permanent high-speed recording 
of the initial phase of reperfusion-induced arrhythmias. The 
electrogram was retrospectively analyzed in a blinded manner, 
and the incidence and time-to-onset of ventricular tachycardia 
(VT) and VF were determined. Arrhythmias were defined 
in accordance with the Lambeth Conventions (35). Thus VT 
was defined as a run of four or more consecutive premature 
beats of ventricular origin, VF as an electrical signal with no 
recognizable QRS complex for which heart rate could not be 
determined, and sustained VF. as an episode of VF lasting for 
more than 120 s.
Heart rate and coronary flow. Throughout the experimental 
protocol, heart rate was determined from the electrogram, and 
flow to each coronary bed was monitored using the in-line flow­
meters attached to each perfusion reservoir.
Size of ischemic zone. At the end of the reperfusion period, the 
left coronary bed (i.e., the tissue mass that had been subjected to 
ischemia and reperfusion) was perfused at 100 cmH20 perfusion 
pressure for 3 min with a solution containing 0.016% wt/vol 
disulfine blue dye. The heart was then removed from the per­
fusion apparatus, the atria and mediastinal tissues were re­
moved, and the stained ventricular tissue was carefully dissected 
away from the unstained tissue. Both fractions were blotted and 
weighed, and the weight of the left coronary bed (i.e., the size of 
the ischemic zone) was expressed as a percent of total ventric­
ular weight.
■Exclusion Criteria
Exclusion criteria, based on our previous experience with this 
model (1, 19), were prospectively defined to minimize inter­
heart variation in heart rate and size of ischemic zone. Hearts 
were excluded if: 1) heart rate before ischemia was <280 or 
>420 beats/min, or 2) size of ischemic zone exceeded 70% of 
total ventricular weight. In addition, hearts were excluded if 
ventricular arrhythmias occurred dining the final 3 s of ische­
mia before reperfusion, as in those hearts it would be impossible 
to distinguish between reperfusion-induced and ischemia-in­
duced arrhythmias. Hearts were also excluded if there was sig-
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nificant cross-flow between right and left coronary ostia. To test 
whether this was occurring, the perfusion line to the left coro­
nary bed was clamped for 10 s at the beginning of each exper­
iment. If right coronary flow increased by >10% of the flow in 
the left coronary bed before clamping, the heart was excluded 
from the study. This criterion was based on the assumption that 
in the rat heart collateral flow alone could, not have been re­
sponsible for such an increase (26).
Of a total of 61 hearts entered into this study, 3 were excluded 
based on heart rate, 4 on size of ischemic zone, 4 on account of 
arrhythmias during the final 3 s of ischemia, and 2 on account 
of cross-flow. When a heart was excluded, it was immediately 
replaced according to the randomization table. T' :
Data Analysis
The general approach to statistical analysis was based on the 
guidelines described by Wallenstein et al. (36). Gaussian-dis- 
tributed variables were expressed as means ± SE and subjected 
to an analysis of variance. .If a difference among mean values 
was established with one-way analysis of variance, intergroup 
comparisons were performed using Tukey’s test. Variables that 
were not Gaussian-distributed (such as time-to-onset of VF) 
were log10 transformed before parametric statistical testing as 
described above. Binomially distributed variables, such as the 
incidences of VT and VF, were compared using the chi-squared 
test for a 2 x 4 table followed by a sequence of 2 x 2 chi-squared 
tests with Yates’ correction. Temporal changes in coronary flow 
and heart rate were assessed by the paired t test. A probability 
of <0.05 (P <  0.05) was considered significant.
RESULTS .
The objective of the present study was to assess the 
effects of various interventions (applied after ischemia) 
on the incidence of reperfusion-induced arrhythmias. 
However, arrhythmias were also quantified in the preced­
ing period of ischemia (during which time the composi­
tion of the perfusate was identical in all study groups) to 
confirm that all groups were in fact identical before the 
onset of reperfusion. This was confirmed by the data 
shown in Table 1, which illustrate that there were no 
significant differences among the four study groups in the 
time-to-onset, incidence, or severity of ischemia-induced 
arrhythmias.
Reperfusion-induced Ventricular Arrhythmias
HCOl-containing groups. The time course of reperfu­
sion-induced ventricular arrhythmias in individual hearts 
is illustrated in Fig. 3A. Almost immediately on reperfu­
sion all hearts developed VT. In 11 of 12 hearts (92%) in 
the control group (pH 7.4 throughout reperfusion), VT 
degenerated into VF within 35 s of reperfusion, and all
Table 1. Incidence, time-to-onset, and duration of arrhythmias during 10-min period of regional ischemia
Incidence Mean Time-to-Onset, s
Mean Duration of 









Control reperfusion 11/12 (92%) 0/12 (0%) 493±19 30±13
Acidic reperfusion 8/12 (67%) 1/12 (8%) 5182:13 473* 16±6
HCOj free 
Control reperfusion 7/12 (58%) 0/12 (0%) 522±17 13±4
Acidic reperfusion 9/12 (75%) 0/12 (0%) 524±25 13±4
Values are means ±  SE; n, 12 hearts/group. * Only 1 heart exhibited ventricular fibrillation.
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Fig. 3. Time course for arrhythmias during 5 min of reperfusion in 
groups reperfused with HCOj-containing solution (A) or HCOj-free 
solution (B). Each horizontal bar represents an individual heart (rt = 12 
hearts/group). Reperfusion was initiated at time 0, at which moment all 
hearts were in sinus rhythm. Hatched areas, ventricular tachycardia; 
solid areas, VF; open areas, sinus rhythm.
episodes of VF were sustained (>120 s). In the acidic 
reperfusion group, only five hearts (42%) exhibited VF 
during reperfusion (P <  0.05), and in four of these the 
arrhythmia reverted to a stable sinus rhythm within 90 s 
of its initiation. In those hearts that exhibited VF during 
reperfusion, the time-to-onset in the acidic reperfusion 
group (72 ±  7 s) was significantly prolonged compared 
with that in the control reperfusion group (16 ±  2 s).
In the acidic reperfusion group, eight hearts were not in 
VF at the end of the 2-min period of acidic reperfusion; 
none of these hearts exhibited de novo episodes of VF 
following the switch to perfusion with solution at pH 7.4.
HCOj-free groups. In the groups that were reperfused 
with HCOj-free solution, the pattern of arrhythmias was 
similar to that observed in the groups reperfused with 
HCOj-containing solution (Fig. SB). Almost immedi­
ately on reperfusion, all of the hearts in the control (pH 
7.4) reperfusion group and 92% of the hearts in the acidic 
reperfusion group developed VT. In the control reperfu-. 
sion group, 100% of hearts exhibited VF during reperfu­
sion, and in 10 of 12 hearts (83%) this was sustained 
(>120 s). In contrast, in the acidic reperfusion group, only 
5 of 12 hearts (42%) exhibited reperfusion-induced VF 
(P <  0.05), which was sustained in only one heart (P <  
0.05). The time-to-onset of VF in the control reperfusion 
group receiving HCOj-free solution (45 ±  14 s) tended to 
be delayed relative to the control reperfusion group re­
ceiving HCOj-containing solution (16 ±  2 s). Transient 
acidic reperfusion tended to produce a further delay in the 
time-to-onset of VF (87 ±  22 s), but this effect did not 
achieve a level of statistical significance.
In the acidic reperfusion group, only 2 of 9 hearts that 
were not in VF at the time of switching the perfusion 
solution from pH 6.6 to 7.4 subsequently exhibited de 
novo episodes of VF.
Heart Rate, Coronary Flow, and Size of Ischemic Zone
HCOj-containing groups. Before ischemia, heart rate 
was 326 ± 6 beats/min in the control (pH 7.4) reperfusion 
group and 333 ±  8 beats/min in the acidic reperfusion 
group (NS). Heart rate did not change significantly dur­
ing the subsequent period of ischemia, and after 9 min of 
ischemia the heart rates were 334 ± 1 1  and 319 ±  13 
beats/min in the control and acidic reperfusion groups, 
respectively. Mean heart rate could not be determined 
during reperfusion due to the high incidence of VT 
and VF.
Right and left coronary flows during the experimental 
protocol are shown in Table 2. Before ischemia, right and 
left coronary flows were similar in the two groups. Right 
coronary flow did not change significantly in either group 
during the 10-min period of regional ischemia in the left
Table 2. Right and left coronary flows before and during regional ischemia and during reperfusion
Coronary
Bed
Coronary Flow, ml-min-1•g wet wt-1
Group Before During ischemia During reperfusion
ischemia 1 min * 5 min 9 min 1 min 3 min 5 min
HCOj containing
Control reperfusion Right 10.2+0.7 10.7±0.8 10.2±0.7 10.1±0.8 16.4±1.5t 15.1±1.2t 14.8±1.4t
Left 11.6+0.6 0 0 0 24.4+2.5t 24.8±2.7f 24.5+2.2t
Acidic reperfusion Right 11.4±0.9 11.5+0.9 11.0+0.9 11.0±1.3 15.4±1.6t 10.3±0.9* 10.4±1.0*
Left 12.1±0.6 0 0 0 22.3±1^| 26.3+0.8t 24.1±0.8t
HCOj free
Control reperfusion Right 11.2±0.7 11.7+0.8 10.9±0.8 11.2±1.0 18.4+1.If 15.3±1.3t 13.4±1.7
Left 12.4±0.9 0 0 0 24.4±2.0f 23.7±1.7t 24.8±1.7t
Acidic reperfusion Right 10.8±0.4 11.2±0.5 10.7+0.5 10.8±0.5 13.1 + 1.1 10.9+1.3* 9.2±1.3*
Left 11.1+0.4 0 0 0 20.1±2.6t 26.1±1.6t 26.4±0.9t
Values are means + SE; n, 12 hearts/group. * P  < 0.05 vs. corresponding control reperfusion group; t P < 0.05 vs. before ischemia.
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coronary bed. On reperfusion, coronary flow increased to 
rates significantly greater than the preischemic values in 
both left and right coronary beds, with the increase in the 
left being substantially greater than that in the right. Left 
coronary flow remained significantly elevated throughout 
the 5 min of reperfusion in both groups. Right coronary 
flow also remained elevated in the control reperfusion 
group but returned toward prereperfusion values within 3 
min in the acidic reperfusion group.
Total ventricular wet weights were 0.70 ±  0.02 and 0.71 
± 0.02 g, and sizes of the ischemic zone were 54 ±  3 and 
53 ±  3% in the control and acidic reperfusion groups, 
respectively (NS).
HCOj-free groups. Before ischemia, heart rate was 
similar in the control and acidic reperfusion groups (332 
± 8 and 328 ±  9 beats/min, respectively). Regional ische­
mia had no significant effect on heart rate which, after 9 
min of ischemia, was 327 ±  10 beats/min in the control 
(pH 7.4) reperfusion group and 319 ±  13 beats/min in the 
acidic reperfusion group. Again, mean heart rate could 
not be determined during reperfusion due to VT and VF.
Right and left coronary flows were similar in the two 
groups before ischemia (Table 2). Right coronary flow did 
not change significantly in either group during regional 
ischemia. Coronary flow increased significantly in both 
beds on reperfusion, and left coronary flow remained 
elevated throughout the 5-min reperfusion period in both 
groups. Right coronary flow returned to the prereperfu- 
sion value within 3 min of reperfusion in the acidic re­
perfusion group, while it remained elevated in the control 
reperfusion group.
Total ventricular wet weights were 0.72 ±  0.01 and 0.71 
±  0.02 g in the control and acidic reperfusion groups, 
respectively (NS); there was no significant difference in 
size of the ischemic zone between the two groups (50 ±  3 
vs. 50 ±  2%).
Buffering Capacity of HCOj-Containing 
and HCOj-Free Solutions
Figure 4 shows the titration curves for the HCOj- 
containing and HCOj-free solutions, which both had an 
initial pH of 7.4. As illustrated by the different slopes of 
the curves, the buffering capacity of the HCOj-con­
taining solution was substantially greater than that of the 
HCOj-free solution containing HEPES as buffer.
D I S C U S S I O N
Two conclusions can be drawn from the data presented 
in this study. First, reperfusion at pH 7.4 with HCOj- 
free HEPES solution had no significant effect on the 
severity of reperfusion-induced arrhythmias relative to 
reperfusion with a HCOj-containing solution of the same 
pH, despite the vastly different buffering capacities of the 
two solutions. Second, acidic reperfusion resulted in a 
significant antifibrillatory effect regardless of the pres­
ence or absence of HCOj. These observations were made 
in preparations with no intergroup differences in vari­
ables such as heart rate, coronary flow, and size of 
ischemic zone, any one of which might influence the 
severity of reperfusion-induced arrhythmias. It appears 




Fig. 4. T itra tion  curves for H COj-containing (open circles) and 
HCOj-free (solid circles) perfusion solutions. Latter contained 5 mmol/1 
H EPES as buffer. T o 1,000 ml of each solution (initially adjusted to pH 
7.4, see te rt)  cumulative amounts of HC1 were added (1 mol/1 in 1-ml 
increments), and  pH  was measured a t each stage. B oth solutions were 
continuously gassed w ith appropriate mixture (95% 0 2-5% C 0 2 for 
H C O j-containing solution and 100% 0 2 for HCOj-free solution).
plays the pivotal role in the antiarrhythmic effect of tran­
sient metabolic acidosis during early reperfusion.
Possible Mechanisms of Antiarrhythmic Effect 
of Transient Metabolic Acidosis
Role of extracellular buffering capacity. Dennis and col­
leagues (10) have demonstrated a positive association be­
tween the buffering capacity of a reperfusion solution and 
the duration of reperfusion-induced arrhythmias. They 
argued that this reflected the effect of extracellular buff­
ering on sarcolemmal Na+-H+ exchange. However, our 
data suggest that in the present model the buffering ca­
pacity of the reperfusion solution is not a critical deter­
minant of the severity of reperfusion-induced arrhyth­
mias. Although there is apparent disagreement between 
the two studies, there are also several potentially impor­
tant differences in methodology.
First, whereas Dennis et al. (10) used 15 min of global, 
low-flow ischemia, we subjected our hearts to 10 min of 
regional, zero-flow ischemia. The severity of ischemia- 
induced acidosis and thus the consequences of subsequent 
reperfusion at pH 7.4 are likely to differ under low-flow 
and zero-flow conditions.' In support of this, compari­
son of the results for hearts from both studies that 
were subjected to reperfusion with solutions containing 
HEPES (5 mmol/1, pH 7.4) shows that the mean total 
duration pf nonsinus rhythm (expressed as a percentage 
of the total duration of reperfusion) was 83 ±  8% in the 
present study and only 34 ±  4% in the study by Dennis 
et al. (10), despite the greater mass of ischemic-reperfused 
tissue in the latter.
The second point to consider is that Dennis et al. (10) 
did not report the incidences of VT and VF in their 
various study groups; thus it is not clear which type of 
arrhythmia was influenced by the buffering capacity of 
the perfusate. In this context, it is noteworthy that in 
both our present and our previous (2,18) studies only the 
incidence of VF, but not that of VT, was influenced by 
the pH of the reperfusion solution.
Finally, the higher concentrations of HEPES (15-50 
mmol/1) used by Dennis et al. (10) were in excess of those 
normally used in physiological solutions for isolated heart
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| studies (e.g., Refs. 22 , 28, and 29). The possibility cannot
! be excluded that at these high concentrations, HEPES
might itself have a direct arrhythmogenic effect on the 
 ^ myocardium. Indeed, there is some evidence (3) that
HEPES may influence the electrical and mechanical ac­
tivities of ventricular muscle in a manner that is inde­
pendent of its properties as a buffer.
Role of Cl~-HCOj exchange. In the presence of C02- 
HCOj, the recovery of intracellular pH from acidosis is 
mediated not only by Na+-H+'exchange but also by a 
Na+-dependent, Cl~-HCOj exchange process (9, 24). As 
proposed earlier, it is possible that the antiarrhythmic 
effect of transient metabolic acidosis during early reper­
fusion (18) may be mediated by inhibition of Cl“- 
HCO3 exchange as a consequence of the low extracellular 
[HCOj]. However, the present study has demonstrated 
that transient acidic reperfusion is protective regardless 
of the presence or absence of HCOj in the perfusate, an 
observation that would argue against such a possibility. 
Indeed, the high incidence of reperfusion-induced VT and 
VF in the hearts reperfused with HCOj-free solution at 
pH 7.4 suggests that Cl“-HCOj exchange may be unim- 
' portant in the genesis of reperfusion arrhythmias. Al­
though this might appear to contradict the studies of 
Curtis and colleagues (5, 13) in which the Cl“-HCOj 
exchange inhibitors SITS and DIDS were shown to in­
hibit the genesis of reperfusion-induced arrhythmias, the 
same group subsequently suggested (6) that SITS may 
! exert an antiarrhythmic action through a reduction in
| ventricular excitability, an effect that might reflect some
nonspecific action of the compound rather than its ability 
| to influence Cl“-HCOj exchange. These observations
suggest that, at least in the present experimental model, 
inhibition of Na+-dependent Cl“-HCOj exchange does 
not contribute to the suppression of reperfusion-induced 
arrhythmias by transient metabolic acidosis. Rather, 
they indicate that the [H+] of the reperfusion solution is 
a more likely candidate for the role of primary determi- 
| nant of the severity of reperfusion-induced arrhythmias.
; Role of Na+-H+ exchange. Several studies in the past 
few years, which used pharmacological inhibitors of sar- 
colemmal Na+-H+ exchange, have supported a role for 
this exchange process in postischemic calcium overload 
i  (27,32), contractile dysfunction (21,28,32), and arrhyth­
mias (10). We propose that the inhibition of Na+-H+ 
exchange is also a likely contributor to the antiarrhyth­
mic effect of high extracellular [H+] during early 
reperfusion.
Vaughan-Jones and Wu (34) have demonstrated in 
sheep Purkinje fibers that H+ extrusion and Na+ influx 
via Na+-H+ exchange during recovery from intracellular 
acidosis is inhibited by high extracellular [H+]. Similar 
observations have also been made in isolated rat myo­
cytes (37). It is therefore highly probable that sarcolem- 
mal Na+-H+ exchange was significantly inhibited during 
reperfusion at pH 6.6 in the present study. As proposed 
by Lazdunski et al. (23), during uncontrolled reperfusion 
the rapid washout of the extracellular H+ may result in 
Na+ influx via Na+-H+ exchange with a consequent in­
crease in intracellular [Ca2+] via Na+-Ca2+ exchange, 
j  Such an increase in intracellular [Ca2+] (“Ca2+ overload”)
has been proposed as a mediator of reperfusion-induced 
arrhythmias, probably via the induction of oscillatory 
release of Ca2+ from the sarcoplasmic reticulum and sub­
sequent delayed afterdepolarizations (31). It is conceiv­
able therefore that the antiarrhythmic effect of acidic 
reperfusion may result from the inhibition of Na+ influx 
via Na+-H+ exchange and the consequent inhibition of 
Ca2+ overload. It should be noted, however, that the in­
hibition of Na+-H+ exchange would inhibit not only Na+ 
influx but also H+ extrusion, which itself may influence 
vulnerability to arrhythmias by maintaining intracellular 
acidosis during early reperfusion.
Role of maintained intracellular and extracellular acido­
sis. Many cellular mechanisms that regulate ion move­
ments are known to be pH sensitive, and their inhibition 
by maintained intracellular. and extracellular acidosis 
during the acidic reperfusion period might contribute to . 
the protective effects observed. Such pH-sensitive ion 
transport mechanisms include the slow inward Ca2+ cur­
rent (20), the fast inward Na+ current (40), and the in­
wardly rectifying K+ current (11). Intracellular acidosis 
has also been shown (12) to inhibit the release of Ca2+ 
from the sarcoplasmic reticulum and, as previously dis­
cussed, oscillatory release of Ca2+ from the sarcoplasmic 
reticulum has been implicated (31) in the genesis of rep­
erfusion-induced arrhythmias. In this context, ryanodine, 
an inhibitor of Ca2+ release from the sarcoplasmic re­
ticulum, has also been shown to suppress .reperfusion- 
induced'arrhythmias (33).
Role of coronary flow during reperfusion. In the present 
study, there was a large increase in left coronary flow on 
reperfusion that was maintained throughout the 5-min 
period of reperfusion in all groups. There were no signif­
icant differences in the magnitude of the hyperemic re­
sponse between control and acidic reperfusion groups. 
However, there were differences between control and 
acidic reperfusion groups in the temporal profiles for 
right coronary flow during reperfusion of the left coronary 
bed, which probably reflected the differences between the 
groups in the severity and duration of reperfusion-in­
duced arrhythmias. Severe ventricular arrhythmias re­
duce extravascular compression, which in turn allows cor­
onary flow to increase even in the bed not subjected to 
ischemia and reperfusion (1). Thus although right coro­
nary flow was significantly elevated in all groups during 
the first minute of reperfusion (during which all hearts 
exhibited episodes of VT and/or VF), in acidic reperfu­
sion grofups it had fallen to prereperfirsion values after 3 
min of reperfusion, by which time a significant propor­
tion of the hearts had reverted to sinus rhythm.
Limitations and Advantages of Present Model
The major limitation of the present study may be the 
use of crystalloid perfusion, which results in coronary 
flows in excess of those encountered in vivo. Such high 
flows may result in faster washout during reperfusion of 
components (such as H+ and K+) that have accumulated 
during the preceding period of ischemia, which in turn 
may lead to an overestimation of the role of washout in 
reperfusion arrhythmogenesis. Although our recent stud­
ies (19) suggest that the rate of reflow may not be a major
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factor in determining vulnerability to reperfusion-in­
duced arrhythmias, it would be of interest to discover the 
antiarrhythmic efficacy of acidic reperfusion in prepara- 
.. tions with more physiological coronary flows.
It may also be argued that the use of the rat heart, 
which has unusual electrophysiological characteristics 
(such as a short action potential duration and a high 
I heart rate), may limit the applicability of the present
findings to other species. With this acknowledgment, it 
, must be pointed out that in terms of arrhythmogenesis
j  the response of the rat heart to ischemia and reperfusion 
resembles that of other species (8). In addition, the model 
| employed in the present study offers many advantages
(1), such as the consistent generation of regional ischemia 
and arrhythmias, the ability to use groups of adequate 
size (due to the low cost of the preparation), and the 
ability to reperfuse the ischemic zone selectively with 
modified solutions.
In conclusion, the present study has confirmed that 
transient (2 min) acidic (pH 6 .6) reperfusion results in a 
significant reduction in the incidence and duration of 
reperfusion-induced VF. This protective effect occurs re­
gardless of the presence or absence of HCOj in the reper­
fusion solution, and our results provide evidence to sug­
gest that it is the [H+] of the reperfusion solution, rather 
than its buffering capacity, that is the primary determi- 
! nant of the severity of reperfusion-induced arrhythmias,
j The likely mechanism of the protective effect of high
extracellular [H+] during early reperfusion appears to be 
the inhibition of sarcolemmal Na+-H+ exchange and the 
consequent inhibition of Na+ influx and H+ efflux, either 
or both of which may result in a reduced vulnerability to 
VF.
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Effects of acidic reperfusion on arrhythmias and 
Na+-K+-ATPase activity in regionally ischemic rat hearts
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Avkiran, Metin, CMkao Ibuki, Yasuyuki Shimada, 
and Peter S. Haddock. Effects of acidic reperfusion on 
arrhythmias and Na+-K+-ATPase activity in regionally isch­
emic rat hearts. Am. J. Physiol. 270 (Heart Circ. Physiol. 39): 
H957—H964,1996.—We studied the effects of acidic reperfu­
sion on 1) the incidence of ventricular fibrillation (VF) and 2) 
sarcolemmal Na+-K+-adenoBinetriphosphatase (ATPase) ac­
tivity. Isolated rat hearts (n = 12/group) were subjected to 
independent perfusion (15 min) of left and right coronary 
beds with pH 7.4 buffer followed by zero-flow ischemia (10 
min) of the former bed. This was then reperfused for 5 min, 
with acidic (pH 6.6) buffer for the first 0 (control), 0.5,1,2, or 4 
min and with pH 7.4 buffer thereafter. In the control group, 
92% of hearts developed VF within 20 s of reperfusion and 
remained in VF. In the 0.5-, 1-, 2-, and 4-min acidic reperfu­
sion groups, only 17,17, 42, and 25% of hearts (P < 0.05 vs. 
control for all groups), respectively, exhibited VF during 
acidic reperfusion. However, on switching to pH 7.4, VF 
occurred in a further 50,58,0, and 0% of hearts, respectively; 
thus the overall incidences of VF were 67,75,42 (P < 0.05 vs. 
control), and 25% (P < 0.05 vs. control), respectively. Addi­
tional hearts (n = 8/group) were used for cytochexnical 
determination of sarcolemmal Na+-K+ -ATPase activity in 
both the ischemic/reperfused left ventricular (LV) and the 
nonischemic right ventricular (RV) free walls. Ischemia (10 
min) reduced LV Na+-K+-ATPase activity from 110 ± 8 to 
25 ±  3% of the RV value. After 0.5,1,2,3, and 4 min of acidic 
reperfusion, LV Na+-K+-ATPase activity was 24 ± 3, 29 ± 3, 
37 ±  5t, 55 ± 6t, and 70 ± 4t, respectively (fP < 0.05 vs. 
10-min ischemia). No significant recovery of LV Na+-K+- 
ATPase activity occurred following up to 4 min of pH 7.4 
reperfusion. In conclusion, 1) at least 2 min of acidic reperfu­
sion is required to achieve sustained protection against VF 
and 2) the protective mechanism may involve enhanced 
recovery of Na+-K+-ATPase activity as well as inhibition of 
Na+ influx.
regional ischemia; reperfusion arrhythmias; intracellular 
sodium; sodium/hydrogen exchange; sodium/bicarbonate sym- 
port; sodium-potassium-adenosinetriphosphatase
lazdunski ET a l . (16) were the first to suggest that the 
rapid washout of extracellular H+ on reperfusion of 
ischemic myocardium may create an intracellular-to- 
extracellular H+ gradient, resulting in Na+ influx 
coupled to H+ extrusion via the Na+/H+ exchanger. 
Recent evidence (33) suggests that, during reperfusion, 
Na+ influx coupled to H+ extrusion may occur also 
through the Na+/HCOg symporter. Such an influx of 
Na+ could result in an increased intracellular Na+ 
concentration ([Na+]j) which, in turn, would favor an 
increase in [Ca2+]i via the Na+/Ca2+ exchanger (16,30). 
An increase in [Ca2+]j on reperfusion {that can be 
ameliorated by the Na+/H+-exchange inhibitor amilo­
ride (31) or by acidic reperfusion (21)} has been demon­
strated in experimental studies and implicated as a 
mediator of postischemic contractile dysfunction (31).
Ca2+ overload via Na+/H+ and Na+/Ca2+ exchange- 
mediated mechanisms has also been proposed as an 
important trigger for reperfusion arrhythmogenesis 
(7). In support of this, modulation of the activity of the 
Na+/H+ exchanger in isolated hearts through the use of 
solutions of reduced buffering capacity (7) or pharmaco­
logical inhibitors {such as amiloride and its analogues 
(7,28,37) or the novel compound HOE 694 (27,37)] has 
been shown to significantly attenuate the severity of 
reperfusion-induced arrhythmias. Our recent studies 
in the isolated rat heart (3, 12) have shown that 
limiting the rate of normalization of extracellular pH 
during early reperfusion, by transient (2 min) acidic 
reperfusion, significantly suppresses the induction of 
ventricular fibrillation (VF). The protection afforded by 
acidic reperfusion was maximal at pH 6 .6 , and the 
abrupt restoration of extracellular pH to 7.4 after 2 min 
of acidic reperfusion did not initiate new episodes of VF 
(3). However, the m in im u m  duration of acidic reperfu­
sion required to achieve such sustained protection 
against VF remains unknown.
Intracellular Na+ homeostasis is maintained largely 
through Na+ extrusion by the sarcolemmal Na+-K+ 
pump, the biochemical correlate of which is the sarco­
lemmal Na+-K+-ATPase. In a number of experimental 
models, Na+ in flu x  during recovery from intracellular 
acidosis has been shown to result in the activation of 
electrogenic Na+ pumping by Na+-K+-ATPase (23, 24) 
that would oppose an increase in [Na+li- However, 
during recovery from intracellular acidosis in the pres­
ence of low extracellular [K+] or ouabain (both of which 
inhibit Na+-K+-ATPase activity) there is a large in­
crease in [Na+]i (1, 19). This is thought to occur via 
Na+/H+ exchange (1) and is associated with an increase 
in [Ca2+]i via Na+/Ca2+ exchange (1,19). It is possible 
therefore that during reperfusion also the magnitude of 
any increase in [Ca2+]i and its unfavorable sequelae 
would depend largely on sarcolemmal Na+-K+-ATPase 
activity. Indeed, recent studies employing pharmacologi­
cal inhibitors of Na+-K+-ATPase have supported a key 
role for the activity of this enzyme during reperfusion 
in determining not only the severity of postischemic 
contractile dysfunction (18) but also the incidence of 
reperfusion-induced VF (32).
From the above, we hypothesized that if the induc­
tion of VF during uncontrolled reperfusion (3,12) was 
initiated by Na+ influx coupled to H+ extrusion and 
consequent Ca2+ overload, then the period of regional 
ischemia employed (10 m in ) must be sufficient to result 
in a significant inhibition of sarcolemmal Na+-K+- 
ATPase activity. Furthermore, there must be a pro gres-
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sive recovery of Na+-K+-ATPase activity during acidic 
reperfusion which, if maintained for a sufficient period, 
would result in reduced susceptibility to VF even after 
a subsequent abrupt normalization of extracellular pH, 
thus providing sustained protection. To determine 
whether a correlation exists between Na+-K+-ATPase 
activity at the moment of the abrupt increase in 
extracellular pH and the likelihood of developing VF 
subsequent to the pH change, we used isolated rat 
hearts subjected to independent perfusion of the left 
and right coronary beds together with a cytochemical 
assay for the in situ measurement of sarcolemmal 
Na+-K+-ATPase activity. In two parallel studies, we 
subjected hearts to 10 min of regional ischemia and 
examined I) susceptibility to VF during transient (0.5, 
1, 2, or 4 min) acidic (pH 6 .6) reperfusion and subse­
quent abrupt normalization of perfusate pH relative to 
that during normal (pH 7.4) reperfusion throughout 
and 2) the changes in sarcolemmal Na+-K+-ATPase 
activity following ischemia and after various durations 
of acidic (pH 6 .6) or normal (pH 7.4) reperfusion.
METHODS
All experiments were conducted in accordance with institu­
tional guidelines and the Home Office “Guidance on the 
Operation of the Animals (Scientific Procedures) Act 1986.”
Animals and Perfusion Technique
Independent dual perfusion of left and right coronary 
arteries in isolated hearts from male Wistar rats (220-280 g; 
B & K Universal, Hull, UK) was performed as described in 
detail by Avkiran and Curtis (2). Perfusion of both coronary 
beds with oxygenated perfusion solution at 37°C was carried 
out at a constant perfusion pressure equivalent to 75 mmHg, 
with left and right coronary flow rates continously monitored 
through in-line flow detectors (Transonic T206 flowmeter 
with IN probes, Transonic Systems, Ithaca, NY). When 
required, the left coronary bed could be selectively perfused 
with modified solution (also at 37°C) from a separate reser­
voir. An additional reservoir held perfusion solution contain­
ing disulphine blue dye (0.016% wt/vol) that could be infused 
unilaterally to delineate the two perfusion beds. To maintain 
sinus rate, the right atrium was continuously superfused 
with oxygenated perfusion solution (37°C) at a rate of 5
, ml/min (2).
Composition of Perfusion Solutions
Standard perfusion solution contained (in mM) 118.5 NaCl,
25.0 NaHCOs, 3.2 KC1, 1.2 MgSO*, 1.2 KH2P04, 1.4 CaCl2, 
and 11.1 glucose. This solution was oxygenated and main­
tained at pH 7.4 by continuous gassing with 95% 0 2-5% C02. 
Acidic (pH 6.6) solution was prepared by lowering [NaHCOs] 
to 4.0 mM while maintaining the same gas mixture contain­
ing 5% C02. [Na+] was kept constant (143 ± 2 mM) in all 
solutions by modifying [NaCl] as necessary. Before use, all 
solutions were filtered through a membrane with 5-pun pore 
size.
Experimental Protocols
In all studies, both coronary beds were perfused with 
standard perfusion solution for an initial 15-min period, after 
which the left coronary bed was subjected to zero-flow isch­
emia. The right coronary bed was perfused with standard 
perfusion solution throughout all experiments.
Arrhythmia study. Regional ischemia was maintained for 
10 min, a duration which in the absence of protective interven­
tions results in a high incidence of reperfusion-induced VF in 
this model (2). At the end of the ischemic period hearts were 
randomly assigned to one of five groups (n = 12/group), and 
the left coronary bed was selectively reperfused for 5 min, 
during which arrhythmias were monitored. In the control 
group, the left coronary bed received the standard solution at 
pH 7.4 throughout the reperfusion period In the acidic 
reperfusion groups, the left coronary bed received the modi­
fied solution at pH 6.6 for the first 0.5, 1, 2, or 4 min of 
reperfusion and the standard solution at pH 7.4 thereafter. In 
a parallel study (see below), Na+-K+-ATPase activity was 
determined at the end of a 10-min period of regional ischemia 
and after 0.5-4 min of acidic or normal reperfusion in 
separate populations of hearts.
Na+-K+-ATPase study. In the acidic reperfusion protocol, 
hearts were randomly assigned to one of seven groups (n = 
8/group) and sectioned at the midventricular level after 15 
min of aerobic perfusion, after 10 min of zero-flow ischemia, 
and after 10 min of zero-flow ischemia followed by 0.5,1,2,3, 
or 4 min of reperfusion of the left coronary bed with the acidic 
(pH 6.6) perfusion solution. In the normal reperfusion proto­
col, hearts were assigned to one of five groups (n = 6/group) 
and similarly sectioned after 15 min of aerobic perfusion, 
after 10 min of zero-flow ischemia, and after 10 min of 
zero-flow ischemia followed by 0.5, 2, or 4 min of reperfusion 
of the left coronary bed with standard (pH 7.4) perfusion 
solution. In all cases, the apical portions of the hearts were 
rapidly frozen by immersion in n-hexane cooled to -70CC. 
The tissues were stored in liquid N2 until they were assayed 
for sarcolemmal Na+-K+-ATPase activity (see Na+-K+- 
ATPase activity).
Measured Variables
Arrhythmias. Arrhythm ias were diagnosed from a unipolar 
electrocardiogram (ECG) that was obtained using a silver 
electrode inserted into the free wall of the left ventricle and a 
reference electrode connected to the aorta. The ECG was 
continuously monitored on a digital storage oscilloscope (Gould 
type 1421, Gould Electronics, Ilford, UK) and recorded on an 
ink-jet recorder (Gould 2200S). The ECG record was retrospec­
tively analyzed (in a blinded manner) for the incidence, time 
to onset, and duration of ventricular tachycardia (VT) and VF. 
All analyses were carried out in accordance with the Lambeth 
Conventions (35). VT was defined as four or more consecutive 
premature beats of ventricular origin, and VF was defined as 
a signal in which both rate, and amplitude varied from cycle to 
cycle.
Coronary flow rate and heart rate. In the arrhythmia study, 
flow rates to each coronary bed (monitored using the in-line 
flowmeters) and heart rate (determined from the ECG) were 
noted at selected time points during the protocol.
Ischemic zone size. At the end of each experiment in the 
arrhythmia study, the left coronary bed was perfused at 
75-mmHg perfusion pressure for 3 min with a solution 
containing 0.016% disulphine blue dye. The heart was then 
removed from the perfusion apparatus, the atria and medias­
tinal tissue were excised, and dye-stained tissue (represent­
ing ventricular myocardium subjected to ischemia and reper­
fusion) was carefully dissected away from the remainder. The 
stained and unstained tissues were lightly blotted and 
weighed. The size of the ischemic zone, expressed as a 
percentage of total ventricular weight, was calculated from 
the equation (wt of stained tiBSue/total ventricular wt) X 100. 
The absolute weights obtained also enabled the calculation of 
flows in left and right coronary beds on the basis of tissue 
weights supplied by each bed (in ml per min per g).
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Na+-K+-ATPase activity. Sequential pairs of midventricu- 
lar sections (10-pm thick) were obtained from each heart 
using an automated cryostat (Bright Instrument, Hunting­
don, UK). The sections were then flash dried onto glass 
microscope slides. Ouabain-sensitive Na+-K+-ATPase activ­
ity was determined in left and right ventricular (RV) free 
walls (supplied by the left and right coronary beds, respec­
tively) using the cytochemical assay initially developed by 
Chayen et al. (5) and subsequently adapted by others to 
quantify localized Na+-K+-ATPase activity in rat kidney 
tubules (15) and ventricular myocardium (9). All reagents 
used were purchased from Sigma (Poole, UK).
Briefly, a Perspex ring was placed around each section to 
enable submersion of the section in a 40% (wt/vol) solution of 
Polypep 5115 in 200 mM tris(hydrpxymethyl)aminomethane 
(Tris) buffer (pH 7.5 at 37°C) containing 100 mM potassium 
acetate. After 10-min exposure to remove excess free inor­
ganic phosphate (that would otherwise produce a strong 
background coloration at a later stage of the assay), this 
medium was removed and immediately replaced by a reaction 
medium consisting of 40% (wt/vol) Polypep 5115 in 200 mM 
Tris buffer (pH 7.5 at 37°C) containing (in mM) 1.0 sodium 
acetate, 410 NaCl, 20.0 MgCl2, 37.5 KC1, 16.5 ATP, and 32 
mg/ml lead ammonium citrate/acetate complex. On each 
slide, one of the two sections was submerged in a similar 
reaction medium containing 1 mM ouabain, which has been 
shown to produce maximal inhibition of ATPase activity in rat 
tissue (15), thus enabling the determination of total ATPase 
activity and ouabain-insensitive ATPase activity in sequen­
tial sections.
After incubation for 15 min at 37°C, the medium was 
removed by aspiration, and the slides were rinsed twice in 
200 mM Tris buffer (pH 7.5 at 37°C). The slides were then 
immersed for 1 -2  min in water saturated with hydrogen 
sulfide and, after being rinsed in distilled water, were allowed 
to dry at room temperature. The density of the reaction 
product (lead sulfide) was then quantified at 585 nm using a 
microdensitometer (model M86, Vickers Instruments, York, 
UK) with a X40 objective and a flying spot of 0.5-pm diameter 
in the plane of the section. At least 10 readings were taken 
from 10 cells per ventricle, and a mean value was calculated. 
Readings were corrected for background coloration, standard­
ized against an internal standard, and data were expressed 
as mean integrated extinction X 100 (MIE x 100). Ouabain- 
sensitive ATPase (i.e., Na+-K+-ATPase) activity was calcu­
lated from the total and ouabain-insensitive ATPase activi­
ties measured in sequential sections. The measurement of 
Na+-K+-ATPase activity in both the left ventricular (LV) free 
wall (selectively subjected to ischemia and reperfusion) and 
the RV free wall (perfused with standard perfusion solution 
throughout) enabled each heart to act as its own control. 
Determinations of Na+-K+-ATPase activity in the various 
Bamples were carried out in a blinded manner.
Exclusion Criteria
Exclusion criteria were the same as those employed in our 
previous studies with this model (2,3,11,12,37). The overall 
exclusion rate was <15%, and the excluded hearts were 
evenly distributed among the study groups.
Data Analysis
Gaussian-distrihuted variables were expressed as means ± 
SE and were subjected to analysis of variance (ANOVA). If a 
difference among mean values was established with ANOVA, 
intergroup comparisons were performed using Tukey’s test. 
Binomially distributed variables, such as the incidences of VT
and VF, were compared using the x2 test for a 2 X  5 table 
followed by a sequence of 2 X  2 x2 tests with Yates’ correction. 
A probability of <0.05 (P < 0.05) was considered significant.
RESULTS
Arrhythmia Study
Reperfusion arrhythmias. Consistent with our ear­
lier studies (3,12), reperfusion after 10 min of regional 
ischemia resulted in the rapid (within a few beats) 
induction of VT in 100% of hearts in all groups regard­
less of the pH of the reperfusion solution. Episodes of 
reperfusion-induced VT were commonly uninterrupted 
until either spontaneous reversion to normal sinus 
rhythm or degeneration into VF. Figure 1 illustrates 
the time course of episodes of VF in individual hearts in 
the various study groups in relation to the duration of 
acidic reperfusion (shaded area). In the control group, 
VF developed within 20 s of the onset of reperfusion in 
92% of hearts; in all hearts that exhibited VF, VF was 
sustained until the end of the reperfusion period. In the 
0.5-, 1-, 2-, and 4-min acidic reperfusion groups, only 
17,17,42, and 25% of hearts, respectively, exhibited VF 
during the period of acidic reperfusion (in all cases P <  
0.05 vs. corresponding period in control group). How­
ever, on switching the reperfusate to pH 7.4, VF 
occurred in a further 50, 58, 0, and 0% of hearts, 
respectively. Thus the overall incidences of VF were 
92% in the control group and 67, 75,42 (P <  0.05), and 
25% (P <  0.05) in the 0.5-, 1-, 2-, and 4-min acidic 
reperfusion groups, respectively (Fig. 2 ). At the end of 
the 5-min reperfusion period, only 8 % of control hearts 
were in normal sinus rhythm; this incidence was 
increased to 58, 75 (P <  0.05), 92 (P <  0.05), and 83% 
(P <  0.05) in the 0.5-, 1-, 2-, and 4-min acidic reperfu­
sion groups, respectively.
Coronary flow rate, heart rate, and ischemic zone size. 
In control and 0.5-, 1-, 2-, and 4-min acidic reperfusion 
groups, preischemic flow rates were similar in both the 
left (14.1 ± 1.0,13.0 ± 0.4,12.6 ± 0.6,12.1 ± 0.6, and 
13.0 ± 0.5 ml-min- 1-g-1, respectively) and the right 
(15.3 ± 0.7, 14.3 ± 0.7, 14.8 ± 0.5, 14.7 ± 0.9, and
15.7 ±1 .1  ml*min-1-g_1, respectively) coronary beds. 
In all groups, on reperfusion, flow rate increased above 
its basal value in both coronary beds regardless of 
perfusate pH, as previously described (3). In the control 
group, the increased flow rates were maintained 
throughout reperfusion. In the acidic reperfusion 
groups, right coronary flow rate returned toward its 
basal value within 2 min of reperfusion, whereas in the 
left coronary bed there was a secondary increase in flow 
rate following the switch to pH 7.4.
Basal heart rate did not differ significantly among 
control and acidic reperfusion groups (360 ± 11,356 ± 
11,343 ± 9,333 ± 8 , and 350 ± 12 beats/min in control, 
0.5-, 1-, 2-, and 4-min acidic reperfusion groups, respec­
tively). Heart rate did not change significantly in any of 
the study groups during the period of regional ischemia 
and could not be measured during early reperfusion 
due to the rapid onset of ventricular arrhythmias in the 
majority of hearts. There was no significant difference 
among groups in ischemic zone size (54 ± 3, 50 ± 3,
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Fig. 1. T im e course of reperfusion-induced ven tricu lar 
fib rilla tion  (VF), indicated  by horizontal black bars, in  
ind iv idual h e a r ts  (n = 12/group) in  control group (A) an d  in 
groups in  which h e a r ts  were subjected to acidic reperfusion 
for 0.5 (B ), 1 (C), 2 (D), or 4 m in (E). Shaded areas  indicate 
period o f acidic (pH 6.6) reperfusion. H earts in  each group 
a re  a rra n g e d  in  o rder in  which experim ents were carried 
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59 ± 2, 53 ± 3, and 55 ± 3% in control, 0.5-, 1-, 2-, and
4-min acidic reperfusion groups, respectively).
N a +-K +-ATPase Study
In the acidic reperfusion protocol, Na+-K+-ATPase 
activity in the RV free wall did not differ significantly 
among the study groups, with values (in MIE X 100) 
ranging from 10.4 ± 0.9 to 12.5 ± 0.6. Figure 3A shows 
Na+-K+-ATPase activity in the LV free wall in nonisch­
emic hearts, those subjected to 10 min of regional 
ischemia, and those subjected to 10 min of regional 
ischemia followed by various periods (0.5—4 min) of 
acidic reperfusion. In nonischemic hearts, Na+-K+- 
ATPase activity in the LV free wall was 110 ± 8 % of 
that in the RV free wall. In contrast, in hearts subjected
to 10 min of regional ischemia, Na+-K+-ATPase activity 
in the LV free wall was reduced significantly to 25 ±  
3%. Hearts subsequently subjected to 0.5, 1, 2, 3, or 4 
min of acidic reperfusion exhibited a progressive recov­
ery of N a+-K“f-ATPase activity, although values re­
mained significantly depressed relative to nonischemic 
hearts. Nevertheless, 2 ,3 , or 4 min of acidic reperfusion 
resulted in a significant recovery of Na+-K+-ATPase 
activity relative to the value obtained at the end of 
ischemia.
In the normal reperfusion protocol also, N a+-K+- 
ATPase activity in the RV free wall did not differ 
significantly among groups (range (in MIE X 100):
12.7 ±  0.6 to 15.2 ±  0.8}. As shown in Fig. 3B, 
N a+-K+-ATPase activity in the LV free wall once again
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Fig. 2. O verall incidence of reperfusion-induced VF in  g roups in 
which h ea rts  w ere subjected to tra n s ie n t acidic reperfusion  for 0 
(control), 0.5, 1, 2, or 4 min (n =  12/group). H atched a reas  indicate 
proportion of h e a rts  in which VF occurred during  period o f acidic (pH 
6.6) reperfusion. *P < 0.05 vs. control.
declined significantly following 10  min of ischemia from 
112 ± 9% in nonischemic hearts to 29 ± 2%. In contrast 
to the observations made with acidic reperfusion, how­
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Fig. 3. N a +-K +-ATPase activity in th e  left ven tricu lar (LV) free wall 
in  h e a r t sam ples collected a t various tim e points d u rin g  acidic 
reperfusion (A; n  = 8/group) and norm al reperfusion (B; n  =  6/group) 
protocols. V alues a re  m eans ±  SE. In  each h eart, N a +-K +-ATPase 
activity in  ischem ic/reperfused LV free wall was calculated  as a 
percentage of activity  in nonischemic rig h t ven tricu lar (RV) free wall 
in  sam e h e a rt. H atched bars, 10-min regional ischem ia followed by 
various periods of acidic (pH 6.6) or norm al (pH 7.4) reperfusion. 
*P  <  0.05 vs. nonischem ic group, f P  <  0.05 vs. 10-min ischem ia 
group.
cantly (relative to the end-ischemic value) following up 
to 4 min of normal reperfusion.
DISCUSSION
The present study has confirmed our earlier finding 
(3) that in isolated rat hearts subjected to 10 min of 
regional ischemia, selective acidic (pH 6 .6 ) reperfusion 
of the ischemic zone protects against reperfusion- 
induced VF. In addition, the present study has shown 
that, to afford sustained protection, the duration of 
acidic reperfusion needs to be at least 2  min; with 
shorter durations of acidic reperfusion, the subsequent 
switch to pH 7.4 may induce new episodes of VF. 
Furthermore, the present study has revealed that 10 
min of regional ischemia results in marked inhibition of 
sarcolemmal N a+-K+-ATPase activity within the isch­
emic zone. A progressive recovery of N a+-K+-ATPase 
activity occurred during subsequent acidic reperfusion, 
which was not observed with normal reperfusion for an 
identical period. The minimum duration of acidic reper­
fusion required to achieve a significant recovery of 
N a+-K+-ATPase activity from ischemia-induced inhibi­
tion matched closely that required to afford sustained 
protection against reperfusion-induced VF. This find­
ing is consistent with the hypothesis that the protective 
mechanism of transient acidic reperfusion may involve 
a pH-mediated inhibition of Na+ influx and addition­
ally suggests that enhanced recovery of N a+-K+- 
ATPase activity also may play a contributory role.
Reperfusion-induced VF: A Role for Loss ofN a  + and  
Ca2+ Homeostasis?
As noted earlier, activation of Na+/H+ exchange (and 
possibly NaVHCOg symport) during uncontrolled re­
perfusion may result in an increased influx of N a+ and, 
consequently, Ca2+ overload via N a+/Ca2+ exchange. 
The latter has been proposed (20) as a progenitor of 
reperfusion-induced severe arrhythmias, probably 
through a mechanism that involves the oscillatory 
release of Ca2+ from the sarcoplasmic reticulum and 
the subsequent induction of delayed afterdepolarizations.
The magnitude and potential detrimental conse­
quences of any increase in [Na+]i that may occur during 
reperfusion due to increased Na+ influx coupled to H+ 
extrusion would be expected to depend on the activity of 
the primary N a+ extrusion pathway, namely sarcolem­
mal N a+-K+-ATPase. Indeed, in the presence of pharma­
cological inhibition of Na+-K+-ATPase, the abrupt cre­
ation of an intracellular-to-extracellular H+ gradient 
has been shown in isolated myocytes (19) and whole 
hearts (1) to result in the rapid intracellular accumula­
tion of Ca2+. Similarly, in the setting of postischemic 
reperfusion, pharmacological inhibition of Na+-K+- 
ATPase has been shown to result in a greater increase 
in [Ca2+]j relative to that observed in the absence of 
such inhibition (18, 32). Of particular relevance to the 
present study is the observation that this increase in 
intracellular Ca2+ accumulation was associated with 
an increased incidence of reperfusion-induced VF (32). 
Recently, Vandenberg et al. (33) have calculated that, 
during reperfusion after 10 min of ischemia in the
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ferret heart, Na+ influx coupled to H+ extrusion may be 
as great as 5 mM/min. Under the ionic conditions that 
are likely to prevail at onset of reperfusion, this high 
rate of influx may only just be countered by Na+ efflux 
via Na+-K+-ATPase running at full activity (33). How­
ever, in the present study, 10 min of ischemia resulted 
in a 75% inhibition of maximal Na+-K+-ATPase activ­
ity. This would be expected to favor intracellular Na+ 
accumulation following an increased Na+ in flu x during  
subsequent uncontrolled reperfusion. Because extracel­
lular acidosis inhibits Na+ influx coupled to H+ extru­
sion (34), it is likely that the protective effect of acidic 
reperfusion in our present and previous (3,12) studies 
was mediated, at least in part, through an inhibition of 
Na+ influx at a time when myocardial capacity to 
extrude Na+ was significantly impaired. However, as 
we have previously noted (3, 37), maintained tissue 
acidosis during acidic reperfusion is likely also to exert 
other actions (e.g., inhibition of Ca2+ and K+ channels, 
Na+/Ca2+ exchange, Ca2+ release from the sarcoplas­
mic reticulum) that might contribute to an antifibrilla- 
tory effect. In this regard, it is important to stress that 
the protective effect of acidic reperfusion appears to be 
a property of the low pH rather than the low bicarbon­
ate content of the perfusate (12).
Nuclear magnetic resonance (NMR) spectroscopic 
studies (22 ) that have failed to show a large increase in 
[Na+]j during uncontrolled reperfusion question an 
important role for intracellular Na+ accumulation in 
reperfusion-induced arrhythmogenesis. It should be 
noted, however, that there is substantial evidence to 
suggest that there may be a subsarcolemmal “fuzzy 
space” where Na+ diffusion is limited and where in­
creased Na+ influx may result in a sufficient increase in 
[Na+] to stimulate Ca2+ influx through the Na+/Ca2+ 
exchanger {see recent review by Carmeliet (4)j. There­
fore, it is feasible that an increased influx of Na+ during 
reperfusion may result in a transient increase in [Na+] 
in this compartment (thus modulating Na+/Ca2+ ex­
changer activity) without an increase in bulk cytosolic 
[Na+]; such a change in [Na+]j may not be detectable by 
currently available techniques, such as NMR spectros­
copy (4). Indeed, even a modest increase in [Na+] in the 
relevant intracellular space would be expected to alter 
significantly the reversal potential of the Na+/Ca2+ ex­
changer, favoring intracellular Ca2+ accumulation (17).
It may be argued that maintained intracellular acido­
sis during acidic reperfusion would be expected to 
result in an increased [Ca2+]i due to altered Ca2+ 
buffering and extrusion (14) and thereby in the exacer­
bation of reperfusion-induced arrhythmias. However, 
reperfusion-induced arrhythmias are believed to occur 
not as a result of an increased [Ca2+li per se but through 
a mechanism that involves the oscillatory release of 
Ca2+ from the sarcoplasmic reticulum and the subse­
quent induction of delayed afterdepolarizations (20 ). 
Because oscillatory Ca2+ release from the sarcoplasmic 
reticulum and delayed afterdepolarizations are inhib­
ited by low pH (20), this might counteract any proar- 
rhythmic effect of an acidosis-induced increase in 
[Ca2+]j.
Ischemia-Induced Inhibition of Sarcolemmal 
Na +-K+-ATPase
Previous studies that have used conventional bio­
chemical techniques involving tissue homogenization 
and membrane purification have provided conflicting 
results regarding the effects of ischemia on sarcolem- 
mal Na+-K+-ATPase activity. Kim et al. (13) faiied to 
show a reduction in Na+-K+-ATPase activity after as 
long as 6 h of ischemia in isolated guinea pig hearts. In 
contrast, in isolated rat hearts, Daly et al. (6) found a 
21-24% reduction in Na+-K+-ATPase activity after 60 
min of global ischemia, with no further change in 
activity following a subsequent 15-min period of reper­
fusion. In porcine myocarium, Winston et al. (36) 
showed that up to 45 m in of ischemia did not affect 
Na+-K+-ATPase activity when measured in tissue ho- 
mogenates; however, using a qualitative histochemical 
method to detect in situ Na+-K+-ATPase activity, these 
investigators were able to demonstrate a marked loss of 
activity after shorter periods of ischemia. This observa­
tion is in agreement with the findings of the present 
study, obtained using a similar (but quantitative) in 
situ assay, which have shown an ~75% reduction in LV 
Na+-K+-ATPase activity after only 10 m in  of ischemia. 
It is possible therefore that factors responsible for 
inhibiting Na+-K+-ATPase activity in situ may be 
partially lost during tissue homogenization and mem­
brane purification, rendering such methods inappropri­
ate for use in the study of ischemia-induced changes in 
enzyme activity. Furthermore, loss of Na+-K+-ATPase 
during tissue processing, the extent of which may vary 
depending on the nature of the tissue (i.e., control vs. 
pathological), may complicate the interpretation of 
results obtained using these methods (26). The cyto- 
chemical method used in the present study, which 
enables the assessment of Na+-K+-ATPase activity in 
situ, avoids the problems associated with enzyme loss 
during tissue homogenization and purification.
In the present study, Na+-K+-ATPase activity in the 
tissue sections was measured under conditions of sub­
strate saturation, optimal pH, and abundant ATP; thus 
the activity measured reflects the maximal activity 
(Vm**) of the enzyme. A reduction in VL.„. as observed 
after ischemia in the present study, may occur due to 1) 
a reduction in tissue Na+-K+-ATPase content and/or 2) 
a reduction in the maximal activity of individual en­
zyme units. Although the present study does not allow 
delineation of the precise mechanism(s) involved, previ­
ous studies have shown that neither the number of 
{3H}ouabain binding sites (26) nor the distribution and 
content of immunoreactive Na+-K+-ATPase (36) is al­
tered during ischemia, suggesting that the former 
mechanism may not be of primary importance. With 
regard to the latter mechanism, it is possible that 
Na+-K+-ATPase activity may be inhibited during isch­
emia as a consequence of changes in cellular glutathi­
one status (10) or in the enzyme’s lipid environment (8 , 
29). Thus the observed recovery of Na+-K+-ATPase 
activity during acidic reperfusion may have been medi­
ated by the reversal of such ischemia-induced changes.
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In this regard, it is interesting to note that, unlike with 
acidic reperfusion, no significant recovery of Na+-K+- 
ATPase activity was observed, following up to 4 min of 
reperfusion with solution at pH 7.4. The mechanisms 
that are responsible for the apparent pH dependency of 
Na+-K+-ATPase recovery from ischemia-induced inhibi­
tion are unclear. However, with regard to the potential 
modulation of Na+-K+-ATPase activity during ischemia 
and reperfusion by reversible changes in myocardial 
glutathione status (10), it is worth noting that certain 
thiol-disulfide in te rchange reactions involving glutathi­
one exhibit pH sensitivity in vitro (25).
Role of Differences in Coronary Flow Profiles
The possibility that pH-mediated differences in left 
and right coronary flow profiles during reperfusion may 
have mediated the intergroup differences in susceptibil­
ity to arrh ythm ias needs to be considered. The increase 
in right coronary flow rate, which occurred in all groups 
on reperfusion, was maintained throughout reperfu­
sion in the control group but normalized rapidly in the 
transient acidic reperfusion groups. However, the sus­
tained increase in right coronary flow rate in Hie 
control group was probably a consequence (rather than 
the cause) of the greater severity of reperfusion- 
induced arrhythmias and may have occurred due to 
reduced extravascular compression (3,12). In all groups 
subjected to transient acidic reperfiision, there was a 
secondary increase in left coronary flow rate following 
the switch to pH 7.4; this occurred regardless of whether 
the antifibrillatory protection was sustained, suggest­
ing that it was not causally related to the induction of 
new episodes of VF.
Limitations of Present Study
Our data have revealed a temporal correlation be­
tween the recovery of Na+-K+-ATPase activity during 
acidic reperfusion in one population of hearts and the 
decline in susceptibility to VF following a subsequent 
increase in perfusate pH in another population of 
hearts. This study design was necessitated because the 
cytochemical assay used allows only a single measure­
ment of Na+-K+-ATPase activity to be made in each 
heart. Thus it was impossible to correlate Na+-K+- 
ATPase activity at the moment of the abrupt change in 
extracellular pH with susceptibility to VF following a 
subsequent increase in perfusate pH on a heart-by- 
heart basis. Therefore, although our findings are consis­
tent with the hypothesis that inhibition of intracellular 
Na+ (and consequently Ca2+) accumulation may be 
involved in the protective actions of acidic reperfusion, 
it does not prove a “cause and effect* relationship 
between Na+-K+-ATPas e activity and susceptibility to 
VF. Indeed, it should be noted that the activity/ 
inactivity of various ion transporting pathways (e.g., 
Na+/H+ and Na+/Ca2+ exchangers) during reperfusion 
are presumed, based on published data, rather than 
measured directly in the present study. In the absence 
of continuous ion measurements simultaneously with 
ECG monitoring, it cannot be deduced whether the
protection afforded by acidic reperfusion was mediated 
by reduced intracellular accumulation of Na+ and/or 
Ca2+ during reperfusion.
A further limitation of the present study may be the 
use of an erythrocyte-free perfusate, which results in 
coronary flows in excess of those encountered in vivo. 
Such high flows may result in faster washout during 
reperfusion of components (such as H+) that have 
accumulated during the preceding period of ischemia, 
which in turn may lead to an overestimation of the role 
of washout phenomena in reperfusion arrhythmogen- 
esis. However, it is worth noting that in the present 
model even a 90% reduction in the rate of reflow is 
unable to suppress reperfusion-induced VF (11).
Despite the above limitations, the model employed in 
the present study offers many advantages in the study 
of the pathophysiological determinants of arrhythmo- 
genesis (2). Of particular advantage in the present 
study was the reproducible coronary distribution af­
forded by the model (2), which enabled the measure­
ment in individual hearts of Na+-K+-ATPase activity in 
myocardium selectively exposed to ischemia and reper­
fusion as well as in “control* myocardium that was not 
exposed to any such intervention.
In conclusion, the present study has shown that, in 
isolated rat hearts subjected to 10 min of regional 
ischemia, a m inim um  of 2 min of acidic reperfusion is 
required to achieve sustained protection against reper- 
fusion-induced VF. Furthermore, the present study has 
revealed for the first time that 10 m in of regional 
ischemia results in a substantial and significant inhibi­
tion of the maximal activity of sarcolemmal Na+-K+- 
ATPase within the ischemic zone. This inhibition has 
been shown to be reversible, with a progressive recov­
ery of Na+-K+-ATPase activity occurring during 4 min 
of acidic reperfusion but not during an identical period 
of normal reperfusion. There was a close similarity in 
the durations of acidic reperfusion required to achieve
1) sustained protection against reperfusion-induced VF 
and 2) significant recovery of maximal Na+-K+-ATPase 
activity from ischemia-induced inhibition. This is con­
sistent with the hypothesis that the protective mecha­
nism of transient acidic reperfusion may involve the 
maintenance of cellular Na+ and Ca2+ homeostasis. 
Furthermore, it suggests that this may occur not only 
through a suppression of Na+ influx coupled to H+ 
extrusion, but also via an enhanced recovery of the 
primary Na+ efflux mechanism, the Na+-K+-ATPase.
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H2430-H2440, 1994.—Activation of sarcolemmal Na+/H+ 
exchange has been proposed as a causal factor in reperfusion 
arrhythmogenesis. To test this hypothesis, we determined the 
antiarrhythmic efficacy of two structurally distinct but equi- 
potentNa+/H+ exchange inhibitors, 5-(2V-ethyl-N-isopropyl)am- 
iloride (EIPA) and the novel drug, 3-methylsulfonyl-4- 
piperidinobenzoyl guanidine (HOE-694), in isolated rat hearts 
(n = 12/group) subjected to independent dual coronary perfu­
sion. After 15 min of aerobic perfusion of both beds, flow to the 
left coronary bed (LCB) was terminated for 10 min; this was 
followed by 5 min of reperfusion. Various concentrations of 
each drug were selectively infused into the LCB either during 
the 5-min period preceding ischemia plus during reperfusion 
or during reperfusion alone. With the former protocol, 0.01,
0.1, 1, and 10 jjlM EIPA reduced the incidence of reperfusion- 
induced ventricular fibrillation (VF) from 92% in controls to 
83, 83, 50, and 0% (P < 0.05); the number of hearts in sinus 
rhythm at the end of reperfusion was increased from 17 to 42, 
25,83 (P < 0.05), and 100% (P < 0.05). HOE-694, at the same 
concentrations, reduced VF incidence from 92% in control to
83,58,50, and 8% (P < 0.05); 25,67, 75 (P < 0.05), and 100% 
(P < 0.05) of hearts were in sinus rhythm, compared with 17% 
of controls, at the end of reperfusion. Even when infused 
during reperfusion alone, both drugs afforded significant 
protection against reperfusion-induced VF, which did not 
differ significantly from that observed when the drugs were 
also given before ischemia. The similar antiarrhythmic efficacy 
of EIPA and HOE-694 is consistent with an arrhythmogenic 
role for activation of Na+/H+ exchange during early reperfu­
sion.
regional ischemia; dual coronary perfusion; 5-(N-ethyl-N- 
isopropyl)amiloride; 3-methylsulfonyl-4-piperidinobenzoyl gua­
nidine; rat heart
recent  studies  in our laboratory (2 , 11) have shown 
that the incidence of reperfusion-induced ventricular 
fibrillation (VF) can be strikingly reduced by using 
transient acidic reperfusion to limit the rate at which 
extracellular H+ is washed out. Because the sarcolem­
mal Na+/H+ exchanger is inhibited by extracellular 
acidosis (32), we proposed that inhibition of the ex­
changer was the most likely mechanism underlying the 
protection afforded by acidic reperfusion (2,11). Indeed, 
pharmacological inhibitors of the Na+/H+ exchanger, 
such as amiloride and its analogues ethylisopropylamilo- 
ride, dimethylamiloride, and hexamethyleneamiloride, 
also have been shown (6 , 7, 19, 25) to afford protection 
against reperfusion-induced arrhythmias.
Despite considerable evidence suggesting that activa­
tion of the Na+/H+ exchanger may be an important
progenitor of reperfusion-induced arrhythmias, the in­
terpretation of many studies is confounded by a number 
of factors. First, in some studies (7, 25), Na+/H+ 
exchange inhibitors were administered before the onset 
of ischemia, thus making it impossible to deduce whether 
the protective mechanisms were operative primarily 
during ischemia or during reperfusion. A second con­
cern is that the chemical structures of the Na+/H+ 
exchange inhibitors used in many previous studies (6, 7, 
19,25) are based on amiloride, which is known to inhibit 
a number of other ion transport processes (e.g., Na+, 
Ca2+, and K+ channels; Na+/Ca2+ exchange) (13). Al­
though amiloride analogues, in which the 5-amino nitro­
gen atom bears one or two substituents, can exhibit 
increased potency as inhibitors of the Na+/H+ ex­
changer (13), the possibility cannot be excluded that 
nonselective actions might contribute to their protective 
effects. A final concern is that, although acidic reperfu­
sion (2, 11) is likely to inhibit the Na+/H+ exchanger 
(32), it is likely also to exert other actions (e.g., inhibi­
tion of Ca2+ and K+ channels, Na+/Ca2+ exchange, and 
Ca2+ release from the sarcoplasmic reticulum) that may 
contribute to an antiarrhythmic effect (2 ).
The present study was designed with the primary 
objective of obtaining stronger evidence for a specific 
involvement of the Na+/H+ exchanger in the induction 
of reperfusion arrhythmias by a mechanism that is 
operative primarily during the reperfusion phase. To 
achieve this, we used as pharmacological tools an amilo­
ride analogue that is a potent inhibitor of the Na+/H+ 
exchanger, 5-(N-ethyl-JV-isopropyl)amiloride (EIPA), and 
compared its effects with those of a recently developed 
inhibitor, 3-methylsulfonyl-4-piperidinobenzoyl guani­
dine (HOE-694) (24), which has a chemical structure 
distinct from that of amiloride and its analogues (Fig. 1). 
To obtain a detailed assessment of the potency and 
efficacy of these drugs and to determine their primary 
phase of action, we used four concentrations of each 
agent and two treatment protocols, one in which the 
drug was given before ischemia and during reperfusion 
and the other in which it was given during reperfusion 
alone. Another novel aspect of the present study was our 
decision to administer selectively the drugs only to the 
zone that was subjected to ischemia and reperfusion; 
this was made possible by our recent development (1) of 
a unique cannula that allows the independent perfusion 
of left and right coronary beds in small mammalian 
hearts. In further studies using Langendorff-perfused 
hearts, we have also investigated the effects of EIPA and 
HOE-694 on contractile function and electrocardio­
graphic parameters under aerobic conditions.
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Fig. 1. Chemical structures of 5-(N-ethyI-N-isopropyl)amiIoride (EIPA; 
A) and 3-methylsulfonyl-4-piperidinobenzoyl guanidine (HOE- 
694; B).
METHODS
This investigation was performed in accordance with the 
Home Office Guidance on the Operation of the Animals 
(Scientific Procedures) Act 1986, published by Her Majesty's 
Stationery Office, London, UK
Arrhythmia Study
Dual coronary perfusion of isolated rat hearts. Isolated 
hearts from male Wistar rats (Bantin and Kingman, North 
Humberside, UK) were subjected to independent perfusion of 
left and right coronary arteries as described in detail by 
Avkiran and Curtis (1). Each coronary bed was initially 
perfused at a constant perfusion pressure equivalent to 75 
mmHg with oxygenated perfusion solution from a temperature- 
regulated reservoir (37°C). The perfusion solution was of the 
following composition (in mM): 118.5 NaCl, 25.0 NaHC03, 3.2 
KC1,1.2 MgS04, 1.2 KH2PO4, 1.4 CaCl2, and 11.0 glucose. The 
solution was filtered (pore size, 5 pm) before use and bubbled 
continuously with 95% 0 2-5% C02 (pH 7.4 at 37°C). Flow to 
each coronary bed was monitored using in-line flow detectors 
(Transonic T206 Animal Research Flowmeter with IN probes, 
Transonic Systems, Ithaca, NY) with a linear detection range 
of0.05-30 ml/min. After 15 min of perfusion of both coronary 
beds, basal flow rate in the left coronary bed was recorded, and 
perfusion of this bed was switched from constant pressure to 
constant flow at the basal flow rate (supplied by a Gilson 
Minipuls 3 roller pump). This enabled the infusion of drug 
solutions or vehicle into the left coronary bed, at a known 
percentage of the total flow supplied to that bed (see Drug 
administration and study protocol). The right coronary bed 
was perfused at constant pressure throughout the experiment. 
The heart was housed in a temperature-regulated chamber at 
37°C throughout the experiment, and the right atrium was 
continuously superfused with oxygenated perfusion solution 
(37°C) at 8 ml/min to maintain sinus rate (1).
Drug administration and study protocol. HOE-694 has 
limited solubility in physiological buffer solutions. Therefore, 
both drugs were dissolved in deionized water at concentrations 
of 0.143, 1.43, 14.3, and 143 pM. When required, these
solutions were infused selectively into the perfusion line 
supplying the left coronary bed at 7% of the total flow rate 
delivered to that bed; this resulted in final perfusate drug 
concentrations of 0.01, 0.1, 1, and 10 pM. Control hearts 
received vehicle (deionized water) at the same infusion rate.
Each concentration of EIPA or HOE-694 was infused into 
the left coronary bed either for 5 min immediately before 
ischemia plus throughout reperfusion or throughout reperfu­
sion alone. All hearts (n = 12/group) were subjected to 10 min 
of regional ischemia (this was achieved by terminating flow to 
the left coronary bed) followed by 5 min of reperfusion. 
Experiments were carried out in a prospectively randomized 
manner.
Measured variables. ARRHYTHMIAS. Arrhythmias were diag­
nosed from a unipolar electrogram (ECG) that was obtained 
through a silver electrode inserted into the free wall of the left 
ventricle and a reference electrode connected to the aorta. The 
ECG was continuously monitored on a digital storage oscillo­
scope (model 1421, Gould Electronic, Ilford, UK) and was 
recorded on an ink-jet recorder (model 2200S, Gould). Chart 
speed was set at 50 mm/s a few seconds before reperfusion so 
as to obtain a permanent high-speed record of the changes in 
the ECG during early reperfusion. The ECG was retrospec­
tively analyzed, in a blinded manner, for the incidence, time to 
onset, and duration of ventricular tachycardia (VT) and VF. 
All analyses were carried out in accordance with the Lambeth 
Conventions (30). VT was defined as four or more consecutive 
premature beats of ventricular origin and VF as a signal in 
which individual QRS deflections could no longer be distin­
guished from one another and for which rate could not be 
determined.
vt  CYCLE LENGTH. VT cycle length was determined 10 s after 
the onset of reperfusion, since at this time point a large 
proportion of the hearts (n = 10-12) were in VT in most 
groups, enabling intergroup statistical comparison. The only 
exception was the group that received 10 pM EIPA before 
ischemia plus during reperfusion; none of the hearts in this 
group exhibited VT (see RESULTS). VT cycle length was calcu­
lated from the number of QRS deflections over a 2-s interval, 
using the high-speed ECG trace (2).
CORONARY FLOW and  HEART RATE. Throughout the experi­
mental protocol, coronary flow was monitored using the in-line 
flow detectors. Heart rate was determined at selected intervals 
from the ECG trace.
SIZE OF ISCHEMIC ZONE. At the end of each experiment, the 
left coronary bed was perfused for 30 s with a solution 
containing 0.02% disulphine blue dye at a perfusion pressure 
of 75 mmHg. The heart was then removed from the perfusion 
apparatus, the atria and mediastinal tissue were removed, and 
the dye-stained tissue (representing ventricular myocardium 
subjected to ischemia and reperfusion) was carefully dissected 
out. The stained and unstained tissues were lightly blotted and 
weighed. The size of the ischemic zone, expressed as a percent­
age of total ventricular weight, was calculated from the 
equation: (weight of stained tissue/total ventricular weight) x 
100. The absolute weights obtained also enabled the calcula­
tion of flows in left and right coronary beds on the basis of 
tissue weights supplied by each bed (ml • min-1 • g-1).
Exclusion criteria. These criteria, selected to minimize 
variations in heart rate and size of ischemic zone (due to 
atypical coronary anatomy) among the hearts, were as previ­
ously described (1, 2, 10, 11). Hearts were also excluded if 
there was cross-flow between right and left coronary ostia, due 
to a mismatch between aorta size and cannula diameter (1, 2, 
10,11). In addition, hearts that exhibited ventricular arrhyth­
mias during the final 3 s of ischemia before reperfusion were 
not included in the analysis of reperfusion-induced arrhyth­
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mias, because in those hearts it would have been impossible to 
differentiate arrhythmias induced by reperfusion from those 
induced by ischemia. Of 230 hearts entered into the arrhyth­
mia study, 5 were excluded on the basis of heart rate, 1 on the 
basis of size of ischemic zone, 4 on account of cross flow, and 4 
on account of arrhythmias during the final 3 s of ischemia. The 
overall exclusion rate was 6%.
Contractile Function Study
Langendorff perfusion o f isolated rat hearts. Hearts were 
excised from male Wistar rats as described in an earlier study 
(1) and were subjected to Langendorff perfusion through a 
conventional single-lumen cannula at a constant perfusion 
pressure equivalent to 75 mmHg. The left atrium was excised, 
and an ultrathin balloon, specially constructed to match the 
dimensions of the ventricular cavity, was inserted into the left 
ventricle. The intraventricular balloon was inflated to give a 
left ventricular end-diastolic pressure (LVEDP) of 6 -8  mmHg, 
and the balloon volume was kept constant thereafter. The 
perfusion solution was identical to that used for dual coronary 
perfusion. After 15 min of perfusion at constant pressure, the 
basal total coronary flow rate was noted, and perfusion was 
switched to a constant-flow system at the basal flow rate. 
Again, 7% of the total flow supplied was from a sidearm 
through which drug solutions or vehicle could be adminis­
tered.
Drug administration and study protocol. For the first 10 
min of constant-flow perfusion, hearts (n = 6 /group) received 
vehicle (deionized water) through the sidearm. Subsequently, 
drug solutions were administered, in a cumulative manner, to 
give final perfusate concentrations of 0.01, 0.1, 1, and 10 jjlM ,  
and perfusion with each drug concentration was maintained 
for 10 min. Hearts in the control group continued to receive 
vehicle (deionized water), at the same infusion rate, through­
out the protocol.
Measured variables. CONTRACTILE FUNCTION. LVEDP and 
left ventricular developed pressure (LVDP), obtained from a 
pressure transducer attached to the intraventricular balloon 
through a fluid-filled catheter, were noted at 2-min intervals 
during perfusion with each drug concentration.
CORONARY VASCULAR RESISTANCE (CVR) AND HEART RATE. 
CVR was determined at 2-min intervals during perfusion with 
each drug concentration, from the total coronary flow (which 
was constant) and the perfusion pressure (which was moni­
tored through a sidearm of the aortic cannula). Heart rate was 
determined at the same intervals from the ECG trace (see 
below).
ECG PARAMETERS. At the end of the 10-min perfusion period 
with each drug concentration, chart speed was increased to 
250 mm/s to obtain a permanent high-speed ECG recording. 
These recordings were utilized to measure the interval from 
the beginning of the P wave to the beginning of the ventricular 
complex (P-R interval) and the width of ventricular complex. 
As a separate T wave is not seen in the rat ECG, the width of 
the ventricular complex was measured at 90% repolarization 
(with the maximum positive deflection of the ventricular 
complex defined as the point of 0% repolarization) and defined 
as QRST90, as previously described (21).
EXCLUSION CRITERIA. These prospectively defined criteria 
demanded that hearts were excluded if basal heart rate was 
< 280 or > 420 beats/min or if basal total coronary flow rate 
was <9 ml/min. Of 18 hearts entered into the contractile 
function study, none were excluded.
Statistical Analysis
Statistical analyses were based on the guidelines described 
by Wallenstein et al. (31). Gaussian-distributed variables were
expressed as means ± SE and were subjected to one-way 
analysis of variance. If a difference among mean values was 
established, comparison with controls was performed using 
Dunnett’s test. Temporal changes in heart rate, developed 
pressure, and coronary vascular resistance were analyzed 
using analysis of variance for repeated measurements. Binomi- 
ally distributed variables, such as the incidence of VT or VF, 
were compared using the chi-squared test for a 2 x n table. If a 
significant difference was revealed, each drug-treated group 
was then compared with the control group using the Fisher 
exact test, with the Bonferroni correction for multiple compari­
sons. A value of P < 0.05 was considered significant.
R E SU L T S
Arrhythmia Study
Repejfusion-induced arrhythmias. Consistent with 
our earlier studies (2 , 11), reperfusion after 10 min of 
regional ischemia frequently resulted in the rapid (within 
a few beats) induction of VT. Reperfusion-induced VT 
was generally polymorphic in nature, and episodes of VT 
were usually uninterrupted until either spontaneous 
reversion to normal sinus rhythm or degeneration into 
VF.
DR UG  A D M IN ISTR A T IO N  BEFORE ISCH EM IA PL U S D U R IN G  
r e p e r f u s i o n .  Figure 2 shows the overall incidence of 
reperfusion-induced VF in control hearts and hearts 
that received EIPA or HOE-694 before ischemia plus 
during reperfusion. Both drugs suppressed the inci­
dence of VF in a concentration-dependent manner, the 




HOE 694 concentration (pmol/L)
Fig. 2. Effects of EIPA  (A) and HOE-694 (B ) when given before 
ischem ia plus du ring  reperfusion on overall incidence of reperfusion- 
induced ventricu lar fibrillation (VF). *P  <  0.05 vs. 0 pM (control).
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concentration of 10 jjlM in both cases. Figure 3 illus­
trates the incidence of VF in each of the study groups 
during 0.5-min intervals throughout the 5-min reperfu­
sion period. The time-to-onset of reperfusion-induced 
VF was not altered by either drug, with the induction of 
VF occurring during the first 0.5 min of reperfusion in 
the majority (67-100%) of hearts that exhibited VF in 
the various study groups.
Although the overall incidence of VF was reduced only 
by the highest concentration (10 p-M) of each drug, in 
the groups that received 1 EIPA or 0.1 jjlM  HOE-694 
there were significant reductions in the incidence of VF 
during some of the later time intervals during reperfu­
sion (Fig. 3). This probably reflected the ability of the 
drugs to enhance spontaneous defibrillation at these 
lower concentrations. The concentration-response char­
acteristics of EIPA and HOE-694 with respect to their 
antifibrillatory actions appeared to be similar (Figs. 2 
and 3), with half-maximal protection obtained within 
the 0.1-1 (jlM concentration range in both cases. The 
maximal protection afforded was also similar for both 
drugs, indicating comparable efficacy. The incidence of 
reperfusion-induced VT was 100% in all control and 
drug-treated groups, except in the group that received 
10 jjiM  EIPA in which reperfusion-induced VT or VF 
was not detected. In both control groups, only 17% of
Fig. 3. Effects of EIPA (A) and HOE-694 (fl) 
when given before ischemia plus throughout reper­
fusion on tim e course of reperfusion-induced VF. 
Incidence of VF was noted during 0.5-min in te r­
vals th roughout the 5-min reperfusion period. 
*P  <  0.05 vs. 0 uM (control) during  correspond­
ing interval.
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hearts were in normal sinus rhythm at the end of the 
reperfusion period. In the groups that received 0.01, 0.1, 
1, and 10 jjlM  EIPA before ischemia and during reperfu­
sion, 42, 25, 83 (P  < 0.05), and 100% (P < 0.05) of 
hearts, respectively, were in sinus rhythm at the end of 
reperfusion. The corresponding values in the groups 
that received HOE-694 were 25, 67, 75 (P < 0.05), and 
100% (P < 0.05), respectively.
DRUG ADMINISTRATION DURING REPERFUSION ALONE. Fig­
ure 4 shows the time course of reperfusion-induced VF 
in the groups that received EIPA and HOE-694 during 
reperfusion alone and in the contemporary control 
groups. Both drugs again suppressed the incidence of VF
and enhanced spontaneous reversion to normal sinus 
rhythm in a concentration-dependent manner. The re­
ductions in the overall incidence of VF, relative to the 
control values of 92%, reached statistical significance at 
the concentration of 10 p.M for both HOE-694 (25%) and 
EIPA (33%). HOE-694 at 0.01 p,M tended to enhance 
spontaneous defibrillation, as indicated by the signifi­
cant reductions in the incidence of VF during some of 
the later time intervals during reperfusion (Fig. 4); 
however, the overall incidence of VF was not signifi­
cantly reduced by this concentration. The concentration- 
response profiles for the drugs (Fig. 4) suggest that HOE 
694 may exhibit greater potency than EIPA when given
Fig. 4. Effects of EIPA (A) and HOE-694 (B) 
when given during  reperfusion alone on tim e 
course of reperfusion-induced VF. Incidence of VF 
was noted during  0.5-min intervals th roughout 
5-min reperfusion period. *P < 0.05 vs. 0 pM 
(control) during  corresponding interval. B
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during reperfusion alone; however, the efficacy of the 
drugs appeared comparable, with similar protection 
afforded by the highest concentration (10 p.M) of each 
agent. The incidence of VT was 100% in all groups, 
regardless of the concentration or identity of the drug. 
In both control groups, only 17% of hearts were in 
normal sinus rhythm at the end of reperfusion. In the 
groups that received 0.01, 0.1, 1, and 10 p.M of EIPA 
during reperfusion, this incidence was increased to 50,
50,50, and 83% (P < 0.05), respectively. The correspond­
ing values in the groups that received identical concen­
trations of HOE-694 during reperfusion were 75 (P < 
0.05), 50, 92 (P < 0.05), and 92% (P < 0.05), respec­
tively.
VT cycle length. As shown in Fig. 5, when adminis­
tered before ischemia plus during reperfusion, both 
drugs produced a concentration-dependent prolongation 
of VT cycle length, when measured 10 s after the 
initiation of reperfusion. In the group that received 10 
p.M of EIPA before ischemia plus during reperfusion, 
VT cycle length could not be measured because none of 
the hearts exhibited reperfusion-induced VT. VT cycle 
length during early reperfusion was not significantly 
different from control when EIPA and HOE-694 were 
administered during reperfusion alone, regardless of 
drug concentration.
Coronary flow, heart rate, and ischemic zone size. As 
shown in Table 1 , there was no significant difference
Table 1. Basal coronary flow, heart rate, and 







Coronary Flow Rate, 






0 (control) 13.6 ±0.5 14.0 ±0.7 350 ±11 60 ± 2
0.01 pre-I + R 14.7 ±1.1 16.8 ±1.0 330 ±5 57 ± 2
0.1 pre-I+ R 13.3 ±0.7 17.1 ±1.3 345 ± 9 60 ± 3
1 pre-I + R 13.1 ±0.8 16.2 ±1.1 352 ± 10 60 ± 2
10 pre-I+ R 14.3 ±0.9 16.4 ±0.7 356 ±12 56 ± 3
0.01 R 13.9 ±0.7 16.4 ±1.3 333 ± 10 56 ± 3
0.1 R 13.0 ±0.9 15.6 ±1.1 368 ± 15 55 ± 2
1 R 13.7 ±0.6 16.6 ±1.2 346 ± 14 61 ± 3
10 R 13.7 ±0.8 16.8 ±0.6 340 ±11 60 ± 3
1 HOE-694
0 (control) 11.6 ±0.3 14.6 ±0.6 322 ± 7 61 ± 2
0.01 pre-I + R 11.0 ±0.4 15.9 ±0.8 334 ± 9 62 ± 3
0.1 pre-I+ R 11.7 ±0.5 16.2 ±0.6 338 ± 6 63 ± 2
1 pre-I + R 10.3 ±0.5 14.3 ±0.7 323 ± 9 63 ±2
10 pre-I + R 13.1 ±0.4 15.2 ±0.7 352 ± 8 56 ±2
0.01 R 11.1±0.4 13.9 ±0.7 321 ± 7 64 ±2
0.1 R 12.1 ±0.7 15.6 ±1.1 339 ± 8 61 ± 2
1 R 10.9 ±0.6 14.5 ±0.9 336 ± 7 59 ± 2
10 R 13.1 ±0.6 15.3 ±0.8 338 ± 7 56 ± 2
Values are means ± SE; n = 12 rat hearts/group. LCB and RCB, left 
and right coronaiy beds, respectively; pre-I, before ischemia; R, during 
reperfusion; EIPA, 5-(N-ethyl-N-isopropyl)amiloride; HOE-694, 
3-methylsulfonyl-4-piperidinobenzoyl guanidine.
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Fig. 5. Effects of EIPA CA) and HOE-694 CB) when given before 
ischemia plus during reperfusion on cycle length of ventricular 
tachycardia (VT) determined 10 s after onset of reperfusion (see 
m e t h o d s ) .  Nos. in columns indicate group size (0 hearts exhibited VT 
in group that received 10 l^M EIPA). *P < 0.05 vs. 0 pM (control).
between control and drug-treated groups in basal left 
and right coronary flow rates, when measured at the end 
of the initial 15-min period of perfusion at constant 
pressure. Thereafter, left coronary flow rate was held 
constant at the basal value; therefore, there were no 
significant intergroup differences in left coronary flow 
rate for the rest of the experimental protocol. Flow rate 
in the right coronary bed (which was perfused at 
constant pressure throughout) did not change signifi­
cantly during the period of zero-flow ischemia in the left 
coronary bed. Right coronary flow rate increased during 
reperfusion commensurate with the severity of reperfu­
sion arrhythmias; this was probably due to reduced 
extravascular compression, as previously described (2 ,
11).
Basal heart rate also did not differ significantly be­
tween control and drug-treated groups (Table 1). The 
infusion of EIPA or HOE-694 into the left coronary bed 
for 5 min immediately before the onset of ischemia had 
no effect on heart rate, regardless of drug concentration. 
Heart rate did not change significantly in any of the 
study groups during the period of regional ischemia and 
could not be measured during early reperfusion due to 
the rapid onset of ventricular arrhythmias in the major­
ity of hearts. There was no difference between control 
and drug-treated groups in the size of the ischemic zone 
(Table 1).
Contractile Function Study
Contractile function, CVR, and heart rate. Through­
out the study, coronary flows in the control, EIPA, and
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HOE-694 groups were kept constant at their basal 
values of 16.2 ± 0.8, 16.4 ± 0.6, and 16.7 ±  0.5 
ml-min- 1-g-1, respectively [not significant (NS)]. Basal 
values (measured after 10 min of constant pressure 
perfusion) for LVEDP were 7.0 ± 0.1, 7.0 ±  0.2, and 
7.0 ± 0.2 mmHg in the control, EIPA, and HOE-694 
groups, respectively (NS). The corresponding values for 
LVDP were 106 ± 3, 105 ± 3, and 119 ± 3 mmHg, 
respectively (NS). LVEDP did not change significantly 
during the remainder of the experimental protocol in 
any of the study groups. The temporal changes in LVDP 
are shown in Fig. 6 . There was a small decline in LVDP 
with time in the control group (Fig. 6A). There was also 
a small decline in LVDP with increasing concentration 
of HOE-694 (Fig. 6C); however, the similarity with the 
control group suggests that this was a time-dependent 
rather than a drug-induced effect. In contrast, EIPA 
resulted in a steeper decline in LVDP during infusion of 
the highest concentration (Fig. 6B) such that by the end 
of the experimental protocol LVDP in this group was 
only 48% of its basal value.
Basal values for CVR were 6.8  ± 0.2, 6.5 ± 0.2, and 
6.3 ±0 . 1  mmHg-ml- 1-min^ in the control, EIPA, and 
HOE-694 groups, respectively (NS). There was a small 
increase in CVR during the first 20 min of constant flow 
perfusion in the control group; thereafter, CVR re­
mained stable (Fig. 6A). The temporal changes in CVR 
in the HOE-694 group resembled those in the control 
group (Fig. 6 C). In the EIPA group, however, CVR 
increased further with increasing concentration of drug 
such that by the end of drug infusion CVR was 170% of 
its basal value (Fig. 6B).
Basal values for heart rate were also similar in the 
control, EIPA, and HOE-694 groups at 323 ±  17, 330 ± 
12, and 315 ± 9 beats/min, respectively (NS). Heart rate 
did not change thereafter in the control (Fig. 6A) and 
HOE-694 (Fig. 6C) groups but started to decline during 
the infusion of 1 ;xM EIPA and reached 75% of its basal 
value following the infusion of 10 p.M EIPA (Fig. 6J3).
ECG parameters. In control, EIPA, and HOE-694 
groups, basal values for P-R interval were 39 ± 3, 41 ± 
3, and 37 ± 2 ms, respectively (NS), and the correspond­
ing values for QRST90 were 57 ± 3, 58 ±  3, and 62 ± 3 
ms, respectively (NS). P-R interval and QRST90 did not 
change significantly throughout the protocol in control 
and HOE-694 groups. During the infusion of 0.01, 0.1, 
and 1 p.M EIPA, these parameters also did not change 
significantly; however, after exposure to 10 |xM EIPA, 
P-R interval was prolonged to 73 ± 5 ms (P < 0.05) and 
QRST90 to 126 ± 12 ms (P < 0.05). One of the six hearts 
that received EIPA developed second-degree (2 to 1) 
atrioventricular (AV) block.
DISCUSSION
The present study has demonstrated that, in isolated 
rat hearts, the selective intracoronary administration of 
EIPA or HOE-694 into the zone subjected to ischemia 
and reperfusion affords substantial protection against 
reperfusion-induced VF. EIPA and HOE-694 exhibit 
both antifibrillatory and defibrillatory properties, with 
similar potency and efficacy. These effects are observed
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Fig. 6. Temporal changes in left ventricular developed pressure 
(LVDP), coronary vascular resistance (CVR), and  h eart ra te  (HR) 
during  infusion of vehicle (control; A), EIPA  (S ), or HOE-694 (C). 
Stippled sections a t bottom  of A-C indicate period o f constant-flow 
perfusion. Nos. in stippled sections indicate drug  concentration (pM), 
w ith 0 denoting vehicle infusion.
even when the agents are administered during reperfu­
sion alone, thus indicating the involvement of a mecha­
nism that is operative primarily during the reperfusion 
phase.
Possible Mechanism(s) of Action of EIPA and HOE-694
N a+IH+ exchange inhibition. Activation of Na+/H + 
exchange during early reperfusion has been proposed to 
result in the intracellular accumulation of Na+ and 
consequently an increase in intracellular Ca2+ concentra­
tion ([Ca2+]) via inhibition or reversal of the sarcolem-
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mal Na+/Ca2+ exchanger (15). There is indeed evidence 
that in the rat heart increased cellular Ca2+ uptake 
occurs during reperfusion, and this can be attenuated by 
pharmacological inhibition of the Na+/H+ exchanger
(28). Such a disturbance of Ca2+ homeostasis has been 
proposed as a progenitor of reperfusion-induced arrhyth­
mias, probably through a mechanism that involves the 
oscillatory release of Ca2+ from the sarcoplasmic reticu­
lum and the subsequent induction of delayed afterdepo­
larizations (17). Indeed, in the light of their activation 
mapping studies in the feline heart, Pogwizd and Corr 
(20) have suggested that the induction of VF during 
reperfusion may be mediated by a nonreentrant mecha­
nism that involves Ca2+ overload-mediated afterdepolar­
izations and triggered activity. In support of such a 
mechanism, the recent studies of Kihara and Morgan 
(12) in aequorin-loaded ferret hearts have provided 
evidence that reperfusion after 20  min of ischemia may 
result in an increase in intracellular [Ca2+], which is 
associated with the transition to VF. Thandroyen et al.
(29), using isolated spontaneously beating ventricular 
myocytes, have also suggested that increased intracellu­
lar [Ca2+] may be a causal factor in the degeneration of 
VT into VF. In addition to its proposed role in the 
induction of VF, there is evidence to suggest that 
increased intracellular [Ca2+] may be important also for 
the maintenance of VF (12,29). In the light of the above, 
the inhibition of Na+ influx through Na+/H+ exchange 
and subsequent Ca2+ overload through Na+/Ca2+ ex­
change could have mediated both the antiflbrillatory 
and the defibrillatory effects of EIPA and HOE-694 
observed in the present study.
PROTECTION BY NA+/H+ EXCHANGE INHIBITION DURING
reper fu sio n . It has been suggested (24, 25) that the 
preischemic administration of Na+/H+ exchange inhibi­
tors could attenuate tissue injury by inhibiting Na+ 
influx during the early minutes of ischemia [before the 
development of significant extracellular acidosis, which 
itself would be expected to inhibit the Na+/H+ ex­
changer (32)]. Therefore, it could be argued that under 
conditions in which Na+/H+ exchange inhibitors are 
administered before ischemia, inhibition of reperfusion- 
induced arrhythmias may occur, at least in part, as a 
consequence of reduced ischemic injury. In the present 
study, EIPA and HOE-694 suppressed reperfusion- 
induced VF not only when they were administered 
before ischemia and during reperfusion but also when 
they were given during reperfusion alone. This observa­
tion provides strong evidence to suggest that the protec­
tive effect was mediated primarily by drug action during 
the reperfusion phase and supports the hypothesis that 
the activity of the Na+/H+ exchanger during early 
reperfusion is an important determinant of the severity 
of reperfusion-induced arrhythmias. Indeed, our studies 
with transient acidic reperfusion (2 , 11) suggest that, in 
this model, inhibition ofNa+/H+ exchange for the first 2 
min of reperfusion may be sufficient to provide sus­
tained protection against VF.
Structure-activity and  specificity  considerations. 
In several cell types, EIPA and HOE-694 have been 
shown to exhibit similar potency as inhibitors of Na+ /H+
exchange (23, 24). The similar concentration-response 
profiles of the two agents observed in the present study 
are consistent with the hypothesis that Na+/H+ ex­
change inhibition is the primary and common mecha­
nism underlying their ability to protect against reperfu­
sion-induced VF. Although HOE-694 is not an amiloride 
analogue, it contains an acyl guanidine moiety in com­
mon with both amiloride and EIPA. Structure-activity 
studies with amiloride analogues in fibroblasts (14) and 
cardiac myocytes (15) have revealed that this moiety is 
important for Na+/H+ exchange inhibitory activity, 
with derivatives that contain a substituted guanidino 
group (e.g., benzamil and dichlorobenzamil) exhibiting 
much reduced potency. The acyl guanidine moiety is 
also present in other agents that interfere with Na+ 
transport, such as tetrodotoxin, and it has been sug­
gested that this moiety may facilitate drug interaction 
with a site involved in Na+ transport (15).
Recent cloning and sequencing studies (18, 33) have 
shown that there are at least four isoforms of the plasma 
membrane Na+/H+ exchanger (NHE-1, NHE-2, NHE-3, 
and NHE-4), which may exhibit differing responsiveness 
to inhibition by amiloride and its analogues (4). Only the 
ubiquitous NHE-1 isoform (18) and, to a lesser extent, 
the NHE-2 (33) and NHE-3 (18) isoforms appear to be 
expressed in the intact adult rat heart. Within the 
context of the present study, it should be noted that 
HOE-694 has been shown recently (4) to exhibit signifi­
cantly greater selectivity than amiloride and its 5-amino- 
substituted derivatives for NHE-1, the predominant 
Na+/H+ exchanger isoform expressed in the rat heart.
VT cycle length. In our earlier acidic reperfusion study 
(2 ), we reported a pH-dependent prolongation of VT 
cycle length during early reperfusion and proposed that 
slowing of VT may be a mechanism through which acidic 
reperfusion exerts its antiflbrillatory action (by enhanc­
ing spontaneous reversion of VT to sinus rhythm and 
inhibiting its deterioration to VF). In the present study, 
the administration of EIPA and HOE-694 before isch­
emia plus during reperfusion resulted in a concentration- 
dependent prolongation of VT cycle length, when mea­
sured 10 s after the onset of reperfusion. This 
prolongation of VT tycle length correlated well with the 
antiflbrillatory effects of both drugs, suggesting a causal 
role. However, the administration of EIPA or HOE-694 
during reperfusion alone did not affect VT cycle length 
but nonetheless had a protective effect comparable to 
that achieved when the drugs were also given before 
ischemia. This would suggest that prolongation of VT 
cycle length during early reperfusion is unlikely to be 
the primary mechanism by which these Na+/H+ ex­
change inhibitors exert their antiflbrillatory effects.
Nonselective effects. In the present study, exposure of 
the hearts to cumulatively increasing concentrations of 
EIPA resulted in negative inotropic and chronotropic 
effects and increased vascular resistance; this is consis­
tent with previous observations with EIPA in the guinea 
pig heart (19). During infusion of the 10 jxM concentra­
tion, EIPA also prolonged the P-R interval and QRSTgo, 
indicative of abnormalities in AV nodal conduction (in 
one heart AV block was observed) and ventricular
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depolarization and/or repolarization. It is well estab­
lished that amiloride (and to a lesser extent its ana­
logues such as EIPA) inhibit a number of other ion 
transport processes (e.g., Na+, Ca2+, and K+ channels, 
Na+/Ca2+ exchange) (13) and can have multiple electro- 
physiological effects (8). In this regard, previous in vitro 
studies have shown that amiloride can slow AV nodal 
conduction without affecting intraventricular conduc­
tion (34), have a negative chronotropic effect on the 
sinoatrial node (22), and prolong the action potential 
duration in Purkinje fibers (16). Interestingly, the pro­
nounced effect on repolarization in Purkinje fibers was 
manifest only after prolonged exposure to amiloride, 
suggesting that this effect may be mediated by the 
intracellular accumulation of the drug (16). In a similar 
manner, the cardiodepressant and electrocardiographic 
effects of EEPA observed in the present study were 
evident only during infusion of the 10 pM concentra­
tion, following prolonged (30 min) exposure to the lower 
concentrations of the drug. Therefore, nonselective ac­
tions (perhaps mediated by intracellular drug accumula­
tion) may have contributed to the protective effects of 
high concentrations of EIPA observed in the present 
study, when the drug was administered before ischemia 
(thus allowing extended exposure to the drug trapped in 
the ischemic bed). Indeed, with this treatment protocol, 
10 pM EIPA totally abolished reperfusion-induced ar­
rhythmias (including VT), a property not shared by 
HOE-694. However, nonselective effects are less likely 
to have played a major role in the protective effects of 
EIPA against reperfusion-induced arrhythmias when 
the drug was infused during reperfusion alone, where 
the duration of exposure to the drug was limited.
Although detailed electrophysiological data on HOE- 
694 are not currently available, some observations from 
the present study suggest that relative to EIPA, HOE- 
694 may exhibit fewer nonselective effects. Thus, unlike 
EIPA, prolonged exposure to increasing concentrations 
of HOE-694 (up to 10 pM) in the absence of ischemia 
and reperfusion did not affect heart rate, contractile 
function, or ECG parameters. This would be the ex­
pected profile of a selective Na+/H+ exchange inhibitor 
which, in bicarbonate-buffered medium under control 
conditions, should not affect intracellular pH or other 
ion transport mechanisms.
Relevance to the Mechanism of 
Repeifusion-Induced Arrhythmias
The results of the present study indicate that the 
activation of Na+/H+ exchange during reperfusion is an 
important arrhythmogenic factor; they do not, however, 
preclude a significant role for other factors [e.g., wash­
out of extracellular K+ (5), generation of oxygen free 
radicals (3)] in reperfusion-induced arrhythmogenesis. 
Indeed, whereas EIPA and HOE-694 significantly inhib­
ited reperfusion-induced VF in a concentration-depen­
dent manner, the incidence of reperfusion-induced VT 
remained at 100% in most groups, thus supporting the 
argument that multiple factors are involved. The only
exception was the group that received 10 jiM EIPA 
before ischemia plus during reperfusion, in which ar­
rhythmias were not detected; however, the nonselective 
effects of EIPA (discussed in Nonselective effects) may 
have contributed to this phenomenon. It is also possible 
that some factors associated with reperfusion, such as 
free radical-induced oxidant stress, may act in a synergis­
tic manner with activation of Na+/H+ exchange to 
disrupt Ca2+ homeostasis (9).
Myocardial ischemia results in the neuronal release 
and extracellular accumulation of catecholamines within 
the ischemic zone, through locally mediated mecha­
nisms (26). Previous studies (27) have shown that 
pharmacological inhibition of the Na+/H+ exchanger 
markedly suppresses this ischemia-induced catechol­
amine release. In the light of the established arrhythmo­
genic potential of adrenergic stimulation, it is probable 
that inhibition of ischemia-induced catecholamine re­
lease may have contributed to the protective effects of 
EIPA and HOE-694 in the present study, particularly 
when the drugs were given before ischemia.
Limitations of the Study
The present study utilized the known pharmacologi­
cal characteristics of two structurally distinct drugs to 
investigate the role of the Na+/H+ exchanger in reperfu­
sion arrhythmogenesis. Because EIPA and HOE-694 
have in common the ability to inhibit the Na+/H+ 
exchanger in an equipotent manner, it is reasonable to 
ascribe their similar protective effects against reperfu­
sion-induced arrhythmias in the present study to inhibi­
tion of the exchanger. However, on the basis of this 
study, it cannot be deduced whether the protection was 
mediated by reduced intracellular accumulation of Na+ 
and/or Ca2+ during reperfusion.
One limitation of the present study may be the use of 
an erythrocyte-free perfusion medium, which results in 
coronary flows in excess of those encountered in vivo; 
such high flows may result in faster washout during 
reperfusion of components (such as H+) that have 
accumulated during the preceding period of ischemia, 
which in turn may lead to an overestimation of the role 
of washout phenomena in reperfusion arrhythmogen­
esis. However, it is worth noting that in the present 
model even a 90% reduction in the rate of reflow is 
unable to suppress reperfusion-induced VF (10).
It may be argued also that the use of the rat heart, 
which has unusual electrophysiological characteristics 
(such as a short action potential duration and a high 
heart rate), may limit the applicability of the present 
findings to other species. Although this is acknowledged, 
it must be pointed out that the model used in the present 
study offers many advantages in the study of the 
pathophysiological determinants of arrhythmogenesis
(1), such as the consistent generation of regional isch­
emia and arrhythmias, the ability to use multiple drug 
concentrations and groups of adequate size (due to the 
low cost of the preparation), and the ability to infuse 
drugs selectively into the ischemic-reperfused zone.
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Concluding Comments
The present study has shown that in isolated rat 
hearts subjected to regional ischemia, the selective 
infusion into the ischemic-reperfused zone of EIPA or 
HOE-694, two structurally distinct but equipotent inhibi­
tors of the Na+/H+ exchanger, significantly suppresses 
the induction of VF during reperfusion and promotes 
spontaneous reversion to normal sinus rhythm. The 
drugs exhibit similar potency and efficacy and are 
effective even when given during reperfusion alone. The 
protective effects are observed in the absence of inter- 
group differences in the size of the ischemic zone, heart 
rate before and during ischemia, the rate of reflow, and 
oxygen tension of the perfusate. These findings are 
consistent with an arrhythmogenic role for activation of 
Na+/H+ exchange during the early moments of reperfu­
sion.
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Exacerbation of reperfusion arrhythmias by 
a | adrenergic stimulation: a potential role for 
receptor mediated activation of sarcolemmal 
sodium-hydrogen exchange
Masahiro Yasutake and Metin Avkiran
Objective: Stimulation of myocardial adrenoceptors causes (1) exacerbation of reperfusion induced 
arrhythmias, and (2) stimulation of sarcolemmal Na7H+ exchange. The aims of this study were to identify the 
a! adrenoceptor subtype involved in the former effect and to determine whether stimulation of the Na7H+ 
exchanger may play a role in this phenomenon. Methods: Isolated rat hearts were subjected to independent 
perfusion of the left and right coronary beds. After 15 min of aerobic perfusion of both beds, the adrenoceptor 
agonist phenylephrine (0.1, 1, or 10 p-M) was infused selectively into the left coronary bed for 2 min. The left 
coronary bed was then subjected to 7 min of zero flow ischaemia and 5 min of reperfusion. Results: The 
incidence of reperfusion induced ventricular fibrillation was increased from 0% in controls to 8%, 42%*, and 
75%* with 0.1, 1, and 10 p,M phenylephrine (*P<0.05); this dose dependent effect occurred in the absence 
of significant intergroup differences in vascular resistance or heart rate. Similar infusion of methoxamine at 
10 |jlM also increased the incidence of reperfusion induced ventricular fibrillation from 13% to 88%*. Infusion 
of 10 pM phenylephrine during reperfusion alone did not affect the incidence of reperfusion induced ventricular 
fibrillation. Infusion of the selective a 1A .adrenoceptor antagonist WB4101 at 0.1, 1, or 10 p,M for 2 min 
immediately before ischaemia (concomitantly with 10 p,M phenylephrine) reduced the incidence of reperfusion 
induced ventricular fibrillation from 83% to 75%, 25%*, and 0%*. Similar infusion of the selective a )B 
adrenoceptor antagonist chloroethylclonidine (0.1 or 1 p.M) or the selective [3] adrenoceptor antagonist atenolol 
(0.1 or 1 pM) did not reduce the incidence of reperfusion induced ventricular fibrillation. The novel NHE-1 
selective Na+/H+ exchange inhibitor HOE694 (10 p-M), when infused into the left coronary bed before ischaemia 
(concomitantly with 10 pM phenylephrine) and throughout reperfusion, reduced the incidence of reperfusion 
induced ventricular fibrillation from 83% to 25%*. In hearts that received 10 p.M phenylephrine before 
ischaemia, HOE694 (10 p.M) was partially effective when infused during reperfusion alone (ventricular 
fibrillation incidence reduced from 83% to 42%). Conclusions: (1) the exacerbation of reperfusion induced 
arrhythmias by a! adrenergic stimulation during ischaemia is mediated by the a ,A adrenoceptor subtype, and 
(2) increased Na7H+ exchanger activity during ischaemia and reperfusion may play a causal role in this 
phenomenon.
Cardiovascular Research 1995;29:222-230
The ai adrenergic contributions to arrhythmogenesis during myocardial ischaemia are well documented.1 Although a! adrenoceptors appear also to play a role in modulating the severity of reperfusion induced 
arrhythmias,2 the receptor subtypes and cellular mechanisms 
involved remain unclear. There is substantial evidence to 
suggest that reperfusion induced arrhythmias may be 
mediated by an increase in intracellular calcium (calcium 
overload) and subsequent delayed afterdepolarisations and 
triggered activity (for review, see Opie and Coetzee3). In this 
context, it is worth noting that in both isolated cardiac 
myocytes4 and Purkinje fibres5 exposure to an a, adreno­
ceptor agonist during simulated ischaemia has been shown 
to result in the induction of delayed afterdepolarisations 
and triggered activity upon subsequent “reperfusion”. In the 
Purkinje fibre, this proarrhythmic effect of a, adrenoceptor 
stimulation appears to be mediated by the WB4101 sensitive 
a IA adrenoceptor subtype5; however, there is only limited
evidence6 to suggest that this receptor subtype may modulate 
reperfusion arrhythmogenesis in the intact heart.
Recent observations in our laboratory7 ‘ have suggested 
that the rapid washout of extracellular H+ may be a major 
progenitor of reperfusion induced arrhythmias, probably 
through the activation or disinhibition of the Na7H+ exchanger. 
Such an increase in Na+/H+ exchanger activity during 
reperfusion may result in an increased intracellular sodium 
and consequently in calcium overload, via inhibition of 
calcium efflux or induction of calcium influx through the 
Na+/Ca2+ exchanger.9,0 Dennis et a l"  were the first to 
provide experimental evidence in favour of a role for this 
mechanism in reperfusion arrhythmogenesis. This hypothesis 
has been supported by the antiarrhythmic efficacy during 
reperfusion of pharmacological inhibitors of the Na+/H+ 
exchanger, such as amiloride and its analogues11-14 and the 
novel drug 3-methylsulphonyl-4-piperidinobenzoyl guanidine 
(HOE694).1516 In the light of the evidence in favour of an
Cardiovascular Research, The Rayne Institute, St Thomas’ Hospital, London SE1 7EH, United Kingdom: M Yasutake, M Avkiran. 
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important role for the Na+/H+ exchanger in the induction of 
arrhythmias during reperfusion, it is interesting to note that 
a] adrenergic stimulation has been shown by several investi­
gators to stimulate this exchanger in cardiac myocytes.17-21 
The possibility exists therefore that activation of the Na7H+ 
exchanger may play a causal role in the exacerbation of 
reperfusion induced arrhythmias by a! adrenergic stimu­
lation. Indeed, Gambassi et al22 have shown recently that a! 
adrenergic stimulation could induce aftercontractions (indicative 
of calcium overload) during recovery of cardiac myocytes 
from acidosis; this proarrhythmic effect could be blocked not 
only by the selective a lx adrenoceptor antagonist WB4101 
but also by the Na+/H+ exchange inhibitor ethylisopropyl- 
amiloride, implicating a causal role for increased exchanger 
activity.
The primary objectives of the present study were: (1) to 
confirm in the intact heart the identity of the adrenoceptor 
subtype involved in the exacerbation of reperfusion induced 
arrhythmias by a! adrenergic stimulation, and (2) to deter­
mine whether stimulation of the Na+/H+ exchanger could 
play a causal role in this phenomenon. In order to achieve 
these objectives we used as pharmacological tools selective 
antagonists of a 1A, a 1B, and 3, adrenoceptors (WB4101, 
chloroethylclonidine, and atenolol, respectively) and a selective 
inhibitor (HOE694) of the predominant Na7H+ exchanger 
isoform expressed in the heart In addition, we used isolated 
rat hearts subjected to independent perfusion of the left and 
right coronary beds,23 which allowed the use of regional 
ischaemia and reperfusion without mechanical damage to 
myocardial or vascular tissue and the administration of die 
drugs under study selectively into the involved zone. Our 
results show that the WB4101 sensitive a ,A adrenoceptor 
subtype mediates the proarrhythmic effects of a, adreno­
ceptor stimulation and suggest that stimulation of the Na+/H+ 
exchanger may play a causal role in this phenomenon.
Methods
This investigation was performed in accordance with the Home Office 
Guidance on the operation of the Animals (Scientific Procedures) Act 
1986, published by HMSO, London.
Dual coronary perfusion of isolated rat hearts 
Isolated rat hearts were subjected to independent perfusion of left and 
right coronary arteries, as described in detail by Avkiran and Curtis.23 
In brief, male Wistar rats were anaesthetised by inhalation of diethyl 
ether, and 100 IU of sodium heparin was injected into a femoral vein. 
The heart was then quickly excised and immersed in perfusion solution 
at 4°C. Within 30 s of excision, the dual perfusion cannula was inserted 
into the ascending aorta and secured in position with a braided silk' 
suture. Alignment of the coronary ostia with the orifices of the cannula 
was achieved using in-line monitoring of left and right coronary flow 
as a guide, the aorta being rotated on the cannula until flow in each 
perfusion bed reached a maximum. The pulmonary artery was then cut 
near its origin and a stainless steel needle was inserted into the left 
ventricle through the apex, to allow adequate drainage of coronary and 
Thebesian venous effluent
In all experimental protocols, each coronary bed was initially 
supplied with oxygenated perfusion solution from a temperature 
regulated reservoir (37°C), at a constant perfusion pressure equivalent 
to 75 mm Hg. The perfusion solution was of the following composition 
(in mmol-litre-1): NaCl 118.5, NaHC03 25.0, KC1 3.2, M gS04 1.2, 
KHjPO* 1.2, CaClj 1.4, glucose 11.0. The solution was filtered 
(pore size, 5 pm) before use and bubbled continuously with 95% 0 2 
plus 5% C 02 (pH 7.4 at 37°C). Flow to each coronary bed was 
monitored using in-line flow detectors with a linear detection range of 
0.05-30 ml min-1. In some experimental protocols (see later), basal flow 
rate in the left coronary bed was noted after 15 min of perfusion at 
constant perfusion pressure and perfusion of this bed was switched to 
constant flow at the basal flow rate, via a roller pump. During constant 
flow perfusion, 7% of the total flow supplied to the left coronary bed 
was from a side arm, through which drug solutions or vehicle could be 
administered. This technique, which has been described previously,16 
allowed the effective administration of adrenoceptor antagonists and 
HOE694 (which has limited solubility in physiological buffer solutions)
concomitantly with phenylephrine, at the required concentrations. The 
right coronary bed was perfused at constant pressure throughout the 
experiment in all protocols. The heart was housed in a temperature 
regulated chamber at 37°C and the right atrium was continuously 
superfused with oxygenated perfusion solution (37°C) at a constant rate 
of 8 ml-min"1 to maintain sinus rate.23
Experimental protocols
DETERMINATION OF DURATION OF REGIONAL ISCHAEMIA
The severity of reperfusion induced arrhythmias is highly dependent on 
the duration of the preceding period of ischaemia. In studies testing 
potential amiarrhythmic interventions in isolated rat hearts, a 10 min 
duration of regional ischaemia is commonly employed, since this 
results in a high incidence of reperfusion induced ventricular 
fibrillation.7 1 For the purpose of demonstrating an a, adrenoceptor 
mediated proarrhythmic effect, it was first necessary to determine an 
appropriate duration of ischaemia that would result in a low incidence 
of ventricular fibrillation in the control group. To achieve this objective, 
hearts (n = 6 per group) were subjected to 6, 7, or 8 min of regional 
ischaemia by stopping flow to the left coronary bed, and arrhythmias 
were analysed during a subsequent 5 min period of reperfusion at 
constant pressure (75 mm Hg).
EFFECTS OF PHENYLEPHRINE AND METHOXAMINE ON REPERFUSION 
ARRHYTHMIAS
This study was designed to test the effects of a t adrenoceptor 
stimulation during ischaemia on reperfusion induced arrhythmias. 
Phenylephrine (a non-selective a, adrenoceptor agonist) was dissolved 
in perfusion solution at concentrations of 0.1, 1, and 10 pM. These 
solutions were supplied selectively to the left coronary bed at constant 
perfusion pressure (75 mm Hg) for 2 min immediately before the 
induction of regional ischaemia by stopping flow to this bed. Control 
hearts received drug-free perfusion solution for an identical period 
(n= 12 per group). Following 7 min of ischaemia (a duration deter­
mined from the protocol described above; see Results), the left coronary 
bed was reperfused with drug-free solution for 5 min, at constant 
pressure (75 mm Hg). In additional studies, the effects of 10 pM 
methoxamine given before ischaemia (n = 8 per group) and 10 pM 
phenylephrine given during reperfusion alone (n = 6 per group) were 
also investigated.
ROLE OF a,„ ADRENOCEPTORS
This study was designed to determine the role of the WB4101 sensitive 
a IA adrenoceptor subtype in any proarrhythmic effect of phenylephrine. 
After 15 min perfusion of both coronary beds at constant pressure, 
perfusion of the left coronary bed was switched to a constant flow 
system, as described earlier. For the 2 min immediately before the 
induction of regional ischaemia, the left coronary bed received 
perfusion solution containing 10 pM phenylephrine. During this period, 
solutions containing WB4101 were infused selectively into the 
perfusion line supplying the left coronary bed at 7% of the total flow 
rate to that bed, to give a final WB4101 concentration of 0.1, 1, or 
10 pM. Control hearts received vehicle (deionised water) at the same 
infusion rate. Subsequently, all hearts (n = 12 per group) were subjected 
to 7 min of regional ischaemia (by stopping flow to the left coronary bed) 
and 5 min of reperfusion with drug-free solution at constant flow.
ROLE OF a„  AND 0 ADRENOCEPTORS
This study was designed to determine the role of a IB and 3, 
adrenoceptor mediated mechanisms in any proarrhythmic effect of 
phenylephrine. The protocol was as described above except that, instead 
of WB4101, the left coronary bed received either chloroethylclonidine 
(a IB adrenoceptor antagonist) or atenolol ($, adrenoceptor antagonist) 
at 0.1 or 1 pM, concomitantly with 10 pM phenylephrine (n = 6 per 
group).
ROLE OF N»7H* EXCHANGER
This study was designed to determine whether stimulation of the 
Nat/H" exchanger could play a causal role in any proarrhythmic effect 
of phenylephrine. The protocol was as described above except that the 
left coronary bed received 10 pM HOE694 (a novel Na'7H+ exchange 
inhibitor132* 23) either for 2 min immediately before ischaemia 
(concomitantly with 10 pM phenylephrine) plus throughout reperfusion 
or throughout reperfusion alone (n = 12 per group). The concentration 
of HOE694 was chosen on the basis of its protective efficacy against 
reperfusion induced arrhythmias in isolated rat hearts in the absence of 
exogenous a, adrenoceptor stimulation.13 16
Measured variables 
Arrhythmias -  Arrhythmias were diagnosed from a unipolar electro- 
gram (ECG) that was obtained through a silver electrode inserted into 
the free wall of the left ventricle and a reference electrode connected 
to the aorta. The ECG was continuously monitored on a digital storage 
oscilloscope and recorded on an ink jet recorder. Chart speed was set 
at 50 mm s*1 a few seconds before reperfusion so as to obtain a
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permanent high speed record of the changes in the ECG during early 
reperfusion. The ECG record obtained during the reperfusion period 
was retrospectively analysed, in a blinded manner, for the incidence, 
time to onset, and duration of ventricular tachycardia and ventricular 
fibrillation. All analyses were carried out in accordance with the 
Lambeth Conventions.26 Ventricular tachycardia was defined as four or 
more consecutive premature beats of ventricular origin and ventricular 
fibrillation as a signal in which both rate and amplitude varied from 
cycle to cycle.
Coronary flow  and heart rate -  Throughout the experimental 
protocol, coronary flow was monitored using the in-line flow detectors. 
Heart rate was determined at selected intervals from the ECG trace.
Size o f  ischaemic zone -  At the end of each experiment, the left 
coronary bed was perfused for 30 s with a solution containing 0.016% 
disulphine blue dye, at 75 mm Hg perfusion pressure. The heart was 
then removed from the perfusion apparatus, the atria and mediastinal 
tissue were removed, and dye stained tissue, representing ventricular 
myocardium subjected to ischaemia and reperfusion, was carefully 
dissected away from the remainder. The stained and unstained tissues 
were lightly blotted and weighed. The size o f the ischaemic zone, 
expressed as a percentage of total ventricular weight, was calculated 
from the equation: (weight of stained tissue/total ventricular weight) X 
100. The absolute weights obtained also enabled the calculation of 
flows in left and right coronary beds on the basis of tissue weights 
supplied by each bed (m l-m in''g"‘).
Drug sources
Phenylephrine, methoxamine, WB4101, and atenolol were purchased 
from Sigma. Chloroethylclonidine was purchased from SEMAT 
(SEMAT Technical Ltd, St Albans, UK). HOE694 was a kind gift from 
Hoechst (Hoechst AG, Frankfurt, Germany).
Exclusion criteria
These criteria, selected to minimise variations in heart rate and size of 
ischaemic zone (due to atypical coronary anatomy) among the hearts, 
were as previously described.7 8 v  Hearts were also excluded if there 
was cross flow between right and left coronary ostia.7 8 23 In addition, 
hearts with ventricular arrhythmias during the final 3 s of ischaemia 
before reperfusion were not included in the analysis of reperfusion 
induced arrhythmias, because in those hearts it would have been 
impossible to differentiate arrhythmias induced by reperfusion from 
those induced by ischaemia. Of a total of 222 hearts entered into this 
study, three were excluded on the basis of heart rate, three on the basis 
o f size of ischaemic zone, four on account of cross flow, and four on 
account of arrhythmias during the final 3 s of ischaemia. Thus the 
overall exclusion rate was 6%.
Statistical analysis
All experiments were carried out in a prospectively randomised manner. 
Gaussian distributed variables were expressed as mean(SEM) and were 
subjected to one way analysis of variance. If a difference among mean 
values was established, comparison with controls was performed using 
Dunnett’s test. Binominally distributed variables, such as the incidence 
o f ventricular tachycardia or fibrillation, were compared using the x2 
test for a 2 X n table. If a significant difference was revealed, each drug 
treated group was then compared with the control group using the 
Fisher exact test, with the Bonferroni correction for multiple 
comparisons. A P value of <0.05 was considered significant.
Results
Reperfusion induced arrhythmias
DETERMINATION OF DURATION OF REGIONAL ISCHAEMIA
Figure 1 shows the incidence of reperfusion induced ven­
tricular tachycardia and ventricular fibrillation in hearts 
subjected to 6 , 7, or 8 min of regional ischaemia. On the 
basis of these results, 7 min of regional ischaemia, which 
resulted in a 67% incidence of reperfusion induced ven­
tricular tachycardia and a 17% incidence of reperfusion 
induced ventricular fibrillation, was chosen for use in 
subsequent protocols designed to test the proarrhythmic 
effects of a | adrenoceptor stimulation and to determine the 
mechanisms of any such effect.
EFFECTS OF PHENYLEPHRINE AND METHOXAMINE ON 
REPERFUSION ARRHYTHMIAS
Figure 2 shows the time course of reperfusion induced 
arrhythmias in the control group and in the groups in which 
the left coronary bed received 0.1, 1, or 10 p-M phenyl­
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Figure 1 The incidence o f  reperfusion induced ventricular 
tachycardia (hatched bars) and ventricular fibrillation (so lid  bars) 
in hearts subjected to 6, 7, o r 8 min o f  regional ischaem ia  
( n - 6  p e r  group).
ephrine for 2 min immediately before 7 min of ischaemia. 
Phenylephrine tended to increase the incidence of re­
perfusion induced ventricular tachycardia from 58% in the 
control group to 67%, 100%, and 100% at concentrations of 
0.1, 1, and 10 p.M, respectively; however, these increases 
were not statistically significant. At the same concentrations, 
phenylephrine also increased the incidence of ventricular 
fibrillation from 0% in the control group to 8% (NS), 42% 
(NS), and 75% (P<0.05), respectively. By the end of the 
reperfusion period, 100% of the control hearts were in 
normal sinus rhythm; phenylephrine reduced this incidence 
to 92% (NS), 58% (NS), and 50% (P<0.05) at concen­
trations of 0.1, 1, and 10 |xM, respectively. Methoxamine 
(10 jjlM) had a similar effect to phenylephrine, increasing 
the incidence of reperfusion induced ventricular fibrillation 
from 13% to 88% (P<0.05) and decreasing the proportion 
of hearts in normal sinus rhythm at the end of reperfusion 
from 88% to 13% (P<0.05). Phenylephrine at 10 p.M, when 
given during reperfusion alone, did not significantly affect 
the incidence of reperfusion induced ventricular tachycardia 
and ventricular fibrillation relative to a contemporary control 
group.
ROLE OF a ,A ADRENOCEPTORS
Figure 3 shows the time course of reperfusion induced 
arrhythmias in four study groups in which the left coronary 
bed received 10 jjlM phenylephrine for 2 min immediately 
before the onset of ischaemia, either in the absence (control) 
or presence of WB4101 (0.1, 1, or 10 p.M). WB4101 
suppressed the proarrhythmic effects of 10 jxM phenyl­
ephrine in a dose dependent manner, such that the incidence 
of reperfusion induced ventricular fibrillation was reduced 
from 83% in the control group to 75% (NS), 25% (P < 0.05), 
and 0% (P<0.05) at concentrations of 0.1, 1, and 10 p.M, 
respectively. The incidence of reperfusion induced ven­
tricular tachycardia was 100% in the control group, and 
100% (NS), 92% (NS), and 0% (P<0.05) in the groups that 
received 0.1, 1, and 10 p,M WB4101, respectively. In the 
control group, only 33% of hearts were in normal sinus 
rhythm at the end of the reperfusion period. The infusion of 
WB4101 at concentrations of 0.1, 1, or 10 p.M increased this 
incidence to 50% (NS), 75% (NS), and 100% (P<0.05), 
respectively.
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F igure 2  Time course o f  reperfusion induced ventricular 
arrhythm ias in individual hearts in the various study groups 
com prising the phenylephrine dose-response study. The numbers 
given above each panel indicate the concentration o f  phenylephrine  
in punol-litre'1. Each horizontal bar represents an individual heart; 
open sections represent normal sinus rhythm, hatched sections 
ventricular tachycardia, and filled  sections ventricular fibrillation. 
For clarity, the hearts in each group (n =  12) are arranged in 
relation to the time o f  reversion to stable sinus rhythm and  not in 
relation to the order in which the experiments were carried out 
(the study was randomised).
ROLE OF a ,B AND p ADRENOCEPTORS
Figure 4 shows the effects of concomitant infusion of chloro- 
ethylclonidine (a,B adrenoceptor antagonist) or atenolol 
0 , adrenoceptor antagonist) on the proarrhythmic effects of 
10 pM phenylephrine. Neither drug produced a significant 
change in the incidence of reperfusion induced ventricular 
tachycardia or ventricular fibrillation, relative to the control 
group that received phenylephrine alone.
          .
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Figure 3 Time course o f  reperfusion induced ventricular  
arrhythmias in individual hearts in the various study groups that 
received 10 p M  phenylephrine either alone or in combination with  
various concentrations o f  WB4101 (WB). The num bers given  
above each panel indicate the concentrations o f  phenylephrine  
and WB4101 in pm o l litre '1. Each horizontal bar represents an 
individual heart; open sections represent normal sinus rhythm, 
hatched sections ventricular tachycardia, and filled  sections  
ventricular fibrillation. For clarity, the hearts in each group  
(n = 12) are arranged in relation to the time o f  reversion to stable  
sinus rhythm and not in relation to the order in which the 
experiments were carried out (the study was randomised).
ROLE OF N a W  EXCHANGE
Figure 5 shows the time course of reperfusion induced 
arrhythmias in the control group in which the left coronary 
bed received 10 pM phenylephrine for 2 min immediately 
before ischaemia and in the two treatment groups in which 
10 pM HOE694 was also given, either concomitantly with 
phenylephrine plus during reperfusion or during reperfusion
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F igure 4  The effects o f  chloroethylclonidine (CEC) and atenolol 
(ATL) on the incidence o f  reperfusion induced ventricular tachy­
cardia (hatched bars) and ventricular fibrillation (solid bars), 
when adm inistered concomitantly with 10 p M  phenylephrine. 
Control hearts received 10 p M  phenylephrine alone (n = 6 per  
group).
alone. The incidence of reperfusion induced ventricular 
tachycardia was 100% in all three groups. When HOE694 
was infused before ischaemia (concomitantly with 10 p,M 
phenylephrine) plus throughout reperfusion, the incidence of 
ventricular fibrillation was reduced from 83% in the control 
group to 25% (P<0.05). In addition, 100% of hearts were 
in normal sinus rhythm at the end of reperfusion, relative to 
only 42% in the control group (P<0.05). The infusion of 
HOE694 during reperfusion alone was partially effective, 
reducing the incidence of ventricular fibrillation from 83% in 
the control group to 42% (NS) and increasing the number of 
hearts in normal sinus rhythm at the end of reperfusion from 
42% in the control group to 92% (P < 0.05).
Ischaemic zone size, coronary flow, and heart rate 
There were no significant differences between the groups 
within each protocol in ischaemic zone size [range: 52(SEM 2) 
to 63(6)%] and basal values for coronary flow rate [range: 
10.0(0.2) to 13.1(1.4) ml-min~'-g' 1 in the left coronary bed, 
10.6(0.9) to 14.8(0.8) m lm nr'g ' 1 in the right coronary bed] 
and heart rate [range: 310(4) to 349(10) beats min"1 ]. In the 
protocol designed to test the effects of phenylephrine on 
reperfusion induced arrhythmias, the effects on vascular 
resistance were determined by continuous monitoring of the 
coronary flow rate during die preischaemic perfusion of 
phenylephrine at constant perfusion pressure. Flow in the 
right coronary bed was not affected during the selective 
infusion of phenylephrine into the left coronary bed. The 
lowest concentration of phenylephrine (0.1 |xM) produced a 
transient vasodilatation in the left coronary bed, whereas 
1 and 10 p-M phenylephrine had no significant effect; by the 
end of the 2 min period of perfusion with control or 
phenylephrine containing solution, there was no significant 
difference in left coronary flow rate between the four study 
groups. Methoxamine (10 p-M) also did not have a 
significant effect on either left or right coronary flow rate. 
During the period of zero flow ischaemia in the left coronary 
bed, flow rate in the right coronary bed did not change 
significantly. During reperfusion, flow rate increased in both 
coronary beds commensurate with the severity of reperfusion 
induced arrhythmias, as previously described.7 8 The absence 
of a significant coronary vasoconstrictor effect with phenyl­
ephrine at concentrations of up to 10 pM allowed the 
infusion of phenylephrine into the left coronary bed at 
constant flow without an increase in perfusion pressure in 
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Figure 5 Time course o f  reperfusion induced arrhythmias in 
individual hearts in the various study groups that received 10 p M  
phenylephrine, with or without H OE694 (HOE). HOE694 was 
infused  either before ischaemia (concomitant with phenylephrine) 
and throughout reperfusion (pre I  + R) or during reperfusion alone  
(R alone). The numbers given above each panel indicate the 
concentrations o f  phenylephrine and HOE694 in p m o lli tr e '1. Each 
horizontal bar represents an individual heart; white sections  
represent normal sinus rhythm, hatched sections ventricular tachy­
cardia, and  black sections ventricular fibrillation. For clarity, 
the hearts in each group (n = 12) are arranged in relation to the 
time o f  reversion to stable sinus rhythm and not in relation to the 
order in which the experiments were carried out (the study was 
randomised).
into the left coronary bed concomitantly with phenylephrine 
through a side arm, as described in Methods.
The selective administration of phenylephrine or 
methoxamine to the left coronary bed for 2 min immediately 
prior to the onset of ischaemia, either alone or con­
comitantly with any of the other agents, did not affect heart 
rate. Heart rate did not change significantly during the 7 min 
period of regional ischaemia in any of the study groups and 
could not be measured during early reperfusion due to the 
rapid onset of ventricular arrhythmias in the majority of 
hearts.
Discussion
This study has shown that, in isolated rat hearts subjected to 
regional ischaemia and reperfusion, selective exposure of
843981
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the ischaemic myocardium to an exogenous, non-selective 
a, adrenoceptor agonist (phenylephrine) exacerbates 
reperfusion induced arrhythmias in a dose dependent 
manner. This proarrhythmic effect is mimicked by another 
nonselective a, adrenoceptor agonist (methoxamine) and can 
be inhibited by an antagonist selective for a 1A adrenoceptors 
but not by antagonists selective for either a 1B or (3, adreno­
ceptors, suggesting that the effect is mediated by a specific 
adrenoceptor subtype. Furthermore, the present study 
provides the first evidence in intact hearts that receptor 
mediated activation of the sarcolemmal Na+/H+ exchanger 
may be involved in the downstream cellular mechanisms of 
this proarrhythmic effect.
Adrenoceptor subtype(s) mediating the effects o f 
phenylephrine
Mammalian postsynaptic ai adrenoceptors have been 
divided into two pharmacologically distinct receptor sub- 
types, termed a 1A and a 1B.27 The a IA subtype exhibits high 
affinity for WB4101, a competitive antagonist, and relative 
insensitivity to chloroethylclonidine, an alkylating agent. In 
contrast, the a 1B subtype exhibits low affinity for WB4101 
and is inactivated irreversibly by chloroethylclonidine. 
Radioligand binding studies28 have shown both adrenoceptor 
subtypes to be present in rat ventricular myocardium, with 
an a lA:a1B ratio of 30:70. Although molecular cloning 
studies29 suggest the existence of additional a, adrenoceptor 
subtypes, their expression and functional role in ventricular 
myocardium have not been fully characterised.
The observation in the present study that WB4101 could 
inhibit (in a dose dependent manner) the proarrhythmic 
effect of phenylephrine suggests that this effect was 
mediated via a ,A adrenoceptors. This possibility is further 
supported by the apparent inability of a 1B and 3, adreno­
ceptor blockade (by chloroethylclonidine and atenolol, 
respectively) to inhibit the proarrhythmic effect of 
phenylephrine. These results are consistent with previous 
observations in canine Purkinje fibres subjected to simulated 
ischaemia and reperfusion5 and are supportive of the pre­
liminary observations of Brittain-Valenti et al6 that a 1A 
adrenoceptor stimulation may exacerbate reperfusion 
induced arrhythmias in vivo. It should be noted that, at 
10 p.mol-litre'1, WB4101 not only reversed the profibrillatory 
effect of phenylephrine but abolished all reperfusion induced 
arrhythmias. This effect may have occurred through 
inhibition of a iA adrenoceptor stimulation by endogenous 
catecholamines or non-specific antiarrhythmic effects of 
WB4101 at high concentration.
Cellular proarrhythmic mechanisms downstream o f 
receptor activation
As noted earlier, there is increasing evidence7 8 11-16 that 
activation of the Na7H+ exchanger may be a major pro­
genitor of reperfusion induced arrhythmias. It is reasonable 
to propose therefore that modulation of exchanger activity 
through a, adrenoceptor mediated mechanisms may have a 
significant impact on the severity of reperfusion induced 
arrhythmias.
Receptor mediated modulation o f Na*/H* exchanger 
activity -  Recent cloning and sequencing studies30 31 have 
shown that there are at least four different isoforms of the 
Na7H+ exchanger (NHE-1, NHE-2, NHE-3, and NHE-4), 
which have distinct regulatory and kinetic properties. In the 
normal adult rat heart (as used in the present study), only the 
ubiquitous NHE-1 isoform of the exchanger family appears 
to be expressed to a significant extent.30 31 Available
evidence suggests that the activity of this isoform is 
increased not only by intracellular acidosis but also by a 
variety of growth factors and neurohormonal agents, through 
receptor mediated mechanisms.32 Of direct relevance to the 
present study, recent studies17-21 in isolated cardiac myocytes 
have shown that stimulation of a, adrenoceptors results in 
increased sarcolemmal Na7H+ exchanger activity. There is 
evidence33 to suggest that, at least in the rat, such activation 
of the exchanger may be mediated by the pharmacologically 
identifiable a 1A adrenoceptor.
Figure 6 depicts the cellular signalling pathways that may 
be involved in a 1A adrenoceptor mediated activation of the 
sarcolemmal Na7H+ exchanger. Recent studies28 have shown 
that stimulation of myocardial a 1A adrenoceptors results in 
phospholipase C activation and phosphoinositide hydrolysis. 
In a variety of tissues and cell types, the consequent pro­
duction of diacylglycerol and release of Ca2+ from intra­
cellular stores results in the activation of protein kinase C 
and its translocation to the cell membrane. Of particular 
relevance to the present study, translocation of protein 
kinase C to the sarcolemma has been shown to occur in 
cardiac myocardium, following exposure to phenylephrine.34 
It is well established that agents that activate protein 
kinase C are capable of activating NHE-1,35 although this is 
unlikely to occur via direct phosphorylation of the exchanger 
by protein kinase C.36 Instead, it has been proposed35 that the 
signalling pathways downstream of receptor activation may 
involve activation of other kinases, possibly including a 
specific NHE kinase. In the present context, a, adrenoceptor 
mediated stimulation of Na7H+ exchanger activity in 
ventricular myocytes has been shown by several 
investigators17-19 to be inhibited by pharmacological 
inhibition or downregulation of protein kinase C (although 
this has been disputed by Puceat and colleagues20). Further­
more, myocardial Na+/H+ exchanger activity is increased by 
phorbol esters which directly activate protein kinase C.37 
There is very recent evidence38 suggesting that receptor 
mediated activation of NHE-1 can also occur via an 
additional mechanism, possibly involving a regulatory 
factor, which does not require phosphorylation of the 
exchanger. The relevance of this mechanism to a, adreno­
ceptor mediated stimulation of Na7H+ exchanger activity in 
cardiac myocytes remains to be determined.
Na*/H* exchanger activity in ischaemia versus reperfusion 
-  In the present study, the proarrhythmic effect of phenyl­
ephrine was significantly reversed by the administration of
Figure 6 Schematic diagram o f cellular signalling pathw ays that 
may be involved in a ,A adrenoceptor m ediated activation o f  sarco­
lemmal Na*/H* exchanger (NHE) activity. G - G  protein; PLC  -  
phospholipase C; PIP2 = phosphatidylinositol 4,5-bisphosphate; 
1P3 =  inositol 1,4,5-trisphosphate; DAG  = diacylglycerol; P K C  = 






HOE694 (a selective inhibitor of NHE-124), concomitantly 
with phenylephrine and during reperfusion. Even when given 
during reperfusion alone, HOE694 provided partial pro­
tection against the proarrhythmic effect of phenylephrine. 
These observations suggest that under the experimental 
conditions employed reperfusion-induced arrhythmias were 
modulated by Na7H+ exchanger activity not only during 
ischaemia but also during reperfusion. Contrary to this 
hypothesis, however, phenylephrine (which, in the absence 
of a! adrenoceptor antagonists should increase Na+/H+ 
exchanger activity) did not affect the severity of reperfusion 
induced arrhythmias when given during reperfusion alone. 
Our recent studies in the same model39 suggest the 
modulation of Na7H+ exchanger activity during reperfusion 
may only affect the incidence of severe arrhythmias if such 
modulation occurs during the first two minutes of 
reperfusion (before recovery of the sarcolemmal Na7K+ 
pump from ischaemia induced inhibition). It is probable 
therefore that the lack of effect of phenylephrine when given 
during reperfusion alone may have been due to inadequate 
activation of the Na7H+ exchanger during this limited 
vulnerable period. In this regard, in isolated ventricular 
myocytes (where drug access to myocardial receptor sites 
should occur more readily thari in intact hearts perfused 
through the coronary vasculature), maximum stimulation of 
exchanger activity by phenylephrine has been, shown to 
occur after three to four minutes of exposure to the 
agonist.21
The sarcolemmal Na7H+ exchanger has been shown to be 
inhibited by extracellular acidosis40 and hypoxia.41 These 
conditions both occur during myocardial ischaemia and 
would be expected to inhibit the Na7H+ exchanger, thus 
allowing little scope for pharmacological inhibition of the 
exchanger during the ischaemic period. Our observation that 
HOE694 provides greater protection when given before 
ischaemia and during reperfusion, relative to when given 
during reperfusion alone, may provide indirect evidence that 
the Na‘7H+ exchanger retains some activity during the period 
of ischaemia employed, at least in the presence of phenyl­
ephrine. Indeed, even in the absence of exogenous a, 
adrenergic stimulation, recent studies42 have shown that
5-(iV-ethyl-N-isopropyl) amiloride (EIPA) can inhibit the 
intracellular accumulation of Na+ during ischaemia, pre­
sumably through inhibition of an active Na7H+ exchanger.
Is calcium the key arrhythmogenic mediator? — As noted 
earlier, intracellular calcium overload has been proposed as 
the key mediator of reperfusion induced ventricular 
arrhythmias.3 Within the context of the present study, there 
is evidence43 that stimulation of myocardial a! adrenoceptors 
may promote calcium overload during reperfusion. Although 
the present study does not provide any direct evidence 
regarding cellular ionic mechanisms, the possibility that the 
proarrhythmic action of phenylephrine may involve receptor 
mediated stimulation of Na7H+ exchanger activity is 
consistent with a key role for intracellular calcium in 
reperfusion anhythmogenesis. As noted earlier, it has been 
proposed that calcium overload during reperfusion may 
occur, at least in part, through mechanisms involving the 
sarcolemmal Na7H+ and Na7Ca2+ exchangers (for recent 
reviews, see Tani10 and Karmazyn and Moffat37). Since 
pharmacological inhibitors of the Na7H+ exchanger have 
been shown to attenuate both calcium overload44 and 
arrhythmias11-16 during reperfusion, agents that stimulate 
the Na+/H+ exchanger would be expected to exacerbate 
calcium overload and arrhythmias under comparable 
conditions.
Modulation of reperfusion arrhythmias by endogenous 
catecholamines
In the present study, we have investigated the potential 
mechanisms of the proarrhythmic effect of an exogenous 
a] adrenergic agonist. There is substantial evidence that 
endogenous catecholamines, which are known to be released 
during ischaemia,45 may also modulate ventricular arrhyth­
mias induced by ischaemia and reperfusion, through a! 
adrenoceptor mediated mechanisms (for review, see 
Corr et all). Thus the potential proarrhythmic mechanisms 
(of phenylephrine) identified in the present study may also 
play a role in modulating reperfusion arrhythmogenesis in 
the absence of exogenous agonists. Indeed, as noted earlier, 
there is preliminary evidence6 that reperfusion induced 
arrhythmias in vivo may be exacerbated by a,A adrenoceptor 
stimulation. Furthermore, there is evidence46 that activation 
of neuronal Na7H+ exchange may enhance the release of 
endogenous catecholamines during ischaemia; inhibition of 
this process may provide an additional mechanism by which 
pharmacological inhibition of the Na7H+ exchanger during 
ischaemia might be beneficial.
Potential limitations of the study
The conclusions of the present study are based on the 
selective pharmacological properties of the agents used. 
Although WB4101, chloroethylclonidine, and atenolol are 
well characterised as selective inhibitors of a IA, a1B, and (3, 
adrenoceptors, respectively, the Na7H+ exchange inhibitor 
HOE694 is a relatively new compound where pharma­
cological characterisation may not be complete. Since 
amiloride analogues (which also inhibit the Na7H+ 
exchanger and with which HOE694 shares certain structural 
similarities23) have been shown47 to possess some a, adreno­
ceptor antagonistic activity, such a mechanism might have 
mediated the reversal of the proarrhythmic effects of phenyl­
ephrine by HOE694. In contrast, however, radioligand 
binding studies have shown that HOE694 does not bind to 
a, adrenoceptors of rat forebrain synaptosomes (W Scholz, 
personal communication). Furthermore, HOE694 has recently 
been shown24 to have greater selectivity than amiloride 
analogues for NHE-1, the predominant Na7H+ exchanger 
isoform expressed in the rat heart In addition, although 
amiloride and its analogues have negative inotropic effects 
because of their secondary pharmacological properties,48 
recent studies in our laboratory16 have shown that HOE694 
does not affect cardiac function under normal aerobic 
conditions. These observations suggest that HOE694 may be 
more selective than amiloride and its analogues as an 
inhibitor of sarcolemmal Na7H+ exchange.
It should be noted that there are significant interspecies 
differences in myocardial a] adrenoceptor content, with rat 
ventricular myocardium possessing a five- to eightfold 
greater receptor density than guinea pig, mouse, pig, calf, 
and man.49 It is possible therefore that any proarrhythmic 
effect of at] adrenoceptor stimulation might be exaggerated 
in the rat. In the light of this, extrapolation of the findings 
of the present study to other species should be undertaken 
with caution.
Concluding comments
Through the application of subtype selective adrenoceptor 
antagonists and a selective inhibitor of the predominant 
NaVH+ exchanger isoform expressed in the heart, the present 
study has (1) shown that the exacerbation of reperfusion 
induced arrhythmias by an exogenous adrenoceptor 
agonist is mediated by the aiA adrenoceptor subtype, and
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(2) suggested that receptor mediated stimulation of sarco­
lemmal Na7H+ exchanger activity may be involved in the 
downstream cellular mechanisms of this proarrhythmic 
effect. Further work is required to determine the relevant 
signal transduction mechanisms and to confirm whether 
similar receptor mediated mechanisms are involved in 
the modulation of reperfusion induced arrhythmias by 
endogenous catecholamines.
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A. INTRODUCTION
In many experimental studies, reperfusion o f myocardium subjected to a brief period of ischemia has been shown to result in the rapid induction o f severe ventricular arrhythmias (for a review, see Manning 
and Hearse1). Commonly, polymorphic ventricular tachycardia (VT) 
develops within a few beats after the onset o f reperfusion, and in the 
absence o f protective interventions, this frequently degenerates into 
ventricular fibrillation (VF).2 Observations made in patients with 
Prinzmetal’s angina3 and silent myocardial ischemia4 suggest that a similar 
pattern of reperfusion-induced arrhythmogenesis may occur also in man.
In several species, a “bell-shaped” relationship has been demon­
strated between the severity of reperfusion-induced arrhythmias and 
the duration of the preceding period o f  ischemia;1 The duration that 
results in maximum susceptibility to reperfusion-induced VF is rela­
tively short: 5-10 minutes in the anesthetized rat,1 10-15 minutes in 
the isolated rat heart,1,5 20-25 minutes in the isolated rabbit heart,6 
and 20-30 minutes in the anesthetized dog.1 With more prolonged 
ischemia, susceptibility to reperfusion-induced VF declines with in­
creasing duration. Although, for obvious ethical reasons, the presence




of a bell-shaped relationship (between ischemia duration and suscepti­
bility to reperfusion-induced arrhythmias) has not been directly tested 
in man, there is circumstantial evidence to suggest that such a rela­
tionship may exist. Thus, reperfusion during cardiac surgery after relatively 
short (< 60 min.) periods o f ischemia has been shown to result in a 
50% incidence of ventricular fibrillation.7 In contrast, as discussed 
previously,8 serious reperfusion-induced ventricular arrhythmias were 
uncommon in large scale clinical trials with intravenously administered 
thrombolytic agents-A contributory factor to this phenomenon may 
have been the fact that thrombolytic therapy was started hours, rather 
than minutes, after the onset of symptoms. Indeed, a survey o f clinical 
trials with intracoronary thrombolysis has revealed a decreasing inci­
dence of severe reperfusion-induced; ventricular arrhythmias with in­
creasing duration of ischemia-9 The malignant nature of the arrhythmias 
observed during reperfusion in experimental studies (polymorphic VT  
and/or VF) has led several investigators to suggest that such arrhythmias 
may underlie some cases o f sudden cardiac, death in man-10,11
The cellular mechanisms o f reperfusion-induced arrhythmias are 
likely to differ from those responsible for ischem ia-induced  
arrhythmias.12*13 Although the fundamental question o f whether the 
arrhythmogenic process is initiated by the washout of substances 
accumulated during ischemia or by the resupply o f substances absent 
during ischemia remains to be resolved,14 several factors have been 
implicated in reperfusion arrhythmogenesis. Among these putative 
arrhythmogenic factors, recent evidence appears to favor a causal in­
volvement for free oxygen radical generation (and associated oxidant 
stress) and, in particular, sarcolemmal Na*/H* exchanger activation.
B. AN INVOLVEMENT OF FREE OXYGEN RADICALS?
A potential link between the generation of free oxygen radicals, 
upon the reintroduction o f oxygen during the early moments o f  
reperfusion, and the induction of arrhythmias first became evident when 
scavengers of such radicals were shown to inhibit reperfusion-induced 
arrhythmias.15 This association was supported by subsequent studies, 
which not only confirmed that reperfusion arrhythmias could be in­
hibited by free oxygen radical scavengers but also showed that they 
could be exacerbated by radical generating systems-16 Further support 
came from studies which showed that a burst of free radical produc­
tion occurs during early reperfusion17 and that reactive oxygen inter­
mediates are sufficient to generate ventricular arrhythmias, in the ab­
sence of ischemia and reperfusion.18,19 However, the results o f studies 
with radical scavenging and generating systems have not been unequivo­
cal,20 and some investigators have argued that free oxygen radicals are 
unlikely to be the prime cause o f ventricular arrhythmias during early 
reperfusion.20,21 In this context, Yamada et al22 have shown that anoxic 
reperfusion delays the cime-to-onset but does not significantly alter
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the incidence o f reperfusion-induced VF. This observation led these 
investigators to conclude that re-establishment of flow and readmis­
sion of oxygen were independent determinants of reperfusion-induced 
arrhythmias and that the latter was not a prerequisite for arrhythmo­
genesis. It appears, therefore, that although free oxygen radicals may 
modulate reperfusion-induced arrhythmias significantly, their genera­
tion may not be the dominant progenitor of these arrhythmias.
C. EVIDENCE FOR A KEY ROLE 
FOR THE Na*/H* EXCHANGER
C .l  M echanism of Activation a n d  Consequences 
o n  Ionic  H omeostasis
Myocardial ischemia is known to result in acidosis, due to a re­
tention of H* from glycolytic adenosine triphosphate (ATP) turnover, 
carbon dioxide accumulation and net ATP breakdown.23 Intracellular 
acidosis during early ischemia would, be expected to stimulate H* ex­
trusion pathways, including the Na*/H* exchanger.23 With maintained 
ischemia, however, extracellular acidosis has been shown to exceed in­
tracellular acidosis, with reversal, o f  the transmembrane H* gradient 
occurring within 10 minutes, in rabbit papillary muscle.24 Since the 
sarcolemmal Na+/H* exchanger is inhibited by extracellular acidosis,25,26 
such an effect on extracellular pH o f  prolonged ischemia would be 
expected to result in a secondary inhibition o f the exchanger.
The potential consequences of postischemic reperfusion on sarcolem­
mal Na*/H* exchanger activity and intracellular ionic homeostasis are 
schematically summarized in Figure 9.1. Lazdunski et aP were the first to 
suggest that the rapid washout o f extracellular H* upon reperfusion 
could reactivate the Na*/H* exchanger (by alleviating. the inhibition 
by extracellular acidosis) and create an. intracellular-to-extracellular H* 
gradient, resulting in a significant influx of Na* via this route. Such an influx 
o f Na*, in the presence o f Na*/K* pump inhibition caused by the preced­
ing ischemia, could then result in an increase in intracellular Na*. Although 
there is controversy over whether a large increase in intracellular Na* con­
centration occurs during early reperfusion,. this may be due partly to the 
inability o f current techniques (e.g.r ion-selective microelectrodes, fluo­
rescent dyes and nuclear magnetic resonance) to measure Na* concentra­
tion in the relevant cellular compartment; the subsarcolemmal “fuzzy space.”28 
Even a modest increase in intracellular; Na* concentration would be ex­
pected to alter significantly the reversal potential of the Na*/Ca2* exchanger 
(which, under normal conditions, operates primarily to extrude Ca2* from 
the cell), favoring intracellular Ca2* accumulation.29 The resulting distur­
bance of Ca2* homeostasis has been proposed as a progenitor o f reperfusion- 
induced arrhythmias,30 probably through a mechanism that involves 
the oscillatory release of Ca2* from the sarcoplasmic reticulum (SR) 
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Fig. 9.1. Schematic depiction of the potential consequences o f reperfusion on Na*/H* exchanger 
activity, ionic homeostasis and cardiac rhythm. According to this scheme, an influx o f Na* through the 
N  a*/H* exchanger results in an increased intracellular Na* concentration (due to inhibition of the Na*/K* 
pum p during preceding ischemia) and thereby an increased Ca2* concentration (Ca2* overload) via the 
Na*/Ca2* exchanger. The resultant oscillatory release o f Ca2* from the sarcoplasmic reticulum (SR) and 
induction o f afterdepolarizations may precipitate ventricular fibrillation (see text for details).
C .2  Ev id e n c e  f o r  a n  A r r h y t h m o g e n ic  R o l e
Dennis ec al32 provided the first experimental evidence to suggest 
that activation o f the Na*/H* exchanger, as proposed by Lazdunski et 
al,27 may contribute to arrhythmogenesis during reperfusion. This hy­
pothesis has been supported further by studies em ploying acidic 
reperfusion in the authors’ laboratory,2*33 which have shown that slow­
ing the rate at which extracellular pH  is restored to its normal physi­
ological value during early reperfusion inhibits the induction o f VF 
and promotes spontaneous reversion from VT to normal sinus rhythm. 
This effect occurred in a pH-dependent manner,2 with significant pro­
tection against VF observed at pH values (pH  6.6 and 6.4) that would 
be expected to inhibit significantly the NaVH*' exchanger.25,26 This is
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consistent with a major arrhythmogenic role for the rapid washout of 
extracellular H* during uncontrolled reperfusion, the most likely mecha­
nism being activation o f the Na*/H* exchanger.27 Furthermore, a re­
cent study in rat hearts by the authors’ group (using a novel dual 
coronary perfusion technique34) has shown that selective administra­
tion o f two structurally distinct pharmacological inhibitors of the 
Na*/H* exchanger (ethyl-isopropyl amiloride a^nd HOE694) into the 
ischemic/reperfused zone reduces, in a concentration-dependent man­
ner, the incidence of reperfusion-induced VF.35 Interestingly, both drugs 
were effective not only when given before ischemia and during 
reperfusion, but also when given only during reperfusion, suggesting 
that the protective action of Na*/H* exchanger inhibition was opera­
tive, at least in part, during the reperfusion phase. Observations con­
sistent with these results have been obtained also with the global ad­
ministration of a range o f Na*/H* exchanger inhibitors, such as amiloride 
and its analogs32,36'38 and the newer compounds H OE69438-40 and 
HOE642.41
C.3 I n te r a c t io n  w i t h  th e . Na*/K* Pump
As discussed earlier arid depicted in Figure 9.1, the magnitude-of 
any increase in intracellular Na* concentration that occurs during early 
reperfusion as a consequence o f Na* influx through the: Na*/H* ex­
changer may depend to a large extent on the activity of the primary 
Na* extrusion pathway, namely the sarcolemmal Na*/K* pump. Even 
under normal conditions, activation o f the Na*/H* exchanger by the 
abrupt creation of an intracellular to extracellular H* gradient can re­
sult in increased intracellular Na* concentration and stimulate electro- 
genic Na* extrusion via the Na*/K* pump.42,43 In the presence o f phar­
macological inhibition o f the Na*/K* pump, the creation o f such a H* 
gradient has been shown, in both isolated myocytes44 and whole hearts,45 
to result in the rapid intracellular accumulation o f Ca2*, most prob­
ably through the Na*/Ca2* exchanger. In a similar manner, the activ­
ity o f  the Na*/K* pump also may modulate intracellular Ca2* accumu­
lation during reperfusion.27,46 In support of this, it has been shown 
that with pharmacological inhibition o f  the Na*/K* pump reperfusion 
results in a greater increase in intracellular Ca2* concentration relative 
to that observed in the absence o f such inhibition.47,48 This increase in 
intracellular Ca2* accumulation during reperfusion has been associated 
with an exacerbation of contractile dysfunction,47 as well as an increased 
incidence of VF.48
In this context, the histochemical studies o f Winston et al49 have 
shown that the activity o f Na*/K* ATPase (the biochemical correlate 
o f the Na*/K* pump) is- depressed significantly during acute ischemia, 
while the tissue enzyme content remains unaffected. It is reasonable 
to propose, therefore, that the protective effect against arrhythmias of 




pharmacological agents or by acidic reperfusion, may be mediated through 
inhibition o f excessive Na* influx at a time when myocardial capacity 
to extrude Na* is significantly impaired. Interestingly, a recent study 
with transient acidic reperfusion in the authors’ laboratory has revealed 
a close similarity in the duration of acidic reperfusion required to achieve: 
(i) a sustained protection against reperfusion-induced VF; and (ii) a 
significant recovery of maximal Na*/K* ATPase activity from ischemia- 
induced inhibition.50 This suggests that the protective mechanism o f  
transient acidic reperfusion may involve not only a suppression o f Na* 
influx coupled to H* extrusion via the Na*/H* exchanger but also an 
enhanced recovery of Na* efflux via the Na*/K* pump.
C.4 Selectivity of Pharmacological Inhibitors
Conventional inhibitors of the Na*/H* exchanger, such as amiloride 
and its 5-amino substituted derivatives, can interact with a number o f  
other cation transporting proteins,51 which may limit their value as 
selective pharmacological tools in delineating the arrhythmogenic role 
o f the Na*/H* exchanger in ischemia and reperfusion. Indeed, recent 
work by Pierce et al52 has shown that, in the rat, amiloride and sev­
eral of its derivatives may exhibit cardiodepressant effects and produce 
changes in action potential characteristics (particularly at high con­
centration and following prolonged exposure), via actions unrelated to 
Na*/H* exchanger inhibition. Such actions may preclude attribution 
of the antiarrhythmic effects of these drugs , to Na*/H* exchanger inhi­
bition. Indeed, it has been suggested53 that the antiarrhythmic action 
o f amiloride may be due partly to an inhibition o f the inwardly recti­
fying K* current (Iki)-
Despite the above, amiloride derivatives still may be of value as 
tools in investigating the role o f the Na*/H* exchanger in ischemia 
and reperfusion, provided drug concentration and period of drug ex­
posure are carefully controlled.52 Furthermore, cardiodepressant actions 
have not been observed with Na*/H* exchanger inhibitory concentra­
tions of newer inhibitors such as HOE694,35 which also may exhibit 
an enhanced selectivity for the cardiac isoform of the exchanger.54 
Nevertheless, HOE694 shares the protective efficacy of other amiloride- 
based exchanger inhibitors against reperfusion-induced arrhythmias.35*38"4^  
Thus, it is likely that the common protection afforded by amiloride 
and its derivatives32,35"38 and by the newer benzoyl guanidine compounds 
(such as HOE69435*38"40 and its structural congener HOE64241) against 
reperfusion-induced arrhythmias is mediated by these agents’ common 
pharmacological action, that is Na*/H* exchanger inhibition.
C.5 Impact of Acute N eurohormonal M odulation
Activity of the sarcolemmal Na*/H* exchanger in mammalian car­
diac myocytes is increased substantially by a variety of neurohormonal 
agents of cardiovascular relevance, including aj-adrenergic agonists,55'59
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endothelin60 and angiotensin II,61 apparently through receptor-medi­
ated mechanisms. The Na*/H* exchanger-stimulatory actions of the former 
two agents appear to be suppressed by putative protein kinase C (PKC) 
inhibitors55,56,59,60 and mimicked by PKC activators (such as phorbol 
esters55,59), although these findings have been disputed.57
In light of the above, it is interesting to note that exposure o f  
isolated rabbit hearts to phorbol esters has been shown62 to increase 
the incidence of VF during hypoxia and reoxygenation. In a similar 
manner, ai-adrenoceptor stimulation has been shown by the authors’ 
studies63 to exacerbate reperfusion-induced VF in isolated rat hearts 
subjected to regional ischemia. The profibrillatory effect o f  
ai-adrenoceptor stimulation was reversed by Na*/H+ exchanger inhibi­
tion, implicating the exchanger in the downstream mechanism(s).63 Since 
there is evidence o f both norepinephrine release64 and a r adrenoceptor 
upregulation65 during myocardial ischemia and reperfusion,. regulation 
o f sarcolemmal Na'7H'* exchanger activity via endogenous catechola­
mines could play a significant role, in modulating the severity o f  
arrhythmias in this setting.
Another endogenous mediator that could play a role in modula­
tion o f Na*/H* exchanger activity in myocardial ischemia and reperfusion 
is thrombin. Thrombin is a multifunctional pro tease which, in addi­
tion to its established role in thrombus formation, induces a variety o f  
cellular responses through the recendy cloned thrombin receptor (for 
review, see Coughlin66). Exposure, to thrombin has been shown to ac­
tivate the plasma membrane Na*/H* exchanger in a number of cell 
types, including platelets,67 endothelial cells6* and smooth muscle cells,69 
through (at least in part) a protein kinase C-mediated pathway. In this 
regard, recent studies in. the authors’ laboratory70 have suggested that a 
functional thrombin receptor may be expressed, also in adult rat ven­
tricular myocytes and may be involved in the regulation of sarcolemmal 
Na+/H* exchanger activity.- Such a regulatory mechanism could have a 
significant impact on suscepdbility to arrhythmias in the setting of ischemia 
and reperfusion. Indeed, Goldstein et ai7t have shown that the inci­
dence of malignant ventricular arrhythmias during acute ischemia is greater 
following thrombotic coronary occlusion than nonthrombodc balloon 
occlusion, implicating an arrhythmogenic role for factors (such as thrombin) 
that are associated with thrombus formation. Furthermore, the same 
group has suggested that during myocardial ischemia activation of the throm­
bin receptor may contribute to arrhythmogenesis by inducing an in­
crease in intracellular Na* concentration,72 an observation which is consistent" 
with sarcolemmal Na*/H+ exchanger activation. Nevertheless, the im­
pact of thrombin receptor activation on the severity- of ischemia and reperfusion- 
induced arrhythmias remains to be determined. An arrhythmogenic role 
for thrombin during ischemia and/or reperfusion via Na*/H* exchanger acti­
vation could have direct clinical implications, since intracoronary 





C.6 P o t e n t ia l  Im pact o f  C h r o n ic  R e g u la t io n
There is considerable experimental evidence that the severity o f  
reperfusion-induced arrhythmias is exacerbated in hearts with pressure 
overload hypertrophy,73'76 although the cellular mechanisms that are 
primarily responsible for this increased susceptibility are unclear. With 
regard to the putative arrhythmogenic scheme depicted in Figure 9.1, 
it is interesting to note that there is evidence of altered expression and 
activity o f both the Na*/K* pump77,78 and the Na*/Ca2* exchanger79,80 
in left ventricular hypertrophy. In this context, mRNA expression o f  
the ubiquitous NHE1 isoform of the: Na*/H* exchanger has been shown 
recently to be upregulated in hypertrophied rabbit myocardium.81 If 
such an increase in the steady-state mRNA level is reflected by an 
increased NHE1 protein expression and sarcolemmal Na*/H* exchanger 
activity (and is applicable to other species and models o f hypertro­
phy), then this could provide a mechanism for the increased suscepti­
bility of hypertrophied myocardium to reperfusion-induced arrhythmias.
D. CALCIUM—THE COMMON ARRHYTHMOGENIC 
MEDIATOR
It is apparent from the evidence presented above that.the sarcolemmal 
Na*/H* exchanger may be a key mediator o f  severe ventricular arrhythmias 
induced by reperfusion. The question that arises is how this relates to 
other putative arrhythmogenic processes (e.g., free oxygen radical gen­
eration and associated oxidant stress) that have been implicated in reperfusion 
arrhythmogenesis. The activation mapping studies of Pogwizd and Corr82 
have supported the hypothesis that the induction of VF during reperfusion 
is mediated by a nonreentrant, mechanism: that involves Ca2* overload- 
mediated afterdepolarizations and triggered, activity. Indeed, the studies 
of Kihara. and Morgan83 in.the- intact ferret heart have shown that 
spontaneous transitions to VF do not occur nnlrss a state of Ca?* over­
load is present and that diastolic Ca2* oscillations precede such transi­
tions. More recently, Brooks et al84 from the same group have demon­
strated a potentially causal association between elevated perfusate Ca2* 
concentration, loss of intracellular Ca2* homeostasis and increased sus­
ceptibility to reperfusion-induced VF in isolated rat hearts. That Ca2* 
overload, and subsequent oscillatory Ca2* release from the SR, may be 
a primary mechanism underlying VF induction during reperfusion is 
supported also by the observation that ryanodine, (which inhibits Ca2* 
release from the SR) prevents the degeneration of VT into VF.85
As discussed above, activation o f the sarcolemmal Na*/H* exchanger 
during early reperfusion is likely to favor Ca2* overload through the 
Na*/Ca2* exchanger. In this regard, Ca2* overload may represent a com­
mon arrhythmogenic mechanism that is precipitated by several com­
ponents associated with reperfusion. Indeed, it has been suggested that 
the induction of oxidant stress and the activation of the Na*/H* ex­
changer during early reperfusion may act in a synergistic manner to
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disrupt intracellular Ca2* homeostasis.86 Consistent with this hypoth­
esis and the putative arrhythmogenic scheme depicted in Figure 9.1, 
oxidant stress has been shown to inhibit the electrogenic Na*/K* pump,87 
stimulate the sarcolemmal Na*/Ca2* exchanger88 and increase the open 
probability o f the SR Ca2* release channel.89 Furthermore, recent stud­
ies have shown that reactive oxygen intermediates can induce arrhythmo­
genic oscillations in membrane potential, indicative of intracellular Ca2* 
overload, in both isolated ventricular muscles90 and isolated myocytes.91 
Thus, in the setting o f reperfusion, the synergistic action o f free oxy­
gen radical generation and sarcolemmal Na*/H* exchanger activation 
may result in a loss o f intracellular Ca2* homeostasis and thereby the 
induction o f severe ventricular arrhythmias.
E. CONCLUDING COMMENTS
Many experimental studies have shown that reperfusion of tran­
siently ischemic myocardium can result in the induction of severe ven­
tricular arrhythmias, such as. VF. Although incidences, of such, arrhythmias 
have been documented in. man,, their truer clinical relevance and po­
tential role in sudden cardiac death remain to be proven conclusively. 
Nevertheless,. available. experimentaL evidence suggests- that during 
reperfusion of ischemic myocardium the intracellular accumulation- of Ca2* 
(Ca2* overload) may be the final trigger- responsible for the induction 
of VF. Ca2* overload itself may arise through the synergistic interaction 
of more than one component associated with reperfusion, with activa­
tion o f the sarcolemmal Na*/H* exchanger playing a dominant role.
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Impact of extracellular buffer composition on 
cardioprotective efficacy of Na+/H+ exchanger inhibitors
YASUYUKI SHIMADA, DAVID J. HEARSE, AND METTN AVKIRAN 
Cardiovascular Research, The Rayne Institute, St. Thomas1 Hospital,
London SE1 7EH, United Kingdom
Shim ada, YasuyuM, D avid  J . H earse, and  M etin  
Avkiran. Impact of extracellular buffer composition on cardio­
protective efficacy of Na+/H+ exchanger inhibitors. Am. J. 
Physiol. 270 {Heart Circ. Physiol. 39): H692-H700, 1996.— 
There is controversy over whether the cardioprotective effects 
of Na+/H+ exchanger inhibitors are exerted primarily during 
ischemia or during subsequent reperfusion, possibly because 
of interstudy differences in experimental conditions. We 
studied the impact of perfusate buffer composition on the 
relative degree of protection afforded by Na+/H+ exchanger 
inhibition during ischemia vs. reperfusion. Isolated rat hearts 
in = 8/group) were perfused (37°C, 75 mmHg) with bicarbon­
ate- or /V’-2-hydroxyethylpiperazine-2V’' -2-ethanesulfonic acid- 
buffered medium and subjected to 20 min of global zero-flow 
ischemia and 45 min of reperfusion. One of two structurally 
distinct Na+/H+ exchanger inhibitors [5-OV^ V-dimethyl)amilo- 
ride (DMA) or (3-methylsulfonyI-4-piperidinobenzoyl)guani- 
dine methanesulfonate (HOE-694), 10 jimol/1] was tran­
siently (5 min) infused 1) immediately before ischemia, 2) 
during initial reperfusion, or 3) during both of these periods. 
With bicarbonate-buffered medium, neither drug improved 
the postischemic recovery of left ventricular developed pres­
sure (LVDP) when given only during reperfusion. In contrast, 
HOE-694 improved the postischemic recovery of LVDP flam 
39 ± 5% in control to 66 ± 6% (P < 0.05) when given before 
ischemia and from 33 ± 4% in control to 65 ± 4% (P < 0.05) 
when given before ischemia plus during reperfusion. With the 
latter protocol, the cardioprotective effect of KOE-694 oc­
curred in a dose-dependent manner at 0.1-10 pmol/L In 
contrast to the results with bicarbonate-buffered medium, in 
the presence of iV-2-hydroxyethylpiperazine-W'-2-ethanesul- 
fonic add-buffered medium, DMA and HOE-694 significantly 
improved recovery of LVDP (from 34 ± 5% in controls to 56 ± 
3 and 71 ± 8%, both P < 0.05) when given only during 
reperfusion. They also provided significant protection when 
given before ischemia or before ischemia plus during reperfu­
sion; with the latter protocol, HOE-694 produced an almost 
complete recovery of LVDP (88 ± 9 vs. 30 ± 7% in controls, 
P < 0.05). In condusion, our results suggest that the influ­
ence of Na+/H+ exchanger activity during reperfusion on the 
extent of functional recovery is modulated significantly by 
perfusate buffer composition. As a consequence, the cardiopro­
tective efficacy of Na+/H+ exchanger inhibitors may be overes­
timated under bicarbonate-free conditions.
HOE-694; dimethylamiloride; bicarbonate; contractile func­
tion; rat heart
there  is substantial evidence  that the sarcolemmal 
Na+/H+ exchanger may be a key mediator of injury 
during myocardial ischemia and reperfusion (for recent 
reviews, see Refs. 11 and 26). However, despite general 
agreement among different investigators (6, 8 , 10,16, 
24, 29) that pharmacological inhibition of the ex­
changer can significantly alleviate postischemic contrac­
tile dysfunction, it is unclear whether the protective
H692
mechanism is operative primarily during ischemia or 
dining reperfusion. In this connection, there is consid­
erable discrepancy between studies on the efficacy of 
Na+/H+ exchange inhibitors when given only at the 
time of reperfusion, with reports of full protection (6 , 
14-16), partial protection (8,29), and lack of effect (10,
. 18, 20). A number of factors might have contributed to 
the apparently contradictory conclusions of the above 
studies.
First, in the majority of studies, a variety of amiloride 
analogues were used to inhibit the Na+/H+ exchanger. 
However, these agents have variable selectivity for the 
Na+/H+ exchanger (12) and may produce cardiodepres­
sant effects [particularly at high concentration and 
after prolonged exposure (23, 32)] that in some cases 
might counteract any benefit arising from Na+/H+ 
exchanger inhibition. Second, some studies in isolated 
hearts have been carried out in the presence of bicarbon­
ate buffer (6,10,17-20,29), whereas others have used 
perfusion media containing the zwitterionic buffer 
N-2-hydroxyethylpiperazine-N'-2 -ethanesulfonic acid 
(HEPES) (14-17, 24). It is probable that in the latter 
instance, where Na+/H+ exchange is the primary mech­
anism of recovery from intracellular acidosis (13), the 
contribution of reperfusion-induced activation of the 
Na+/H+ exchanger to contractile dysfunction (and hence 
the protective efficacy of pharmacological inhibition of 
the exchanger during reperfusion) may be overesti­
mated.
The primary objective of the present study was to 
determ ine whether the relative degree of protection 
afforded by Na+/H+ exchanger inhibition during isch­
emia vs. during reperfusion is influenced by perfusate 
buffer composition. To achieve this, we used isolated rat 
hearts subjected to zero-flow global ischemia, with 
transient infusion of an Na+/H+ exchanger inhibitor 
into the coronary circulation I) immediately before 
ischemia, 2) during the initial phase of reperflxsion, or 
3) during both of these periods. Tb distinguish the 
effects of Na+/H+ exchanger inhibition from any second­
ary effects of amiloride analogues, we used two structur­
ally distinct Na+/H+ exchanger inhibitors: 1) 5-(N,N- 
dimethyl)amiloride (DMA), a potent inhibitor of the 
Na+/H+ exchanger (4, 12), which has been used previ­
ously in studies of myocardial ischemia and reperfusion 
(9,16,17), and 2) (3-methylsulfonyl-4-piperidinobenz- 
oyl)guanidine methanesulfonate (HOE-694), a recently 
developed agent that has an Na+/H+ exchanger inhibi­
tory potency comparable to those of 5-amino-substi­
tuted amiloride derivatives (4,28) but does not appear 
to share the cardiodepressant actions of such com­
pounds (32).
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MATERIAL AND METHODS
This investigation was performed in accordance with the 
Home Office Guidance on the Operation of the Animals 
(Scientific Procedures) Act 1986 (Her Majesty’s Stationery 
Office, London).
Langendorff Perfusion of Isolated Rat Hearts
Adult male WIstar rats (B & K Universal, Hull, UK) were 
anesthetized by inhalation of diethyl ether. Heparin (200IU) 
was then injected into a femoral vein, and the heart was 
quickly excised and immersed in perfusion solution at 4°C. 
Within 30 s of excision, hearts were subjected to Langendorff 
perfusion at a constant perfusion pressure equivalent to 75 
mmHg. The pulmonary artery was then cut near its origin to 
facilitate the drainage of coronary effluent. The left atrium 
was excised, and an ultrathin balloon specially constructed to 
match the dimensions of the ventricular cavity (1) was 
inserted into the left ventricle. The intraventricular balloon 
was inflated to give a left ventricular end-diastolic pressure 
(LVEDP) of 5—7 mmHg, and the balloon volume was kept 
constant thereafter. Two different perfusion solutions were 
used: one was buffered with COyHCOg (bicarbonate), and 
the other contained the zwitterionic buffer HEPES. The 
bicarbonate solution was of the following composition (in 
mmol/1): 118.5 NaCl, 4.8 KC1, 1.2 MgS04, 1.2 KH2P04, 1.4 
CaCl2, 11.0 glucose, and 25.0 NaHC03. The solution waB 
gassed continuously with 95% 0 2-5% C02 (pH 7.4 at 37°C). 
HEPES solution contained (in mmol/1) 143.0 NaCl, 4.8 KC1, 
1.2 MgS04, 1.2 KH2PO4, 1.4 CaCl2, 11.0 glucose, and 6.0 
HEPES. The pH was adjusted to 7.4 at 37°C by the addition of 
HC1, and the solution was gassed continuously with 100% 0 2. 
Both solutions were filtered (pore size 5 pm) before use and 
maintained at 37°C throughout the experiment. Coronary 
flow was monitored lining an in-line flow detector (model T206 
Animal Research Flowmeter with 2N probe, Transonic Sys­
tems, New York, NY) with a linear detection range of 0.1-150 
ml/min. After 15 min of perfusion at constant pressure, the 
basal coronary flow rate was recorded, and perfusion was 
switched to a constant-flow system (supplied by a Gilson 
Minipuls 3 roller pump) at the basal flow rate. When required 
(see later), this enabled the infusion of drug solutions or 
vehicle via a Bidearm at a known percentage of the total flow 
rate. The heart was maintained in a temperature-regulated 
chamber at 37°C throughout the experiment, and the right 
atrium was continuously superfused with oxygenated perfu­
sion solution (37°C) at 6 ml/min.
Drug Administration and Study Protocol
HOE-694 has limited long-term solubility in physiological 
buffer solutions. Therefore HOE-694 and DMA were dis­
solved in deionized water at 1.25,12.5, or 125 pmol/1. When 
required, these solutions were inflised into the perfusion line 
supplying the coronary vasculature at 8% of the total flow 
rate; this resulted in final perfusate drug concentrations of 
0.1, 1, or 10 pmol/1, respectively. Control hearts received 
vehicle (deionized water) at the same infusion rate during the 
corresponding period. The concentrations of DMA and HOE- 
694 were selected in accordance with published data (15,32).
A t th e  e n d  o f  th e  in i t ia l  15 -m in  perio d  o f  co n stan t-p resB u re  
p e rfu s io n , b a s a l  c a rd ia c  fu n c tio n  (see Measured Variables) 
w a s  a s s e s se d  a n d  p e rfu s io n  w a s  sw itch ed  to  a  conB tant-fiow  
sy s te m , a s  d e sc rib e d  above. I n  t h e  v a rio u s s tu d y  su b sec tio n s 
(n =  8 /g ro u p ), d ru g  o r  v eh ic le  w a s  in fu se d  in to  th e  p erfu s io n  
l in e  su p p ly in g  th e  c o ro n a ry  v a s c u la tu re  fo r 5 m in  im m ed i­
a te ly  p re c e d in g  isc h e m ia  (p re -I), fo r  th e  f irs t  5 m in  o f  re p e r fu ­
s io n  (R), o r  d u r in g  b o th  o f  th e s e  p e rio d s  (p re-I + R). A ll h e a r ts
were subjected to 20 min of zero-flow global ischemia and 45 
min of reperfusion with constant-flow perfusion maintained 
throughout the reperfusion period. Reperfusion frequently 
resulted in the induction of episodes of ventricular tachyar­
rhythmias; however, all hearts reverted to a stable sinus 
rhythm within 35 min of reperfusion. Postischemic cardiac 
function was assessed at the end of the 45-min period of 
reperfusion, by which time each heart had been in stable 
sinus rhythm for an interrupted period of &10 min. All 
experiments in each study subsection were carried out in a 
prospectively randomized manner with contemporary controls.
Measured Variables
Left ventricular developed pressure (LVDP) and LVEDP 
were obtained from a pressure transducer attached to the 
intraventricular balloon through a fluid-filled catheter. Coro­
nary vascular resistance was derived from the coronary flow 
rate monitored via the in-line flow detector and the perfusion 
pressure (monitored through a sidearm of the aortic cannula). 
A unipolar electrogram (electrocardiogram) was obtained 
through a silver electrode inserted into the free wall of the left 
ventricle and a reference electrode connected to the aorta, 
from which heart rate was derived. The electrocardiogram, 
left ventricular pressure (LVDP and LVEDP), perfusion pres­
sure, and coronary flow rate were recorded on an ink-jet 
recorder (model RS3400, Gould). Values for LVDP, LVEDP, 
coronary vascular resistance, and heart rate were noted 1 
min before the start of vehicle or drug infusion (to obtain 
basal values), at 1-min intervals during vehicle or drug 
infusion, and at the end of 45 min of reperfusion (after &10 
min of stable sinus rhythm; see Drug Administration and 
Study Protocol).
Expression of Results and Statistical Analysis
The recovery of LVDP after reperfusion was expressed as a 
percentage of the preischemic basal value (obtained before 
the start of drug or vehicle infusion) in the same heart. 
Statistical analyses were based on the guidelines described 
by Wallenstein et al. (31). Gaussian-distributed variables 
were expressed as means ± SE and were subjected to one-way 
analysis of variance. If a difference among mean values was 
established, comparison with controls was performed using 
Dunnett’s test. P < 0.05 was considered significant.
RESU LTS
Effects of DMA and HOE-694 on Preischemic 
Cardiac Function
The temporal changes in functional indexes that 
occurred during the preischemic infusion of vehicle, 
DMA (10 pmol/1), and HOE-694 (10 pmol/l) were as­
sessed using data from all hearts that received such 
infusions (i.e., pre-I and pre-I + R protocols, n = 
16/group).
Bicarbonate buffer. Basal values for LVDP, LVEDP, 
coronary vascular resistance, and heart rate in the 
various study groups are shown in Table 1. These 
values did not differ significantly between control, 
DMA, and HOE-694 groups within each study subsec­
tion. There were no significant changes in LVDP, 
LVEDP, coronary vascular resistance, and heart rate in 
control hearts during the preischemic infusion of ve­
hicle. The infusion of DMA or HOE-694 also did not 
affect these indexes, such that there were no significant
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C ontrol 125 ± 6 6.2 ±0.7 8.4 ± 0 .5 341 ± 1 6
DMA 122 ± 7 6.2 ± 0 .7 8.3 ± 0 .4 360 ± 1 3
HOE-694 117 ± 6 5.5 ±0 .6 8.5 ± 0 .9 345 ± 2 0
R
Control 114 ± 8 5.9 ±0.4 5.5 ± 0 .4 359 ± 1 4
DMA 118 ± 6 4.8 ± 0 .3 4.8 ± 0 .2 353 ± 1 8
HOE-694 101 ± 4 5.1 ± 0 .6 5.8 ± 0 .3 326 ± 1 6
P re - I+  R
C ontrol 132 ± 9 5.2 ± 1 .0 4.5 ± 0 .2 333 ± 1 7
DMA 124 ± 5 5.4 ± 0 .8 4.8 ± 0 .5 356 ± 1 6
HOE-694 134 ± 3 6.4 ± 0 .6 4.4 ± 0 .3 358 ± 1 2
H E P E S buffer
Pre-I
C ontrol 117 ± 4 5.7 ± 0 .6 13.0 ± 1 .2 276 ± 8
DMA 112 ± 4 4.3 ±0 .6 9.0 ±0.7* 261 ± 5
HOE-694 121 ± 7 4.6 ± 0 .7 10.0 ± 1 .0 272 ± 6
R
C ontrol 106 ± 7 6.2 ± 0 .6 11.9 ± 0 .8 296 ± 8
DMA 93 ± 5 6.4 ±1.1 12.8 ± 0 .7 278 ± 9
H OE-694 89 ± 3 6.9 ± 0 .4 13.0 ± 0 .4 285 ± 7
P re-I +  R
C ontrol 95 ± 6 7.0 ± 0 .9 14.6 ± 1 .6 285 ± 5
DMA 97 ± 5 6.0 ± 0 .8 13.1 ± 1 .0 273 ± 11
HOE-694 94 ± 2 6.8 ± 0 .8 13.2 ± 1 .0 259 ± 4
Values are  m eans ± SE. n =  8/group. DMA, 5-(N,/V-dimethyl)amilo- 
rid e ; H O E-694, (3-m ethylsulfonyl-4-piperidinobenzoyl)guanidine 
m ethanesu lfonate ; Pre-I, drug/vehicle adm in istra tion  before isch­
em ia; R, drug/vehicle adm in istra tion  during  early  reperfusion; 
P re-I + R, drug/vehicle adm inistra tion  before ischem ia plus during  
early  reperfusion. D rug concentration was 10 pmol/1 in  all cases. All 
values w ere obtained before drug adm inistra tion . *P <  0.05 vs. 
re le v a n t control receiving vehicle.
differences between hearts receiving DMA or HOE-694 
and controls at any time during this preischemic infu­
sion period. The relevant data for coronary vascular 
resistance and heart rate are illustrated in Figs. LA 
and 2A, respectively.
HEPES buffer. Basal values for functional indexes in 
hearts receiving perfusate containing HEPES buffer 
are also shown in Table 1 . Once again, these values did 
not vary significantly between control, DMA, and HOE- 
694 groups within each study subsection for the major­
ity of indexes. The only exception was the significantly 
lower basal coronary vascular resistance observed in 
the group that received DMA before ischemia. How­
ever, because the study was carried out in a prospec- 
tively randomized manner, this difference (which was 
observed before any drug infusion) probably occurred 
by chance. Once again, the preischemic infusion of 
vehicle did not result in a significant change in LVDP, 
LVEDP, coronary vascular resistance, and heart rate. 
During infusion of DMA or HOE-694, LVDP and LVEDP 
did not change significantly, and there were no signifi­
cant differences from the control group at any time 
point during this period. However, in contrast to the 
observations made with bicarbonate buffer, the infu­
sion of DMA or HOE-694 in the presence of HEPES 
buffer resulted in a progressive increase in coronary
vascular resistance (Fig. LB) and a corresponding 
decrease in heart rate (Fig. 2B). In the DMA and 
HOE-694 groups, coronary vascular resistance was 
significantly greater from 3 min (Fig. LB) and heart 
rate was significantly lower from 1 min (Fig. 2B) after 
the onset of drug infusion than time-matched values 
from control hearts receiving vehicle.
Effects of DMA and HOE-694 on Postischemic 
Cardiac Function
Bicarbonate buffer. Postischemic recovery of LVDP in 
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Fig. 1. C oronary vascular resistance  du ring  infusion of vehicle (O), 
5-(N,N-dim ethyl)am iloride (DMA, 10 pmol/1; ■), or (3-methylsulfonyl- 
4 -p iperid inobenzoyl)guan id ine m e th an esu lfo n a te  (HOE-694, 10 
pmol/1; ▲) before ischem ia (n “  16/group). E xperim ents were carried  
out u s ing  bicarbonate  (A) or H E P E S (B) as buffer in perfusion 
solution. Values a re  m eans ±  SE. *P <  0.05 vs. vehicle.
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Fig. 2. Heart rate during infusion of vehicle (O), DMA (10 pmol/1; ■), 
or HOE-694 (10 pmol/1; a ) before ischemia (n = 16/group). Experi­
ments were carried out using bicarbonate (A) or HEPES (.B ) as buffer 
in perfusion solution. Values are means ± SE. *P <  0.05 vs. vehicle.
given before ischemia or before ischemia plus during 
early reperfusion, DMA (10 pmol/1) did not improve the 
recovery of LVDP. In contrast, HOE-694 (10 pmol/1) 
significantly improved the recovery of LVDP when 
infused before ischemia (from 39 ± 5% in controls to 
66 ± 6%) and when given before ischemia plus during 
early reperfusion (from 33 ± 4% in controls to 65 ± 4%). 
When given during reperfusion alone, neither DMA nor 
HOE-694 improved the postischemic recovery for LVDP 
(Fig. 3A). The lack of effect on postischemic recovery 
was evident throughout the period of reperfusion 
(Fig. 4A).
Postischemic values of LVEDP, coronary vascular 
resistance, and heart rate in the various study groups
are given in Table 2. When given before ischemia, DMA 
and HOE-694 resulted in a significant reduction in 
postischemic LVEDP, indicating an improved diastolic 
function. With HOE-694, this improvement of postisch­
emic diastolic function was observed also when the 
drug was given before ischemia plus during reperfu­
sion; however, this infusion protocol resulted in a loss of 
efficacy with DMA. Neither drug affected postischemic 
LVEDP significantly when given during reperfusion 
alone. Postischemic coronary vascular resistance and 
heart rate were not affected significantly by either 
drug, regardless of the infusion protocol. With all 
treatment protocols, 50-100% of hearts in each group 




|_ _ _ _ _ _ _ _ p e r io d  o f  d r u g  in fu s io n _ _ _ _ _ _ _ _ |
Fig. 3. Recovery of left ventricular developed pressure (LVDP) at end 
of 45 min of reperfusion expressed as percentage of preischemic basal 
value (n = 8/group). Hearts were perfused with vehicle (open bars), 
DMA (10 pmol/1, hatched bars), and HOE-694 (10 pmol/1, filled bars) 
before ischemia (pre-I), during reperfusion (R), and before ischemia 
plus during reperfusion (pre-I + R). Experiments were carried out 
using bicarbonate (A) or HEPES (B) as buffer in perfusion solution. 
Values are means ± SE. *P < 0.05 vs. vehicle.
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sion, DMA improved the postischemic recovery of LVDP 
from 30 ±  7% in controls to 54 ± 8% CP <  0.05); with 
this drug infusion protocol, HOE-694 resulted in al­
most complete restoration of preischemic systolic func­
tion, with the postischemic recovery of LVDP reaching 
88 ± 9% (P <  0.05). When the drugs were given during 
early reperfusion alone, the postischemic recoveries of 
LVDP were 34 ± 5% in controls, 56 ± 3% with DMA 
(P <  0.05), and 71 ± 8% with HOE-694 (P <  0.05). In 
addition to improving the ultimate recovery of LVDP, 
HOE-694 also accelerated the recovery of LVDP during 
the reperfusion period (Fig. 4B).
As shown in Table 2, DMA and HOE-694 did not 
significantly affect postischemic LVEDP, coronary vas­
cular resistance, and heart rate in most cases. Indeed, 
the only significant differences from control were ob­
served with DMA infusion before ischemia, which 
resulted in a lower postischemic coronary vascular 
resistance (which was probably a reflection of the lower 
basal coronary vascular resistance in this group) and a 
small reduction in postischemic heart rate. The inci­
dence of tachyarrhythmias during reperfusion was not 
affected by either drug with any treatment protocol, 
with 50-100% of hearts in each group exhibiting such 
arrhythmias.
Dose-Response Relationships for DMA and HOE-694
To determine whether the reduced cardioprotective 
efficacy of HOE-694 and the loss of efficacy of DMA in
Table 2. Postischemic values for functional indexes
0 5 10 15 20 25 30 35 40 45
duration of reperfusion (min)
Fig. 4. Recovery of LVDP du ring  45 m in of reperfusion  expressed as 
percentage of preischem ic basa l value (n =  8/group). H earts  received 
vehicle (O), DMA (10 punol/1; ■), or HOE-694 (10 pmol/1; ▲) during 
first 5 m in of reperfusion, as ind icated  by shaded  box above horizontal 
axis. E xperim ents were carried  ou t u sing  bicarbonate  (A) or H EPES 
(B) as buffer in  perfusion solution. Values are  m eans ±  SE, w ith  
recovery assum ed as 0 in  h e a r ts  th a t  were in  su sta ined  tach y arrh y th ­
m ia a t any  of d a ta  collection tim e points. *P  <  0.05 vs. vehicle.
sion, indicating a lack of effect of DMA and HOE-694 on 
the incidence of such arrhythmias in this model.
HEPES buffer. In contrast to our observations with 
bicarbonate buffer, in the presence of HEPES buffer 
DMA (10 pmol/1) and HOE-694 (10 pmol/1) significantly 
improved the postischemic recovery of LVDP in all drug 
infiision protocols (Fig. 3B ). When the drugs were given 
before ischemia, the postischemic recoveries of LVDP in 
control, DMA, and HOE-694 groups were 37 ± 5%, 54 ±  
4% (P <  0.05), and 54 ± 3% (P <  0.05), respectively. 
When given before ischemia plus during early reperfu­
LVEDP,
m m H g
Coronary Vascular 
Resistance, 
mmHg. ml~1 • min • g




Control 7 1 ± 5 9.4 ±0 .4 319 ± 3 0
DMA 58 ±4* 9.5 ± 0 .6 326 ± 1 6
HOE-694 49 ±4* 9.3 ± 0 .7 335 ± 2 8
R
Control 69 ± 5 6.9 ± 0 .3 329 ± 1 2
DMA 82 ± 8 6.6 ± 0 .5 324 ± 2 3
HOE-694 67 ± 3 6.9 ±0 .3 274 ± 2 0
P re - I+  R
Control 86 ± 7 6.9 ±0 .5 348 ± 1 8
DMA 82 ± 1 0 7.4 ± 0 .6 320 ± 1 9
HOE-694 55 ±4* 5.8 ±  0.2 333 ± 6
H E P E S buffer
Pre-I
Control 6 0 ± 5 15.3 ±2 .7 313 ± 8
DMA 4 8 ± 3 8.9 ±0.5* 263 ±20*
HOE-694 50 ± 4 11.4 ± 0 .8 293 ± 9
R
Control 79 ± 4 14.6 ± 0 .9 305 ± 1 6
DMA 71 ± 4 13.2 ± 1 .3 285 ±11
HOE-694 66 ± 5 13.0 ± 0 .8 298 ± 1 7
P re - I+  R
Control 62 ± 4 20.1 ± 5 .1 310 ± 1 0
DMA 56 ± 7 14.8 ± 2 .6 290 ± 1 9
HOE-694 47 ± 8 13.4 ±  1.6 256 ± 1 4
Values a re  m eans ±  SE; n -  8/group. D rug concentration was 10 
pmol/1 in  all cases. All values were obtained a t  end of 45-m in period of 
reperfusion . See Table 1 footnote for definition of abbreviations. *P <  
0.05 vs. re lev an t control receiving vehicle.
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the presence of bicarbonate buffer could have been due 
to the use of excessive drug concentrations (which 
might produce unfavorable secondary effects), a dose- 
response study was carried out utilizing two additional 
lower concentrations of each drug. Figure 5 illustrates 
the postischemic recovery of LVDP in hearts that 
received vehicle and those that received DMA or HOE- 
694 at three concentrations (0.1,1, or 10 pmol/1) before 
ischemia and during early reperfusion. HOE-694 in­
creased the postischemic recovery of LVDP in a dose- 
dependent manner from 33 ±  4% in control hearts to 
40 ± 7%, 48 ± 5% (P  <  0.05), and 65 ± 4% (P <  0.05) at 
0.1, 1, and 10 pmol/1, respectively. DMA did not signifi­
cantly affect the ischemic recovery of LVDP at any 
concentration.
DISCUSSION
Our results suggest that, in the isolated rat heart, 
the relative degree of protection afforded by Na+/H+ 
exchanger inhibition during ischemia vs. during reper­
fusion is influenced significantly by the perfusate buffer 
composition. Furthermore, DMA and HOE-694 appear 
to exhibit differential cardioprotective efficacy, despite 
their comparable potency as inhibitors of NHE-1 (4), 
which is the predominant N a+/H+ exchanger isoform 
expressed in the rat heart (21).
Differential Efficacy of DMA and HOE-694
In the presence of bicarbonate, only HOE-694 im­
proved the postischemic recovery of systolic function, 
and only when present during ischemia. This may 
indicate that under these conditions HOE-694 exhibits 
distinct cardioprotective properties (in addition to 
N a+/H+ exchanger inhibition) that are not shared by 
DMA. Alternatively, this observation may reflect the 
greater selectivity of HOE-694 for the Na+/H+ ex­







Fig. 5. Recovery of LVDP a t end  of 45 m in  of reperfusion  expressed as 
percentage of preischem ic basa l value. H earts  (n = 8/group) received 
vehicle (open bar), DMA (0.1, 1, or 10 pmol/1; hatched bars), or 
HOE-694 (0 .1 ,1 , or 10 pmol/1; filled bars) before ischem ia plus during 
reperfusion. All experim ents w ere carried  o u t using  bicarbonate as 




not to have a cardiodepressant effect in the rat (32), 
unlike amiloride and several of its 5-amino-substituted 
derivatives (23,32). In other words, under these experi­
mental conditions, cardiodepressant effects arising from 
secondary pharmacological properties of DMA may 
partially counteract the beneficial effects of Na+/H + 
exchanger inhibition by this agent. The absence of a 
significant cardiodepressant effect during the preisch­
emic infusion of DMA in the present study may at first 
appear contrary to this hypothesis. However, it should 
be noted that the negative effects of DMA on the 
contractile function of rat myocardium are much more 
pronounced after prolonged exposure to the drug (23). 
Therefore, in the present study, cardiodepressant ef­
fects of DMA may only become manifest during reperfu­
sion, after prolonged exposure to the drug during its 
entrapment within the ischemic myocardium. In this 
regard, even under aerobic conditions, exposure of rat 
right ventricular myocardium to 20 pM DMA for 30 min 
(equivalent to the total duration of drug infusion plus 
global ischemia in the present study) has been shown to 
result in —70% suppression of developed tension, with 
only incomplete recovery after washout of the drug (23). 
In the presence of bicarbonate, neither drug exhibited a 
protective effect when given only during reperfusion. 
This implies that, under such conditions, Na+/H+ ex­
changer activity during reperfusion may not play a 
significant role in determining the extent of postisch­
emic functional recovery. Indeed, it is noteworthy that 
the majority of studies in which the administration of 
Na+/H+ exchanger inhibitors only during reperfusion 
has been reported to dramatically improve postisch­
emic contractile function have been carried out in the 
absence of bicarbonate (14—17). Consistent with our 
observation, other studies have shown that the infusion 
of NaVH+ exchanger inhibitors only during reperfusion 
in the presence of bicarbonate is ineffective (10,18, 20) 
or provides only minimal protection (8,29).
In the presence of HEPES buffer, DMA and HOE-694 
significantly improved the postischemic recovery of 
systolic function, not only when present during isch­
emia but also when given only during reperfusion. This 
observation is consistent with earlier studies carried 
out with N a+/H+ exchanger inhibitors in the absence of 
bicarbonate (14-17) and suggests that, under such 
conditions, exchanger activity during reperfusion may 
be of greater significance in determining the severity of 
postischemic contractile dysfunction. Similar to the 
observations made in the presence of bicarbonate, 
HOE-694 exhibited a greater cardioprotective efficacy 
than DMA, once again probably due to the greater 
selectivity of this agent for the Na+/H+ exchanger. 
Indeed, when HOE-694 was given before ischemia plus 
during reperfusion in the presence of HEPES buffer, an 
additive effect was observed such that by the end of the 
reperfusion period systolic function had recovered al­
most completely to its preischemic level. Nevertheless 
it should be stressed that under these conditions DMA 
also provided significant protection with all drug admin­
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istration protocols. Thus, in bicarbonate-free condi­
tions, the beneficial effects of Na+/H+ exchanger inhibi­
tion may outweigh any cardiodepressant effects arising 
from nonselective actions of DMA.
In this study, neither DMA nor HOE-694 affected the 
incidence of reperfusion-induced tachyarrhythmias, re­
gardless of the perfusate buffer composition. This may 
at first appear contrary to our earlier observations (32) 
with HOE-694 and 5-(AT-ethyl-2V-isopropyl)amiloride 
(EIPA), another 5-amino-substituted derivative of amilo- 
ride. However, the present study used 20 min of global 
ischemia vs. 10 min of regional ischemia in our earlier 
study (32). Because reperfusion-induced arrhythmias 
are believed to originate within the ischemic/reper- 
fused zone and are modulated significantly by the size 
of this zone (5), it is probable that the lack of effect of 
DMA and HOE-694 on reperfusion arrhythmias in the 
present study was a reflection of the greater arrhythmo- 
genic insult presented by 20  m in  of global ischemia.
Impact of Perfusate Buffer Composition
The above observations suggest that the influence of 
Na+/H+ exchanger activity during reperfusion on the 
extent of postischemic functional recovery is signifi­
cantly modulated by perfusate buffer composition. As a 
consequence, the cardioprotective efficacy of Na+/H+ 
exchanger inhibitors may be overestimated when used 
under bicarbonate-free conditions. In isolated myocytes 
(13) and whole hearts (7), recovery from intracellular 
acidosis in the presence of bicarbonate and under 
aerobic conditions has been shown to occur through not 
only the Na+/H+ exchanger but also the Na+-HCOg 
symporter, with the e x c h a n g e r  becoming the predomi­
nant pH recovery mechanism only in the absence of 
bicarbonate. In a s i m i l a r  m a n n er, during reperfusion in 
the presence of bicarbonate, the Na+/H+ exchanger and 
the Na+-HCOa symporter appear to play comparable 
roles in intracellular pH recovery, and both may contrib­
ute significantly to a Na+ influx (30). Despite this 
possibility, however, there is a paucity of studies inves­
tigating the effects of inhibition of the Na+-HCOj 
symporter on postischemic recovery of contractile func­
tion and intracellular Na+ and Ca2+ homeostasis, prob­
ably due to a lack of selective inhibitors (30). If the 
Na+-HCOg symporter also plays a significant role in 
ischemia and reperfusion-induced loss of ionic homeo­
stasis and contractile dysfunction, then inhibition of 
the Na+/H+ exchanger would be expected to result in 
only partial protection in the presence of bicarbonate. 
Conversely, when this mechanism is inhibited through 
the removal of bicarbonate from the perfusion medium, 
the Na+/H+ exchanger could assume a more significant 
role in mediating such dysfunction. Consequently, the 
cardioprotective efficacy of Na+/H+ exchanger inhibi­
tors would be enhanced, particularly during reperfu­
sion. This hypothesis is consistent with the observa­
tions made in the present study and needs to be tested 
further by studies designed specifically to determine 
the role of bicarbonate-dependent mechanisms in myo­
cardial ischemia and reperfusion.
Effects of DMA and HOE-694 on Preischemic 
Cardiac Function
In the presence of bicarbonate, neither drug had a 
significant effect on contractile function, coronary vas­
cular resistance, or heart rate. In contrast, in the 
presence of HEPES buffer, DMA and HOE-694 pro­
duced a reduction in heart rate and an increase in 
coronary vascular resistance, although contractile func­
tion was once again unaffected. Significant coronary 
vasoconstrictive and negative chronotropic effects in 
the presence of bicarbonate have been reported previ­
ously with prolonged infusion of EEPA in isolated hearts 
from the guinea pig (22 ) and the rat (32). However, in 
the absence of similar effects with HOE-694 under 
identical conditions, such actions of EIPA have been 
attributed to nonselective effects of the drug (32). In 
contrast, the similarity of the effects of DMA and 
HOE-694 on heart rate and coronary vascular resis­
tance during their short-term infusion in the presence 
of HEPES buffer in the present study suggests that 
these effects may have been mediated through the 
common mechanism of action of these agents, that is, 
Na+/H+ e x c h a n g e r  i n h i b i t io n .  The cellular mechanisms 
downstream of exchanger inhibition cannot be ascer­
tained from the present study, although they may 
involve alterations in intracellular pH in the relevant 
cell types (i.e., sinoatrial node and coronary vascular 
smooth muscle cells) under these conditions. Neverthe­
less, with regard to the therapeutic potential of Na+/H+ 
exchanger inhibitors, it is important to stress that 
such vasoconstrictive and negative chronotropic ef­
fects are not seen with Na+/H+ exchanger inhibitory 
concentrations of 5-(iV-methyl-iV-isobutyl)-amiloride 
(M. Karmazyn, personal communication) or with newer 
agents such as HOE-694 (32), under physiological 
conditions where bicarbonate-dependent pH regulatory 
mechanisms remain operative.
Although the present study was not designed specifi­
cally to compare cardiac function in the presence and 
absence of bicarbonate, in hearts perfused with solu­
tion containing HEPES basal values for LVDP and 
heart rate were lower and those for coronary vascular 
resistance were higher. It is unclear, however, whether 
these differences were due to the absence of bicarbon­
ate or the presence of HEPES, particularly because 
there is some evidence (2) that HEPES may influence 
electrical and mechanical activity in ventricular muscle 
independently of its function as a buffer. ,
Therapeutic Potential ofNa+/H+ Exchanger Inhibitors
Our results have shown that the cardioprotective 
efficacy of Na+/H+ exchanger inhibition during reperfu­
sion may be overestimated in in vitro studies employ­
ing bicarbonate-free conditions. Nevertheless the pre­
sent study and many previous studies have shown that 
Na+/H+ exchanger inhibitors can provide significant 
cardioprotection in isolated rat hearts, even in the 
presence of bicarbonate, particularly when given as 
pretreatment before the onset of ischemia. Such protec­
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tion has been observed with amiloride (10, 29), with a 
variety of its 5-amino-substituted analogues (3,17,18, 
29), and with novel inhibitors such as HOE-694 (28) 
and its structural congener HOE-642 (27). Indeed, 
Na+/H+ exchanger inhibitors have also been shown to 
be cardioprotective (with this effect manifest as im­
proved postischemic contractile function or reduced cell 
necrosis) in isolated hearts from other species [e.g., 
guinea pig (18) and rabbit (20)] perfused with aqueous 
media, as well as in blood-perfused preparations, includ­
ing rabbit myocardium in vitro (8 ,9) and porcine hearts 
in vivo (25). This unusual degree of conformity among 
different investigators, drugs, species, and models sug­
gests that Na+/H+ exchanger inhibitors may possess 
genuine cardioprotective potential in a variety of set­
tings associated with ischemia and reperfusion.
Concluding Comments
The present study has demonstrated that, in isolated 
rat hearts perfused with an aqueous medium and 
subjected to global ischemia and reperfusion, the buffer 
composition of the medium has a significant impact on 
the cardioprotective efficacy of two structurally distinct 
inhibitors of the Na+/H+ exchanger. This phenomenon 
may be mediated by the inactivation of bicarbonate- 
dependent pH regulatory mechanisms (such as the 
Na+-HC03  symporter) in the presence of bicarbonate- 
free medium, such that the Na+/H+ exchanger becomes 
the predominant mechanism  of H+ extrusion linked to 
Na+ influx. As a result, the cardioprotective efficacy of 
Na+/H+ exchanger inhibitors, particularly during reper­
fusion, may be overestimated under bicarbonate-free 
conditions, although these agents clearly retain signifi­
cant efficacy, even under more physiological conditions.
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Na+/H+ Exchanger Activity Does Not Contribute 
to Protection by Ischemic Preconditioning in the 
Isolated Rat Heart
Alex R. Shipolini, FRCS; Hiroyuki Yokoyama, MD; Manuel Galinanes, MD, PhD;
Stephen J. Edmondson, FRCS; David
Background Despite evidence that pharmacological inhibi­
tion of the Na+/H+ exchanger (NHE) is cardioprotective, 
activation of NHE has been proposed as a protective mecha­
nism of ischemic preconditioning (PC)..
Methods and Results In isolated rat ventricular myocytes (n=8 
to 11 per group) loaded with the fluorescent pH indicator 
C-SNARF-1, we showed that HOE-642 (HOE) was a potent 
inhibitor of the sarcolemmal NHE (80% inhibition at 1 /unol/L); 
such inhibition was readily reversible by washout of the drug. We 
confirmed that 1 pmol/L HOE produces significant and reversible 
inhibition of NHE activity in isolated rat hearts as well (n=4), and 
in this model, we tested (n=8 per group) whether the presence of 
the drug during (1) the prolonged period of ischemia (40 or 60 
minutes) or (2) the preceding brief periods of PC ischemia (3 
minutes plus 5 minutes) modulates the protective efficacy of PC. 
In protocol 1, HOE was infused for 5 minutes immediately before 
the prolonged ischemic period. With 40 minutes of prolonged 
ischemia, the postischemic recovery of left ventricular developed 
pressure (LVDP) was 15±2% in controls and was improved to 
45±7% with HOE (P<.05), 55±5% with PC (Pc.05), and
The remarkable cardioprotective efficacy of ische­mic preconditioning has stimulated an intense investigative effort aimed at delineating its cel­
lular mechanisms (for a recent review, see Downey and 
Cohen1). One noteworthy consequence of ischemic pre­
conditioning, which has been reported by several inde­
pendent investigators,2"6 is a significant reduction in the 
severity of intracellular acidosis during the prolonged 
period of ischemia. This “antiacidotic” effect has re­
ceived considerable attention as a potential mechanism 
mediating the cardioprotective actions of ischemic pre­
conditioning.7-10 However, despite the general agree­
ment that ischemic preconditioning attenuates intracel­
lular acidosis during subsequent ischemia, there is no 
consensus regarding the mechanism that underlies this 
effect. Recently, Ramasamy and colleagues* proposed 
that the sarcolemmal Na+/H+ exchanger (NHE), which 
is a primary route for H+ efflux from cardiac myo-
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68±2% with PC+HOE (P<.05 versus all groups). When the 
prolonged ischemic period was extended to 60 minutes, an 
additive effect of PC and HOE was readily apparent and LVDP 
recovery with PC+HOE (66±2%) was almost double that ob­
served with HOE (37±4%) or PC (34±5%) alone (Pc.05). In 
protocol 2, HOE was infused for 3 minutes immediately before 
each episode of PC ischemia and was subsequently washed out 
before a 40-minute prolonged ischemic period (HOE+PC). 
LVDP recovery was 34±4% in controls and was improved to 
57±2% with PC (PC.05) and 55±3% with HOE+PC (Pc.05). 
Improved recovery of LVDP was matched by reduced creatine 
kinase leakage in all cases.
Conclusions Because coadministration of HOE (at a concen­
tration sufficient to inhibit NHE activity) did not reduce the 
efficacy of PC in either protocol, we conclude that NHE activity 
does not contribute to the cardioprotective actions of PC On the 
contrary, NHE inhibition during the prolonged ischemic period 
may enhance the protection afforded by PC (Circulation. 
1997;96:3617-3625.)
Key Words •  ischemia •  sodium •  myocytes
cytes,11,12 may be stimulated after ischemic precondition­
ing and that this may contribute to both the attenuation 
of intracellular acidosis and the amelioration of ische­
mia/reperfusion-induced injury in preconditioned 
hearts.*
On the basis of available evidence, it is reasonable to 
suggest that ischemic preconditioning may result in a 
greater activity of the sarcolemmal NHE and that this 
may contribute to a reduced severity of intracellular 
acidosis during the prolonged ischemic period. However, 
the proposal* that such stimulation of NHE may be a 
cardioprotective mechanism appears contrary to the 
substantial body of evidence suggesting that in the 
setting of myocardial ischemia and reperfusion, pharma­
cological inhibition of NHE is protective, whereas phar­
macological activation of NHE is detrimental (for recent 
reviews, see References 12 through 15). An alternative 
possibility is that activation of NHE is an epiphenome- 
non that accompanies ischemic preconditioning but is 
not causally involved in its cardioprotective actions. On 
the contrary, it is possible that any activation of NHE 
may limit the extent Of the cardioprotection afforded by 
preconditioning.
In light of the above, the primary objective of the 
present study was to determine whether NHE activity 
during either (1) the prolonged ischemic period or (2) 
the brief preconditioning ischemic periods contributes to 
the cardioprotective effect of ischemic preconditioning.
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Selected Abbreviations and Acronyms
C-SNARF-1 = carboxy-seminaphthorhodafluor-l 
LVDP = left ventricular developed pressure 
LVEDP = left ventricular end-diastolic pressure 
LVSP = left ventricular systolic pressure 
NHE = Na+/H+ exchanger 
PC = preconditioning 
pH = intracellular pH
To attain this objective, we first determined the effects of 
HOE-642, a novel benzoyl guanidine-based NHE inhib­
itor,16 on sarcolemmal NHE activity in rat ventricular 
myocytes. Subsequently, we subjected isolated rat hearts 
to an ischemic preconditioning protocol (which we have 
previously shown6,17,18 to provide significant cardiopro- 
tection) in conjunction with the administration of HOE- 




Adult male Wistar rats (200 to 300 g body weight; 6&K 
Universal Ltd, Hull, UK) were used in all studies. The animals 
were anesthetized with sodium pentobarbital (60 mg/kg IP) 
and systemically anticoagulated with heparin (300 IU IV). 
After a transverse thoracotomy, the heart was excised and 
immediately immersed in perfusion solution at 4PC for subse­
quent use in isolated myocyte or whole-heart studies. The 
investigation was conducted in accordance with the Home 
Office Guidance on the Operation of the Animals (Scientific 
Procedures) Act 1986, published by Her Majesty’s Stationery 
Office, London, UK.
Effects of HOE-642 on NHE Activity in 
Isolated Myocytes 
Myocyte Isolation
Ventricular myocytes were isolated by a collagenase-based 
enzymatic digestion technique, as we have described previous­
ly.19 In brief, hearts were retrogradely perfused (37°C) in the 
Langendorff mode at a constant flow rate of 10 mL • min-1 • g_1 
for four sequential periods, as follows: (1) with Tyrode’s 
solution (containing, in mmol/L, NaQ 137, KC15.4, CaG2 1.8, 
MgClj 0.5, HEPES 10, and glucose 10, adjusted to pH 7.4 at 
34°C with NaOH) for 5 minutes, (2) with nominally Ca2+-free 
Tyrode’s solution (NaQ 135, KG 5.4, NaH2P 04 0.33, MgG2 
1.0, HEPES 10, and glucose 10, adjusted to pH 1 2  at 34°C with 
NaOH) for 5.5 minutes, (3) with nominally Ca2+-ffee Tyrode’s 
solution containing collagenase (Worthington type 1, 100 
U/mL) for 10 minutes, and (4) with storage buffer (KOH 78, 
KG 30, KH2P 04 30, MgS04 3, EGTA 0.5, HEPES 10, glutamic 
acid 50, taurine 20, and glucose 10, adjusted to pH 7.2 at 34°C 
with KOH) for 5 minutes. All solutions were gassed with 100%
0 2. After the perfusion procedure, the ventricles were removed 
and chopped into several pieces in storage buffer. The tissue 
fragments were then gently agitated to facilitate cell dispersion, 
and the cell suspension was maintained in storage buffer at 
25°C for at least 1 hour before use in the microepifluorescence 
studies.
Measurement of pHt and NHE Activity
pHj was measured in single ventricular myocytes with the 
pH-sensitive fluorescent dye C-SNARF-1, as we have described 
previously.19 Cells loaded with C-SNARF-1 were allowed,to 
settle on a glass coverslip at the bottom of a chamber mounted 
on the stage of an inverted microscope (Nikon Diaphot) and 
were superfused (3.5 mL/min, 34°C) with Tyrode’s solution. 
Cells were excited with light at 540 nm, and the resulting
fluorescence emission intensity from a selected area of a single 
myocyte was measured simultaneously at 580 nm (I^q) and 640 
nm (Imo) with a dual-emission photometer system (model 
D104C, Photon Technology International). The emission in­
tensity ratio (Ism/Imo) was calculated and converted to a pH; 
scale by use of in situ calibration data obtained by exposing 
cells loaded with C-SNARF-1 to nigericin-containing calibra­
tion solutions.19
All experiments were carried out in the nominal absence of 
HC03" (thereby precluding an involvement of HC03- -depen- 
dent pHrregulatory mechanisms), such that the rate of acid 
efflux (JH) could be used as a direct index of sarcolemmal NHE 
activity.19 JH was estimated during recovery from acute intra­
cellular acidosis from the equation JH=ft * dpH/dt, where ft is 
the intrinsic buffering power and dpH/dt is the rate of recovery 
ofpHj.
Experimental Protocol
The main objective of these studies was to determine the 
inhibitory efficacy of HOE-642 on sarcolemmal NHE activity. 
To this end, intracellular acidosis was induced (to activate 
sarcolemmal NHE) in the cells by the washout of NH*Q 
(20 mmol/L) after its transient (3 minutes) application. The 
initial (1 minute) washout of NF^Cl was with Na+-free Tyrode’s 
solution (NaG replaced by choline chloride) to ensure NHE 
inactivity during H+ loading. Subsequently, NHE was reacti­
vated by the reintroduction of Na+-containing Tyrode’s solu­
tion in the absence or presence of various concentrations of 
HOE-642 (0.0001 to 1 pmol/L; n=8 to 11 cells per group). JH 
was calculated from the initial dpHj/dt value (obtained by linear 
regression analysis of pH data collected during the first 1 
minute after the reintroduction of Na+) and the ft value 
corresponding to the appropriate pH, (estimated from the 
equation ft=-34.9  • pHj+273-5).19
In additional experiments, the reversibility of sarcolemmal 
NHE inhibition by HOE-642 was studied. Myocytes (n=3) 
were subjected to two consecutive acid pulses by the N H G  
washout method, separated by 15 minutes of normal superfu­
sion. During both pulses, NILQ washout was with normal 
Tyrode’s solution; however, during the second pulse the initial 
(3 minutes) washout solution additionally contained 1 /unol/L 
HOE-642.
Effects of HOE-642 on NHE Activity in 
Whole Hearts 
Isolated Heart Perfusion
Hearts were retrogradely perfused in the Langendorff mode 
at a constant coronary flow rate of 12 mL/min via a roller pump 
(Gilson Minipuls 3). The nominally HC03"-free perfusion 
solution was of the following composition (in mmol/L): NaG  
143.5, KG 4.7, MgS04 1.2, KH2P 04 1.2, HEPES 20.0, CaG2 
1.4, and glucose 11.0 (adjusted to pH 7.4 at 37°C with NaOH, 
maintained at 37°C, and gassed continuously with 100% 0 2). 
The solution contained, in addition, 20 mmol/L N H G  when 
required. The pulmonary artery was incised to facilitate coro­
nary effluent drainage. Left ventricular pressure was monitored 
by means of an intraventricular, isovolumic balloon20 connected 
to a pressure transducer and was recorded with an ink-jet 
recorder. The right atrium was excised, and hearts were paced 
at 360 bpm throughout via an electrode attached to the right 
ventricle to avoid potential complications in data interpretation 
arising from pH-induced changes in sinus rate and/or atrioven­
tricular conduction. HOE-642 (a gift from Hoechst-Marion- 
Roussel, Frankfurt, Germany) was dissolved in perfusion solu­
tion immediately before use to obtain a drug concentration of 
14.3 pmol/L. When required, this solution was infused into the 
perfusion line at 7% of the total flow rate to give a final drug 
concentration of 1 pmol/L (chosen on the basis of the isolated 
myocyte studies; see below).
106
Shipolini et al Na+/H+ Exchange and Ischemic Preconditioning 3619
Experimental Protocol
The main objective here was to confirm  tha t 1 pm o l/L  
HOE-642 was sufficient to produce significant inhibition of 
sarcolem m al N H E  activity in the whole heart. In the  absence of 
a facility for the continuous m easurem ent o f p H ; in the whole 
heart (eg, nuclear magnetic resonance spectroscopy), we used 
LV D P as a surrogate for pH, during the infusion and w ashout 
o f NH,C1 (20 m m ol/L). The selection o f  this surrogate index 
was based on the work of Grace e t al,21 who used hearts 
perfused with H C 0 3"-free solution under conditions o f con­
stant coronary flow and heart rate (as in the present study), 
which has shown that (1) changes in LV D P during NH„C1 
pulses m irror closely the changes that occur in p H  and (2) 
N H E  inhibition suppresses the recovery o f LV D P after N H 4Q  
washout, which reflects a delay in the recovery o f pH, from  
acidosis. A fter 15 m inutes of perfusion with the  standard 
perfusion solution, hearts (n= 4) were perfused with solution 
containing NR,C1 for 5 minutes and with standard so lution for 
a fu rther 20 m inutes (first acid pulse). Subsequently, this cycle 
was repeated  (second acid pulse), bu t this time with H O E-642 
(1 pm ol/L ) also present during the infusion of N H »Q  and the 
first 10 m inutes o f its washout.
D uring initial perfusion with standard solution, the  intraven- 
tricu lar balloon was inflated to obtain a LV E D P of 4 m m  Hg, 
and the balloon volume was kept constant thereafter. LV D P 
was calculated as the difference between LV E D P and LVSP 
and was noted a t 1- to 2-minute intervals throughout each 
experim ent.
Effects of HOE-642 on Cardioprotective Efficacy of 
Ischemic Preconditioning 
Isolated Heart Perfusion
H earts were perfused in the Langendorff m ode as described 
above, but this time at a constant perfusion pressure of 
75 m m  Hg. Furtherm ore, the perfusion solution contained the 
physiological buffer H C 0 3'  (25.0 m m ol/L  N a H C 0 3) ra ther 
than  H EPES and was gassed continuously with a m ixture of 
95% O J5%  C 0 2 (pH  7.4 at 37”C). D uring preischem ic perfu ­
sion, hearts were paced at 360 bpm via an electrode a ttached  to 
the right atrium; pacing was discontinued from  2 m inutes into 
the prolonged ischemic period and recom m enced on reperfu ­
sion. H OE-642 was dissolved in deionized w ater to m ake a 
1 m m ol/L  stock solution, which was stored a t 4°C for a 
maximum of 5 days. The stock solution was diluted in perfusion 
solution to obtain a  final drug concentration o f 1 p m o l/L  
im m ediately before use.
Experimental Protocols
As sum m arized schematically in Fig 1, there  were two main 
protocols in this part of the project (n = 8  hearts per group), 
which were designed to determ ine the  effects o f N H E  inhibi­
tion during either (1) the prolonged ischemic period  (protocol 
1) o r (2) the  preceding brief preconditioning ischemic periods 
(protocol 2). A fter the interventions illustrated in Fig 1, hearts 
were subjected to norm otherm ic global zero-flow ischemia for 
40 o r 60 m inutes in protocol 1 and for 40 m inutes in protocol 
2, followed in each case by 40 minutes o f reperfusion. Associ­
ated with protocol 2, an additional experim ent was perform ed 
to  confirm the adequate washout of H O E-642 before the 
prolonged ischemic period, as described in “R esults.”
Left ventricular pressure was m onitored via an intraventric- 
ular balloon, as described above, and coronary flow rate  was 
m easured by tim ed collection of the coronary effluent. Basal 
values o f LV D P and coronary flow ra te  were m easured  at the 
end o f the initial 15-m inute period of aerobic perfusion. Left 
ventricular pressure was also m onitored during the period  of 
ischemic arrest and throughout reperfusion to  allow assessm ent 
o f the tem poral profiles of the developm ent o f ischemic 
contracture and the postischemic recovery o f contractile  func­
tion. The final postischemic recoveries of LV D P and coronary
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Fig 1. Schematic of main experimental protocols for PC stud­
ies. Only periods before induction of prolonged ischemia are 
shown; open bars indicate aerobic perfusion with standard 
perfusion solution, shaded bars aerobic perfusion with perfusion 
solution containing HOE-642 (1 pmol/L), and solid bars global 
zero-flow ischemia. All hearts (n=8/group) were subsequently 
subjected to 40 minutes (protocols 1 and 2) or 60 minutes 
(protocol 1 only) of global zero-flow ischemia, followed by 40 
minutes of reperfusion. Functional indices were measured at end 
of reperfusion period and expressed as percentage of their 
respective values obtained at end of initial 15 minutes of aerobic 
perfusion.
flow were assessed by expressing the values obtained at the end 
o f the reperfusion period as a percentage o f their respective 
basal values. Total creatine kinase leakage (expressed as IU /g 
h eart dry wt) was assessed by spectrophotom etric analysis of 
enzyme activity in the coronary effluent collected during reper­
fusion with a commercially available kit (Sigma Diagnostics).
Statistical Analysis
Experim ents within each protocol were carried out in a 
prospectively random ized m anner. Gaussian-distributed vari­
ables were expressed as m ean± S E M  and were subjected to 
one-way ANOVA. If a difference am ong m ean values was 
established, intergroup com parisons were perform ed with the 
Student-Newman-Keuls test. A  value of P<.05  was considered 
significant.
Results
Effects of HOE-642 on NHE Activity in 
Isolated Myocytes 
Basal and Minimal pH{
Values for basal pH, (measured immediately before 
exposure to NH4CI) and minimal pH (measured at the 
end of NH4CI washout with Na+-free Tyrode’s solution) 
did not differ significantly between the various study 
groups. The ranges observed were from 7.16±0.04 to 
7.24±0.04 for basal pH  and from 6.68±0.04 to 
6.77±0.05 for minimal pH-
Sarcolemmal NHE Activity
Fig 2A shows representative recordings of pH during 
NH4CI pulses in a control cell and in a cell in which 
extracellular Na+ was reintroduced in the presence of 
1 pmol/L HOE-642. There was a rapid recovery of pH  
from acidosis under control conditions, whereas pH  
recovery was slowed significantly by HOE-642. The 
quantitative effects of HOE-642 on sarcolemmal NHE 
activity are illustrated in Fig 2B, which shows JH as a 
function of drug concentration. JH was 7.51±  
1.49 mmol/L per minute in control cells and was reduced 
by HOE-642 in a concentration-dependent manner, by 
10%, 27%, 50% (Pc.05), 68% (Pc.05), and 77% 
(Pc.05) at 0.0001, 0.001, 0.01, 0.1, and 1 pmol/L, 
respectively.
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Fig 2. A, Intracellular pH recordings during acid pulses (in­
duced by transient exposure to 20 mmol/L NH4CI in H C 03'-free  
medium) in control myocyte (open symbols) and one that re­
ceived 1 /omol/L HOE-642 during reintroduction of extracellular 
Na* (solid symbols). B, Initial H+ efflux rate (Jh) in control 
myocytes (open bar) and those that were exposed to various 
concentrations of HOE-642 during reintroduction of extracellular 
Na+ (solid bars) (n=8 to 11/group). *P<.05 vs control.
Fig 3 shows representative pHf recordings from a 
myocyte subjected to two consecutive acid loads, the first 
in the absence of HOE-642 and the second in the 
transient presence of 1 /i.mol/L HOE-642. As expected 
from the above observations, pH* recovery was markedly 
suppressed in the presence of HOE-642; however, pH; 
recovery (at a rate similar to that under control condi­
tions) was rapidly restored on removal of HOE-642 from 
the superfusion solution, indicating that the inhibition of 
exchanger activity was readily reversible.
Effects of HOE-642 on NHE Activity in
Whole Hearts
Basal Cardiac Function
The basal value of LVDP, measured immediately 






Fig 3. Intracellular pH recordings in an isolated rat ventricular 
myocyte during two consecutive acid pulses (induced by tran­
sient exposure to 20 mmol/L NH4CI in H C 03'-free  medium). 
During first pulse (open symbols), NH4CI washout was under 
control conditions. During second pulse (solid symbols), initial (3 
minutes) washout of NH4CI was in presence of 1 /xmol/L HOE- 
642, which was subsequently removed from superfusion solu­
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Fig 4. LVDP at various time points during two consecutive 
NH4CI pulses (comprising the 5-minute infusion and 20-minute 
washout of 20 mmol/L NH4CI) in isolated hearts perfused with 
nominally H C03"-free solution. LVDP is expressed as percent­
age of basal value obtained immediately before start of NH4CI 
infusion during each pulse. Open bars indicate first pulse; solid 
bars, second pulse. During second pulse, 1 pmol/L HOE-642 
was present during NH4CI infusion and first 10 minutes of its 
washout. *P < .05 vs first pulse.
LVDP declined slightly after recovery from the first acid 
pulse, and the basal value measured immediately before 
the second exposure to NILC1 was 104±5 mm Hg.
Cardiac Function During Acid Pulses 
Fig 4 illustrates LVDP, expressed as a percentage of 
the basal value, at various time points during the two 
consecutive acid pulses. As can be seen, during both 
pulses, the 5-minute infusion of NH.C1 produced a 
positive inotropic effect (probably because of a rise in 
pHi21), and the washout of NJt,Cl depressed LVDP 
within 1 minute (probably because of a rapid drop in 
pHj21). In the first pulse, which occurred in the absence 
of HOE-642, there was a rapid biphasic recovery of 
LVDP. In the second pulse, which occurred in the 
presence of 1 p.mol/L HOE-642, LVDP was further 
depressed by 2 minutes of washout, and recoveiy was 
markedly delayed, with a significant difference in LVDP 
values between the pulses during the first 2 to 10 minutes 
of NH4C1 washout. This most likely reflected a delayed 
recovery of pHj from acidosis due to drug-induced 
inhibition of NHE activity,21 the major H+ extrusion 
pathway under these experimental conditions. After the 
removal of HOE-642 from the perfusion solution, there 
was a rapid secondary recovery of LVDP, such that there 
was no significant difference between the pulses in 
LVDP values by 16 minutes of NH4CI washout.
Effects of HOE-642 on Cardioprotective Efficacy of 
Ischemic Preconditioning 
Basal Cardiac Function 
Basal values of LVDP and coronary flow did not differ 
significantly between groups within each study protocol 
and ranged from 136 ±4 to 148 ±5 mm Hg and from 
11.4±0.5 to 12.2±0.5 mL/min, respectively.
Postischemic Cardiac Function 
Protocol 1: Effects of NHE inhibition during prolonged 
ischemic period. In this protocol, the objective was to 
determine whether NHE inhibition during the pro­
longed ischemic period influences the cardioprotection
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Fig 5 . Left ventricular pressure profiles during the 40-minute 
period of prolonged ischemia and subsequent reperfusion in 
various study groups in protocol 1 (n=8/group). HOE indicates 
hearts that received HOE-642 (1 /unol/L) immediately before 
prolonged ischemic period; PC, preconditioned hearts; and 
PC+HOE, preconditioned hearts that also received HOE-642 
(1 /imol/L) immediately before prolonged ischemic period (see 
Fig 1 for details). Horizontal black bar above time axis illustrates 
period of ischemia, and vertical dashed lines indicate times to 
onset of ischemic contracture in control and PC groups. At each 
time point during reperfusion, higher symbol indicates LVSP and 
lower symbol LVEDP; thus, difference (shaded area) represents 
LVDP.
afforded by ischemic preconditioning. Fig 5 shows the 
left ventricular pressure profiles during 40 minutes of 
ischemia and subsequent reperfusion in the four study 
groups. As can be seen, the time to onset of ischemic 
contracture (defined as the time at which left ventricular 
pressure rose 4 mm Hg above baseline) was significantly 
shorter in PC (5.0±0.2 minutes) relative to control 
(9.0±0.6 minutes). HOE-642 did not alter the time to 
onset of ischemic contracture when given alone (HOE; 
9.0±0.6 minutes) and did not inhibit the acceleration of 
the onset of ischemic contracture by PC when given in 
combination (PC+HOE; 5.0±0.2 minutes). It is also
apparent from this figure that in all three treatment 
groups, the postischemic recovery of contractile function 
was markedly improved relative to control, with end- 
reperfusion LVSP values of 96±2, 111±4 (P<.05), 
115±4 (P<.05), and 121±3 (P<.05) mm Hg and 
LVEDP values of 75±2, 53±6 (P<.05), 40 ±4 (Pc.05), 
and 28 ±2 (Pc.05) mm Hg in control, HOE, PC, and 
PC+HOE, respectively. At this time, LVDP recovery 
was 15±2% in controls. This was significantly increased, 
to 45±7% by HOE-642 alone (HOE) and to 55±5% by 
ischemic preconditioning alone (PC). With the combi­
nation of both interventions (PC+HOE), LVDP recov­
ery was further improved to 68±2%, a value that was 
significantly greater than those obtained in HOE and in 
PC. Creatine kinase leakage during reperfusion mea­
sured 494±49 IU/g in controls and was reduced signifi­
cantly to 350±35, 291 ±36, and 272±33 IU/g in HOE, 
PC, and PC+HOE, respectively (with no significant 
difference between the values obtained in the three 
treatment groups). Postischemic recovery of coronary 
flow was 56±3% in the untreated control group; this was 
significantly increased in all treatment groups, to 
78±3%, 72±3%, and 80±4% in HOE, PC, and 
PC+HOE, respectively.
As shown above, although the recovery of contractile 
function after 40 minutes of prolonged ischemia was 
significantly enhanced in PC+HOE relative to PC or 
HOE alone, the improvement in final LVDP recovery 
was small and was not matched by a significant reduction 
in creatine kinase leakage during reperfusion. There­
fore, we performed an additional study with the objec­
tive of testing whether any additive protection afforded 
by the combination of ischemic preconditioning and 
HOE-642 would be more readily revealed under more 
severe conditions. To this end, the duration of prolonged 
ischemia was extended from 40 minutes to 60 minutes. 
Fig 6 shows the postischemic recovery of LVDP (Fig 6A) 
and creatine kinase leakage during reperfusion (Fig 6B) 
in the control, HOE, PC, and PC+HOE groups. Under 
these conditions also, LVDP recovery was significantly 
improved and creatine kinase leakage significantly re­
duced in all three treatment groups relative to control. 
However, with this extended duration of prolonged 
ischemia, LVDP recovery in PC+HOE (66±2%) was 
almost double that in HOE (37±4%) or PC (34±5%); 
furthermore, this time the improved contractile recovery 
was accompanied by a significant reduction in creatine 
kinase leakage, supporting an additive effect.
Protocol 2: Effects of NHE inhibition during precondi­
tioning ischemic periods. In this protocol, the objective 
was to determine whether NHE inhibition during the 
short periods of preconditioning ischemia influences the 
cardioprotection afforded by ischemic preconditioning. 
Relative to control, the postischemic recovery of LVDP 
was once again significantly increased in PC (57±2% 
versus 34±4%), and this effect was accompanied by a 
significant reduction in creatine kinase leakage during 
reperfusion (410±25 versus 523±31 IU/g) (Fig 7). How­
ever, in contrast to our observations with the infusion of 
HOE-642 immediately before the prolonged ischemic 
period, when the drug was infused before each of the 
preconditioning ischemic periods and subsequently 
washed out (HOE+PC), there was no significant differ­
ence in LVDP recovery or creatine kinase leakage 
relative to PC (Fig 7). A similar pattern was seen with
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Fig 6. A, Postischemic recovery of LVDP and B, creatine 
kinase leakage during reperfusion in various study groups in 
protocol 1 (n=8/group), which were subjected to 60 minutes of 
prolonged ischemia. HOE indicates hearts that received HOE- 
642 (1 /unol/L) immediately before prolonged ischemic period; 
PC, preconditioned hearts; and PC+HOE, preconditioned 
hearts that additionally received HOE-642 (1 pmol/L) immedi­
ately before prolonged ischemic period (see Fig 1 for details). 




Fig 7. A, Postischemic recovery of LVDP and B, creatine 
kinase leakage during reperfusion in the various study groups in 
protocol 2 (n-8/group), which were subjected to 40 minutes of 
prolonged Ischemia. PC indicates preconditioned hearts; 
HOE+PC, preconditioned hearts that also received HOE-642 
(1 pmol/L) for 3 minutes immediately before each of two pre­
conditioning ischemic periods (drug was washed out before 
prolonged ischemic period; see Fig 1 for details). *P<.05 vs 
control.
respect to the postischemic recovery of coronary flow: 
57±4% in control, 70±3% in PC (P<.05), and 72±2% 
in HOE+PC (Pc.05). The time to onset of ischemic 
contracture was once again significantly shortened in PC 
(from 10.9±0.4 minutes in control to 6.4±0.4 minutes), 
and this effect was unaffected by the coadministration of 
HOE-642 (7.3 ±0.6 minutes in HOE+PC, Pc.05 versus 
control).
A potential complication in the interpretation of the 
above study is the possibility that the washout of HOE- 
642 in the HOE+PC group might have been inadequate. 
Thus, even if NHE inhibition during the brief precondi­
tioning ischemic periods did abolish the cardioprotective 
actions of preconditioning, such an effect might have 
been obscured by any cardioprotection arising from 
residual drug presence during the prolonged ischemic 
period. To test whether the washout period used was 
sufficient, an additional study was performed in which 
1 pmol/L HOE-642 was infused for 6 minutes (equiva­
lent to the total duration of drug infusion in the above 
protocol) and hearts were subjected to ischemia either 
(1) immediately after drug infusion or (2) after 15 
minutes of washout (equivalent to the duration of drug 
washout in the above protocol). The control group once 
again received no intervention. Postischemic recovery of 
LVDP was significantly improved, from 32 ±2% in con­
trol to 46±4% by the infusion of HOE-642 immediately 
before ischemia. In contrast, there was no significant 
change in LVDP recovery (31 ±4%) when the drug was
washed out for 15 minutes before the induction of 
ischemia, indicating that a 15-minute washout period 
was sufficient to reduce the tissue drug content to a level 
that does not affect postischemic cardiac function.
Discussion
The present study has demonstrated that, in isolated 
rat hearts, administration of HOE-642 (at a concentra­
tion sufficient to inhibit sarcolemmal NHE activity in 
isolated myocytes and delay recovery of contractile 
function from acidosis-induced depression in whole 
hearts) before either the prolonged ischemic period or 
the preceding brief preconditioning ischemic periods 
fails to impair the cardioprotective efficacy of ischemic 
preconditioning. This finding questions the suggested 
role* of NHE activity as a determinant of the cardiopro­
tective effect of ischemic preconditioning.
Is NHE Activity Necessary for Cardioprotection 
by Preconditioning?
Ramasamy et al8 recently proposed a role for stimu­
lation of NHE activity in the protective action of ische­
mic preconditioning in the isolated rat heart. This pro­
posal was based on the observation that the 
intracoronary infusion of ethylisopropylamiloride 
(EIPA), an inhibitor of NHE, immediately before the 
prolonged ischemic period could attenuate the improved 
LVDP recovery and reduced creatine kinase leakage 
afforded by ischemic preconditioning. This finding con­
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trasts with a large body of evidence (for recent reviews, 
see References 12 through 15), obtained with a variety of 
pharmacological NHE inhibitors (including EIPA) and 
species, that inhibition of NHE is cardioprotective. 
Indeed, in accordance with our earlier work,22 the pres­
ent study has confirmed that infusion of the NHE 
inhibitor HOE-642 immediately before the prolonged 
ischemic period affords significant cardioprotection. 
Furthermore, the present study has shown that the 
cardioprotective effects of ischemic preconditioning and 
NHE inhibition, as assessed by increased LVDP recov­
ery and reduced creatine kinase leakage (as in the study 
by Ramasamy et al8), are additive rather than 
counteractive.
The observations of the present study do not support 
a role for NHE activity in determining die cardioprotec­
tive consequences of ischemic preconditioning. On the 
contrary, in light of the present study, it may be specu­
lated that any increase, in NHE activity in precondi­
tioned hearts (the evidence for which is critically as­
sessed below) may represent an undesirable side effect 
of ischemic preconditioning, which detracts from its 
cardioprotective efficacy. Thus, the true protective po­
tential of ischemic preconditioning may be revealed only 
by concomitant inhibition of NHE activity during the 
prolonged ischemic period. The observation in the pres­
ent study that the combination of ischemic precondition­
ing and infusion of HOE-642 immediately before the 
prolonged ischemic period afforded significantly greater 
protection than either intervention alone is consistent 
with this hypothesis.
Cardiac Actions of NHE Inhibitors.
The factors that may potentially account for the 
divergent findings of the present study compared with 
that by Ramasamy and colleagues8 must be considered. 
Both studies used identical species, models, and func­
tional end points, although the mode of perfusion (con­
stant pressure versus constant flow) differed and may 
have contributed to the divergence in findings. However, 
the most significant factor is likely to have been the 
difference between the studies in the characteristics and 
concentration of the pharmacological NHE inhibitor 
used. Although 5-amino-substituted derivatives of 
amiloride (such as EIPA) are potent inhibitors of NHE, 
they are relatively nonspecific® and have been shown to 
produce electrophysiological abnormalities24,25 and car­
diodepressant effects,25,26 particularly at concentrations 
that exceed 1 /imol/L.25 For this reason, we chose not to 
use an amiloride derivative and selected HOE-642, 
which is a novel, benzoylguanidine-based NHE inhibitor 
that exhibits marked selectivity for the cardiac isoform of 
the exchanger.16 Indeed, in our myocyte studies, we 
confirmed that HOE-642 is a potent inhibitor of the 
sarcolemmal NHE in rat ventricular myocytes, with the 
1 pmol/L concentration (as used in our preconditioning 
studies) resulting in »80% inhibition of exchanger ac­
tivity at a pH of—6.75. This finding is consistent with 
recent work with HOE-694 (a structural congener of 
HOE-642) in guinea pig ventricular myocytes.27 It is 
important to note that these benzoylguanidine deriva­
tives do not affect the activity of other pH-regulating 
carriers27 or Na+ transport mechanisms.16 Furthermore, 
unlike EIPA, they do not appear to exhibit cardiode­
pressant effects at NHE-inhibitoiy concentrations,16,26 a
’ property that enhances their value as pharmacological 
tools in the delineation of the physiological/pathophys­
iological role(s) of NHE. In light of the above argu­
ments, it may be speculated that the results of the study 
by Ramasamy and colleagues8 were complicated by the 
use of a relatively high concentration of a less selective 
NHE inhibitor, whose nonspecific actions might have 
contributed to the apparent abolition of the protective 
effect of ischemic preconditioning. In this regard, it is 
important to note that Bugge and Ytrehus28 showed that 
coadministration of EIPA at a lower concentration 
(1 pmol/L versus 3 pmol/L in the study by Ramasamy et 
al8) provides additional protection to preconditioned rat 
hearts, which is in keeping with our findings with 
HOE-642.
Role of NHE Activity During Preconditioning 
Ischemic Periods
In both previous studies in which EIPA was used in 
combination with ischemic preconditioning,8,28 the NHE 
inhibitor was present during the prolonged ischemic 
period. In the present study, we additionally addressed, 
for the first time, the question of whether NHE activity 
during the preconditioning ischemic periods might be 
involved in the signaling mechanism(s) mediating the 
protective response. Our observation that the infusion of 
HOE-642 before each of the preconditioning ischemic 
periods (followed by its washout) does not diminish the 
cardioprotective action of preconditioning suggests that 
NHE activity during these periods also is not involved in 
the underlying protective mechanisms. It may be argued 
that residual drug presence during the prolonged ische­
mic period might have complicated the interpretation of 
these studies. However, our demonstration of the ready 
reversibility by drug washout of (1) HOE-642-induced 
depression of pHj recovery in acid-loaded myocytes (Fig 
3), (2) HOE-642r-induced depression of LVDP recovery 
in acid-loaded hearts (Fig 4), and (3) the cardioprotec­
tive effect of HOE-642 in hearts subjected to ischemia/ 
reperfusion would argue against significant residual drug 
presence.
t
NHE Activity and Ischemic Contracture
In the present study, the infusion of HOE-642 imme­
diately before the prolonged ischemic period did not 
alter the time to onset of ischemic contracture. However, 
consistent with recent observations from our laborato­
ry,6,18 ischemic preconditioning significantly accelerated 
the onset of ischemic contracture. The combination of 
the two interventions resulted in an accelerated contrac­
ture profile similar to that observed with ischemic pre­
conditioning alone. On the basis of these observations, it 
can be concluded that, in the isolated rat heart, NHE 
activity is not a determinant of the rate of development 
of ischemic contracture (although different observations 
have been made in the rabbit heart29). Previous studies 
by Hearse et al30 in the isolated rat heart have shown that 
the onset of ischemic contracture is closely linked to the 
rate at which the tissue ATP content declines, a rela­
tionship that appears to hold true in preconditioned 
hearts as well.6,18 Thus, the inability of HOE-642 to 
modify the profile of ischemic contracture may be due to. 
the inability of NHE inhibition to significantly alter the 
rate of ATP depletion during global zero-flow ischemia,
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as revealed by studies that used NMR spectroscopy for 
continuous analysis of tissue ATP content.29-31,32
Is NHE Activity Increased by Preconditioning?
Within the context of the present study and the 
arguments presented above, a key issue to consider is 
whether ischemic preconditioning actually increases 
NHE activity. Before the evidence for this can be 
critically assessed, it should be stressed that the primary 
activator of NHE is intracellular acidosis.33 Activation by 
other stimuli, such as ai-adrenoceptor agonists34,35 and 
thrombin,19 arises from a change in the pH sensitivity of 
the exchanger, so that at a given pH the exchanger has 
greater activity after stimulation. Therefore, compari­
sons of NHE activity between two or more groups are 
informative only if activity is determined at a similar pH  
in all cases.
The primary evidence for an increased NHE activity 
after ischemic preconditioning is the observation by 
Ramasamy et al8 that preconditioned rat hearts exhibit 
an enhanced ability to recover from acute intracellular 
acidosis induced in the absence of ischemia. However, 
because that study was carried out in hearts perfused 
with HC0 3 _-containing medium, it is impossible to 
ascribe the accelerated recovery from acidosis to an 
increase in NHE activity.36 Furthermore, it should be 
noted that the method used to induce acute intracellular 
acidosis (transient exposure to NHCl) resulted in 
greater acidosis in preconditioned (pH=6.54 ±0.02) 
than in control (pH=6.72±0.02) hearts.8 Because the 
rate of acid-equivalent extrusion via not only NHE but 
also Na+/HC03" symport is inversely related to pH.36 it 
is likely that the faster initial recovery from acidosis in 
preconditioned hearts may have arisen as a consequence 
of the lower starting pH in this group. Indeed, de 
Albuquerque and colleagues37 recently showed that, in 
the presence of a similar acid load, the rate of pH  
recovery is similar in control and preconditioned rat 
hearts.
Ramasamy et al8 provided additional evidence that 
ischemic preconditioning increases intracellular Na+ ac­
cumulation during the prolonged ischemic period and 
that this effect is attenuated by EIPA. When taken 
together with the earlier reports of reduced acidosis,2-6 
an enhanced Na+ accumulation that is sensitive to 
inhibition by EIPA is supportive of an increased NHE 
activity in preconditioned hearts. However, the report­
ed8 enhancement of Na+ accumulation in precondi­
tioned hearts contrasts with earlier observations by 
Steenbergen et al5 in a similar model. Thus, it would 
appear that the question of whether ischemic precondi­
tioning results in increased NHE activity cannot be 
resolved on the basis of the evidence currently available.
Potential Limitations of the Study
In the present study, sarcolemmal NHE activity in 
control versus preconditioned hearts, with and without 
coadministration of HOE-642, was not determined. 
Nevertheless, on the basis of our work with acid-loaded 
isolated ventricular myocytes (Fig 2) and whole hearts 
(Fig 4), it is highly likely that the 1 jimol/L concentration 
of HOE-642 used in our preconditioning studies was 
sufficient to inhibit sarcolemmal NHE activity. This is 
supported by the ability of this concentration of the drug
to afford significant protection in hearts subjected to 
ischemia/reperfusion.
The present interpretation of the data from our 
preconditioning studies is contingent on NHE inhibition 
being the primary pharmacological action of HOE-642 
and the sole mechanism of its cardioprotective effect at 
the 1 jumol/L concentration used. If the cardioprotective 
effect arose from a hitherto unidentified secondary 
action of the drug (that is distinct from NHE inhibition), 
then any diminution of the cardioprotective efficacy of 
ischemic preconditioning by HOE-642-induced NHE 
inhibition might be masked by such a secondary action. 
Although this possibility cannot be discounted, because 
HOE-642 is a new drug whose actions may not yet be 
comprehensively characterized, it should also be noted 
that there is currently no evidence to support it.
Finally, caution should be exercised in extrapolating 
the findings of the present study to other species or 
models, particularly when a different index of injury (eg, 
infarct size, arrhythmias) might be used to quantify the 
cardioprotective efficacy of HOE-642 or ischemic 
preconditioning.
Concluding Comments
The present study has shown that the application of a 
potent NHE inhibitor in combination with ischemic 
preconditioning does not attenuate the cardioprotective 
efficacy of ischemic preconditioning; on the contrary, the 
NHE inhibitor provides additional protection when 
present during the prolonged ischemic period. Assuming 
that NHE inhibition is the principal action of the drug at 
the concentration used, these observations indicate that 
NHE activity during either the prolonged ischemic pe­
riod or the preceding brief preconditioning ischemic 
periods does not contribute to the cardioprotection 
afforded by ischemic preconditioning. Furthermore, they 
dispute the. proposal8 that increased NHE activity may 
represent a protective mechanism of ischemic 
preconditioning.
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Protection of the Myocardium During Ischemia
and Reperfusion 
Na+/H+ Exchange Inhibition Versus Ischemic Preconditioning
Metin Avkiran, PhD
The hypothesis that sarcolemmal Na'TH* exchanger activity may contribute to myocardial injury during ischemia and reperfusion was first published in 1985,1 
preceding by 1 year the first description of the ischemic 
preconditioning phenomenon.2 Initial pharmacological evi­
dence in support of the Na+/H+ exchanger hypothesis was 
subsequently provided by Karmazyn,3 who showed that 
amiloride (an inhibitor of the exchanger) enhanced the 
postischemic recovery of contractile function and reduced 
creatine kinase leakage in rat hearts subjected to global 
ischemia and reperfusion. Since then, a number of Na+/H+ 
exchange inhibitors, including highly specific novel inhibi­
tors such as HOE-694, HOE-642 (cariporide), and EMD- 
85131, have been shown to afford cardioprotective benefit in 
a variety of animal models of ischemia and reperfusion.4 
Nevertheless, as an innovative approach to the protection of 
ischemic myocardium, Na+/H+ exchange inhibition has failed 
to capture the imagination of cardiologists (experimental and 
clinical alike) to quite the same extent as ischemic precondi­
tioning. Indeed, a survey of articles published in Circulation 
and Circulation Research over the past decade reveals only 
14 articles whose title or abstract contains the keywords 
“Na+/H+ exchanged) and ischemia,” whereas 115 articles are 
identified when the combination “preconditioning and ische­
mia” is used. Is this a fair reflection of the relative cardio­
protective efficacy, and perhaps the therapeutic potential, of 
these interventions?
, See p 2519
In this issue of Circulation, Gumina and colleagues5 report 
on a comparison of the efficacy of Na+/H+ exchange inhibi­
tion (achieved with BIIB-513, the latest addition to the family 
of novel Na+/H+ exchange inhibitors) versus ischemic pre­
conditioning in limiting infarct size in dog hearts subjected to 
regional ischemia and reperfusion in vivo. This is the first 
such comparison in a large animal, and the findings carry 
additional weight because they originate from a laboratory 
that has made a major contribution to the characterization of
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the powerful preconditioning phenomenon. The most striking 
result of the study is that extending the duration of index 
ischemia from 60 to 90 minutes abolishes the protective 
effect of ischemic preconditioning but does not affect the 
protection afforded by Na+/H+ exchange inhibition. This 
indicates that at least in dog myocardium, Na+/H+ exchange 
inhibition may afford greater protection against ischemia and 
reperfusion-induced injury than does ischemic precondition­
ing. Furthermore, other data reported in the article5 suggest 
that the combination of partial Na+/H+ exchange .inhibition 
and ischemic preconditioning may be more effective in 
limiting infarct size than either intervention alone. In consid­
ering the mechanistic and therapeutic implications of these 
findings, it is appropriate to address several pertinent 
questions.
Does Ischemic Preconditioning Alter Na+/H+ 
Exchanger Activity?
Some of the issues raised in the study by Gumina et al5 
warrant a brief overview of the potential effects of ischemic 
preconditioning on Na+/H+ exchanger activity. Intracellular 
acidosis occurs even during the brief periods of ischemia that 
are used to trigger preconditioning and is a potent stimulus 
for sarcolemmal Na+/H+ exchanger activity. In addition to 
such allosteric activation of the exchanger by intracellular 
acidosis, ischemic preconditioning may also initiate post- 
translational regulatory mechanisms (eg, phosphorylation of 
the exchanger and/or its regulatory proteins) that increase 
Na+/H+ exchanger activity by altering its sensitivity to 
intracellular H+. In this regard, it is notable that stimuli that 
can mimic ischemic preconditioning, such as ar adrenergic 
receptor stimulation,8 also increase sarcolemmal Na+/H+ 
exchanger activity, through an enhancement of its sensitivity 
to intracellular HV Nevertheless, it has been shown recently 
that, after the induction of an intracellular add load of 
comparable severity, the rate of recovery of intracellular pH 
is identical in preconditioned and nonpreconditioned myocar­
dium under aerobic conditions.* From this, it appears that any 
stimulation of sarcolemmal Na+/H+ exchanger activity in 
preconditioned myocardium may not persist beyond the 
triggering ischemic episodes.
During index ischemia, a commonly observed consequence 
of ischemic preconditioning is a reduction in the severity of 
intracellular addosis. Although other potential mechanisms 
for this “antiaddotic” effect exist (eg, reduced metabolic H+ 
production9), the pertinent question within the context of this 
editorial is whether this effect arises from increased cellular 
H+ extrusion via the sarcolemmal Na+/H+ exchanger. Al­
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though the evidence outlined above8 would argue against 
such a possibility, 2 recent studies9*10 have addressed this 
question by determining the effects of Na+/H+ exchange 
inhibitors on intracellular pH. Unfortunately, the results have 
been contradictory, with Na+/H+ exchange inhibition shown 
both not to alter9 and to significantly attenuate10 the antiaci- 
dotic effect of ischemic preconditioning. Furthermore, it has 
been suggested that this effect may arise from increased H+ 
extrusion through an alternative pathway.11 Therefore, from 
the available data, it is not possible to deduce that ischemic 
preconditioning increases Na+/H+ exchanger activity during 
index ischemia. Conversely, unless ischemic preconditioning 
increases the exchanger’s sensitivity to intracellular H+, 
attenuated intracellular acidosis during index ischemia in 
preconditioned hearts would be expected to reduce Na+/H+ 
exchanger activity.
Na+/H+ Exchanger Inhibition and Ischemic 
Preconditioning: Counteractive or Additive?
Regardless of whether ischemic preconditioning alters sar­
colemmal Na+/H+ exchanger activity, an important question 
is whether an active exchanger is necessary to achieve 
cardioprotective benefit from this intervention. A number of 
studies have addressed this issue, again by using pharmaco­
logical inhibitors to suppress Na+/H+ exchanger activity at 
various times during the experimental protocol: during the 
cycles of triggering ischemia,12*13 during index ische­
mia,9*12*14-16 or during both periods.17 Although contradictory 
findings have also been reported,13*14 the majority of these 
studies9*12*15-17 have shown that the cardioprotective benefit 
of ischemic preconditioning is not attenuated by Na't7H+ 
exchange inhibition, indicating that an active exchanger is not 
necessary to achieve such benefit To the contrary, in some 
studies,12*17 the combination of Na+/H+ exchange inhibition 
with ischemic preconditioning has been shown to provide an 
additive benefit with the limitation of infarct size17 or the 
improvement in the recovery of contractile function12 appear­
ing to be significantly greater with the combined intervention 
relative to either intervention alone. Provided that the Na+/H+ 
exchange inhibitor doses and ischemic preconditioning pro­
tocols used in these studies were those that each afforded the 
maximum attainable protection, then the additive effects 
observed12*17 may indicate independent mechanisms of 
action.
It is notable that both of the previous studies that have 
shown additive benefit with the combination of Na+/H+ 
exchange inhibition and ischemic preconditioning were car­
ried out in rat hearts12*17 and that no similar additive effect has 
been observed in the rabbit15*16 At first consideration, this 
might appear to indicate species-specific responses, with 
Na+/H+ exchange inhibition and ischemic preconditioning 
possessing distinct mechanisms of action in the rat but 
sharing a common mechanism of action in the rabbit This 
scenario is unlikely, however, because in the rabbit heart, 
interventions that abolish the cardioprotective benefit of 
ischemic preconditioning (such as protein kinase C inhibition 
and ATP-sensitive K+ channel blockade) do not seem to 
affect the cardioprotective efficacy of Na+/H+ exchange 
inhibition.15*18 Furthermore, the study by Gumina et al5 in this
issue provides evidence that, in the dog heart also, the 
combination of Na+/H+ exchange inhibition and ischemic 
preconditioning affords greater cardioprotective benefit than 
either intervention alone, with an' index ischemia of 90 
minutes’ duration. A unique feature of this study5 is that a 
marked reduction in infarct size was afforded by the combi­
nation of Na+/H+ exchange inhibition by low-dose BHB-513 
and ischemic preconditioning, even though either interven­
tion alone did not produce a statistically significant effect 
The authors describe this effect of the combined intervention 
as “greater than additive,”5 which is akin to the textbook 
definition of synergism. However, the data may not reflect a 
true synergistic interaction between Na+/H+ exchange inhi­
bition and ischemic preconditioning, because each interven­
tion alone tended to reduce infarct size by ~25% (Figure 3 in 
Reference 5) and the effect of the combined intervention was 
not substantially greater than the sum of the individual 
effects.5 Instead, the apparent greater-than-additive effect 
could have arisen by chance, in view of the intragroup 
variability in infarct size, which most likely reflected a 
variable collateral flow. Another potential confounding factor 
is that low-dose BIIB-513 is unlikely to have produced a 
complete suppression of Na+/H+ exchanger activity (as evi­
denced by the enhanced protection afforded by a 4-fold 
greater dose), which makes it difficult to interpret mechanis­
tically the effects of combining this intervention with ische­
mic preconditioning. Regardless of these issues, however, the 
important new data provided by Gumina et al,5 considered 
together with other pertinent evidence in the literature, 
strongly suggest that Na+/H+ exchange inhibition and ische­
mic preconditioning can each afford significant cardioprotec­
tion in ischemia and reperfusion (most likely through inde­
pendent mechanisms) and that the former intervention does 
not counteract (but may add to) the protection afforded by the 
latter.
Na+/H+ Exchange Inhibition Versus Ischemic 
Preconditioning: Is One Superior to 
the Other?
A recent Special Report in Circulation19 stated that “. . .  other 
than early reperfusion, preconditioning is the strongest form 
of in vivo protection against myocardial ischemic injury.” 
While there can be no argument that reperfusion is an 
absolute prerequisite for the salvage of ischemic myocardium 
and that ischemic preconditioning is a powerful cardiopro­
tective intervention, the new evidence provided by Gumina et 
al5 and other published data do not wholly support this 
statement The Table summarizes the protocols and main 
findings of 5 studies, 2 of them in vivo, which (to the best of 
the author’s knowledge) constitute all of the studies in the 
literature that have directly compared the cardioprotective 
efficacy of Na+/H+ exchange inhibition versus ischemic 
preconditioning. In these studies, ischemic preconditioning 
was shown to afford marked protection against ischemia-and- 
reperfusion-induced injury, which was manifest as an atten­
uation of contractile dysfunction and creatine kinase leak­
age12 or a limitation of infarct size.5*15-17 The earlier 
studies12*15-17 all showed that Na+/H+ exchange inhibition is 
equally as effective as ischemic preconditioning in protecting
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Relative Cardioprotective Efficacy of Na+/H+ Exchange Inhibition Versus 
Ischemic Preconditioning
Ischemia, min Reperfusion, min
Reference Model Trigger Index Trigger Index NHEI
Relative
Efficacy
Bugge et al17 
Shipolini et al12 
Sato et alis

























































NHEI indicates Na+/H+ exchange inhibitor; BPA, 5-(/V-ethyl-/\Msopropyl)-amiloride; and PC, ischemic precondi­
tioning. HOE-642 is also known as cariporide.
the myocardium during ischemia and reperfusion. The current 
findings of Gumina and colleagues5 similarly demonstrate 
comparable efficacies with both interventions in dog hearts 
subjected to 60 minutes of index ischemia, but they suggest 
that Na+/H+ exchange inhibition may afford superior protec­
tion when this is extended to 90 minutes.
In discussing the relative efficacy of Na+/H+ exchange 
inhibition and ischemic preconditioning, Gumina et al5 
coined the phrase “ceiling of protection” to describe the 
minimum duration of index ischemia against which a partic­
ular intervention cannot afford significant protection. Their 
data suggest that in the dog in vivo and with infarct size as the 
index of injury, this ceiling is between 60 and 90 minutes for 
ischemic preconditioning but >90 minutes for Na+/H+ ex­
change inhibition. Although it may not be entirely helpful to 
extend the architectural analogy, it is probable that the higher 
ceiling for Na+/H+ exchange inhibition simply reflects a 
further extension of the time window during which myocar­
dial salvage can be achieved by reperfusion. The Figure 
illustrates this concept by showing hypothetical “injury 
curves” that describe the relationship between ischemia 
duration and infarct size in 3 groups of hearts: untreated 






Hypothetical curves describing relationship between ischemia 
duration and infarct size in hearts without treatment (control) 
and after ischemic preconditioning (PC) or treatment with a 
Na+/H + exchange inhibitor (NHEI). See text for details.
hearts pretreated with the maximally effective dose of a 
Na+/H+ exchange inhibitor. It should be stressed that al­
though the early sections of these curves have been drawn 
with the guidance of data from Gumina et al,5 the sections 
beyond 90 minutes (shaded area) are speculative. Neverthe­
less, the figure illustrates that the greater limitation of infarct 
size afforded by Na+/H+ exchange inhibition versus ischemic 
preconditioning after extended ischemia may arise from a 
greater delay in the progression of ischemic injury, depicted 
as a further shift to the right of the injury curve. By increasing 
the amount of viable tissue remaining at the time of reperfu­
sion, this would then allow significant myocardial salvage to 
be achieved even after extended ischemia.
The scheme proposed above does not take into account any 
potential contribution of reperfusion injury to the infarct size 
measured after ischemia and reperfusion. Recent work by 
Matsumura and colleagues20 suggests that in dog hearts 
subjected to 90 minutes of ischemia followed by reperfusion 
(as in the study by Gumina et al5 ), a substantial proportion of 
the infarcted myocardium is viable at the end of the ischemic 
period but loses viability after 180 minutes of reperfusion. In 
this context, it is important to highlight earlier evidence from 
Gumina and colleagues,21 also in the dog, that has shown that 
administration of a Na+/H+ exchange inhibitor shortly before 
reperfusion can produce a significant limitation of infarct 
size. Interestingly, preliminary evidence for this mode of 
action has been obtained in humans as well, in a recent study 
in which patients with anterior myocardial infarction received 
the Na+/H+ exchange inhibitor cariporide shortly before 
undergoing primary percutaneous transluminal coronary an­
gioplasty.22 Therefore, it is reasonable to suggest that Na+/H+ 
exchange inhibition may provide superior protection by 
limiting the loss of myocardial viability not only during 
ischemia but also during reperfusion.5
The preclinical evidence4 that Na+/H+ exchange inhibition 
represents an effective approach to the limitation of myocar­
dial injury during ischemia and reperfusion has been strength­
ened substantially by the work reported by Gumina and 
colleagues,5 whose data suggest that, at least in the dog, the
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protection afforded by this intervention may be superior to 
that provided by ischemic preconditioning. Because specific 
and apparently well-tolerated inhibitors of the Na+/H+ ex­
changer are now available, a further advantage of Na+/H+ 
exchange inhibition over ischemic preconditioning may arise 
from the greater practicability of assessing its therapeutic 
potential. Indeed, a multicenter clinical trial, designed with 
the objective of assessing the potential benefits of cariporide 
in patients with acute coronary syndromes,23 was recently 
completed. Although the preliminary results of this trial (as 
presented at the American College of Cardiology Scientific 
Session in March 1999) have not shown a significant overall 
benefit, subgroup differences suggest that cariporide treat­
ment may have provided benefit when ischemia was termi­
nated by reperfusion. This finding, if confirmed by detailed 
analysis, would be wholly consistent with the established 
actions of Na+/H+ exchange inhibitors in animal models.4 
The challenge now is to design and perform further trials that 
reflect the knowledge that has been accumulated from such 
recent clinical experience and through extensive preclinical 
investigation; ultimately, only these can provide the acid test 
for Na+/H+ exchange inhibition as a novel therapeutic ap­
proach in ischemic heart disease.
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Na+/H+ Exchanger Inhibitor HOE-642 Improves 
Cardioplegic Myocardial Preservation 
Under Both Normothermic and 
Hypothermic Conditions
Alex R. Shipolini, FRCS; Manuel Galinanes, MD, PhD; Stephen J. Edmondson, FRCS; 
David J. Hearse, PhD, DSc; Metin Avkiran, PhD
Background The sarcolemmal Na'TH* exchanger has been 
implicated in the pathogenesis of myocardial injury during 
ischemia/reperfusion. We determined the cardioprotective ef­
ficacy of the Na+/H+ exchanger inhibitor HOE-642 (HOE) as 
an alternative, adjunct, or additive to cardioplegia (CP).
Methods and Results In isolated working rat hearts (n=6 per 
group) subjected to 25 minutes of ischemia at 37°C, the 
postischemic recovery of aortic flow (AF) was 5 ±3% in con­
trols; this was improved to 18 ±4% by the preischemic infusion 
of 1 jumol/L HOE (P<.05 versus control) and to 53±7% by CP 
(P<.05 versus control and HOE). In hearts subjected to CP 
and 35 minutes of ischemia at 37°C, AF. recovered to 9±3% 
with CP alone; this was improved to 18±3% by the adjunctive 
administration of HOE during early reperfusion (CP+repHOE, 
.P<.Q5 versus CP) and to 27±4% by the use of HOE as an additive 
to CP (CP+HOE, P<.05 versus CP and CP+repHOE). With 120
The introduction of CP has dramatically improved myocardial protection during cardiac surgery.1 Nevertheless, in some cases, ischemia and reperfusion-induced cardiac dysfunction remains an im­
portant factor in the development of perioperative com­
plications; consequently, efforts continue to further im­
prove the efficacy of cardioprotective strategies.
In recent years, considerable experimental evidence 
has accumulated to suggest that activation of the sar­
colemmal Na+/H+ exchanger may be an important factor 
in the development of myocardial injury during ischemia 
and reperfusion, probably by contributing to the distur­
bance of Na+ and Ca2+ homeostasis (for reviews, see 
Karmazyn and Moffat2 and Avkiran3). Much of this 
evidence is based on the cardioprotective properties of 
amiloride-based Na+/H+ exchanger inhibitors; however, 
the utility of these .agents as pharmacological tools or 
potential therapeutic agents is compromised by their 
nonspecificity,4’3 In 1993, HOE-694, a novel compound 
with a structure distinct from amiloride, was reported to 
be a potent Na+/H+ exchanger inhibitor.6 Additionally, 
HOE-694 was shown to possess cardioprotective prop-
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minutes of ischemia at 28°C, AF recoveries were 16±3% in CP, 
32±3% in CP+repHOE (P<.Q5 versus CP) and to 50±4% in 
CP+HOE (PC.05 versus CP and CP+repHOE). With 300 min­
utes of ischemia at 15°C, the corresponding values were 30±4%, 
45±5% (Pc.05 versus CP), and 63±5% (Pc.05 versus CP and 
CP+repHOE). Improved recovery of pump function was often 
accompanied by a reduction in creatine kinase leakage during 
reperfusion.
Conclusions (i) HOE alone affords significant protection at 
normothermia but is not a superior alternative to CP, and (ii) 
the use of HOE as an adjunct or additive to CP provides 
significant benefit at normothermia, moderate hypothermia, 
and severe hypothermia. (Circulation. 1997;96[suppl 
II]:n-266-n-273.)
Key Words •  cardioplegia •  hypothermia •  ischemia •  
Na+/H+ exchanger •  HOE-642
erties during ischemia and reperfusion,6 an observation 
which has been supported by subsequent studies.7-11 
More recently, it has been demonstrated that HOE, a 
structural congener of HOE-694, may have even greater 
potency than HOE-694 as a Na+/H+ exchanger inhibitor 
and a cardioprotective agent.12 HOE also exhibits 
greater selectivity than HOE-694 for the NHE-1 isoform 
of the exchanger12 (believed to be the predominant 
isoform expressed in the heart13), and its therapeutic 
efficacy is currently being evaluated in humans. In view 
of the marked cardioprotective efficacy of HOE and the 
evidence that Na+/H+ exchanger activity may contribute 
to the loss of ionic homeostasis during ischemia even 
under hypothermic conditions,14 this agent may prove to 
be of clinical value as an alternative, adjunct, or additive 
to CP in cardiac surgery. However, experimental evi­
dence for this is currently lacking.
In the light of the above, the objectives of the present 
study were to use an isolated working rat heart model to 
assess: (i) the potential of HOE as an alternative to CP 
and (ii) the efficacy of HOE as an adjunct or additive to 
CP. When used as an adjunct to CP, HOE was admin­
istered during early reperfusion; when used as an addi­
tive, it was included as a component of the cardioplegic 
solution.
Methods
All experiments were performed in accordance with the 
Home Office Guidance on the Operation of the Animals
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Selected Abbreviations and Acronyms 
CP = cardioplegia 
HOE = 4-isopropyl-3-methylsulfonylbenzoyl-guamdine 
HOE-694 = 3-methylsulfonyl-4-piperidinobenzoyl-guamdine
(Scientific Procedures) Act 1986, published by Her Majesty’s 
Stationery Office, London, UK
Experimental Preparation
Adult male Wistar rats (B & K, Hull, UK) weighing 250 to 
320 g were anesthetized with sodium pentobarbitone (60 mg/kg 
intraperitoneally). Thirty seconds after administration of hep­
arin (300 IU intravenously), the chest was opened, and the 
heart was excised and immersed in cold (4°C) perfusion 
medium, thus achieving ventricular standstill within 10 to 15 s. 
The aorta was immediately cannulated, and retrograde perfu­
sion in the Langendorff mode was initiated at a constant 
pressure of 75 mmHg. During Langendorff perfusion, the 
pulmonary artery was incised to facilitate coronary drainage, 
and the left atrium was cannulated to complete a working left 
heart circuit with a fixed preload of 15 mm Hg and afterload of 
75 mm Hg. During perfusion in the working mode, aortic flow 
was measured by a flowmeter. (Metergate, Hemel Hempstead, 
UK) positioned in-line with the aortic cannula, and coronary 
flow was calculated by timed collection of the coronary effluent. 
Aortic pressure was monitored via a pressure transducer 
connected to a side arm of the aortic cannula and recorded on 
a Gould RS3400 inkjet chart recorder (Geveland, Ohio). Heart 
rate was derived from the pressure trace. Hearts that did not 
achieve an aortic flow of ^40 mT 7min and a spontaneous heart 
rate of s300 beats/min during an initial 20-minute period of 
aerobic perfusion in the working mode were excluded from the 
study (excluded hearts numbered <10% of the total used). The 
cardiac output (aortic flow plus coronary effluent) was filtered 
(5 /xm pore size) and returned to the perfusion circuit via a 
roller pump (Watson Marlow, Falmouth, UK).
Solutions
All solutions were filtered (5 /xm pore size) before use. The 
standard perfusion solution contained (in mmol/L): NaG  
118.5, KG 4.7, MgS04 1.2, KH2P 0 4 1.2, NaHC03 25.0, CaG2 
1.4, and glucose 11.0. The perfusion solution was maintained at 
37°C and gassed continuously with a mixture of 95% 0 2 + 5% 
C 02 (pH 7.4). St Thomas’ Hospital cardioplegic solution 
(composition in mmol/L: NaG 110, MgG2 16, KG 16, CaG2 
1.2, NaHCOj 10, pH adjusted to 7.8) was infused retrogradely 
via the aortic cannula at a constant perfusion pressure of 
45 mm Hg at 37, 28 or 75°C. HOE (Hoechst-Marion-Roussel, 
Frankfurt, Germany) was dissolved in de-ionized water to 
make a stock solution of 1 mmol/L, which was stored at 4CC for 
up to 5 days. This was diluted in the perfusion solution or 
cardioplegic solution immediately before use to obtain a final 
concentration of 1 /xmoJ/L This concentration was chosen on 
the basis of our preliminary work, which has shown 1 /xmol/L 
HOE to inhibit sarcolemmal Na+/H+ exchanger activity in rat 
ventricular myocytes by >75% and to provide optimal protec­
tion13 (of a magnitude comparable to that afforded by ischemic 
preconditioning16) in isolated rat hearts subjected to normo- 
thermic global ischemia.
Study Protocols
In all protocols, basal values for aortic flow, coronary flow, 
cardiac output (the sum of aortic flow and coronary flow), and 
heart rate were measured before ischemia (at the end of the 
initial 20-minute period of perfusion in the working mode). In 
all cases, values obtained at the end of reperfusion (15 minutes 
in the Langendorff mode and 30 minutes in the working mode) 
were expressed as a percentage of their respective preischemic
basal values to assess functional recovery. In some protocols, 
coronary effluent was collected during the Langendorff reper­
fusion period for assessment of creatine kinase leakage as an 
additional index of myocardial injury. Furthermore, because it 
has been suggested that Na+/H+ exchanger inhibition may 
preserve tissue high-energy phosphates by reducing Na+ influx, 
and thereby Na+/K+ ATPase activity,17 hearts were freeze- 
clamped at the end of the total reperfusion period for analysis 
of high-energy phosphate content
Potential of HOE as an Alternative to CP
The objective of this study was to determine the cardiopro­
tective efficacy of preischemic infusion of HOE relative to that 
of CP under normothermic conditions. To this end, after the 
assessment of basal function, three groups of hearts (n=6 per 
group) were perfused for an additional 5 minutes with standard 
perfusion solution (control), perfusion solution containing 
1 /xmol/L HOE, of St Thomas’ Hospital cardioplegic solution, 
all at 37°C. Subsequently, hearts were subjected to global 
zero-flow ischemia at 37°C for 25 minutes.
Efficacy of HOE as an Adjunct or Additive to CP
Our objective was to test whether the use of HOE as an 
adjunct (ie, given during early reperfusion) or an additive (ie, 
included as a component of the cardioplegic solution) can 
enhance the cardioprotection afforded by CP. Studies were 
carried out at three temperatures; at each temperature, the 
ischemic duration used was one that resulted in a postischemic 
functional recovery of 10 to 30% in the CP alone group, thus 
allowing sufficient scope for any improvement arising from the 
adjunctive or additive use of HOE to be readily demonstrated.
, Normothermia (37°C). All groups (n=6 hearts per group) 
underwent CP (37°C) for 5 minutes immediately before the 
induction of normothermic ischemia for 35 minutes. One group 
(CP) received no other intervention. In a second group 
(CP+repHOE), hearts received 1 /xmol/L HOE as an adjunct 
during the first 5 minutes of Langendorff reperfusion, whereas 
in a third group (CP+HOE), 1 /xmol/L HOE was used as an 
additive to the cardioplegic solution.
Moderate hypothermia (28°C). All groups (n=6 hearts per 
group) were again arrested by a 5-minute infusion of cardiople­
gic solution, this time at 28°G Furthermore, the myocardium 
was maintained at this temperature during a subsequent 120- 
minute period of ischemia, with a 5-minute reinfusion of the 
cardioplegic solution after the first 60 minutes of ischemia. As 
above, one group (CP) received no additional intervention. In 
a second group (CP+repHOE), hearts received 1 /xmol/L 
HOE as an adjunct during the first 5 minutes of Langendorff 
reperfusion, whereas in a third group (CP+HOE), 1 /xmol/L 
HOE was used as an additive to the cardioplegic solution.
Severe hypothermia (7JeC). As in the above two protocols, all 
groups (n=6 hearts per group) were subjected to CP for 5 
minutes immediately before the induction of ischemia. How­
ever, this time the cardioplegic solution was infused at 7.5°C 
and hearts were subjected to 300 minutes of ischemia at this 
temperature. Once again, one group (CP) received no addi­
tional intervention, another (CP+repHOE) received 1 /xmol/L 
HOE as an adjunct during the first 5 minutes of Langendorff 
reperfusion, and a third (CP+HOE) received 1 /xmol/L HOE 
as an additive to the cardioplegic solution.
Biochemical Analyses 
Creatine Kinase Leakage
Creatine kinase content of the coronary effluent collected 
during Langendorff reperfusion was assayed spectrophoto- 
metrically using a kit from Sigma Diagnostics (Poole, UK). 
Creatine kinase leakage was expressed in International Units 
(IU)/heart.
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Basal (Preischemic) Values for Functional Indices
Aortic Row Cardiac Output Coronary Row Heart Rate
Study Group (mL/min) (mL/min) (mL/min) (beats/min)
Potential of HOE as an alternative to
cardioplegia
Control 55 ±2 71 ±3 16±1 327+19
HOE 56+2 . 73±3 17+1 325+16
CP 56+3 73+3 17+1 340+6
Efficacy of HOE as an adjunct or additive to
cardioplegia
Normothermia (37°C)
CP 59 ±2 77 ±2 18±1 340+17
CP+repHOE 58±2
CO+l 15±1 331+15
CP+HOE 58±2 75+3 17+1 345+14
Moderate hypothermia (28°C)
CP 63 ±2 82 ±2 19±1 330+15
CP+repHOE 67 ±2 85+3 19+1 354+8
CP+HOE 59+3 81 ±4 21 ±2 336+13
Severe hypothermia (7.5*C)
CP 59+3 77±3 18+1 311+10
CP+repHOE 56 ±2 73±2 17±1 316+12
CP+HOE 58±4 76±4 18+1 310+10
n»6 hearts per group.
HOE indicates 1/imol/L HOE-642 4-isopropyl-3-methylsulfonylbenzoyl-guanidine; CP, cardioplegia alone; CP+repHOE, 
cardioplegia plus HOE administered as an adjunct during the first 5 minutes of reperfusion; CP+HOE, cardioplegia with HOE 
included as an additive to the cardioplegic solution.
Myocardial High-Energy Phosphate Content
Frozen ventricular samples were stored in liquid nitrogen 
before lyophilization. Subsequently, the tissue contents of ATP, 
ADP, and creatine phosphate were analyzed by using high- 
pressure liquid chromatography, as previously described.1* 
Data were expressed in micromoles per gram dry weight , of 
ventricle.
Statistical Analyses
Experiments within each protocol were carried out in a 
randomized manner. Gaussian-distributed variables were ex­
pressed as mean+SEM and subjected to ANOVA. If a differ­
ence between groups was established, intergroup comparisons 
were performed using the Student-Newman-Keuls test. A value 
of P < .05 was considered significant.
\ Results
There was no significant difference among the study 
groups within each protocol in the basal values for 
functional indices (Table 1).
Potential of HOE as an Alternative to CP
The postischemic recovery of aortic flow was only 
5 ± 3 %  in the control jproup (with no recovery in three of 
the six hearts); this was improved to 18±4% with HOE 
(P<.05 versus control) and to 53±7% with CP (P<.05 
versus control and HOE), with all hearts exhibiting some 
recovery of pump function in both of the latter groups. 
The postischemic recovery of cardiac output followed a 
pattern similar to that of aortic flow, with values of 
16+3%, 35±4%, (Pc.05 versus control), and 62±5% 
(Pc.05 versus control and HOE) in the control, HOE, 
and CP groups, respectively. Recovery of coronary flow 
was 55 ±7% in the control group and was significantly 
improved to 85±7% and 86±6% in the HOE and CP 
groups, respectively. Heart rate recovered fully in all 
groups, excluding the three hearts in the control group, 
which exhibited no recovery of pump function.
Efficacy of HOE as an Adjunct or Additive to CP 
Normothermia (37°C)
As illustrated in Fig 1A, the postischemic recovery of 
aortic flow was 9±3% in the CP group. This was 
significantly improved to 18±3% by the adjunctive use 
of HOE during early reperfusion (CP+repHOE). How­
ever, the best recovery of 27±4% (Pc.05 versus CP and 
CP+repHOE) was observed when HOE was used as an 
additive to CP (CP+HOE). The postischemic recovery 
of cardiac output followed a similar pattern, with values 
of 21±3, 31 it 3 (Pc.05 versus CP), and 41±4% (Pc.05 
versus CP and CP+repHOE) in the CP, CP+repHOE, 
and CP+HOE groups, respectively. The recovery of 
coronary flow was similar (74±3, 76±3, and 83±3%), 
and heart rate recovered to basal values in all groups. 
The intergroup differences in the recovery of pump 
function were reflected by differences in creatine kinase 
leakage (Fig IB), which measured 12.6±1.6 IU in the 
control group, 9.7±1.3 IU in the CP+repHOE group, 
and 4.7±0.7 RJ in the CP+HOE group (Pc.05 versus 
CP and CP+repHOE).
Moderate Hypothermia (28°C)
Under conditions of moderate hypothermia with mul­
tidose cardioplegic infusion, the adjunctive use of HOE 
again improved the myocardial preservation afforded by 
CP; however, once again, the greatest benefit was ob­
tained when the Na+/H+ exchanger inhibitor was used as 
an additive to the cardioplegic solution. Thus, the post­
ischemic recovery of aortic flow was improved from 
16±3% with CP to 32±3% with CP+repHOE (Pc.05 
versus CP) and to 50±4% with CP+HOE (Pc.05 versus 
CP and CP+repHOE) (Fig 2A). The corresponding 
values for cardiac output were 30±3%, 40±3% (Pc.05 
versus CP), and 60±3% (Pc.05 versus CP and 
CP+repHOE). Once again, coronary flow recovered to 
a similar extent (77±3%, 71±5%, and 85±4%), and 








F ig  1. Postischemic recovery of aortic flow (A) and creatine 
kinase leakage (B) during reperfusion in hearts (n=6 per group) 
arrested by a 5-minute infusion of St Thomas’ Hospital car­
dioplegic solution (37°C) and subjected to 35 minutes of global 
ischemia at 37°C. CP indicates cardioplegia alone; CP+repHOE, 
cardioplegia plus HOE (1 /xmol/L) administered as an adjunct 
during the first 5 minutes of reperfusion; CP+HOE, cardioplegia 
with HOE (1 /xmol/L) included as an additive to the cardioplegic 
solution. *P<.05 versus CP, fP < .0 5  versus CP+repHOE.
leakage was unaltered by the adjunctive use of HOE 
(CP+repHOE) but was significantly reduced when the 
drug was used as an additive (CP+HOE) (Fig 2B). 
Despite the intergroup differences in the postischemic 
recovery of pump function and creatine kinase leakage, 
there were no significant differences in the tissue con­
tents of ATP (10.3±0.6, 10.3±0.4, and 10.5±0.2 
prnol/g), ADP (2.2±0.1, 2.2±0.1, and 2.3±0.1 /xmol/g), 
and creatine phosphate (12.2±1.2, 12.2± 1.0, and 
15.8± 1.1 pmol/g) in the CP, CP+repHOE, and 
CP+HOE groups, respectively, at the end of 
reperfusion.






F ig  2. Postischemic recovery of aortic flow (A) and creatine 
kinase leakage (B) during reperfusion in hearts (n=6 per group) 
arrested by a 5-minute infusion of St Thomas’ Hospital car­
dioplegic solution (28°C) and subjected to 120 minutes of global 
ischemia at 28°C, with a 5-minute reinfusion of the cardioplegic 
solution after 60 minutes. CP indicates cardioplegia alone; 
CP+repHOE, cardioplegia plus HOE (1 /xmol/L) administered as 
an adjunct during the first 5 minutes of reperfusion; CP+HOE, 
cardioplegia with HOE (1 /xmol/L) included as an additive to the 
cardioplegic solution. *P<.05 versus CP, tP < -0 5  versus 
CP+repHOE.
Severe Hypothermia (7.5°C)
In this protocol involving cardioplegic arrest and an 
extended period (300 minutes) of global ischemia at 
7.5°C, the use of HOE as an adjunct or additive to CP 
provided additional benefit, with the latter affording the 
greatest protection. As illustrated in Fig 3A, the postis­
chemic recovery of aortic flow was 30±4% in the CP 
group, and this was significantly improved to 45 ±5% in 
the CP+repHOE group and to 63±5% in the CP+HOE 
group. The postischemic recovery of aortic flow with 
CP+HOE was significantly greater than that with 
CP+repHOE. The recovery of cardiac output was 
44±4%, 56±5% (P<.05 versus CP), and 72±5% (PC.05
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F ig  3 . Postischemic recovery of aortic flow (A) and creatine 
kinase leakage (B) during reperfusion in hearts (n=6 per group) 
arrested by a 5-minute infusion of St Thomas' Hospital car­
dioplegic solution (7.5°C) and subjected to 300 minutes of global 
ischemia at 7 .5°C. CP indicates cardioplegia alone; 
CP+repHOE, cardioplegia plus HOE (1 /xmol/L) administered as 
an adjunct during the first 5 minutes of reperfusion; CP+HOE, 
cardioplegia with HOE (1 /xmol/L) included as an additive to the 
cardioplegic solution. *P < .05 versus CP, fP c .0 5  versus 
CP+repHOE.
versus CP and CP+repHOE) in the CP, CP+repHOE, 
and CP+HOE groups, respectively. The corresponding 
values for coronary flow were 84±5%, 90±5%, and 
96 ±4% (P=NS), and heart rate recovered to basal 
values in all groups. Under these conditions, creatine 
kinase leakage was significantly reduced from 11.0 ±2.0 
IU with CP to 4.6±0.7 IU by the use of HOE as an 
adjunct (CP+repHOE) and to 2.6±0.3 IU by the use of 
the drug as an additive (CP+HOE) (Fig 3B). Once 
again, the significant intergroup differences in the post- 
ischemic recovery of pump function and creatine kinase 
leakage were not reflected by the tissue contents of ATP 
(15.7±0.4, 16.2±0.3, and 17.1±0.5 /xmol/g), ADP
(2.8±0.1, 3.2±0.1, and 3.1±0.1 /xmol/g), and creatine 
phosphate (17.3±1.3, 19.0±1.9, and 20.3±0.5 /xmol/g) 
in the CP, CP+repHOE, and CP+HOE groups, respec­
tively, at the end of reperfusion.
Discussion
The present study is the first to characterize the 
cardioprotective efficacy of HOE as an alternative, 
adjunct, or additive to CP. Our findings show that the 
preischemic infusion of HOE affords significant car­
dioprotection under normothermic conditions; how­
ever, this is not as great as that provided by CP. 
Nevertheless, as an adjunct or an additive, HOE 
significantly enhances the cardioprotective efficacy of 
CP under both normothermic and hypothermic 
conditions.
Pharmacological Inhibitors of the Na/H Exchanger
Amiloride and its structural derivatives are known 
to inhibit the Na/H exchanger with variable potency4 
and have been frequently used as pharmacological 
tools to investigate the role of the sarcolemmal 
Na+/H+ exchanger in the genesis of myocardial injury 
during ischemia and reperfusion (for a recent review, 
see Avkiran3). However, the utility of these agents is 
limited by their nonspecificity4 and, of particular 
relevance
to studies of cardiac pathophysiology, their ability to 
depress contractile function5,7 and to induce electro- 
physiological effects5,19-21 in ventricular myocardium. 
The recently developed benzoylguanidine-based 
agents HOE-694 and HOE offer significant advan­
tages over amiloride and its derivatives, both as 
pharmacological tools and as potential therapeutic 
agents, because of: (i) a high inhibitory potency on the 
sarcolemmal Na+/H+ exchanger,15,22 and (ii) a lack of 
effect on cardiac contractile function,7,12 electrogenic 
Na+ transport pathways (such as the Na+/Ca2+ ex­
changer and the noninactivating Na+ current),12 and 
pHj-regulatory mechanisms other than Na‘7H + ex­
changer.22 As stated in a recent editorial,23 HOE in 
particular represents a highly attractive potential ther­
apeutic agent because of its high selectivity for the 
predominant Na+/H+ exchanger isoform expressed in 
the heart. Indeed, this agent has now been selected for 
clinical evaluation as the prototype of a novel cardio­
protective approach in the therapy of acute coronary 
syndromes. For these reasons, in the present study, we 
chose to use HOE in preference to other N a7H + 
exchanger inhibitors.
Potential of HOE as an Alternative to CP
Consistent with our previous studies using HOE- 
694 in a similar model with less severe normothermic 
ischemia,11 the present study has shown that HOE 
alone can provide significant cardioprotection when 
given as a pretreatment. Nevertheless, the protection 
was not as great as that afforded by CP, which suggests 
that HOE is unlikely to be a viable alternative to CP.
It is well established that the primary protective 
mechanism of CP is membrane depolarization and the 
rapid induction of diastolic arrest, resulting in the 
preservation of myocardial high-energy phosphates.1 
As part of a spectrum of beneficial actions in main­
taining cellular integrity during ischemia and reperfu-
122
Shipotini et al Na+/H+ Exchanger Inhibitor in Cardioplegia 11-271
sion,1 such preservation of tissue high-energy phos­
phates is also likely to aid the maintenance and/or 
restoration of cellular ionic homeostasis by preserving 
the activity of energy-consuming ion transporters 
(such as the sarcolemmal Na+/K+ ATPase and the 
sarcolemmal /sarcoplasmic reticular Ca2+ ATPases). 
Additionally, CP attenuates intracellular acidosis dur­
ing early ischemia,24 which would be expected to limit 
sarcolemmal Na+/H+ exchanger activity because the 
exchanger is stimulated primarily by a reduction in 
pH j.25 In contrast, the primary (and possibly the sole) 
cardioprotective mechanism of HOE, when given 
alone, is the direct inhibition of sarcolemmal Na+/H+ 
exchanger activity. Thus, it is probable that the greater 
cardioprotective efficacy of CP relative to HOE arises 
from the broader range of salutary actions of the 
former intervention on the detrimental processes that 
accompany ischemia and reperfusion.1
Efficacy of HOE as an Adjunct or Additive to CP 
at Normothermia
In the present study, the use of HOE either as ah 
adjunct or as an additive was found to significantly 
enhance the cardioprotective efficacy of CP under 
normothermic conditions. However, the maximal ben­
efit was obtained when HOE was infused into the 
coronary vasculature before the onset o f ischemia, as 
an additive to the cardioplegic solution, rather than as 
an adjunct during early reperfusion. This is consistent 
with our earlier study with HOE-694 in the absence of 
CP,11 which revealed superior protection with preis­
chemic versus postischemic treatment in hearts per­
fused with bicarbonate-buffered medium. These find­
ings suggest that in rat hearts subjected to 
cardioplegic arrest, Na+/H+ exchanger activity during 
both ischemia and subsequent reperfusion contributes 
to myocardial injury. Thus, HOE can provide signifi­
cant benefit when used either as an additive or as an 
adjunct, and the superior protection afforded by the 
former approach probably arises from reduced 
Na+/H+ exchanger activity during ischemia, as well as 
during reperfusion. In this regard, it is worth noting 
that our results with HOE are consistent with those of 
a recent study by Koike et al,26 in which the cardio­
protective efficacy of dimethylamiloride (a nonspecific 
Na+/H+ exchanger inhibitor) as an additive to CP was 
investigated, and suggest that Na7H+ exchanger inhi­
bition may be a common mechanism of the benefit 
afforded by both drugs.
In considering the mechanism(s) that might under­
lie the superior myocardial protection afforded by the 
additive (cf. adjundtive) use of a Na+/H+ exchanger 
inhibitor, an important issue to address is whether the 
sarcolemmal Na+/H + exchanger retains significant ac­
tivity during ischemia in hearts subjected to cardiople­
gic arrest. In this regard, studies with nuclear mag­
netic resonance spectroscopy and amiloride-based 
Na+/H+ exchanger inhibitors*7-28 suggest that in the 
absence of cardioplegic arrest, sarcolemmal Na+/H+ 
exchanger activity contributes significantly to intracel­
lular Na+ accumulation dining ischemia. Thus, the 
extracellular acidosis that develops during ischemia 
(and may in fact exceed intracellular acidosis29) does 
not seem to abolish sarcolemmal Na+/H+ exchanger 
activity, despite the known inhibitory effects of a low
pH0 on the exchanger.30,31 In this regard, Vaughan- 
Jones and Wu31 have shown that H+ efflux (and 
concomitant Na+ influx) via the sarcolemmal Na+/H+ 
exchanger can be maintained even when the trans- 
sarcolemmal H+ gradient is inwardly directed, pro­
vided pH is sufficiently low. Within the context of the 
present study, it is important to note that cardioplegic 
arrest attenuates but does not abolish the induction of 
intracellular acidosis during normothermic ischemia.24 
Thus, it is reasonable to propose that hearts subjected 
to cardioplegic arrest may retain significant Na+/H+ 
exchanger activity during ischemia and that inhibition 
of this activity may contribute to the superior protec­
tion afforded by the additive use of agents such as 
HOE and dimethylamiloride.
Efficacy of HOE Under Conditions of Hypothermia
In many surgical settings, cardioplegic arrest is 
combined with hypothermia to achieve optimal myo­
cardial preservation.1 It is therefore important to 
determine whether the benefit afforded by the adjunc­
tive or additive use of HOE is sustained under 
hypothermic conditions. The importance of this is 
further highlighted by the ability of hypothermia per 
se to significantly alter cellular ionic homeostasis. 
With particular reference to Na+/H+ exchanger, there 
is evidence that hypothermia increases the activity of 
this exchanger, in both erythrocytes32 and cultured 
chick embryonic myocytes.33 Furthermore, hypother­
mia may inhibit the activity of the primary Na+ 
extrusion pathway, the sarcolemmal Na+/K+ ATPase.33 
Thus, it is probable that although hypothermia un­
doubtedly provides substantial benefit when combined 
with chemical CP,1 it may also induce a potentially 
detrimental response by promoting intracellular Na+ 
accumulation. Of particular relevance to the present 
study, the studies of Askenasy and colleagues34 in 
isolated rat hearts have shown that intracellular Na+ 
accumulation during hypothermic ischemia increases 
with decreasing temperature and that an amiloride- 
sensitive mechanism contributes significantly to such 
accumulation under conditions of severe hypothermia 
(4°C).14
In the present study, we have studied the effects of 
using HOE as an adjunct or additive to CP under two 
hypothermic conditions: at 28°C with multidose car­
dioplegic infusion (as often employed during cardiac 
surgery) and at 7.5°C (as may be used for donor heart 
preservation for transplantation). It is possible that in 
the former setting, the moderate degree of hypother­
mia may limit the temperature-mediated effects on 
ion transporters such as the Na+/H+ exchanger and 
Na+/K+ ATPase; however, sarcolemmal Na+/H+ ex­
changer activity may still play an important role 
because this is likely to be stimulated by the washout 
of the extracellular medium (and, hence, the relative 
alkalinization of pHJ during the second cardioplegic 
infusion. Indeed, superior benefit was afforded by the 
use of HOE as an additive at both 28 and 7.5°C. 
Under both hypothermic conditions, the myocardial 
high-energy phosphate content was well preserved by 
CP and was not altered significantly by the adjunctive 
or additive use of HOE. This supports the hypothesis 
that the benefit obtained from the use of HOE in 
combination with CP is likely to have arisen from an
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improved maintenance of myocardial ionic homeosta­
sis rather than from metabolic effects. Our findings 
are consistent with previous studies in hearts sub­
jected to cardioplegic arrest under normothermic25 
and hypothermic (4°C)35 conditions, in which the use 
of other Na+/H + exchanger inhibitors in combination 
with CP has been shown to improve the postischemic 
recovery of contractile function without an effect on 
myocardial high-energy phosphate content.
Potential Limitations of Study
In the present study, changes in pH; or the intracellu­
lar Na+ concentration were not determined during car­
dioplegic arrest in the presence or absence of HOE. 
Thus, the mechanism(s) of the additive protective effect 
of HOE cannot be determined definitively. It is interest­
ing to note that pretreatment with a Na+/H+ exchanger 
inhibitor (given either as an additive to CP25 or alone14) 
has been shown to increase intracellular acidosis under 
normothermic25 and hypothermic14 conditions, but only 
after periods of ischemia longer than those used here 
under comparable conditions. It is possible that with 
such prolonged durations of ischemia, Na+/H+ ex­
changer inhibition may have an attenuated beneficial 
impact on functional recovery, perhaps by promoting 
apoptosis due to an exacerbation of intracellular 
acidosis.35
Clinical Implications
The present study has shown that in an experimen­
tal model of cardiopulmonary bypass, the use of the 
specific and potent Na+/H + exchanger inhibitor HOE 
as an adjunct or additive to CP provides a significant 
improvement in myocardial preservation under con­
ditions of normothermia, moderate hypothermia, and 
severe hypothermia. At all temperatures studied, the 
best preservation was obtained when HOE was used 
as an additive to CP. Provided the safety and cardio­
protective efficacy of HOE in humans is proven by the 
ongoing clinical trials, then this agent may be of 
significant benefit when used in combination with CP 
for myocardial preservation in cardiac surgery and 
transplantation.
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Rational Basis for Use of 
Sodium-Hydrogen Exchange Inhibitors in 
Myocardial Ischemia
M etin A vkiran, PhD
The cardiac sarcolemmal Na+/H+ exchanger extrudes 
intracellular H+ in exchange for Na+, in an eledroneu- 
tral process. Of the 6 mammalian exchanger isoforms 
identified to date, the Na+/H+ exchanger (NHE)-l is 
believed to be the molecular homolog of the sarcolem­
mal Na+/H+ exchanger. The exchanger is activated 
primarily by a reduction in intracellular pH (intracellular 
acidosis), although such activation is subject to modula­
tion by a variety of endogenous mediators (e.g., cat­
echolamines, thrombin, endothelin) through receptor- 
mediated mechanisms. A large body of predinical 
evidence now suggests that inhibition of the sarcolem­
mal Na+/H+ exchanger attenuates many of the unfa­
vorable consequences of acute myocardial ischemia and 
reperfusion. Much of this evidence has been obtained 
with recently developed potent, selective inhibitors of the 
exchanger, such as HOE-642 (cariporide) and its struc­
turally related congener HOE-694, in studies using both
N a+/H+ exchangers (NHEs) are membrane pro­teins that transport H+ in exchange for Na+ in an 
electroneutral manner, utilizing for their driving force 
the transmembrane Na+ gradient.1-3 To date, 6 mam­
malian isoforms of NHE have been identified; these 
have been termed NHE-1-6.4-7 NHE-1-4 are located 
in the plasma membrane; little is known about the 
localization and function of NHE-5, and NHE-6 ap­
pears to be the molecular homolog of the mitochon­
drial exchanger. With respect to tissue distribution, 
NHE-1 and NHE-6 are ubiquitous (the latter ex­
pressed abundantly in tissues with high mitochondrial 
content), whereas NHE-2-5 show restricted expres­
sion.4-7 To date, only NHE-1 and NHE-6 transcripts 
have been detected in the heart,4-7 and it is believed 
that the sarcolemmal NHE of cardiac myocytes is 
composed predominantly, if not exclusively, of the 
NHE-1 isoform.8
Recently, the sarcolemmal NHE has received at­
tention as a potential mediator of various physiologic 
and pathophysiologic phenomena in myocardium, 
such as increased myofilament sensitivity to Ca2+ in 
response to stimulation of a variety of G protein- 
coupled receptors9-11 and the induction of hypertro­
phy by both mechanical12 and neurohormonal13 stim­
uli. However, perhaps the strongest evidence for an 
important role for the sarcolemmal NHE in cardiac 
pathophysiology is that which implicates the ex-
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in vitro and in vivo models of ischemia and reperfusion 
in a variety of species. The data from these studies 
indicate that Na+/H+ exchange inhibition leads to a 
decreased susceptibility to severe ventricular arrhyth­
mia, attenuates contractile dysfunction, and limits tissue 
necrosis (i.e., decreases infarct size) during myocardial 
ischemia and reperfusion. Such protection is likely to 
arise, at least in part, from attenuation of "Ca2+ over­
load,' which has been linked causally with all of these 
pathologic phenomena. The consistent and marked car­
dioprotective benefit that has been observed with cari­
poride and related compounds in predinical studies sug­
gests that Na+/H+ exchange inhibition may represent a 
novel and effective approach to the treatment of acute 
myocardial ischemia in humans. ©1999 by Excerpta 
Medica, Inc.
Am J Cardiol 1999;83:10G-18G
changer in the unfavorable sequelae of ischemia and 
reperfusion, such as arrhythmia, contractile dysfunc­
tion, and infarction. Such evidence was obtained ini­
tially with nonspecific NHE inhibitors (NHEIs), such 
as amiloride and its 5-amino-substituted derivatives 
(for reviews, see Avkiran14 and Frohlich and 
Karmazyn15), and has been substantiated by more 
recent studies with novel benzoylguanidine deriva­
tives, such as HOE-694,16 HOE-642 (cariporide),17 
and EMD-85131.18 These agents have proved to be of 
considerable investigative value since they are potent 
inhibitors of NHE,16-18 do not appear to inhibit other 
ion transport16-17 or pH regulatory19 systems, and ex­
hibit marked selectivity for the NHE-1 isoform of the 
exchanger.17-18-20 Published studies that have investi­
gated the effects of these novel NHEIs on arrhythmia, 
contractile dysfunction, and infarct size in animal 
models of myocardial ischemia and reperfusion are 
briefly reviewed below.
CARDIOPROTECTIVE EFFECTS OF 
NHEI IN ISCHEMIA AND 
REPERFUSION
Ventricular arrhythmia: Several studies have shown 
NHEIs to exhibit marked efficacy against severe ven­
tricular arrhythmia, in particular ventricular fibrilla­
tion (VF), during both ischemia and reperfusion. 
Scholz et al16 were the first to report that HOE-694, 
included in the perfusion solution throughout, inhibits 
reperfusion-induced VF in isolated rat hearts sub­
jected to 15 minutes of regional ischemia. In the same 
study,16 evidence was also presented that preischemic 
administration of HOE-694 abolishes the incidence of
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VF during 15 minutes of regional ischemia in the 
anesthetized rat in vivo. Yasutake et al21 subsequently 
showed that selective infusion of HOE-694 into the 
ischemic/reperfused zone of isolated rat hearts sub­
jected to 10 minutes of regional ischemia suppresses 
the incidence of reperfusion-induced VF in a dose- 
dependent manner. Interestingly, similar protection 
was observed, regardless of whether HOE-694 was 
administered before ischemia and during reperfusion 
or during reperfusion alone, suggesting that NHE ac­
tivity during reperfusion was the most important de­
terminant of susceptibility to reperfusion-induced VF 
in this model21 The potent inhibitory effect of HOE- 
694 on reperfusion-induced VF has also been demon­
strated in the pig in vivo.22 More recent studies have 
shown that cariporide shares the antiarrhythmic effi­
cacy of HOE-694 in the setting of myocardial isch­
emia and reperfusion, indicating that this is not a 
drug-specific, but a class effect. Thus, cariporide, 
given before coronary artery occlusion, has been 
shown to inhibit ischemia and reperfusion-induced VF 
in isolated rat hearts,17 and in rat17*23 and dog23 hearts 
in vivo. Therefore, the evidence that NHEIs inhibit 
potentially lethal ventricular arrhythmia appears well 
established; it is important to note, however, that this 
effect is not mediated via a classic antiarrhythmic drug 
action (i.e., inhibition of electrogenic ion currents]) 
and most likely occurs as a consequence of decreased 
severity of myocardial injury during ischemia and 
reperfusion.
Contractile dysfunction: A critical consequence of 
ischemia is a deficit in myocardial contractile capacity 
(and hence in ventricular function) that is maintained 
after the restoration of coronary flow. In most species, 
the contractile dysfunction observed during reperfu­
sion after relatively short periods (up to 15-20 min­
utes) of ischemia is reversible, and normal function 
can be restored after prolonged reperfusion (this phe­
nomenon has been termed “myocardial stunning”). 
After longer periods of ischemia, the contractile dys­
function observed during reperfusion is not reversible 
since it arises, at least in part, from myocardial necro­
sis. The evidence in the literature suggests that NHEIs 
can protect against both forms of contractile dysfunc­
tion.
In isolated working rat hearts subjected to 20 min­
utes of global ischemia, du Toit and Opie24 showed 
that HOE-694 attenuated myocardial stunning to a 
similar extent when given before ischemia or during 
early reperfusion. In contrast, Shimada et al25 reported 
that, in rat hearts subjected to 20 minutes of global 
ischemia in the presence of bicarbonate-containing 
perfusate (as in the study by du Toit and Opie24), 
HOE-694 provided no significant improvement in 
postischemic contractile recovery when given only 
during reperfusion. Nevertheless, the drug afforded 
substantial benefit when it was administered before 
the onset of ischemia.25 That pretreatment with HOE- 
694 improves the postischemic recovery of contractile 
function has been demonstrated also in a porcine 
model of myocardial stunning, in which HOE-694 
was given as a preischemic intravenous bolus fol­
lowed by continuous infusion 22 Thus, although there 
is agreement among studies from different laborato­
ries that NHEIs can significantly attenuate contractile 
dysfunction after relatively short periods of ischemia, 
some controversy exists as to whether the primary 
benefit arises from NHE inhibition during ischemia 
itself or during subsequent reperfusion.
The efficacy of NHEIs against postischemic con­
tractile dysfunction has also been studied with longer 
durations of ischemia in a variety of models. Hendrikx 
et al26 found that, in isolated blood-perfused rabbit 
hearts subjected to 45 minutes of global ischemia, 
preischemic administration of HOE-694 significantly 
improved the recovery of contractile function after 
reperfusion. In contrast, administration of HOE-694 
during reperfusion alone provided only marginal ben­
efit.26 Electron-microscopic assessment of tissue sec­
tions in this study revealed marked preservation of 
ultrastructural integrity in myocytes from hearts pre­
treated with the NHEI, with complete absence of 
classic manifestations of irreversible injury.26 In pig 
hearts in vivo subjected to 45 minutes of regional 
ischemia, preischemic administration of HOE-694 
significantly improved regional systolic shortening af­
ter 24 hours of reperfusion, whereas no such benefit 
was seen when the drug was given shortly before 
reperfusion 27 Similarly, in isolated working rat hearts 
subjected to global low-flow ischemia for 60 minutes, 
the presence of HOE-694 in the perfusion medium 
from 15 minutes before the onset of ischemia signif­
icantly improved recovery of aortic flow during reper­
fusion. In contrast, late administration of the drug 
(from 15 or 30 minutes after the onset of ischemia) 
was of no significant benefit.28 Thus, as with shorter 
periods of ischemia, the consistent finding is that 
preischemic treatment with NHEI significantly im­
proves recovery of contractile function during reper­
fusion. In contrast, any benefit afforded by these drugs 
when given only during reperfusion is insignificant or, 
at best, inconsistent.
In a recent study, Shipolini et al29 have compared 
the ability of cariporide to improve postischemic con­
tractile function with that of ischemic preconditioning, 
which is widely accepted as a potent cardioprotective 
intervention. It was found that, in isolated rat hearts 
subjected to 60 minutes of global ischemia, preisch­
emic administration of cariporide and ischemic pre­
conditioning afforded similar improvements in the 
recovery of left ventricular-developed pressure dur­
ing reperfusion 29 Interestingly, with each cardiopro­
tective intervention, improved recovery of contractile 
function during reperfusion was associated with de­
creased creatine kinase leakage, suggesting that at 
least part of the functional benefit arose from a reduc­
tion in myocardial necrosis 29
Myocardial necrosis: The first direct evidence that 
novel NHEIs inhibit the development of myocardial 
necrosis during ischemia and reperfusion came to light 
in 1995, in the form of 2 reports on the effects of 
HOE-694 on infarct size in pig hearts subjected to 
regional ischemia in vivo.27*30 Rohmann et al30 re­
ported that HOE-694 given before ischemia signifi­
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cantly decreased infarct size (assessed at the end of 
reperfusion by tetrazolium staining and expressed rel­
ative to the volume of ischemic ventricular myocar­
dium at risk of necrosis), from 78 ±  4% in controls to 
4 ±  1%. Interestingly, HOE-694 given shortly before 
reperfusion also decreased infarct size significantly (to 
38 ±  6%), which was presented as evidence for the 
existence of “reperfusion injury.”30 Consistent find­
ings with respect to the effects of pretreatment with 
HOE-694 were reported by Klein et al,27 who also 
showed significant reduction in infarct size, from 
65 ±  7% in controls to 13 ±  3%. In this study, how­
ever, HOE-694 produced no significant reduction in 
infarct size when given shortly before reperfusion.27
Since 1995, 4 additional studies have been pub­
lished in which the relative efficacy in decreasing 
infarct size of preischemic versus prereperfusion treat­
ment with an NHEI (cariporide or EMD-85131) has 
been reported. Garcia-Dorado et al31 and Miura et al32 
have obtained data in the pig and rabbit, respectively, 
that are consistent with the observations of Klein et 
a l27 while Linz et al33. in the rabbit and Gumina et al18 
in the dog have reported findings that support the 
observations of Rohmann et al.30 The main findings of 
these important and potentially clinically relevant 
studies are summarized in Figure 1. Despite the dif­
ferences in the NHEI and/or the dose used, the species 
under study, and the durations of ischemia and reper­
fusion, the consistent finding, which once again 
emerges, is that a large and significant cardioprotec­
tive benefit is obtained when the NHEI is administered 
before onset of ischemia. In contrast, when the NHEI 
is administered shortly before reperfusion, only an 
intermediate (and, in half of the studies, insignificant) 
effect is observed. It appears, therefore, that although 
NHE activity during both ischemia and reperfusion 
may contribute to the overall extent of myocardial 
injury, exchanger activity during ischemia is the more 
important factor, such that inhibition of the exchanger 
during this period slows progression of injury and 
allows greater myocardial salvage by reperfusion.
The Klein group has recently published 2 further 
studies34-35 that may help better quantify the benefit 
afforded by pretreatment with an NHEI and ascertain 
the period during which the exchanger needs to be 
inhibited to achieve reduction in infarct size. The first 
of these studies34 showed that infarct size obtained in 
pigs pretreated with cariporide and subjected to 70 
minutes of regional myocardial ischemia was compa­
rable to that seen in untreated controls subjected to 45 
minutes of ischemia. The investigators interpreted this 
to suggest that, in this model, NHE inhibition in­
creases tolerance to ischemia/reperfusion-induced in­
jury by approximately 25 minutes. An alternative in­
terpretation of these data may be that, in this model, 
the window for myocardial salvage (see later) is ex­
tended by at least 25 minutes, since precise quantifi­
cation of the “bought time” would require determina­
tion of the duration of ischemia that results in maxi­
mum infarct size with and without pretreatment with 
the NHEI. In a subsequent study, in pigs subjected to 
60 minutes of regional ischemia with residual flow,
Klein et al35 showed that a significant reduction in 
infarct size could be obtained with cariporide admin­
istered 15 minutes after the onset of ischemia. How­
ever, such benefit was lost when cariporide was ad­
ministered 45 minutes after the onset of ischemia, 
suggesting that, even in the presence of residual flow, 
inhibition of NHE during early ischemia is essential to 




The most likely mechanism through which NHEIs 
exert their cardioprotective action is attenuation of the 
loss of Na+ and Ca2+ homeostasis, and subsequent 
“Ca2+ overload,” during ischemia and reperfusion,15 
particularly since Ca2+ overload has been causally 
implicated in the genesis of VF, contractile dysfunc­
tion, and tissue necrosis in this setting. The original 
“Lazdunski hypothesis”36 proposed that increased sar­
colemmal NHE activity, arising from the rapid nor­
malization of extracellular pH and the generation of an 
outwardly directed H+ gradient upon reperfusion, 
may play a role in reperfusion injury. Although this 
hypothesis is supported by studies that have shown 
cardioprotective benefit with NHEIs when given 
shortly before or during reperfusion, it is not consis­
tent with the majority of studies that have shown 
superior benefit when the NHEI is given before or 
early during ischemia (see above). In this regard, the 
evidence that NHEIs attenuate intracellular Na+37-39 
and Ca2+38 accumulation during ischemia in parallel 
with their cardioprotective effects also suggests that 
NHE activity is maintained during ischemia and con­
tributes substantially to the loss of ionic homeostasis 
and the overall extent of injury.
Figure 2 summarizes the likely sequence of events 
that involves the sarcolemmal NHE during ischemia 
and reperfusion, as suggested by currently available 
data. Although the exchanger is quiescent under basal 
conditions, it becomes activated during ischemia in 
response to intracellular acidosis,36’40 which is known 
to develop rapidly 41 and possibly to other NHE-stim- 
ulatory factors (see below). The resulting influx of 
Na+, occurring in the presence of ischemia-induced 
inhibition of Na+/K+ adenosine triphosphatase (the 
primary Na+ extrusion pathway from the cardiac 
myocyte), causes the intracellular accumulation of 
Na+. Such an increase in intracellular Na+ concentra­
tion in turn alters the reversal potential of the Na+/ 
Ca2+ exchanger in a manner that inhibits Ca2+ efflux 
and/or enhances Ca2+ influx through this bidirectional 
mechanism—the end result being a pathologic in­
crease in intracellular Ca2+ (i.e., Ca2+ overload). 
NHEIs are likely to afford their cardioprotective effect 
during ischemia, at least in part by inhibiting this 
sequence at an early stage, through the limitation of 
Na+ influx. An important caveat to this probable 
scheme is that the studies that showed NHEIs to 
decrease intracellular Na+ accumulation during isch­
emia used amiloride and its analogs,37-39 and the pos-
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FIGURE 1. Infarct size, assessed a t the end of the reperfusion period by tetrazolium staining and  expressed as  a  percentage of the volume 
of ischemic ventricular myocardium a t risk of infarction, in animals receiving an  intravenous (iv) injection or short infusion of an  N a +/H + 
exchange inhibitor (HOE-694, cariporide, or EMD-85131), either 1 0 -1 5  minutes before occlusion of an  epicardial coronary artery to induce 
regional ischemia (pre-l) o r 5 -1 5  minutes before release of the occluder to institute reperfusion (pre-R). Data a re  from (4) Rohmann et a l,30 
(B) Klein et a l,27 (C) G arcia-Dorado et al,31 (D) Miura et al,32 (F) Linz et al,33 and  (F) G umina et a l . '8 Note that, under control conditions, 
dog hearts (F) exhibit a  smaller infarct size com pared with pig (jA—C) and  rabbit (D,F) hearts subjected to an  equivalent or shorter duration 
of ischemia, due  to a  g rea te r collateral flow  in the first species. I =  ischem ia; R =  reperfusion. *p < 0 .0 5 .
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FIGURE 2. The likely sequence of events tha t involves the sarcolem m al N a +/H + exchanger (NHE) during ischem ia an d  reperfusion. 
Although the exchanger is au iescent under basa l conditions, it becom es activated  during ischem ia in response to intracellular acidosis 
an d  other NHE-stimulatory factors. The resulting influx of N a +, occurring in the presence of ischem ia-induced inhibition of the 
N a +/K + adenosine  triphospha tase  (the prim ary  N a + extrusion pathw ay), causes the intracellular accum ulation of N o* . Such an  in­
crease in the intracellular N a + concentration in turn alters the reversal potential of the N a +/C a 2+ exchanger in a  m anner tha t inhib­
its Ca3+ efflux a n d /o r  enhances C a3+ influx through this bidirectional m echanism . The end  result is a  pathologic increase in intracel­
lular C a2+ (Ca2+ overload), which has  been  causally im plicated in the genesis of ventricular fibrillation, contractile dysfunction, and  
m yocardial necrosis. NHE inhibitors a re  likely to afford their cardioprotective effects, a t least in p art, by  inhibiting this sequence a t  an  
early  s tage , through the limitation of N a + influx.
sibility cannot be discounted that the observed effects 
might have arisen through inhibition of Na+ influx 
pathway(s) other than the sarcolemmal NHE, such as 
the noninactivating Na+ channel.42 There appears to 
be a need, therefore, to test whether novel NHEIs that 
do not inhibit this channel (e.g., cariporide17) also 
attenuate Na+ (and Ca2+) accumulation during isch­
emia.
Although the sarcolemmal NHE is activated by 
intracellular acidosis, it is subject to inhibition by 
extracellular acidosis,40-43 which also develops rapidly 
during ischemia.44 Thus, exchanger activity would be 
expected to decline with prolonged ischemia (which 
may help explain the requirement to inhibit NHE early 
during ischemia to achieve cardioprotective bene­
fit28-35). The rapid normalization of extracellular pH 
during early reperfusion would be expected to disin- 
hibit the sarcolemmal NHE, reactivate the sequence 
depicted in Figure 1, and lead to further injury, in 
accordance with the Lazdunski hypothesis.36 Thus, 
inhibition of the sarcolemmal NHE during ischemia 
and reperfusion could be of benefit through an iden­
tical mechanism, namely, the attenuation of Na+ in­
flux. Other potential mechanisms through which NHE 
inhibition could be of benefit during ischemia and 
reperfusion include: (1) slowing of the recovery of 
intracellular pH from acidosis during reperfusion,26-39 
which may limit the development of hypercontrac- 
ture26-45-46; (2) inhibition of myocardial edema47; and 
(3) attenuation of myocyte apoptosis.48
SA R CO LEM M A L N H E ACTIVITY 
IN ISC H EM IA
How does the sarcolemmal NHE retain significant 
activity, at least during early ischemia, despite the 
rapid development of extracellular acidosis? First, al­
though the sarcolemmal NHE is undoubtedly inhibited 
by extracellular acidosis,40-43 such inhibition is not 
absolute. Contrary to a common misconception, the 
primary regulator of NHE activity is not the trans­
membrane H+ gradient, but the intracellular pH, 
through the interaction of intracellular H+ with the 
so-called “H+ sensor” site of the exchanger protein.2 
Indeed, the sarcolemmal NHE can remain active and 
extrude H + against an inwardly directed H+ gradient, 
provided the intracellular pH is sufficiently low.43 
Second, certain processes associated with ischemia, 
such as the accumulation of lipid metabolites and the 
imposition of oxidant stress, may upregulate NHE 
activity, since exogenous lysophosphatidylcholine49 
and hydrogen peroxide50-51 have both recently been 
shown to stimulate the sarcolemmal exchanger in cul­
tured neonatal50 and freshly isolated adult49-51 rat ven­
tricular myocytes. Finally, various endogenous recep­
tor-mediated stimuli of relevance to myocardial isch­
emia have been shown to stimulate sarcolemmal NHE 
activity, apparently by increasing the sensitivity of the 
exchanger to intracellular H+. Such stimuli include 
thrombin,52 endothelin,9-53-54 and a  j -adrenergic ago­
nists.55-57 Recent data suggest that a,-adrenergic 
stimulation of sarcolemmal NHE activity is likely to
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FIGURE 3 . The tem poral an d  spatial progression  of m yocardial injury during  ischem ia a n d  the potential therapeutic  benefit of 
N a+/H + exchange (NHE) inhibitors. Through an  extension of the time w indow  for m yocardial sa lvage  by reperfusion , NHE inhibitors 
m ay decrease  infarct size (and thereby  im prove ventricular function an d  dec rease  mortality) even after relatively long periods of isch­
em ia (see tex t for further detail). Additional benefit m ay be provided by NHE inhibitors through the suppression of ventricular fibrilla­
tion (and thereby of sudden card iac death) an d  amplification of the benefits of reperfusion by inhibition of NHE-m ediated reperfusion 
injury.
be mediated selectively via the a 1A-adrenoceptor 
(AR) subtype,58 which may have clinical significance 
since the a 1A-AR is the dominant a r AR subtype 
expressed in human myocardium.59 Notably, a,-ad- 
renergic stimulation retains its ability to increase sar­
colemmal NHE activity in the presence of extracellu­
lar acidosis,55 which has important implications for 
NHE regulation under ischemic conditions.
In considering adrenergic regulation of the sar­
colemmal NHE, it is important to also note that, in 
contrast to the effect of a,-AR stimulation, /3r AR 
stimulation inhibits sarcolemmal NHE activity 53-57'60 
Therefore, the effects of the endogenous cat­
echolamines norepinephrine and epinephrine on sar­
colemmal NHE activity may depend on the relative 
density or availability of a ,-  versus /3,-ARs, which 
can be modulated by diseases such as heart failure 
(which is associated with /3,-AR downregulation) and 
myocardial ischemia (which enhances a,-AR signal­
ing), as well as by pharmacologic therapy (particularly 
with adrenergic antagonists).
THERAPEUTIC POTENTIAL O F  NHEI 
IN ACUTE M Y O C A R D IA L ISCHEM IA
Myocardial ischemia initiates a continuum of pro­
gressively more severe cellular changes that culminate 
in cell death and tissue necrosis.61 This progression 
from reversible to irreversible injury (depicted sche­
matically in Figure 3) may be viewed at the whole 
organ level as the development of an endocardial 
infarct and the progression of a wavefront of cell death 
to form a transmural infarct.62 The absolute prerequi­
site for myocardial salvage in this setting is early 
reperfusion, during the period of ischemia in which
most or part of the ischemic myocardium has not yet 
progressed to irreversible injury. This concept of a 
temporal progression of ischemic injury has been es­
tablished not only in animal models62 but also in 
humans.63 Thus, a recent analysis of 4 prospective 
randomized trials of thrombolytic therapy has re­
vealed that each 30-minute increase in symptom (i.e., 
ischemia) duration before reperfusion is associated 
with an increase in infarct size of 1 % of the myocar­
dium.63 Accordingly, although thrombolysis achieved 
significant myocardial salvage (the extent of which 
decreased with increasing symptom duration) when 
instituted within 4 hours after symptom onset, com­
parable infarct sizes were seen in patients treated 4 - 6  
hours after symptom onset and in those who did not 
receive thrombolytic therapy.63
The predinical data with NHEIs, in particular the 
substantial evidence that these agents decrease infarct 
size significantly when given before the onset of isch­
emia, suggest that NHE inhibition slows progression 
of myocardial injury during ischemia. Thus, as illus­
trated in Figure 3, a key benefit of treatment with an 
NHEI may be an extension of the time window for 
myocardial salvage by reperfusion, resulting in de­
creased infarct size (and hence improved ventricular 
function and decreased mortality) even after relatively 
long periods (> 4  hours) of ischemia. In addition to 
this potential extension of the window for myocardial 
salvage, NHEIs are expected to be of therapeutic 
value by suppressing occurrence of VF (and thereby 
decreasing sudden cardiac death) and amplifying the 
undoubted benefits of reperfusion through inhibition 
of any NHE-mediated reperfusion injury.
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CONCLUSIONS
As presented above, there is now a wealth of 
evidence from preclinical studies that NHEIs provide 
significant cardioprotection in the setting of ischemia 
and reperfusion, particularly when administered be­
fore the onset of ischemia (a requirement that has been 
incorporated into the design of the GUARD During 
Ischemia Against Necrosis [GUARDIAN] study, in 
which patients with acute coronary syndromes receive 
the NHEI cariporide during the period of risk for 
myocardial infarction64). The uncommon degree of 
conformity between different investigators, drugs, 
species, and models regarding the cardioprotective 
efficacy of NHEIs suggests a genuine therapeutic po­
tential, which may be translated into development of a 
novel and effective approach to the treatment of acute 
myocardial ischemia in humans.
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DISCUSSION
Pierre Theroux, MD (Montreal, Quebec, Canada):
Before moving to the more clinical part of the sym­
posium, we will take some questions on concepts and 
on the basics of the exchange system.
Audience member: Amiloride is a diuretic that 
blocks the Na+/H+ exchange system in the kidneys. 
How is cariporide different from this diuretic?
Metin Avkiran, PhD (London, United Kingdom): 
There is plenty of experimental evidence that amilo­
ride and amiloride-based compounds afford cardio- 
protection as do the newer, benzoylguanidine-based 
compounds like cariporide. However, the concentra­
tions of amiloride that are required to inhibit NHE-1 
are in excess of 1 mmol/L, compared with 1/x.mol/L 
for cariporide. Such high plasma concentrations of 
amiloride are not achieved through use of this drug as 
a diuretic. I don’t know if there is any clinical evi­
dence that patients who are taking amiloride as a 
diuretic tolerate acute myocardial ischemia better.
Dr. Theroux: Is hyperkalemia observed with caripo­
ride?
Dr. Avkiran: No, I don’t think there is any evidence 
for that.
Dr. Theroux: You said that Na+/H+ exchange sys­
tems can be expressed differently in various organs. 
Can you elaborate on this?
Dr. Avkiran: There are at least 6 different isoforms 
of the Na+/H+ exchanger. By that I mean 6 have been 
identified and cloned. NHE-1 is ubiquitous but is the 
only one expressed in the cardiac sarcolemma. NHE- 
2 -4  are localized to epithelial cells of the gastrointes­
tinal tract and kidneys. NHE-5 is not very well known; 
it is only a partial clone at the moment. NHE-6 was 
discovered only a couple of months ago; it is believed 
to be the mitochondrial Na+/H+ exchanger. The data 
we have available in the literature suggest strongly 
that cariporide and related compounds are selective 
for the NHE-1 isoform.
Audience member: I expect the Na+/H+ exchanger 
functions only during anoxia or hypoxia. So if you 
constantly inhibit it, would it have any effect on the 
nonischemic heart?
Dr. Avkiran: That is a very good point, one that I 
tried to illustrate in the first part of my talk. It is 
important to restress that the exchanger is inactive 
under normal physiologic conditions. It only becomes 
active under pathologic conditions, such as ischemia. 
Therefore, its inhibition under normal circumstances 
is not expected to have much of an effect. In many 
respects, cariporide can be seen as an ischemia-selec­
tive agent. The exchanger becomes active only in 
conditions such as ischemia, which produce intracel­
lular acidosis; its inhibition would only have a func­
tional impact under those conditions.
Dr. Theroux: So we should not expect depression of 
function in nonischemic myocardial cells during re­
gional ischemia?
Dr. Avkiran: That is correct. This has been looked at 
by a number of investigators, including in my own 
laboratory. The inhibitors of the Na+/H+ exchanger 
don’t depress myocardial function under normal aer­
obic conditions.
Audience member: Does sodium influx influence 
the action potential of the cell, making it unstable?
Dr. Avkiran: There is no evidence of direct electro- 
physiologic effects of cariporide. Indeed, you 
wouldn’t expect to see such an effect because the 
exchange system is electroneutral. For each positively 
charged sodium ion that enters the cell, a positively 
charged hydrogen ion leaves. From the studies in the 
literature, there are no direct effects on the action 
potential. The antiarrhythmic effects of drugs like 
cariporide are likely to arise from inhibition of sodium 
and calcium overload during ischemia and reperfu­
sion, and attenuation of its arrhythmogenic conse­
quences, such as disruption of cell-to-cell conduction 
and generation of delayed afterpotentials.
Audience member: I was quite intrigued by the 
potentiation between preconditioning and cariporide. 
Could you add to this observation?
Dr. Avkiran: I don’t really want to upset any pre­
conditioning people in the audience. All I can say is 
that Na+/H+ exchanger inhibition appears to be as
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protective as ischemic preconditioning, at least in our from Milwaukee presented some evidence obtained in
hands; there also is evidence for this from other lab- a canine model of ischemia and reperfusion that the
oratories, measuring different endpoints such as in- protective effect of ischemic preconditioning wanes
farct size. Interestingly, 2 weeks ago, at the North with very prolonged ischemia, whereas the protection
American Section meeting of the International Society afforded by Na /H+ exchanger inhibition is still
for Heart Research, Dr. Garrett Gross and colleagues present. These results need to be confirmed.
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Metin Avkiran Protection of the ischaemic myocardium
by Na+/H+ exchange inhibitors: 
potential mechanisms of action
Introduction
As reviewed recently (1, 16) and discussed elsewhere in 
this issue of Basic Research in Cardiology, there is sub­
stantial experimental evidence that pharmacological 
inhibitors of the Na+/H+ exchanger (NHE) attenuate the 
detrimental consequences of myocardial ischaemia and 
reperfusion, such as arrhythmias, contractile dysfunc­
tion, and tissue necrosis. The objective of this review is 
to consider the cellular mechanisms through which NHE 
inhibitors may preserve myocardial integrity and func­
tion during ischaemia and reperfusion.
Modulation of trans-sarcolem m al cation 
(Na+, Ca2+, H+) transport
The mechanism which has been most commonly cited as 
the principal mechanism underlying the cardioprotec­
tive actions of NHE inhibitors during ischaemia and 
reperfusion is the attenuation of the loss of Na+ and Ca2+ 
homeostasis and subsequent “Ca2+ overload”. The origi-
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nal hypothesis by Lazdunski et al. (21) proposed that 
increased sarcolemmal NHE activity, arising from the 
rapid normalisation of extracellular pH and the genera­
tion of an outwardly directed H+ gradient upon reperfu­
sion, may play a role in reperfusion injury. Although this 
hypothesis is supported by the studies which have shown 
cardioprotective benefit with NHE inhibitors when given 
from shortly before or early during reperfusion (dis­
cussed elsewhere in this issue), it is not consistent with 
the majority of studies (starting with the original obser­
vations of Karmazyn (15)) which have shown superior 
benefit when the NHE inhibitor is given prior to the onset 
of or early during ischaemia (5, 12,17, 18,25,35,37). In 
this context, it has been suggested that the relative inef­
ficacy of NHE inhibitors when given from shortly before 
or early during reperfusion in intact hearts may arise 
from inadequate drug delivery to the site of action (24). 
However, the recent work of Klein et al. (18) has shown 
that late administration of an NHE inhibitor by intra­
coronary infusion does not limit infarct size in pigs in 
vivo, even when an effective drug concentration is 
achieved in coronary venous blood prior to the onset of 
reperfusion. Furthermore, the evidence obtained with 
NHE inhibitors of the amiloride class, which have been 
shown to attenuate intracellular Na+ (26,28,41) and Ca2+ 
(26) accumulation during ischaemia in parallel with their 
cardioprotective effects, suggests that NHE activity is 
maintained and contributes substantially to the loss of 
ionic homeostasis during ischaemia, and that this is a key 
determinant of the overall extent of injury during 
ischaemia and reperfusion. Nevertheless, the conclu­
sions of these studies have been open to conjecture, on 
the basis that amiloride and its derivatives can addition­
ally inhibit ion transporting proteins other than the 
sarcolemmal NHE that may also contribute to the loss of 
Na+ and Ca2+ homeostasis during ischaemia (10). There­
fore, it is important to emphasise recent studies which 
have shown that the highly specific NHE inhibitor cari- p 
poride (previously known as HOE-642 (34)) also attenu- I
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ates the intracellular accumulation of Na+ (11) and Ca2+ 
(40) during ischaemia and improves the post-ischaemic 
recovery of contractile function (11, 40). These findings 
provide further support for the concept that NHE activ­
ity contributes significantly to the loss of ionic home­
ostasis during ischaemia and, through this mechanism, 
to myocardial injury and post-ischaemic contractile dys­
function.
Figure 1 summarises the likely sequence of events that 
involve the sarcolemmal NHE during ischaemia. 
Although the exchanger is relatively quiescent under 
basal conditions, it becomes activated during ischaemia 
in response to intracellular acidosis and possibly to other 
NHE-stimulatory factors (see below). The resulting 
influx of Na+, occurring in the presence of ischaemia- 
induced inhibition of the Na+/K+ ATPase (the primary 
Na+ extrusion pathway from the cardiac myocyte), 
causes the intracellular accumulation of Na+. Such a rise 
in the intracellular Na+ concentration alters the reversal 
potential of the Na+/Ca2+ exchanger in a manner that 
inhibits Ca2+ efflux and/or enhances Ca2+ influx through 
this bi-directional mechanism, thus producing intracel­
lular Ca2+ overload. NHE inhibitors are likely to afford a 
cardioprotective effect during ischaemia by inhibiting 
this sequence at an early stage, through the limitation of 
Na+ influx.
Although the sarcolemmal NHE is activated by intra­
cellular acidosis, it is subject to inhibition by extracellu­
lar acidosis, which also develops during ischaemia. Thus, 
during a prolonged period of ischaemia, NHE activity 
would be expected to be high soon after the onset of 
ischaemia but to decline subsequently, which may help 
explain the requirement to inhibit NHE early during
ischaemia in order to achieve maximum cardioprotective 
benefit (17,18). The rapid normalization of extracellular 
pH during early reperfusion would be expected to dis- 
inhibit the sarcolemmal NHE, reactivate the sequence 
depicted in Fig. 1, and lead to further injury (in accor­
dance with the Lazdunski hypothesis (21)). Thus, inhibi­
tion of the sarcolemmal NHE during ischaemia and 
reperfusion could be of benefit through an identical 
mechanism, that is the attenuation of Na+ influx. Indeed, 
data from van Emous et al. (42) indicates the presence of 
NHE-mediated Na+ influx during early reperfusion. 
However, in accordance with recent evidence (14), it is 
likely that Na+ accumulation during ischaemia is the 
more critical factor and that the principal mechanism 
through which NHE inhibitors protect the ischaemic and 
reperfused myocardium is the attenuation of Na+ influx 
during the ischaemic period.
Regardless of the relative importance of NHE-medi­
ated Na+ influx during ischaemia versus during reper­
fusion, there is substantial evidence that increased sar­
colemmal NHE activity contributes significantly to H+ 
efflux during the latter period. Thus, NHE inhibitors of 
the amiloride class (28) as well as the newer agents such 
as HOE-694 (12) and cariporide (11,40) have been shown 
to slow the recovery of intracellular pH from ischaemia- 
induced acidosis during early reperfusion. Furthermore, 
such slowed recovery of intracellular pH during early 
reperfusion has been proposed as a cardioprotective 
mechanism of NHE inhibition, potentially through the 
desensitisation of myofilaments and consequent inhibi­
tion of the development of hypercontracture (12,20,31). 
It appears, therefore, that the cardioprotective conse­
quences of NHE inhibition arise from a combination of
Fig. 1 Putative mechanism through 
which sarcolemmal NaVH" exchanger 
(NHE) activity contributes to the intra­
cellular accumulation of Na4 and Ca}* 
during myocardial ischaemia. 
WCfNaVCa2’  exchanger, NKA NaVK" 
ATPase. See text for details.
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1) the reduced intracellular accumulation of Na+ and 
Ca2+, particularly during ischaemia, and 2) the mainte­
nance of a lower intracellular pH during early reper­
fusion. It should be re-emphasised, however, that the 
former mechanism is likely to predominate.
Role of intracellular Na+and Ca2+ accumulation -  
discordant findings
Contrary to much of the evidence discussed above, some 
recent studies have provided data that contradict a key 
role for reduced intracellular Na+ and Ca2+ accumulation 
during ischaemia in the cardioprotective mechanisms of 
NHE inhibitors. For example, studies in rat isolated ven­
tricular myocytes have shown that NHE inhibition by 
cariporide does not affect the intracellular accumulation 
of Na+ and Ca2+ during anoxia, but inhibits the develop­
ment of hypercontracture upon reoxygenation (31, 33). 
It is likely that the metabolic challenge associated with 
anoxia in quiescent myocytes in vitro differs significantly 
from that imposed by ischaemia in beating intact hearts 
in vitro or in vivo. Furthermore, the myocyte model is 
devoid of the neurohormonal stimuli that may regulate 
sarcolemmal NHE activity during ischaemia in the intact 
heart (see below). Therefore, it is not possible to con­
clude, on the basis of the myocyte studies (31, 33), that 
the protection afforded by NHE inhibitors in the intact 
heart occurs independently of an attenuation of Na+ and 
Ca2+ accumulation during ischaemia. Nevertheless, the 
observation that NHE inhibitors can attenuate reoxy­
genation induced hypercontracture in isolated myocytes, 
without affecting Na+ and Ca2+ accumulation during the 
preceding period of anoxia, raises the intriguing possi­
bility that these agents may possess additional, currently 
unidentified, cardioprotective properties.
Contrary to many earlier studies (11,14,23,26,28,42), 
a recent report has suggested that the intracellular Na+ 
concentration does not rise significantly during 
ischaemia of the intact rat heart in vitro, even in the 
absence of an NHE inhibitor (27). This apparent contra­
diction is likely to have arisen from methodological dif­
ferences. For example, the fluorimetric method used by 
Park et al. (27) detects Na+ signals primarily from an epi- 
cardial layer of cells, whereas NMR spectroscopy, as used 
in the other studies (11, 14, 23, 26, 28, 42), provides a 
global estimate of the intracellular Na+ concentration in 
ischaemic myocardium. Importantly, the measurement 
of the intracellular Na+ concentration by an independent 
method (Na+-selective intracellular electrodes) has also 
shown significant Na+ accumulation during ischaemia, in 
arterially perfused rabbit papillary muscles subjected to 
ischaemia in an anoxic medium (46). Furthermore, the 
intracellular accumulation of Na+ during ischaemia was 
accelerated when the muscles were exposed to a throm­
bin receptor-activating peptide (46), which was subse­
quently shown to stimulate sarcolemmal NHE activity 
(47). Finally, while Park et al. (27) found no increase in 
the intracellular Na+ concentration during ischaemia in 
hearts which were paced at 120 beats/min (after destruc­
tion of the sinoatrial and atrioventricular nodes), they 
did observe a significant increase when the hearts were 
paced at 300 beats/min, which is closer to the sponta­
neous sinus rate of the rat heart in vitro. In this regard, in 
the NMR spectroscopy studies which have reported sig­
nificant increases in the intracellular Na+ concentration 
in isolated rat hearts during ischaemia, the hearts were 
either allowed to beat spontaneously (23,26) or paced at 
240-300 beats/min (14,28,42).
Regulation of sarcolemmal NHE activity 
during ischaemia
If it is accepted that intracellular Na+ accumulation 
occurs during ischaemia and that Na+ influx through the 
sarcolemmal NHE contributes significantly to this accu­
mulation, an important question to address is how the 
exchanger retains its activity, at least during early 
ischaemia, despite the rapid development of extracellu­
lar acidosis. Firstly, although the sarcolemmal NHE is 
undoubtedly inhibited by extracellular acidosis, such 
inhibition is not absolute. Contrary to a common mis­
conception, the primary regulator of NHE activity is not 
the trans-sarcolemmal H+ gradient, but the intracellular 
pH, through the interaction of intracellular H+ with the 
so-called "H+ sensor” site of the exchanger protein (44). 
Indeed, the sarcolemmal NHE can remain active and 
extrude H+ against an inwardly directed H+ gradient, 
provided the intracellular pH is sufficiently low (43). Sec­
ondly, processes associated with ischaemia, such as the 
accumulation of lipid metabolites and the imposition of 
oxidant stress, may upregulate NHE activity, since exoge­
nous lysophosphatidylcholine (13) and hydrogen perox­
ide (32, 38) have both been shown recently to stimulate 
the sarcolemmal NHE in rat ventricular myocytes. 
Finally, various endogenous receptor-mediated stimuli 
of relevance to myocardial ischaemia have been shown to 
stimulate sarcolemmal NHE activity, apparently by 
increasing the sensitivity of the exchanger to intracellu­
lar H \ Such stimuli include thrombin (47), endothelin 
(19), angiotensin II (9) and ot,-adrenergic agonists (45). 
Recent data suggest that a,-adrenergic stimulation of 
sarcolemmal NHE activity is likely to be mediated selec­
tively via the a 1A-adrenoceptor subtype (39,48); this may 
have clinical significance since the a 1A-adrenoceptor is 
the dominant oq-adrenoceptor subtype expressed in 
human myocardium (29). It is notable also thatch-adren­
ergic stimulation retains its ability to increase sarcolem­
mal NHE activity in the presence of extracellular acido­
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sis (30), which has important implications for NHE 
regulation under ischaemic conditions.
A role for NHE inhibition in non-myocardial cells?
It is apparent from the evidence reviewed above that 
much of the work aimed at identification of the cardio­
protective mechanisms of NHE inhibitors during 
ischaemia and reperfusion has, perhaps not surprisingly, 
focused on the cardiac sarcolemmal NHE. It should be 
borne in mind, however, that the novel NHE inhibitors 
which have been developed as putative cardioprotective 
agents (such as cariporide (34), EMD-85131 (8), BIIB-513 
(7), SL-59.1227 (22) and CP-597396 (4)) all exhibit 
marked selectivity for the NHE-1 isoform, which is 
expressed not only in the cardiac sarcolemma but also in 
the plasma membrane of almost every cell type in the 
body (3). In the context of myocardial ischaemia and 
reperfusion in the in vivo setting, it is possible that inhi­
bition of the plasma membrane NHE of other cellular 
components of the cardiovascular system (such as neu­
trophils, endothelial cells, platelets) may also modulate 
the extent of myocardial injury and dysfunction that 
arises. In support of this, there is preliminary evidence to 
suggest that inhibition of the neutrophil NHE may atten­
uate neutrophil-induced contractile dysfunction during 
reperfusion (36) and that NHE inhibitors may inhibit 
neutrophil adherence to activated vascular endothelium 
(2). Furthermore, in a recent comprehensive study, 
Gumina et al. (6) have shown that NHE inhibition atten­
uates neutrophil accumulation within ischaemic/reper­
fused myocardium, in an in vivo canine model of regional
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ischaemia and reperfusion. Their data additionally indi­
cate that the in vitro activation of canine isolated neu­
trophils by platelet activating factor or a phorbol ester is 
inhibited by pretreatment of the cells with the NHE 
inhibitor BIIB-513 (6). On the basis of these findings, fur­
ther work appears warranted to determine the contribu­
tion of reduced NHE activity in non-myocardial cells to 
the cardioprotective actions of NHE-l-selective 
inhibitors.
Conclusions
The balance of published evidence indicates that the 
potent cardioprotective actions of NHE inhibitors in 
experimental models of ischaemia and reperfusion arise 
primarily from the attenuation of the intracellular accu­
mulation of Na+ (and consequently Ca2+) in ischaemic 
myocardium, with any attenuation of a further distur­
bance in Na+ homeostasis during early reperfusion likely 
to play a less critical role. A slowed recovery from intra­
cellular acidosis during early reperfusion may also con­
tribute to the protection afforded by NHE inhibitors, by 
inhibiting the development of myocardial hypercontrac­
ture. Finally, there is suggestive evidence that, particu­
larly in the in vivo setting, inhibition of NHE activity in 
cell types other than cardiac myocytes may also help 
ameliorate myocardial injury and dysfunction, although 
further investigation is required to substantiate the con­
tribution of this mechanism.
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Thrombin Activates the Sarcolemmal 
Na+-H+ Exchanger
Evidence for a Receptor-Mediated Mechanism 
Involving Protein Kinase C
Masahiro Yasutake, Robert S. Haworth, Anna King, Metin Avkiran
Abstract Thrombin can activate the plasma membrane Na+- 
H+ exchanger in a variety of noncardiac cells. "We have studied 
(1) the effect of thrombin on the activity of the sarcolemmal Na+- 
H+ exchanger in freshly isolated quiescent ventricular myocytes 
from the adult rat heart and (2) the signaling mechanism(s) un­
derlying any effect Reverse-transcription polymerase chain re­
action analysis revealed thrombin receptor mRNA expression in 
a myocyte-enriched cell preparation. As an index of Na+-H+ ex­
changer activity, acid efflux rates (7Hs) were determined in single 
myocytes (n=4 to 11 per group) loaded with the pH-sensitive 
fluoroprobe carboxy-seminaphthorhodafluor-1 after two consec­
utive intracellular acid pulses (induced by transient exposure to 
20 mmol/L NHtCl) in bicarbonate-free medium. At a pH of 6.9, 
/ H did not change significantly during the second pulse relative 
to the first in control cells. However, when the second pulse oc­
curred in the presence of 0.2,1, or 5 U/mL thrombin, JH increased 
by 30%, 62% (PC.05), and 87% (/*<.05),.respectively. A hex- 
americ thrombin receptor-activating peptide (SFLLRN) mim­
icked the effect of thrombin and increased JH by 73% (PC.05)
T he sarcolemmal Na+-H+ exchanger is a major acid 
extrusion system in cardiac myocytes and plays 
an important role in restoration of pH following 
an acid load.1 Recent evidence suggests that the ex­
changer may also play an important role in determining 
the severity of the unfavorable sequelae of myocardial 
ischemia and reperfusion, such as arrhythmias, contractile 
dysfunction, and infarction.1,2 In cardiac myocytes, as in 
other cell types, the activity of the Na+-H+ exchanger is 
regulated not only by pH but also by a number of extra­
cellular stimuli (such as exposure to adrenergic agonists, 
endothelin, angiotensin II, and adenosine triphosphate) 
through receptor-mediated mechanisms (for recent re­
view, see Puceat and Vassort3).
Thrombin is a multifunctional protease, which, in ad­
dition to its established role in blood coagulation and 
thrombus formation, induces a variety of cellular re­
sponses through the recently cloned thrombin receptor 
(for review, see Coughlin4). The receptor can be activated 
not only by thrombin but also by synthetic peptides 
(thrombin receptor-activating peptides), which mimic the
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at 25 /imol/L. In contrast, an inactive control peptide (FLLRN) 
was without effect at 25 fitnol/L. In cells pretreated with 100 
nmol/L GF109203X or 5 /unol/L chelerythrine (protein kinase C 
inhibitors), neither 5 U/mL thrombin nor 25 /imol/L SFLLRN 
produced a significant increase in JH. In the presence of 10 
/rmol/L HOE-694 (a Na+-H+ exchanger inhibitor), pH did not 
recover after an acid load, even during exposure to 5 U/mL 
thrombin or 25 /xmol/L SFLLRN, confirming that the Na+-H+ 
exchanger was the primary acid efflux mechanism under the con­
ditions used. Neither 5 U/mL thrombin nor 25 /rmol/L SFLLRN 
affected resting pH and Ca2+ or background acid loading. We 
conclude that (1) adult rat ventricular myocytes express a func­
tional thrombin receptor, whose stimulation results in increased 
activity of the sarcolemmal Na+-H+ exchanger, and (2) this effect 
appears to occur through a protein kinase C-mediated mecha­
nism. (Circ Res. 1996;79:705-715.)
Key Words • thrombin receptor • protein kinase, C • 
Na+-H+ exchanger • heart • myocyte
“tethered ligand” domain of the receptor that is revealed 
after cleavage, by thrombin.4 A number of cell types 
within the cardiovascular system, including platelets,5 en­
dothelial cells,5 and vascular smooth muscle cells,6 have 
been shown to express mRNA coding for the cloned 
thrombin receptor. Indeed, exposure to thrombin can pro­
duce a range of physiological effects in these cell types; 
these include activation of the plasma membrane Na+- 
H+ exchanger, which occurs (at least in part) through a 
PKC-mediated pathway.7'9 With respect to cardiac myo­
cytes, Steinberg et al10 have shown that thrombin can alter 
phosphoinositide metabolism and cytosolic Ca2+ in cul­
tured neonatal rat ventricular myocytes. In a similar 
model, Glembotski et al11 have demonstrated recently 
that the cloned thrombin receptor is expressed and may 
mediate a hypertrophic response after exposure to throm­
bin. However, there is a paucity of data regarding the 
effects of thrombin in adult cardiac myocytes and the role 
of the cloned thrombin receptor in this cell type, partic­
ularly with regard to regulation of sarcolemmal Na+-H+ 
exchanger activity.
The primary objectives of the present study were to 
use freshly isolated adult rat ventricular myocytes to (1) 
obtain molecular evidence for expression of die cloned 
thrombin receptor in this cell type, (2) determine the ef­
fects of thrombin and a thrombin receptor-activating pep­
tide on sarcolemmal Na+-H+ exchanger activity, and (3) 
delineate the roles of intracellular Ca2+ and PKC in me­
diating any regulation of exchanger activity via the
141
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Selected Abbreviations and Acronyms
fa = intracellular intrinsic buffering 
power
C-SNARF-1 = carboxy-semin aphthorhodafluor-1 
HOE-694 = 3-methylsulfonyl-4-
piperidinobenzoyl guanidine 
/ 405, 14U, hao> /mo = fluorescence emission intensity at 
405, 485, 580, and 640 nm 
JH = rate of acid efflux 
PCR = polymerase chain reaction 
PKC = protein kinase C
thrombin receptor. Our results provide molecular and 
physiological evidence that adult rat ventricular myocytes 
express a functional thrombin receptor, whose stimula­
tion results in increased activity of the sarcolemmal Na+- 
H+ exchanger. This effect occurs in the absence of a de­
tectable increase in [Ca2+]i and appears to involve a 
PKC-mediated mechanism.
M aterials and  M ethods
The present investigation was performed in accordance with 
the Home Office Guidance on the Operation of the Animals (Sci­
entific Procedures) Act of 1986, published by Her Majesty’s Sta­
tionery Office, London, UK.
Isolation of Ventricular Myocytes
Ventricular myocytes were isolated from the hearts of adult 
male Wistar rats (200 to 250 g body weight) using a collagenase- 
based enzymatic digestion technique, which has been described 
previously.12 In brief, rats were anesthetized by inhalation of di­
ethyl ether, and hearts were excised and perfused (37°Q, ip the 
Langendorff mode for four sequential periods, as follows: (1) 
with Tyrode’s solution (mmol/L: NaCl 137, KC1 5.4, CaG2 1.8, 
MgG2 0.5, HEPES 10, and glucose 10, adjusted to pH 7.4 at 
34°C with NaOH) for 5 minutes, (2) with nominally Ca2+-free 
Tyrode’s solution (mmol/L: NaG 135, KQ 5.4, NaH2P04 0.33, 
MgG2 1.0, HEPES 10, and glucose 10, adjusted to pH 12  at 
34°C with NaOH) for 5.5 minutes, (3) with nominally Ca2+-free 
Tyrode’s solution containing collagenase (Worthington type 1, 
200 U/mL) for 10 minutes, and (4) with storage buffer (mmol/L: 
KOH 78, KG 30, KH2P04 30, MgS04 3, EGTA 0.5, HEPES 10. 
glutamic acid 50, taurine 20, and glucose 10, adjusted to pH 12. 
at 34°C with KOH) for 5 minutes. All solutions were gassed with 
100% O* After the perfusion procedure, the ventricles were re­
moved and chopped into several pieces in storage buffer. The 
tissue fragments were then gently agitated to facilitate cell dis­
persion, which commonly resulted in a myocyte yield of >80% 
rod-shaped cells. The cell suspension was maintained in storage 
buffer at 25°C for at least 1 hour before use in the microepiflu- 
orescence studies. When required for RNA extraction, myocyte- 
enriched preparations were obtained by centrifugation (25g for 5 
minutes) of the cell suspension, followed by gravity sedimenta­
tion for 15 minutes.
Extraction of RNA From Myocyte-Enriched 
Preparations
Myocyte-enriched preparations («2X 10® cells per heart) were 
pelleted by centrifugation at 160g for 5 minutes. The supernatant 
was discarded, and total RNA was prepared from the cell pellet 
using Trisolv reagent (Biotecx Laboratories Inc) according to the 
manufacturer’s instructions. mRNA was subsequently prepared 
from total RNA using the Invitrogen FastTrack mRNA isolation 
kit (R & D Systems Europe Ltd) as recommended by the 
manufacturer.
Reverse-Transcription PCR
mRNA (1 fig) from myocyte-enriched preparations was re­
verse-transcribed in a volume of 20 /iL, using the Invitrogen
cDNA Cycle kit and oligo dT primer (R & D Systems Europe 
Ltd). Samples were extracted with phenol/chloroform, and the 
cDNA was precipitated with ethanol at -70°C for 20 minutes. 
The cDNA was dissolved in 20 fj.L RNase-free water before PCR. 
Aliquots (5 fiL) were subjected to 35 cycles of PCR (1 minute at 
94°C, 1 minute at 55°C, and 1 minute at 72°C) using primers 
(100 pmol) specific for the rat thrombin receptor (5'-TGTGA- 
ACTGATTATGTCAATT-3' and 5'-TAACCAGGAAAAGGA- 
TATG-3'), as described by Glembotski et al.11 As a negative 
control, reverse transcriptase was omitted from the cDNA syn­
thesis step. As a positive control, plasmid (1 pg) containing sub­
cloned rat thrombin receptor cDNA (see Glembotski et al11) was 
also subjected to PCR amplification. PCR products were incu­
bated for 60 minutes in the presence or absence of the restriction 
enzyme EcoRV before separation on 5% acrylamide.gels. Based 
on the known sequence of the rat thrombin receptor cDNA,11 the 
intact PCR product obtained using these primers should be 946 
bp, while cleavage at the EcoKV recognition site should result in 
two products of 585 and 361 bp. To further confirm the identity 
of the intact PCR product obtained from myocyte cDNA, this 
was additionally subjected to,sequence analysis in both direc­
tions, using the primers described above and an ABI 373 auto­
mated sequencing system (Molecular Medicine Unit, King’s Col­
lege, London, UK).
Determination of Sarcolemmal Na+-H+ 
Exchanger Activity 
Measurement of pH t
pH was monitored in single ventricular myocytes using the 
pH-sensitive fluorescent dye C-SNARF-1, as described previ­
ously.1314 Briefly, aliquots of cells were loaded with C-SNARF- 
1 within 6 hours of their isolation by incubating them in a 4 
x^mol/L solution of the acetoxymethyl ester (Calbiochem) for 10 
minutes at room temperature. Cells loaded with C-SNARF-1 
Were then allowed to settle on a glass coverslip at the bottom of 
a 100-/iL chamber, mounted on the stage of an inverted micro­
scope (Nikon Diaphot), and viewed using a X40 oil immersion 
objective with a numerical aperture of 1.3. After adherence to the 
coverslip, cells were superfused (3.5 mL/min) with Tyrode’s so­
lution at 34°C. Cells were excited with light at 540 nm, and the 
resulting fluorescence emission intensity from a selected afea of 
a single myocyte was measured simultaneously at 580 nm (Is*>) 
and 640 nm (/mo), using a dual-emission photometer system 
(model D104C, Photon Technology International Inc), which 
contained an adjustable aperture and two multialkali photomul­
tiplier tubes (type R928, Hamamatsu Photonics UK Ltd). Back­
ground fluorescence was measured using an identical aperture 
and subtracted from the signal. After current-voltage 
conversion, the acquired signals were digitized at 1.7 Hz and 
stored on computer hard disk, using pGamp software (Axon 
Instruments).
Calibration of Fluorescence Signal
The emission intensity ratio (JskJIh0) was calculated and con­
verted to a pH, scale, using in situ calibration data obtained by 
exposing cells loaded with C-SNARF-1 to nigeririn-containing 
calibration solutions of pH 5.8 to 8.0.13 The calibration solutions 
consisted of 140 mmol/L KG, 1 mmol/L MgG2, and 10 /tmol/L 
nigericin and were buffered with 10 mmol/L of one of the fol­
lowing zwitterionic buffers: MES at pH 5.8, 6.2, and 6.4; PIPES 
at pH 6.6, 6.8, and 7.0; and HEPES at pH 7.2, 7.4, 7.7, and 8.0. 
All calibration solutions were adjusted to the correct pH with 
NaOH. Fig 1A shows a recording from a typical calibration ex­
periment in a single cell. The data acquired from each such cal­
ibration experiment were normalized by dividing all htsJIfM ratios 
by the ratio obtained in that cell at a pH of 7.01#; thus, the nor­
malized hsollbia ratio at pH 7.0 was always 1. The calibration 
curve shown in Fig IB was obtained by a nonlinear least squares 
fit of the normalized data from seven cells to the equation given 
below, with the curve constrained to pass through the point hav­
ing the coordinates (/W/«o)/(/sso//6«o)pH7=1.0, pH 7.0.16
142

















5-  1.2 -
1.0 -
0.8
^  0.6 - 
0.4-
0.0 -
5.6 5.8 6.0 6.2 6.4 6.6 6.8 7.0 72 7.4 7.6 7.8 8.0 8.2
pH,
F ig 1. A, Representative recording of the C-SNARF-1 fluores­
cence emission intensity ratio (/s w A d  from a single cell during 
exposure to  nigericin-containing calibration solutions of varying 
pH (numbers indicate pH). In this trace, the /W/eao ratio was 
averaged over 5-second intervals for clarity. B, Calibration curve 
constructed using normalized /MO//a*o ratio data from seven ex­
periments (see text for details).
m W /6 4 0 . , r 10^-^ 10(7-pK) ]
w  ( W W p r n ' Ll + 1 0 (pH' pK) 1 + l O ^ J
The best-fit values for pK and a  were 7 .1 2  and -1 .3 8 ,  
respectively.
Estimation o f Pi 
Pi was estim ated by stepwise removal o f  extracellular NH*C1, 
as described in detail previously.17,18 T w elve ce lls  from three dif­
ferent hearts were exposed to Tyrode’s solution containing 20  
m m ol/L NH,C1 for 1 to 2 minutes, fo llow ed  by a stepwise re­
duction o f  extracellular N H *+ to 10, 5, 2.5, 1, and 0 mmol/L. 
At each step, calculated changes in [N H i+]i and measured 
changes in pH were used to estimate P it from the equation  
A = A [N H 4 +]i/ApHj. These experiments were carried out in the 
presence o f  30 /maol/L H O E-694 in order to prevent acid extru­
sion via the N a +-H + exchanger and 5 m m ol/L  B a2+ to reduce 
N H »+ efflux through K + channels.11 By plotting p , as a function  
o f  p H  from 5 1 determinations and subsequent linear least squares 
regression analysis, the follow ing equation was obtained:
(2) /? ,= —34 .9  • pH j+ 273 .5
Equation 2 was used in all subsequent experim ents to estim ate P-, 
at different p H  values.
Calculation o f Sarcolemmal Acid Efflux 
Since all experiments were carried out in the nominal absence 
o f  bicarbonate, J H was used as a direct index o f  sarcolemmal N a +- 
H + exchanger activity.18 J H was estimated during recovery from  
an intracellular acidosis using the equation J»= P , • dpH /dt (where
dpHj/dt is  the rate o f  recovery o f  pH), as previously described.18 
N o corrections were made for cell volum e-to-surface area ratio, 
since all experim ents were carried out in the same cell type (ie, 
adult rat ventricular m yocytes) in a randomized manner, with  
contemporary controls. Intracellular acidosis w as induced by the 
washout (6 minutes) o f 20 m m ol/L  NH,C1 after its transient (2- 
to 3-m inute) application. The pH trace during the recovery phase 
was fitted to a single exponential function, as previously d e­
scribed.19 A t pH intervals o f  0.05 during this phase, JH values  
were calculated from Pi (estimated as described above) and 
dpHj/dt (calculated as the differential derivative o f  the exponen­
tial fit), thus enabling the construction o f  pHr versus-yH relation­
ships. A  rightward shift o f  this curve (signifying a greater J H at 
a given pH) was taken to indicate an increased N a+-H + e x ­
changer activity.
Estimation of Intracellular Ca2+
[Ca2+]i was estimated using the C a2+-sensitive fluorescent dye  
indo 1 (Cambridge B ioScience), as described previously.20 A li­
quots o f  ce lls  were loaded with indo 1, by incubating them for 
20  minutes at room temperature in a 10 junol/L solution o f  the 
acetoxym ethyl ester. A s in the studies with pH measurement, 
cells w ere superfused (3.5 m L/min) with Tyrode’s solution at 
34°C. The m icroepifluorescence approach used w as also similar 
to that described above for C -SN A R F-1, except that only a por­
tion o f  a selected  ce ll was illuminated (at 360 nm ), and the flu­
orescence em ission intensity was measured simultaneously at 405  
and 485  nm, through the use o f  appropriate optical filters. The 
em ission intensity ratio (/W A ss) was used as an index o f  [C a2+]i, 
without calibration.20
Solutions
A ll chem icals were purchased from Sigma Chemical C o, un­
less stated otherwise. The thrombin receptor-activating peptide 
SFLLRN and the inactive control peptide FLLRN w ere gifts from  
Glaxo (Greenford, UK). The N a +-H + exchanger inhibitor HO E- 
694 w as a gift from Hoechst (Frankfurt, Germany).
A ll experiments were performed in HEPES-buffered T yrode’s 
solution. In N a*-free Tyrode’s solution, NaCl was replaced with  
137 m m ol/L  choline chloride, and pH was adjusted to 7 .4  with  
KOH. NH*C1 (20  mmol/L) was added directly to Tyrode’s so ­
lution without osm otic compensation. Stock solutions o f  throm­
bin (T -6759 , Sigm a) and HO E-694 were prepared in deionized  
water; SFLLRN and FLLRN were d issolved directly in Tyrode’s 
solution. The PKC inhibitors G F 109203X  (Calbiochem ) and 
chelerythrine were dissolved in dimethyl sulfoxide and subse­
quently diluted with Tyrode’s solution to obtain appropriate stock  
solutions. A ll agents were added to superfusion solutions, at the 
appropriate concentrations, shortly before the beginning o f  
experim ents.
Experimental Protocols
Experiments were performed using the protocols described be­
low , unless stated otherwise. Basal p H  was noted after 5 to 10 
minutes o f  superfusion with normal Tyrode’s solution (pH 7 .4). 
T o study the effects o f thrombin and SFLLRN on resting p H , 
cells w ere then exposed to these agents for a further 5 minutes. 
T o study the effects o f  these stimuli on sarcolemmal N a +-H + 
exchanger activity, cells were subjected to intracellular acidosis  
by consecutive transient exposures to NH»C1. A fter the initial 6- 
minute period o f  NH.C1 washout (first acid pulse), ce lls  were 
superfused with normal Tyrode’s solution for an additional 6 
minutes to allow  further recovery o f  p H  before the second tran­
sient exposure to NH«C1 (second acid pulse). In control cells, both 
acid pulses occurred under identical conditions. W hen studying 
the effects o f  thrombin, SFLLRN, or FLLRN, these agents w ere 
present throughout the second pulse (ie, during exposure to and 
washout o f  NH«C1). When studying the effects o f  thrombin and 
SFLLRN in the presence o f  G F 109203X  or chelerythrine, these 
agents w ere included in all solutions from 6 minutes before the 
second pulse to the end o f  the experim ent 7H-versus-pH  curves
143
708 Circulation Research Vol 79, No 4 October 1996
were constructed using data obtained during the p H  recovery 
phases fo llow ing both acid pulses. This double-pulse protocol 
was necessitated by the intercell variability in JH even at identical 
pH values (eg, see Figs 4 , 5 , and 7) and enabled paired data 
analysis. At the end o f  every experiment, the ce ll under study 
was exposed to nigericin-containing calibration solution at pH 
7.0 , thus enabling normalization o f  the /W /m o ratios. Equation 1 
and the fitted values for pK and the constant a  w ere then used to 
calculate p H  from the normalized /W /m o values.
To study the effects o f  thrombin and SFLLRN on [Ca2+]j. each  
cell was consecutively exposed to (1) field stimulation at 0 .5  Hz 
(to enable the recording o f  C a2+ transients), (2) Tyrode’s solution  
with or without 5 U /m L o f  thrombin or 25 /xmol/L o f  SFLLRN, 
and (3) Tyrode’s solution with 10 m m ol/L o f  caffeine (at an in­
creased superfusion rate o f  12 to 15 mL/min), w ith the indo 1 
em ission  intensity ratio (/.hm/L m) monitored throughout
Statistical Analysis
Experiments within each study subsection w ere carried out in 
a randomized manner, with contemporary controls. Gaussian-dis- 
tributed variables w ere expressed as m ean±SE M . To assess  
changes in  J H within groups (ie, between first and second acid  
pulses), a paired r test was used. For intergroup com parisons, data 
were subjected to one-w ay A N O V A . If a difference among mean 
values w as established, further analysis was carried out using  
either Dunnett’s test (to compare every group with the control 
group) or Tukey’s test (to compare every group with every other).
A  value o f  P c .0 5  was considered significant.
Results
Thrombin Receptor Expression in 
V entricular Myocytes
Fig 2 illustrates the results of reverse-transcription PCR 
analysis of mRNA from myocyte-enriched preparations. 
No signal was obtained in the absence of reverse transcrip­
tase (lane 2), confirming the absence of contamination. 
The intact PCR product (lane 3) was 946 bp in size, as 
expected from the known thrombin receptor cDNA se­
quence, and matched exactly that obtained by PCR am­
plification of thrombin receptor cDNA (lane 6). Cleavage 
of the PCR products by EcoRV gave two bands of the sizes 
585 and 361 bp (lanes 4 and 7, respectively), as expected 
from the rat thrombin receptor cDNA sequence, regardless 
of the source of the template cDNA. These results suggest 
that mRNA coding for the cloned thrombin receptor was 
expressed in this cell preparation. The identity of the intact 
reverse-transcription PCR product was further confirmed 
by sequence analysis (data not shown), which revealed it 
to be homologous with the published rat thrombin receptor 
cDNA sequence.11
Effects of Thrombin Receptor Stimulation on 
Resting pH,
Neither thrombin (5 U/mL) nor SFLLRN (25 /^mol/L) 
produced a significant change in resting pH  (n=3 per 
group). In control cells and those exposed to thrombin or 
SFLLRN, basal pH was 7.27±0.06, 7.31 ±0.08, and 
7.24±0.07 (P=NS), respectively. After 3 minutes of ex­
posure to vehicle, thrombin, or SFLLRN, pH, remained at 
similar values, measuring 7.23±0.07, 7.25±0.09, and 
7.20±0.06 (P=NS), respectively.
Regulation of Sarcolemmal Na+-H+ Exchanger 
Activity via the Thrombin Receptor
The Table shows basal and minimal pH values in the 
various study groups, obtained just before and immedi­
ately after the first and second acid pulses. Within each
1 2  3 4  5 6  7
946 bp-^  
585 b p J
361 b p J
Fig 2 . Reverse-transcription PCR analysis of thrombin receptor 
m RNA expression. Acrylamide gel electrophoresis w as used to 
analyze the products from PCR amplification of either cD NA ob­
tained by reverse transcription of mRNA from m yocyte-enriched  
preparations (lanes 3 and 4) or rat thrombin receptor cDNA (lanes 
6 and 7). Lanes 3 and 6 show intact PCR products, and lanes 4 
and 7 show products obtained after exposure to  EcoRV. Lane 2 
shows negative control (no reverse transcriptase), and lanes 1 
and 5 show pGEM DNA markers (Promega) of the sizes (from 
the top) 2645, 1605, 1198, 676, 517, 460, 396, 350 , 222, and 
179 bp. The sizes of the PCR products were 946 bp without 
exposure to EcoRV and 585 and 361 bp after exposure to  EcoRV, 
as predicted from the rat thrombin receptor cDNA sequence.
study subsection, there was no significant difference be­
tween groups in basal or minimal pH at either time point. 
The overall mean value for basal pH before exposure to 
any acid load or pharmacological intervention, talcing into 
account data from all cells included in this part of the 
study, was 7.25±0.01 (n=93). This value is comparable 
to basal pH values previously reported for rat ventricular 
myocytes maintained in HEPES-buffered medium.21'23
Fig 3 shows representative recordings of pH during two 
consecutive acid pulses in single myocytes as well as the 
pH-versus-yH relationships constructed using data from 
several such experiments. In control experiments (Fig 3A), 
the profiles of pH, recovery from intracellular acidosis 
were similar after both pulses; consequently, the acid ef­
flux curves were superimposed. Thus, at any given pH, JH 
values were similar at both time points during the exper­
imental protocol, showing that temporal changes in Na+- 
H+ exchanger activity do not occur in the absence of ag­
onist stimulation.
When cells were exposed Jo 5 U/mL of thrombin during 
the second acid pulse, pH recovery from intracellular ac­
idosis was accelerated (Fig 3B). This effect was reflected 
by a rightward shift of the pH-versus-7H curve such that 
over the pH range of 6.80 to 7.10, JH was significantly 
greater in the presence of thrombin. In order to investigate 
the dose dependence of the effects of thrombin, such ex­
periments were performed with three concentrations of 
thrombin, ranging from 0.2 to 5 U/mL. Fig 4 shows JH at 
an identical pH  of 6.9 after both the first acid pulse (in the 
absence of thrombin) and the second acid pulse (in the 
presence of thrombin). Thrombin increased JH in a dose- 
dependent manner, with statistically significant increases 
of 62% and 87% at 1 and 5 U/mL, respectively.
The effect of the synthetic thrombin receptor-activating 
peptide SFLLRN was also examined to determine whether 
this could mimic the Na+-H+ exchanger stimulatory effect 
of thrombin, thereby supporting an involvement of the 
cloned receptor. As with thrombin, SFLLRN produced a 
dose-dependent rightward shift of the pH-versus-/H curve. 
Consequently, JH at pH 6.9 was increased in a dose-de­
pendent manner, resulting in a statistically significant in­
crease of 73% at 25 /zmol/L (Fig 5). Indeed, with this
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Mean Values for Basal pH* (Measured Just Before NH4CI Application) and Minimal 
pH| (Measured Immediately After NH4CI Washout) During the First and Second 
Acid Pulses
F ir s t  A c id  P u ls e S e c o n d  A cid  P u ls e
S tu d y  G ro u p B a s a l  pH , M in im al p H  B a s a l  p H  M in im al p H
E ffec ts  o f th ro m b in  a n d  th ro m b in  
re c e p to r -a c tiv a tin g  p e p tid e  
C o n tro l 11 7 .2 3 + 0 .0 4  6 .7 0 ± 0 .0 4  7 .1 8 ± 0 .0 4  6 .6 9 ± 0 .0 5
T h ro m b in  (0.2 U/m L) 7  7 .2 2 + 0 .0 5  6 .7 3 + 0 .0 6  7 .1 1 + 0 .0 3  6 .7 3 ± 0 .0 5
T h ro m b in  (1 U/m L) 6  7 .1 8 + 0 .0 6  6 .5 9 + 0 .0 9  7 .0 3 + 0 .0 4  6 .5 0 + 0 .0 7
T h ro m b in  (5 U/m L) 5  7 .2 4 + 0 .0 4  6 .7 3 ± 0 .0 6  7 .1 1 + 0 .0 6  6 .6 5 + 0 .0 9
SFL L  (1 /jm ol/L) 4  7 .2 5 + 0 .0 6  6 .7 1 + 0 .0 8  7 .1 3 + 0 .0 6  6 .7 0 ± 0 .0 8
SFL L  (5 /im ol/L) 4  7 .2 1 + 0 .0 4  6 .6 9 + 0 .0 9  7 .1 0 + 0 .0 5  6 .7 1 + 0 .0 9
SFLL (25 /im ol/L) 8  7 .2 7 ± 0 .0 3  6 .6 3 + 0 .0 5  7 .1 4 + 0 .0 4  6 .6 2 ± 0 .0 5
FLL (25 Mmol/L) 5  7 .2 8 + 0 .0 3  6 .6 6 + 0 .0 9  7 .1 4 + 0 .0 3  6 .6 5 + 0 .0 7
R ole o f PK C
C o n tro l 6  7 .2 3 + 0 .0 2  6 .6 8 + 0 .0 4  7 .2 2 ± 0 .0 5  6 .71 ± 0 .0 3
T h ro m b in  (5 U/m L) 5  7 .2 7 + 0 .0 6  6 .6 5 ± 0 .0 5  7 .2 5 + 0 .0 4  6 .6 7 + 0 .0 6
SFL L  ( 2 5 /im ol/L) 5  7 .2 4 ± 0 .0 7  6 .6 0 + 0 .0 3  7 .1 8 + 0 .0 4  6 .6 6 + 0 .0 5
G F  a lo n e  5  7 .3 0 + 0 .0 3  6 .6 8 + 0 .0 5  7 .1 8 ± 0 .0 3  6 .7 3 + 0 .0 4
T h ro m b in  (5 U /m L )+ G F  5  7 .2 2 + 0 .0 4  6 .5 5 + 0 .0 4  7 .2 7 + 0 .0 4  6 .6 6 + 0 .0 5
SFL L  (25  /im o!/L )+ G F  5  7 .3 6 + 0 .0 4  6 .6 8 + 0 .0 3  7 .2 7 + 0 .0 3  . 6 .7 5 + 0 .0 3
C H  a lo n e  4  7 .2 7 + 0 .0 6  6 .7 0 ± 0 .0 5  7 .2 0 + 0 .0 7  6 .7 2 + 0 .0 7
T h ro m b in  (5 U /m L )+ C H  4  7 .2 2 + 0 .0 5  6 .6 8 + 0 .0 7  7 .1 9 + 0 .0 4  6 .7 1 + 0 .0 5
SFLL (25 /im ol/L )+ C H ________________ 4 7 .2 4 + 0 .0 7  6 .7 2 ± 0 .0 6  7 .2 2 ± 0 .0 5  6 .7 3 + 0 .0 7
SFLL in d ic a te s  SFLLRN; FLL, FLLRN; G F, G F 109203X  (100 nm ol/L); a n d  CH, ch e lery th rin e  (5 /im ol/L). 
V a lu e s  a re  m e a n + S E M .
concentration, JH was increased significantly throughout 
the pH, range of 6.70 to 7.05. In contrast, 25 /imol/L of 
the inactive control peptide FLLRN did not produce any 
significant increase in JH throughout this pH, range (data 
not shown).
Role of Intracellular C a2+
The intracellular Ca2+ study was carried out to deter­
mine whether thrombin and SFLLRN (at the concentra­
tions shown to increase sarcolemmal Na+-H+ exchanger 
activity) could also increase [Ca2+]j within an appropriate 
tiine frame, thereby implicating a role for Ca2+ in the rel­
evant signaling mechanism(s). Fig 6 shows a representa­
tive recording of the indo 1 emission intensity ratio from 
a single cell, during consecutive exposure to field stimu­
lation, 5 U/mL of thrombin, and 10 mmol/L of caffeine. 
Although predictable changes in the signal were observed 
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Fig 3. Representative pH, recordings (top) and pH r vs-v/H curves (bottom) obtained during two consecutive acid pulses in control cells 
(A  n = 1 1) and cells in which 5 U /m L thrombin was present throughout the second pulse (B, n=5). Thrombin accelerated recovery from  
acidosis and resulted in a  rightward shift in the pH r vs-JH relationship.
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Fig 4. J H values at an identical pH, of 6.9 after consecutive acid 
pulses in control cells (C, n=11) and in cells that were exposed  
to thrombin (0.2 U /m L, n=7 ; 1 U/mL, n=6 ; and 5 U/m L, n=5 )  
throughout the second pulse. Open columns indicate the first 
pulse; hatched columns, the second pulse. * P < .05.
feine (at the beginning and end of the protocol), there was 
no detectable change in the signal during 3 minutes of 
exposure to thrombin. Similar observations were made 
during exposure to 25 /imol/L of SFLLRN or Tyrode’s 
solution alone (n=3 per group).
Role of PKC
The PKC inhibitor study was carried out to determine 
the role of PKC in thrombin receptor-mediated stimula­
tion of sarcolemmal Na+-H+ exchanger activity. To this 
end, the effects of thrombin and SFLLRN on the pHj-ver- 
sus-/H relationship were reexamined in the presence of one 
of two PKC inhibitors, GF109203X24 or chelerythrine,25 
at concentrations shown in our preliminary studies26 to be 
sufficient to inhibit phorbol ester-induced stimulation of 
sarcolemmal Na+-H+ exchanger activity. The results are 
summarized in Fig 7. GF109203X (100 nmol/L) and chel­
erythrine (5 /xmol/L) had no significant effect on JH in 
control cells. Consistent with our earlier observations, in 
the absence of the PKC inhibitors, both 5 U/mL of throm­
bin and 25 /imol/L of SFLLRN produced significant in­
creases in JH of 74% and 81%, respectively. However, in 
the presence of either GF109203X or chelerythrine, throm­
bin and SFLLRN were no longer able to produce a signif­
icant increase in JH.
Effect of N a+-H + Exchanger Inhibition
The Na+-H+ exchanger inhibitor study was carried out 
to confirm that the accelerated recovery of pH, following 
intracellular acidosis (and hence the rightward shift of the 
pHr versus-7H relationship) in the presence of thrombin or 
SFLLRN was mediated exclusively through activation of 
the sarcolemmal Na+-H+ exchanger. Cells (n=3 per 
group) were once again subjected to consecutive acid 
pulses, this time both in the presence of 5 U/mL of throm­
bin or 25 /tmol/L of SFLLRN and with 10 /imol/L of 
HOE-694 (a novel Na+-H+ exchanger inhibitor27) also 
present during the second pulse. As illustrated by the rep­
resentative recordings in Figs 8A and 9A, a rapid recovery 
of pHj was observed after the first acid pulse in both cases. 
However, there was little recovery of pH, after the second 
pulse, in the presence of HOE-694, despite the continued 
presence of thrombin or SFLLRN. These observations 
confirm that in the nominally bicarbonate-free conditions 
used, the sarcolemmal Na+-H+ exchanger is the primary
mechanism of pH, recovery from acidosis and that acti­
vation of other acid equivalent efflux mechanisms is un­
likely to play a significant role in mediating the actions of 
thrombin and SFLLRN.
Role of Background Acid Loading
The acid-loading experiment was carried out, using a 
protocol that has been described previously,28 to confirm 
that the accelerated recovery of pH, following intracellular 
acidosis in the presence of thrombin or SFLLRN was not 
due to an inhibition of background acid-loading mecha­
nisms (eg, metabolic acid production) under low pH, con­
ditions. Cells (n=3 per group) were subjected to an acid 
pulse in the nominal absence of extracellular Na+ (to block 
Na+-dependent acid efflux mechanisms), and 5 U/mL of 
thrombin or 25 /xmol/L of SFLLRN was applied after the 
induction of intracellular acidosis. As illustrated by the 
representative recordings in Figs 8B and 9B, under these 
conditions, background acid loading was not observed, 
and neither thrombin nor SFLLRN had any significant ef­
fect on pHj.
Discussion
The present study provides evidence, for the first time, 
that thrombin is capable of activating the sarcolemmal 
Na+-H+ exchanger in isolated adult rat ventricular myo­
cytes. This effect of thrombin is mimicked by the synthetic 
thrombin receptor-activating peptide SFLLRN, thus in­
dicating the involvement of a receptor-mediated mecha­
nism. The Na+-H+ exchanger stimulatory actions of both 
thrombin and SFLLRN are abolished by selective inhibi­
tors of PKC, suggesting an important role for this enzyme 
in the intracellular signaling mechanisms downstream 
from thrombin receptor activation.
Assessment of Na+-H + Exchanger Activity
In the present study, an agonist-induced rightward shift 
of the pHi-versus-7H relationship (in the absence of bicar­
bonate-dependent pHj regulatory mechanisms) has been 
taken to indicate activation of the Na+-H + exchanger. 
Similar approaches have been used in various cell types 
to study changes in plasma membrane Na+-H+ exchanger 
activity (eg, in response to pharmacological manipula­
tion16 or oncogenic transformation29). Of particular rele­
vance to the present study, shifts in the pHi-versus-^H 






F ig 5. J H values at an identical p H  of 6.9 after consecutive acid 
pulses in control cells (C, n=11) and in cells that w ere exposed 
to SFLLRN (1 /im ol/L, n=4 ; 5 /xmol/L, n = 4 ; and 2 5  /xmol/L, n = 8 )  
throughout the second pulse. Open columns indicate the first 
pulse; hatched columns, the second pulse. * P < .05.
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Fig S. Recording of the indo 1 fluorescence emission intensity ratio (/« s //« s )  from a single ceil during consecutive exposure to field 
stimulation (left), 5 U /m L of thrombin (middle), and 10 m m ol/L of caffeine (right). In the middle and right panels, arrows indicate the  
start of superfusion with solution containing thrombin or caffeine. The recording is representative of three experiments following an 
identical protocol.
ular myocytes as indicators of altered sarcolemmal Na+- 
H+ exchanger activity in response to extracellular ago­
nists.18,22 Recently, Wu et al21 have suggested that even in 
nominally bicarbonate-free medium, bicarbonate-depen­
dent pHj regulatory mechanisms may be operative, thereby 
complicating the interpretation of data with regard to Na+- 
H + exchanger activity. Nevertheless, under the conditions 
used in the present study, mechanisms other than sarco­
lemmal Na+-H+ exchange are unlikely to have contributed 
significantly to acid equivalent efflux, since pH( recovery 
from acidosis was blocked completely in the presence of 
the Na+-H+ exchanger inhibitor HOE-694. Furthermore, 
thrombin and SFLLRN did not appear to alter background 
acid loading within the relevant pH* range. Thus, it is rea­
sonable to assume that any rightward shift of the pHr ver- 
sus-/H relationship in response to thrombin receptor acti­
vation, by either thrombin or SFLLRN, was indeed a 
reflection of increased sarcolemmal Na+-H+ exchanger 
activity.
Actions of Thrombin on Cardiac Myocytes 
The role of thrombin in modulating cardiac myocyte 
function has received little attention to date. Steinberg et 
al10 were the first to study the effects of thrombin on mam­
malian myocytes, by showing that it could modulate phos- 
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Fig 7 . J H values at an identical pH, of 6.9 after consecutive acid 
pulses in control cells (C) and in cells that were exposed to 5 
U /m L of thrombin (Th) or 25 ^m ol/L of SFLLRN (SFLL) throughout 
the second pulse, in the absence of PKC inhibitor (left) or in the 
presence of either 100 nmol/L of G F109203X (GF, middle) or 5 
^m ol/L  of chelerythrine (CH, right). Open columns indicate the 
first pulse; hatched columns, the second pulse. Respective group 
sizes for C, Th, and SFLL were as follows: n = 6 , 5, and 5 in the 
absence of PKC inhibitor; n =5 , 5, and 5 in the presence of GF; 
and n = 4 , 4, and 4  in the presence of CH . * P < .05.
neonatal rat ventricular cells. Subsequently, the same 
group showed that thrombin-induced phosphoinositide hy­
drolysis in these cultured cells could be enhanced by hyp­
oxia.30 Recently, Glembotski et al11 have demonstrated 
that the thrombin receptor is expressed by cultured neo­
natal rat ventricular myocytes, thereby providing a mech­
anistic basis for the cellular effects of thrombin in this 
preparation. With regard to adult mammalian cardiac myo­
cytes, there is evidence that thrombin can activate the L- 
type Ca2+ channel in guinea pig cells31 and induce lyso- 
phosphatidylcholine accumulation in rabbit cells,32 with 
the latter effect mimicked by a thrombin receptor-activat-
A  thrombin
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NH.CI 1 min
F ig  8. A, Representative pH, recording (n=3) from a single myo­
cyte during two consecutive acid pulses in the presence of 
throm bin (5 U/m L). During the second pulse, H O E -694  (10  
/xmol/L) was also present. B, Representative pH, recording from  
a single myocyte (n=3) during an acid pulse in the absence of 
extracellular N a+. Thrombin (5 U/mL) was applied for 3.5 minutes, 
as indicated, after the induction of intracellular acidosis.
via Thrombin Receptor 711
C affe ine  (10 mmol/L)
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F ig 9. A, Representative pH, recording (n=3) from a single myo­
cyte during two consecutive acid pulses in the presence of 
SFLLRN (25 /imol/L). During the second pulse, H O E-694 (10 
//moi/L) w as also present. B, Representative pH, recording from  
a single myocyte (n=3) during an acid pulse in the absence of 
extracellular N a*. SFLLRN (25 /imol/L) was applied for 3 .5  
minutes, as indicated, after the induction of intracellular acidosis.
ing peptide.32 However, the present study is the first to 
provide molecular as well as physiological evidence 
for thrombin receptor expression in adult ventricular 
myocytes.
It is distinctly possible that contaminating cells of non­
myocyte origin (eg, fibroblasts, endothelial cells, or 
smooth muscle cells) may have contributed to the throm­
bin receptor mRNA expression detected in our myocyte- 
enriched cell preparation by reverse-transcription PCR 
analysis. However, the stimulatory effects of thrombin and 
SFLLRN on sarcolemmal Na+-H+ exchanger activity 
(monitored in individual myocytes) are strongly sugges­
tive of functional thrombin receptor expression by the 
myocyte fraction. It may be argued that such effects on 
cardiac myocytes could have a paracrine basis, through the 
thrombin receptor-mediated release (from contaminating 
nonmyocyte cells) of an unknown Na+-H+ exchanger 
stimulatory factor. However, this is unlikely for several 
reasons. First, all visible cells that adhered to the coverslip 
at the bottom of the cell chamber had the morphological 
characteristics of cardiac myocytes. Second, cell density 
in the chamber was very low, ensuring considerable dilu­
tion of any paracrine factor that is released from contam­
inating nonmyocyte cells. Finally, the cells in the chamber 
were continuously superfused at 3.5 mL/min (equivalent 
to a complete change of the chamber volume every 1.7 
seconds); thus, any released paracrine factor would be
rapidly removed. Nevertheless, definitive confirmation 
of thrombin receptor expression by cardiac myocytes 
awaits analysis by immunocytochemistry and/or in situ 
hybridization.
Regulation of Sarcolemmal Na+-H+ Exchanger 
Activity via the Thrombin Receptor
Thrombin has been shown to increase the activity of the 
plasma membrane Na+-H+ exchanger in other cell types 
of the cardiovascular system, such as platelets,7 endothe­
lial cells,8 and vascular smooth muscle ceils.9 Our obser­
vations show that thrombin increases the activity of the 
sarcolemmal Na+-H+ exchanger also in adult rat ventric­
ular myocytes and that this effect occurs in a dose-depen­
dent manner. Furthermore, by demonstrating that the Na+- 
H + exchanger stimulatory effect of thrombin can be 
mimicked by SFLLRN, our study strongly suggests the 
involvement of the cloned thrombin receptor.4 It is im­
portant to note that thrombin receptor stimulation in­
creased Jh (ie, acid efflux via the Na+-H+ exchanger) 
throughout a pH, range of <=>6.70 to 7.10. Despite this, 
however, thrombin receptor stimulation did not alter rest­
ing pH, over a 5-minute period. This is probably because 
the actual JH achieved at pH, values approaching basal pH, 
(mean value of 7.25) was very low (<1 mmol/L/min), 
even in the presence of thrombin or SFLLRN.
Signaling Mechanisms Downstream From 
Receptor Stimulation
The thrombin receptor is a member of the seven-trans- 
membrane-domain receptor family, and its stimulation has 
been linked with G protein-mediated activation of phos- 
pholipase C and, subsequently, PKC.33 Indeed, in several 
cell types, thrombin-induced activation of the Na+-H+ ex­
changer has been shown to be mediated, at least in part, 
via PKC activation.7,9 Our demonstration that the thrombin 
receptor-mediated stimulation of sarcolemmal Na+-H+ 
exchanger activity is abolished by both GF109203X and 
chelerythrine, two potent and selective inhibitors of 
PKC,24,25 suggests a key role for this enzyme in the rele­
vant intracellular signaling pathway in rat ventricular myo­
cytes. This is consistent with previous studies in this cell 
type that have shown that agents capable of activating 
PKC (eg, phorbol esters,22,26 a r adrenergic agonists,22,26 
and endothelin23) are potent activators of the sarcolemmal 
Na+-H+ exchanger.
Which of the isoforms of PKC are involved in thrombin 
receptor-mediated stimulation of sarcolemmal Na+-H+ 
exchanger activity cannot be deduced on the basis of the 
present study. The lack of a rapid effect on [Ca2+]j by 
thrombin and SFLLRN (at concentrations sufficient to in­
crease sarcolemmal Na+-H+ exchanger activity), taken to­
gether with the marked inhibitory effects of GF109203X 
and chelerythrine, might suggest a role for Ca2+-indepen- 
dent isoforms of PKC in thrombin receptor-mediated 
stimulation of exchanger activity. In this regard, the Ca2+- 
independent novel PKC isoforms 6 and e have been de­
tected as the most abundant isoforms of this enzyme in 
adult rat ventricular myocardium (for recent review, see 
Sugden and Bogoyevitch34) and have been shown to be 
readily activated by exposure to a number of extracellular 
stimuli.35,36 However, it should be noted that regardless of 
the identity of the isoform(s) involved, PKC is unlikely to 
regulate sarcolemmal Na+-H+ exchanger activity by direct 
phosphorylation of the exchanger.37
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It is important to note also that the lack of effect of 
thrombin receptor stimulation on [Ca2+]j in our quiescent 
myocytes is contrary to observations made in platelets7 
and vascular smooth muscle cells.9 This apparent discrep­
ancy is likely to have arisen because of the insignificant 
role played by phosphoinositide hydrolysis products in in­
ducing Ca2+ release from intracellular stores in mamma­
lian cardiac myocytes,38,39 relative to other cell types.40 
The dominant mechanism of Ca2+ release from the sar­
coplasmic reticulum in cardiac myocytes is widely ac­
cepted to be Ca2+-induced release via ryanodine recep­
tors ,39,41 which itself might be subject to some modulation 
by phosphoinositide hydrolysis products.38,39 Therefore, 
the possibility cannot be discounted that thrombin receptor 
stimulation may affect [Ca2+]i regulation in nonquiescent 
myocardium. Indeed, recent evidence42 suggests that in 
spontaneously contracting or electrically driven neonatal 
rat ventricular myocytes, thrombin receptor activation by 
a high concentration (300 /imol/L) of SFLLRN can in­
crease both systolic and diastolic [Ca2+]i.
Physiological/Pathophysiological Relevance
Glembotski et al11 have shown that in cultured neonatal 
rat ventricular myocytes, activation of the thrombin recep­
tor induces the phenotypic and morphological character­
istics of cellular hypertrophy. Although other extracellular 
agonists that can induce a hypertrophic response in this 
preparation (eg, phenylephrine43 and endothelin44) also 
share the ability to activate the sarcolemmal Na+-H+ ex­
changer,3 it is currently unclear whether this action plays 
a role in the initiation of the hypertrophic response.
As noted earlier, the sarcolemmal Na+-H+ exchanger 
has been implicated as a key determinant of the severity 
of ischemia/reperfusion-induced cardiac dysfunction, 
including arrhythmias. 1,2 Therefore, it is possible that 
thrombin-induced activation of the sarcolemmal Na+- 
H+ exchanger could modulate the outcome of ischemia 
and reperfusion. In this regard, we have shown that al­
though reperfusion-induced arrhythmias are suppressed 
by interventions designed to inhibit the Na+-H+ ex­
changer,43,46 they are exacerbated by stimuli that can 
activate the exchanger.47 Of particular relevance to the 
present study, Goldstein et al48 have shown that the in­
cidence of malignant ventricular arrhythmias during 
acute ischemia is greater after thrombotic coronary oc­
clusion than after nonthrombotic balloon occlusion, im­
plicating an arrhythmogenic role for factors (such as 
thrombin) that are associated with thrombus formation. 
More recently, the same group suggested that during 
myocardial ischemia, activation of the thrombin recep­
tor may contribute to arrhythmogenesis by inducing an 
increase in intracellular Na+,49 an observation that is 
consistent with Na+-H+ exchanger activation. An ar­
rhythmogenic role for thrombin during ischemia/reper- 
fusion, possibly via Na+-H+ exchanger activation, 
could have clinical significance, since intracoronary 
thrombosis is the commonest cause of acute ischemia in 
patients with coronary artery disease.50
Potential Limitations of Study
Although the concentrations of thrombin (1 and 5 U/mL) 
that we have shown to significantly activate the sarcolem­
mal Na+-H+ exchanger in freshly isolated adult rat ven­
tricular myocytes are within the range proposed to occur 
in the vicinity of intracoronary thrombi,48 they are never­
theless higher than those previously shown to elicit cellular 
responses in cultured neonatal ventricular myocytes from 
the same species.10,11 In contrast, the concentration of 
SFLLRN that significantly increased sarcolemmal Na+- 
H+ exchanger activity in the present study was comparable 
to that shown recently to induce physiological responses 
in cultured neonatal rat ventricular myocytes.51 This may 
be a reflection of partial receptor proteolysis during our 
collagenase-based cell isolation procedure, since it is 
known that the cleaved thrombin receptor becomes desen­
sitized to further activation by thrombin.52 Indeed, we have 
preliminary evidence (data not shown) that in myocytes 
isolated using a combination of protease and collagenase 
(rather than collagenase alone), the Na+-H+ exchanger is 
no longer activatable by thrombin. It would be of interest 
to determine whether in these cells SFLLRN retains the 
ability to increase the exchanger’s activity. It would also 
be of value to determine whether the maximal responses 
elicited by thrombin versus SFLLRN in our cells, in terms 
of stimulation of sarcolemmal Na+-H+ exchanger activity, 
are comparable.
The sequence of the thrombin receptor-activating pep­
tide SFLLRN is based on the human thrombin receptor 
sequence and differs by one amino acid from the correspond­
ing sequence of the rat thrombin receptor (SFFLRN). 
Therefore, it may be argued that this could have led to an 
underestimation of the effects of SFLLRN in rat ventric­
ular myocytes. Contrary to this, however, it has been 
shown recently53 that the thrombin receptors of rat vas­
cular smooth muscle cells can be activated with compa­
rable potency by synthetic receptor-activating peptides 
based on either the human or the rat thrombin receptor 
sequence.
It should be noted that the findings of the present study 
do not preclude an involvement of changes in [Ca2+]t in 
the signaling pathway(s) underlying thrombin receptor- 
mediated stimulation of sarcolemmal Na+-H+ exchanger 
activity. In this regard, in the present study, the effects of 
thrombin and SFLLRN on [Ca2+]j were examined only 
under conditions in which pHs was unaffected. To ascer­
tain the potential role of changes in [Ca2+]i, it would be 
necessary to determine whether thrombin and SFLLRN 
modulate [Ca2+]i under conditions in which they also in­
crease Na+-H+ exchanger activity (ie, in the presence of 
acute intracellular acidosis).
Concluding Comments
In conclusion, the present study indicates that adult rat 
ventricular myocytes express a functional thrombin recep­
tor, whose stimulation leads to increased activity of the 
sarcolemmal Na+-H+ exchanger. PKC appears to play a 
key role in the intracellular signaling mechanisms(s) 
downstream from thrombin receptor stimulation, although 
direct phosphorylation of the Na+-H+ exchanger by this 
enzyme is unlikely to be involved. The physiological and/ 
or pathophysiological significance of thrombin receptor- 
mediated regulation of sarcolemmal Na+-H+ exchanger 
activity remains to be determined.
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Regulation of Sarcolemmal Na+/H+ Exchanger Activity by 
Angiotensin II in Adult Rat Ventricular Myocytes
Opposing Actions via ATX Versus AT2 Receptors
Suba Gunasegaram, Robert S. Haworth, David J. Hearse, Metin Avkiran
Abstract— Increased sarcolemmal Na+/H+ exchanger activity has been implicated as a mediator of the cardiac actions of 
angiotensin II. We studied the receptor subtypes and signaling pathways involved in the regulation of sarcolemmal 
Na+/H+ exchanger activity by angiotensin II in adult rat ventricular myocytes. Cells were loaded with the pH-sensitive 
fluoroprobe carboxy-seminaphthorhodafluor-1, and acid efflux rates estimated during recovery from intracellular 
acidosis were used to quantify, exchanger activity. Sarcolemmal Na+/H + exchanger activity was not affected by 
angiotensin II alone but was increased by angiotensin II plus PD123319 (AT2 antagonist). In contrast, angiotensin II plus 
losartan (AT, antagonist) or CGP42112A (AT2 agonist) did not affect exchanger activity. The increase in Na+/H+ 
exchanger activity induced by angiotensin II plus PD 123319 was blocked by losartan, PD98059 (extracellular 
signal-regulated kinase inhibitor), GF109203X (protein kinase C inhibitor), and tyiphostin AG 1478 (epidermal growth 
factor receptor kinase inhibitor). Extracellular signal-regulated kinase phosphorylation and activity, measured by 
immunoblot analysis and an immune-complex kinase assay, respectively, were increased significantly by angiotensin II 
plus PD123319; these increases were blocked by losartan and PD98059. The increase in extracellular signal-regulated 
kinase phosphorylation induced by angiotensin II plus PD123319 was blocked also by GF109203X and tyrphostin 
AG1478. These data show that AT, stimulation increases sarcolemmal Na+/H + exchanger activity in adult rat ventricular 
myocytes and that this response requires extracellular signal-regulated kinase activation through a protein kinase C - and 
epidermal growth factor receptor-mediated mechanism. The positive effect of AT, stimulation on Na+/H+ exchanger 
activity is coqnteracted by simultaneous AT2 stimulation through a mechanism that does not involve direct inhibition 
of the exchanger or attenuation of extracellular signal-regulated kinase activation. (Circ Res. 1999;85:919-930.)
Key W ords: angiotensin ■ myocyte ■ Na+/H+ exchanger ■ signal transduction 
■ extracellular signal-regulated kinase
The sarcolemmal Na+/H+ exchanger (NHE) of cardiac myocytes consists of the ubiquitous NHE1 isoform of 
this multigene family1 and plays an important role in medi­
ating recovery of intracellular pH (pH,) from acidosis.2 
Although sarcolemmal NHE activity is regulated primarily by 
pH, and is increased in response to acidosis, it is also subject 
to modulation by a number of neurohormonal stimuli,3 such 
as a,-adrenergic agonists4 endothelin Is and thrombin.6 These 
agonists appear to stimulate sarcolemmal NHE activity, 
through their respective Gq protein-coupled receptors, by 
increasing the exchanger’s affinity for intracellular H+, which 
is the primary mechanism underlying receptor-mediated reg­
ulation of NHEl.7
Several recent studies have suggested that angiotensin II 
also may stimulate sarcolemmal NHE activity and that a 
relative intracellular alkalosis that arises from increased H+ 
extrusion through the exchanger may underlie the positive 
inotropic action of this peptide.8-9 However, studies with
ventricular myocytes isolated from adult rat and rabbit hearts 
have revealed that (1) H+ efflux rate via the exchanger is 
increased only moderately by angiotensin II and only over a 
very limited pH, range (*=*6.95 to 7.00),9 which is contrary to 
observations made with other mediators that stimulate ex­
changer activity via Gq protein-coupled receptors,4-6 and
(2) the degree of intracellular alkalosis and the magnitude of 
the positive inotropic effect induced by angiotensin II are 
markedly smaller than those induced by endothelin l,8 
another vasoactive peptide that has been shown to stimulate 
the exchanger.5 Thus, the role of angiotensin II as an 
important modulator of sarcolemmal NHE activity appears 
open to question.
In light of the above, it is interesting to note that (1) both 
AT, and AT2 subtypes of the angiotensin receptor are ex­
pressed in the ventricular myocardium of many species, 
including rat,10 rabbit,11 and human,12-13 and (2) in a variety of 
cell types in culture, AT, and AT2 mediate opposing actions,
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Mean Values for Basal pH, (Measured Just Before NH4CI Application) and Minimal pH( 
(Measured Immediately After NH4CI Washout) During the First and Second Acid Pulses
First Acid Pulse Second Acid Pulse
Study Group n* Basal pH| Minimal pH, Basal pH, Minimal pH,
Effect of sim ultaneous stimulation of AT, and AT2
Control 8 7.25 ± 0 .07 6 .6 5± 0 .05 7 .2 2 ± 0 .0 5 6 .6 6 ± 0 .0 8
ANG 10 8 7 .2 5± 0 .04 6.68 ± 0 .0 8 7 .2 0 ± 0 .0 4 6 .6 5 ± 0 .1 5
ANG 100 8 7 .2 2± 0 .03 6 .7 0 ± 0 .0 4 7 .1 8 ± 0 .0 9 6 .6 8 ± 0 .0 5
ANG 1000 8 7.28 ± 0 .05 6 .6 8 ± 0 .0 9 7 .2 5 ± 0 .0 9 6.65 ± 0 .0 8
Effect of selective stimulation of AT,
Control 8 7 .2 8± 0 .05 6.75 ± 0 .0 3 7.25 ± 0 .0 6 6 .7 9 ± 0 .0 4
ANG 100 8 7 .2 5 ± 0 .1 0 6.68 ± 0 .0 5 7 .2 0 ± 0 .0 5 6.65 ± 0 .0 3
ANG 100+ P D  10 8 7 .3 0 ± 0 .0 9 6.65 ± 0 .0 9 7.25 ± 0 .0 6 6 .6 0 ± 0 .0 6
ANG 100+P D  30 8 7.25 ± 0 .0 6 6.58 ± 0 .0 5 7 .2 8 ± 0 .0 4 6 .6 0 ± 0 .0 7
ANG 100+P D  100 8 7 .2 9 ± 0 .0 3 6.67 ± 0 .0 8 7.25 ± 0 .0 5 6 .6 9 ± 0 .0 9
PD 100 8 7 .3 3 ± 0 .0 9 6 .7 0± 0 .15 7 .3 0 ± 0 .1 5 6 .7 5 ± 0 .0 8
Control 7 7 .1 9 ± 0 .0 9 6 .6 0± 0 .05 7 .0 0 ± 0 .0 6 6 .5 5 ± 0 .0 5
ANG 10+PD  100 7 7 .2 8 ± 0 .0 6 6 .6 5± 0 .07 7 .2 0 ± 0 .0 7 6 .6 2 ± 0 .0 5
ANG 30+P D  100 7 7.20± 0 .11 6.65 ± 0 .0 9 7 .1 5 ± 0 .0 9 6 .6 3 ± 0 .0 8
ANG 100+ P D  100 7 7.25 ± 0 .0 9 6.70 ± 0 .0 8 7 .2 2 ± 0 .1 0 6 .7 5 ± 0 .0 7
Control 10 7 .2 5± 0 .05 6.78 ± 0 .0 9 7.21 ± 0 .0 9 6 .8 0 ± 0 .0 6
ANG 100+P D  100 10 7 .1 8 ± 0 .0 9 6 .7 3 ± 0 .0 6 7 .2 0 ± 0 .0 5 6.75 ± 0 .0 5
ANG 100+P D  100+ L 0S  10 10 7 .2 8 ± 0 .0 9 6.75 ± 0 .0 4 7 .2 5 ± 0 .0 4 6 .6 9 ± 0 .0 9
ANG 100+P D  10 0+ L 0S  30 10 7 .1 9 ± 0 .1 5 6 .6 4 ± 0 .1 5 7 .2 0 ± 0 .0 4 6 .6 5 ± 0 .1 7
ANG 100+P D  100+ L 0S  100 10 7 .2 8 ± 0 .1 9 6 .7 0 ± 0 .0 9 7 .2 5 ± 0 .0 6 6 .7 5 ± 0 .1 3
PD 10 0+ L 0S  100 10 7 .1 9 ± 0 .0 9 6 .7 3 ± 0 .0 6 7 .2 4 ± 0 .0 5 6 .7 0 ± 0 .0 6
Effect of selective stimulation of AT2
Control 9 7 .1 8± 0 .05 6 .7 5 ± 0 .0 7 7 .2 0 ± 0 .0 7 6 .8 0 ± 0 .0 5
ANG 100 9 7 .2 8 ± 0 .0 9 6 .7 4 ± 0 .0 8 7 .2 5 ± 0 .0 5 6.75 ± 0 .0 6
ANG 1 0 0 + LOS 10 9 7 .1 8± 0 .15 6 .6 8 ± 0 .1 7 7 .2 8 ± 0 .0 3 6.70 ± 0 .0 7
ANG 1 0 0+ L 0S  30 9 7 .1 8± 0 .13 6.65 ± 0 .1 5 7 .1 5 ± 0 .1 7 6 .6 5 ± 0 .1 4
ANG 1 0 0+ L 0S  100 9 7 .2 3 ± 0 .0 6 6 .7 9 ± 0 .0 9 7 .2 0 ± 0 .0 9 6 .8 0 ± 0 .1 3
LOS 100 9 7.25 ± 0 .0 4 6 .7 3 ± 0 .0 5 7 .2 2 ± 0 .0 8 6 .7 0 ± 0 .0 6
Control 8 7 .2 8 ± 0 .0 9 6 .6 5 ± 0 .1 5 7 .2 2± 0 .11 6 .6 8 ± 0 .0 9
CGP 20 8 7.25 ± 0 .05 6.62 ± 0 .0 9 7 .2 2 ± 0 .0 9 6.65 ± 0 .0 6
Role of the ERK pathway
Control 8 7.25 ± 0 .0 4 6 .6 4 ± 0 .0 3 7 .2 2 ± 0 .0 9 6 .6 0 ± 0 .0 5
ANG 100+P D  100 8 7 .1 9 ± 0 .0 5 6 .6 8 ± 0 .0 5 7 .2 5 ± 0 .1 5 6 .6 8 ± 0 .0 9
ANG 100+P D  1 0 0 + MEW 10 8 7 .2 5± 0 .04 6 .6 0 ± 0 .0 8 7 .2 7 ± 0 .1 5 6 .6 0 ± 0 .1 0
ANG 100+P D  100+MEW 50 8 7 .2 3± 0 .08 6.65 ± 0 .1 5 7 .2 0 ± 0 .0 9 6 .7 0 ± 0 .0 5
MEW 50 8 7 .3 0± 0 .15 6 .7 0 ± 0 .0 9 7 .2 8 ± 0 .0 5 6 .7 5 ± 0 .0 5
Upstream regulators of AT,-mediated actions
Control 7 7 .2 3 ± 0 .0 6 6.65 ± 0 .0 7 7 .2 2 ± 0 .0 8 6 .6 4 ± 0 .0 6
GF 1 7 7.25 ± 0 .0 8 6 .6 3 ± 0 .0 9 7 .2 3 ± 0 .0 7 6 .6 3 ± 0 .1 8
AG 250 7 7 .2 3 ± 0 .0 8 6.62 ± 0 .1 5 7 .2 0 ± 0 .0 9 6 .6 8 ± 0 .0 9
ANG 100+P D  100 7 7 .2 4± 0 .06 6 .6 5± 0 .15 7.21 ± 0 .0 9 6.68 ± 0 .0 9
ANG 100+P D  100+G F 1 7 7 .2 2± 0 .17 6.68 ± 0 .1 9 7 .1 8 ± 0 .1 8 6 .6 5 ± 0 .0 9
ANG 100+P D  100+AG 250 7 7 .2 5 ± 0 .0 9 6 .6 5 ± 0 .0 9 7 .2 3 ± 0 .1 5 6 .6 4 ± 0 .0 8
ANG Indicates angiotensin II; PD, PD123319 (AT2-selective antagonist); LOS, losartan (AT,-selective antagonist); 
CGP, CGP42112A (AT2-selective agonist); MEW, PD98059 (MEK Inhibitor); GF, GF109203X (PKC inhibitor); and AG, 
tyrphostin AG1478 (EGF receptor kinase Inhibitor). Numbers in first column indicate concentration In nmol/L, except 
for MEW and GF, which are in /nmol/L 
*Number of myocytes per group; in each protocol, the cells w ere obtained from 6 to 10 separate  hearts.
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particularly in growth regulation.14-16 Furthermore, in some 
preparations,1718 AT2 stimulation has been shown to counter­
act AT,-mediated activation of extracellular signal-regulated 
kinases 1 and 2 (ERK1/ERK2). Because this pathway of the 
mitogen activated protein kinase signaling cascade is a key 
mediator of growth factor-induced stimulation of NHE1,19 it 
is possible that AT! and AT2 may mediate opposing actions 
also in the regulation of sarcolemmal NHE activity.
In an effort to gain a  better understanding of angiotensin 
II-mediated regulation of sarcolemmal NHE activity, the 
objectives of the present study were to determine, in adult rat 
ventricular myocytes, whether (1) simultaneous stimulation 
of AT! and AT2 by angiotensin II alters sarcolemmal NHE 
activity, (2) selective stimulation of ATi or AT2 by angioten­
sin II alters sarcolemmal NHE activity, (3) the ERK pathway 
is involved in any regulation of the exchanger by angiotensin 
II, and (4) protein kinase C (PKC) and/or the epidermal 
growth factor (EGF) receptor are upstream mediators of any 
effects of angiotensin II on ERK and sarcolemmal NHE 
activity.
M a te r ia ls  a n d  M e th o d s  
S tudies in  A du lt M yocytes 
Cell Isolation
Ventricular myocytes were isolated from hearts of adult male Wistar 
rats by enzymatic digestion4-6-20-21 for the study of drug effects on 
sarcolemmal NHE activity or cellular ERK phosphorylation and 
activity.
Determination of Sarcolemmal NHE Activity 
A microepifluorescence technique was used to record pH, in single 
myocytes loaded with cSNARF-1, and the rate of acid efflux (J»), 
calculated at pH, intervals of 0.05 during recovery from intracellular 
acidosis, was used as the indicator of NHE activity.4-6-20-21 Cells 
(n=7 to 10 per group, obtained from 6 to 10 hearts in each protocol) 
were subjected to acidosis by transient exposure to NR»C1 (first acid 
pulse), which was repeated -"15 minutes later (second acid pulse).4-6 
Within each protocol, there was no significant difference between 
groups in basal or minimal pH, (Table). In control cells, both acid 
pulses occurred in the absence of drug. When the effects of 
angiotensin II (Sigma) were studied, this was present during the 
second pulse. When used, the AT2-selective antagonist PD 123319 
(Research Biochemicals International) and/or the AT,-selective an­
tagonist losartan (gift from Merck Sharp and Dohme, Inc) were 
present from 3 minutes before the second acid pulse. When studying 
the effects of angiotensin II plus PD123319 in the presence of a 
kinase inhibitor (mitogen-activated protein kinase kinase [MEK] 
inhibitor PD98059, PKC inhibitor GF109203X, or EGF receptor 
kinase inhibitor tyrphostin AG 1478; Calbiochem-Novabiochem 
Corp), this was present from 10 minutes before the second acid 
pulse.
Determination o f Cellular ERK Phosphorylation 
and Activity
Angiotensin II-mediated regulation of ERK was studied by the 
following 2 approaches: (1) determination, by Western analysis, of 
ERK phosphorylation on both threonine and tyrosine residues of the 
regulatory TEY motif, and (2) measurement, by an immune-complex 
kinase assay, of ERK activity. Drug exposure protocols were 
identical to those used to study sarcolemmal NHE activity.
Determination o f Cellular AT2 Expression 
AT2 expression was determined by Western analysis, using a rabbit 
polyclonal AT2 antibody22-23 (gift from Dr R.M. Carey, University of 
Virginia Health Sciences Center, Charlottesville, VA). Membrane
Regulation of NHE Activity by Angiotensin H  921
protein from HEK293 cells stably transfected with AT2 was a gift 
from Dr A.J. Balmforth (University of Leeds, UK).
Studies in  N eonatal M yocytes
Ventricular myocytes isolated from hearts of 2-day-old Wistar rats of 
mixed sex were cultured in 6-well plates (on coverslips for micro­
epifluorescence studies) for 2 to 3 days and transferred to serum-free 
medium 24 hours before use. Drug effects on cellular ERK phos­
phorylation and sarcolemmal NHE activity were determined as 
described for adult cells.
Statistical Analysis
Data are presented as mean±SEM. To assess changes in J» within 
groups (ie, between the first and second acid pulses), a paired t test 
was used. For intergroup comparisons of the change in JH at pH, 6.90 
(A7H69) or of ERK phosphorylation/activity, data were subjected to 
ANOVA, followed by the Dunnett test (to compare every group with 
the control group) or Student-Newman-Keuls test (to compare every 
group with every other). P < 0.05 was considered significant.
An expanded Materials and Methods section is available onbne at 
http://www.circresaha.org.
R esults 
Studies in  A du lt M yocytes
Effect o f Simultaneous Stimulation o f AT, and AT2 on 
Sarcolemmal NHE Activity
Angiotensin II at 10 to 1000 nmol/L had no significant effect 
on JH throughout the pH, range 6.75 to 7.10 (Figure 1). 
Therefore, AJH6.9 did not differ significantly from control 
(0.5±0.6 mmol/L • min'1) in the groups that received 10 
(0.2±0.8 mmol/L • min'1), 100 (0.2±0.4 mmol/L • min'1), or 
1000 (0.5 ±0.3 mmol/L • min'1) nmol/L angiotensin II. These 
data indicate that simultaneous stimulation of AT, and AT2 by 
angiotensin II does not significantly affect sarcolemmal NHE 
activity. Consistent with this, exposure of myocytes to 100 
nmol/L angiotensin II for 10 minutes did not significantly 
affect resting pH, (7.28±0.03 and 7.29±0.04, respectively, 
before and after angiotensin 13; n=3).
Effect of Selective Stimulation o f AT, on Sarcolemmal 
NHE Activity
Figure 2 shows representative recordings of pH, during the 
consecutive acid pulses in single myocytes as well as the 
7H-versus-pH, relationships constructed using data from 8 
such experiments in each of the 3 key groups of this 
subsection of the study. In control experiments (Figure 2A), 
the profiles of pH, recovery from intracellular acidosis were 
similar after both pulses; consequently, the 7H-versus-pH, 
curves were superimposed, indicating that temporal changes 
in NHE activity do not occur in the absence of drug exposure. 
Similar results were obtained when cells were exposed to 100 
nmol/L angiotensin II during the second acid pulse (Figure 
2B), as described above. However, when cells were pre­
treated with 100 nmol/L PD123319, 100 nmol/L angiotensin 
II accelerated pH, recovery from intracellular acidosis and 
produced a rightward shift of the 7H-versus-pH, curve, such 
that over the pH, range 6.75 to 7.00, JH was significantly 
greater in the presence of angiotensin II (Figure 2C).
Figure 3A shows 7 H at pH, 6.90 ( 7 H6.») during the first and 
the second acid pulses in the various study groups and 
illustrates the dose-dependent action of PD123319 in reveal­
ing the NHE-stimulatory effect of angiotensin II. As shown,
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Figure 1. Effect of simultaneous stimulation of AT, and AT2 on 
sarcolemmal NHE activity in adult rat ventricular myocytes. 
v/H-vs-pH| curves obtained during the first (O) and second ( • )  
acid pulses are shown in control cells (A) and in cells that were 
exposed to angiotensin II at 10 (B), 100  (C), or 1000 (D) nmol/L 
throughout the second pulse (n = 8  cells per group, obtained 
from 6 hearts). ANG  indicates angiotensin II.
100 nmol/L angiotensin II significantly increased JH6., only in 
the presence of pretreatment with 30 or 100 nmol/L 
PD 123319; importantly, 100 nmol/L PD 123319 alone did not 
significantly affect / H69, indicating that the increase in NHE 
activity did not arise from a direct exchanger-stimulatory 
action of the AT2 antagonist. In these experiments, although 
A7h6.9 was not significantly different from control in cells that 
received angiotensin II alone or PD123319 alone, PD123319 
dose-dependently revealed a stimulatory response to angio­
tensin II (Figure 3B). The ability of angiotensin II to increase 
sarcolemmal NHE activity only in the presence of the AT2 
antagonist suggests that this response may arise from selec­
tive AT, stimulation.
B. ANG (100 nmol/L)
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Figure 2. Effect of selective stimulation of AT, on recovery from  
intracellular acidosis and pH, sensitivity of sarcolemmal NHE 
activity in adult rat ventricular myocytes. Representative pH, re­
cordings (left panels) and J H-vs-pH, curves (right panels) 
obtained during the first (O) and second ( • )  acid pulses are 
shown in control cells (A) and in cells that were exposed to 100 
nmol/L angiotensin II throughout the second pulse in the 
absence (B) or presence (C) of 100 nm ol/L PD123319. *P < 0 .0 5  
vs first pulse (n = 8  cells per group, obtained from 9 hearts).
ANG indicates angiotensin II; PD, PD 123319.
To determine the dose-dependency of the NHE stimulatory 
effect of angiotensin II in the presence of AT2 blockade, we 
also studied the effects of various concentrations of angio­
tensin II (10, 30, or 100 nmol/L) in combination with 100 
nmol/L PD 123319. As shown in Figure 4A, under these 
conditions, angiotensin II produced a significant increase in 
JH6.9 at all 3 concentrations. The dose dependency of the 
response is illustrated in Figure 4B, which shows that A7H6., 
was significantly greater than control in the groups that 
received 30 or 100 nmol/L angiotensin II in combination with 
100 nmol/L PD123319.
To confirm that the NHE stimulatory effect of the 
PD 123319/angiotensin II combination that was observed in 
the studies described above was indeed mediated via AT,, we 
sought to determine whether this effect could be inhibited by 
losartan, an AT,-selective antagonist. As shown in Figure 5A, 
the combination of 100 nmol/L PD 123319 and 100 nmol/L 
angiotensin II once again significantly increased 7H6 9, con­
firming our earlier findings. This effect, however, was par­
tially inhibited by 10 nmol/L losartan and was completely 
abolished by 30 and 100 nmol/L losartan. As shown in Figure 
5B, relative to control, AJH69 was significantly increased by
C. ANG (100 nmol/L) + PD (100 nmol/L)
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A NG (nm ol/L) 0  1 0 0  1 0 0  1 0 0  1 0 0  0
P D  (nm ol/L) 0  0  10  3 0  1 0 0  100
Figure 3. Effect of selective stimulation of AT, on sarcolemmal 
NHE activity in adult rat ventricular myocytes. values during 
the first ( □ )  and second ( ■ )  acid pulses (A) and M * .#  values 
during the second pulse relative to the first (B) are shown in 
control cells and in cells that were exposed to combinations of 
angiotensin II (100 nmol/L) and PD 123319 (10, 30, or 100 
nmol/L) during the second pulse. *P < 0 .0 5  between indicated 
groups (n = 8  cells per group, obtained from 9 hearts). ANG indi­
cates angiotensin II; PD, PD 123319.
the PD 123319/angiotensin II combination, but this effect was 
inhibited, in a dose-dependent manner, by losartan. The 
combination of 100 nmol/L PD 123319 and 100 nmol/L 
losartan was without effect on JH in the absence of angioten­
sin II. Furthermore, the inhibitory effect of losartan on the 
response to the PD 123319/angiotensin II combination was 
sustained throughout the pH range 6.75 to 7.05 (data not 
shown). These findings provide further support for the 
hypothesis that selective stimulation of AT, increases sar­
colemmal NHE activity.
Effect of Selective Stimulation o f AT2 on Sarcolemmal 
NHE Activity
The inability of angiotensin II to increase sarcolemmal NHE 
activity unless AT2 is blocked suggests that stimulation of this 
receptor subtype opposes AT,-mediated activation of the 
exchanger. To determine whether this negative regulatory 
effect is mediated by a direct inhibition of the exchanger, we 
next determined the effect of selective stimulation of AT2 on 
sarcolemmal NHE activity. This was achieved by exposing 
cells either to 100 nmol/L angiotensin D in the presence of 
increasing concentrations (10 to 100 nmol/L) of losartan or to 
the AT2-selective agonist CGP42112A (20 nmol/L). These 
experiments revealed that neither angiotensin II in combina­
tion with losartan nor CGP42112A had any effect on JH 
throughout the pH range studied (data not shown). These 
findings indicate that the negative effect of AT2 stimulation
Regulation of NHE Activity by Angiotensin II 923
ANG (nm ol/L) 0  10 3 0  100
P D  (nm ol/L) 0  1 0 0  1 0 0  100
Figure 4. Effect of selective stimulation of AT, on sarcolemmal 
NHE activity in adult rat ventricular myocytes. Jne.a values during 
the first ( □ )  and second ( ■ )  acid pulses (A) and AJh6.9 values 
during the second pulse relative to the first (B) are shown in 
control cells and in cells that were exposed to combinations of 
angiotensin II (10, 30, or 100 nmol/L) and P D 123319 (100  
nmol/L) during the second pulse. * P < 0.05 between indicated 
groups (n = 7  cells per group, obtained from 6 hearts). ANG indi­
cates angiotensin II; P D ,,PD 123319.
on AT,-mediated activation of the sarcolemmal NHE is likely 
to occur not by direct inhibition of the exchanger but by 
inhibition of the signaling pathway(s) that mediate the AT, 
response.
AT2 Expression in Adult Rat Ventricular Myocytes 
The pharmacological data presented above suggest that AT, 
and AT2 mediate opposing actions in the regulation of 
sarcolemmal NHE activity in adult rat ventricular myocytes. 
Contrary to this, however, some radioligand binding studies 
suggest that AT2 may be absent in adult rat myocardium.24-25 
To determine whether AT2 is expressed at protein level in the 
adult rat ventricular myocytes used in the present study, we 
used Western analysis with an AT2 antibody that has been 
recently characterized by Wang et al.23 The immunoblot 
illustrated in Figure 6 reveals that this antibody detected a 
protein of “ 44 kDa, which is believed to represent AT2,23 in 
protein extracts from 3 independent adult rat ventricular 
myocyte preparations, as well as in a membrane protein 
sample from HEK293 cells stably transfected with AT2. This 
finding is consistent with the recent immunocytochemical 
data of Wang et al23 and earlier radioligand binding studies in 
rat ventricular tissue10-26 and supports the existence of func­
tional AT2 in adult rat ventricular myocytes.
Role o f the ERK Pathway in the Regulation o f 
Sarcolemmal NHE Activity by Angiotensin II 
In studying the role of the ERK pathway in the regulation of 
sarcolemmal NHE activity by angiotensin II, we initially
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A NG (nm ol/L) 0  100  1 0 0  100  100 0
P D  (nm ol/L) 0  100  1 0 0  100  1 00  100
L O S (nm ol/L) 0  0  1 0  3 0  1 0 0  100
F ig u re  5. Effect of lo sa rtan  on A T ,-m ed ia ted  stim ulation of s a r ­
co lem m al NHE activity in adu lt ra t ventricu lar m yocy tes. J ^ .e  
v alues during  th e  first ( □ )  an d  s e c o n d  (■ )  ac id  p u lse s  (A) and  
A JH6.9 v a lu es  during  th e  s e c o n d  p u lse  relative to  th e  first (B) a re  
show n  in con tro l cells a n d  in ce lls th a t w ere  e x p o se d  to  various 
com b in a tio n s  of ang io tensin  II (100 nmol/L), P D 123319 (100 
nmol/L), an d  lo sa rtan  (10, 30, or 100 nmol/L) during th e  se c o n d  
pu lse. *P < 0 .0 5  be tw een  ind ica ted  g ro u p s  (n = 1 0  ce lls p e r 
group , o b ta in e d  from  9 hearts). ANG ind ica tes  ang io tensin  II; 
PD. PD 123319, an d  LOS, losartan .
examined whether combinations of angiotensin II and 
PD123319 produce progressive activation of this pathway in 
parallel with their effects on sarcolemmal NHE activity. As 
shown in Figure 7, in the presence of 100 nmol/L PD 123319, 
angiotensin II produced a dose-dependent increase in ERK1/ 
ERK2 phosphorylation, which mirrored its dose-dependent 
effects on sarcolemmal NHE activity (see Figure 4B). This 
finding is consistent with a causal association between 
activation of the ERK pathway and stimulation of NHE 
activity.
F ig u re  6. AT2 ex p ress io n  in adu lt rat ventricular m yocy tes. Au­
to rad iog ram  is from  a  W estern  b lo t using  a  polyclonal AT2 an ti­
body  an d  illustrates AT2 ex p ress io n  (at 44  kDa) in a m em b ran e  
s am p le  from  HEK293 ce lls  s tab ly  tra n sfe c te d  with th e  hum an  
AT2 (lane 1) a n d  in p ro te in  ex trac ts  from  3 in d e p en d en t adu lt rat 
ventricu lar m yocy te  p rep ara tio n s  (lanes 2 to  4). Forty m icro­
g ram s of pro te in  w as  lo ad ed  per lane, and  th e  prim ary antibody  
w as  u s e d  a t 1 :500 dilution.
A NG (nm oi/L ) 0







Figure 7. Effect of ang io tensin  II on  cellu lar ERK1/ERK2 p h o s ­
phorylation in adu lt rat ventricular m yocy tes . ERK1/ERK2 p h o s ­
phorylation is sh o w n  in contro l ce lls  an d  in ce lls  th a t w ere  
e x p o s e d  to  co m b in a tio n s  of an g io tensin  II (10, 30, o r 100 
nmol/L) an d  P D 123319  (100 nmol/L). T he au to rad io g ram  sh o w s 
a  rep resen ta tiv e  W este rn  blot (phospho ry la ted  ERK1/ERK2; 
pERK1/2). *P < 0 .0 5  b e tw e en  ind ica ted  g ro u p s  (n = 4  experi­
m en ts , using ce lls o b ta in ed  from  4 hearts). ANG ind ica tes  a n ­
g io tensin  II; PD, PD 123319.
To determine whether activation of the ERK pathway is a 
necessary step in AT,-mediated stimulation of sarcolemmal 
NHE activity, we then tested whether PD98059 (which 
selectively inhibits MEK, the upstream activator of ERK1/ 
ERK2)2728 inhibits this response. As shown in Figure 8A, 
JH6.9 was again significantly increased by the PD123319/an- 
giotensin II combination; however, this effect was abolished 
in the presence of 10 or 50 p.mol/L PD98059, although even 
the higher concentration of the MEK inhibitor was without 
significant effect when given alone. Thus, as shown in Figure 
8B, AV» was significantly greater than control in the group 
that received the PD 123319/angiotensin II combination but 
was unaffected by this combination in the presence of 
PD98059 or by PD98059 alone. Indeed, AJH6, in response to 
the PD 123319/angiotensin combination was significantly 
smaller in the presence of either concentration of the MEK 
inhibitor than in their absence. This finding suggests that 
AT,-mediated stimulation of the sarcolemmal NHE requires 
ERK activation.
To confirm the role of the ERK pathway in AT,-mediated 
NHE stimulation, we next tested whether selective AT) 
stimulation does indeed increase cellular ERK1/ERK2 phos­
phorylation and activity in our system and whether the 
interventions that we have shown to inhibit AT,-mediated 
NHE stimulation (such as losartan and PD98059) inhibit any 
such increase. Additionally, we compared the effects of 
selective AT, stimulation versus simultaneous AT,/AT2 stim­
ulation, to determine whether the different effects of these 
stimuli on sarcolemmal NHE activity could arise from dif­
ferent magnitudes of ERK activation. Figure 9 shows the 
effects of the various interventions on myocyte ERK1/ERK2 
phosphorylation (Figure 9A) and activity (Figure 9B). As 
shown, ERK phosphorylation and activity were both in­
creased significantly by selective AT, stimulation, and these 
effects were abolished by losartan and by PD98059 (losartan 
or PD98059 alone did not significantly affect ERK activity; 
data not shown). The parallel effects of these interventions on
mss
HEK293 adult ventricular myocytes 
k D a 1 i 11 2 3 4 1
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A. A. pERKl/2
B.
. 1 . .
A N G  (nm ol/L) 0  100  1 00  1 0 0  0
P D  (nm ol/L) 0  1 0 0  1 0 0  1 0 0  0
MEKi (pm ol/L) 0  0  10  5 0  50
Figure 8. Effect of MEK inhibition on AT,-m ediated stimulation 
of sarcolemmal NHE activity in adult rat ventricular myocytes. 
Jhc.s values during the first ( □ )  and second ( ■ )  acid pulses (A) 
and AJha.9 values during the second pulse relative to the first (B) 
are shown in control cells and in cells that were exposed to var­
ious combinations of angiotensin II (100 nmol/L), PD 123319  
(100 nmol/L), and PD 98059 (10 or 50 ^mol/L) during the second 
pulse. *P < 0 .0 5  between indicated groups (n = 8  cells per group, 
obtained from 8 hearts). ANG indicates angiotensin II; PD, 
PD 123319, and MEKi, PD 98059 (MEK inhibitor).
ERK phosphorylation/activity (Figure 9) and sarcolemmal 
NHE activity (see Figures 5 and 8) support the hypothesis 
that ERK activation is required for AT,-mediated stimulation 
of the exchanger. Notably, however, ERK activation by 
simultaneous AT! and AT2 stimulation was similar in mag­
nitude to that by selective AT! stimulation in both assays 
(Figure 9A and 9B). These data suggest that the ability of AT2 
stimulation to oppose AT,-mediated NHE activation does not 
arise from an attenuation of ERK1/ERK2 activation.
Upstream Regulators o f ATr Mediated Actions 
Previous studies suggest that AT,-mediated activation of the 
ERK pathway is PKC dependent in cultured neonatal rat 
ventricular myocytes,29 but protein tyrosine kinase dependent 
(via EGF receptor transactivation) in adult rat vascular 
smooth muscle cells30 and neonatal rat cardiac fibroblasts.3' 
To delineate the roles of these pathways in AT,-mediated 
activation of the ERK pathway in adult rat ventricular 
myocytes, they were exposed to angiotensin II plus 
PD123319 in the presence of 1 p.mol/L GF109203X (PKC 
inhibitor) or 250 nmol/L tyrphostin AG 1478 (EGF receptor 
kinase inhibitor). As shown in Figure 10, both kinase inhib­
itors abolished the increase in ERK phosphorylation induced 
by angiotensin II plus PD 123319, suggesting roles for both 
PKC and the EGF receptor as upstream mediators of the ERK
B.
ANG (nmol/L) 0 100 100 100 100
PO (nmol/L) 0 0 100 100 100
LOS (nmol/L) 0 0 0 100 0
MEKI (pmol/L) 0 0 0 0 50
pqk i H H H H H B j l l
» *
ANG (nmol/L) 0 100 100 100 100
PO (nmol/L) 0 0 100 100 100
LOS (nmol/L) O 0 0 100 0
MEKI (ymd/L) 0 0 0 0 50
Figure 9. Effect of angiotensin II on cellular ERK1/ERK2 phos­
phorylation and activity in adult rat ventricular myocytes. ER K1/ 
ERK2 phosphorylation (A) and activity (B) are shown in control 
cells and in cells that were exposed to various combinations of 
angiotensin II (100 nmol/L), PD 123319 (100 nmol/L), losartan 
(100 nmol/L), and PD 98059 (50 fim ol/L). Autoradiograms show  
representative W estern blots (phosphorylated ERK1/ERK2  
[pERK1/2]; phosphorylated Elk1 [pElkl]). *P < 0 .0 5  between indi­
cated groups (n = 4  experiments with each assay, using cells 
obtained from 8 hearts). ANG indicates angiotensin II; PD, 
PD123319; and MEKi, PD 98059 (MEK inhibitor).
response to AT, stimulation. This finding led us to determine 
the effects of GF109203X and tyrphostin AG1478 also on 
AT,-mediated stimulation of sarcolemmal NHE activity. 
Figure 11 illustrates that, in parallel with their inhibitory 
effects on ERK activation (Figure 10), GF109203X and 
tyrphostin AG1478 also inhibited AT,-mediated NHE activa­
tion. This is consistent with our conclusion above that ERK 
activation is necessary for AT,-mediated stimulation of the 
exchanger.
Studies in Neonatal Myocytes
Because angiotensin receptor expression in rat myocardium is 
subject to developmental regulation,10 the effects of angio­
tensin II on ERK and NHE activity may differ between 
neonatal and adult myocytes. To ascertain whether this is the 
case, we determined the effects of angiotensin II, given alone 
or together with PD 123319, on cellular ERK and sarcolem­
mal NHE activity also in neonatal rat ventricular myocytes
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p E R K 1/2 A.
■ I I I..
ANG (nmol/L) 0 0 0 100 100 100
PD (nmol/L) 0 0 0 100 100 100
GF(ymol/L) 0 1 0  0 1 0
AG (nmol/L) 0 0 250 0 0 250
Figure 10. Effects of PKC and EGF receptor kinase inhibition on 
AT,-m ediated stimulation of cellular ERK1/ERK2 phosphoryla­
tion in adult rat ventricular myocytes. ERK1/ERK2 phosphoryla­
tion is shown in control cells and in cells that were exposed to 
various combinations of angiotensin II (100 nmol/L), PD 123319  
(100 nmol/L), G F109203X (1 pmol/L), and tyrphostin AG 1478  
(250 nmol/L). Autoradiogram shows a representative Western 
blot (phosphorylated ERK1/ERK2; pERK1/2). *P < 0 .0 5  between 
indicated groups (n = 4  experiments, using cells obtained from 4 
hearts). ANG indicates angiotensin II; PD, PD 123319; GF, 
G F109203X; and AG, tyrphostin AG 1478.
maintained in culture. Figure 12A shows that, in this prepa­
ration, angiotensin II increased cellular ERK activity to a 
similar extent regardless of the presence or absence of the 
AT2-selective antagonist. This is consistent with the previous 
findings of Sadoshima et al32 in a similar neonatal myocyte 
preparation and with our observations in adult ventricular 
myocytes as described above (Figure 9). Distinct from our 
observations in adult myocytes (Figure 3), however, angio­
tensin II induced no increase in sarcolemmal NHE activity in 
neonatal myocytes, in the presence of up to 100 nmol/L 
PD123319 (Figure 12B).
Discussion
The present study provides the first evidence in adult ven­
tricular myocytes that AT, and AT2 mediate opposing actions 
in determining a physiological response to angiotensin II, 
namely an increase in sarcolemmal NHE activity. To delin­
eate the roles of AT, and AT2 in the regulation of sarcolem­
mal NHE activity, we have used the endogenous agonist 
angiotensin II (which has similar affinity for both receptor 
subtypes) in combination with PD123319 (an AT2-selective 
antagonist) and/or losartan (an AT|-selective antagonist). Our 
data show that, in freshly isolated adult rat ventricular 
myocytes, angiotensin II increases sarcolemmal NHE activity 
only in the presence of AT2 blockade and that this effect is 
inhibited by AT! blockade. These observations (which are 
distinct from those made in rat aortic smooth muscle cells33) 
suggest that, in adult rat ventricular myocytes, (1) AT, 
stimulation increases sarcolemmal NHE activity, and (2) this 
effect is opposed by AT2 stimulation. In view of the signaling 
pathways that AT, shares in common with other Gq protein- 
coupled receptors that mediate increased sarcolemmal NHE 
activity in this cell type (such as a,-adrenergic,4 endothelin,5 
and thrombin6 receptors), it is probable that AT2 may atten-
B.
A NG (nm ol/L) 0  0  0  100  100  100
PD  (nm ol/L) 0  0  0  100  100  100
G F  (pm ol/L) 0  1 0  0  1 0
AG (nm ol/L) 0  0  2 5 0  0  0  2 5 0
Figure 11. Effects of PKC and EGF receptor kinase inhibition on 
AT,-m ediated stimulation of sarcolemmal NHE activity in adult 
rat ventricular myocytes. Jm.» values during the first ( □ )  and 
second ( ■ )  acid pulses (A) and AJhss values during the second 
pulse relative to the first (B) are shown in control cells and in 
cells that were exposed to various combinations of angiotensin 
II (100 nmol/L), PD 123319 (100 nmol/L), G F109203X (1 fimol/L), 
and tyrphostin A G 1478 (250 nmol/L) during the second pulse. 
*P < 0 .0 5  between indicated groups (n = 7  cells per group, 
obtained from 10 hearts). ANG indicates angiotensin II; PD, 
PD 123319; GF, G F109203X; and AG, tyrphostin AG 1478.
uate exchanger activation by other neurohormonal stimuli 
also, although confirmation of this awaits further 
investigation.
On a more fundamental level, our data support the exis­
tence of functional AT, and AT2 on adult rat ventricular 
myocytes, an issue that has been subject to question.34-35 
Although it may be argued that the regulation of sarcolemmal 
NHE activity by angiotensin II in the present study could 
have a paracrine basis through the release from contaminating 
nonmyocyte cells of unknown NHE-regulatory factor(s), this 
is unlikely for several reasons. First, all visible cells that 
adhered to the coverslip at the bottom of the cell chamber had 
the morphological characteristics of cardiac myocytes. Sec­
ond, cell density in the chamber was very low, ensuring 
considerable dilution of any paracrine factor(s) that are 
released from contaminating nonmyocyte cells. Finally, the 
myocytes under study were continuously superfused at 3.5 
mL/min (equivalent to a complete change of the chamber 
volume every 2 seconds), thereby ensuring that any paracrine 
factor(s) released into the superfusion medium would be 
rapidly removed. Thus, it is highly likely that, in the present 
study, angiotensin receptor-mediated regulation of sarcolem­
mal NHE activity was mediated through the interaction of 







A NG (nm ol/L) 0  1 0 0  1 0 0  1 0 0  1 0 0  0
P D  (nm ol/L ) 0  0  10  3 0  1 0 0  1 00
Figure 12. Effects of angiotensin II on cellular ERK1/ERK2 
phosphorylation (A) and sarcolemmal NHE activity (B) in neona­
tal rat ventricular myocytes. ERK1/ERK2 phosphorylation (A; 
n = 3  experiments, using cells obtained from 3 different prepara­
tions) and Jh6.9 values during the first ( □ )  and second ( ■ )  acid 
pulses (B; n = 1 2  cells per group, obtained from 8 separate prep­
arations) are shown in control cells and in cells that were 
exposed to combinations of angiotensin II (100 nmol/L) and 
PD 123319 (10, 30, or 100 nmol/L). Autoradiogram in panel A 
shows a representative W estern blot (phosphorylated ERK1/ 
ERK2; pERK1/2). 'P < 0.05 between indicated groups. ANG indi­
cates angiotensin II; PD, PD 123319.
Although this is the first report of opposing actions of 
angiotensin receptor subtypes in adult cardiac myocytes, analo­
gous observations have been reported previously with regard to 
angiotensin II-mediated regulation of several physiological pro­
cesses of cardiovascular relevance. The first such reports showed 
that AT2 mediates an antiproliferative effect and counteracts the 
growth-promoting action of AT, stimulation in vascular smooth 
muscle cells18 and coronary endothelial cells.14 More recently, 
evidence has been obtained that AT2 stimulation opposes AT,- 
mediated hypertrophic effects in neonatal rat ventricular myo­
cytes,16 induction of new protein synthesis in adult rat hearts,36 
and chronotropic effects in adult mouse hearts.37 Further infor­
mation on the roles of AT2 in cardiovascular regulation will 
undoubtedly arise from studies in transgenic mice, in which the 
AT2 gene has been either disrupted38*39 or overexpressed,37 
which have already revealed that AT2 attenuates AT,-mediated 
pressor responses to angiotensin II. 37- 39 Taken together, these 
findings (1) challenge the notion that AT, is the primary 
mediator of the cardiovascular actions of angiotensin II (see also 
recent review by Matsubara40) and (2) illustrate that cardiovas­
nnli
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cular responses to angiotensin II may vary significantly depend­
ing on the relative availability of AT, and AT2. Indeed, in the 
present study, angiotensin II in the presence of an equimolar 
concentration of PD 123319 increased sarcolemmal NHE activ­
ity in adult myocytes but failed to do so in neonatal myocytes. 
This may reflect the greater density of AT2 in neonatal myocar­
dium,10 although roles for developmental changes in other 
pertinent signaling mechanisms cannot be excluded.
In the present study, we have also investigated the mech­
anisms through which the opposing actions of AT, versus 
AT2 on sarcolemmal NHE activity in adult ventricular myo­
cytes may be mediated. The obvious possibility that AT2- 
mediated pathways may directly inhibit sarcolemmal NHE 
activity, thereby resulting in functional antagonism of the 
AT,-mediated response, was excluded on the basis that 
selective AT2 stimulation was without effect on exchanger 
activity. This finding indicates that the ability of AT2 stimu­
lation to oppose NHE activation via AT, is likely to be 
mediated by inhibition of the signaling pathway(s) that 
mediate the AT, response. Although NHE1 is subject to 
regulation by multiple signaling pathways in various cell 
types (see recent reviews in References 41 and 42), we 
elected to concentrate initially on the role of the ERK 
pathway, on the basis of several recent findings. First, work in 
cultured fibroblasts has shown that the ERK pathway is a 
critical mediator of NHE1 activation by exogenous stimuli 
such as thrombin,19 which we have shown to increase 
sarcolemmal NHE activity in adult rat ventricular myocytes.6 
Second, AT| stimulation has been shown to induce ERK 
activation in cultured neonatal ventricular myocytes,32 as well 
as in other cell types.17*43 Finally, AT2 stimulation appears to 
oppose ATr mediated ERK activation in various cell types in 
culture, such as vascular smooth muscle cells18 and brain 
neuronal cells.17
In our studies, (1) PD98059, a pharmacological inhibitor of 
the ERK pathway, inhibited the AT,-mediated increase in 
sarcolemmal NHE activity; (2) selective AT, stimulation, 
which increased sarcolemmal NHE activity, also produced 
increases in ERK1/ERK2 phosphorylation and activity; and
(3) losartan and PD98059, which inhibited the AT,-mediated 
increase in sarcolemmal NHE activity, also inhibited the 
AT,-mediated increases in ERK1/ERK2 phosphorylation and 
activity. Such findings strongly suggest that ERK activation 
is mechanistically involved in AT,-mediated stimulation of 
sarcolemmal NHE activity in adult rat ventricular myocytes. 
Furthermore, our observation in adult myocytes that simulta­
neous AT, and AT2 stimulation produced an increase in 
myocyte ERK1/ERK2 phosphorylation and activity similar to 
that of selective AT, stimulation suggests that (1) AT2- 
mediated inhibition of the AT,-mediated increase in sar­
colemmal NHE activity in this cell type does not arise from 
an attenuation of ERK activation and (2) ERK activation is 
not sufficient to increase sarcolemmal NHE activity. The 
latter conclusion is supported also by our observations in 
neonatal ventricular myocytes, in which angiotensin II in­
duced significant increases in ERK1/ERK2 phosphorylation 
without parallel increases in sarcolemmal NHE activity, even 
in the presence of up to 100 nmol/L PD 123319. It appears, 
therefore, that, although ERK activation is necessary for
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AT,-mediated stimulation of sarcolemmal NHE activity, it is 
not the sole signaling mechanism that mediates this response.
In the broader context of angiotensin receptor-mediated 
regulation of myocardial ERK activity, it is important to note 
that our common finding in adult and neonatal rat ventricular 
myocytes, that simultaneous AT, and AT2 stimulation and 
selective AT, stimulation both produce a similar activation of 
the ERK pathway, is consistent with earlier data. Thus, 
Masaki et al37 and Sadoshima et al3 2 have previously shown 
that, in wild-type adult mouse hearts and in neonatal rat 
ventricular myocytes, respectively, angiotensin II alone pro­
duces a significant increase in ERK1/ERK2 activity that is 
comparable in magnitude with that produced by the combi­
nation of angiotensin II and PD 123319.
In the present study, we have also investigated the potential 
roles of PKC and the EGF receptor as upstream mediators of 
the effects of AT, stimulation on ERK and NHE activity in 
adult rat ventricular myocytes. Our observation that the PKC 
inhibitor GF109203X and the EGF receptor kinase inhibitor 
tyrphostin AG 1478 could each inhibit AT,-mediated activa­
tion of both ERK and NHE suggests that, in this cell type, 
PKC activation and EGF receptor transactivation are both 
necessary to achieve such responses. Notably, analogous 
findings with regard to the regulation of myocyte ERK 
activity by a different stimulus have recently been reported by 
Seko et al,44 who showed that activation of the ERK pathway 
by pulsatile stretch in neonatal myocytes could be blocked 
equally effectively by the PKC inhibitor calphostin C and by 
the tyrosine kinase inhibitor genistein. One possible mecha­
nism that might explain our data is a requirement for PKC 
activity for AT,-mediated transactivation of the EGF recep­
tor. Such a requirement has been shown to exist in HEK293 
cells for transactivation of the EGF receptor by another 
member of the G, protein-coupled receptor family, namely, 
the ml muscarinic receptor. 45 Determination of the role of 
PKC in any AT,-mediated transactivation of the EGF recep­
tor in adult rat ventricular myocytes requires further study.
Our present results do not allow delineation of the mech­
anism^) through which AT2 stimulation opposes the AT,- 
mediated increase in sarcolemmal NHE activity. One poten­
tial mechanism is AT2-mediated inhibition of exchanger- 
stimulatory AT, signaling downstream from ERK1/ERK2 
activation. In this regard, although ERK1/ERK2 can phos- 
phorylate in vitro a fusion protein that contains the carboxyl- 
terminal region of NHEl,4 6  the work of Bianchini et al19 
suggests that ERK-mediated stimulation of NHE1 activity in 
intact cells is not by direct phosphorylation but most likely 
involves intermediary proteins. A candidate NHE-regulatory 
intermediary protein, the regulation of which by AT, and AT2 
in adult rat ventricular myocytes warrants investigation, is the 
90-kDa ribosomal S6  kinase, given that this enzyme lies 
downstream of ERK1/ERK2 in vascular smooth muscle cells 
and has been proposed as a putative NHE1 kinase 47 Another 
potential mechanism that is consistent with our findings is an 
AT2-mediated activation of distinct signaling pathways that 
do not affect basal NHE activity but oppose ERK1/ERK2- 
mediated stimulation of the exchanger. Potential such path­
ways include those mediated via p38 kinase,48 protein kinase 
D,49 and a calcineurin homologous protein, 5 0  given that these
pathways have been proposed to have negative NHE- 
regulatory roles in other cell types.
It is important to consider briefly the potential physiolog­
ical/pathophysiological and therapeutic implications of the 
novel opposing actions of AT, and AT2 reported here. First, 
our findings may help explain the relative inefficacy of 
angiotensin II in increasing sarcolemmal NHE activity (eg, 
see Matsui et al9 versus Yokoyama et al4) and enhancing 
myocardial inotropic status. 8 They may also have relevance to 
the opposing effects of AT, versus AT2 in the induction of 
myocyte hypertrophy, 16 given that upregulation of NHE has 
recently been associated with hypertrophy in both in vivo51 
and in vitro5 2 *53 models. Finally, in considering the potential 
therapeutic implications of our findings, it should be noted 
that sarcolemmal NHE activity is believed to be a critical 
determinant of the severity of cardiac injury and dysfunction, 
including the induction of ventricular fibrillation, in myocar­
dial ischemia and reperfusion (for a recent review, see 
Avkiran54). On the.basis of the present data, it is reasonable 
to speculate that selective antagonists of AT, may possess 
cardioprotective efficacy. This may arise from inhibition of 
sarcolemmal NHE activation during ischemic episodes, not 
only by angiotensin II itself (through blockade of positive- 
regulatory AT,) but also by other neurohormonal stimuli 
(through enhanced stimulation of negative-regulatory AT2), 
particularly given that treatment with AT, antagonists appears 
to increase the plasma angiotensin II concentration. 55 Indeed, 
in view of the evidence that the AT2:AT, ratio is increased in 
the failing human heart, 12*13 it is possible that such a cardio­
protective mechanism may have contributed to the reduction 
in sudden cardiac death that has recently been reported in 
heart failure patients treated with losartan. 56
In conclusion, the present study has shown, for the first 
time, that AT, stimulation increases sarcolemmal NHE activ­
ity in adult rat ventricular myocytes and that this effect is 
opposed via AT2-mediated pathways. Our work has also 
revealed that (1) ERK activation is necessary but not suffi­
cient for AT,-mediated NHE activation, (2) activation of 
ERK and NHE by AT, stimulation.both occur via a PKC- and 
EGF receptor-mediated pathway, and (3) the AT2-mediated 
inhibitory effect on ATr mediated stimulation of NHE activ­
ity does not occur via direct NHE inhibition or an attenuation 
of ERK activation. In view of the potential impact that 
changes in sarcolemmal NHE activity have on cardiac func­
tion in health and disease, further investigation of the molec­
ular signaling mechanisms that mediate such regulation of the 
exchanger by angiotensin receptors appears warranted.
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a^-Adrenergic Stimulation of Sarcolemmal Na+-H+ 
Exchanger Activity in Rat Ventricular Myocytes
Evidence for Selective Mediation by the a 1A-Adrenoceptor Subtype
Hiroyuki Yokoyama, Masahiro Yasutake, Metin Avkiran
Abstract— a r Adrenoceptor ( a r AR) stimulation increases sarcolemmal Na+-H+ exchanger (NHE) activity. The present 
study was designed to determine the role(s) of a,-AR subtype(s) in mediating this response. As an index of NHE 
activity, acid efflux rates (JHs) were determined in single rat ventricular myocytes loaded with the pH-sensitive 
fluoroprobe carboxy-seminaphthorhodafluor- 1  after 2  consecutive intracellular acid pulses in bicarbonate-free medium. 
J H at pHj 6.90 did not change significantly during the second pulse relative to the first in control cells but increased in 
a dose-dependent manner when the second pulse occurred in the presence of phenylephrine (nonselective a r AR 
agonist) or A61603 (a 1A-AR-selective agonist), with EC50 values of 1.24 /xmol/L and 3.6 nmol/L, respectively (both 
agonists given together with 1 /nmol/L atenolol). Stimulation of NHE activity by 10 /xmol/L phenylephrine was inhibited 
in a dose-dependent manner by the competitive antagonists prazosin, WB4101, and 5-methylurapidil, with IC50 values 
of 12, 32, and 149 nmol/L, respectively. Analyses of the relative EC50 and IC50 values obtained (and Kx values estimated 
from the antagonist ICS0s) in relation to the relative potencies of these agents at native rat a,-AR subtypes and their 
relative affinities for recombinant rat a r ARs suggest that a r adrenergic stimulation of sarcolemmal NHE activity is 
likely to be mediated selectively by the a lA-AR. (Circ Res. 1998;82:1078-1085.)
Key W ords: Na+-H+ exchanger ■ a,-adrenoceptor subtype ■ myocyte ■ receptor selectivity
T he sarcolemmal NHE is a primary acid extrusion mech­
anism in cardiac myocardium1,2 whose activity is subject 
to modulation by neurohormonal stimuli.3 In this regard, there 
is now convincing evidence that a,-adrenergic stimulation 
increases sarcolemmal NHE activity in ventricular myo­
cytes.4 - 6  However, the question of whether this response is 
mediated by a specific a-,-AR subtype(s) has not been 
addressed.
In recent years, there has been considerable confusion 
regarding the classification of a r AR subtypes, particularly 
over the relationship between pharmacologically identified 
native a r ARs and the cloned a r ARs. However, much of this 
confusion has now been resolved (see Ford et al7 and Graham 
et al8), such that the classification currently recommended by 
the International Union of Pharmacology’ identifies a,-AR 
subtypes as a 1A-, a 1B-, and a 1D-ARs, which correspond 
respectively to the recombinant subtypes previously referred 
to as a lc-, a lb-, and atld-ARs (the last of which has also been 
referred to as the a u- or a la/d-AR). Within the context of the 
present study, it is important to note that a 1A- and a 1B-AR 
transcripts represent the dominant subtypes that are expressed 
in adult rat myocardium (81% of total in isolated myocytes10 
and 97% of total in whole hearts11). A similar pattern of 
expression may exist at the protein level also, on the basis of 
radioligand binding studies in adult rat myocardium that have
shown ( 1 ) the presence of 2  high-affinity binding sites with 
the characteristics of a 1A- and a 1B-ARs12,13 and (2) the absence 
of a high-affinity binding site for BMY7378, an a 1D-AR- 
selective antagonist. 14
Determination of the role of a 1A-AR versus a 1B-AR sub- 
types in mediating physiological responses to a,-adrenergic 
stimulation in myocardium (as in other tissues) is compli­
cated by the paucity of highly selective ligands (ie, ligands 
that possess at least a 1 0 0 - to 1 0 0 0 -fold higher affinity for one 
subtype relative to the other) . 8 Studies with recombinant 
a r ARs have confirmed that endogenous catecholamines and 
the synthetic agonist phenylephrine do not discriminate be­
tween a 1A- and a 1B-ARs. 15,16 In contrast, the recently de­
scribed potent a,-adrenergic agonist A61603 appears to 
exhibit considerable selectivity for the a 1A-AR. 17 The alky­
lating agent CEC inactivates primarily the a 1B-AR but can 
produce partial inactivation of the other subtypes also, par­
ticularly with prolonged exposure at high concentration. 15,16 
Of available competitive antagonists, prazosin is nonselec­
tive, but WB4101 and 5-methylurapidil exhibit s25-fold 
greater affinity for a 1A- versus a 1B-ARs (although WB4101 
exhibits high affinity also for a iD-ARs) . 15,16 From the above, 
it is clear that characterization of a r AR subtype-mediated 
responses in intact myocardium or isolated myocytes may be 
achieved only through the methodical application of multiple 
agents.
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Selected Abbreviations and Acronyms
AR =  adrenoceptor 
C-SNARF-1 =  carboxy-seminaphthorhodafluor-1 
CEC =  chloroethylclonidine 
/«  =  rate of acid efflux 
•Am.9 =  */h at pH| 6.9 
NHE =  Na+-H+ exchanger
The objective of the present study was to determine the 
role(s) of a r AR subtype(s) in mediating a,-adrenergic stim­
ulation of sarcolemmal NHE activity. Toward this aim, we 
have used isolated ventricular myocytes from the adult rat 
heart in conjunction with a microepifluorescence-based assay 
for sarcolemmal NHE activity. In preliminary experiments, 
we studied the relative effects of CEC versus WB4101 on 
phenylephrine-induced stimulation of NHE activity to deter­
mine the likelihood of a receptor subtype-selective response. 
The results of the preliminary experiments led us to formulate 
the hypothesis that a,-adrenergic stimulation of sarcolemmal 
NHE activity is mediated selectively by the a 1A-AR subtype. 
In order to test this hypothesis rigorously, we then carried out 
extensive dose-response studies with 2  agonists (phenyleph­
rine and A61603) and 3 antagonists (prazosin, WB4101, and 
5-methylurapidil; all in conjunction with phenylephrine) and 
compared the relative ECjq and ICjq values obtained (and 
the Ki values estimated from the antagonist ICjoS) with the 
relative potencies and affinities of these agents at native and 
recombinant rat a,-AR subtypes.
M a teria ls  a n d  M ethods
This investigation was performed in accordance with the Home 
O ffice Guidance on the Operation o f  the Anim als (Scientific Proce­
dures) A ct 1986, published by Her M ajesty’s Stationery Office, 
London, UK.
Determination of Sarcolemmal NHE Activity in 
Isolated Ventricular Myocytes
Sarcolemmal NHE activity was determined in single ventricular 
m yocytes from the rat heart using a m icroepifluorescence-based  
approach that w e have used in previous studies."-10 In brief, adult 
male Wistar rats (200  to 250 g body w eight) were anesthetized by  
inhalation o f  diethyl ether, and hearts w ere excised  and perfused 
(37°C) in the Langendorff m ode for four sequential periods as 
follows: (1) with Tyrode’s solution (m m ol/L: N a G  137, K G  5.4, 
C aG 2 1.8, M gG j 0 .5 , HEPES 10, and g lu cose 10, adjusted to pH 7.4  
at 34°C  with NaOH) for 5 minutes, (2) with nominally Ca1+-free 
Tyrode’s solution (mmol/L: N a G  135, K G  5.4, NaH2P 0 4 0.33, 
M gCl2 1.0, HEPES 10, and glucose 10, adjusted to pH 7 .2  at 34°C  
with NaOH) for 5.5 minutes, (3) with nom inally Ca1+-free Tyrode’s 
solution containing collagenase (W orthington type 1, 94  U/mL) for 
8.5 minutes, and (4) with storage buffer (mmol/L: KOH 78, K G  30, 
KH2P 0 4 30, M g S 0 4 3, EGTA 0.5, HEPES 10, glutamic acid 50, 
taurine 20, and g lucose 10, adjusted to pH 7 .2  at 34°C  with KOH) for 
5 minutes. A ll solutions were gass&d with 100% 0 2. After the 
perfusion procedure, the ventricles w ere removed and chopped into 
several pieces in storage buffer. The tissue fragments were then 
gently agitated to facilitate cell dispersion, and the ce ll suspension  
(> 80%  rod-shaped ce lls" ) was maintained in storage buffer at 25°C  
for at least 1 hour before use in the m icroepifluorescence studies.
pH, was m onitored in s in g le  ventricular m yocytes using the 
pH -sensitive flu orescen t dye C -SN A R F -1 . C ells loaded with 
C -SN A R F-1 w ere p laced on a g lass coverslip  in a 100 /xL 
chamber and continuously  superfused (3 .5  m L/m in) with T y­
rode’s solution  (34°C ) o f  the com position  described above. S in ce  
ce lls  w ere m aintained in bicarbonate-free m edium  throughout the 
experim ental p rotocol, J H calculated during recovery from  intra­
cellu lar acidosis (see  b elow ) could be used as an indicator o f  
sarcolem m al N H E  a ctiv ity ." -10
Experimental Protocols
Experiments were performed according to a protocol involv ing 2  
consecutive acid pulses, as w e have described previously." After 5 to 
10 minutes o f  superfusion with normal Tyrode’s solution (pH 7 .4), 
cells (n = 7  to 10 per group) were subjected to intracellular acidosis  
by transient (3-m inute) exposure to 20 m m ol/L NH<Q (first acid 
pulse). After a 6-m inute period o f  NH4G  washout, cells w ere 
superfused with Tyrode’s solution for an additional 6  minutes before 
a second transient exposure to NH4Q  (second acid pulse). In control 
cells , both acid pulses occurred under identical conditions. W hen  
studying the effects o f  phenylephrine (0.1 to 100 /xmol/L) or A 61603  
(0.1 to 300 nm ol/L), the a ,-A R  agonist was present throughout the 
second pulse (ie , during exposure to and washout o f N H 4C1) together 
with 1 /xmol/L atenolol (to preclude 0,-A R -m ed iated  effects). W hen  
studying the effects o f  phenylephrine (100  /xmol/L) in the presence  
o f  the alkylating agent CEC (3 /xmol/L) or the com petitive a ,-A R  
antagonist W B4101 (3 /xmol/L) in our preliminary studies, these 
agents were included in all solutions from 6 minutes before the 
second pulse to the end o f  the experiment. W hen the inhibition  
curves were constructed for prazosin (0.1 to 300 nm ol/L), W B4101  
(1 to 1000 nm ol/L), and 5-methylurapidil (3 to 3000 nmol/L) versus 
phenylephrine (10  /xmol/L), the antagonists were included in all 
solutions from 3 m inutes before the second pulse. J H was calculated  
at pH, intervals o f  0 .05  during the recovery phases after both acid  
pulses." Each ce ll received only a single drug intervention.
Drugs
Drugs w ere purchased from Sigm a Chem ical C o and were dissolved  
directly in Tyrode’s solution, unless stated otherwise. Prazosin, 
W B 4101, and 5-methylurapidil w ere purchased from Research 
Biochem icals International (via Semat Technical) and w ere d is­
solved in deionized water, ethanol, and dimethyl sulfoxide, respec­
tively. A 61603  was a gift from Abbott Laboratories (Abbott Park, 111) 
and was d issolved in 0.3 m m ol/L ascorbate. A ll stock solutions w ere 
diluted 1:1000) in Tyrode’s solution to obtain the appropriate 
concentrations shortly before the beginning o f  experiments (concom ­
itant controls received the appropriate vehicle).
Data Analysis
Experiments w ithin each study subsection w ere carried out in a 
randomized manner. Data are expressed as m ean ±S E M . W ithin  
individual groups, the paired t test was used to assess changes in J H 
at identical pH, levels betw een the first and second acid pulses 
(P < 0 .0 5  w as considered significant). A gonist dose-response and 
antagonist inhibition curves were constructed by measuring as the 
agonist response the change in J m9  during the second pulse (ie, in the 
presence o f  agonist) relative to the first (ie, in the absence o f  
agonist). The curves were fitted to a variable slope logistic equation, 
and ECjo and ICjo values were determined using Prism 2.0 for 
Macintosh software (GraphPad).
R esults
Effects of CEC and WB4101 on 
Phenylephrine-Induced Stimulation of 
Sarcolemmal NHE Activity
The objective of this preliminary study was to determine 
whether the NHE-stimulatory effect of 100 /xmol/L phenyl­
ephrine (a concentration shown previously to significantly 
increase sarcolemmal exchanger activity in ventricular myo­
cytes from both guinea pig5 and rat6) could be inhibited by 
pretreatment with either CEC or WB4101. Figure 1 shows
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Figure 1. Representative pH, recordings (left) 
and J H-vs-pH, curves (right) obtained during 2 
consecutive acid pulses in control cells (A) and 
in cells that were exposed to 100 /xmol/L phen­
ylephrine throughout the second pulse in the 
absence (B) or presence of 3 /xmol/L CEC (C) 
or 3 /xmol/L W B4101 (D). In all cases, phenyl­
ephrine was administered together with 
1 /xmol/L atenolol. * P < 0.05 vs first pulse (n = 7  
cells per group).
representative recordings of pH, from single myocytes, as 
well as quantitative data in the form of 7H-versus-pH, curves, 
in 4 study groups. In control cells, in which the consecutive 
acid pulses occurred under identical conditions, the profiles 
of pH, recovery from acidosis and the 7H-versus-pH, curves 
were similar during both acid pulses (Figure 1A), indicating 
that temporal changes in NHE activity do not occur in the 
absence of agonist stimulation. In contrast, exposure to 
100 /xmol/L phenylephrine plus 1 /xmol/L atenolol during the 
second pulse accelerated recovery from intracellular acidosis 
and produced an upward shift of the in-versus-pH, curve 
(Figure IB). At pH, ^7.15, JH was significantly greater in the 
presence of 100 /xmol/L phenylephrine, indicating increased 
sarcolemmal NHE activity in response a,-adrenergic stimu­
lation (in agreement with earlier reports4-8). When cells were 
pretreated with 3 /xmol/L CEC before exposure to 
100 /xmol/L phenylephrine, the NHE-stimulatory response to 
the a,-AR agonist was retained (Figure 1C); in contrast, when 
cells were pretreated with 3 /xmol/L WB4101, the response to 
phenylephrine was abolished (Figure ID). This finding sug­
gests that the a ,B-AR may not be the primary mediator of the 
NHE-stimulatory action of phenylephrine and implicates a 
role for the a 1A-AR.
Relative Potencies of Phenylephrine and A61603 in 
S tim ulating Sarcolem m al N HE Activity
As a first step in testing rigorously the hypothesis that 
a,-adrenergic stimulation of sarcolemmal NHE activity is 
mediated selectively by the a 1A-AR subtype, we determined 
and compared the dose-response characteristics of phenyl­
ephrine and A61603. Figure 2A shows the effects of the 2 
agonists on JH6, during the second acid pulse; as can be seen, 
both phenylephrine and A61603 increased -/h6.9 in a dose- 
dependent manner. The agonist dose-response curves derived 
from these data (Figure 2B) revealed ECso values of
1.24 /xmol/L and 3.6 nmol/L for phenylephrine and A61603, 
respectively, indicating a 340-fold greater potency for the 
latter agonist.
Relative Inh ib ito ry  Potencies of Prazosin, WB4101, 
and 5-M ethylurapidil Against 
Phenylephrine-Induced S tim ulation of 
Sarcolem m al N HE Activity
To further examine the role of the a ,A-AR in stimulating 
sarcolemmal NHE activity, we also determined the inhibitory 
potencies of the competitive a,-AR antagonists prazosin, 
WB4101, and 5-methylurapidil against the stimulatory effect 
induced by phenylephrine at the 10 /xmol/L concentration. In
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Figure 2. Panel A shows ./,*.# during the second acid pulse in 
the presence of various concentrations of phenylephrine or 
A61603 (n=7 to 10 cells per concentration). Solid symbols indi­
cate the mean Jhs.s during the first acid pulse, in the absence of 
agonist, in the same cells. In all cases, phenylephrine or A61603 
was administered together with 1 jimol/L atenolol. Panel B 
shows the agonist dose-response curves, which revealed ECso 
values of 1.24 /imol/L for phenylephrine and 3.6 nmol/L for 
A61603.
concomitant experiments with phenylephrine alone (n=27 
cells), /h 6.9 was 3.80±0.45 mmol/L per minute during the first 
pulse and was increased by 98% to 7.51 ±0.52 mmol/L per 
minute during the second pulse. Figure 3 shows the effects of 
the agonist on / H6.9 during the second pulse, in the presence of 
various concentrations of prazosin (Figure 3A), WB4101 
(Figure 3B), or 5-methylurapidil (Figure 3C). As illustrated, 
the NHE-stimulatory response to phenylephrine was inhibited 
in a dose-dependent manner by all 3 antagonists. The antag­
onist inhibition curves derived from these data (Figure 3D) 
revealed IC50 values of 12, 32, and 149 nmol/L for prazosin, 
WB4101, and 5-methylurapidil, respectively. These ICjo val­
ues and the phenylephrine EC50 (1.24 /xmol/L) were then 
entered into a functional equivalent of the Cheng-Prasoff 
equation (Craig21) to obtain estimates of antagonist Kt values 
for comparison with published Kx values (from radioligand 
binding studies) at recombinant rat a,-AR subtypes (Table 1).
D iscussion
aj-AR Subtype(s) Mediating o^-Adrenergic 
Stimulation of Sarcolemmal NHE Activity
In previous studies investigating adrenergic modulation of 
sarcolemmal NHE activity, a stimulatory role for the a r AR
was concluded on the basis of (1) the ability of a r AR 
agonists, such as phenylephrine5-6 or 6 -fluoronorepinephrine4 
(usually in the presence of a /3i-AR antagonist), to increase 
NHE activity and (2) the ability of a,-AR antagonists, such as 
prazosin,4-5 to inhibit such NHE-stimulatory effects. How­
ever, because of the lack of selectivity of the agents used, it 
is not possible to draw any conclusions from these studies 
regarding the identity of the a r AR subtype(s) involved in the 
NHE-stimulatory response.
In the present study, the novel a 1A-AR-selective agonist 
A61603 exhibited a 340-fold greater potency than phenyl­
ephrine in stimulating sarcolemmal NHE activity. Relative 
to phenylephrine, A61603 has been shown to possess 
330-fold greater potency in inducing contraction of the rat 
vas deferens (an a 1A-AR-mediated response), only 40-fold 
greater potency in inducing contraction of the rat spleen 
(an a 1B-AR-mediated response), and 33-fold less potency 
in inducing contraction of rat aortic rings (an a 1D-AR- 
mediated response) . 17 The close agreement between the 
relative potencies of A61603 and phenylephrine in induc­
ing contraction of the rat vas deferens (as reported by 
Knepper et al17) and stimulating sarcolemmal NHE activity 
(as shown in the present study) is supportive of our 
hypothesis that a r adrenergic stimulation of sarcolemmal 
NHE activity is mediated by the a iA-AR subtype. Further­
more, the absolute ECjo values for A61603 and phenyleph­
rine obtained in the present study (3.6 nmol/L and
1.24 /xmol/L, respectively) are comparable to those re­
ported by Knepper et al17 for a ,A-AR-mediated contraction 
of the rat vas deferens (6.2 nmol/L and 2.05 /xmol/L, 
respectively) but not for a 1B-AR-mediated contraction o f . 
the rat spleen (380 nmol/L and 15.70 /xmol/L, respec­
tively) or a ,D-AR-mediated contraction of rat aortic rings 
(6.55 /xmol/L and 198 nmol/L, respectively).
In interpreting our data with prazosin, WB4101, and 
5-methylurapidil, the relative affinities of these antagonists 
for recombinant a,-AR subtypes, expressed in a,-AR-defi- 
cient cells, need to be taken into consideration. Such consid­
eration is hindered, however, by the variability in the K, 
values reported for these antagonists at recombinant receptors 
expressed in cell lines such as COS-7 and Rat-1 (Table 2), 
which may arise (at least in part) from differences in the 
species of origin of the receptors (eg, see Shibata et al22). In 
this regard, only Laz et al15 have reported AT, values for 
prazosin, WB4101, and 5-methylurapidil (the 3 antagonists 
used in the present study) at recombinant a,-AR subtypes 
exclusively of rat origin. Therefore, in view of the common­
ality in species, we have chosen to use the these values for 
comparison with those estimated in the present study. As 
shown in Table 1, both the absolute and the relative Kt values 
for prazosin, WB4101, and 5-methylurapidil estimated in the 
present study are in good agreement with those reported for 
these antagonists at recombinant a lA-ARs but not a 1B- or 
a 1D-ARs of rat origin. This observation provides additional 
support for our hypothesis that a r adrenergic stimulation of 
sarcolemmal NHE activity is mediated selectively by the 
a )A-AR subtype.
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Figure 3. Panels A through C show 
Jhg.s during the second acid pulse in 
the presence of 10 p.mol/L phenyl­
ephrine in cells that received various 
concentrations of prazosin (A),
WB4101 (B), or 5-methylurapidil (C) 
(n=7 to 9 cells per concentration). 
Solid symbols indicate the mean 
Jh6.« during the first acid pulse, in 
the absence of agdnist or antago­
nist, in the same cells. In all cases, 
phenylephrine was administered 
together with 1 p.mol/L atenolol. 
Panel D shows the antagonist inhibi­
tion curves, which revealed ICSo val­
ues of 12 nmol/L for prazosin, 32 




Myocardial aj-ARs have been implicated as mediators of a 
variety of physiological and pathophysiological responses to 
adrenergic stimulation (for reviews, see Fedida et al23 and 
Terzic et al24). a iA-AR-mediated stimulation of sarcolemmal 
NHE activity is likely to contribute to at least some of these 
responses, such as enhanced contractility (see Capogrossi25 
versus Pucdat26) and increased susceptibility to ischemia- and 
reperfusion-induced dysfunction,27 with the latter most prob­
ably resulting from the exacerbation of intracellular Na+ and 
Ca2+ accumulation.2* With regard to ischemia and reperfu­
sion, a,-AR stimulation has also been implicated in the
TABLE 1. Antagonist K\ Values
Estimated AClt* 
nmol/L
Reported / ( , t  nmol/L
a,*-AR £*1B-AR a 10-AR
Prazosin 1.3 (1) 0 .3 (1) 0 .2 (1) 0 .3(1)
WB4101 3.6 (3) 0.9 (3) 22(110) 2(7)
5-Methylurapidil 16 .4(13) 4.0(13) 118(590) 40(133)
Values In parentheses Indicate K relative to prazosin.
•Estimated from the antagonist IC* and agonist (phenylephrine) ECM values 
(see Figures 2 and 3) and the functional equivalent of the Cheng-Prusoff 
equation (Craig21), in which A H C so/p +(A/ECso)], with A denoting the agonist 
concentration used (10 p.mol/L).
-(-Reported by Laz e t al15 for recombinant a,-AR subtypes of rat origin, 
expressed in COS-7 cells.
induction of ischemic preconditioning in rat myocardium.29 
Since ischemic preconditioning is associated with reduced 
intracellular acidosis during the prolonged ischemia,30 it is 
possible that a lx-AR-mediated stimulation of sarcolemmal 
NHE activity may contribute to this phenomenon. However, 
Gabel et al31 have shown recently that H+ efflux during 
prolonged ischemia is not increased in precondidoned hearts. 
Furthermore, any sdmuladon of sarcolemmal NHE activity is 
unlikely to contribute to the cardioprotective mechanism(s) of 
ischemic preconditioning, since we have shown such protec­
tion to be retained (and indeed enhanced) in the presence of 
NHE inhibition.20
a 1A-AR-mediated stimulation of exchanger activity may be 
involved in the induction of hypertrophy by a,-adrenergic 
agonists, since the a 1A-AR subtype has been implicated as the 
mediator of this response in cultured myocytes32 and since 
other stimuli that can induce such a response (eg, thrombin33 
and endothelin34) also share the ability to increase sarcolem­
mal NHE activity.18,35 On a related note, Rokosh et al36 have 
shown recently that hypertrophy of rat myocardium is asso­
ciated with transcriptional induction of the a iA-AR subtype, 
suggesting that a 1A-AR-mediated responses (such as stimu­
lation of sarcolemmal NHE activity) may assume greater 
significance in hypertrophied myocardium. Finally, our find­
ings may have particular relevance to cardiac a r adrenergic 
(patho)physiology in humans, since the a lx-AR appears to be 
the predominant subtype expressed in human ventricular 
myocardium.37
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TABLE 2. Antagonist Xj Values at Recombinant a,-AR Subtypes
“ ia-AR oib'AR a,o-AR
Expression
System Reference*X, nmol/L Origin X, nmol/L Origin X, nmol/L Origin
Prazosin 0.37 Bovine 0.56 Rat 0.33 Rat COS-7 38
0.27 Bovine 0.41 Hamster 0.33 Rat C0S-7/HeLa 39
0.30 Rat 0.20 Rat 0.30 Rat COS-7 15
0.18 Bovine 0.07 Hamster 0.19 Rat HeLa 40
NA 0.14 Hamster NA CHO 41
0.20 Human 0.19 Hamster 0.16 Rat COS-7 42
0.21 Bovine 0.05 Hamster 0.10 Rat LTK 17
0.59 Human 0.55 Human 0.33 Human LM (tk—) 43
0.13 Human 0.32 Human 0.04 Human Rat-1 44
0.50 Bovine 0.13 Hamster 0.08 Rat Rat-1 44
0.39 Human 0.07 Human 0.16 Human COS-7 45
2.20 Bovine 0.38 Hamster 0.34 Rat Rat-1 46
0.19 Bovine 0.06 Hamster 0.10 Rat LTK- 47
0.17 Human 0.25 Human 0.07 Human CHO 22
0.19 Rat 0.38 Hamster 0.35 Rat Rat-1 48
0.13 Human 0.08 Human 0.09 Human Rat-1 48
Mean 0 .4 0 ± 0 .1 3 0 .2 4 ± 0 .0 4 0 .2 0 ± 0 .0 3
WB4101 0.68 Bovine 28.6 Rat 2.10 Rat COS-7 38
0.62 Bovine 38.0 Hamster 2.00 Rat C0S-7/HeLa 39
0.90 Rat 22.0 Rat 2.00 Rat COS-7 15
0.21 Rat 6.2 Hamster 14.10 Rat COS-1 16
0.08 Bovine 3.7 Hamster 0.43 Rat HeLa 40
NA 5.2 Hamster NA CHO 41
0.23 Human 4.5 Hamster 0.31 Rat COS-7 42
0.39 Human 4.6 Human 0.91 Human LM ( tk - ) 43
1.25 Human 10.0 Human 1.25 Human Rat-1 44
0.63 Bovine 7.9 Hamster 1.25 Rat Rat-1 44
0.40 Human 1.6 Human 0.59 Human COS-7 45
1.38 Bovine 6.9 Hamster 1.35 Rat Rat-1 46
0.04 Bovine 0.6 Hamster 0.12 Rat LTK- 47
0.21 Human 3.5 Human 0.26 Human CHO 22
0.17 Rat 6.9 Hamster 1.94 Rat Rat-1 48
0.29 Human 2.4 Human 0.47. Human Rat-1 48
Mean 0 .50± 0 .11 9 .5 ± 2 .7 1 .9 4± 0 .89
5-Methylurapidil 6.8 Bovine 340 Hamster 330 Rat C0S-7/HeLa 39
4.0 Rat 118 Rat 40 Rat COS-7 15
3.4 Rat 430 Hamster 282 Rat COS-1 16
1.2 Bovine 62 Hamster 18 Rat HeLa 40
4.1 Human 160 Hamster 32 Rat COS-7 42
NA 180 Hamster NA CHO 41
0.6 Bovine 42 Hamster 14 Rat LTK 17
2.1 Human 174 Human 12 Human LM ( tk - ) 43
3.2 Human 251 Human 63 Human Rat-1 44
2.0 Bovine 316 Hamster 79 Rat Rat-1 44
2.0 Human 23 Human 30 Human COS-7 45
2.6 Bovine 91 Hamster 62 Rat Rat-1 46
0.6 Bovine 38 Hamster 14 Rat LTK- 47
0.9 Human 39 Human 10 Human CHO 22
0.8 Rat 100 Hamster 50 Rat Rat-1 48
1.0 Human 34 Human 12 Human Rat-1 . 48
Mean 2 .4 ± 0 .4 1 5 0 ± 31 7 0 ± 2 5
Origin refers to the species of origin of the recombinant receptor, and expression system  refers to the cell type(s) in which receptors 
were expressed. NA indicates not applicable.
*ln cited articles, recombinant receptors of the a 1A-AR subtype may be referred to as a 1c-ARs, the a 1B-AR subtype as  a 1b-ARs, and 
the oti0-AR subtype as  a t ,- ,  or a ^ A R s .
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Concluding Comments
By the application of an established microepifluorescence- 
based assay for sarcolemmal NHE activity and a variety of 
pharmacological tools to stimulate or block a,-AR subtypes, 
the present study has shown that a r adrenergic stimulation of 
the exchanger is likely to be mediated selectively by the 
a 1A-AR subtype. Since this pathway may be of significance in 
mediating a variety of physiological and pathophysiological 
responses to a,-adrenergic stimuli, definitive confirmation of 
the role of the a 1A-AR in regulating sarcolemmal NHE 
activity (perhaps through targeted disruption of a 1A-AR 
expression) appears desirable.
Acknowledgments
This study was supported by a Basic Science Senior Lectureship 
Award from the British Heart Foundation (BS/93002) and equipment 
grants from the Special Trustees for St Thom as’ Hospital (523) and 
The W ellcome Trust (048021/Z/96/Z) to Dr Avkiran. Drs Yokoyama 
and Yasutake were Visiting Research Fellows from the Nippon 
Medical School, Tokyo, whose visits were supported in part by the 
Daiwa Anglo-Japanese Foundation.
References
1. Lazdunski M, Frelin C, Vigne P. The sodium/hydrogen exchange system 
in cardiac cells: its biochemical and pharmacological properties and its 
role in regulating internal concentrations of sodium and internal pH. J 
Mol Cell Cardiol. 1985;17:1029-1042.
2. Karmazyn M, Moffat MP. Role of Na+/H+ exchange in cardiac phys­
iology and pathophysiology: mediation of reperfusion injury by the pH 
paradox. Cardiovasc Res. 1993;27:915-924.
3. Pucdat M, Vassort G. Neurohormonal modulation of intracellular pH in 
the heart Cardiovasc Res. 1995;29:178-183.
4. Wallert MA, Frohlich O. a,-Adrenergic stimulation of Na-H exchange in 
cardiac myocytes. Am J Physiol. 1992;263:C1096-C1102.
5. Lagadic-Gossmann D, Vaughan-Jones RD. Coupling of dual acid 
extrusion in the guinea-pig isolated ventricular myocyte to a,- and 
0-adrenoceptors. J Physiol (Lond). 1993;464:49-73.
6 . Pucdat M, Cldment-Chomienne O, Terzic A, Vassort G. a,-Adrenoceptor 
and purinoceptor agonists modulate Na-H antiport in single cardiac cells. 
Am J Physiol. 1993;264:H310-H319.
7. Ford APDW, Williams TJ, Blue DR, Clarice DE. a,-Adrenoceptor clas­
sification: sharpening Occam’s razor. Trends Pharmacol Sci. 1994;15: 
167-170.
8 . Graham RM, Perez DM, Hwa J, Piascik MT. a,-Adrenergic receptor 
subtypes: molecular structure, function, and signaling. Circ Res. 1996; 
78:737-749.
9. Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz 
RJ, Minneman KP, Ruffolo RR Jr. International Union of Pharmacology, 
X: recommendation for nomenclature of a,-adrenoceptors: consensus 
update. Pharmacol Rev. 1995;47:267-270.
10. Stewart AFR, Rokosh DG, Bailey BA, Kams LR, Chang KC, Long CS, 
Kariya K, Simpson PC. Cloning of the rat aic-adrenergic receptor from 
cardiac myocytes: aIC, al(, and a|„ mRNAs are present in cardiac 
myocytes but not in cardiac fibroblasts. Circ Res. 1994;75:796-802.
11. Scofield MA, Liu F, Abel PW, Jeffries WB. Quantification of steady state 
expression of mRNA for alpha-1 adrenergic receptor subtypes using 
reverse transcription and a competitive polymerase chain reaction. 
J Pharmacol Exp Ther. 1995;275:1035-1042.
12. Michel MC, Hanft G, Gross G. Radioligand binding studies of 
a,-adrenoceptor subtypes in rat heart. Br J Pharmacol. 1994;111: 
533-538.
13. Lazou A, Fuller SJ, Bogoyevitch MA, (Mali KA, Sugden PH. Charac­
terization of stimulation of phosphoinositide hydrolysis by a|-adrenergic 
agonists in adult rat hearts. Am J Physiol. 1994;267:H970-H978.
14. Deng XF, Chemtob S, Varma DR. Characterization of aID-adienoceptor 
subtype in rat myocardium, aorta and other tissues. Br J Pharmacol. 
1996;119:269-276.
15. Laz TM, Forray C, Smith KE, Bard JA, Vaysse PJ, Branchek TA, 
Weinshank RL. The rat homologue of the bovine au-adrenergic receptor
shows the pharmacological properties of the classical a IA subtype. Mol 
Pharmacol. 1994;46:414-422.
16. Perez DM, Piascik MT, Malik N, Gavin R, Graham RM. Cloning, 
expression, and tissue distribution of the rat homolog of the bovine 
aic-adrenergic receptor provide evidence for its classification as the a 1A 
subtype. Mol Pharmacol. 1994;46:823-831.
17. Knepper SM, Buckner SA, Brune ME, DeBemardis JF, Meyer MD, 
Hancock AA. A-61603, a potent a,-adrenergic receptor agonist, selective 
for the a,A receptor subtype. J Pharmacol Exp Ther. 1995;274:97-103.
18. Yasutake M, Haworth RS, King A, Avkiran M. Thrombin activates the 
sarcolemmal Na+-H+ exchanger: evidence for a receptor-mediated 
mechanism involving protein kinase C. Circ Res. 1996;79:705-715.
19. Haworth RS, Yasutake M, Brooks G, Avkiran M. Cardiac Na+/H+ 
exchanger during postnatal development in the rat: changes in mRNA 
expression and sarcolemmal activity. J Mol Cell Cardiol. 1997;29: 
321-332.
20. Shipolini AR, Yokoyama H, Galifianes M, Edmondson SJ, Hearse DJ, 
Avkiran M. Na+/H+ exchanger activity does not contribute to protection 
by ischemic preconditioning in the isolated rat heart. Circulation. 1997; 
96:3617-3625.
21. Craig DA. The Cheng-Prusoff relationship: something lost in the trans­
lation. Trends Pharmacol Sci. 1993;14:89-91.
22. Shibata K, Foglar R, Horie K, Obika K, Sakamoto A, Ogawa S, 
Tsujimoto G. KMD-3213, a novel, potent, a1A-adrenoceptor-selective 
antagonist: characterization using recombinant human a,-adrenoceptors 
and native tissues. Mol Pharmacol. 1995;48:250-258.
23. Fedida D, Braun AP, Giles WR. a,-Adrenoceptors in myocardium: func­
tional aspects and transmembrane signaling mechanisms. Physiol Rev. 
1993;73:469-487.
24. Terzic A, Puceat M, Vassort G, Vogel SM. Cardiac a,-adrenoceptors: an 
overview. Pharmacol Rev. 1993;45:147-175.
25. Capogrossi MC. Stimulation of sarcolemmal sodium-hydrogen exchange 
in cardiac myocytes as a mediator of the positive inotropic action of a, 
adrenergic agonists. Cardiovasc Res. 1995;29:276-277.
26. Puciat M. Stimulation of sarcolemmal sodium-hydrogen exchange in 
cardiac myocytes is not responsible for the positive inotropic action of a, 
adrenergic agonists. Cardiovasc Res. 1995;29:275-276.
27. Yasutake M, Avkiran M. Exacerbation of reperfusion arrhythmias by 
a,-adrenergic stimulation: a potential role for receptor-mediated acti­
vation of sarcolemmal sodium-hydrogen exchange. Cardiovasc Res. 
1995;29:222-230.
28. Avkiran M. Sodium-hydrogen exchange in myocardial ischemia and 
reperfusion: a critical determinant of injury? In: Kannazyn M, ed. Myo­
cardial Ischemia: Mechanisms, Reperfusion, Protection. Basel, Swit­
zerland: Birkhauser Verlag; 1996:299-311.
29. Baneijee A, Locke Winter C, Rogers KB, Mitchell MB, Brew EC, Cairns 
CB, Bensard DD, Harken AH. Preconditioning against myocardial dys­
function after ischemia and reperfusion by an a,-adrenergic mechanism. 
Circ Res. 1993;73:656-670.
30. Asimakis GK, Inners-McBride K, Medellin G, Conti VR. Ischemic pre­
conditioning attenuates acidosis and postischemic dysfunction in isolated 
rat heart Am J Physiol. 1992;263:H887-H894.
31. Gabel SA, Cross HR, London RE, Steenbergen C, Murphy E. Decreased 
intracellular pH is not due to increased H+ extrusion in preconditioned rat 
hearts. Am J Physiol. 1997;273:H2257-H2262.
32. Knowlton KU, Michel MC, Itani M, Shubeita HE, Ishihara K, Brown JH, 
Chien KR. The aIA-adrenergic receptor subtype mediates biochemical, 
molecular, and morphologic features of cultured myocardial cell hyper­
trophy. JBiol Chem. 1993;268:15374-15380.
33. Glembotski CC, Irons CE, Krown KA, Murray SF, Sprenkle AB, Sei CA. 
Myocardial a-thrombin receptor activation induces hypertrophy and 
increases atrial natriuretic factor gene expression. J Biol Chem. 1993;268: 
20646-20652.
34. Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, Nogami A, 
Murumo F, Hiroe M. Endothelin-1 is an autocrine/paracrine factor in the 
mechanism of angiotensin II-induced hypertrophy in cultured rat cardio- 
myocytes. J Clin Invest. 1993;92:398-403.
35. Kramer BK, Smith TW, Kelly RA. Endothelin and increased contractility 
in adult rat ventricular myocytes: role of intracellular alkalosis induced by 
activation of the protein kinase C-dependent Na+-H+ exchanger. Circ 
Res. 1991;68:269-279.
36. Rokosh DG, Stewart AFR, Chang KC, Bailey BA, Karliner JS, Camacho 
SA, Long CS, Simpson PC. a ,-Adrenergic receptor subtype mRNAs are 
differentially regulated by aradrenergic and other hypertrophic stimuli in
170
Yokoyama et al June 1, 1998 1085
cardiac myocytes in culture and in vivo: repression of aIB and aID but 
induction of aic. J Biol Chem. 1996;271:5839-5843.
37. Price DT. Lefkowitz RJ, Caron MG, Berkowitz D, Schwinn DA. Local­
ization of mRNA for three distinct at-adrenergic receptor subtypes in 
human tissues: implications for human a-adrenergic physiology. Mol 
Pharmacol. 1994;45:171-175.
38. Lomasney JW, Cotecchia S, Lorenz W, Leung WY, Schwinn DA, Yang 
Feng TL, Brownstein M, Lefkowitz RJ, Caron MG. Molecular cloning 
and expression of the cDNA for the aIA-adrenergic receptor: the gene for 
which is located on human chromosome 5. J Biol Chem. 1991;266: 
6365-6369.
39. Schwinn DA, Lomasney JW. Pharmacologic characterization of cloned 
a,-adrenoceptor subtypes: selective antagonists suggest the existence of a 
fourth subtype. Eur J Pharmacol. 1992;227:433-436.
40. Faure C, Pimoule C, Arbilla S, Langer SZ, Graham D. Expression of 
a,-adrenoceptor subtypes in rat tissues: implications for -^adrenoceptor 
classification. Eur J Pharmacol. 1994;268:141-149.
41. Horie K, Hirasawa A, Tsujimoto G. The pharmacological profile of 
cloned and stably expressed a)B-adrenoceptor in CHO cells. Eur 
J Pharmacol. 1994;268:399-407.
42. Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G. Use of recom­
binant aradrenoceptors to characterize subtype selectivity of drugs for 
the treatment of prostatic hypertrophy. Eur J Pharmacol. 1995;288: 
201-207.
43. Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, 
Hartig PR, Weinshank RL, Branchek TA, Gluchowski C. The 
a,-adrenergic receptor that mediates smooth muscle contraction in human 
prostate has the pharmacological properties of the cloned human aIC 
subtype. Mol Pharmacol. 1994;45:703-708.
44. Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman 
NP, Campbell S, Fidock MD, Furness M, Parry-Smith DJ, Peter B, Bailey 
DS. Cloning and pharmacological characterization of human alpha-1 
adrenergic receptors: sequence corrections and direct comparison with 
other species homologues. J Pharmacol Exp Ther. 1995;272:134-142.
45. Weinberg DH, Trivedi P, Tan CP, Mitra S, Perkins-Barrow A, Borkowski 
D, Strader CD, Bayne M. Cloning, expression and characterization of 
human a adrenergic receptors a1A, aIB and aic. Biochem Biophys Res 
Commun. 1994;201:1296-1304.
46. Goetz AS, Lutz MW, Rimele TJ, Saussy DL. Characterization of alpha-1 
adrenoceptor subtypes in human and canine prostate membranes. 
J Pharmacol Exp Ther. 1994;271:1228-1233.
47. Buckner SA, Oheim KW, Morse PA, Knepper SM, Hancock AA. 
a,-Adrenoceptor-induced contractility in rat aorta is mediated by the oID 
subtype. Eur J Pharmacol. 1996;297:241-248.
48. Saussy DL, Goetz AS, Queen KL, King HK, Lutz MW, Rimele TJ. 
Structure activity relationships of a series of buspirone analogs at alpha-1 
adrenoceptors: further evidence that rat aorta alpha- 1 adrenoceptors are of 
the alpha-lD-subtype. J Pharmacol Exp Ther. 1996;278:136-144.
171
Roles of Mitogen-Activated Protein Kinases and Protein 
Kinase C in a 1A-Adrenoceptor-Mediated Stimulation of the 
Sarcolemmal Na+-H+ Exchanger
Andrew K. Snabaitis, Hiroyuki Yokoyama, Metin Avkiran
Abstract—Activation of the sarcolemmal Na+-H+ exchanger (NHE) has been implicated as a mechanism of inotropic, 
arrhythmogenic, antiacidotic, and hypertrophic effects of a r adrenoceptor (AR) stimulation. Although such regulation 
of sarcolemmal NHE activity has been shown to be selectively mediated through the a 1A-AR subtype, distal signaling 
mechanisms remain poorly defined. We investigated the roles of various kinase pathways in a ]A-AR-mediated 
stimulation of sarcolemmal NHE activity in adult rat ventricular myocytes. As an index of NHE activity, 
franj-sarcolemmal acid efflux rate (JH) was determined through microepifluorescence in single cells, during recovery 
from intracellular acidosis-in bicarbonate-free conditions. Extracellular signal-regulated kinase (ERK), p38-mitogen- 
activated protein kinase (MAPK), and p90rik activities were indexed on the basis of analysis of their phosphorylation 
status. In control cells, there was no change in JH in response to vehicle. Phenylephrine and A61603, an a 1A-AR 
subtype-selective agonist, increased JH, as well as cellular ERK and p90rak activities. Neither agonist affected p38 
activity, which was increased with sorbitol. The MAPK kinase inhibitor PD98059 abolished phenylephrine- and 
A61603-induced increases in JH and cellular ERK and p90"k activities. In contrast, the PKC inhibitor GF109203X 
abolished phenylephrine- and A61603-induced increases in JH but failed to prevent the increases in ERK and p90rsk 
activities. Our findings suggest that a 1A-AR-mediated stimulation of sarcolemmal NHE activity in rat ventricular 
myocytes requires activation of the ERK (but not the p38) pathway of the MAPK cascade and that the ERK-mediated 
effect may occur via p90rek. Activation of PKC is also required for a 1A-AR-mediated NHE stimulation, but such 
regulation occurs through an ERK-independent pathway. (Circ Res. 2000;86:214-220.)
Key Words: Na+-H+ exchange ■ receptors, adrenergic ■ signal transduction ■ protein kinases
T he sarcolemmal Na+-H+ exchanger (NHE) consists of 
the ubiquitous NHE-1 isoform of the multigene NHE 
family1 and is an important H+ extrusion mechanism that 
contributes to the integrated control of intracellular pH (pH,) 
in cardiac myocytes.2 Although sarcolemmal NHE activity is 
regulated primarily by pH, and is markedly increased in 
response to acidosis,2 it is also subject to modulation by 
several stimuli that act via Gq protein-coupled receptors 
(GqPCRs), such as a r adrenergic agonists,3 endothelin,4 
thrombin,3 and angiotensin n.6 These stimuli increase sar­
colemmal NHE activity by enhancing the affinity of the 
exchanger for intracellular H+, which is the primary mecha­
nism underlying receptor-mediated regulation of NHE-1.7
Of the various GqPCR signaling pathways that regulate 
sarcolemmal NHE activity, those that are activated by a,- 
adrenoceptors (a,-ARs) warrant attention because they are 
likely to mediate important physiological and pathophysio­
logical responses. In this regard, increased sarcolemmal NHE 
activity and consequent increases in pH,, intracellular Na+, or 
both have been suggested to be causally involved in the
positive inotropic,8 arrhythmogenic,9 and hypertrophic10-11 
consequences of myocardial a,-AR stimulation. Furthermore, 
a,-AR-mediated stimulation of sarcolemmal NHE activity 
may contribute to the antiacidotic effect during ischemia of 
ischemic or pharmacological preconditioning.12 In an effort to 
delineate the molecular mechanisms that underlie a,- 
adrenergic stimulation of sarcolemmal NHE activity, we 
recently demonstrated that such regulation of the exchanger is 
mediated selectively through the a 1A-AR subtype.13 Never­
theless, pertinent signaling pathways distal to the GqPCR 
remain controversial (eg, see Wallert and Frohlich3 versus 
Puc6at et al14 on the role of protein kinase C [PKC]) and 
incompletely characterized.
The results of recent studies in noncardiac cells suggest 
that intracellular signals transduced via the extracellular 
signal-regulated kinase (ERK)15- 17 and p3818 pathways of the 
mitogen-activated protein kinase (MAPK) cascade may be 
important contributors to GqPCR-mediated regulation of 
NHE-1 activity. Furthermore, GqPCR (including a,-AR) 
stimulation has been shown to activate both ERK and p38 in
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isolated rat hearts19 and cultured neonatal rat ventricular 
myocytes,20-21 through mechanisms that may involve 
PKC.21-22 However, the potential roles and interactions of 
ERK, p38, and PKC in a 1A-AR-mediated regulation of 
sarcolemmal NHE activity have not been investigated.
The present study was undertaken to determine the in­
volvement of ERK, p38, and PKC pathways in a 1A-AR- 
mediated stimulation of sarcolemmal NHE activity in freshly 
isolated adult rat ventricular myocytes. To achieve this, we 
used established techniques for the determination of NHE and 
various kinase activities, in conjunction with 2 agonists of 
distinct o^-AR subtype selectivity and specific kinase inhib­
itors. Our data suggest that a 1A-AR-mediated stimulation of 
sarcolemmal NHE activity in adult rat ventricular myocytes 
requires activation of the ERK (but not the p38) pathway of 
the MAPK cascade. Activation of PKC is also required for 
this response, but PKC and ERK appear to be independent 
regulators of NHE activity in response to Q£iA-AR stimulation.
M a te ria ls  an d  M ethods
This investigation was performed in accordance with the Home 
Office "Guidance on the Operation of the Animals (Scientific 
Procedures) Act 1986,” published by HMSO (London).
Isolation of Ventricular Myocytes
Ventricular myocytes were isolated from the hearts of adult male 
Wistar rats (weight 200 to 250 g) through enzymatic digestion for the 
study of drug effects on sarcolemmal NHE3-6-13-23 or cellular kinase6 
activity.
Determination of Sarcolemmal NHE Activity
Sarcolemmal NHE activity was determined in single myocytes 
loaded with the pH-sensitive fluoroprobe cSNARF-1, through the 
use of a microepifluorescence technique.5-6-13-23 Cells were main­
tained in bicarbonate-free medium (34°C) throughout each experi­
ment, thus enabling the rate of acid efflux (7„) to be used as the 
indicator of sarcolemmal NHE activity. To quantify drag-induced 
changes in NHE activity, J„ values were determined at pH, intervals 
of 0.05 during recovery from intracellular acidosis.
Determination of Cellular MAPK and 
p90rek Activities
MAPK activities were determined through the detection of dual 
phosphorylation of ERK1/2 and p38 on the Thr and Tyr residues of 
their regulatory Thr-Xaa-Tyr motifs, by Western analysis with dual 
phosphospecific antibodies (New England Biolabs).6 The activity of 
P90"1 was determined through the detection of Ser381 phosphory­
lation with a phosphospecific antibody (New England Biolabs). To 
confirm equal protein loading, we used nonphosphospecific antibod­
ies for ERK2 (Santa Cruz Biotechnology), p38 (Santa Cruz Biotech­
nology), and p90nk (Transduction Laboratories). Specific protein 
bands were detected with enhanced chemiluminescence and autora­
diography, and phosphorylation status was quantified with laser 
densitometry.
Experimental Protocols
For the determination of drug effects on NHE activity, myocytes (10 
per group, obtained from 7 to 9 separate hearts in each protocol) 
were subjected to intracellular acidosis through transient (3 minutes) 
exposure to 20 mmol/L NH*C1 (first acid pulse), which was repeated 
*=15 minutes later (second acid pulse).3-6-13 In control cells, both acid 
pulses occurred in the absence of any drag. When the effects of 
phenylephrine (Sigma), a non-subtype-selective a,-AR agonist, or 
A61603 (gift from Abbott Laboratories), an a 1A-AR subtype-selec­
tive agonist, were studied, this was present during the second pulse. 
When the effects of either agonist in the presence of the MAPK
kinase (MEK) inhibitor PD98059 (Calbiochem-Novabiochem) or the 
PKC inhibitor GF109203X (Calbiochem-Novabiochem) were stud­
ied, the inhibitor was present from 10 minutes before the second acid 
pulse. Drug vehicles were included in superfusion solutions, as 
appropriate. For determination of the effects on kinase activity, 
myocytes in suspension were exposed to the same drugs with the use 
of identical concentrations and exposure times (4 experiments with 
each protocol, with cells from 4 separate hearts).
Statistical Analysis
Values are given as mean±SEM. Experiments in each microepifluo­
rescence protocol were randomized, with contemporary controls. A 
paired t test was used to assess changes in J„ between the first and 
second acid pulses. For an intergroup comparison of the change in JH 
at pH, 6.90 (A7H69) or of protein kinase phosphorylation, data were 
subjected to ANOVA; further analysis was made with Dunnett’s test 
to compare each treatment group with the control group. P<0.05 was 
considered significant
R esu lts
Role of ERK1/2 in a1A-AR-Mediated Stimulation 
of Sarcolemmal NHE Activity
Figure 1 shows the / H-versus-pH, relationships obtained after 
2 consecutive acid pulses in the 6 groups of this protocol, 
which addressed the role of ERK1/2 in a 1A-AR-mediated 
stimulation of sarcolemmal NHE activity. During the second 
acid pulse, control cells (Figure 1A) continued to receive 
agonist-free superfusate, whereas the other groups were 
exposed to phenylephrine (Figure IB) or A61603 (Figure 1C) 
in the absence or presence of PD98059. The concentrations of 
phenylephrine and A61603 were selected on the basis of our 
dose-response studies13 and were those that produced near- 
maximal stimulation of sarcolemmal NHE activity. In control 
cells, the 7H-versus-pH, curves obtained after both acid pulses 
were superimposed (Figure 1A, left), indicating that temporal 
changes in NHE activity do not occur in the absence of drug 
exposure. In these cells, PD98059 alone had no effect on the 
7H-versus-pH, curve (Figure 1A, right). Consistent with our 
previous data that a 1A-AR stimulation increases sarcolemmal 
NHE activity,13 phenylephrine and A61603 both produced 
rightward shifts of the JH-versus-pH, curve such that over the 
range of pH, 6.80 to 7.20, JH was significantly greater in the 
presence of either agonist (Figures IB and 1C, left). How­
ever, in the presence of PD98059, neither phenylephrine nor 
A61603 produced a significant shift in the in-versus-pH, 
curve (Figures IB and 1C, right). Figure 3A shows A7H6.9 
values in the 6 study groups and allows a comparison of the 
effects of the different stimuli on sarcolemmal NHE activity. 
As illustrated, in the absence of PD98059, AJH6.9 was signif­
icantly greater in cells that received phenylephrine or 
A61603. In contrast, in the presence of PD98059, there was 
no significant difference in A7H69 between control cells and 
those exposed to either a,-AR agonist. Because PD98059 
inhibits Raf-mediated activation of MEK1/2 24 which in turn 
activates ERK 1/2,25 these data suggest that activation of the 
ERK pathway is a necessary step in a^-AR-mediated stim­
ulation of sarcolemmal NHE activity.
Role of PKC in a^-AR-Mediated Stimulation of 
Sarcolemmal NHE Activity
Figure 2 shows the 7H-versus-pHi relationships obtained in 
this protocol, which was analogous to that described earlier
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F igu re  1. Effect of MEK inhibition on a 1A-AR-mediated stimula­
tion of sarcolemmal NHE activity in adult rat ventricular myo­
cytes. JH-versus pH, curves obtained during first (O) and second 
(• )  acid pulses are shown in control cells (A) and in cells 
exposed to 10 /xmol/L phenylephrine (B) or 30 nmol/L A61603 
(C) during second pulse in absence or presence of MEK inhibi­
tor PD98059 (50 /xmol/L) (10 cells per group, obtained from 7 
hearts).
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F ig u re  2. Effect of PKC inhibition on a 1A-AR-mediated stimula­
tion of sarcolemmal NHE activity in adult rat ventricular myo­
cytes. JH-versus pH, curves obtained during first (O) and second 
( • )  acid pulses are shown in control cells (A) and in cells 
exposed to 10 /xmol/L phenylephrine (B) or 30 nmol/L A61603 
(C) during second pulse in absence or presence of PKC inhibitor 
GF109203X (1 /xmol/L) (10 cells per group, obtained from 9 
hearts).
except that it tested the role of the PKC pathway. In control 
cells, the / H-versus-pHj curves obtained after both acid pulses 
were again superimposed (Figure 2A, left). GF109203X had 
no effect on the 7H-versus-pH, curve in control cells (Figure 
2A, right) but abolished the rightward shifts of the curve 
induced by phenylephrine (Figure 2B) or A61603 (Figure 
2C). As illustrated in Figure 3B, in the absence of 
GF109203X, A7H69 was again significantly greater in cells 
that received phenylephrine or A61603, reflecting a,A-AR- 
mediated stimulation of sarcolemmal NHE activity. In con­
trast, in the presence of GF109203X, there was no significant 
change in A7H6.9 in response to either a,-AR agonist. Because 
GF109203X is a selective inhibitor of PKC,26 these data 
suggest that PKC is a critical component of the distal 
signaling pathways of the a 1A-AR that mediate the stimula­
tion of sarcolemmal NHE activity.
Regulation of Sarcolemmal NHE Activity 
via PKC and ERK1/2: Contiguous or 
Independent Pathways?
These data suggest that in a 1A-AR-mediated stimulation of 
sarcolemmal NHE activity, both PKC and ERK 1/2 are critical 
components of the signaling pathways distal to the GqPCR. 
This situation could arise if (1) PKC and ERK 1/2 are 
proximal and distal components of a contiguous signaling 
pathway or (2) PKC and ERK1/2 mediate independent 
signaling pathways, but activation of both is necessary to 
achieve the full response. To address this issue, we deter­
mined the effects on ERK activity of a,-AR stimulation in the 
absence or presence of GF109203X. Figure 4 shows that in 
parallel with their effects on sarcolemmal NHE activity, 
phenylephrine and A61603 produced significant increases in 
ERK activity. GF109203X failed to prevent significant in­
creases in ERK activity in response to phenylephrine and
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Figure 3. Effect of MEK or PKC inhibition on a1A-AR-mediated 
increases in sarcolemmal NHE activity in adult rat ventricular myo­
cytes. Change in JH at pH| 6.9 (AJhb.9) during second acid pulse 
relative to first is shown in control cells and in cells exposed to 
10 n.mol/L phenylephrine or 30 nmol/L A61603 during second 
pulse in absence or presence of MEK inhibitor PD98059 
(50 mol/L) (A) or PKC inhibitor GF109203X (1 nmol/L) (B).
*P <0.05 vs control (10 cells per group, obtained from 7 to 9 
hearts).
A61603, whereas PD98059 abolished ERK activation by 
each agonist. The distinct effects of the 2 kinase inhibitors on 
ERK activation (Figure 4), despite their common ability to 
prevent a 1A-AR-mediated stimulation of sarcolemmal NHE 
activity (Figure 3), allow the following conclusions to be 
made: (1) in adult rat ventricular myocytes, a,-AR-mediated 
activation of ERK 1/2 occurs, to a large extent, through 
PKC-independent mechanisms, and (2) activation of both 
pathways is required for a 1A-AR-mediated stimulation of 
sarcolemmal NHE activity.
The lack of an effect of GF109203X on ERK activation might 
reflect the absence of PKC-mediated ERK regulation or the 
dissociation of such regulation from the a,-AR-mediated re­
sponse. To address this issue, we determined the effects on ERK 
activity of direct PKC activation by phorbol 12-myristate 13- 
acetate (PM A). As shown in Figure 5, PM A produced a 
significant increase in ERK activity, indicating that PKC- 
mediated ERK activation is functional in adult rat ventricular 
myocytes. Figure 5 also shows that GF109203X abolished 
PMA-induced ERK activation, thus confirming that the concen­
tration used was sufficient to block PKC-mediated responses.
Role of p38 in a 1A-AR-M ediated Stimulation of 
Sarcolemmal NHE Activity
In some cardiac preparations,19-21 a,-AR stimulation has been 
shown to activate p38, which has been implicated in GqPCR-
® ~£R K 2  
total ERK2
F ig u re  4 . Effect of a^-AR stimulation, in absence or presence of 
PKC or MEK inhibition, on ERK activity in adult rat ventricular 
myocytes. Cells were exposed to vehicle (control), 10 junol/L 
phenylephrine (PHEN), or 30 nmol/L A61603 in absence or pres­
ence of PKC inhibitor GF109203X (1 fimol/L) or MEK inhibitor 
PD98059 (50 /tmol/L). Autoradiograms show representative 
Western blots with phosphospecific (top) and nonphosphospe- 
cific (bottom) ERK antibodies (see Materials and Methods).
*P < 0.05 vs control (4 experiments, with cells from 4 hearts).
mediated regulation of plasma membrane NHE activity in rat 
vascular smooth muscle cells.18 Therefore, we tested whether 
p38 could also be involved in a,A-AR-mediated regulation of 
sarcolemmal NHE activity in adult rat ventricular myocytes. 
However, as illustrated in Figure 6, neither phenylephrine nor 
A61603 produced a significant increase in p38 activity. In 
contrast, osmotic stress, induced by exposure to 0.5 mol/L 
sorbitol and used as a positive control, produced a significant 
increase in p38 activity (Figure 6). The common inability of 
the a,-AR agonists to increase p38 activity at concentrations 
that were sufficient to increase sarcolemmal NHE activity 
precludes a role for the p38 pathway in a,A-AR-mediated 
regulation of the exchanger.
® ~ €R K 2  
total ERK2
no  inhibitor ■  G F 1 0 9 ? 0 3 X
F ig u re  5. Effect of PKC activation on ERK activity in adult rat 
ventricular myocytes. Cells were exposed to vehicle (control) or 
30 nmol/L PMA in absence or presence of PKC inhibitor 
GF109203X (1 /xmol/L). Autoradiograms show representative 
Western blots with phosphospecific (top) and nonphosphospe- 
cific (bottom) ERK antibodies (see Materials and Methods). 
*P<0.05 vs control (4 experiments, with cells from 4 hearts).
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Figure 6. Effect of a,-AR stimulation versus osmotic stress on 
p38 activity in adult rat ventricular myocytes. Cells were 
exposed to vehicle (control), 30 nmol/L A61603, 10 p.mol/L 
phenylephrine (PHEN), or 0.5 mol/L sorbitol. Autoradiograms 
show representative Western blots with phosphospecific (top) 
and nonphosphospecific (bottom) p38 antibodies (see Materials 
and Methods). *P < 0.05 vs control (4 experiments, with cells 
from 4 hearts).
Downstream Effectors of ERK1/2
The 90-kDa ribosomal S6 kinase (p90^), which is activated 
by ERK1/2, has been shown to phosphorylate the regulatory 
domain of NHE-117-27-28 and may mediate serum- or 
endothelin-induced stimulation of NHE activity in cultured 
fibroblasts27 and neonatal rat ventricular myocytes.28 To 
determine whether p90"k could be a downstream effector in 
ERK-mediated regulation of the sarcolemmal NHE in adult 
rat ventricular myocytes, we determined the effects of a,-AR 
stimulation on the activity of this kinase. As shown in Figure 
7, both phenylephrine and A61603 significantly increased
Figure 7. Effect of a,-AR stimulation, in absence or presence of 
PKC or MEK inhibition, on p90r,k activity in adult rat ventricular 
myocytes. Cells were exposed to vehicle (control), 10 p.mol/L 
phenylephrine (PHEN), or 30 nmol/L A61603 in absence or pres­
ence of PKC inhibitor GF109203X (1 p.mol/L) or MEK inhibitor 
PD98059 (50 /xmol/L). Autoradiograms show representative 
Western blots with phosphospecific (top) and nonphosphospe­
cific (bottom) p90rsk antibodies (see Materials and Methods). 
*P<0.05 vs control (4 experiments, with cells from 4 hearts).
p90,,k activity. The activation of p90rek by a,-AR stimulation 
was abolished by PD98059 but unaffected by GF109203X, 
suggesting that such activation occurred via an ERK- 
dependent but PKC-independent pathway. This is consistent 
with an effector role for p90nik in ERK-mediated regulation of 
the sarcolemmal NHE, in response to a u-AR stimulation.
Discussion
Our main novel findings, which were obtained in adult rat 
ventricular myocytes, are that (1) inhibition of either MEK 
(the upstream activator of ERK 1/2) or PKC abolishes stim­
ulation of sarcolemmal NHE activity by the a,-AR agonists 
phenylephrine and A61603; (2) inhibition of MEK, but not 
PKC, abolishes ERK activation by both agonists; (3) activity 
of p90rsk, a putative NHE-1 kinase, is regulated in parallel 
with that of ERK1/2; and (4) phenylephrine and A61603 do 
not activate p38.
The ability of the MEK inhibitor PD98059 to abolish 
phenylephrine- and A61603-induced increases in the activi­
ties of both sarcolemmal NHE and cellular ERK 1/2 provides 
the first evidence that ERK activation is a critical step in 
a u-AR-mediated stimulation of the exchanger in adult rat 
ventricular myocytes. This finding, considered together with 
our recent work in the same system on the regulation of 
sarcolemmal NHE activity via the angiotensin II type 1 (ATi) 
receptor6 and other pertinent data from noncardiac cells15-17 
and cultured neonatal rat ventricular myocytes,28-29 suggests 
that the ERK pathway is a critical regulator of NHE-1 activity 
in response to multiple stimuli in various cell types. Further­
more, the parallel changes observed in NHE, ERK1/2, and 
p90rsk activities in response to a,-AR stimulation, in the 
absence or presence of the MEK and PKC inhibitors, are 
consistent with an effector role for p90r,k in ERK-mediated 
regulation of the sarcolemmal NHE. In this regard, recent 
studies have revealed that the regulatory domain of NHE-1 is 
a substrate for p90rsk|7-27-28 and that phosphorylation of 
NHE-1 by p90rsk at Ser703 stimulates exchanger activity.27
Our finding that PKC inhibition by GF109203X also 
abolishes a,x-AR-mediated stimulation of sarcolemmal NHE 
activity supports earlier data from Wallert and Frohlich,3 who 
studied the effects on exchanger activity of the a,-AR agonist 
6-fluoronorepinephrine, and from studies with other GqPCR 
agonists, such as endothelin,4 thrombin,5 and angiotensin II.6 
In another pertinent study,14 however, GF109203X was 
shown not to inhibit phenylephrine-induced stimulation of 
sarcolemmal NHE activity. In that study,14 phenylephrine 
was used at a concentration of 100 /xmol/L, which is 10-fold 
greater than that used in our present work. Furthermore, this 
concentration is &80-fold greater than the EC*, value of 
phenylephrine for stimulation of sarcolemmal NHE activity13 
or phosphoinositide hydrolysis30 in adult rat ventricular 
myocytes and for translocation of PKCe in neonatal rat 
ventricular myocytes.20 To determine whether the difference 
in agonist concentration could account for the contrasting 
effects of GF109203X in our study and that by Puceat et al,14 
we carried out additional experiments with a 10-fold greater 
concentration (100 /xmol/L) of phenylephrine. In these ex­
periments, GF109203X failed to inhibit the stimulation of 
sarcolemmal NHE activity by phenylephrine, which in­
0_p9Orsk
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creased / H69 from 4.1±0.5 to 9.5±0.8 mmol • L"1 • min"1 
(P<0.05) when administered alone and from 3.5±0.6 to 
8.4±1.2 mmol • L"1 • min"1 CP<0.05) when administered 
after pretreatment with GF109203X (8 cells per group, from 
3 hearts). This suggests that in the presence of a supramaxi­
mal a r AR agonist concentration, non-PKC-mediated path­
ways may be sufficient to effect increased sarcolemmal NHE 
activity. However, with agonist concentrations that are likely 
to be of greater physiological relevance, PKC activation 
appears to be a necessary component of the pertinent signal­
ing pathways distal to the a^-AR.
The common ability of GF109203X and PD98059 to 
inhibit a 1A-AR-mediated stimulation of sarcolemmal NHE 
activity may suggest that PKC and ERK are proximal and 
distal components, respectively, of a contiguous NHE- 
regulatory signaling pathway. Indeed, our recent work in an 
identical system has shown that PKC and ERK1/2 participate 
in such a contiguous pathway in response to AT] receptor 
stimulation.6 In our present work, however, ERK activation 
by the a,-AR agonists was not prevented by GF109203X 
(Figure 4). This indicates that PKC and ERK1/2 mediate 
largely independent signaling pathways and that the activa­
tion of both pathways is necessary to achieve a,A-AR- 
mediated stimulation of sarcolemmal NHE activity. With 
regard to the inability of GF109203X to prevent ERK 
activation by o-i-adrenergic stimulation, it is notable that 
a lx-AR-mediated ERK activation has recently been reported 
to be PKC independent in PC 12 cells stably transfected with 
this receptor subtype.31 Furthermore, at a concentration of 
1 fimol/L, GF109203X has been shown to produce only 
marginal inhibition of endothelin-induced ERK activation in 
neonatal rat ventricular myocytes.21 This observation is sim­
ilar to our present findings in adult rat ventricular myocytes, 
in which the same concentration of GF109203X reduced the 
magnitude but did not prevent the occurrence of significant 
ERK activation by a,-adrenergic stimulation (Figure 4). We 
did not test higher concentrations of GF109203X because 
1 jumol/L was sufficient to abolish PMA-induced ERK 
activation (which confirms that it was sufficient to inhibit 
PKC-mediated responses) and due to concern for potential 
nonspecific effects.26
Significant ERK activation was achieved through the 
exposure of adult rat ventricular myocytes to PM A (Figure 5), 
which illustrates that PKC can function as a proximal 
activator of the ERK pathway in this cell type. However, our 
observation that GF109203X prevented ERK activation by 
PMA (Figure 5) but not that by phenylephrine or A61603 
(Figure 4) indicates that the PKC-mediated mechanism is not 
the major mechanism of ERK activation in response to 
aj-adrenergic stimulation. This contrasts with our recent 
findings regarding ERK activation via the AT! receptor6 and 
suggests the existence of receptor-specific differences in the 
role of PKC in G^PCR-mediated ERK activation.
In contrast to recent reports in neonatal rat ventricular 
myocytes21 and intact adult rat hearts,19 we found no activa­
tion of p38 in response to either ac,-AR agonist. This points 
toward a difference between neonatal and adult myocyte 
preparations in GqPCR-mediated regulation of p38 activity, 
although it is unclear whether this reflects a maturational
difference or arises from the maintenance of neonatal cells in 
culture. It should also be noted that in the earlier studies, 
neonatal myocytes21 or isolated hearts19 were exposed to 
100 pmol/L phenylephrine, which produced peak p38 activation 
after 10 minutes19-21 In contrast, in our study, myocytes were 
exposed to 10 pmol/L phenylephrine for 3 minutes (which was 
sufficient to stimulate the sarcolemmal NHE) before the assess­
ment of p38 activity. These differences in agonist concentration 
and duration of exposure may contribute to the distinct findings. 
Regardless of these issues, the inability of phenylephrine and 
A61603 to alter p38 activity in the present study precludes a role 
for the p38 pathway in NHE-regulatory signaling mechanisms 
distal to the a 1A-AR in adult rat ventricular myocytes.
Our results have shown that in isolated adult rat ventricular 
myocytes, a 1A-AR-mediated stimulation of sarcolemmal 
NHE activity requires activation of the ERK (but not the p38) 
pathway of the MAPK cascade. Activation of PKC is also 
required for this response, but PKC and ERK are independent 
regulators of NHE activity in response to a 1A-AR stimulation. 
Stimulation of NHE activity by the ERK pathway is likely to 
occur via activation of p90nk, which phosphorylates the 
exchanger at Ser703 and may alter its interaction with 
accessory proteins that regulate exchanger activity.27 Al­
though the mechanism through which PKC contributes to 
aIA-AR-mediated stimulation of NHE activity is unknown, 
PKC does not directly phosphorylate the regulatory domain 
of the exchanger,32 and altered phosphorylation of accessory 
proteins may play an important role. In view of the potential 
physiological and pathophysiological significance of a r  
adrenergic stimulation of sarcolemmal NHE activity, further 
work is required to fully characterize the relevant signaling 
pathways.
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SPECIAL REPORT
Adenosine Ai receptor stimulation inhibits ai-adrenergic activation 
of the cardiac sarcolemmal Na + /H + exchanger
^Metin Avkiran & ^iroyuki Yokoyama
'Centre for Cardiovascular Biology and Medicine, King’s College London, The Rayne Institute, St Thomas’ Hospital,
London SE1 7EH
Sarcolemmal Na+/H+ exchanger (NHE) activity is increased by stimulation of Gq protein-coupled 
receptors (GqPCRs), but the roles of other GPCRs are largely unknown. We determined the effects 
of N-[(lS,trans)-2-hydroxycyclopentyl]adenosinc (GR79236), a selective agonist of the GiPCR 
adenosine A| receptor, on sarcolemmal NHE activity in adult rat ventricular myocytes (n = 8-10 per 
group). NHE activity was indexed by the H + efflux rate after intracellular acidification, measured by 
microepifluorescence. GR79236 alone (0.01-10 fiM) had no effect on NHE activity. However, co­
administration of GR79236 inhibited, in a concentration-dependent manner, the stimulation of 
NHE activity by the ai-adrenoceptor agonist phenylephrine (10 /iM). The inhibitory effect of 
GR79236 (10 /iM) was abolished by (1) the selective A! antagonist l,3-dipropyl-8-cyclopentyl- 
xanthine (0.1 /iM), confirming an Aj receptor-mediated action, and (2) pre-treatment with pertussis 
toxin (5 fig ml-1 for 60 min), indicating a Gj protein-mediated mechanism. Our data suggest the 
existence of inhibitory crosstalk between the GiPCR adenosine A| receptor and the GqPCR o,- 
adrenoceptor in the regulation of sarcolemmal NHE activity.
British Journal o f Pharmacology (2000) 131, 659-662 
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Abbreviations: AR, adrenoceptor; CABG, coronary artery bypass graft; DPCPX, l,3-dipropyl-8-cyclopentylxanthine; GPCR, G 
protein-coupled receptor; NHE, Na+/H + exchanger; PARI, protease-activiated receptor 1
Introduction The sarcolemmal Na+/H+ exchanger (NHE) is 
the ubiquitously expressed product of the NHE1 gene (Fliegel 
& Dyck, 1995) and is an important H+ extrusion mechanism 
that contributes to the control of intracellular pH (pHi) in 
cardiac myocytes (Leem et al., 1999). Nevertheless, increased 
activity of the sarcolemmal NHE has been implicated in the 
development of myocardial injury and dysfunction during 
ischaemia and repcrfusion, and NHE1-selective pharmacolo­
gical inhibitors have been shown to be cardioprotective in this 
setting in numerous animal studies (Avkiran, 1999a). Recent 
clinical data suggest that one such inhibitor, cariporide, may 
provide cardioprotective benefit in patients with anterior 
myocardial infarction who receive early reperfusion by direct 
coronary angioplasty (Rupprecht et al., 2000) and in high-risk 
patients who undergo global myocardial ischaemia and 
reperfusion during coronary artery bypass graft (CABG) 
surgery (Theroux et al., 2000).
Sarcolemmal NHE activity is regulated primarily by pHj 
and increases markedly in response to intracellular acidosis 
(Leem et al., 1999); it is also subject to stimulation by agents 
that act via Gq protein-coupled receptors (GqPCRs), such as 
^-adrenoceptor (ar AR) agonists, endothelin, thrombin and 
angiotensin II (reviewed by Avkiran, 1999b). However, there is 
little known about the regulation of sarcolemmal NHE activity 
by receptors outside the GqPCR family.
Adenosine is an adenine nucleoside that has been shown to 
possess cardioprotective efficacy in animal models of 
myocardial ischaemia and reperfusion (Lasley & Mentzer, 
1996). The therapeutic potential of adenosine has also recently 
been tested in humans, as an adjunct to thrombolysis in 
patients with acute myocardial infarction (Mahaffey et al.,
1999) and as an additive to cardioplegia in patients undergoing
•Author for correspondence; E-mail: metin.avkiran@kcl.ac.uk
CABG surgery (Mentzer et al., 1999), with encouraging 
results. Although adenosine can potentially afford myocardial 
protection during ischaemia and reperfusion through the 
stimulation of multiple adenosine receptors in a variety of cell 
types, direct stimulation of myocardial A) receptors appears to 
be an important component of such protection (Lasley & 
Mentzer, 1996). Indeed, hearts from transgenic mice with 
cardiac-specific overexpression of the Ai receptor have been 
shown to exhibit reduced susceptibility to ischaemia and 
reperfusion-induced injury (Matheme et al., 1997). The 
mechanisms through which the myocardial AI receptor, which 
is a member of the GiPCR family, exerts protection are 
unclear.
Our recent work has shown that stimulation of another 
GiPCR, the angiotensin AT2 receptor, inhibits sarcolemmal 
NHE activation via the GqPCR angiotensin ATi receptor 
(Gunasegaram et al., 1999). The possibility exists that 
adenosine Ai receptors may also initiate signalling events that 
negatively regulate sarcolemmal NHE activity. Therefore, the 
present study was undertaken to determine the effects of 
adenosine Ai receptor stimulation by the selective agonist N- 
[(lS,trans)-2-hydroxycyclopentyI]adenosine (GR79236) (Gur- 
den et al., 1993) on sarcolemmal NHE activity, in the resting 
state and following GqPCR stimulation. Preliminary results of 
the study have been published in abstract form (Yokoyama & 
Avkiran, 2000).
Methods This investigation was performed in accordance 
with the Home Office ‘Guidance on the Operation of the 
Animals (Scientific Procedures) Act 1986’, published by 
HMSO, London.
Isolation of ventricular myocytes Ventricular myocytes were 
isolated from hearts of adult (200-250 g body weight) male 
Wistar rats (B&K Universal, Hull, U.K.) by enzymatic
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digestion, as previously described (Yasutake et al., 1996; 
Yokoyama et al., 1998; Gunasegaram et al., 1999; Snabaitis et 
al., 2000).
Determination of sarcolemmal NHE activity Sarcolemmal 
NHE activity was determined in single myocytes loaded 
with the pH-sensitive fluoroprobe cSNARF-1, using an 
established microepifluorescence technique (Yasutake et al., 
1996; Yokoyama et al., 1998; Gunasegaram et al., 1999; 
Snabaitis et al., 2000). Cells were superfused with 
bicarbonate-free Tyrode’s solution (34°C) throughout each 
experiment and the rate of acid efflux (JH) was used as the 
index of sarcolemmal NHE activity. JH was determined at 
an intracellular pH (pH) of 6.90 (Jm.9), during recovery 
from intracellular acidosis that was induced by transient 
exposure to NH4CI (see below).
Experimental protocols Myocytes were subjected to intracel­
lular acidosis by a 3-min exposure to 20 mmol/1 NH 4CI (first 
acid pulse), which was repeated 15 min later (second acid 
pulse) (Yasutake et al., 1996; Yokoyama et al., 1998; 
Gunasegaram et al., 1999; Snabaitis et al., 2000). In control 
cells, both acid pulses occurred in the absence of any drug. 
When studying the effects of GR79236 (gift from GlaxoWell- 
come, Stevenage, U.K.) alone, this was present during the 
second acid pulse. When studying the effects of GR79236 on 
the response to phenylephrine or thrombin (both from Sigma, 
Poole, U.K.), the G„PCR agonist was given during the second 
acid pulse and GR79236 was present from 6 min before this 
pulse. l,3-Dipropyl-8-cyclopentylxanthine (DPCPX; Sigma), 
when used, was given concomitantly with GR79236. Stock 
solutions of drugs, except DPCPX, were dissolved in deionized 
water and were diluted (>1000 fold) in Tyrode’s solution to 
obtain appropriate final concentrations; the DPCPX stock 
solution was dissolved in dimethylsulphoxide (final concentra­
tion 0.005%). Phenylephrine solutions contained 1 pM 
atenolol (Sigma), to preclude ,^-AR-mediated actions (Yo­
koyama et al., 1998). When required, cells were pre-treated 
with 5 pg ml-1 pertussis toxin (Sigma) for 60 min, in order to 
inactivate Gj proteins (Obayashi et al., 1997).
Statistical analysis Data are expressed as mean + s.e.mean. 
Each protocol comprised 4 -8  study groups and experiments 
within it were carried out in a randomized manner (r» = 8-10  
myocytes per group, obtained from 5-15 hearts). For inter­
group comparison of the changes in JH6.9 (AJH6 9) in response 
to vehicle or drug(s), data were subjected to ANOVA; if a 
significant difference was found, further analysis was by 
Dunnett’s test, to compare each treatment group with the 
control group. P<0.05 was considered significant.
Results Effects of GR79236 alone JH69 values during 
recovery from the first acid pulse in control cells and in those 
that received 0.01, 0.1, 1 or 10 pM GR79236 (n = 10 cells per 
group, from 10 hearts) were 3.56 + 0.31, 3.28±0.45, 
3.71+0.70, 4.36±0.77 and 3.06±0.41 mM min- ', respec­
tively (NS). There was no significant change in 7H6.9 during 
the second acid pulse in any group, with A7H6.9 values of 
13±19, 18± 25, 13± 20, 4 + 12 and 10±31%, respectively 
(NS). These findings indicate that acute exposure to GR79236 
does not significantly affect sarcolemmal NHE activity in the 
resting state.
Effects of GR79236 on the response to phenylephrine We next 
determined whether exposure to GR79236 affects the 
stimulation of sarcolemmal NHE activity by phenylephrine.
■7h6.9 values during the first acid pulse did not differ 
significantly between the eight study groups (n = 10 cells per 
group, from 15 hearts) and were as follows: 
3.18±0.48 mM min-1 in control cells; 3.21 ±0.44 mM min- ' 
in cells that received phenylephrine (10 pM) alone; 2.5±0.29, 
2.78±0.50, 2.73 + 0.69 and 3.33+0.27 mM min-1, respec­
tively, in cells that received phenylephrine (10 pM) in 
combination with 0.01, 0.1, or 10 pM GR79236; 3.80+0.69 
and 3.13±0.49 mM min-1, respectively, in cells that received 
1 or 10 pM GR79236 alone. Figure 1 illustrates the A7H6.9 
values in these groups. Consistent with our earlier findings 
(Yokoyama et al., 1998; Snabaitis et al., 2000), phenylephrine 
alone produced a large and significant increase in sarcolemmal 
NHE activity. GR79236 inhibited the NHE-stimulatory effect 
of phenylephrine in a concentration-dependent manner, such 
that the arAR agonist no longer produced a significant 
increase in NHE activity when given in combination with 1 or 
10 pM GR79236. Once again, 1 or 10 jtM GR79236 alone 
failed to produce a significant change in sarcolemmal NHE 
activity. These data indicate that exposure to GR79236 inhibits 
oq-AR-mediated stimulation of sarcolemmal NHE activity.
Reversal of the inhibitory effect of GR79236 by DPCPX In 
order to confirm that the inhibitory effect of GR79236 on the 
ai-adrenergic response was mediated via the A] receptor, 
rather than through a non-specific action, we tested the 
reversibility of this effect by the selective A| receptor 
antagonist DPCPX. yH6.9 values during the first acid pulse did 
not differ significantly between the five study groups (n = 9 cells 
per group, from seven hearts) and ranged between 2.48+0.44 
and 3.08±0.30 mM min-1. Figure 2 illustrates the AJH6.9 
values. As expected, 10 pM phenylephrine produced a 
significant increase in NHE activity and this response was 
again abolished when phenylephrine was given in combination 
with 10 p u  GR79236. However, when GR79236 was given 
concomitantly with 0.1 pM DPCPX, the A, agonist was no 
longer able to inhibit a,-AR-mediated stimulation of 
sarcolemmal NHE activity. DPCPX alone was without effect. 
These findings confirm that the inhibitory effect of GR79236 
on ai-adrenergic stimulation of sarcolemmal NHE activity was 
mediated via the Aj receptor.
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Figure 1 The change in H+ efflux rate at pHj 6.90 (AJH6 9) in the 
control group and in response to phenylephrine (PHE) and GR79236 
(GR), alone or in combination. Tlie protocol comprised 80 myocytes 
(w = 10 per group) obtained from 15 hearts. *P<0.05 vs control.
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Figure 2 The change in H+ efflux rate at pHj 6.90 (A/ H6 9) in the 
control group and in response to phenylephrine (PHE), GR79236 
(GR) and l,3-dipropyl-8-cyclopentylxanthine (DPCPX), alone or in 
combination. The protocol comprised 45 myocytes (n=9 per group) 
obtained from seven hearts. *P<0.05 vs control.
Reversal of the inhibitory effect of GR79236 by pertussis 
toxin In order to probe the signalling mechanisms distal to 
the Ai receptor that mediate the inhibitory effect of GR79236, 
we examined the consequences of inactivating the Gj protein, 
by a 60-min pertussis toxin pre-treatment. JH69 values during 
the first acid pulse were similar between the eight study groups 
(n = 8 cells per group, from 14 hearts) within this protocol and 
ranged between 2.81 ±0.47 and 3.30+0.40 mM min-1. Figure 
3 illustrates the A/H6.s values. Our observations in cells pre-' 
treated with vehicle for 60 min were essentially identical to 
those illustrated in Figure 1; 10 pM phenylephrine significantly 
increased sarcolemmal NHE activity and this response was 
abolished by 10 pM GR79236 (Figure 3, top panel). In 
contrast, in cells pre-treated with pertussis toxin for 60 min, 
10 pu  GR79236 was no longer able to inhibit the stimulation 
of sarcolemmal NHE activity by 10 pM phenylephrine (Figure 
3, bottom panel). It appears therefore that Gj protein 
activation is a critical step in the signalling mechanisms 
downstream of the A! receptor that mediate the inhibitory 
effect of GR79236 on oq-adrenergic stimulation of sarcolem­
mal NHE activity.
Effects of GR79236 on the response to thrombin Finally, we 
determined whether GR79236 could inhibit the stimulation of 
sarcolemmal NHE activity by another GqPCR agonist, namely 
thrombin (Yasutake et al., 1996). In this protocol also, 6.» 
values during the first acid pulse were similar between the four 
study groups (range from 3.75±0.75 to 4.13 ±0.71 mMmin-1; 
n = 8 cells per group, from five hearts). As expected from our 
earlier work (Yasutake et al., 1996), relative to control (AJH6.9 
14 + 19%), 5 u ml-1 thrombin significantly increased sarco­
lemmal NHE activity (A/H6.9 126±34%); however, this 
response was attenuated by 1 pM GR79236 (AJH6.9 50 ±22%) 
and abolished by 10 pM GR79236 (AJH6.9 26±16%). These 
data suggest that GR79236 can inhibit the stimulation of 
sarcolemmal NHE activity by multiple GqPCR agonists.
Discussion Although the anti-/?radrenergic effect of adeno­
sine Aj receptor stimulation (thought to be mediated primarily 
through a Gj protein-mediated reduction in adenylyl cyclase 
activity) is well established, the present data represent the first 
demonstration of an anti-a,-adrenergic effect of A! receptor 
stimulation in cardiac myocytes. Specifically, our data have
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Figure 3 The change in H+ efflux rate at pH; 6.90 (A/H69) in the 
control group and in response to phenylephrine (PHE) and GR79236 
(GR), alone or in combination. The protocol comprised 64 myocytes 
(n = 8  per group) obtained from 14 hearts. The cells were pre-treated 
for 60 min with either vehicle (lop panel) or S pg ml pertussis 
toxin (PTX; bottom panel). *P<0.05 vs control.
shown that the Ai agonist GR79236 inhibits oci-adrenergic 
stimulation of sarcolemmal NHE activity, a response that is 
mediated via the aIA-AR (Yokoyama et al., 1998). The 
inhibitory effect of GR79236 occurs via stimulation of the A) 
receptor (based on its reversibility by the Ai antagonist 
DPCPX) and requires a functional Gj protein (based on its 
abolition following pertussis toxin pre-treatment). Importantly, 
the effect was not limited to inhibition of the aradrenergic 
response, since GR79236 also inhibited the stimulation of 
sarcolemmal NHE activity by thrombin, a response that is 
mediated by the thrombin receptor (Yasutake et al., 1996), now 
termed protease-activated receptor 1 (PARI). Since both the 
o£iA-AR and PARI are members of the GqPCR family, our data 
suggest the existence of a novel inhibitory crosstalk mechanism 
between the GiPCR adenosine A! receptor and multiple 
GqPCRs, at least in rat ventricular myocytes. If confirmed, 
such a mechanism may have implications beyond the regulation 
of sarcolemmal NHE activity.
In view of the important role that sarcolemmal NHE 
activity is believed to play in the development of myocardial 
injury and dysfunction during ischaemia and reperfusion 
(Avkiran, 1999a), inhibition of GqPCR-mediated NHE 
activation is likely to contribute to the mechanisms underlying 
the cardioprotective effects of adenosine A! receptor stimula­
tion, by GR79236 (Louttit et al., 1999) and other interventions 
(Lasley & Mentzer, 1996). However, during ischaemia and 
reperfusion, sarcolemmal NHE activity may be stimulated not 
only by a variety of endogenous mediators (e.g. catechola­
mines, thrombin, endothelin) that act via GqPCRs, but also by 
factors such as oxidant stress and exposure to lipid metabolites 
(Avkiran, 1999b). Therefore, it would be of interest to
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determine whether Aj receptor stimulation attenuates the 
stimulation of sarcolemmal NHE activity by these additional 
factors.
Of relevance to the present work, increased sarcolemmal 
NHE activity and consequent increases in pHj and/or 
intracellular [Na+] have been suggested also to be causally 
involved in the positive inotropic and hypertrophic con­
sequences of myocardial arAR stimulation. In the light of 
our data, it is reasonable to expect that adenosine A] receptor 
stimulation may attenuate these effects. Indeed, there is 
preliminary evidence that, in rat ventricular myocytes 
stimulated at 0.5 Hz, GR79236 inhibits the positive effects of 
phenylephrine on (1) cell shortening under normal conditions, 
and (2) the recovery of cell shortening following intracellular 
acidosis (P. Krishnan and J.C. Kentish, King’s College 
London, personal communication).
Our data suggest that the inhibitory effect of adenosine Aj 
receptor stimulation on the oti-adrenergic response is mediated 
via the Gj protein. However, the relevant mechanisms that are 
downstream of G( protein activation are unclear. In view of the 
inability of GR79236 to significantly reduce NHE activity 
when given alone (e.g. Figures 1 and 3), the inhibitory effect is 
unlikely to reflect functional antagonism through an indepen­
dent signalling pathway. Rather, it appears that Aj receptor 
stimulation may initiate events that interfere with the NHE-
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R. S. H aw orth , M. W. Goss, E. R ozengurt and M. A vkiran . Expression and Activity of Protein Kinase D/Protein 
Kinase Cp in Myocardium: Evidence for o -^Adrenergic Receptor- and Protein Kinase C-Mediated Regulation. 
Journal of Molecular and Cellular Cardiology (2000) 32, 1013-1023. Protein kinase D (PKD), which is also known 
as protein kinase C (PKC) p, is a novel serine/threonine kinase that can be activated in parallel with or downstream 
of PKC in various cell types, but its expression and regulation in myocardium have not been characterized. In 
the present study, two proteins of 110 and 115 kDa were detected in rat ventricular myocardium using antibodies 
directed at the extreme N- or C-terminus of PKD. Both proteins were highly expressed in the fetal heart but 
showed a developmental decline in abundance. Fractionation studies showed that PKD was distributed between 
myocyte and non-myocyte fractions in the neonatal heart, but was found predominantly in the non-myocyte 
fraction in the adult heart. In cultured neonatal rat ventricular myocytes, an in vitro kinase assay revealed 
increased autophosphorylation of PKD (EC50 2.8 d m ) in response to phorbol-12-myristate-l3-acetate (PMA). 
Exposure to norepinephrine also induced a dose-dependent increase in PKD autophosphorylation (EC50 0.6 pM). 
Pretreatment with the ( -^adrenergic receptor (AR) antagonist prazosin blocked norepinephrine-induced PKD 
autophosphorylation, while the fa-AR antagonist atenolol had no effect, indicating that activation of PKD by 
norepinephrine occurred via the 0C]-AR. Involvement of the a,-AR was confirmed by exposure of myocytes to the 
otj-AR agonist phenylephrine, which induced a similar profile of PKD autophosphorylation to norepinephrine 
(EC50 0.6 p m ) .  The effects of both aj-AR stimulation and PMA on PKD autophosphorylation were mediated by 
PKC, since these effects could be attenuated by pretreatment of myocytes with the PKC inhibitor bi- 
sindolylmaleimide. These data show that PKD is expressed in rat ventricular myocardium, where its expression 
is subject to developmental control, and that PKD activity in ventricular myocytes is regulated through ot]-AR- 
and PKC-mediated pathways. © 2000 Academic Press
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Introduction
Gq protein-coupled receptor (GqPCR)1 signaling 
pathways, which commonly involve activation of 
protein kinase C (PKC),1 have been implicated in 
adaptive and maladaptive responses of myocardium 
to stress and injury (see recent review by Dorn 
and Brown, 19992). Consistent with this, directly 
increasing myocardial PKC activity by molecular 
means is sufficient to induce hypertrophy3 and 
improve resistance to simulated ischemia* in cul­
tured neonatal rat ventricular myocytes, and to 
produce cardiomyopathy in transgenic mice.5 Fur­
thermore, PKC-mediated pathways have been im­
plicated in the neurohumoral induction of myocyte 
hypertrophy6,7 and regulation of other important 
physiological and pathophysiological processes in 
myocardium, such as sarcolemmal ion transport 
(e.g. by ion exchangers8,9 and channels10"12), con­
tractility13,14 and protein synthesis.15 Despite the 
apparent importance of PKC signaling in myo­
cardium, however, the downstream targets of PKC 
in myocytes remain incompletely characterized.
Protein kinase D (PKD) is a recently identified 
serine/threonine kinase16 which has distinct struc­
tural and enzymatic properties and is found in most 
tissues (see review by Rozengurt et al.17). PKD, 
which is also known as protein kinase C/i,18 has a 
catalytic domain that is distantly related to Ca2+- 
regulated kinases and shows little similarity to the 
highly conserved regions of the kinase subdomains 
of the PKC family. Consistent with this, PKD does 
not phosphorylate a variety of substrates utilized 
by PKCs,16,19 indicating that PKD is a protein kinase 
with distinct substrate specificity. The N-terminal 
region of PKD contains a tandem repeat of cysteine- 
rich motifs which bind phorbol esters with high 
affinity16,19 and immunopurified PKD is stimulated 
in vitro by either diacylglycerol or biologically active 
phorbol esters in the presence of phosphat- 
idylserine.19 More recently, a second mechanism of 
PKD activation has been identified, which involves 
phosphorylation of PKD via a PKC-dependent 
pathway.20 The finding that PKD can be activated 
in parallel with or downstream of PKC raises 
the possibility that some cellular responses that 
arise from PKC activation may be mediated by 
PKD.
In view of the potential importance of PKC/PKD 
signaling in the heart, in the present study we have 
(i) determined the expression of PKD in ventricular 
myocardium and in myocyte and non-myocyte frac­
tions during development of the rat heart, and (ii) 
examined the regulation of PKD activity in primary 
cultures of neonatal rat ventricular myocytes,
in particular by adrenergic receptors (ARs) and 
PKC-mediated pathways.
Methods
Animals and  m aterials
Wistar rats (adult males, late term pregnant females, 
and 1 -2 -day-old neonates of mixed sex) were pur­
chased from B&K Universal (Hull, UK). The in­
vestigation was performed in accordance with the 
Home Office Guidance on the Operation of the Animals 
(Scientific Procedures) Act, 1986, published by 
HMSO, London. [y-32P]-ATP (370 MBq/ml), ECL re­
agent, PVDF membrane and protein A sepharose 
were from Amersham Pharmacia Biotech (Little 
Chalfont, UK). Phorbol-12-myristate-l 3-acetate 
(PMA), phenylephrine and norepinephrine were 
from Sigma Aldrich (Poole, UK). Bis- 
indolylmaleimide I was from Calbiochem (Not­
tingham, UK).
Preparation of card iac  m yocytes
Ventricular myocytes were isolated from the hearts 
of neonatal and adult rats using collagenase-based 
enzymatic digestion techniques, as previously de­
scribed.8,21 Adult hearts were excised and perfused 
(3 7 °C) in the LangendorfT mode for three sequential 
periods, as follows: (i) 5 min with Tyrode solution 
containing NaCl (137 m M ) ,  KC1 (5.4 m M ) ,  CaCl2 
(1.8 m M ) ,  MgCl2 (0.5 m M ) ,  N-2-hydroxy- 
ethylpiperazine-N/-2-ethanesulfonic acid (HEPES; 
10 m M ) ,  glucose (10 m M ) ,  adjusted to pH 7.4 with 
NaOH, (ii) 5.5 min with nominally Ca2+-free Tyrode 
solution containing NaCl (135 m M ) ,  KC1 (5.4 m M ) ,  
NaH2P04 (0.33 h i m ) . MgCl2 (1.0 m M ) ,  HEPES 
(10 m M ) ,  glucose (10 m M ) ,  adjusted to pH 7.2 with 
NaOH, (iii) 10 min with nominally Ca2+-free Tyrode 
solution containing collagenase (Worthington Type 
1, 200U/ml), and (iv) 5 min with storage buffer 
containing KOH (78 m M ) ,  KC1 (30 m M ) ,  KH2P04 
(30 m M ) ,  MgS04 (3 m M ) ,  ethylene glycol-bis (/?- 
aminoethyl ether)-N,N,N',N'-tetraacetic acid 
(EGTA; 0.5 m M ) ,  HEPES (10 m M ) ,  glutamic acid 
(50 m M ) ,  taurine (20 m M ) ,  glucose (10 m M ) ,  
adjusted to pH 7.2 with KOH. All solutions were 
gassed with 100% 0 2. After the perfusion procedure, 
the heart was removed from the cannula, and the 
atria and non-ventricular tissue carefully trimmed 
away. The tissue fragments were gently agitated in 
storage buffer to disperse ventricular cells. The cells
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were subsequently filtered through a 40 fim  mesh 
filter to remove undissociated tissue, pelleted by 
centrifugation (600 g for 7 min) and resuspended 
in plating medium (68% DMEM, 17% M199, 15% 
fetal calf serum (FCS), 100 units/ml penicillin and 
100 /xg/ml streptomycin). To separate myocytes 
from non-myocytes, the suspension was incubated 
in tissue culture dishes in a C02 incubator for 
1 h. The unattached myocytes were removed and 
collected by centrifugation. The non-myocytes at­
tached to the dish were washed twice with plating 
medium, and incubated for 4 days prior to har­
vesting.
Neonatal myocytes were prepared from 2-day- 
old animals as follows. The hearts from 24 animals 
were excised, the atria trimmed off and the vent­
ricles cut into small pieces. Tissue was incubated 
with mixing for 20 min at 37°C in a solution 
containing collagenase (112U/ml), pancreatin 
(5 mg/ml), NaCl (117 him), HEPES (20 him). 
NaH2P04 (0.87 mM), glucose (5.6 mM), KC1 
(5.4 mM) and MgS04 (1 mM), adjusted to pH 7.4 
with NaOH. Intact tissue was allowed to settle, and 
the dispersed cells were removed and added to 2 ml 
FCS. A further four incubations with collagenase 
solution were performed. The cells were sedimented 
at 600 g for 6 min, pooled, filtered, sedimented and 
resuspended in plating medium. Again, myocytes 
were enriched by the differential plating method, 
with the non-myocyte fraction being cultured for 
4 days prior to harvesting. For studies with cultured 
neonatal myocytes, the enriched myocyte pre­
paration (90-95% myocytes, as determined by cell 
morphology) was cultured in 6-well plates for 2 -3  
days. Cells were transferred to serum-free medium 
24 h prior to experiments.
Protein preparation
For whole ventricle studies, the hearts were rapidly 
excised and rinsed in ice-cold PBS. After the atria 
and connective tissue were trimmed away, the 
ventricles were mechanically homogenized in a lysis 
buffer containing 50 mM Tris/HCl (pH 7.5), 2mM 
EGTA, 2 mM EDTA, 1 mM DTT, 10 fig/ml aprotinin, 
10 fig/m\ leupeptin, 1 mM 4-(2'-aminoethyl)-benz- 
enesulfonyl fluoride hydrochloride and 1% Triton 
X-100. Cell debris was removed by centrifugation 
at 10 000 g for 30 min. Cultured neonatal and adult 
non-myocytes, cultured neonatal myocytes and 
freshly isolated adult myocytes were washed three 
times with ice-cold PBS and lysed in 100 /d of the 
lysis buffer described above.
W estern blots
After tissue/cell lysis, protein samples (15 fig) were 
subjected to SDS-PAGE on 7.5% acrylamide gels, 
and transferred to PVDF membrane using a Phar­
macia LKB Multiphor II transfer apparatus. Mem­
branes were probed for the presence of PKD using 
polyclonal antibodies against the N-terminus (sc- 
638; amino acids 6-25; Santa Cruz Biotechnology, 
Inc., Santa Cruz, California, USA) or the C-terminus 
(sc-935; amino acids 893-912; Santa Cruz Bio­
technology, Inc.), or with a mouse monoclonal 
antibody against a central domain (P26720; amino 
acids 314-517; Transduction Laboratories, Lex­
ington, USA). In some experiments, antibody sc- 
935 was preincubated with immunizing peptide sc- 
9 3 5P for 30 min on ice prior to Western blotting. 
Donkey anti-rabbit and sheep anti-mouse horse­
radish peroxidase-conjugated antibodies (Amer- 
sham) were used at a dilution of 1:2000 to label 
bound antibody, and the antibody complex was 
detected using the Amersham ECL system, as re­
commended by the manufacturer.
In vitro k inase  a ssa y s
PKD was immunoprecipitated from tissue or cell 
lysates at 4 °C for 2 h with the PA-1 anti-peptide 
serum (1:100 dilution). PA-1 was raised against 
the synthetic peptide EEREMKALSERVSIL, which 
corresponds to amino acids 904-918  of PKD, as 
described previously.16 Immune complexes were re­
covered by the addition of 30 /d protein A-sepharose 
(100 mg/ml), and pellets were washed three times 
with lysis buffer and three times with assay buffer 
[30 mM Tris/HCl (pH 7.5), 10 mM MgCl2 and 1 mM 
DTT]. The final pellet was resuspended to a total 
volume of 40 ft1 with assay buffer. To initiate the 
phosphorylation reaction, 10 //I of phosphorylation 
mix (assay buffer containing 100 /zm /y-32P]-ATP; 
4 00 -600  cpm/pmol) was added. The mixture was 
incubated at 30 °C for 5 min, and the reaction 
terminated by the addition of hot SDS-PAGE sample 
buffer. After boiling for 5 min, the samples were 
subjected to SDS-PAGE. Gels were dried, subjected 
to autoradiography and 32P incorporation was 
quantified from autoradiographs (digitized with a 
Hewlett Packard ScanJet lie flatbed scanner) using 
NTH Image software (version 1.59).
In one set of experiments, in vitro phos­
phorylation of the peptide syntide-2 (PLAR- 
TLSVAGLPGKK) was determined as an additional 
index of PKD activity.16 For this study, syntide-2 
(2.5 mg/ml) was added to the phosphorylation
185
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mix. After incubation for 5 min, the reaction was 
terminated by adding 100 fA of ice-cold 75 mM 
H3PO4, and 100 /d of the reaction mix was spotted 
onto P-81 phosphocellulose paper. Free [y-32P]- 
ATP was removed by washing the P-81 paper 
four times for 5 min in 75 mM H3P04. The 
radioactivity incorporated into syntide-2 was de­
termined by Cerenkov counting.
Pharmacology protocols
Cells were maintained in 1 ml serum-free medium 
for 24 h prior to experiments with an adrenergic 
agonist (norepinephrine or phenylephrine) or 
PMA. The adrenergic agonist or PMA was added 
in 1 ml of serum-free medium 20 min prior to 
harvesting of cells. Where appropriate, bis- 
indolylmaleimide or an adrenergic antagonist (pra­
zosin or atenolol) was added 5 min prior to the 
adrenergic agonist or PMA, and was present until 
harvesting of cells.
Results
PKD is p resen t in the  ra t heart, and is sub ject to 
developm ental regulation
Western analysis of protein from ventricular tissue 
of fetal, neonatal and adult rat hearts revealed the 
presence of PKD in all samples (Fig. 1A). A distinct 
decline in the amount of immunoreactive protein 
was observed with increasing age. Interestingly, 
two immunoreactive bands (at 110 and 115kDa) 
were detected by polyclonal antibodies raised 
against the extreme N-terminus (sc-638) or the 
extreme C-terminus (sc-935). as well as by a mono­
clonal antibody (P26720) directed against the cent­
ral domain of PKD (Fig. 1A). Both bands were lost 
when sc-935 was preincubated with the im­
munizing peptide (Fig. 1A), confirming the speci­
ficity of the antibody. In contrast to our findings in 
rat ventricular myocardium, mouse PKD expressed 
in transiently-transfected COS-7 cells was detected 
as a single immunoreactive protein of 115 kDa (Fig. 
IB).
Basal PKD activity in ventricular tissue from 
neonatal and adult rat hearts was assessed by an 
in vitro kinase assay following immunoprecipitation, 
using autophosphorylation as the indicator of ac­
tivity.19 The 110 and 115 kDa forms were both 
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Figure 1 PKD expression and activity in the  developing 
ra t heart. A: R epresentative W estern blots (n = 3 )  of 
protein from fetal (F), n eonatal (N) and adult (A) ra t 
hearts using the  antibodies sc-638 (recognizes aa  6 -2 5 ) , 
P 2 6 7 2 0  (recognizes a a  3 1 4 -5 1 7 ) , and  sc-935 (re­
cognizes aa  8 9 3 -9 1 2 ) , and  th e  la tte r e ither alone or 
following p re incubation  w ith  th e  im m unizing peptide sc- 
935P, as indicated. B: Representative W estern blot (n =  
3) of protein from COS-7 cells transfected w ith  m ouse 
PKD cDNA (M) and  fetal ra t h ea rt (F), using sc-935 
antibody. C: R epresentative au to rad iogram  (n =  4) of PKD 
au tophosphorylation  after im m unoprecip itation  from 
neonatal (N) and  adu lt (A) ra t hearts. A uto­
phosphorylation  w as assessed by an  in vitro kinase assay 
(IVK), as described in M ethods.
both forms incorporated 32P (Fig. 1C). Greater ac­
tivity was observed in neonatal myocardium, con­
sistent with the greater abundance of PKD protein 
in these samples.
To determine the presence of PKD in different 
cardiac cell types, fractionation of myocytes and 
non-myocytes was performed in both neonatal and 
adult rat ventricular tissue. Western blotting of 
equal quantities of protein with the sc-93 5 antibody 
revealed the presence of PKD in each fraction (Fig. 
2A). PKD appeared to be more abundant in neonatal 
myocytes than in adult myocytes, since long ex­
posures were required to detect PKD in adult myo­
cytes (not shown). PKD was readily detectable in
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Figure 2 Tissue distribution of PKD in the ra t. A: Rep­
resentative W estern blot (n =  2) of equal am ounts of 
protein (15 /rg) from m yocyte (M) and non-m yocyte (NM) 
fractions and w hole venticles (V) of neonatal and adu lt ra t 
hearts, using sc-935 antibody. B: Representative W estern 
blot (n =  4) of protein from equal num bers of neonatal 
and adult myocytes (60  0 0 0  cells/lane), using sc-935 
antibody. C: R epresentative W estern blot (n = 2 )  of equal 
am ounts of protein (15 /rg) from  n eonata l (N) and adult 
(A) tissues, using sc-935 antibody.
the non-myocyte fractions of both neonatal and 
adult samples. When protein samples from equal 
numbers of myocytes (60 000 cells/lane) were used, 
again PKD was more abundant in neonatal myo­
cytes than in adult myocytes (Fig. 2B). Interestingly, 
in the adult cells, PKD was detected almost ex­
clusively as an immunoreactive protein of 115 kDa 
(Fig. 2B).
To characterize the expression of PKD in different 
tissues of the rat, we also carried out a comparative 
Western analysis of protein from liver, lung, kidney 
and brain. As shown in Figure 2C, PKD was present 
in all four tissues, with a developmental decline in 
PKD protein expression, as in the heart.
PKD is activated by PMA in cultured neonatal myocytes
Activation of PKD by phorbol ester is well es­
tablished in other cell types.1619,20 To determine 
whether PKD is activated by PMA in cardiac myo­
cytes, we used a cultured neonatal myocyte pre­
paration. Cells were incubated in serum-free 
medium for 24 h prior to treatment with PMA, 
since preliminary experiments showed that PKD 
was activated by serum (data not shown). In vitro 
kinase assays revealed a concentration-dependent 
increase in 32P incorporation into PKD in response to 
PMA (Fig. 3A). Maximal PKD autophosphorylation 
was seen at 100 nM PMA, with an ECS0 of 2.8 nM 
(Fig. 3B).
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Figure 3 PMA activates PKD in cultured  neonatal 
myocytes. A: Representative au to rad iogram  (n =  8) 
show ing PKD autophosphory lation  follow’ing exposure 
of cells to various concen trations of PMA for 2 0  m in 
prior to cell lysis and  PKD im m unoprecip itation . B: 
C oncentration-dependent effects of PMA on UP in ­
corporation  in to  PKD. A utophosphorylation  u>as as­
sessed by an in vitro kinase assay (IVK), as described 
in M ethods. D ata a re  expressed as percentage of the 
control (vehicle) v a lue  (n =  8).
PKD is activated by norepinephrine in cultured neonatal 
myocytes
In the light of the data obtained with PMA, we 
next determined whether a physiological stimulus 
could also activate PKD in neonatal myocytes. 
Exposure to norepinephrine for 20 min prior to 
cell lysis increased 32P incorporation into PKD 
in a concentration-dependent manner (Fig. 4A), 
indicating activation of the kinase. The maximal 
increase in PKD autophosphorylation occurred 
with 100 /xM norepinephrine, but measured only 
3-4-fold over control (Fig. 4B), compared with 
approximately 16-fold in response to PMA (Fig. 
3B). The EC50 for norepinephrine was 0.6 / i m .  
The concentration-response profile of PKD au­
tophosphorylation was mimicked by the con­
centration-response profile of syntide-2 
phosphorylation, which was used as an additional 
index of PKD activity (Fig. 4B), confirming that 
PKD autophosphorylation status accurately reflects 
PKD activity in cultured neonatal myocytes.
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Figure 4 N orepinephrine  activates PKD in cultured  neo­
n a ta l m yocytes. A: R epresentative  au to rad iogram  (n =  
6) show ing PKD au tophosphory la tion  following exposure 
of cells to various c o n cen tra tio n s  of norepinephrine or 
PMA for 2 0  m in  p rio r to  cell lysis and PKD im­
m unoprecip ita tion . B: C oncen tration-dependen t effects of 
norep inephrine on  3’P inco rpo ra tion  into PKD (solid bars) 
and syntide-2 (ha tched  bars). A utophosphory lation  and 
syntide-2 phosphory lation  w’ere bo th  assessed by an  in 
vitro kinase assay  (IVK), as described in M ethods. Data 








NE (pM) 0 








10 0 10 0 
100 100 0 0 
0 0 1 1
Figure 5 N orepinephrine-induced activation of PKD in 
cu ltu red  neo n ata l m yocytes is inhibited by a !-adrenergic 
receptor an tagon ist. Effects of norepinephrine on 32P 
incorporation  into PKD in the  absence (solid bars) or 
presence of th e  a,-A R an tagon ist prazosin (hatched bars) 
o r the  /?,-AR a n tagon ist atenolol (stippled bars). D ata are 
expressed as percentage of the  contro l (vehicle) value 
(n =  4 -1 0 ) . N orepinephrine was p resent for 2 0  m in prior 
to  cell lysis an d  PKD im m unoprecipitation, and each 
an tagon ist w as p resen t for 5 m in  p rior to and  during  
norep inephrine exposure. * P < 0 .0 5  v contro l (open bar).
Norepinephrine activates  PKD via a , adrenergic 
receptors in cultured neonatal m yocytes
To determine whether norepinephrine-induced ac­
tivation of PKD occurs via ar  or /?,-ARs, we next 
tested the effects of the ar AR-selective antagonist 
prazosin and the /?]-AR-selective antagonist at­
enolol on this response. Prazosin (100 nM) or at­
enolol (1 pM) alone had little effect on PKD activity 
(Fig. 5). Atenolol also had no significant effect on 
PKD activation by norepinephrine, but prazosin 
inhibited this response in a concentration-de­
pendent manner (Fig. 5). This finding suggests that 
norepinephrine activates PKD selectively via oij- 
ARs in cultured neonatal myocytes.
Phenylephrine activates  PKD in cultured neonatal 
myocytes
To confirm that a,-AR stimulation is sufficient to 
activate PKD in cultured neonatal myocytes, we 
also tested the effects of the a,-AR-selective agonist 
phenylephrine. Phenylephrine induced a pattern of
500
o
0 0.1 0.3 1 3 10 30
[phenylephrine] (pM)
Figure 6  P henylephrine activates PKD in cultured  neo­
na ta l m yocytes. C oncentration-dependent effects of the  
otj-AR agon ist phenylephrine on 32P incorporation  Into 
PKD. D ata are  expressed as percentage of th e  control 
(vehicle) va lue  (n = 1 0 ) .
PKD activation similar to that seen with no­
repinephrine, with an EC50 of 0.6 pM (Fig. 6). The 
maximal increase in PKD autophosphorylation was
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once again 3-4-fold, which is similar to that seen in 
response to norepinephrine. These findings confirm 
that PKD is activated via ar AR stimulation in 
cultured neonatal myocytes.
PKD activation in cultured neonatal myocytes is 
m ediated by PKC
In vivo activation of PKD by phorbol ester in 
other cell types has been shown to involve direct 
phosphorylation of PKD by PKC.20,22 To determine 
whether phorbol ester-induced activation of PKD 
in cardiac myocytes occurs via a PKC-dependent 
pathway, we determined the effects of the PKC 
inhibitor bisindolylmaleimide on the PMA re­
sponse. As shown in Figure 7A, there was marked 
32P incorporation into PKD following exposure to 
PMA (lane 1). However, when cells were incubated 
with bisindolylmaleimide prior to and during 
exposure to PMA, PKD autophosphorylation was 
significantly reduced (lane 2). Importantly, ex­
posure to bisindolylmaleimide in vitro (i.e. after 
PKD immunoprecipitation) had no effect on PKD 
autophosphorylation (lane 3), precluding a direct 
effect of bisindolylmaleimide on PKD activity.
To further characterize the role of PKC in the 
phorbol ester-induced response and to determine 
the involvement of PKC signaling in oej-AR- 
mediated activation of PKD, we then quantified 
the effects of bisindolylmaleimide on the responses 
to phenylephrine and PMA. As shown in Figure 
7B, exposure of control cells to bisindolylmaleimide 
led to a decrease in basal PKD activity, suggesting 
that maintenance of such activity requires active 
PKC. Phenylephrine once again induced a 3-4- 
fold increase in PKD activity, but this response 
was completely inhibited by pretreatment with 
1 fiM bisindolylmaleimide. As before, exposure of 
cells to PMA (100 nM) induced a much greater 
(16-17-fold) increase in PKD activity; this response 
was attenuated, in a concentration-dependent 
manner, by pretreatment of cells with bi­
sindolylmaleimide. These observations confirm a 
key role for PKC in PKD activation in response 
to ai-AR stimulation or exposure to PMA. In 
order to further define the role of PKC in the 
regulation of PKD activity in cultured neonatal 
myocytes, we also tested the effects of bi­
sindolylmaleimide on the PKD response to the re- 
introduction of serum. Exposure to 10% FCS 
induced a 12-fold increase in PKD au­
tophosphorylation, and this response was also 
attenuated, in a concentration-dependent manner, 
by bisindolylmaleimide. This indicates that the
BIS in vivo (pM) 
BIS in vitro (pM)
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Figure 7 PKD activation in cultured neonatal myocytes 
is mediated by PKC. A: Representative autoradiogram 
(n = 2) showing PKD autophosphorylation following ex­
posure of cells to 100 nM PMA for 20 min, under control 
conditions (lane 1) or in the presence of the PKC inhibitor 
bisindolylmaleimide (BIS) prior to cell lysis (in vivo; lane 
2) or during the kinase assay (in vitro; lane 3). B: Effects 
of phenylephrine (PE), PMA and FCS on 3:P incorporation 
into PKD in the absence (solid bars) or presence (hatched 
bars) of the PKC inhibitor bisindolylmaleimide (BIS). PE, 
PMA or FCS was present for 20 min prior to cell lysis 
and PKD immunoprecipitation, and BIS was present for 
5 min prior to and during PE, PMA or FCS exposure. 
Autophosphorylation was assessed by an in vitro kinase 
assay (IVK), as described in Methods. Data are expressed 
as percentage of the control (vehicle) value (n = 4). 
* P<0.05 v control (open bar), t  P<0.05 v PE, PMA or 
FCS alone (solid bars).
factor(s) in serum which activate PKD induce this 
response by mechanism(s) that involve PKC.
PKD is not activated by phenylephrine or norepinephrine 
in cultured neonatal non-m yocytes
To determine whether contaminating non-myo­
cytes could make a significant contribution to the 
a,-AR-mediated stimulation of PKD activity in our 
neonatal myocyte preparations, we additionally
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Figure 8 Pheny lephrine and  norepinephrine do n o t ac­
tivate PKD in cu ltu red  n eonata l non-m yocytes. Effects of 
phenylephrine (PE), norepinephrine (NE) and PMA on 
3JP incorporation  in to  PKD in the absence (solid bars) or 
presence (hatched bars) of the  PKC inhibitor bi­
sindolylmaleimide (BIS). PE, NE or PMA w as present for 
20  m in prior to cell lysis and  PKD im m unoprecipitation, 
and BIS w as p resen t for 5 m in prior to and during PMA 
exposure. A utophosphorylation  w as assessed by an  in 
vitro k inase assay, as described in Methods. D ata are 
expressed as percentage of the  control (vehicle) value 
(n =  3). * P < 0 .0 5  v con tro l (open bars), tP < 0 .0 5  v PMA 
alone.
studied the effects of norepinephrine and phenyl­
ephrine in cultured neonatal non-myocytes. As 
shown in Figure 8, neither phenylephrine nor no­
repinephrine produced a significant change in PKD 
activity in the non-myocyte preparations, at con­
centrations that produced maximum stimulation of 
PKD activity in neonatal myocytes (see Figs 4 and 
6). In contrast, PMA produced significant PKC- 
mediated PKD activation in cultured non-myocytes 
(Fig. 8), as in cultured myocytes. This indicates 
that the ar AR-mediated increases in PKD activity 
in our neonatal myocyte preparations reflect such 
increases in myocytes themselves rather than in 
contaminating non-myocyte cells.
PKD is activated by PMA in freshly isolated adult 
myocytes
Since PKD was expressed in adult rat ventricular 
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Figure 9 PMA activates PKD in freshly isolated adult 
m yocytes. Tim e-dependent effects of PMA (1 0 0  nM) on 
UP incorpora tion  in to  PKD. A utophosphorylation  w as 
assessed by an  in vitro kinase assay, as described in 
M ethods. D ata are expressed as percentage of the  control 
(vehicle) value (n =  4).
neonatal ventricular myocytes, we also tested the 
effects of PMA on PKD activity in this cell type. 
Time-response experiments with PMA (100 nM) in 
freshly-isolated adult rat ventricular myocytes 
(500 000 cells/time point) revealed a modest 2.5- 
fold increase in 32P incorporation into PKD, which 
peaked after 10 min of exposure to the phorbol 
ester (Fig. 9).
Discussion
The present study represents the first detailed 
characterization of myocardial PKD expression, ac­
tivity and regulation. Our main conclusions are 
that, in the rat: (i) functional PKD is present in 
ventricular myocardium and its level of expression 
is subject to developmental regulation, (ii) PKD 
is abundant in both myocyte and non-myocyte 
fractions of neonatal ventricular myocardium, but 
PKD abundance in the myocyte fraction declines 
in adulthood, (iii) PKD activity in primary cultures 
of neonatal ventricular myocytes is increased by 
exposure to PMA, FCS and a]-adrenergic agonists, 
and (iv) increased PKD activity in these cells in 
response to such stimuli occurs downstream of PKC 
activation.
An intriguing finding of our study was the con­
sistent detection by Western blotting of two proteins
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of 110 and 115 kDa, in ventricular myocardium 
and other tissues of neonatal and adult rats. These 
two proteins were immunoreactive to three in­
dependent antibodies that had been raised against 
distinct PKD/PKC/i domains in the rabbit (sc-638 
and sc-935) or the mouse (P26720), and they were 
not detected when antibody (sc-935) was incubated 
with immunizing peptide prior to Western blotting. 
These observations strongly suggest that both pro­
teins are PKD moieties, rather than related proteins. 
Furthermore, our observation that rabbit polyclonal 
antibodies directed against either the extreme N- 
or the extreme C-terminus of PKD (sc-638 and 
sc-935, respectively) both detected the same two 
moieties suggests that the 110 kDa band does not 
arise from proteolytic cleavage of the 115 kDa pro­
tein. A shift in PKD mobility upon activation, 
ascribed to PKD phosphorylation by PKC, has been 
reported previously in COS-7 cells (see Fig. 4C in 
Zugaza et a l, 199620). However, the shift in PKD 
mobility induced by activation in that study was 
much more discrete than the difference in mobility 
between the two PKD moieties in our study, which 
suggests that these moieties may not arise as a 
consequence of such phosphorylation. In support 
of this, in our study, there was no significant change 
in the mobility of the two bands upon increased 32P 
incorporation following activation, and treatment of 
protein samples with alkaline phosphatase prior to 
Western blotting had no effect on the mobility of 
either band (data not shown). Possible alternative 
explanations are that the 110 and 115 kDa proteins 
arise from: (i) two highly homologous genes, (ii) 
differential splicing of a single gene, or (iii) post- 
translational modification/protein maturation pro­
cesses other than phosphorylation. Interestingly, 
unlike neonatal and adult ventricular tissue and 
neonatal ventricular myocytes, adult myocytes ap­
pear to express predominantly the 115 kDa protein, 
although the molecular basis of this divergence is 
currently unclear.
Consistent with previous observations regarding 
other signaling proteins (e.g. PKC isoforms,23 com­
ponents of the mitogen-activated protein kinase 
cascade24), our data suggest that PKD expression in 
the rat heart declines dramatically with maturation. 
The apparent difference in PKD abundance between 
neonatal and adult ventricular myocytes was re­
tained even when protein samples from equal num­
bers of cells (as opposed to equal amounts of protein) 
were subjected to immunoblot analysis, indicating 
that the difference did not arise from an artefactual 
“dilution" of the target protein, due to changes 
in cardiac protein composition during post-natal 
maturation (such as hypertrophic growth of cardiac
myocytes, with an associated increase in contractile 
protein content). The greater abundance of PKD in 
fetal and neonatal myocardium relative to the adult 
may suggest that PKD plays a role during de­
velopment of the rat heart. Furthermore, we have 
observed a reduced immunoreactive PKD content 
in adulthood additionally in non-cardiac tissues 
(Fig. 2B), suggesting that expression of this kinase 
may be subject to developmental regulation in a 
tissue-independent manner. In this context, it is 
interesting to note that the expression of PKC/t, the 
PKD homologue, in mouse epidermis has also been 
reported to decline during the first week after birth.25
In primary cultures of neonatal rat ventricular 
myocytes, we have established that myocardial PKD 
can be activated by PMA in a dose-dependent man­
ner, and that this activation is dependent upon 
activation of PKC. The latter conclusion is based 
on the effects of the PKC inhibitor bi­
sindolylmaleimide: as shown before in other cell 
types, myocardial PKD activity in vitro was not 
directly inhibited by bisindolylmaleimide, which 
nevertheless inhibited PMA-induced activation of 
this kinase in vivo (Fig. 7). In the neonatal myocyte 
preparation, PKD was activated also by exposure 
to FCS, as well as the synthetic af]-AR agonist 
phenylephrine and the endogenous catecholamine 
norepinephrine. PKD activation by norepinephrine 
occurred via the o -^AR, since it was inhibited by 
the <X]-AR antagonist prazosin but not by the /?]- 
AR antagonist atenolol. Importantly, like the PMA- 
induced response, PKD activation by each of these 
stimuli was also sensitive to inhibition by bi­
sindolylmaleimide, suggesting that PKC plays a 
central role in the in vivo regulation of myocardial 
PKD activity by diverse stimuli.
A potential problem in the interpretation of data 
obtained in cultured neonatal myocyte preparations 
is the unknown contribution from contaminating 
non-myocytes, mostly fibroblasts, to the detected 
signal. However, our studies in cultured neonatal 
non-myocyte cells revealed no increase in PKD ac­
tivity in response to norepinephrine or phenyl­
ephrine, indicating that non-myocytes were 
unlikely to have contributed to the aj-AR-mediated 
stimulation of PKD activity observed in the myocyte 
experiments. This is consistent with earlier reports 
that neonatal rat cardiac fibroblasts do not express 
oti-AR mRNA,26 and do not respond to ct]-adrenergic 
stimulation.27 In contrast, a contribution from the 
non-myocyte fraction to the PMA-induced response 
cannot be discounted, since PMA produced a sig­
nificant increase in PKD activity in cultured non­
myocytes, as in the myocyte preparations.
In our studies in neonatal myocytes, the maximal
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increase in PKD autophosphorylation was markedly 
greater following exposure to PMA (16-17-fold) 
than following otj-AR stimulation by phenylephrine 
or norepinephrine (3-4-fold). This difference in PKD 
activation may reflect quantitative and/or qual­
itative differences in PKC activation in response to 
the distinct stimuli. In this regard, previous studies 
in neonatal rat ventricular myocytes have shown 
greater PKC activation by PMA than by no­
repinephrine.28 Furthermore, other work in the 
same model has shown that phorbol ester treatment 
activates PKCa, PKC<5 and PKCe, whereas stimuli 
that act via GqPCRs, such as ax-AR agonists, activate 
a limited subset of PKC isoforms.29,30 The latter 
observation may be significant, since PKD appears 
to be differentially regulated by distinct PKC iso­
forms.20
To date, there is little information available re­
garding the physiological substrate(s) and func­
tion^) of PKD in cardiac myocytes, or indeed in 
other cell types. An inhibitory role for PKD has 
been proposed in regulating glucagon-stimulated 
cAMP production in COS-7 cells31 and antigen re­
ceptor complex-initiated signaling in B-cell lines.32 
Most recently, work from our laboratory has re­
vealed that PKD may mediate a novel inhibitory 
pathway in the regulation of plasma membrane 
Na+/H+ exchanger activity, in both COS-7 and A- 
10 cells.33 With regard to myocardial PKD, there 
has been only one previous study in the literature, 
also from our laboratory;34 this investigated the 
potential role of PKD in the phenomenon of ischemic 
preconditioning, but failed to establish an in­
volvement. Our novel finding in the present study 
that PKD activity in neonatal rat ventricular myo­
cytes is subject to regulation by a variety of stimuli 
(including ai-AR agonists) through a PKC-mediated 
pathway may suggest roles for PKD in modulating 
myocardial responses previously ascribed to PKC 
activation. In this context, primary cultures of neo­
natal rat ventricular myocytes have been used 
widely to study the regulation of myocyte growth 
and hypertrophy by humoral factors that signal via 
GqPCRs (see reviews by Chien et al., 19913S and 
Dorn and Brown, 19992). Many studies have im­
plicated PKC activation as an important proximal 
event in the induction of a hypertrophic phenotype 
in this preparation,36,37 particularly following oq- 
adrenergic stimulation.6,7 In the light of the above 
and the current interest in the delineation of GqPCR 
signaling pathways that mediate cardiac adaptive 
and maladaptive responses,2 the functional sig­
nificance of aj-adrenoceptor- and PKC-mediated 
activation of PKD in myocardium warrants in­
vestigation.
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Protein kinase D inhibits plasma membrane 
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Haworth, Robert S., James Sinnett-Smith, Enrique 
Rozengurt, and Metin Avkiran. Protein kinase D inhibits 
plasma membrane Na+/H+ exchanger activity. Am. J. Physiol. 
277 (Cell Physiol. 46): C1202-C1209, 1999.—The regulation 
of plasma membrane Na+/H+ exchanger (NHE) activity by 
protein kinase D (PKD), a novel protein kinase C- and phorbol 
ester-regulated kinase, was investigated. Tb determine the 
effect of PKD on NHE activity in vivo, intracellular pH (pHj) 
measurements were made in COS-7 cells by microepifluores- 
cence using the pH indicator cSNARF-1. Cells were trans­
fected with empty vector (control), wild-type PKD, or its 
kinase-deficient mutant PKD-K618M, together with green 
fluorescent protein (GFP). NHE activity, as reflected by the 
rate of acid efflux (Jh). was determined in single GFP-positive 
cells following intracellular acidification. Overexpression of 
wild-type PKD had no significant effect on Jh (3.48 ± 0.25 vs. 
3.78 ± 0.24 mM/min in control at pHj 7.0). In contrast, 
overexpression of PKD-K618M increased «7h (5.31 ± 0.57 
mM/min at pHi 7.0; P < 0.05 vs. control). Transfection with 
these constructs produced similar effects also in A-10 cells, 
indicating that native PKD may have an inhibitory effect on 
NHE in both cell types, which is relieved by a dominant- 
negative action of PKD-K618M. Exposure of COS-7 cells to 
phorbol ester significantly increased <7h hi control cells but 
failed to do so in cells overexpressing either wild-type PKD 
(due to inhibition by the overexpressed PKD) or PKD-K618M 
(because basal Jh was already near maximal). A fusion 
protein containing the cytosolic regulatory domain (amino 
adds 637-815) of NHE1 (the ubiquitous NHE isoform) was 
phosphorylated in vitro by wild-type PKD, but with low 
stoichiometry. These data suggest that PKD inhibits NHE 
activity, probably through an indirect mechanism, and repre­
sents a novel pathway in the regulation of the exchanger.
pH regulation; COS-7; A-10; green fluorescent protein; sodium/ 
hydrogen exchanger type 1; protein kinase Cp
IN r e c e n t  y e a r s ,  the type 1 isoform of the Na+/H+ 
exchanger (NHE1) has been the focus of considerable 
investigative effort as an important modulator of cellu­
lar function. Indeed, altered activity of this exchanger 
has been implicated in such diverse pathologies as 
cancer (17), epilepsy (5), hypertension (20), arterial 
restenosis (18), myocardial hypertrophy (40), and post- 
ischemic cardiac dysfunction (31). NHE1 is predicted to 
consist of two domains: an NH2-terminal membrane- 
bound transport domain and a COOH-terminal cyto-
The costs of publication of this article were defrayed in part by the 
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plasmic regulatory domain (25, 37). The exchanger is 
quiescent at physiological intracellular pH (pH;) but is 
activated rapidly in response to intracellular acidosis 
via an allosteric modifier site in its transport domain 
(36). Several stimuli, including growth factors, hor­
mones, hypertonic stress, and mechanical stretch, also 
increase NHE 1 activity through various signaling path­
ways (25, 37). These include direct phosphorylation of 
the cytoplasmic regulatory domain (28), binding of 
calmodulin (2), and interaction with accessory proteins 
[e.g., CHP (23)]. Although NHEl-regulatory roles have 
been suggested for several kinase pathways (4, 22, 26, 
33), the most extensively studied kinase-mediated mech­
anism of NHE1 activation involves protein kinase C 
(PKC). Thus activation of PKC, either directly by 
phorbol esters (8, 38) or indirectly via cell surface 
receptors (29, 38, 41), leads to increased exchanger 
activity in a variety of cell types, and putative PKC 
inhibitors inhibit such effects (38,41). There is evidence 
that negative regulators of NHE1 activity also exist 
(21, 24), but less is known about inhibitory signaling 
pathways.
The recently identified protein kinase D [PKD; also 
known as PKCp (16)] is a novel serine/threonine kinase
(34) that has distinct structural and enzymatic proper­
ties and is found in most tissues [see review by Rozen­
gurt et al. (27)]. The catalytic domain of PKD is 
distantly related to Ca2+-regulated kinases and shows 
little similarity to the highly conserved regions of the 
kinase subdomains of the PKC family. Consistent with 
this, PKD does not phosphorylate a variety of sub­
strates utilized by PKCs (34, 35), indicating that PKD 
is a protein k in a s e  with distinct substrate specificity. 
The NH2-terminal region of PKD contains a tandem 
repeat of cysteine-rich motifs that bind phorbol esters 
with high affinity (34, 35), and immunopurified PKD is 
stimulated in vitro by either diacylglycerol or biologi­
cally active phorbol esters in the presence of phosphati- 
dylserine (35). More recently, a second mechanism of 
PKD activation has been identified, which involves 
phosphorylation of PKD via a PKC-dependent pathway 
(43).
In light of the evidence that PKD can be activated in 
parallel with or downstream of PKC, we determined 
whether PKD may be involved in the regulation of 
NHE1 activity. The results presented here suggest that 
PKD mediates a novel inhibitory pathway in the regula­
tion of the exchanger and counteracts the stimulatory 
effects of the PKC pathway.
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EXPERIMENTAL PROCEDURES
Cell culture. Stock cultures of COS-7 (African Green mon­
key kidney) and A-10 (rat aortic smooth muscle) cells were 
maintained at 37°C in DMEM supplemented with 10% fetal 
bovine serum (FBS) in a humidified atmosphere containing 
5% C02. For experimental purposes, cells were plated in 
90-mm dishes, with or without acid-washed 15-mm diameter 
glass coverslips, at 6 x 10® cells/dish.
Transfection o f cultured cells. The wild-type PKD cDNA 
fragment spanning bases —125 to 3179 was inserted into the 
mammalian expression vector pcDNA3, as described earlier
(35). The kinase-deficient mutant PKD-K618M was also 
inserted into pcDNA3 (43). cDNA for green fluorescent pro­
tein (GFP), in the mammalian expression vector pCAGGS, 
was a kind gift from Drs L. Wightman and M. Marber (Depart­
ment of Cardiology, St. Thomas’ Hospital, London, UK).
Cultured cells (40-50% confluent) were transfected with 
the various plasmids using Lipofectin (Life Technologies), as 
recommended by the manufacturer. A total of 12 pg DNAwas 
used per 90-mm dish, consisting of 6 pg pCAGGS-GFP and 
6 pg pcDNA3, pcDNA3-PKD, or pcDNA3-PKD-K618M. Briefly, 
DNA was mixed with 1 ml Opti-MEM I (Life Technologies) 
and then mixed with Lipofectin (20 pi in 1 ml Opti-MEM I). 
After 20 min, the Lipofectin/DNA complex was diluted to 5 ml 
with Opti-MEM I and overlaid onto the cells. After overnight 
incubation, the procedure was completed by the addition of 
5 ml of Opti-MEM I containing 20% FBS. Cells were used 
24-48 h later.
Western blots. Cultured cells were washed three times with 
ice-cold PBS and lysed in 1 ml of lysis buffer, which contained 
50 mM Tris HCl (pH 7.5), 2 mM EGTA, 2 mM EDTA, 1 mM 
dithiothreitol (DTT), 10 pg/ml aprotinin, 10 pg/ml leupeptin, 
1 mM 4-(2'-aminoethyl)-benzenesulfonyl fluoride hydrochlo­
ride, and 1% Triton X-100. Samples of cell lysate (15 pg 
protein) were then subjected to SDS-PAGE and transferred to 
polyvinylidene difluoride membrane (Amersham, Bucks, UK), 
using a Pharmacia LKB Multiphor H transfer apparatus. 
Membranes were probed with commercial antibody that 
recognizes both wild-type PKD and its kinase-deficient mu­
tant (sc-935; Autogen Bioclear UK, Caine, UK). Donkey 
anti-rabbit horseradish peroxidase-conjugated antibody (Am­
ersham) was used at a dilution of 1:2,000 to label bound 
antibody, and the antibody complex was detected using the 
Amersham enhanced chemiluminescence system, as recom­
mended by the manufacturer.
NHE activity measurement. pH; was measured in single 
cells using an adaptation of the microepifluorescence method 
that we have used previously in neonatal (9) and adult (9,31, 
41, 42) rat cardiac myocytes. Cultured cells grown on cover­
slips were mounted in a 150-pl volume imaging chamber 
(Warner RC-25F; Clark Electromedical Intruments, Reading, 
UK) and visualized on a Nikon Diaphot 300 inverted micro­
scope, with a X40 oil-immersion objective (numerical aper­
ture 1.3). The cells were loaded with the fluorescent indicator 
carboxy-seminaphthorhodofluor-1 (cSNARF-1) by immersion 
in 5 pM of its acetoxymethyl ester for 20 min at room 
temperature, after which they were superfused with Tyrode 
solution (in mM: 137 NaCl, 5.4 KC1,1.8 CaCl2, 0.5 MgCl2, 10 
HEPES; pH 7.4 at 34°C) at a flow rate of 2 -3  ml/min. To select 
successfully transfected cells for pHj measurement, GFP 
fluorescence was initially visualized following excitation of 
cells at 486 nm. A single cell emitting green light was then 
selected and framed with adjustable shutters for cSNARF-1 
fluorescence measurements. Fluorescence emission at 580 
and 640 nm was detected during excitation at 540 nm, using a 
dual emission photometer system [model D-104; Photon
Technology International (PTI), Surbiton, UK] with photon- 
counting photomultipliers (model 710; PTI). Emission inten­
sity data were acquired at 2 Hz and stored on disk using PTI 
Felix software (version 1.1). The 580:640 emission intensity 
ratios were converted to pHi values by reference to calibration 
curves constructed using nigericin, and cellular intrinsic 
buffering capacity Oj) measurements were made during 
progressive washout of extracellular NH 4 CI, as described 
previously (9, 41). Because experiments were performed in 
bicarbonate-free medium, the rates of acid efflux (.Jh) esti­
mated during recovery from intracellular acidosis (induced by 
transient exposure to 20 mM NH 4 CI) could be used as 
indicators of plasma membrane NHE activity (9, 31, 41, 42). 
As described previously (9, 41), Jh  was calculated at various 
pH* during recovery from acidosis, from the equation <7h = 
dpH/d£ • fli, in which dpHj/df is the rate of change of pH;.
Generation o f glutathione-S-transferase (GST)-NHE fusion 
protein. The regulatory domain of rabbit NHE1 was ex­
pressed as a fusion protein using the vector pGEX-3X (Phar­
macia; see Ref. 32). DNA for the COOH-terminal 178 amino 
acids of NHE1 was amplified from rabbit heart cDNAby PCR 
using the primers 5'-GCG GAT CCT GCA GAA GAC CCG 
GCAGCG GCT-3' and 5'-AAG AAT TCT ACT GCC CTT TGG 
GGATGA-3'. The product generated was digested with EcoR 
I and BamH  I and ligated into pGEX-3X. Fusion protein 
expression in several strains of Escherichia coli was tested, as 
problems with degradation were encountered using DH5a 
(32). Fusion protein expressed in the protease-deficient strain 
BL21 (ompT- , Ion- ) was largely intact after purification 
using a glutathione-Sepharose 4B column, as recommended 
by the manufacturer (Pharmacia). Attempts to separate GST 
from the NHE1 fragment with Factor Xa led to degradation of 
the NHE1 portion, so intact fusion protein was used for in 
vitro phosphorylation assays. GST alone, expressed and 
purified in the same system, was used as control.
NHE1 phosphorylation assay. NHE1 phosphorylation by 
PKD was assessed following immunoprecipitation of the 
kinase as described previously (34, 35, 43). Cultured COS-7 
cells were washed three times with ice-cold PBS and lysed in 
1 ml of lysis buffer. PKD was immunoprecipitated from the 
cell lysate at 4°C for 3 h with the PA-1 anti-peptide serum 
[1:100 dilution (34)]. Immune complexes were recovered by 
the addition of 50 pi protein A-Sepharose (Pharmacia; 100 
mg/ml), and pellets were washed three times with lysis buffer 
and three times with assay buffer [30 mM Tris-HCl (pH 7.5), 
10 mM MgCl2 and 1 mM DTT]. The final pellet was resus­
pended to a total volume of 40 pi with assay buffer. To initiate 
the phosphorylation reaction, 10 pi of phosphorylation mix 
[assay buffer containing GST-NHE fusion protein or GST (10 
pg/ml) and 100 pM [-y-32P]ATP; 400-600 counts-min-1-pmol-1] 
were added. The mixture was incubated at 30°C for 5 min, 
and the reaction was terminated by the addition of hot 
SDS-PAGE sample buffer. After boiling for 5 min, the samples 
were subjected to SDS-PAGE followed by autoradiography.
Statistical analysis. Data are expressed as means ± SE. 
Intragroup comparisons were by Student’s paired f-test, 
whereas intergroup comparisons were by ANOVA followed by 
Bonferroni f-test. P  <  0.05 was considered significant.
RESULTS
Characterization of NHE activity in COS-7 cells. To 
determine plasma membrane NHE activity selectively 
in transfected cells, we measured such activity in 
individual cells expressing the transfection marker 
GFP. The fluorescence characteristics of GFP and 
cSNARF-1 and the emission filters used precluded
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signal interference between the two fluorophores. To 
confirm the absence of either such interference or a 
GFP-induced change in the pH* sensitivity of cSNARF-1, 
we compared the pH; calibration curves in nontrans­
fected COS-7 cells and those transfected with GFP. As 
illustrated in Fig. 1 , the calibration curves from these 
populations of cells were superimposed, indicating that 
expression of GFP does not affect the utility of 
cSNARF-1 as a pH; indicator.
Because (3; is determined largely by intracellular 
protein composition and is a critical factor in calculat­
ing Jh (3), we tested whether overexpression of PKD 
affects (3j. To this end, (3; was determined at various pH; 
in COS-7 cells transfected with pcDNA3 (control) wild- 
type PKD, or PKD-K618M, all concomitantly with GFP. 
Over the pH; range 6 .90 -7 .30  (mean 7.07 ± 0.01), there 
was no significant difference between the three groups 
in Pi (30.2 ± 1.5, 32.8 ±  2.0, and 31.8 ± 1.5 mM, 
respectively; n  = 10 cells/group), indicating that overex­
pression of PKD has no effect on (3; ini these cells.
To exclude an involvement of bicarbonate-dependent 
mechanisms in pH; regulation, all microepifluorescence 
experiments were carried out in bicarbonate-free me­
dium; under these conditions NHE represents the 
primary route of acid extrusion in other cell types (9, 
17, 41). To verify that this is the case in COS-7 cells, we 
tested the effect of the NHE inhibitor HOE-642 (30) on 
pH; recovery from acidosis. At 3 pM, HOE-642 com­
pletely inhibited pH; recovery from acidosis after tran­
sient exposure to NH4C1 (data not shown). This substan­
tiates that, under the experim ental conditions used, 
NHE activity represents the primary route of acid 
extrusion. Furthermore, it confirms that such activity 
arises from the NHE1 isoform, which is the only 
isoform that has been shown to be expressed in COS-7 
cells (24), since at 3 pM HOE-642 is NHE1 selective 
(30).
control wild type K618M
o non-transfected cells 
•  GFP-expressing cells
i.oo-
0 .5 0 -
0.00 -
5 .6 0  6 .0 0  6 .4 0  6 .0 0  7 .2 0  7 .6 0  8 .0 0  8 .4 0
pHj
Fig. 1. Green fluorescent pro te in  (GFP) does not interfere w ith 
cSNARF-1 fluorescence. COS-7 cells grow n on coverslips were tran s­
fected w ith pCAGGS-GFP as described in  e x p e r i m e n t a l  P R O C E D U R E S .  
Transfected cells were identified by G FP fluorescence, and cSNARF-1 
emission in tensity  was m easured  a t  580 ( h so) and 640 (Jmo) nm in the 
presence of nigericin-containing calibration  buffers of various pH. 
The normalized calibration curves, constructed as described by 
Yasutake et al. (41), for G FP-expressing cells ( • )  and nontransfected 
cells ( O )  were superim posed (10 cells/group).
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Fig. 2. Overexpression of protein k inase D (PKD)-K618M increases 
N a+/H + exchanger (NHE) activity in  COS-7 cells. A: W estern blot of 
cell extracts. COS-7 cells were transfected w ith pCAGGS-GFP to­
gether w ith pcDNA3 (control), pcDNA3-PKD (wild type), or pcDNA3- 
PKD-K618M (K618M). Proteins from cell extracts were separated  by 
SDS-PAGE, transfe rred  to polyvinylidene difluoride (PVDF) mem­
brane, and probed for presence of PKD using sc-935 antibody (1:500 
dilution). Blot is representative  of 3 experim ents. B: representative 
p H  recordings from single cells from each group. COS-7 cells grown 
on coverslips w ere transfected w ith  pCAGGS-GFP together with 
pcDNA3 (control, • ) ,  pcDNA3-PKD (wild type, O ), or pcDNA3-PKD- 
K618M (K618M, ▲). pH, recordings were m ade from GFP-positive 
cells, and acid efflux (Jh ) was estim ated  as an index of NHE activity, 
as described in  e x p e r i m e n t a l  p r o c e d u r e s . C: Jn-vs.-pH; curves for all 
groups (n = 3 6 -3 7  cells/group). *P  <  0.05 vs. control; t P  <  0.05 vs. 
wild type, a t sam e pHj.
Overexpression o f  PKD-K618M  increases N H E  activ­
ity in COS-7 cells. To determine whether PKD had any 
effect on NHE activity in COS-7 cells, these were 
transfected w ith pcDNA3 (control), wild-type PKD, or 
the kinase-deficient mutant PKD-K618M before being 
exposed to intracellular acidosis. Figure 2A shows a 
representative Western blot of protein samples from 
COS-7 cells and illustrates the presence of native PKD 
in control cells as well as the equivalent overexpression 
of wild-type PKD and PKD-K618M following transfec­
tion. There was no significant difference between the 
groups in resting pH; measured before exposure to 
NH4C1 (control, 7.31 ± 0.01; wild-type PKD, 7.31 ±  
0.01; PKD-K618M, 7.34 ±  0.01; n = 3 6 -37  cells/group), 
and a similar extent of intracellular acidification was 
achieved in each group following NH4C1 washout. Fig­
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ure 2B shows representative pH; recordings from a 
control cell and cells transfected with wild-type PKD or 
PKD-K618M. As illustrated, the rates of pHj recovery 
from acidosis were similar in the cell transfected with 
wild-type PKD and the control cell transfected with  
empty vector; the salient feature in Fig. 2 is that 
recovery from intracellular acidosis was markedly faster 
in the cell transfected with PKD-K618M. Figure 2C 
shows quantitative data, in the form of Jn-vs.-pH, 
curves, from several such experiments (n = 36-37  
cells/group). In cells transfected with wild-type PKD, 
J H was slightly lower than control at pH; <  7.10, 
although this difference did not reach statistical signifi­
cance. In marked contrast, in cells transfected with  
PKD-K618M, J H was significantly greater than control 
over the pH; range 6.90-7 .15. This indicates that 
overexpression of the kinase-deficient PKD mutant 
increases NHE activity in COS-7 cells.
Overexpression o f  PKD-K618M  increases N H E  activ­
ity in A-10 cells. To determine whether NHE activity is 
regulated in a similar manner in cell types other than  
COS-7, A-10 cells were also transfected with pcDNA3 
(control), wild-type PKD, or the kinase-deficient mu­
tant PKD-K618M. Figure 3A shows a representative 
Western blot of protein samples from A-10 cells, demon­
strating once again both the presence of native PKD 
and the equivalent overexpression of wild-type PKD 
and PKD-K618M following transfection. Over the pH; 
range 6 .60-7 .20  (mean 6.96 ±  0.03), there was no
c o n t ro l  w ild  t y p e  K 6 1 8 M
I 1 I II 1
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Fig. 3. Overexpression of PKD-K618M increases NHE activity in 
A-10 ceils. A: W estern blot of cell extracts. A-10 cells were transfected 
w ith pCAGGS-GFP together w ith  pcDNA3 (control), pcDNA3-PKD 
(wild type), or pcDNA3-PKD-K618M (K618M). Proteins from cell 
extracts were separated  by SDS-PAGE, transferred  to FVDF mem­
brane, and probed for presence of PKD using sc-935 antibody (1:500 
dilution). Blot is representative  of 3 experiments. B: Jn-vs.-pH, 
curves for all groups. A-10 cells grown on coverslips were transfected 
w ith pCAGGS-GFP together w ith pcDNA3 (control, • ) ,  pcDNA3- 
PKD (wild type, O ) ,  or pcDNA3-PKD-K618M (K618M, a ) .  pH, 
recordings were m ade from GFP-positive cells, and J h was estim ated 
as an index of NHE activity, as described in e x p e r i m e n t a l  p r o c e ­
d u r e s  (n = 30 -35  cells/group). *P <  0.05 vs. control; t P < 0.05 vs. 
wild type, a t sam e pH;.
significant difference between the three groups of A-10 
cells in (19.0 ±  1.2,19.4 ± 1.8, and 15.9 ± 1.3 mM for 
control, wild-type PKD, and PKD-K618M groups, re­
spectively; n = 8 cells/group), indicating that, as in 
COS-7 cells, overexpression of PKD had no effect on (3;. 
Nevertheless, mean Pi in the overall population was 
significantly lower in A-10 cells than in COS-7 cells 
(18.1 ±  0.8 vs. 31.5 ± 0.9 mM; P  <  0.05).
There was again no significant difference between 
the groups in resting pH, measured before exposure to 
NH4C1 (control, 7.09 ± 0.03; wild-type PKD, 7.09 ± 
0.02; PKD-K618M, 7.07 ± 0.02; n = 3 0 -35  cells/group), 
which was —0.2 pH unit lower than that observed in 
COS-7 cells. As in COS-7 cells, pH; recovery from 
acidosis was inhibited by 3 pM HOE-642 (data not 
shown), confirming that, in A-10 cells also, such recov­
ery arose from NHE1 activity. Figure 35  shows that J H 
values were similar in control cells and cells trans­
fected with wild-type PKD but were increased in cells 
transfected with PKD-K618M over the pH; range 6 .85 -  
6.95 (n = 3 0 -3 5  cells/group). These data indicate that, 
in common w ith our finding in COS-7 cells, overexpres­
sion of the kinase-deficient PKD mutant markedly 
increases NHE activity in A-10 cells. This common 
observation in two distinct cell types suggests that 
PKD may mediate a novel inhibitory pathway in the 
regulation of NHE, such that overexpression of its 
kinase-deficient mutant stim ulates exchanger activity 
by attenuating the inhibitory action of native PKD.
PKD inhibits PKC-induced stim ula tion  o f N H E  activ­
ity in COS-7 cells. Direct activation of PKC is known to 
increase N H E 1 activity in many cell types. Consistent 
with this, we have verified that in nontransfected 
COS-7 cells phorbol 12-myristate 13-acetate (PMA) 
increases plasma membrane NHE activity jas reflected 
by increases in J H at pHj 7.00 [J h (7.oJ> with an EC50 of 24 
nM (Fig. 4A)]. The data illustrated in Figs. 2 and 3 and 
the regulatory association between PKC and PKD led 
us to hypothesize that cellular PKD activity may 
oppose PKC-mediated stimulation of the exchanger, lb  
test this hypothesis, we determined the response to 
PMA of NHE activity in COS-7 cells transfected with 
pcDNA3 (control), wild-type PKD, or the kinase- 
deficient mutant PKD-K618M. As would be expected 
from the data shown in Fig. 4A, 100 nM PMA signifi­
cantly increased Jnn.o) hi control cells transfected with 
empty vector (Fig. 45 ). In striking contrast, PMA failed 
to increase Jun.o) hi cells transfected with wild-type 
PKD, although basal J h ( 7.o) was similar to that observed 
in control cells (Fig. 45). This is consistent with our 
hypothesis that PKD mediates a novel inhibitory path­
way, such that overexpression of wild-type PKD counter­
acts the NHE-stimulatory effect of the PKC pathway.
Figure 4B  additionally shows that PMA failed to 
increase Jaa.o) also in cells transfected with PKD- 
K618M. It should be noted, however, that basal Jh(7.o) in 
these cells was greater than that in control cells, which 
is consistent w ith the findings reported above (Fig. 2C). 
Indeed, basal Jnn.o) in cells overexpressing PKD- 
K618M (7.34 ±  1.55 mM/min) was greater than the
h ( 7 .o )  obtained in response to PMA in control cells
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Fig. 4. PKD inhib its PKC-m ediated stim ulation of NHE activity in 
COS-7 cells. J h  a t pH, 7.00 [Jh(7.o)1 w as determ ined in single COS-7 
cells following 2 consecutive exposures to intracellu lar acidosis, 1st 
under control conditions and 2nd in presence of phorbol 12-myristate 
13-acetate (PMA) or vehicle. A: PM Adose-response curve in non trans­
fected cells, where AJnaoj represen ts  relative increase in  Jh<7.o> in  
response to PMA. B: Jh<7.o> in absence (open bars) and presence (solid 
bars) of exposure to 100 nM PMA in COS-7 cells transfected w ith 
pCAGGS-GFP together w ith pcDNA3 (control), pcDNA3-PKD (wild 
type), or pcDNA3-PKD-K618M (K618M). *P  <  0.05 (n «= 8 -1 2  
cells/group).
(5.45 ± 0.53 mM/min). Thus it is likely that PMA did 
not increase NHE activity in cells transfected with the 
kinase-deficient PKD mutant, because NHE activity in 
these cells was already near maximal.
PKD phosphorylates N H E l in vitro. To establish  
whether the observed inhibitory effect of PKD on NHE 
activity could arise from direct phosphorylation of the 
exchanger, we determined whether the regulatory re­
gion of N H E l, corresponding to the COOH-terminal 
178 amino acids, was a substrate for PKD. COS-7 cells, 
transiently transfected with wild-type PKD, were 
treated with 200 nM PDB (to activate PKD) or vehicle 
for 10 min and lysed. PKD was immunoprecipitated 
from cell extracts with the PA-1 antibody, and the 
immune complexes were incubated with [y-32P]ATP in 
the absence or presence of the GST-NHE fusion protein 
(50 kDa). As shown in Fig. 5A, and in agreement with  
previous results (35, 43), PKD activity (as reflected by 
PKD autophosphorylation) was markedly increased by 
PDB stimulation of intact cells (lanes 1 and 2; ~  10-fold 
increase). GST-NHE incubated with wild-type PKD 
showed some phosphorylation under basal conditions 
(lane 5), and this was markedly increased by PDB 
stimulation, concomitantly w ith PKD autophosphoryla­
tion {.lane 6 ). These results indicate that PKD phos­
phorylates the COOH-terminal regulatory domain of 
N H E l in vitro.
To confirm that phosphorylation of the NHE fusion 
protein requires active PKD, we also transfected COS-7
cells with the kinase-deficient mutant PKD-K618M 
and incubated PKD immunoprecipitates from these 
cells with GST-NHE in the presence of [y-32P]ATP. In 
contrast to the results obtained with wild-type PKD, 
immune complexes from cells transfected with PKD- 
K618M did not catalyze GST-NHE phosphorylation 
under basal conditions or after PDB stimulation (lanes 
7 and 8 ). Indeed, consistent with earlier findings (43), 
PDB stimulation did not increase PKD activity in cells 
transfected with the kinase-deficient mutant (lanes 3 
and 4). These results verify that the PDB-inducible 
N H E l kinase activity observed in PA-1 immunoprecipi­
tates was dependent on the kinase activity of PKD. 
Additional experiments confirmed that GST alone (30 
kDa) was not significantly phosphorylated by activated 
PKD, suggesting that phosphorylation of the GST-NHE 
fusion protein occurred in the NHE domain (Fig. 5B).
To establish the potential functional importance of 
the observed phosphorylation by PKD of the NHE 
fusion protein, we determined the stoichiometry of this 
phosphorylation. Time course experiments showed that 
maximal 32P incorporation into the NHE fusion protein 
occurred at 30 min and was maintained for up to 5 h 
(data not shown). Subsequent phosphorylation reac­
tions were performed for 2 h, using known amounts of 
the GST-NHE fusion protein and the protocol described 
earlier. After autoradiography, the band corresponding 
to the fusion protein was excised from the gel and 
subjected to liquid scintillation counting. The stoichiom­
etry of phosphorylation was calculated from the radio­
active count, the specific activity of the [-y-32P]ATP used, 
and the GST-NHE content of the reaction mix, as 0.068 ± 
0.004 mol phosphate/mol fusion protein (n = 10).
D IS C U S S IO N
The data presented above, which show the effects of 
changing the cellular PKD composition in intact cells 
on plasma membrane NHE activity, strongly suggest 
that PKD mediates a novel NHE-inhibitory pathway, 
through a mechanism that is dependent on its kinase 
activity. This conclusion is based to a significant extent 
on the ability of transfection with the kinase-deficient 
mutant PKD-K618M to increase plasma membrane 
NHE activity, in two distinct cell types. Kinase- 
deficient mutants of an extensive range of protein 
kinases [e.g., Raf (11), M E K (l), andAkt/PKB (19)] have 
been shown to exert dominant-negative effects in a 
variety of systems. Of more direct relevance to our 
work, recent studies have shown that kinase-deficient 
PKD/PKCp m utants can also act in a dominant- 
negative fashion (14, 15). Thus, although an indirect 
effect of PKD-K618M cannot be completely discounted, 
the most likely mechanism underlying our findings is 
that native PKD exerts an inhibitory effect on NHE 
activity and that this inhibition is abolished by the 
dominant-negative action of the kinase-deficient PKD 
mutant.
Inhibition of NHE by a kinase that is downstream of 
PKC may at first appear paradoxical, since PKC activa­
tion is known to stim ulate N H E l activity in many cell 
types, as confirmed by our present findings in nontrans­
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Fig. 5. PKD phosphorylates N H E l regulatory  dom ain in  vitro. A: NHE phosphorylation assay. A fusion pro tein  of 
the COOH-term inal 178 amino acids of N H E l coupled to GST (GST-NHE) was p repared  as described under 
e x p e r i m e n t a l  p r o c e d u r e s . COS-7 cells w ere transfected  w ith pcDNA3-PKD (wild type) or pcDNA3-PKD-K618M 
(K618M). Cells from wild type (Lanes 1, 2, 5, and 6) and K618M (lanes 3, 4, 7, and 8) groups were incubated for 10 
min either in absence (—) or presence ( + ) of 200 nM PDB, and PKD was im m unoprecipitated from cell lysates using 
antiserum  PA-1 (1:100 dilution). A fter recovery of im m une complexes w ith  pro te in  A-Sepharose, in  vitro 
phosphorylation assays were perform ed in  e ithe r the absence (.lanes 1 -4 )  or the  presence (lanes 5 -8 )  of 10 pg/ml 
GST-NHE. After SDS-PAGE, 32P  incorporation w as visualized by autoradiography. S im ilar resu lts  were obtained in 
3 experim ents. B: GST phosphorylation assay. Cells from wild-type group were incubated for 10 m in in presence of 
100 nM PMA, and  PKD was im m unoprecipitated from cell lysates using antiserum  PA-1 (1:100 dilution). After 
recovery of im m une complexes w ith  pro tein  A-Sepharose, in  vitro  phosphorylation assays were perform ed in 
presence of 10 pg/ml GST (lane 1) or 10 pg/ml GST-NHE (lane 2). After SDS-PAGE, WP incorporation was visualized 
by autoradiography. S im ilar resu lts  w ere obtained in  3 experim ents.
fected COS-7 cells exposed to PMA. However, our 
results may be readily reconciled with a hypothetical 
scheme whereby PKC stim ulates NHE activity via a 
PKD-independent pathway, as w ell as activating PKD.
Indeed, activation of PKD m ay curb PKC-mediated 
stimulation of the exchanger (which is supported by our 
observation that PMA cannot stim ulate NHE activity 
in COS-7 cells that overexpress wild-type PKD), thereby 
allowing tighter control over NHE activity. In this 
regard, it would be informative to determine the time 
course of activation in response to PMA of the NHE- 
stimulatory pathway and to compare this w ith the time 
course of PKD activation. Unfortunately, such a com­
parison is not possible at present, since the identity of 
the NHE-stimulatory pathway that is downstream of 
PKC is unknown. In the context of the hypothesis 
proposed above, it is also notable that a parallel activa­
tion of both NHE-stimulatory and NHE-inhibitory path­
ways (mediated by ERK1/2 and p38 MAPK, respec­
tively) has recently been reported in cultured rat 
vascular smooth muscle cells exposed to angiotensin II 
(21). Thus the PKD pathway may not be unique as an 
NHE-inhibitory pathway that is activated in parallel 
with an NHE-stimulatory pathway, in response to a 
given stimulus.
Despite our observation that transfection with PKD- 
K618M increases NHE activity in both COS-7 and A-10 
cells, basal pH, was not affected in either system  by 
transfection w ith this kinase-deficient mutant. This is 
likely to arise from the absence of an increase in NHE
activity at basal pH;, since at p H  >  7.20 and 7.00 in the 
COS-7 and A-10 systems, respectively, J H was almost 
identical in cells transfected with PKD-K618M and 
those transfected with empty vector. Thus PKD- 
mediated inhibition of the exchanger may be of greater 
physiological impact under conditions of intracellular 
acidosis (which is commonly encountered in disease 
conditions such as ischemia) or during exposure to 
stimuli that increase cellular PKC activity (which, as 
noted above, are associated with stimulation of NHE 
activity).
Although considerable progress has been made in the 
understanding of the cellular regulation of PKD activ­
ity (13, 27, 35, 43, 44) since the original cloning and 
characterization of this enzyme (34), little is known 
about its cellular substrate(s). The present study indi­
cates, for the first time, that PKD phosphorylates the 
regulatory COOH-terminal domain of N H E l in vitro. 
However, the stoichiometry of this phosphorylation was 
<0.1 mol phosphate/mol fusion protein. For compari­
son, earlier studies have revealed stoichiometries of 
0.5-1 , 1, and 3 mol/mol, respectively, for the in vitro 
phosphorylation of similar NHE fusion proteins by 
ERK1/2 (39), p90rsk (21), and Ca2+/calmodulin-depen- 
dent protein kinase II (6 ). Thus, relative to PKD, other 
putative regulators of NHE activity appear to possess 
greater efficiency as N H E l kinases, suggesting that 
direct phosphorylation may not be the primary mecha­
nism underlying PKD-mediated regulation of the ex­
changer. N evertheless, such in vitro data may not
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reflect accurately the efficiency of PKD as an NHE1 
kinase in vivo and do not preclude a role for direct 
phosphorylation in PKD-mediated regulation of NHE 
activity in the intact cell. In this regard, recent evi­
dence (33) suggests that a COOH-terminal-truncated 
NHE1 mutant, in which the region that we have shown 
to be phosphorylated by PKD in vitro has been deleted, 
exhibits increased basal activity in vivo. This is consis­
tent with the existence of autoinhibitory domain(s) 
within the PKD-phosphorylatable region of the ex­
changer.
In our studies, we have used the expression of GFP as 
the marker for successful transfection, to enable the 
measurement of pH] (and thereby NHE activity) selec­
tively in cells transfected with a wild-type or mutant 
PKD construct. Although we have confirmed that GFP 
expression does not interfere with the measurement of 
pHj in single cells, we cannot be certain that 100% of 
the cells that expressed GFP also expressed the cotrans­
fected PKD construct. At present, it is impossible to 
determine the proportion of GFP-positive cells that also 
express the cotransfected PKD construct by conven­
tional approaches such as immunocytochemistry, 
because available antibodies would not differentiate 
between native and transfected PKD protein. Neverthe­
less, in cotransfection experiments, it is generally 
accepted that cells that take up one expression vector 
axe highly likely to also take up cotransfected vector(s), 
with numerous examples in the literature. Indeed, in a 
recent study, Ho et al. (10) have used cotransfection 
with GFP in a manner similar to ours, to monitor 
intracellular Ca2+ transients selectively in single cells 
transfected with various regulators of the ERK path­
way. On this issue, it is important to stress that, even if 
the efficiency of cotransfection in our experiments was 
<100%, this would lead to an underestimation of the 
effects of wild-type PKD and PKD-K618M on plasma 
membrane NHE activity and would not invalidate our 
novel findings.
The majority of the work in the literature on the 
regulation of NHE activity has concentrated on the 
identification of stimuli that increase exchanger activ­
ity, such as a variety of growth factors/mitogens (28,29) 
and neurohormonal and other mediators (7, 38,41,42), 
as well as the delineation of their s ig n alin g  pathways 
(2, 4, 12, 22, 41). However, NHE-inhibitory pathways, 
such as those that involve Ga12 (24), CHP (23), and p38 
MAPK (21), also exist and are likely to be important in 
determining exchanger activity in various cell types. 
The findings of the present study strongly suggest that 
PKD mediates a novel NHE-inhibitory pathway, regard­
less of whether this inhibition occurs by direct phosphor­
ylation of the exchanger or via intermediary proteins. A 
better understanding of NHE-inhibitory pathways may 
lead to the development of novel approaches to therapy, 
in diseases in which altered exchanger activity has 
been implicated as a caused mechanism.
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R. S. H a w o r t h ,  M. Y a s u t a k e ,  G. B r o o k s  a n d  M. A v k i r a n .  Cardiac Na+-H+ Exchanger During Postnatal 
Development in the Rat: Changes in mRNA Expression and Sarcolemmal Activity. Journal of Molecular and Cellular 
Cardiology (1997) 29, 321-332. We examined Na+-H+ exchanger isoform 1 (NHE-1) mRNA expression in 
ventricular myocardium and its correlation with sarcolemmal NHE activity in isolated ventricular myocytes, 
during postnatal development in the rat. The expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
mRNA did not change in ventricular myocardium between 2 and 42 days after birth. Therefore, at seven time 
points within that age range, GAPDH expression was used to normalize NHE-1 mRNA levels, as determined by 
reverse transcription polymerase chain reaction analysis. There was a progressive five-fold reduction in NHE-1 
mRNA expression in ventricular myocardium from 2 days to 42 days of age. As an index of NHE activity, acid 
efflux rates (/h) were determined in single neonatal (2-4-day-old) and adult (42-day-old) ventricular myocytes 
(n= 16/group) loaded with the pH fluoroprobe carboxy-seminaphthorhodafluor-1. In HEPES-buffered medium, 
basal intracellular pH (pH) was similar at 7.28 ±0.02 in neonatal and 7.31+0.02 in adult myocytes, but 
intrinsic buffering power was lower in the former age group. The rate at which pH recovered from a similar 
acid load was significantly greater in neonatal than in adult myocytes (0.36±0.07 v 0.16±0.02 pH units/min 
at pH = 6 .8). This was reflected by a significantly greater JH (22±4 v 9 ± 1  pmol/cm2/s at pH = 6 .8), indicating 
greater sarcolemmal NHE activity in neonatal myocytes. The concomitant reductions in tissue NHE-1 mRNA 
expression and sarcolemmal NHE activity suggest that myocardial NHE-1 is subject to regulation at the mRNA 
level during postnatal development. © 1997 Academic Press Limited
K e y  W o r d s :  Na+-H+ exchanger; Gene expression; Activity; Development; Rat.
Introduction
The regulation of intracellular pH (pH,) is important 
in all .cell types because numerous intracellular 
events are directed or modulated by changes in pH. 
In cardiac myocardium [in which pH, is a key 
modulator of contractility (Orchard and Kentish, 
1990)], a primary regulator of pH| is the sar­
colemmal Na+-H + exchanger (NHE), which ex­
trudes intracellular H+ in exchange for extracellular 
Na+ in an electroneutral manner (Karma2yn and
Moffat, 1993). To date, four different isoforms of 
NHE have been described in the rat and other 
species (Sardet et ah, 1989; Tse et ah, 1991, 1992, 
1993; Orlowski et al., 1992), although the major 
isoform present in the heart is NHE-1 (Fliegel and 
Dyck, 1995; Orlowski et ah, 1992). In the absence 
of pharmacological modulation, the cardiac sa- 
colemmal NHE is quiescent at physiological pH|, 
but is activated rapidly in response to intracellular 
acidosis (Wallert and Frohlich, 1989, 1992).
There is evidence that a significant reduction
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in sarcolemmal NHE activity may occur during 
postnatal development of the rabbit myocardium 
(Meno et a l,  1989) and that this might be re­
sponsible, at least in part, for age-dependent 
differences in myocardial susceptibility to con­
tractile dysfunction during respiratory or meta­
bolic acidosis (Meno et al., 1989; Nakanishi et 
al., 1990). More recent studies in the same species 
have shown that cardiac NHE-1 mRNA ex­
pression decreases after birth (Chen et al., 1995; 
Takewaki et al., 1995), an observation that might 
provide a molecular basis for the earlier ob­
servation of reduced sarcolemmal NHE activity 
(Meno et al., 1989). However, it is presently 
unknown whether the postnatal reduction ob­
served in cardiac NHE-1 expression in the rabbit 
is a myocyte- or species-specific phenomenon. 
Furthermore, little is known regarding post-natal 
changes in NHE activity in intact myocytes, be­
cause the only published study was carried out 
in sarcolemmal vesicles (Meno et al., 1989). In 
view of the multiple intracellular regulatory 
mechanisms (e.g. phosphorylation, calmodulin 
binding) that may be involved in determining 
the activity of the NHE-1 protein (Counillon and 
Pouyssfigur, 1995), it is possible that the activity 
measured in reconstituted sarcolemmal vesicles 
may not reflect accurately that present in intact 
cells.
The objectives of the present study were to 
determine: (1) whether a change in ventricular 
NHE-1 expression occurs during post-natal de­
velopment in the rat; and (2 ) whether any such 
change in expression is reflected by a change in 
sarcolemmal NHE activity in intact myocytes.
Materials and Methods
Animals and materials
Adult (approximately 42-day-old) male and late- 
term pregnant Wistar rats were purchased from 
B & K Universal (Hull, UK). The investigation 
was performed in accordance with the Home 
Office Guidance on the Operation of the Animals 
(Scientific Procedures) Act, 1986 , published by 
HMSO, London. Oligo dT cellulose was purchased 
from Becton Dickinson Labware (Bedford, MA, 
USA). TaqDNA polymerase, pancreatin, fetal calf 
serum and Dulbeeco’s modified Eagles medium 
containing glutamax were from Gibco BRL Life 
Technologies Ltd. (Paisley, UK). All other chem­
icals were of the purest grade commercially avail­
able.
PolyA+-enriched RNA preparation
To determine changes in myocardial NHE-1 ex­
pression during postnatal development, ventricular 
tissue was obtained from rats aged 2, 5, 10, 14, 
21, 28, and 42 days. Tissue samples were frozen 
in liquid nitrogen immediately after excision, 
ground to a powder using a pestle and mortar, pre­
cooled with liquid nitrogen, and stored in liquid 
nitrogen until required. PolyA+ RNA was prepared 
from 300-500  mg of powdered tissue by mech­
anical homogenization in a buffer containing NaCl 
(200 d i m ) ,  Tris(hydroxymethyl)aminomethane 
(Tris, 200 m M , pH 7.5), magnesium chloride 
(150 fiM), sodium dodecyl sulfate (SDS; 2%) and 
proteinase K (200 ^g/ml). In the case of ventricular 
tissue from very young rats, hearts from more than 
one animal were pooled (ten hearts at 2  days, six 
hearts at 5 days and three hearts at 10 days). The 
lysate was forced through a 2 1 -gauge needle until 
a homogeneous viscosity was obtained. Samples 
were incubated at 4 5 °C for 12 h with gentle agita­
tion. Oligo dT cellulose was hydrated for 60 min in 
binding buffer containing NaCl (0.5 m ) , Tris 
(10 m M , pH 7.5), washed once with binding buffer, 
and added to the lysate. NaCl was added to a final 
concentration of 0.5 m , followed by incubation at 
room temperature with gentle agitation for 60 min. 
The bound polyA+ RNA was washed six times with 
binding buffer, and eluted with Tris (10 m M , pH 
7.5). PolyA+ RNA concentration was determined 
by measuring absorption at 260 nm.
Dot blots
Nylon membrane (Hybond-N, Amersham Inter­
national) was pre-soaked first in RNase free water 
for 5 min and then 20 x saline-sodium citrate (SSC; 
20  x SSC contains NaCl (3 m ) and trisodium citrate 
(0.3 m ; pH 7.0)) for 1 h. Samples of polyA+ RNA 
(0.5 fig) were denatured (6 8 °C for 15 min) and 
applied directly to the membrane, using vacuum 
filtration in conjunction with a dot blot manifold 
(Schleicher and Schuell; Keene, NH, USA). The 
RNA was cross-linked to the membrane using a 
Stratagene UV Stratalinker 2400  (200 p.] x 100 s). 
The membrane was prehybridized in formamide 
(50%), 5 x SSC, 5 xDenhardt’s solution, SDS (0.1%) 
and denatured herring sperm DNA (100 /ig/ml) for 
5 h at 42°C. The dot blots were first exposed to an 
oligo(dT)i5 probe, stripped by boiling in 1 x SSC for 
15 min, and subsequently exposed to a gly- 
ceraldehyde-3-phosphate dehydrogenase (GAPDH)
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probe. The oligo(dT)15 probe was prepared by label­
ling the oligonucleotide (Promega; 0.5 jig) using 
the Promega DNA 5'-End Labelling System, as re­
commended by the manufacturer. The GAPDH 
probe was prepared using the Multiprime DNA 
Labelling Kit (Amersham International, Amersham, 
UK), as recommended by the manufacturer, with a 
1-kb rat GAPDH fragment (100 ng) used as tem­
plate. Following column purification and heat de- 
naturation, the probes (specific activity 2 x 1 0 7ct/ 
min/fig) were added directly to the prehybridization 
solution, and incubation continued at 42°C over­
night. Dot blots were washed with 2xSSC/0.1%  
SDS for 15 min and 1 x SSC/0.1% SDS for 30 min, 
both at 42°C. For GAPDH, a final wash with 
0.1 x SSC/0.1% SDS for 30 min at 65°C was also 
performed. The membrane was exposed to film 
(Kodak X-OMAT-AR) for different time periods to 
ensure that the linear range of the film was not 
exceeded. The signals obtained at 6 h (which were 
within the linear range) were quantified using an 
LKB Ultrascan XL Laser Densitometer.
Reverse transcription polymerase chain reaction (RT- 
PCR)
Samples of mRNA (1 fig) were reverse-transcribed 
using the Invitrogen cDNA Cycle Kit, as re­
commended by the manufacturer. Following eth­
anol precipitation, the cDNA samples were dissolved 
in RNase-free water (20 /d). An aliquot (1 /d) was 
diluted to 50 /d prior to PCR. At this dilution, the 
products of both NHE-1 and GAPDH amplification 
were within the linear phase of the reaction (data 
not shown). PCR was performed using 1 n  1 of diluted 
cDNA in a total volume of 50 //I containing HEPES 
(50 mM, pH 7.9), MgCl2 (1.5 mM), dNTPs (100 fm  
each), lOOpmol each of the forward and reverse 
primers, and 2.5 U of Taq DNA polymerase. The 
reactions also contained 1 /iCi of [a32P] dCTP 
(3000 Ci/mmol). The following primers were used: 
NHE-1 forward primer 5'-ACC CTG CTC TTC TGC 
CTC-3', NHE-1 reverse primer 5'-TGC GGA TCT CCT 
CCT CCT T-3', GAPDH forward primer 5'-CCT TCA 
TTG ACC TCA AC-3', GAPDH reverse primer 5'- 
AGT TGT CAT GGA TGA CC-3'. The primers were 
designed to span one intron for each gene, thus 
reducing the possibility of signals due fo genomic 
DNA contamination. Amplification was for 30 
cycles of 94°C for 45 s, 62°C for 45 s and 72°C 
for 90s, using a Techne PHC-3 Thermal Cycler. 
Duplicate aliquots (10 /d) were resolved on 9% 
polyacrylamide gels. Gels were exposed to Kodak
X-OMAT-AR film to identify amplified DNA. Radio­
labelled bands were excised and quantitated by 
liquid scintillation counting.
Northern blots
Samples of mRNA (5 fig) were subjected to electro­
phoresis using a 1% agarose/6% formaldehyde gel 
and transferred to a nylon membrane (Hybond- 
N; Amersham International, Amersham, UK). The 
membrane was prehybridized in formamide (50%), 
5xSSC, 5xDenhardt’s solution, SDS (0.1%) and 
denatured herring sperm DNA (100 /xg/ml) for 4 h 
at 42°C. The membrane was subsequently hy­
bridized to a gel-purified 1.3-kb PstI fragment from 
the rat NHE-1 cDNA (100 ng), radiolabelled to 
a specific activity of 3 x 107 ct/min//ig using the 
Amersham Multiprime DNA Labelling Kit, by add­
ing the probe directly to the prehybridization so­
lution. The membrane was washed in 2 x SSC/0.1% 
SDS for 15 min at room temperature, followed by
0.1 x SSC/0.1% SDS for 30 min at 60°C, prior to 
autoradiography using Kodak X-Omat AR film. The 
blot was stripped by boiling in 0.1 x SSC for 30 min, 
and re-probed using the GAPDH probe described 
earlier.
Preparation of cardiac myocytes
For estimation of cell volume and surface area, and 
measurement of intracellular pH and NHE activity, 
ventricular myocytes were isolated from the hearts 
of neonatal and adult rats using collagenase-based 
enzymatic digestion techniques.
Adult hearts were excised and perfused (37°C) 
in the Langendorff mode for three sequential 
periods, as follows: (1 )5  min with lyrode solution 
containing NaCl (1 3 7 mM), KC1 (5 .4 mM), CaCl2 
(1.8 mM), MgCl2 (0.5 mM), N-2-hydroxy- 
ethylpiperazine-N'-2-ethanesulfonic acid (HEPES; 
10 mM), glucose (10 mM), adjusted to pH 7.4 with 
NaOH; (2) 5.5 min with nominally Ca2+-free Tyrode 
solution containing NaCl (135 mM), KC1 (5 .4 mM), 
NaH2P04 (0.33 mM), MgCl2 (1.0 him ) HEPES 
(10 mM), glucose (10 mM), adjusted to pH 7.2 with 
NaOH; (3) 10 min with nominally Ca2+-free lyrode 
solution containing collagenase (Worthington lype 
1, 200U/ml); and (4) 5 min with storage buffer 
containing KOH (78 mM), KC1 (30 mM), KH2P04 
(30 mM), MgS04 (3 mM), ethylene glycol-bis(/l- 
aminoethyl ether)-N,N,N',N'-tetraacetic acid 
(EGTA; 0.5 mM), HEPES (10 mM), glutamic acid 
(50 him ), taurine (20 mM), glucose (10 mM),
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adjusted to pH 7.2 with KOH. All solutions were 
gassed with 100% 0 2. After the perfusion procedure, 
the heart was removed from the cannula, and the 
atria and non-ventricular tissue carefully removed. 
The tissue fragments were gently agitated in storage 
buffer to disperse ventricular cells. The cells were 
suspended in storage buffer at 25°C for 60 min 
prior to loading with fluorescent dye (see later) and 
were used within 6 h of preparation.
Neonatal myocytes were prepared from 2-4-day- 
old animals as follows. The hearts from ten animals 
were excised, the atria trimmed off and the vent­
ricles cut into small pieces. Tissue was incubated 
with continuous stirring for 20 min at 37°C in a 
solution containing collagenase (1 1 2 U/ml), pan- 
creatin (5 mg/ml), NaCl (117 mM), HEPES (20 mM), 
NaH2P04 (0.87 mM), glucose (5.6 mM), KC1 
(5.4 mM) and MgS04 (1 mM), adjusted to pH 7.4 
with NaOH. Intact tissue was allowed to settle, and 
the dispersed cells were removed and added to fetal 
calf serum (FCS; 10% v/v final concentration) for 
10-20  min. The cells were then sedimented at 
200 x g for 2 min and resuspended in Dulbecco’s 
modified Eagles medium (DMEM) containing glu- 
tamax at 25°C for 60 min, prior to loading with 
fluorescent dye. Cells were used within 6 h of pre­
paration.
Estimation of cell volume and surface area
Cell dimensions were measured on a calibrated 
monitor, using a CCD camera in conjunction with 
the 40 x objective lens. The volumes of neonatal 
myocytes were estimated from cell diameter meas­
urements, assuming a spherical shape (Rook et 
al, 1988). The volumes of adult myocytes were 
calculated from the length and width of each 
cell, using the formula volume =
width x length x 0.00759 pl//tm2 (Satoh et al., 
1996). To obtain an estimate of cell surface area, 
capacitance measurements were made using heat- 
polished patch electrodes, made from thin-walled 
glass capillaries (1.5 mm o.d., 1.2 mm i.d.; World 
Precision Instruments, New Haven, CT, USA) using 
a two-stage horizontal microelectrode puller (DMZ- 
Universal Puller; Munich, Germany). Electrode re­
sistance ranged from 2-8M ft. The electrode so­
lution contained aspartic acid (110 mM), KCl 
(20 mM), EGTA (10 him ), HEPES (10 mM), ATP 
(5 mM) and MgCl2 (5.92 him ), adjusted to pH 7.2 
with KOH. A hydraulic micromanipulator (model 
MO-102, Narishige Scientific Instruments, Tokyo, 
Japan) was used to position the electrode near the 
centre of the cell. A seal was established between
the electrode tip and the membrane by applying 
slight negative pressure. After compensation for 
stray capacitance, the patch membrane was rup­
tured. Recordings of membrane current were made 
using a patch clamp amplifier, with a holding po­
tential of — 80 mV. Voltage clamp pulses (to 
— 85mV) were generated using pClamp software 
(Axon Instruments, Foster City, CA, USA), and 
membrane capacitance calculated, as previously 
described (Benitah et al, 1993). In estimating cell 
surface area, a specific capacitance of 1 pF/100 fim 2 
was assumed (Satoh et al, 1996).
Measurement of intracellular pH
Intracellular pH (pHd was monitored in single vent­
ricular myocytes using the pH-sensitive fluorescent 
dye carboxy-seminapththorhodafluor-1 (C.SNARF- 
1), as previously described (Yasutake et a l, 1996). 
Aliquots of cells were loaded with C.SNARF-1 by 
incubating them in a 5/im solution of the acet- 
oxymethyl ester (Calbiochem, Nottingham, UK) for 
10 min at room temperature. Cells loaded with 
C.SNARF-1 then were allowed to settle on a glass 
coverslip at the bottom of a 1 0 0 /d chamber, 
mounted on the stage of an inverted microscope 
(Nikon Diaphot) which comprised a 
40 x magnification oil immersion objective with a 
numerical aperture of 1.3. After adherence to the 
coverslip, cells were superfused (3.5 ml/min) with 
Tyrode solution at 34°C. Cells were excited with 
light at 540 nm and the resulting fluorescence 
emission intensity from a selected area of a single 
myocyte measured simultaneously at 580 nm (I580) 
and 640 nm (Imo), using a dual emission pho­
tometer system (Model D104C; Photon Technology 
International Inc., London, UK) which comprised 
an adjustable aperture and two multialkali photo­
multiplier tubes (Type R928; Hamamatsu Photonics 
UK Ltd., Enfield, UK). Background fluorescence was 
measured using an identical aperture and sub­
tracted from the signal. After I-V conversion, the 
acquired signals were digitized at 1.7 Hz and stored 
on digital acquisition tape and computer hard disk, 
the latter using pClamp software (Axon In­
struments, Foster City, CA, USA).
The emission intensity ratio (Iseo^hw) was cal­
culated and converted to a pH, scale, using in situ 
calibration data obtained by exposing cells loaded 
with C.SNARF-1 to nigericin-containing calibration 
solutions of pH 5.8-8.0. The calibration solutions 
consisted of KCl (140 mM), MgCl2 (1 mM), and ni- 
gericin (10 /im), and were buffered with 10 mM of
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one of the following buffers: 2-[N-morpho- 
lino]ethanesulphonic acid (MES) at pH 5.8, 6.2 
and 6.4, piperazine-N,N'-bis[2-ethanesulfonic acid] 
(PIPES) at pH 6 .6 , 6.8  and 7.0, and HEPES at pH
7.2, 7.4, 7.7 and 8.0. All calibration solutions were 
adjusted to the correct pH with NaOH. The data 
acquired from calibration experiments were nor­
malized by dividing all ISBo^ h*o ratios by the ratio 
obtained at a pH, of 7.0; thus, the normalized I580/ 
I640 ratio at pH, 7.0 was always 1 (Gupta et al.,
1994). A calibration curve was obtained by a non­
linear least-squares fit of the normalized data to the 
equation given below, with the curve constrained 
to pass through the point having the coordinates
fs8o/f64C>/(f58o/^ 64o)pH7 =  1 -0, pH =  7.0.
_ W U _  f 10(pH—pK) 10(7—pK) '
(W I .« W  L1 + 10(pH -  pK) 1 + 10,7-pK)_
The best-fit values for pK and a were 7.12 ± 0 .0 3  
and —1.384 +  0.03, respectively. No significant dif­
ference was observed in the respective calibration 
curves for adult and neonatal myocytes.
Determination of intrinsic buffering power
Intracellular intrinsic buffering power (/?,) was es­
timated by stepwise removal of extracellular NH4C1 
(Lagadic-Gossmann et al., 1992). Cells were exposed 
to Tyrode solution containing 2 0 mMNH4Cl for
1 -2  min, followed by a stepwise reduction of extra­
cellular NH4+ to 10, 5, 2.5, 1 and OmM. At each 
step, calculated changes in [NH4+]i and measured 
changes in pH, were used to estimate /?„ from 
the equation /?,=A[NH4+],/ApH,. These experiments 
were carried out in the presence of HOE-694 
(30 /xm) in order to prevent acid extrusion via the 
Na+-H + exchanger and BaCl2 (5mM) to reduce 
NH4+ efflux through potassium channels.
Calculation of sarcolemmal acid efflux
Because all experiments were carried out in the 
nominal absence of bicarbonate, the rate of acid 
efflux (JH) was used as a direct index of sarcolemmal 
Na+/H + exchanger activity (Lagadic-Gossmann et 
al., 1992). Intracellular acidosis was induced by 
the wash-out (for 6 min) of NH4C1 (20 mM), after 
its transient (2-3 min) application. At the end of 
every experiment, the cell under study was exposed 
to nigericin-containing calibration solution at pH
7.0, thus enabling normalisation of the I58o/l6*o
ratios. Equation 2 and the fitted values for pK 
and a were then used to calculate pH, from the 
normalized hso^hio values. The pH, trace during 
the recovery phase was fitted to a single exponential 
function (Boyarsky et al., 1988). At pH, intervals 
of 0.05 during this phase, dpH,/dt (rate recovery of 
pH,) was calculated as the differential derivative of 
the exponential fit. To take account of the differences 
in the size of neonatal versus adult myocytes, “true” 
JH was calculated, in units of pmol/cm2/s, using the 
equation /H =  jff, x dpH,/d£ x v/s, where v/s rep­
resents the estimated cell volume:surface area ratio 
in the appropriate age group (Bevensee and Boron, 
1995).
Statistical analysis
Gaussian-distributed variables were expressed as 
mean+s.E.M. Multiple comparisons were by ana­
lysis of variance, followed by Dunnetts test for 
comparison with the 2-day-old group. To assess 
changes between two groups, an unpaired t-test 
was used. A P value of <0.05 was considered 
significant.
Results
tfentricular GAPDH mRNA expression
The level of expression of GAPDH mRNA relative 
to the total ventricular mRNA pool was determined 
by dot blot analysis of samples from animals aged 
2, 5, 10, 14, 21, 28, and 42 days. The results are 
presented in Figure 1. Data were obtained from 
three separate experiments performed at different 
times and, in each experiment, individual GAPDH: 
oligo (dT) ,5 ratios were expressed as a percentage 
of the ratio obtained with the 2-day-old sample in 
that experiment. No significant change in GAPDH 
mRNA expression was seen over the age range 
investigated, thereby validating its use as an in­
ternal standard in subsequent studies using RT- 
PCR.
\fentricular NHE-1 mRNA expression
Typical RT-PCR results are shown in Figure 2, in 
the form of an autoradiogram. NHE-1 (upper panel) 
and GAPDH (lower panel) were detected using 
simultaneous PCR analysis of samples from the 
same reverse-transcription reaction. The lengths of 
the fragments obtained matched those predicted
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Figure 1 Postna ta l changes in GAPDH mRNA ex­
pression, determ ined by dot blot analysis. mRNA samples 
w ere probed using a GAPDH cDNA fragm ent and oligo 
(dT)15, and  the  signals obtained  quan tita ted  by scanning  
densitom etry. The results are presented as m ean±s.E .M . 
of the GAPDHioligo (dT))5 signal ratios in the  various 
age groups, norm alized to th e  ratio  seen a t 2 days (n =  
3).
from the published sequences for rat NHE-1 
(Orlowski etal., 1992) and GAPDH (Fort etal, 1985). 
The mean NHE-1 :GAPDH ratios, obtained from 3-5  
experiments, are shown in Figure 3. As can be seen, 
there was a progressive five-fold reduction in NHE-1 
mRNA expression during the first 21 days after birth, 
which then remained constant for the rest of the 
period studied. These findings obtained with RT-PCR
Figure 3 Postna ta l changes in NHE-1 mRNA expression 
determ ined by RT-PCR analysis. D ata are  presented as 
m ean±s.E .M . of the  NHE-1 :GAPDH ratios in the  various 
age groups (n =  3 -5 ) . *P < 0.05  v 2-day-old.
were supported by additional analysis of NHE-1 
mRNA expression in 2-day-old and 42-day-old 
samples using Northern blotting (Fig. 4) and a dot 
blot assay (data not shown).
Cell volume and surface area
The size characteristics of neonatal (2-4-day-old 
and adult (42-day-old) myocytes are presented in
& ✓/
Figure 2 R epresentative au to rad iogram  illustrating  the detection of NHE-1 and  GAPDH mRNA, using  RT-PCR. mRNA. 
samples isolated from w hole ventricles of ra ts  of different ages were subjected to reverse transcrip tion  and polymerase 
chain reaction . For PCR, specific prim ers were used to amplify NHE-1 (upper panel) o r GAPDH (lower panel), as 
described in M aterials and  M ethods.
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GAPDH
Figure 4 N orthern  blot of adult (42-day-old) an d  neo­
na ta l (2-day-old) ven tricu lar mRNA probed for NHE-1 
(upper panel) and GAPDH (lower panel). The lengths of 
the  detected mRNA species are  as indicated in the  Figure.
Table 1 Size characteristics of neonatal (2-4-day-old) 
and adult (42-day-old) ven tricu lar myocytes
N eonate 
(n =  2 1 )
Adult 
(n =  18)
Diam eter (pm) 2 7 .5 ± 0 .4 NA
W idth (pm) NA 20  ± 2
Length (pm) NA 108 ± 3
Volume (pi) 1 .3 9 ± 0 .0 7 3 4 ± 3 *
Capacitance (pF) 9 .7  +  0.4 1 9 7 ± 1 2 *
Surface area  (pm 2) 9 7 0 ± 4 0 19 7 0 0  +  1200*
NA: not applicable. *P<0.05 v neonate.
Table 1. As expected, both surface area and cell 
volume were significantly greater in adult v neo­
natal myocytes. The estimated volumes of neonatal 
and adult myocytes were comparable to previously 
reported values, based on morphometric analysis 
(Anversa et al., 1980) and a volume rendering 
algorithm used in conjunction with confocal micro­
scopy (Satoh et al., 1996). Cell volume:surface area 
ratios (v/s) based on the data shown in Table 1 
were subsequently used to calculate the rates of 
acid efflux (see Materials and Methods) in the two 
age groups.
pH| regulation
Because NHE-1 has been shown to be essentially 
quiescent at physiological values of pH,, an acute 















Figure 5 R epresentative recordings of pH, recovery in 
individual neo n ata l [2-day-old; (a)] and  adult [42-day- 
old; (b)] ven tricu lar m yocytes following an  acid load. 
In tracellu lar acidosis w as induced by transien t exposure 
to NH4CI (20  m M ).
(2-4-day-old) and adult (42-day-old) myocytes 
loaded with C.SNARF-1 by transient exposure to 
NH4CI (Frohlich and Wallert, 1995). Recordings 
from typical experiments with both a neonatal 
(upper panel) and an adult (lower panel) myocyte 
are shown in Figure 5, which illustrates that in 
both age groups pH, was able to recover from acute 
acidosis. To demonstrate that, under the nominally 
bicarbonate-free conditions employed, the recovery 
of pH( from acidosis was due to NHE activity, some 
cells were exposed to a Na+-free Tyrode solution 
(in which NaCl was replaced iso-osmotically with 
choline chloride) during the first 3 min of NH4C1 
wash-out. This was then followed by superfusion 
with Na+-containing Tyrode solution. The results 
of typical experiments with both a neonatal (upper 
panel) and an adult (lower panel) myocyte are 
shown in Figure 6 . In the absence of extracellular
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Figure 6  R epresentative illustration  of the N a 4-de­
pendency o f pH, recovery from acidosis in both  n eon ata l 
[2-day-old; (a)] and adult [42-day-old; (b)] ventricu lar  
m yocytes. Intracellu lar acidosis w as induced by tran sien t  
exposure to N H 4C1 (2 0  m M ). There w as n o recovery of 
pH, in either age group u ntil extracellu lar N a + w a s  re­
introduced.
Na+, there was no recovery of pH, from acidosis in 
either'neonatal or adult cells. pH, recovery was 
initiated only upon the re-introduction of extra­
cellular Na+, confirming that such recovery oc­
curred via NHE in both age-groups.
Basal pH, was not significantly different between 
the two age groups (7.28 +  0.02 (n =  34) and 
7 .31± 0.02  (n =  23), in neonatal and adult myo­
cytes, respectively). Although a similar degree of 
alkalosis was observed in the two age groups fol­
lowing exposure to NH4C1 (maximum pH, of 
7.89 ± 0 .03  and 7.82 + 0.02, in neonatal and adult 
myocytes, respectively), the rate at which pH, re­
covered from such alkalosis during the 3 min ex­
posure period was different, with average pH, 
changes of 0.27 ± 0 .02  and 0.39 ±0 .02  units in 
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Figure 7 D ep en dency o f the rate o f pH, recovery (dpH,/ 
dt) on  pH, in n eon ata l (2 -4 -d a y -o ld ) ( • )  and adult (4 2 -  
day-old) (O )  ven tricu lar m yocytes. Data are expressed  
as m ean ± s.E .M . (n =  1 6 ). * P < 0 .0 5  v adult.
(P<0.05). Presumably, as a consequence of this, the 
maximum acidification attained following NH4C1 
wash-out tended to be greater in adult myocytes 
(minimum pH, =  6.65 ±0 .04) than in neonatal cells 
(minimum pH, =  6.73 ±0.03).
The rates of change of pH, (dpH,/dt) following 
NH4C1 wash-out, as a function of pH,, are shown 
in Figure 7. Little difference was observed between 
the two age groups at physiological pH, (pH>7.1). 
However, at lower pH,, dpH/dt was significantly 
greater in neonatal myocytes.
Intrinsic buffering power
The dependence of intrinsic buffering power (/?,) on 
pH, in neonatal (2-4-day-old) and adult myocytes 
is shown in Figure 8 . Linear regression analysis 
revealed very similar correlation coefficients of 0.63 
and 0.62 for neonatal and adult myocytes, re­
spectively. The gradients of the best-fit lines were 
— 23 and —35 mM/pH unit for neonatal and adult 
cells, respectively, indicating a 33% lower /?, in the 
younger age group.
Sarcolemmal NHE activity
Figure 9 shows the pH, v JH relationships in neonatal 
(2-4-day-old) and adult myocytes. As shown, JH 
was significantly greater in neonatal cells at pH,
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Figure 8  Dependency of the intrinsic buffering power 
(/?i) on p ^  in neonatal (2-4-day-old ( • )  and adult (42- 
day-old) (O) ventricular myocytes. Data from 15-20  
cells in each age group were pooled into 0.2 pH unit bins 
(n = 8-31), and are expressed as the mean±s.E.M.
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Figure 9 Dependency of the rate of acid efflux (/h) on 
pH, in neonatal (2-4-day-old) ( • )  and adult (42-day- 
old) (O) ventricular myocytes. Data are presented as the 
mean±s.E.M. (n=16). *P<0.05 v adult.
6.80-7.15, indicating 120-140%  greater NHE ac­
tivity in this age group within this pH, range.
Additional experiments were carried out to con­
firm that this marked difference in NHE activity 
arose from intrinsic age-dependent differences, 
rather than differences in the cell isolation protocols 
used at the two ages. In these experiments, adult 
myocytes were isolated as described earlier but an 
aliquot of cells was exposed to FCS (10%v/v) for 
2 0  min, which is equivalent to the maximum dura­
tion for which neonatal myocytes were exposed to 
FCS. These cells were then resuspended in DMEM
containing glutamax at 25°C for 60 min prior to 
loading with fluorescent dye, as with the neonatal 
cells. These studies revealed that there was no 
significant difference in /H between cells (n = 7 or 
8 /group) exposed to FCS/DMEM with glutamax (/H 
range of 5 .1 +  2 .0 -0 .9 ± 0 .1  pmol/cm2/s over the 
pH, range 6 .75-7 .05) and contemporary controls 
(/H range of 5.9 ±  1.0-9 + 0.1 pmol/cm2/s over the 
pH, range 6.75-7.05). This suggests that exposure 
to FCS/DMEM with glutamax is unlikely to account 
fully for the greater NHE activity observed in neo­
natal myocytes.
Discussion
In the present study, we have determined the steady- 
state mRNA levels of the Na+-H + exchanger (NHE- 
1 isoform) in the developing rat ventricular myo­
cardium, and correlated these with the relative 
activity of the sarcolemmal exchanger in intact 
neonatal v adult ventricular myocytes. Our findings 
with respect to postnatal changes NHE-1 mRNA 
expression are qualitatively similar to data obtained 
recently from studies in the rabbit (Chen et al., 
1995; Takewaki et al., 1995), which also utilized 
GAPDH as an internal control. Indeed, GAPDH has 
been used frequently as a control housekeeping 
gene in studies of myocardial gene expression in 
a variety of settings, on the assumption that its 
expression remains constant. However, recently, 
Knoll et al. (1994) have provided data that chal­
lenge the dogma of invariable GAPDH expression 
in the myocardium. In view of this, we initially 
investigated whether the steady-state GAPDH 
mRNA level (relative to the total mRNA pool) in 
rat ventricular myocardium changed significantly 
in our experimental setting, namely during post­
natal development. Our observation of a constant 
level of GAPDH expression during the first 42 days 
after birth confirms that, at least in the rat, the use 
of GAPDH as an internal housekeeping gene in the 
study of postnatal changes in myocardial gene 
expression is a valid approach.
Although qualitatively similar, the extent of the 
decline in NHE-1 mRNA expression in rat myo­
cardium in the present study (five-fold reduction 
between 2 days of age and adulthood) was notably 
greater than that previously reported in rabbit vent­
ricular myocardium (1 .6-fold reduction between
2-5  days of age and adulthood (Chen et al., 1995). 
Although the reason for this is unclear, it may 
be related to species-differences in the extent of 
maturity at birth and/or the rate of postnatal de­
velopment. In this regard, it is interesting to note
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that for the sarcolemmal Na+-Ca2+ exchanger also, 
the relative profiles of steady-state mRNA levels in 
the developing rat v rabbit myocardium apppear to 
exhibit such a quantitative difference [eight-fold 
reduction between 1 day of age and adult in the 
rat v 2 .8-fold reduction over the same period in 
the rabbit (Boerth et al., 1994)]. It remains to be 
determined whether the postnatal reduction in the 
steady-state NHE-1 mRNA level observed in rat 
myocardium in the present study is due to a re­
duction in the rate of transcription and/or in mRNA 
stability. In this regard, direct evidence of the factors 
involved in transcriptional regulation of the NHE- 
1 gene has only recently begun to emerge (Kolyada 
et al., 1994, 1995; Dyck et al., 1995), although 
there is still little known regarding the role of 
changes in the rate of mRNA degradation in regu­
lating NHE-1 expression (Fliegel and Dyck, 1995).
Data based solely on whole tissue mRNA ex­
pression (Chen et al., 1995; Takewaki et al., 1995) 
is difficult to interpret in relation to the mechanisms 
that may be involved in the regulation of the 
sarcolemmal Na+-H + exchanger, because: (1) a 
heterogeneous population of cells (not just myo­
cytes, but also cardiac fibroblasts, vascular smooth 
muscle cells and endothelial cells) may contribute 
to the message; and (2) changes in NHE-1 mRNA 
expression may not necessarily reflect changes in 
NHE-1 protein expression. With regard to the latter 
point, it has not been possible to detect NHE-1 
protein by the conventional methods of im- 
munoprecipitation and Western blotting in rat or 
rabbit ventricular myocardium (authors’ un­
published observations), most likely due to the very 
low level of expression of the protein in cardiac 
tissue (Fliegel and Dyck, 1995). In the absence of 
data on NHE-1 protein expression, the qualitative 
similarity of the developmental changes observed 
in NHE-1 mRNA expression in rabbit ventricular 
tissue to the previously reported changes in Na+-H + 
exchanger activity in sarcolemmal vesicles from the 
same species (Meno etal., 1989) prompted Chen et 
al. (1995) to hypothesize that the NHE-1 mRNA 
level may determine cardiac Na+-H + exchanger 
activity. Although this is a feasible hypothesis (par­
ticularly in the light of the results of the present 
study—see below), it should be noted that age- 
dependent differences in Na+-H + exchanger ac­
tivity in isolated sarcolemmal vesicles may not 
reflect accurately developmental changes in sar­
colemmal Na+-H + exchanger activity in intact 
myocytes, because: (1) vesicles from different age 
groups may not represent similar sarcolemmal 
membrane fractions or have comparable properties 
of orientation and permeability (Artman et al.,
1995); and (2) in intact cells, there are a variety 
of post-translational regulatory mechanisms (e.g. 
phosphorylation, calmodulin binding) that are in­
volved in determining Na+-H + exchanger activity 
(Counillon and Pouyssegur, 1995), which them­
selves may be subject to developmental regulation 
and which may be impaired or lost in reconstituted 
vesicles.
The present study is the first to determine 
Na+-H + exchanger activity, in terms of the H+- 
effiux rate via the exchanger per unit area of cell 
membrane, in intact myocytes from neonatal and 
adult ventricular tissue. Our observation of a sig­
nificant decline in such activity, occurring con­
comitantly with the decline in tissue NHE-1 mRNA 
expression, suggests that: (1) the changes in tissue 
mRNA levels may reflect the changes in myocyte 
mRNA levels; and (2) transcriptional/post-tran- 
scriptional regulatory mechanisms may indeed play 
a dominant role in determining sarcolemmal 
Na+-H + exchanger activity. These findings are ana­
logous to those of Artman and colleagues with 
respect to the sarcolemmal Na+-Ca2+ exchanger 
(Boerth et al., 1994; Artman et al., 1995). It should 
be noted, however, that between the neonatal 
period and adulthood, the decline in sarcolemmal 
Na+-H + exchanger activity (approximately 2 -3- 
fold) was less than that in tissue NHE-1 mRNA 
expression (approximately five-fold). This suggests 
that changes in cells other than myocytes may 
have contributed to the changes in the message, 
and/or that sarcolemmal Na+-H + exchanger ac­
tivity may be additionally subject to translational/ 
post translational regulation during post-natal de­
velopment.
During our determination of sarcolemmal 
Na+-H + exchanger activity, we observed a sig­
nificant difference in the responses of neonatal v 
adult myocytes to the NH4C1 pulse, such that adult 
myocytes exhibited a greater rate of recovery from 
alkalosis during the period of exposure to NH4C1. 
The primary mechanism of recovery from in­
tracellular alkalosis in mammalian myocytes is the 
C1~-HC03- exchanger (Vaughan-Jones, 1986). 
However, because our experiments were carried 
out in HC03" -free medium, it is unlikely that a 
difference in the activity of the CI~-HC03~ ex­
changer contributed significantly to the age-de­
pendent difference in the rate of recovery from 
alkalosis. This difference is more likely to have 
arisen from a difference in membrane permeability 
to NH4+, the influx (probably through K+ channels) 
of which is thought to mediate pH) recovery during 
exposure to NH4C1 (Roos and Boron, 1981; Wu et 
al, 1994). We also observed a greater intrinsic
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buffering power in adult myocytes relative to their 
neonatal counterparts. Because intrinsic intra­
cellular buffers [i.e. buffers that cannot traverse the 
cell membrane (Bevensee and Boron, 1995)] are 
believed to comprise H+-titratable groups on cyto­
plasmic proteins (Bountra et a l, 1990), the age- 
dependent difference in the intrinsic buffering power 
is likely to reflect a change in the protein com­
position of the myocyte during postnatal de­
velopment.
In conclusion, we have demonstrated, for the 
first time, a concomitant postnatal decline in the 
steady-state NHE-1 mRNA level in ventricular myo­
cardium and the sarcolemmal activity of the 
Na+-H + exchanger in isolated intact ventricular 
myocytes in the same species, namely the rat. These 
findings, taken together with previous observations 
in rabbit ventricular myocardium (Chen et al., 
1995; Takewaki et al., 1995) and rabbit 
sarcolemmal vesicles (Meno et al., 1989), support 
an important role for transcriptional/post- 
transcriptional mechanisms in the regulation of 
the sarcolemmal Na+-H + exchanger. Furthermore, 
they are consistent with the hypothesis (Meno et 
al., 1989; Nakanishi et al., 1990) that a greater 
sarcolemmal Na+-H + exchanger activity may be 
responsible for the reduced susceptibility of neonatal 
myocardium to dysfunction during respiratory or 
metabolic acidosis.
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Effects of moderate hypothermia on sarcolemmal Na + /H  + 
exchanger activity and its inhibition by cariporide in 
cardiac ventricular myocytes
'Kimihiko Hoshino & * 'Metin Avkiran
'Centre for Cardiovascular Biology and Medicine, King’s College London, London SE1 7EH
1 Specific inhibitors of the sarcolemmal Na+/H+ exchanger (NHE) such as cariporide are being 
evaluated for cardioprotective therapy during cardiac surgery. We determined the effects of 
moderate hypothermia (25°C), as occurs during cardiac surgery, on (1) sarcolemmal NHE activity 
and (2) the NHE-inhibitory potency of cariporide, in isolated adult rat ventricular myocytes.
2 As the index of NHE activity, trans-sarcolemmal acid efflux rate (JH) was determined by 
microepi fluorescence in single cells (n = 8 to 11 per group), during recovery from intracellular 
acidosis in bicarbonate-free conditions.
3 Initially, myocytes were subjected to two consecutive acid pulses; these both occurred at 37°C in 
the normothermic control.group but the second pulse was at 25°C in the moderate hypothermia 
group. JH values obtained after the first pulse were superimposed in both groups, indicating 
comparable cell populations. However, after the second pulse, values in the moderate 
hypothermia group were approximately 50% of those in the normothermic control group over 
the pH* range 6.80-7.10.
4 Similar results were obtained in cells subjected to a single acid pulse at 37 or 25°C, with J» 
values in the latter group measuring approximately 60% of those in the former over the pH; range
6.80-7.10.
5 Cariporide (0.01, 0.03, 0.1, 0.3, 1.0 or 3.0 /rM), present during recovery from a single acid pulse, 
reduced JH in a concentration-dependent manner, with IC50 values of 150 and 130 nM at 37 and 
25°C, respectively.
6 We conclude that moderate hypothermia produces (1) a significant, but partial, inhibition of 
sarcolemmal NHE activity, and (2) no significant effect on the NHE-inhibitory potency of 
cariporide.
British Journal o f Pharmacology (2001) 134, 1587-1595 
Keywords: Na+/H+ exchange; cariporide; hypothermia; temperature; myocyte
Abbreviations: fa, intrinsic buffering power; cSNARF-1, carboxy-seminaphthorhodafluor-1; GUARDIAN, Guard During 
Ischaemia Against Necrosis trial; HOE-642, 4-isopropyl-3-methylsulphonylbenzoyl-guanidine methanesulpho- 
nate; Jh, rate of acid efflux; NHE, Na+/H+ exchange; pHj, intracellular pH
In troduction
There is substantial pre-clinical evidence that recently- 
developed, specific Na+/H+ exchanger (NHE) inhibitors 
protect the myocardium during ischaemia and reperfusion 
(see reviews by Avkiran (1999b) and Karmazyn et al. 
(1999)). Indeed, the degree of protection afforded by NHE 
inhibition appears to be at least as good as that afforded 
by ischaemic preconditioning (Avkiran, 1999a; Gumina et 
al., 1999; Shipolini et al., 1997b). In the vast majority of 
pre-clinical studies with NHE inhibitors, hearts have been 
subjected to ischaemia and reperfusion under normothermic 
conditions, in an attempt to mimic the situation that 
occurs during spontaneous coronary occlusion and sub­
sequent revascularization in patients with coronary artery 
disease. Nevertheless, a few studies (Kim et al., 1998a, b; 
Myers & Karmazyn, 1996; Shipolini et al., 1997a;
‘ Author for correspondence at: Centre for Cardiovascular Biology and 
Medicine, King’s College London, The Rayne Institute, St Thomas’ 
Hospital, London SE1 7EH; E-mail: metin.avkiran@kcl.ac.uk
Yamauchi et al., 1997) have employed global hypothermic 
ischaemia, as encountered during cardiac surgery and 
transplantation, and have used NHE inhibitors in combina­
tion with established surgical cardioprotection techniques 
(such as hyperkalaemic cardioplegic arrest), with encoura­
ging findings. For example, our laboratory was the first to 
show that the specific NHE inhibitor cariporide (HOE-642; 
4-isopropyl-3-methylsulphonylbenzoyl-guanidine methanesul- 
phonate), used as an adjunct or additive to crystalloid 
cardioplegia, provides additional cardioprotective benefit 
under conditions of both moderate hypothermia (28°C), as 
encountered during routine cardiac surgery, and severe 
hypothermia (7.5°C), as used for cardiac preservation for 
transplantation (Shipolini et al., 1997a). Interestingly, data 
from the GUARDIAN trial (Theroux et al., 2000) indicate 
that a subgroup of high-risk patients subjected to 
iatrogenic myocardial ischaemia during coronary artery 
bypass graft surgery uniquely benefited from treatment with 
cariporide.
214
1588  K. Hoshino & M. Avkiran Effecb of hypothermia on Na*/H* exchange and Its inhibition
Its common occurrence under hypothermic conditions is 
a potentially important factor that distinguishes iatrogenic 
myocardial ischaemia during cardiac surgery from myo­
cardial ischaemia that manifests during spontaneous 
coronary events. Despite the experimental work that has 
been carried out to determine the cardioprotective efficacy 
of NHE inhibitors under conditions of normothermic and 
hypothermic ischaemia, however, the effects of reduced 
temperature per se on sarcolemmal NHE activity and on 
the potency of NHE inhibitors have not been fully 
characterized. Therefore, the objectives of the work 
described here were to determine, in adult rat ventricular 
myocytes, the effects of moderate hypothermia (25°Q on 
(1) sarcolemmal NHE activity and (2) the NHE-inhibitory 
potency of cariporide.
[NH4+]j and measured changes in pH; were used to estimate 
fa, from the equation /?j =  [NH4 +]i/pHj.
Determination o f  sarcolemmal N H E  activity
The myocytes were maintained in bicarbonate-free Tyrode’s 
solution throughout each experiment, thus enabling the rate 
of acid efflux (JH), which was calculated from the equation 
Jh = /Ij-dpHj/dt (where dpHj/dt is the rate of recovery of pH;), 
to be used as an indicator of sarcolemmal NHE activity 
(Yasutake et al., 1996). Jh values were determined either at 
pH; intervals of 0.05 throughout recovery from intracellular 
acidosis (when studying the effects of temperature) or during 
the first 60 s after the induction of intracellular acidosis 
(when studying the effects of cariporide).
Methods
This investigation was performed in accordance with the 
Home Office ‘Guidance on the Operation of the Animals 
(Scientific Procedures) Act 1986’, published by Her Majesty’s 
Stationery Office, London.
Isolation o f  ventricular myocytes
Adult male Wistar rats (200-250 g) were anaesthetized with 
sodium pentobarbitone (60 mg kg-1 i.p.) and injected with 
heparin (50 u i.v.), and their hearts were excised for the 
isolation of ventricular myocytes by enzymatic digestion, as 
described previously (Yasutake et al., 1996).
Measurement o f  pH t
Intracellular pH (pH;) was monitored in single myocytes 
loaded with the pH-sensitive fluoroprobe carboxy-semi- 
naphthorhodafluor-1 (cSNARF-1), using an established 
microepifluorescence technique (Avkiran & Yokoyama., 
2000; Gunasegaram et al., 1999; Haworth et al., 1997; 
1999; Snabaitis et al., 2000; Yasutake et al., 1996; 
Yokoyama et al., 1998; 2000). Calibration of the 
cSNARF-1 signal was carried out in situ at both 37°C (13 
cells) and 25°C (10 cells) using nigeridn-containing calibra­
tion solutions, as described in detail previously (Yasutake et 
al., 1996). Also as described previously (Yasutake et al.,
1996), at the end of each experiment, myocytes were exposed 
to the pH 7.0 calibration solution and the normalized 
fluorescence emission ratios were converted to pHj values 
by reference to a calibration curve that was obtained by a 
nonlinear least-squares fit of data to the equation given 
below.
Ino /Im  [ 10(ph-pk> 10<7-p*> '
(/580//640)pH7 U + 10(PH~PK) 1 + 10(’-«*>.
Estimation o f intracellular intrinsic buffering power
Intracellular intrinsic buffering power (/?;) was estimated by 
stepwise removal of extracellular NH4C1 at both 37°C (10 
cells) and 25°C (11 cells), as described in detail previously 
(Yasutake et al., 1996). At each step, calculated changes in
Experimental protocols
In initial studies, myocytes (n = 9 or 10 per group) were 
subjected to intracellular acidosis by transient exposure to 
20 mM NH4C1 and its subsequent washout for 8 min (first 
acid pulse), which was repeated 10-12  min later (second 
acid pulse) (Avkiran & Yokoyama., 2000; Gunasegaram et 
al., 1999; Snabaitis et al., 2000; Yasutake et al., 1996; 
Yokoyama et al., 1998). In both normothermic control and 
moderate hypothermia groups, the first acid pulse occurred 
at 37°C and was induced by a 4 min exposure to NH4C1. 
In the normothermic control group, cells were maintained 
at 37°C throughout the experiment and the second acid 
pulse was induced under identical conditions to the first. In 
contrast, in the moderate hypothermia group, cells were 
switched to superfusion at 25°C from 10 min before the 
second acid pulse and were maintained at this temperature 
thereafter; in this group, the second acid pulse was induced 
by a 6 min exposure to NH4C1. In subsequent experiments, 
cells (n = 8 to 11 per group) were subjected to a single acid 
pulse at either 37 or 25°C by transient (4 min at 37°C, 
6 min at 25°C) exposure to 20 mM NH4C1 and its 
subsequent washout for 8 min; when used, cariporide 
(0.01, 0.03, 0.1, 0.3, 1.0 or 3.0 pM) was present throughout 
NH4C1 washout.
Data analysis
Data are expressed as mean±s.e.mean. Experiments within 
each protocol were randomized. For inter-group comparisons 
of data, either analysis of variance (for multi-group 
comparisons) or the unpaired /-test (for comparisons between 
normothermic control and moderate hypothermia groups) 
was used. P<0.05 was considered significant. Dose-response 
curves and IC50 values were obtained by nonlinear regression 
analysis, using GraphPad Prism software.
Results
Effects o f  moderate hypothermia on 
cSNARF-1 calibration
The in situ calibration curves obtained at 37 and 25°C are 
shown in Figure 1. As illustrated, moderate hypothermia 
altered the pHj-dependence of the fluorescence emission ratio
British Journal of Pharm acology vol 134 (7)
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Figure 1 Calibration curves constructed using normalized Ism/Imo 
ratio data obtained during exposure of adult rat ventricular myocytes 
to nigericin-containing calibration solutions at (A) 37°C («= 13 cells) 
or (B) 25°C (n= 10 cells). See text for details.
of cSNARF-1, with estimated pK values for the fluoroprobe 
of approximately 7.00 at 37°C and 7.15 at 25°C. A 
comparable temperature-dependent pK change has been 
reported previously for another pH-sensitive fluoroprobe, 2 
7-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein (Graber 
et al., 1992). In subsequent experiments, fluorescence 
emission ratios were converted to pHj values by reference 
to the calibration curve obtained at the appropriate 
temperature (Figure 1).
Effects o f moderate hypothermia on Pi
As shown in Figure 2, moderate hypothermia produced a 
small change in the pHr dependence of Pi, such that Pi tended 
to be greater at 25°C than at 37°C, particularly under non- 
acidic conditions. For the calculation of Jh in subsequent 
experiments, Pi was estimated by reference to the /?,-versus-
£
pHj
Figure 2 The relationship between intracellular pH (pH;) and 
intrinsic buffering power (ft) in adult rat ventricular myocytes at 
37°C (n= 10 cells, open symbols) and 25°C (n = ll cells, solid 
symbols). Inset shows the equations obtained by linear regression 
analysis of the data obtained at each temperature.
pHj relationship obtained at the appropriate temperature 
(Figure 2).
Effects o f moderate hypothermia on 
sarcolemmal NHE activity
In the first set of experiments to determine the effect of 
moderate hypothermia on sarcolemmal NHE activity, two 
groups of cells were subjected to consecutive acid pulses, after 
each of which NHE activity was determined. The first pulse 
was at 37°C in both groups (to confirm comparable cell 
populations) while the second pulse was at either 37°C 
(normothermic control group, n=10) or 25°C (moderate 
hypothermia group, n = 9). Basal pHs values at 37°C, 
obtained prior to the first acid pulse, were comparable in 
the normothermic control and moderate hypothermia groups, 
measuring 7.31 ±0.02 and 7.28 ±0.04, respectively (NS). Cells 
in the normothermic control and moderate hypothermia 
groups acidified to a similar extent during the first acid pulse 
at 37°C, with minimum pHj values of 6.62 ±0.03 and 
6.64 ±0.07, respectively; during the second acid pulse, 
however, the minimum pHj was 6.66 ±0.03 in the normother­
mic control group but tended to be higher at 6.76 ±0.06 in 
the moderate hypothermia group. Figure 3 shows the JH- 
versus-pHj curves obtained after both acid pulses in the two 
study groups. NHE activity during recovery from the first 
acid pulse at 37°C was similar in both groups, with 
comparable Jh values obtained throughout the pHj range 
6.80-7.10 (Figure 3A). For example, JH at pHj 6.90 was 
3.79±0.75 m M  min-1 in the normothermic control group and 
3.78±0.43 m M  min-1 in the moderate hypothermia group 
(NS). In contrast, after the second acid pulse (which was 
carried out at 37°C in the normothermic control group but at 
25°C in the moderate hypothermia group), Jh in the 
moderate hypothermia group measured approximately 50% 
of that seen in the normothermic control group throughout 
the pHj range 6.80-7.10 (Figure 3B). This difference between 
the groups arose predominantly from an increase in NHE 
activity between the two acid pulses in the normothermic
37* C A= -39.8-pHj+308
25‘C A == -29.9*pHj+245
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Figure 3 Effect of moderate hypothermia on sarcolemmal NHE 
activity in adult rat ventricular myocytes subjected to two consecutive 
acid pulses. Figure shows the ./H-versus-pHj curves obtained during 
(A) the first acid pulse and (B) the second acid pulse. In the 
normothermic control group (h = 1 0  cells, open symbols) both acid 
pulses occurred at 37°C, whereas in the moderate hypothermia group 
\n = 9 cells, solid symbols) cells were switched from 37 to 25°C from 
10 min before the second acid pulse. The curves were constructed by 
determining Jh values at pHj intervals of 0.05 in each cell, 
throughout recovery from both acid pulses.
control group but not in the moderate hypothermia group. It 
appears therefore that consecutive acid pulses produce an 
increase in sarcolemmal NHE activity in adult rat ventricular 
myocytes under normothermic conditions and that this 
increase is inhibited by exposure of the cells to moderate 
hypothermia.
To determine the effect of moderate hypothermia on 
NHE activity in the absence of any changes arising from 
repeated episodes of intracellular acidosis, we next exam­
ined NHE activity in two groups of cells (n = 8 or 9 per 
group) subjected to a single acid pulse, at either 37 or 
25°C. In these experiments, the basal pH; value obtained 
prior to the acid pulse was 7.32 + 0.07 in the normothermic 
control group (n = 9) but was significantly higher at 
7.46 ±0.03 in the moderate hypothermia group (n =*= 8). 
The minimum pH; achieved during the acid pulse was also 
significantly higher in the moderate hypothermia group 
(6.83 ±0.03) relative to the normothermic control group 
(6.67 ±0.04). Figure 4 shows the /H-versus-pH curves 
obtained in both study groups; as can be seen, the curve 
was shifted to the left under conditions of moderate 








Figure 4 Effect of moderate hypothermia on sarcolemmal NHE 
activity in adult rat ventricular myocytes subjected to a single acid 
pulse. Figure shows the JH-versus-pHj curves for the normothermic 
control group (n = 9 cells, open symbols), in which the acid pulse 
occurred at 37°C, and the moderate hypothermia group (n — 8 cells, 
solid symbols), in which the acid pulse occurred at 25°C. The curves 
were constructed by determining Jh values at pHj intervals of 0.05 in 
each cell, throughout recovery from the acid pulse.
throughout the pHf range 6.80-7.10. For example, JH at 
pH; 6.90 was 3.91 ±0.55 mM min-1 in the normothermic 
control group but measured only 59% of that, at 
2.32±0.24mM min-1, in the moderate hypothermia group 
(P<0.05).
Effects o f moderate hypothermia on the NHE-inhibitory 
potency o f cariporide
In this protocol, we sought to determine whether the 
NHE-inhibitory potency of cariporide is altered under 
conditions of moderate hypothermia. Twelve groups of 
cells (n = 8 to 11 per group) were again subjected to a 
single acid pulse at either 37 or 25°C, with cariporide 
(0.01-3.0 (j.m) present in the superfusion solution through­
out the recovery phase. Since cariporide inhibits recovery 
from intracellular acidosis, JH was determined only at the 
nadir of the acid pulse, as illustrated in Figure 5. The 
basal pHj value obtained prior to the acid pulse was 
7.25±0.01 in the cells studied at 37°C (n = 52) and again 
was significantly higher at 7.45 ±0.02 in the cells studied 
at 25°C (n = 53). The minimum pHj value, obtained upon 
NH4CI washout, was 6.64 ±0.02 in the cells studied at 
37°C (n=* 52) and was also significantly higher at
6.72 ±0.02 in the cells studied at 25°C (n = 53). At each 
temperature, however, there was no significant difference in 
either the basal pH,- or the minimum pH between the six 
groups that received the different concentrations of 
cariporide (Table 1).
Figure 6A shows the JH values obtained in the various 
study groups at 37 and 25°C. As can be seen, in the presence 
of each concentration of cariporide, the JH obtained at 25°C 
was approximately 50-60% of that obtained at 37°C, which 
is consistent with our observations above. At both 
temperatures, cariporide produced a concentration-dependent 
reduction in Jh (Figure 6A). Notably, even in the presence of 
3.0 pM cariporide, was not completely abolished, most 
likely due to residual Na+/HC03-  cotransport activity (Wu
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Figure 5 Effect o f cariporide on recovery from intracellular acidosis in adult rat ventricular myocytes. Figure shows representative 
pHj recordings obtained in cells exposed to a low, non-inhibitory concentration (0.01 / i M )  or a high, inhibitory concentration 
(1.0 / iM )  of cariporide during acid pulses carried out under conditions o f (A) normothermia (37°C) or (B) moderate hypothermia 
(25°C). Shaded areas indicate the period during which was estimated from the rate o f recovery o f pHj.
Table 1 Basal and minimum pHj values in cells exposed to cariporide at 37 or 25°C.
Cariporide
(MM) n
3 T C  
basal pHj min pH, n
25° C  
basal pH j min pH j
0.01 9 7.23 ± 0.03 6.62 ±0.03 9 7.44 ± 0.03 6.78 ±0.03
0.03 8 7.23 ±0.03 6.66 ±0.06 9 7.51 ± 0 .04 6.75 ± 0.05
0.1 9 7.25 ± 0.04 6.59 ±0.03 8 7.41 ± 0 .04 6.68 ± 0 .06
0.3 8 7.29 ± 0.04 6.70 ± 0 .04 8 7.47 ± 0 .06 6 .74± 0.04
1.0 9 7.31 ±0.03 6.67 ±0.03 11 7.45+0.04 6.72±0.03
3.0 9 7.22 ±00.3 6.58 ± 0 .02 8 7.43 ± 0 .03 6.66 ±0.03
For each group, n indicates the number o f  cells studied. In each cell, basal and minimum pH; values were noted immediately before 
exposure to and immediately after washout o f N H 4C1, respectively.
e t a l., 1994). Figure 6B illustrates the dose-response curves 
for NHE inhibition by cariporide, obtained after the 
correction of JH values for residual Na+/HC03" cotransport 
activity, at both 37 and 25°C. As can be seen, moderate 
hypothermia did not have a significant effect on the NHE- 
inhibitory potency of cariporide, with I C 5 0  values of 
approximately 150 nM at 37°C and 130 nM at 25°C.
Discussion
Although several studies have attempted to determine the 
effects of moderate hypothermia (20-30°C) on plasma 
membrane NHE activity, their findings have been somewhat 
contradictory, probably due to the variety of cell types that 
have been used and the manner in which NHE activity has
1 min
cariporide
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Figure 6 Effect o f moderate hypothermia on the NHE-inhibitory 
potency o f cariporide in adult rat ventricular myocytes. Figure shows 
(A) absolute J H values and (B) relative NHE activity, in cells 
subjected to a single acid pulse under conditions o f normothermia 
(37°C, open bars and symbols) or moderate hypothermia (25°C, solid 
bars and symbols), in the presence o f 0.01, 0.03, 0.1, 0.3, 1.0 or 
3.0 fiM cariporide (ri = 8 to 11 cells per group). *?< 0 .05  versus 37°C.
been assessed. In guinea-pig erythrocytes, lowering the 
temperature from 37 to 20°C has been shown to produce 
an increase in Na* influx that is sensitive to inhibition by the 
NHE inhibitor amiloride, which is indicative of a hypother­
mia-induced increase in NHE activity (Zhou & Willis, 1989). 
More recent work has shown that lowering the temperature 
from 37 to 27°C induces rapid swelling of rat glial cells in a 
manner that is inhibited by the amiloride analogue 
ethylisopropylamiloride, again suggesting increased NHE 
activity under conditions of moderate hypothermia (Plesnila 
et al., 2000). In contrast, the rate of swelling of rat 
lymphocytes following exposure to sodium propionate has 
been shown to be considerably slower at 22 and 27°C than at 
37°C (and to be inhibited at each temperature by the NHE 
inhibitor FR 168888), suggesting a hypothermia-induced 
decrease in NHE activity (Yamauchi et al., 1997). In the 
above studies (Plesnila et al., 2000; Yamauchi et al., 1997), 
NHE activity was surmized from the inhibitory effects of 
NHE inhibitors on the observed increase in cellular volume 
and direct measurements of NHE activity (i.e. the rate of 
NHE-mediated Na* influx or H + efflux) at known values of 
pHj, which is the principal regulator of NHE activity 
(Wakabayashi et al., 1997), are scarce. In this context,
Graber et al. (1992) have measured the rate of recovery of 
pHj after the induction of an intracellular acid load in 
opossum kidney cells and shown this to be slower at 25°C 
than at 37°C. A similar observation has been reported in 
sheep cardiac Purkinje fibres, upon lowering of the ambient 
temperature from 37 to 22°C (Ellis & Macleod, 1985). 
Although these findings may indicate a reduction in NHE 
activity in the presence of moderate hypothermia, it is 
notable that, in both studies, the rate of recovery of pHj was 
measured at a different level of intracellular acidosis under 
conditions of normothermia versus moderate hypothermia.
The present study is the first detailed characterization of 
the effects of moderate hypothermia on sarcolemmal NHE 
activity in adult mammalian ventricular myocytes, and 
demonstrates a significant inhibition of such activity upon 
lowering of the ambient temperature from 37 to 25°C. 
Notably, this inhibition is not absolute, such that at 25°C 
sarcolemmal NHE activity is retained at approximately 50- 
60% of that observed at 37°C. A recent preliminary report 
indicates that moderate hypothermia (27°C) may produce a 
similar degree of inhibition of sarcolemmal NHE activity in 
guinea-pig ventricular myocytes also (Ch’en & Vaughan- 
Jones, 2000). Interestingly, other evidence in the literature 
suggests that pathophysiologically significant sarcolemmal 
NHE activity may be retained even under conditions of 
severe hypothermia (<20°C). Thus, Na+ has been shown to 
accumulate intracellularly during 6 h storage of embryonic 
chick cardiac myocytes at 10°C (Knerr & Lieberman, 1993) 
and 12 h storage of adult rat hearts at 4°C (Askenasy et al., 
1996) in a manner that was significantly attenuated by the 
NHE inhibitor ethylisopropylamiloride.
In our experiments that employed two consecutive acid 
pulses, there was a marked increase in sarcolemmal NHE 
activity after the second acid pulse relative to the first, when 
both pulses occurred at 37°C (Figure 3). In contrast, no such 
increase in NHE activity was observed when the second pulse 
was at 25°C (Figure 3). In our previous studies that used 
similar 2-pulse protocols at 34°C (Avkiran & Yokoyama, 
2000; Gunasegaram et al., 1999; Snabaitis et al., 2000; 
Yasutake et al., 1996; Yokoyama et al., 1998), there was only 
a small (<30%) increase in NHE activity after the second 
acid pulse (in the absence of any other intervention) and this 
increase was not statistically significant. It appears therefore 
that repeated episodes of intracellular acidosis can lead to 
increased sarcolemmal NHE activity, through a mechanism 
that is very sensitive to the ambient temperature. It would be 
of interest to determine the role of altered activity of NHE- 
regulatory signalling pathways (such as the protein kinase C 
and extracellular signal regulated kinase pathways (Moor & 
Fliegel, 1999; Snabaitis et al., 2000)) in such stimulation of 
sarcolemmal NHE activity by repeated episodes of acidosis. 
Regardless of the precise mechanisms underlying this 
interesting phenomenon, however, it is important to note 
that a similar reduction in sarcolemmal NHE activity by 
moderate hypothermia was evident also when cells were 
exposed to a single acid pulse (Figure 4). Therefore, it is 
likely that this negative effect of moderate hypothermia arose 
principally from the inhibition of sarcolemmal NHE activity 
per se rather than the attenuation of its stimulation by 
repeated episodes of intracellular acidosis.
The present work has also revealed that cariporide inhibits 
sarcolemmal NHE activity with comparable potency at 25
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and 37°C, with an IC50 of 130-150 nM under each condition. 
Such an IC50 value is approximately 15 fold greater than that 
we have previously estimated for this drug in rat ventricular 
myocytes (Shipolini et a l, 1997b). However, in our earlier 
study (Shipolini et al., 1997b), intracellular acidosis to 
activate the exchanger was induced in the absence of 
extracellular Na+, which was reintroduced concomitantly 
with cariporide. In contrast, in the present study, intracellular 
acidosis was induced by the washout of NH4 C1 with Tyrode’s 
solution, which contains N a+ at a concentration of 137 mM. 
Extracellular N a+ is known to antagonize competitively the 
binding of benzoylguanidine-based inhibitors such as car* 
iporide to NHE (Baumgarth et al., 1998), which is likely to 
underlie the different IC50 values obtained in our studies. 
Indeed, in guinea-pig ventricular myocytes, the IC50 for 
HOE-694 (another benzoylguanidine-based NHE inhibitor 
that is closely related to cariporide structurally) has been 
estimated to be approximately 16 fold greater in the presence 
of an extracellular Na+ concentration of 150 mM, relative to 
the value obtained in the virtual absence of extracellular Na+ 
(Loh et al., 1996).
An interesting observation in the present study was the 
difference in basal pH* under conditions of normothermia 
versus moderate hypothermia, such that this was 0.15-0.20 
pH unit greater at 25°C than at 37°C. To our knowledge, this 
is the first report of this phenomenon in isolated ventricular 
myocytes, although similar effects o f moderate hypothermia 
have been reported previously in sheep Purkinje fibres (pHj 
increase of 0.21 (Ellis & Macleod, 1985) or 0.31 (Bright & 
Ellis, 1994) on reducing temperature from 35 to 21-22°Q , 
isolated rat hearts (pHj increase of 0.16 on reducing 
temperature from 36 to 20°C (Gruwel et a l ,  1998)) and 
sheep myocardium in vivo (pHf increase of 0.19 on reducing 
temperature from 37 to 26°C (Swain et a l , 1991)). Although 
the precise mechanism(s) underlying this increase in steady- 
state pHj have not been determined, hypothermia-induced 
changes in the pK of intracellular buffers, such as the 
imidazole moiety of histidine, are likely to play an important 
role (Roos & Boron, 1981). In this context, it is notable that 
the pK of imidazole has been estimated to be 6.75 at 37°C 
but to increase to 7.30 at 25°C (Durand et a l, 1998). On the 
basis that a low level of sarcolemmal NHE activity appears 
to be retained under steady-state conditions in ventricular 
myocytes (Leem et a l ,  1999), our data suggest that the 
inhibition of such activity may also contribute to the increase 
in basal pHj during exposure to moderate hypothermia.
Previous data in sheep Purkinje fibres suggest that, under 
conditions of moderate hypothermia, the higher steady-state 
pH; is associated with an attenuated level of intracellular 
acidification in response to the NH4 CI pulse (Ellis & 
Macleod, 1985). Since pHj is a critical determinant of NHE 
activity (Wakabayashi et a l ,  1997), we attempted to 
compensate for this and obtain comparable levels of 
intracellular acidosis in the normothermic control and 
moderate hypothermia groups, by extending the duration of
the NH4 CI pulse from 4 min at 37°C to 6  min at 25°C. This 
approach was only partially successful, however, in that the 
minimum pH; achieved at 25°C remained approximately 0.10 
pH unit higher than that at 37°C. This difference is unlikely 
to contribute to the lower NHE activity observed at 25°C 
(Figures 3 and 4), since values were compared at identical 
pHj values in the two groups. Nevertheless, in the cariporide 
study, where /h  was determined at the nadir of the acid 
pulse, a higher minimum pHj value may have contributed to 
the lower NHE activity at 25°C. Indeed, in the presence of a 
non-inhibitory concentration of cariporide (0.01 /im), Jh at 
25°C was only 45% of that at 37°C (Figure 6 A). In contrast, 
when the comparison was made at identical values of pH; in 
a similar protocol in the absence of cariporide (Figure 4), 
hypothermia-induced inhibition of sarcolemmal NHE activity 
was somewhat attenuated, with JH values at 25°C measuring 
approximately 60% of those at 37°C.
The temperature-independence of the NHE-inhibitory 
potency of cariporide, at least within the temperature range 
that we have studied, suggests that this agent is likely to retain 
its cardioprotective efficacy under moderately hypothermic 
conditions. This is indeed borne out by our earlier work in 
isolated rat hearts (Shipolini et a l, 1997a), which revealed that 
the use of cariporide as an additive to crystalloid cardioplegia 
improved the recovery of contractile function and reduced the 
leakage of creatine kinase following 1 2 0  min of global 
ischaemia at 28°C. This property is potentially important in 
relation to the application of cariporide for surgical 
myocardial protection and distinguishes this agent from other 
ion transport inhibitors, such as L-type calcium channel 
blockers. In this context, unlike cariporide (Shipolini et a l,  
1997a), verapamil (Hearse et a l ,  1984) and nifedipine 
(Fukunami & Hearse, 1985) have been shown to provide no 
significant cardioprotective benefit in isolated rat hearts when 
used as an additive to hyperkalaemic cardioplegia under 
conditions of moderate hypothermia, although both were 
effective at temperatures > 30°C.
In conclusion, our work in isolated adult rat ventricular 
myocytes has shown that moderate hypothermia (25°C) 
produces a significant, but only partial, inhibition of 
sarcolemmal NHE activity. Furthermore, the NHE-inhibitory 
potency of cariporide is not affected by such a reduction in 
temperature. These findings may help provide a mechanistic 
basis for the previously demonstrated ability of cariporide to 
protect ischaemic myocardium under conditions of moderate 
hypothermia and suggest that this effect is likely to arise from 
the inhibition of retained NHE activity.
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Abstract
Objective: To characterise the effects of exogenous H20 2 on sarcolemmal Na"*7H* exchanger (NHE) activity and determine the roles 
of extracellular signal-regulated kinase (ERK), p38 mitogen-activated protein kinase (p38 MAPK) and protein kinase C (PKC) in 
observed effects. Methods: Sarcolemmal H+ efflux rate ( JH) was determined by microepifluorescence at a pH, of 6.70 in adult rat 
ventricular myocytes, after two consecutive acid pulses in HCOJ-free medium; before the second pulse, cells (n=7-10/group) were 
exposed to H20 2 or vehicle and the change in JH (AJH) was used to quantify the change in NHE activity. ERK and p38 MAPK activities 
were determined by immunoblotting with phosphospecific antibodies. Results: Relative to control, AJH was increased by a 10-min 
exposure to 100, but not 1 or 10 p.M H20 2 (1000 p.M was not tolerated); 3 or 6 min exposure to 100 p.M H20 2 was without effect. ERK 
and p38 MAPK activities were both increased by 100 jjlM H20 2 (peak at 6 min); the ERK kinase inhibitor PD98059 (10 p.M), but not the 
p38 MAPK inhibitor SB203580 (1 |xM), inhibited the H20 2-induced increase in A /H. H20 2-induced ERK activation was inhibited not 
only by PD98059 (10 p.M), but also by the non-selective tyrosine kinase inhibitor genistein (3-100 p.M), the EGF receptor kinase 
inhibitor AG1478 (3-300 nM) and the Src family kinase inhibitor PP2 (0.1-10 p.M). The PKC inhibitors GF109203X (0.3-10 p-M) and 
chelerythrine (1 -30 p.M) were without effect on ERK activation, although the former abolished the H20 2-induced increase in AJH. 
Conclusions: Our data demonstrate that, in adult rat ventricular myocytes, (i) hydrogen peroxide stimulates sarcolemmal NHE activity, 
(ii) this response requires activation of ERK and PKC, but not p38 MAPK, (iii) ERK activation occurs through tyrosine kinase-mediated, 
but PKC-independent, mechanisms © 2002 Elsevier Science B.V. All rights reserved.
Keywords: Free radicals; Myocytes; Na/H-exchanger; Signal transduction; Protein kinases
1. Introduction
The sarcolemmal Na+/H + exchanger (NHE) is encoded 
by the NHE-1 gene [1] and contributes to the integrated 
control of intracellular pH (pH() in cardiac myocytes [2]. 
Basal activity of the sarcolemmal NHE is low under 
physiological conditions [2] but increased exchanger ac­
tivity and resultant increases in intracellular Na+ and/or 
pHs may mediate the inotropic responses of myocardium to 
neurohormonal stimuli [3-6] and myocardial stretch [7]. 
With respect to cardiac pathophysiology, sarcolemmal 
NHE activity may play a permissive role in the hy­
pertrophic response of cardiac myocytes to neurohormonal
•Corresponding author. Tel.: +44-20-7928-9292, ext. 3375; fax: +44- 
20-7928-0658.
E-mail address: metin.avkiran@kcl.ac.uk (M. Avkiran).
[8] and mechanical [9] stimuli in vitro and in the adverse 
ventricular remodelling that occurs following myocardial 
infarction in vivo [10-12], Perhaps the strongest ex­
perimental evidence for a pathophysiological role for the 
sarcolemmal NHE, however, is that which implicates the 
exchanger in the development of myocardial injury and 
dysfunction during ischaemia and reperfusion (see reviews 
by Avkiran [13] and Karmazyn et al. [14]). Importantly, 
recent studies suggest that NHE inhibition by the NHE-1- 
selective inhibitor cariporide may provide cardioprotective 
benefit in certain clinical settings also, such as in high-risk 
patients who are subjected to elective myocardial is­
chaemia and reperfusion during coronary artery bypass 
graft surgery [15].
There is strong evidence that oxidative stress also
Time for primary review 25 days.
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contributes to the development of myocardial injury and 
dysfunction during ischaemia and reperfusion [16,17]. 
Intriguingly, data from Karmazyn’s laboratory suggest that 
the adverse myocardial effects of oxidative stress (induced 
by exposure to H20 2), when applied either alone [18] or in 
combination with ischaemia and reperfusion [19], are 
attenuated by NHE inhibition. Although sarcolemmal NHE 
activity was not determined in either study, these findings 
raise the possibility that an increase in such activity may 
mediate some of the detrimental consequences of exposure 
to H20 2, or that NHE inhibitors (or the consequences of 
NHE inhibition) may enhance myocardial tolerance to such 
oxidative stress. Recent data from neonatal rat ventricular 
myocytes are consistent with the former possibility [20]. 
However, the effects of oxidative stress induced by H20 2 
on sarcolemmal NHE activity in adult myocardium and the 
signalling mechanism(s) underlying any such effects are 
unknown. Notably, qualitative and quantitative changes are 
known to occur during post-natal development in the 
myocardial expression of NHE-regulatory signalling mole­
cules, such as ERK [21] and protein kinase C (PKC) 
[22-24], Furthermore, the basal expression and activity of 
NHE differs significantly between neonatal and adult rat 
ventricular myocytes [25]. Thus, the regulation of NHE 
activity by H20 2 may differ between adult and neonatal 
myocardium.
The present study used adult rat ventricular myocytes to 
characterise the time- and dose-dependent effects of H20 2 
on the activities of the sarcolemmal NHE and the putative 
NHE-regulatory signalling pathways mediated by ERK and 
p38 MAPK. Subsequently, any causal link between the 
observed changes was probed through the use of specific 
inhibitors of ERK kinase (MEK) and p38 MAPK. Finally, 
we explored the proximal signalling mechanisms that are 
responsible for H20 2-induced ERK activation.
2. Materials and methods
The present investigation was performed in accordance
with the Home Office Guidance on the Operation of the
Animals (Scientific Procedures) Act 1986, published by
HMSO, London.
2.1. Isolation of ventricular myocytes
Ventricular myocytes were isolated from the hearts of
adult male Wistar rats (200-250 g) using a collagenase-
based enzymatic digestion technique that provides a yield
of >80% rod-shaped myocytes, as described previously
[26],
2.2. Determination of sarcolemmal NHE activity
Sarcolemmal NHE activity was determined in quiescent
single myocytes loaded with the pH-sensitive fluoroprobe
471
cSNARF-1, using a microepifluorescence technique [26- 
29]. Cells were maintained in HCO^-free medium (34°C) 
throughout each experiment, thus enabling the rate of acid 
efflux (JH) to be used as the indicator of sarcolemmal NHE 
activity. JH was determined at a pH( of 6.70 during 
recovery from intracellular acidosis before and after expo­
sure to H20 2, and the change in JH (AJH) used to quantify 
H20 2-induced changes in NHE activity.
2.3. Determination of cellular MAPK, p90 ribosomal S6 
kinase (p90rsk)  and Src tyrosine kinase activities
Protein samples (40 |xg) from whole cell lysates were 
separated by SDS-PAGE on 9% polyacrylamide gels. 
MAPK activities were determined through the detection of 
dual phosphorylation of ERK1/2 and p38 MAPK by 
immunoblot analysis using phosphospecific antibodies 
(New England BioLabs, MA), as described previously 
[27,28]. Activities of p90r‘k and Src tyrosine kinase were 
determined by the detection of Ser381 or Tyr416 phos­
phorylation, respectively, using phosphospecific antibodies 
(New England BioLabs) [27,28]. To confirm equal protein 
loading, non-phosphospecific antibodies for ERK2, p38, 
p60Src (all from Santa Cruz Biotechnology, CA) and p90rtk 
(Transduction Laboratories, KY) were used. Specific pro­
tein bands were detected by enhanced chemiluminescence 
and autoradiography, and phosphorylation status was quan­
tified by using a LKB 2222 Bromma Ultroscan XL laser 
densitometer.
2.4. Determination of cellular MAPK-activated protein 
kinase-2 (MAPKAPK-2) activity
The inhibitory effect of SB203580 on the cellular 
activity of p38 MAPK was determined by immuno- 
precipitating MAPKAPK-2 (which is phosphorylated and 
activated by p38 MAPK) from cell lysates and subjecting 
it to an in vitro kinase assay (Upstate Biotechnology, NY). 
In this assay, activity of MAPKAPK-2 is determined by 
incubation of the immune complex with the specific 
MAPKAPK-2 substrate peptide KKLNRTLSVA in a re­
action mixture containing [y-32P]:ATP and quantifying the 
resulting incorporation of 32P into the peptide by scintilla­
tion counting [30].
2.5. Experimental protocols
For determination of H20 2-induced changes in NHE 
activity, myocytes were subjected to intracellular acidosis 
by transient exposure to 20 mM NH4C1 (first acid pulse), 
which was repeated 17-27 min later (second acid pulse). 
Dose-dependent effects of H20 2 were assessed by expos­
ing cells to vehicle or 1, 10, 100 or 1000 p-M H20 2 
(Sigma-Aldrich, Poole, UK) from 10 min before the 
second acid pulse (see Fig. 1A). Time-dependent effects
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Fig. 1. Experimental protocols used to determine the effects of H20 2 on sarcolemmal N a4 /H 4 exchanger activity. Protocols are shown for the 
determination of (A) dose-dependent, (B) time-dependent and (C) protein kinase-mediated effects of H20 2 on sarcolemmal N a4 /H 4 exchanger activity in 
adult rat ventricular myocytes. Solid bars represent the periods of exposure to 20 mM NH4C1, whose washout produced intracellular acidosis; J„ was 
determined during recovery from such acidosis (shaded areas).
were assessed by exposing cells to vehicle or 100 p,M 
H20 2 from 3, 6 or 10 min before the second acid pulse 
(see Fig. IB). When studying the effects of the MEK 
inhibitor PD98059 (10 p.M), the p38 MAPK inhibitor 
SB203580 (1 p,M) or the PKC inhibitor GF109203X (1 
P-M) (all from Calbiochem-Novabiochem, Nottingham, 
UK), the kinase inhibitor was present from 10 min before 
the start of exposure to 100 p,M H20 2 (see Fig. 1C). The 
concentrations of PD98059 and GF109203X were selected 
on the basis of our earlier work on receptor-mediated NHE 
regulation in the same preparation [27,28] and the con­
centration of SB203580 was selected since it fully inhibits 
p38 MAPK activity while not affecting other kinase 
pathways in neonatal myocytes [31].
For the determination of H20 2 effects on kinase activity 
(n= 4  experiments in each protocol, with each experiment 
using cells from a separate heart), myocytes in suspension 
were exposed to H20 2, using identical concentrations and 
exposures to those described above; in time-response 
studies, duration of H20 2 exposure was additionally
extended to 20 and 30 min. When studying the effects of 
PD98059 (10 p,M) or SB203580 (1 jjlM ) on H20 2-induced 
kinase activation, this was present from 10 min before the 
start of exposure to 100 p.M H20 2 (10 min), as above. 
When studying the effects of PKC inhibitors (GF109203X 
and chelerythrine), the non-selective tyrosine kinase inhib­
itor genistein, the Src family kinase inhibitor PP2 and the 
epidermal growth factor (EGF) receptor kinase inhibitor 
AG1478 (all from Calbiochem-Novabiochem) on H20 2- 
induced kinase activation, various concentrations of each 
inhibitor were present from 30 min before the start of 
exposure to 100 p,M H20 2 (10 min).
Stock solutions of all kinase inhibitors were dissolved in 
DMSO, which was also included in superfusion solutions 
(at its final concentration of 0.05%) in control and H20 2- 
only experiments, for the appropriate periods.
2.6. Statistical analysis
Data are mean±S.E.M. For the microepifluorescence
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experiments, cells from one heart were used on each day 
and these were allocated in a randomised manner to the 
experimental groups of the protocol under study; eight to 
10 separate hearts were required to complete each protocol 
(see figure legends), within which each experimental group 
comprised seven to 10 myocytes. The biochemical experi­
ments were repeated four times, each time using myocytes 
from a separate heart. For inter-group comparison of AJH 
or protein kinase phosphorylation, data were subjected to 
ANOVA; further analysis was by Dunnett’s test, to com­
pare each treatment group with the control group. P<0.05 
was considered significant.
3. Results
3.1. Effects of H20 2 on sarcolemmal NHE activity
3.1.1. Dose-response studies
In control cells that were exposed to vehicle, there was 
little change in JH during the second acid pulse relative to 
the first, as reflected by a A7H of around zero (Fig. 2A). 
Relative to the control group, a 10-min exposure to 100 
|i,M H20 2 produced a significant increase in AJH; in 
contrast, AJH was not changed significantly by a similar 
exposure to 1 or 10 pM H20 2 (Fig. 2A). Following a 
10-min exposure to 1000 pM H20 2, cells became hyper- 
contracted and detached from the cover slip during the 
second acid pulse; thus, AJH could not be determined in 
this group. These data indicate that H20 2 stimulates 
sarcolemmal NHE activity in a dose-dependent manner, 
such that >10 pM H 20 2 is required to achieve a signifi­
cant effect.
3.1.2. Time-response studies
These experiments were performed to delineate the 
temporal profile of H20 2-induced stimulation of NHE 
activity. Consistent with the above results, a 10-min 
exposure to 100 pM H20 2 again produced a significant 
increase in A7H (Fig. 2B). However, when exposure time 
was limited to 3 or 6 min, there was no significant change 
in A7h in response to 100 pM H20 2 (Fig. 2B). These data 
indicate that H20 2-induced stimulation of sarcolemmal 
NHE activity requires an exposure time of > 6  min.
3.2. Effect of H20 2 on cellular ERK and p38 MAPK
activity
We next determined the dose- and time-dependent 
effects of H20 2 on ERK and p38 MAPK activity, to test 
whether either pathway is activated in a manner that is 
consistent with a potential NHE-regulatory role. Exposure 
of cells to 1-1000 pM H20 2 for 10 min produced dose- 
dependent activation of both ERK1/2 and p38 MAPK, 
with significant increases in activity achieved with 100 pM 
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Fig. 2. Dose- and time-dependent effects o f H20 2 on sarcolemmal 
N a+/H + exchanger activity. The change in JH (AJH) during the second 
acid pulse relative to the first is shown in (A) cells exposed to vehicle or 
1 ,10  or 100 pM H20 2 from 10 min before the second acid pulse, and (B) 
cells exposed to vehicle or 100 pM H20 2 from 3, 6 or 10 min before the 
second acid pulse. *P<0.05 versus control (seven to 10 cells per group, 
obtained from 10 hearts).
ventricular myocytes, ERK2 (cf. ERK1) was the pre­
dominant isozyme detected by the ERK1/2 phosphos- 
pecific antibody with readily detectable basal phosphoryla­
tion in the untreated control cells. Therefore, subsequent 
quantitation of the effects of H20 2 on ERK activity was 
based on the change in the phosphorylation status of 
ERK2. The temporal profiles indicated that peak ERK and 
p38 MAPK activation occurred after 6 min of exposure to 
100 pM  H2O z, and that such activation was sustained for
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Fig. 3. Dose- and time-dependent effects o f H 20 2 on ERK and p38-MAPK activity. Cells were exposed to (A) vehicle or 1, 10, 100 and 1000 pM  H20 2 
for 10 min, and (B) vehicle or 100 pM  H 20 2 for 3, 6, 10, 20 or 30 min. Autoradiograms show representative Western blots with phosphospecific (top 
panel) and non-phosphospecific (bottom panel) for ERK and p38-MAPK antibodies. *P<0.05 versus control (four experiments, with cells from four 
hearts).
approximately 10 min (Fig. 3B). The concordance between 
the dose- and time-dependence characteristics of H20 2- 
induced activation of ERK and p38 MAPK and H20 2- 
induced stimulation of sarcolemmal NHE activity suggests 
that either kinase may play a role in the latter response.
3.3. Role o f ERK and p38 MAPK in H20 2-induced 
stimulation o f sarcolemmal NHE activity
This protocol was designed to test whether activation of 
the ERK and/or the p38 MAPK pathway was necessary 
for  H20 2-induced stimulation of sarcolemmal NHE activi­
ty. In the absence of any pre-treatment, a 10-min exposure 
to 100 p,M H20 2 again produced a significant increase in 
AJh (Fig. 4A). This effect was abolished by pre-treatment 
of cells with the MEK inhibitor PD98059 but was unaf­
fected by pre-treatment with the p38 MAPK inhibitor 
SB203580 (Fig. 4A). The lack of effect of SB203580 was 
not due to inadequate inhibition of p38 MAPK activity, 
since H20 2-induced activation of MAPKAPK-2 was 
abolished by the SB203580 pre-treatment protocol (Fig. 
4B). These data indicate that H20 2-induced stimulation of 
sarcolemmal NHE activity requires activation of the ERK 
but not the p38 MAPK pathway.
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Fig. 4. Effects of MAPK inhibition on H 20 2-induccd increases in 
sarcolemmal N a4 /H * exchanger and cellular MAPKAPK-2 activities. In 
(A), cells were subjected to two consecutive acid pulses. The change in J„ 
(AJH) during the second acid pulse relative to the first is shown in cells 
exposed to vehicle or 100 p.M H 20 2 from 10 min before the second acid 
pulse, in the absence or presence of pre-treatment with the MEK inhibitor 
PD98059 (10 p.M) or the p38 MAPK inhibitor SB203580 (1 piM). 
*P< 0.05 versus control (seven to 10 cells per group, obtained from 10 
hearts). In (B), cells were exposed to vehicle or 100 p.M H20 2 for 10 min 
in the absence or presence of pre-treatment with the p38 MAPK inhibitor 
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Fig. 5. Effects of MEK inhibition on H 20 2-induced increases in ERK 
and p90"k activity. Cells were exposed to vehicle or 100 (J.M H20 2 for 10 
min in the absence or presence of pre-treatment with the MEK inhibitor 
PD98059 (10 jjlM). Autoradiograms show representative Western blots 
with phosphospecific (top panel) and non-phosphospecific (bottom panel) 
antibodies for (A) ERK and (B) p90”k. *P < 0.05 versus control (four 
experiments, with cells from four hearts).
To explore whether the inhibitory effect of PD98059 on 
NHE stimulation occurred through the predicted mecha­
nism of MEK inhibition, we next determined its effect on 
ERK activity. As shown in Fig. 5, a 10-min exposure to 
100 p.M H20 2 activated not only ERK (thus confirming 
our earlier observation) but also its downstream substrate 
p90rsk, which is a putative NHE-1 kinase [32,33], 
PD98059 abolished H20 2-induced increases in ERK and 
p90rsk activity, whilst having no effect on basal activity 
(Fig. 5). These data support an effector role for ERK
and/or p90rsk in H20 2-induced stimulation of sarcolemmal 
NHE activity.
3.4. Role o f PKC in H20 2-induced stimulation o f 
sarcolemmal NHE activity
Our previous work has shown that, in addition to ERK/ 
p90rsk activation, PKC activation is also necessary for the 
stimulation of sarcolemmal NHE activity through a 1A- 
adrenergic [28] and angiotensin II AT, [27] receptors.
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Fig. 6. Effects of PKC inhibition on H 20 2-induced increases in sarcolem­
mal N a4/H * exchanger activity. The change in JH (AJ„) during the 
second acid pulse relative to the first is shown in cells exposed to vehicle 
or 100 pM  H 2O j from 10 min before the second acid pulse in the 
absence or presence of pre-treatment with the PKC inhibitor GF109203X 
(1 pM ). *P< 0.05 versus control (seven to 10 cells per group, obtained 
from eight hearts).
Here, we tested whether this holds true also for H20 2- 
induced stimulation of sarcolemmal NHE activity. As 
shown in Fig. 6, pre-treatment with the PKC inhibitor 
GF109203X (used at a concentration of 1 pM, which we 
have shown previously to inhibit phorbol ester-induced 
effects in an identical preparation [28]) completely 
abolished the H20 2-induced increase in AJH. This suggests 
that, in addition to ERK/p90r,k activation, PKC activation 
is also necessary for the stimulation of sarcolemmal NHE 
activity by H20 2.
3.5. Proximal regulators o f ERK activity: role o f PKC
In cultured neonatal rat ventricular myocytes, H20 2- 
induced ERK activation has been suggested to occur 
through a PKC-mediated mechanism [20,34], However, 
when we examined the effects of GF109203X (Fig. 7A) 
and the structurally distinct PKC inhibitor chelerythrine 
(Fig. 7B), we found no inhibition of the H20 2-induced 
increase in ERK activity over a broad concentration range. 
Thus, it appears that H20 2-induced ERK activation in 
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Fig. 7. Effects of PKC inhibition on H20 2-induced increases in ERK 
activity. Cells were exposed to vehicle or 100 pM  H20 2 for 10 min in the 
absence or presence o f pre-treatment with the PKC inhibitor (A) 
GF109203X (0 .3 -10  pM ) or (B) chelerythrine (1 -3 0  pM ). Autoradio­
grams show representative Western blots with phosphospecific (top panel) 
and non-phosphospecific (bottom panel) antibodies for ERK. *P< 0.05 
versus control (four experiments, with cells from four hearts).
3.6. Proximal regulators o f ERK activity: role of 
tyrosine kinases
In the light of the above, we examined whether H20 2- 
induced ERK activation might be mediated through 
tyrosine kinase pathways. To address this, we initially 
determined the effects of the non-selective tyrosine kinase 
inhibitor genistein, which produced a dose-dependent 
inhibition of the H20 2-induced increase in ERK activity
(Fig. 8A). Daidzein, a structural analog of genistein 
without tyrosine kinase inhibitory activity, had no effect on 
the H20 2-induced response. Thus, relative to control, 
H20 2 increased ERK phosphorylation by 4.1±0.5-fold in 
the absence of daidzein and by 4.0±0.3-, 3.3±0.4-, 
3.1 ±0.8- and 4.8± 1.2-fold in the presence of 3,10, 30 and 
100 p.M daidzein, respectively (four experiments, with 
cells from four hearts). These findings indicate that H20 2-
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Fig. 8. Effects of tyrosine kinase inhibition on H 20 2-induced increases in 
ERK activity. Cells were exposed to vehicle or 100 pM  H 20 2 for 10 min 
in the absence or presence of pre-treatment with (A) the non-selective 
tyrosine kinase inhibitor genistein (3-100 p.M), (B) the Src-family kinase 
inhibitor PP2 (0 .1-10 pM ) or (C) the EGF receptor kinase inhibitor 
AG1478 (3-300 nM). Autoradiograms show representative Western blots 
with phosphospecific (top panel) and non-phosphospecific (bottom panel) 
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Fig. 9. Time-dependent effects of H 20 2 on Src tyrosine kinase activity. 
Cells were exposed to vehicle or 100 pM  H 20 2 for 1, 3, 6, 10, 20 or 30 
min. Autoradiograms show representative Western blots with phosphos­
pecific (top panel) and non-phosphospecific (bottom panel) antibodies for 
Src tyrosine kinase. *P<0.05 versus control (four experiments, with cells 
from four hearts).
induced ERK activation in the adult myocyte occurs 
through tyrosine kinase-mediated mechanisms.
To explore the role of non-receptor tyrosine kinases of 
the Src family, which have been shown to play an 
important role in H20 2 signalling in neonatal myocytes 
[35], we next determined the effects of the Src-selective 
inhibitor PP2. This agent, like genistein, produced a dose- 
dependent inhibition of the H20 2-induced increase in ERK 
activity (Fig. 8B), indicating a key role for Src family 
tyrosine kinases in this response. Indeed, Src tyrosine 
kinase was found to be activated rapidly upon exposure to 
H20 2 (Fig. 9), which supports a proximal role for Src- 
family tyrosine kinases in the H20 2-induced increase in 
ERK activity. In other cell types, c-Src (a member of the 
Src family) can phosphorylate the EGF receptor and 
thereby facilitate its full activation [36], and activation of 
this receptor tyrosine kinase has been implicated in ERK 
activation by H20 2 [37], We therefore also investigated the 
effects of the EGF receptor kinase inhibitor AG1478 in our 
adult myocyte system. The data revealed that AG 1478 
inhibited H20 2-induced ERK activation in a dose-depen­
dent manner (Fig. 8C), suggesting that the signalling 
mechanisms underlying this response are likely to involve 
activation of the EGF receptor.
4. Discussion
The present study has shown that exposure to H20 2 
stimulates sarcolemmal NHE activity in freshly isolated
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adult rat ventricular myocytes. Our data extend earlier 
findings of accelerated recovery from intracellular acidosis 
in response to H20 2 in cultured neonatal rat ventricular 
myocytes [20], and provide additional evidence that H20 2- 
induced stimulation of NHE activity requires activation of 
not only the ERK (but not the p38) pathway of the MAPK 
cascade, but also PKC. Intriguingly, unlike in neonatal 
myocytes [20], in our adult myocyte preparation PKC and 
ERK activation are not proximal and distal components, 
respectively, of a contiguous signalling pathway. Instead, 
H20 2-induced ERK activation in the adult myocyte ap­
pears to occur through the activation of tyrosine kinases of 
both receptor and non-receptor families.
Fig. 10 is based on the data obtained in the present study 
with rationally selected concentrations of specific kinase 
inhibitors (shown in italics) and the information that is 
available in the literature, and illustrates the signalling
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Fig. 10. Potential integration of signalling pathways in H 20 2-induced 
stimulation of sarcolemmal N a * /H * exchanger activity in adult rat 
ventricular myocytes. The kinase inhibitors used in the present study are 
shown in italics, with their target enzymes indicated (see Section 4 for
details).
processes that are likely to mediate H20 2-induced stimula­
tion of sarcolemmal NHE activity in the adult myocyte. 
According to this model, H20 2-induced stimulation of 
sarcolemmal NHE activity requires the parallel activation 
of PKC and ERK, in an analogous manner to a  ^ -adreno­
ceptor-mediated stimulation of the exchanger [28]. In 
response to H20 2, activation of both PKC and ERK may 
be facilitated through the activation of non-receptor 
tyrosine kinases, including members of the Src family. 
Exposure to H20 2 has been shown to activate a variety of 
PKC isozymes, including PKC8 and PKCe (the predomi­
nant PKC isozymes in adult rat myocardium [24]), in 
transfected COS-7 cells, through tyrosine phosphorylation 
by unidentified kinases [38]. ERK is also activated by 
H20 2, as shown by previous work in neonatal myocytes 
[20,34,35] and the present study in adult myocytes. 
Although it has been suggested that this activation may 
occur through a PKC-mediated pathway in cultured 
neonatal myocytes [20,34], contradictory data have also 
been reported [35]. Our present data with GF109203X and 
chelerythrine oppose a PKC-mediated mechanism for 
H20 2-induced ERK activation in freshly isolated adult 
myocytes. Instead, our data suggest that ERK activation in 
these cells occurs through tyrosine kinase-mediated mecha­
nisms that involve both Src family enzymes (which are 
inhibited selectively by PP2) and the EGF receptor (which 
is inhibited selectively by AG1478). EGF receptor activa­
tion has been suggested previously to mediate ERK 
activation in response to H20 2 in vascular smooth muscle 
cells [37]; furthermore, recent evidence suggests that c-Src 
can facilitate EGF receptor activation by direct phos­
phorylation of the receptor [36]. Such complementary 
interaction between Src family kinases and the EGF 
receptor would be consistent with our observations that 
genistein (a non-selective tyrosine kinase inhibitor), PP2 
and AG 1478 each inhibited H20 2-induced ERK activation 
in adult ventricular myocytes. In this context, it is notewor­
thy that, in adult guinea pig hearts, perfusion with H20 2 
activates Src, as well as ERK and p90rsk [39]. Further­
more, in neonatal myocytes, overexpression of C-terminal 
Src kinase (a negative regulator of Src family tyrosine 
kinases) by transfection has been shown to inhibit H20 2- 
induced ERK activation [35]. On the basis of the above, it 
is likely that H20 2 activates PKC through tyrosine phos­
phorylation (by an as yet unidentified kinase) and ERK 
through Src-dependent EGF receptor activation and sub­
sequent stimulation of the classical Ras-Raf-MEK path­
way.
A potential limitation of the present study is the reliance 
on pharmacological kinase inhibitors to dissect the in­
tracellular signalling pathways that mediate H20 2-induced 
stimulation of sarcolemmal NHE activity. In previous 
studies in a variety of cell types, these inhibitors have been 
used widely as pharmacological tools and have contributed 
significantly to the delineation of the physiological roles of 
pertinent pathways. Furthermore, extensive characterisa-
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tion of inhibitors such as PD98059 [40], SB203580 [41], 
GF109203X [42], chelerythrine [43], AG1478 [44], and 
PP2 [45] indicates that, over the carefully selected con­
centration ranges used in the present study, they inhibit 
their target kinases but not a variety of other common 
kinases. Indeed, recent reports of non-specific effects of 
some of these kinase inhibitors [31,46] have observed such 
effects at concentrations that are considerably higher than 
those which produced significant effects in the present 
study.
An issue that is pertinent to the scheme proposed in Fig. 
10 is how parallel activation of ERK and PKC may result 
in the stimulation of sarcolemmal NHE activity. Activation 
of the ERK pathway can lead to the phosphorylation of 
serine residues in the regulatory C-terminal domain of the 
NHE-1 protein, either directly by ERK itself [47] or 
indirectly through p90rsk [32], in a manner that may alter 
the interaction of this domain with accessory protein(s) that 
regulate exchanger activity. PKC, in contrast, does not 
directly phosphorylate the regulatory domain of NHE-1 
[48] and, as we have suggested previously [28], may 
promote the stimulation of NHE activity by producing a 
concomitant change in the phosphorylation status of 
pertinent accessory protein(s).
There are likely to be cell type-dependent differences in 
the manner in which p90rsk activity is regulated in 
response to H20 2. The ability of the MEK inhibitor 
PD98059 to inhibit H20 2-induced p90r,k activation in the 
present study suggests that such activation in adult rat 
ventricular myocytes occurs predominantly through ERK. 
In contrast, Abe et al. [49] have shown that, in cultured 
fibroblasts and Jurkat cells, H20 2-induced p90r,k activa­
tion occurs through an ERK-independent pathway that is 
mediated via Fyn and Ras.
In conclusion, the present study has shown that H20 2 
stimulates sarcolemmal NHE activity of adult rat ventricu­
lar myocytes, through the concomitant (but independent) 
activation of PKC- and ERK-mediated signalling path­
ways. In these cells, H20 2-induced stimulation of ERK 
occurs through Src family kinase- and EGF receptor 
kinase-mediated mechanisms. H20 2-induced stimulation of 
sarcolemmal NHE activity is likely to have functional 
consequences, particularly in the setting of myocardial 
ischaemia and reperfusion.
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ABSTRACT: The cardiac sarcolemmal Na+/H+ exchanger (NHE) extrudes one 
H+ in exchange for one Na+ entering the myocyte, utilizing for its driving force 
the inwardly directed Na+ gradient that is maintained by the Na+/K* ATPase. 
The exchanger is quiescent at physiological values of intracellular pH but be­
comes activated in response to intracellular acidosis. Recent evidence suggests 
that a variety of extracellular signals (e.g^ adrenergic agonists, thrombin, and 
endothelin) also modulate sarcolemmal NHE activity by altering its sensitivity 
to intracellular IT*. Since sarcolemmal NHE activity is believed to be an impor­
tant determinant of the extent of myocardial Injury during ischemia and rep­
erfusion, regulation of exchanger activity by endogenous ligands associated 
with ischemia is likely to be of pathophysiological importance.
The plasma membrane Na+/H+ exchanger (NHE) is a ubiquitous electroneutral 
exchanger that extrudes one H* in exchange for one Na+, utilizing as its driving force 
the inwardly directed Na+ gradient maintained by Na+/K+ ATPase.1,2 The exchanger 
is thought to mediate a number of physiological functions in various cell types, in­
cluding the regulation of intracellular pH and cell volume (by virtue of the ability of 
the exchanger to transport H* and Na+, respectively) and the control of cell growth 
and proliferation (by mediating the actions of a number of mitogens and growth fac­
tors) .3 Abnormalities in NHE activity have also been implicated in pathophysiolog­
ical processes, such as renal acid-base disorders.3
With respect to the cardiovascular system, increased NHE activity has been 
linked with hypertension,4  platelet activation,5 and the proliferative response of ar­
terial smooth muscle cells to injury.6 Additionally, recent evidence suggests that up- 
regulation of NHE expression and/or activity may be associated with cardiac 
hypertrophy in both in vivo1 and in vitro*  ^models. However, as discussed in depth 
elsewhere in this volume, the strongest evidence for an important role for NHE in
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cardiac pathophysiology is that implicating the sarcolemmal exchanger in the unfa­
vorable sequelae of ischemia and reperfusion, such as arrhythmias, contractile dys­
function, and infarction (for reviews see Avkiran10 and Frohlich and Karmazyn11). 
Indeed, novel pharmacological inhibitors o f  the exchanger, such as HOE69412 and 
cariporide (HOE642),13 have been developed for potential use in the therapy o f is­
chemic heart disease.14 Notably, the clinical efficacy o f  cariporide is currently being 
evaluated in a multi-national study (the “Guard in Ischemia Against Necrosis 
[GUARDIAN]” study) involving 12,000 patients with acute coronary syndromes. 
Despite these exciting advances, however, much remains unknown regarding the 
molecular mechanisms that regulate cardiac sarcolemmal NHE activity, particularly 
in the setting o f ischemia and reperfusion.
CARDIAC SARCOLEMMAL NHE ACTIVITY DURING 
ISCHEMIA AND REPERFUSION
The sarcolemmal NHE o f cardiac myocytes comprises the ubiquitous NHE1 iso- 
form o f  this multi-gene family15; the exchanger is quiescent at physiological values o f  
intracellular pH but becomes activated in response to intracellular acidosis,16,17 which 
is known to develop rapidly during myocardial ischemia.18 Lazdunski and 
colleagues16 were the first to propose a role for the sarcolemmal NHE in the pathogen­
esis o f ischemia and reperfusion-induced injury in myocardium. According to the 
“Lazdunski Hypothesis,” the sarcolemmal NHE is inactive during ischemia, despite 
the presence o f intracellular acidosis, due to inhibition by extracellular acidosis. How­
ever, according to this hypothesis, the rapid normalization o f extracellular pH upon 
reperfusion results in the generation o f  an outwardly directed IF*' gradient, leading to 
increased sarcolemmal NHE activity and thereby predisposing the myocardium to in­
tracellular Na+ and Ca2+ overload, with detrimental consequences. Consistent with 
this, several studies have shown that pharmacological inhibitors o f NHE, given only at 
the time o f reperfusion, can afford substantial cardioprotection.19-22 Nevertheless, in 
other studies, such treatment protocols have been found to be ineffective23-27 or to 
provide only partial protection,28-32 relative to treatment before the onset of ischemia. 
In contrast, as reviewed previously,10 there is widespread consensus among published 
studies regarding the significant cardioprotective benefit afforded by NHE inhibitors 
when given before the onset o f ischemia (which in many cases23-32 has been shown to 
be superior to that afforded by these drugs when given only during reperfusion), re­
gardless o f inter-study variations in models, severity o f ischemia, and functional end­
points. On the basis o f  the available data, therefore, it is likely that the sarcolemmal 
NHE retains significant activity during ischemia as well as during subsequent reperfu­
sion, and that exchanger activity during both periods is important in determining the 
ultimate extent o f  injury. Thus, the superior protection afforded by pre-ischemic treat­
ment with NHE inhibitors in many studies probably arises from inhibition o f exchang­
er activity during ischemia and early reperfusion. In this regard, the hypothesis that 
significant sarcolemmal NHE activity is retained during ischemia is supported by stud­
ies that have shown that intracellular Na+ accumulation during ischemia is attenuated 
in the presence o f NHE inhibitors.
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How does the sarcolemmal NHE retain its activity during ischemia in the face of 
the significant extracellular acidosis known to accompany intracellular acidosis? 
Firstly, it is important to note that, although the sarcolemmal NHE is undoubtedly 
inhibited by extracellular acidosis,17,35 such inhibition is not absolute. Contrary to a 
common misconception, the primary regulator of NHE activity is not the trans-mem­
brane H+ gradient, but the intracellular pH, through the interaction of intracellular 
H+ with the “H+ sensor” site of the exchanger protein. 1 Indeed, work from the 
Vaughan-Jones laboratory has shown that the sarcolemmal NHE can remain active 
and extrude H* against an inwardly directed H+ gradient, provided the intracellular 
pH is sufficiently low.35 Secondly, certain processes associated with ischemia, such 
as the accumulation of lipid metabolites and the imposition of oxidant stress, may 
upregulate NHE activity, since exogenous lysophosphatidylcholine36 and hydrogen 
peroxide37,38 have both been shown recently to stimulate the sarcolemmal exchanger 
in cultured neonatal37 and freshly isolated adult36,38 rat ventricular myocytes. Final­
ly, as discussed in some detail below, various endogenous, receptor-mediated path­
ways with relevance to ischemia have been shown to stimulate sarcolemmal NHE 
activity, apparently by increasing the sensitivity of the exchanger to intracellular H*.
REGULATION OF CARDIAC SARCOLEMMAL NHE ACTIVITY 
BY ENDOGENOUS LIGANDS
Effects of Catecholamines
It is well established that myocardial ischemia results in the activation of the sym­
pathetic nervous system, as well as the local release of norepinephrine within the is­
chemic zone.39 Furthermore, there is evidence that (Xj-adrenergic signaling is 
upregulated in ischemic myocardium.40 In this regard, it is interesting to note that 
the majority of the published work on catecholamine-induced changes in sarcolem­
mal NHE activity has concentrated on the role of ccj-adrenoceptors (o^-ARs). Thus, 
in isolated ventricular myocytes from the rat and guinea pig, it has been shown that 
aj-AR agonists (such as phenylephrine41,42 and 6-fluoronorepinephrine,43 usually 
in the presence of a Pj-AR antagonist) increase sarcolemmal NHE activity, while tXj- 
AR antagonists (such as prazosin42,43) inhibit such NHE-stimulatory effects. Nota­
bly, 0 4 -adrenergic stimulation appears to retain its ability to increase sarcolemmal 
NHE activity in the presence of extracellular acidosis,41 which has important impli­
cations for NHE regulation under ischemic conditions.
Due to the lack of selectivity of the pharmacological agents used in previous stud­
ies, it has not been possible until recently to draw any conclusions regarding the 
identity of the (Xj-AR subtype(s) involved in aj-adrenergic stimulation of sarcolem­
mal NHE activity. (Xj-AR subtypes are classified by the International Union of 
Pharmacology44 as a ^ - ,  a 1B-, and a 1D-ARs, which correspond respectively to the 
recombinant subtypes previously referred to as <xlc, a lb, and a 1(j-ARs (the last of 
which has also been referred to as the a la- or a la/d-AR). Prompted by (1) the sub­
stantial evidence supporting a key role for sarcolemmal NHE activity in the patho­
genesis of ischemia-reperfusion-induced injury (see above), (2 ) the reported ability 
of non-selective dj-adrenergic agonists to increase sarcolemmal NHE activity41-43 
and (3) our earlier observation45 that the pro-arrhythmic effect of the non-selective
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FIGURE 1. cq-Adrenergic stimulation of sarcolemmal NHE activity in adult rat ven­
tricular myocytes. Figure shows agonist dose-response curves for A616103 (O) and phe­
nylephrine (□), as well as antagonist inhibition curves for prazosin (•) , WB4101 (■), and 
5-methylurapidil (A) (all antagonists tested against 10 |imol/l phenylephrine). EC50 = 
3.6 nmol/1 for A61603 and 1.24 pmol/1 for phenylephrine. IC50 = 12 nmol/1 for prazosin, 
32 nmol/1 for WB4101, and 149 nmol/1 for 5-methylurapidil. (Data from Yokoyama et aL46)
CXJ-adrenergic agonist phenylephrine could be reversed not only by NHE inhibition 
but also by an a 1A-AR-selective antagonist, we have recently attempted to delineate 
the roles of aj-AR subtypes in regulating sarcolemmal NHE activity in adult rat ven­
tricular myocytes.
F ig u re  1, adapted from our earlier study,46 shows the stimulatory effects of phe­
nylephrine and the a 1A-AR-selective agonist A61603 on sarcolemmal NHE activity 
and the inhibitory effects of the competitive antagonists prazosin, WB4101, and 5-me­
thylurapidil on the response to 10 pM phenylephrine. Comparison of the relative po­
tencies of these agents, as depicted in F ig u re  1, with their reported relative potencies 
and affinities at native47 and recombinant48 ccj-AR subtypes of rat origin provides ev­
idence, for the first time, that aj-adrenergic stimulation of sarcolemmal NHE activity 
is likely to be mediated selectively via the a 1A-AR subtype.46 Since the a 1A-AR is the 
dominant ctj-AR subtype expressed in human myocardium49 and myocardial hyper­
trophy appears to be accompanied by its transcriptional induction,50 confirmation of 
a iA-AR-mediated regulation of sarcolemmal NHE activity may not only provide a 
potential target for therapeutic intervention but may also reveal a mechanism for the 
increased susceptibility of hypertrophied myocardium to the consequences of is­
chemia and reperfusion (such as arrhythmias and contractile dysfunction).
In considering adrenergic regulation of the sarcolemmal NHE, it is important to 
note that (3-adrenergic stimulation also affects exchanger activity. There is agree­
ment among published studies that, in contrast to the effect of (Xj-adrenergic stimu­
lation, pi-adrenergic stimulation inhibits sarcolemmal NHE activity in a variety of 
species, *51’52 probably through a cAMP-mediated pathway.51-53 Therefore, the ef­
fects of the endogenous catecholamines norepinephrine and epinephrine on sar-
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colemmal NHE activity may depend on the relative density or availability of a j- 
versus PpARs, which can be modulated by genetic factors (which may account for 
species-specific responses); accompanying disease (such as heart failure, which is 
associated with Pj-AR downregulation, or ischemia, which enhances cCj-AR signal­
ing); or pharmacological therapy (in particular, the use of adrenergic antagonists).
Effects of Thrombin .
The most common cause of acute myocardial ischemia in man is intracoronary 
thrombosis,54 and thrombosis is associated with elevated levels of thrombin in the 
vicinity of the evolving thrombus 55 Therefore, the biological actions of thrombin 
may be of pathophysiological significance during myocardial ischemia in the clini­
cal setting. In this regard, it is now well-established that, in addition to its role in 
blood coagulation and thrombus formation, thrombin induces a variety of cellular re­
sponses through receptor-mediated pathways (for review see Coughlin56). Recently, 
we have published the first evidence that both thrombin and the synthetic thrombin 
receptor activating hexapeptide SFLLRN increase sarcolemmal NHE activity in 
adult rat ventricular myocytes.57 The common ability of thrombin and SFLLRN to 
stimulate sarcolemmal NHE activity is consistent with this action being mediated by 
the thrombin receptor first cloned by Vu and colleagues58 and is now known as pro- 
tease-activated receptor 1 (PARI), the mRNA for which we have shown to be ex­
pressed by adult rat ventricular myocytes.57 However, recent findings suggest that 
other protease-activated receptors may also be involved. In this regard, Connolly and 
colleagues59 have recently shown that in mice with targeted disruption of the PARI 
gene, responsiveness to thrombin is lost in some cell types (e.g., fibroblasts) but re­
tained in others (e.g., platelets). This indicates the existence of additional thrombin 
receptor(s) and has led to the suggestion that different thrombin receptors may have 
tissue-specific roles.59 Indeed, a second thrombin receptor (PAR3) has now been 
cloned and appears to be expressed in human myocardium.60 Furthermore, there is 
preliminary evidence61 for the expression of functional PAR2, a trypsin-activated re­
ceptor that is responsive also to the PARl-activating peptide SFLLRN,62 in neonatal 
rat ventricular myocytes. These developments necessitate verification of the hypoth­
esis that cardiac sarcolemmal NHE is regulated by PARI and require determination 
of the roles, if any, of PAR2 and PAR3. Defining which of these receptors regulate 
sarcolemmal NHE activity clearly is critical to the potential therapeutic manipula­
tion of this signaling pathway.
Effects ofEndotheUn
There is evidence that endothelin is released during myocardial ischemia and 
reperfusion63 and that this release is accompanied by upregulation of endothelin re­
ceptors.64 Therefore, the cellular actions of endothelin may also assume pathophys­
iological importance during myocardial ischemia and reperfusion. Within the 
context of the present article, it is notable that endothelin has been shown to stimu­
late sarcolemmal NHE activity, in isolated rat ventricular myocytes65,66 as well as in 
canine cardiac Purkinje fibers.52
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FUNCTIONAL IMPACT OF NHE-STTMULATORY LIGANDS 
IN ISCHEMIA AND REPERFUSION
What is the functional impact o f receptor-mediated stimulation o f sarcolemmal 
NHE activity in the setting of myocardial ischemia and reperfusion? Much o f the ev­
idence in this area has been obtained through the application o f exogenous agonists 
in in vitro models o f ischemia and reperfiision. Thus, work in Kannazyn’s laboratory 
has shown that, in isolated rat hearts, both a r AR stimulation (in the presence o f  an 
adenosine antagonist)67 and endothelin68 exacerbate post-ischemic contractile dys­
function. Of particular relevance to the present article, the deleterious effects o f both 
stimuli could be reversed by NHE inhibition,67,68 thus implying a key role for the 
exchanger in the injurious mechanisms downstream o f receptor activation. Consis­
tent with this, Brunner and Opie69 have shown recently that the deleterious effects 
of endothelin during ischemia and reperfusion could be attenuated not only by ETA 
receptor antagonism but also by NEDS inhibition. Furthermore, (Xj-AR stimulation 
selectively within the ischemic zone has been shown by the authors’ group45 to ex­
acerbate reperfusion-induced arrhythmias, with this proarrhythmic effect abolished 
by a 1A-AR antagonism or NHE inhibition, implicating the exchanger in the down­
stream mechanisms.
Within the context o f ischemia and reperfiision, c^-AR stimulation has also been 
implicated in the induction o f ischemic preconditioning in rat myocardium.70 Since 
ischemic preconditioning is associated with reduced intracellular acidosis during the 
prolonged ischemia,71 it is possible that cq-adrenergic stimulation o f sarcolemmal 
NHE activity may contribute to this phenomenon. However, Gabel and colleagues72 
have shown recently that H+ efflux during the prolonged ischemic period is not in­
creased in preconditioned hearts. Furthermore, any stimulation o f sarcolemmal NHE 
activity is unlikely to contribute to the cardioprotective mechanism(s) o f  ischemic 
preconditioning, since we have shown such protection to be retained (and indeed en­
hanced) in the presence o f NHE inhibition.73
With regard to thrombin-induced effects during ischemia and reperfusion, Gold­
stein and colleagues74 have shown that, in the canine heart in vivo, the incidence o f ma­
lignant ventricular arrhythmias during acute ischemia is greater following thrombotic 
coronary occlusion than non-thrombodc balloon occlusion, implicating an arrhyth- 
mogenic role for factors (such as thrombin) associated with thrombus formation. In­
deed, thrombin has now been shown to induce a potent arrhythmogenic effect during 
ischemia and reperfusion in isolated rat hearts,75,76 in a manner that appears to be re­
versible by NHE inhibition.76 A role for the sarcolemmal NHE in mediating the ar­
rhythmogenic action o f thrombin is supported by evidence that activation o f the 
thrombin receptor exacerbates the intracellular accumulation o f Na+ during is­
chemia,77 an observation that is consistent with stimulation o f exchanger activity.
CO NCLUSIO N
It is clear from the evidence discussed above that sarcolemmal NHE activity is 
modulated by a number o f endogenous stimuli (e.g., catecholamines, thrombin, and 
endothelin), through receptor-mediated mechanisms, and that stimulation o f the ex­
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changer through these receptors may be of pathophysiological significance during 
ischemia and reperfiision. Undoubtedly, there are other, currently unidentified, re­
ceptors that also regulate sarcolemmal NHE activity in a positive or negative manner. 
The identification of such receptors and delineation of the intracellular signaling 
mechanisms that facilitate receptor-mediated regulation of sarcolemmal NHE activ­
ity may identify common pathways, which might represent fertile targets for the de­
velopment of novel therapies for ischemic heart disease.
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Regulation of Cardiac Sarcolemmal Na+/H+ Exchanger 
Activity: Potential Pathophysiological Significance of 
Endogenous Mediators and Oxidant Stress
M etin  A v k ira n  a n d  A n d rew  K . S n a b a itis  
Cardiovascular Research, The Rayne Institute, St. Thomas' 
Hospital, London, UK
Abstract. The cardiac sarcolemmal NaVH+ exchanger 
(NHE) extrudes one H+ in exchange for one Na+ entering 
the myocyte, utilizing for its  driving force the inwardly 
directed Na+ gradient maintained by the Na+, K+-ATPase. 
The exchanger is quiescent a t physiological values o f in tra ­
cellular pH but becomes activated in  response to  intracel­
lular acidosis. Recent evidence suggests th a t a  variety of 
extracellular signals (e.g., adrenergic agonists, thrombin, 
endothelin, and oxidant stress) also modulate sarcolemmal 
NHE activity by altering its sensitivity to  intracellular H+. 
Because sarcolemmal NHE activity is believed to  be an 
im portant determinant o f the extent of myocardial injury 
during ischemia and reperfiision, regulation o f exchanger 
activity by factors th a t are associated with ischemia is 
likely to  be pathophysiological importance.
Key Words: NHE, catecholamines, oxidant stress, thrombin, 
endothelin, ischemia, reperfiision
The plasma membrane Na+/H+ exchanger (NHE) is 
ubiquitous electroneutral exchanger that extrudes one 
H+ in exchange for one Na+, utilizing as its driving force 
the inwardly directed Na+ gradient maintained by Na+, 
K+-ATPse [1,2]. The exchanger is thought to mediate a 
number of physiological functions in various cell types, 
including regulation of intracellular pH and cell volume 
(by virtue of its ability to transport H+ and Na+, respec­
tively) and control of cell growth and proliferation (by 
mediating the actions of a number of mitogens and 
growth factors) [3]. Abnormalities in NHE activity 
have also been implicated in pathophysiological proc­
esses, such as renal add-base disorders [3].
With respect to the cardiovascular system, in­
creased NHE activity has been linked to hypertension 
[4], platelet activation [5], and the proliferative re­
sponse of arterial smooth muscle cells to injury [6]. 
Additionally, recent evidence suggests that upregula- 
tion of NHE expression and/or activity may be assoti- 
ated with cardiac hypertrophy in both in vivo [7] and in 
vitro [8,9] models. However, as discussed in depth else­
where in this issue, the strongest evidence for an im­
portant role for NHE in cardiac pathophysiology is 
that implicating the sarcolemmal exchanger in the un­
favorable sequelae of ischemia and reperfusion, such as
arrhythmias, contractile dysfunction, and infarction 
(for reviews, see Avkiran [10] and Frohlich and Kar­
mazyn [11]). Indeed, novel pharmacological inhibitors 
of the exchanger, such as HOE694 [12] and cariporide 
(HOE642) [13], have been developed for potential use 
in the therapy of ischemic heart disease [14]. Notably, 
the clinical efficacy of cariporide is currently being 
evaluated in a multinational study (the Guard in Is­
chemia Against Necrosis [GUARDIAN] study) involv­
ing 12,000 patients with acute coronary syndromes. 
Despite these exciting advances, much remains un­
known regarding the molecular mechanisms that regu­
late cardiac sarcolemmal NHE activity, particularly in 
the setting of ischemia and reperfusion.
Cardiac Sarcolemmal NHE Activity 
During Ischemia and Reperfusion
The sarcolemmal NHE of cardiac myocytes comprises 
the ubiquitous NHE1 isoform of this multigene family 
[15]. The exchanger is quiescent at physiological values 
of intracellular pH but becomes activated in response to 
intracellular acidosis [16,17], which is known to develop 
rapidly during myocardial ischemia [18]. Lazdunski and 
colleagues [16] were the first to propose a role for sar­
colemmal NHE in the pathogenesis of ischemia and 
reperfusion-induced injury in myocardium. According 
to the Lazdunski Hypothesis, sarcolemmal NHE is inac­
tive during ischemia, despite the presence of intracellu­
lar acidosis, due to inhibition by extracellular acidosis. 
However, it states that rapid normalization of extracel­
lular pH on reperfusion results in the generation of an 
outwardly directed H+ gradient, leading to increased 
sarcolemmal NHE activity and thereby predisposing 
the myocardium to intracellular Na+ and Ca2+ overload, 
with detrimental consequences. Consistent with this, 
several studies have shown that pharmacological inhibi­
tors of NHE, given only at the time of reperfusion, can 
afford substantial cardioprotection [19-22]. Neverthe-
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less, in other studies such treatment protocols have 
been found to be ineffective [23-27] or to provide only 
partial protection [28-32] relative to treatment before 
the onset of ischemia.
In contrast, as reviewed previously [10], there is 
widespread consensus among published studies regard­
ing the significant cardioprotective benefit afforded by 
NHE inhibitors when given before the onset of ischemia 
(which in many cases [23-32] has been shown to be supe­
rior to that afforded by these drugs when given only 
during reperfusion), regardless of interstudy variations 
in models, severity of ischemia, and functional end­
points. On the basis of the available data, therefore, it is 
likely that sarcolemmal NHE retains significant activ­
ity during ischemia as well as during subsequent reper­
fusion, and that exchanger activity during both periods 
is important in determining the ultimate extent of in­
jury. Thus, the superior protection afforded by preis- 
chemic treatment withNHE inhibitors in many studies 
probably arises from inhibition of exchanger activity 
during ischemia and early reperfusion. In this regard, 
the hypothesis that significant sarcolemmal NHE activ­
ity is retained during ischemia is supported by studies 
that have shown intracellular Na+ accumulation is at­
tenuated in the presence of NHE inhibitors during both 
normothermic [33,34] and hypothermic [35] ischemia.
How does the sarcolemmal NHE retain its activity 
during ischemia in the face of the significant extracellu­
lar acidosis that is known to accompany intracellular 
acidosis? Firstly, it is important to note that although 
the sarcolemmal NHE is undoubtedly inhibited by ex­
tracellular acidosis [17,36], such inhibition is not abso­
lute. Indeed, the primary regulator of NHE activity is 
not the transmembrane H+ gradient, but intracellular 
pH, through the interaction of intracellular H+ with the 
so-called H+ sensor site of the exchanger protein [2]. 
Regarding cardiac NHE, work from the Vaughan-Jones 
\ laboratory has shown that sarcolemmal NHE can re­
main active and extrude H+ against an inwardly di­
rected H+ gradient, provided the intracellular pH is suf­
ficiently low [36]. Secondly, certain processes associated 
with ischemia, such as the accumulation of lipid metabo­
lites, may upregulate NHE activity, because exogenous 
lysophosphatidylcholine has been shown recently [37] 
to stimulate the sarcolemmal exchanger in freshly iso­
lated adult rat ventricular myocytes. Finally, as dis­
cussed in some detail later, various endogenous, recep­
tor-mediated pathways with relevance to ischemia as 
well as oxidant stress have been shown to stimulate sar­
colemmal NHE activity, apparently by increasing the 
sensitivity of the exchanger to intracellular H+.
Regulation of Cardiac Sarcolemmal 
NHE Activity by Endogenous Factors
E ffe c ts  o f  a d re n e rg ic  s t im u la t io n
It is well established that myocardial ischemia results in 
activation of the sympathetic nervous system, as well as
local release of norepinephrine within the ischemic zone 
[38]. Furthermore, there is evidence that aradrenergic 
signaling is upregulated in ischemic myocardium [39]. 
In this regard, it is interesting to note that the majority 
of the published work on catecholamine-induced 
changes in sarcolemmal NHE activity has concentrated 
on the role of aradrenoceptors (arARs). Thus, in iso­
lated ventricular myocytes from the rat and guineapig, 
it has been shown that aj-AR agonists (such as phenyle­
phrine [40,41] and 6-fluoronorepinephrine [42], usually 
in the presence of a fJrAR antagonist) increase sar­
colemmal NHE activity, whereas arAR antagonists 
(such as prazosin [41,42]) inhibit such NHE-stimulatory 
effects. Notably, aradrenergic stimulation appears to 
retain its ability to increase sarcolemmal NHE activity 
in the presence of extracellular acidosis [40], which has 
important implications for NHE regulation under is­
chemic conditions.
Due to the lack of selectivity of the pharmacological 
agents used, it has not been possible until recently to 
draw any conclusions regarding the identity of the ar  
AR subtype(s) that are involved in aradrenergic stimu­
lation of sarcolemmal NHE activity. Prompted by (1) 
the substantial evidence supporting a key role for sar­
colemmal NHE activity in the pathogenesis of ischemia 
and reperfusion-induced injury, (2) the reported ability 
of nonselective ar adrenergic agonists to increase sar­
colemmal NHE activity [40-42], and (3) our earlier ob­
servation [43] that the proarrhythmic effect of the non- 
selective ar adrenergic agonist phenylephrine could be 
reversed not only by NHE inhibition but also by an au - 
AR-selective antagonist, we have recently attempted 
to delineate the roles of arAR subtypes in regulating 
sarcolemmal NHE activity in adult rat ventricular myo­
cytes. This work has revealed that ar adrenergic stimu­
lation of sarcolemmal NHE activity is likely to be medi­
ated selectively via the au -AR subtype [44]. Because 
the alA-AR is the dominant ar AR subtype expressed in 
human myocardium [45] and myocardial hypertrophy 
appears to be accompanied by its transcriptional induc­
tion [46], confirmation of a^-AR-mediated regulation 
of sarcolemmal NHE activity may not only provide a po­
tential target for therapeutic intervention but may also 
reveal a mechanism for the increased susceptibility of 
hypertrophied myocardium to the consequences of is­
chemia and reperfusion (such as arrhythmias and con­
tractile dysfunction).
In considering adrenergic regulation of the sar­
colemmal NHE, it is important to note that ^-adrener­
gic stimulation also affects exchanger activity. There is 
agreement among published studies that, in contrast to 
the effect of ar adrenergic stimulation, Pi-adrenergic 
stimulation inhibits sarcolemmal NHE activity in a va­
riety of species [41,47,48], probably through a cAMP- 
mediated pathway [47-49]. Therefore, the effects of the 
endogenous catecholamines norepinephrine and epi­
nephrine on sarcolemmal NHE activity may depend on 
the relative density or availability of ar  versus Px-ARs, 
which can be modulated by genetic factors (which may
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account for species-specific responses), accompanying 
disease (such as heart failure, which is associated with 
pr AR downregulation, ischemia, which enhances ar  
AR signaling), or pharmacological therapy (in particu­
lar, the use of adrenergic antagonists).
E ffe c ts  o f  th ro m b in
The commonest cause of acute myocardial ischemia in 
humans is intracoronary thrombosis [50], and thrombo­
sis is associated with elevated levels of thrombin in the 
vicinity of the evolving thrombus [51]. Therefore, the 
biological actions of thrombin may be of pathophysi­
ological significance during myocardial ischemia in the 
clinical setting. In this regard, it is now well estab­
lished that, in addition to its role in blood coagulation 
and thrombus formation, thrombin induces a variety of 
cellular responses through receptor-mediated path­
ways (for review, see Coughlin [52]).
Recently, we have published the first evidence that 
both thrombin and the synthetic thrombin receptor 
activating hexapeptide SFLLRN increase sarcolem­
mal NHE activity in adult rat ventricular myocytes 
[53]. The common ability of thrombin and SFLLRN to 
stimulate sarcolemmal NHE activity is consistent with 
this action being mediated by the thrombin receptor 
that was first cloned by Vu and colleagues [54] and is 
now known as proteose-activated receptor 1 (PARI), 
the mRNA for which we have shown to be expressed 
by adult rat ventricular myocytes [53].
However, recent findings suggest that other pro- 
tease-activated receptors may also be involved. In this 
regard, Connolly et a l [55] have recently shown that in 
mice With targeted disruption of the PARI gene, re­
sponsiveness to thrombin is lost in some cell types (e.g., 
fibroblasts) but retained in others (e.g., platelets). This 
indicates the existence of additional thrombin recep­
tors) and has led to the suggestion that different 
thrombin receptors may have tissue-specific roles [55]. 
Indeed, a second thrombin receptor (PAR3) has been 
cloned and appears to be expressed in human myocar­
dium [56]. Furthermore, there is preliminary evidence 
[57] for the expression of functional PAR2, a trypsin- 
activated receptor that is also responsive to the PAR1- 
activating peptide, SFLLRN [58], in neonatal rat ven­
tricular myocytes. These developments necessitate 
verification of the hypothesis that cardiac sarcolemmal 
NHE is regulated by PARI and require determination 
of the roles, if any, of other protease-activated recep­
tors. Defining the receptors that regulate sarcolemmal 
NHE activity clearly is critical to the potential thera­
peutic manipulation of this signaling pathway.
E ffe c ts  o f  e n d o th e lin
There is evidence that endothelin is released during 
myocardial ischemia and reperfusion [59] and that this 
is accompanied by upregulation of endothelin receptors 
[60]. Therefore, the cellular actions of endothelin may 
also assume pathophysiological importance during
myocardial ischemia and reperfusion. Within the con­
text of the present article, it is notable that endothelin 
has been shown to stimulate sarcolemmal NHE activ­
ity in isolated rat ventricular myocytes [61,62] as well 
as in canine cardiac Purkinje fibers [48],
E ffe c ts  o f  o x id a n t  s t r e s s
For many years, increased oxidant stress has been 
implicated as a major contributing factor in the patho­
physiology of ischemia and reperfusion-induced injury 
in the heart; however, despite intensive study in many 
laboratories, the cellular mechanisms responsible for 
this remain unclear. Recently, it was shown that con­
tractile dysfunction during aerobic perfusion [63] or 
following ischemia and reperfusion [64] could be in­
duced or exacerbated by the application of exogenous 
hydrogen peroxide (H2O2). These effects were re­
versed by the selective NHE inhibitor HOE 642 
[63,64], thereby implicating NHE as the mediator. We 
have recently shown [65] that exogenous H202 can 
significantly increase sarcolemmal NHE activity, but 
only at acidic intracellular pH levels (6.7-6.9) that are 
readily attained during ischemia [66,67]. Based on the 
observation that the myocardium is subjected to in­
creased oxidative stress during early reperfusion 
[68,69], it is tempting to suggest that subsequent con­
tractile dysfunction may be partly mediated by oxidant 
stress-induced activation of sarcolemmal NHE.
The precise mechanism by which increased oxidant 
stress (exogenous H ^^ increases sarcolemmal NHE 
activity is not fully understood but has been proposed to 
involve a group of cytosolic protein kinases known as 
the extracellular regulated kinases (ERKs) [70]. The 
ERKs are members of the mitogen activated protein 
kinase (MAPK) superfamily of serine/threonine ki­
nases, which also include other protein kinases, such as 
the p38 MAPK[71] and c-Jun N-terminus kinases 
(JNKs) [72]. p38 MAPK and JNKs are also activated by 
oxidant stress and various other cellular stresses, such 
as ischemia (p38 MAPK) and reperfusion (JNKs) [73]. 
In addition, there is recent evidence to suggest that in 
vascular smooth muscle cells, p38 MAPK may behave as 
a negative regulator of sarcolemmal NHE activity [74]. 
This suggests that, at least in some cell types, a complex 
inter relationship may exist between ERKs (activation 
of NHE) and p38 MAPK (inhibition of NHE), which 
may impact upon oxidant stress-induced regulation of 
exchanger activity. Obviously, further investigation and 
clarification of this concept is needed.
Functional Impact of 
NHE-Stimulatory Factors in 
Ischemia and Reperfusion
What is the functional impact of the NHE-regulatory 
factors discussed earlier in the setting of myocardial 
ischemia and reperfusion? Much of the evidence in this
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area has been obtained through the application of the 
relevant exogenous stimuli in in vitro models of is­
chemia and reperfusion, and assessment of the resul­
tant injury and dysfunction- As discussed later, the 
deleterious effects of these stimuli can be reversed by 
NHE inhibition, thus implying a key role for the ex­
changer in the downstream injurious mechanisms.
E n d o th e lin
Khandoudi and coworkers [75] have demonstrated that 
the most potent of the endothelin isoforms, endothelin- 
1 (ET-1), is able to (1) depress contractile function, (2) 
increase resting tension, and (3) increase vascular re­
sistance in the isolated rat heart. In addition, pretreat­
ment with ET-1 prior to the onset of ischemia resulted 
in reduced recovery of contractile function during 
reperfusion. These effects of ET-1 were inhibited by 
administration of the NHE inhibitor methylisobutyl 
amiloride (MIA) prior to pretreatment with ET-1. Con­
sistent with this, Brunner and Opie [76] have shown 
recently that the deleterious effects of endothelin dur­
ing ischemia and reperfusion could be attenuated not 
only by ETA receptor antagonism, but also by NHE 
inhibition- These observations strongly implicate NHE 
as a key mediator of the deleterious consequences in­
duced by endothelin receptor stimulation.
A d r e n e r g ic  s t im u la t io n
Phenylephrine-induced stimulation of ar ARs selec­
tively within the ischemic zone has been shown by the 
authors’ group [43] to exacerbate reperfusion-induced 
arrhythmias, with this proarrhythmic effect abolished 
by au -AR antagonism or NHE inhibition, implicating 
the exchanger in the downstream mechanisms. Within 
the context of ischemia and reperfusion, arAR stimu­
lation has also been implicated in the induction of is­
chemic preconditioning in rat myocardium [77]. Be- 
' cause ischemic preconditioning is associated with 
reduced intracellular acidosis during the prolonged is­
chemia [78], it is possible that aradrenergic stimula­
tion of sarcolemmal NHE activity may contribute to 
this phenomenon. However, Gabel et al [79] have 
shown recently that H+ efflux during the prolonged 
ischemic period is not increased in preconditioned 
hearts. Furthermore, any stimulation of sarcolemmal 
NHE activity is unlikely to contribute to the cardiopro­
tective mechanism(s) of ischemic preconditioning be­
cause we have shown such protection to be retained 
(and indeed enhanced) in the presence of NHE inhibi­
tion [80].
T h ro m b in
With regard to thrombin-induced effects during is­
chemia and reperfusion, Goldstein et al. [81] have 
shown that in the canine heart in vivo, the incidence of 
malignant ventricular arrhythmias during acute is­
chemia is greater following thrombotic coronary occlu­
sion than nonthrombotic balloon occlusion, implicating
an arrhythmogenic role for factors (such as thrombin) 
that are associated with thrombus formation. Indeed, 
thrombin has now been shown to induce a potent ar­
rhythmogenic effect during ischemia and reperfusion 
in isolated rat hearts [82,83] in a manner that appears 
to be reversible by NHE inhibition [83]. A role for the 
sarcolemmal NHE in mediating the arrhythmogenic 
action of thrombin is supported by evidence that acti­
vation of the thrombin receptor exacerbates the intra­
cellular accumulation of Na+ during ischemia [84], an 
observation that is consistent with stimulation of ex­
changer activity.
O x id a n t  s t r e s s
Hoque and Karmazyn [63] have reported that the con­
tractile dysfunction and impairment of myocyte meta­
bolism induced by the perfusion of isolated rat hearts 
with H202 could be attenuated by selective NHE in­
hibitor HOE 642. In the setting of ischemia and reper­
fusion, recent evidence has suggested that the exacer­
bation of myocardial injury by H20 2 could be reversed 
by pretreatment of hearts with HOE 642 [64]. These 
findings suggest that an increase in sarcolemmal NHE 
activity may play a key role in the perturbations of 
cardiac function and metabolism induced by H20 2.
Concluding Comments
It is clear from the evidence discussed herein that 
sarcolemmal NHE activity is modulated by a number 
of endogenous stimuli (e.g., catecholamines, thrombin, 
endothelin, and oxidant stress), and that stimulation of 
the exchanger by these factors may be of pathophysi­
ological significance during ischemia and reperfiision. 
Undoubtedly, there are other, currently unidentified 
factors that also regulate sarcolemmal NHE activity in 
a positive or negative manner. The identification of 
these factors and delineation of their intracellular sig­
naling mechanisms may identify common pathways 
that might represent fertile targets for the develop­
ment of novel therapies for ischemic heart disease.
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The cardiac sarcolemmal Na+/H+ exchanger (NHE) 
extrudes one H+ in exchange for one Na+ entering the 
myocyte, utilizing for its driving force the inwardly directed 
Na+ gradient that is maintained by the Na+/K+ ATPase.
The exchanger is quiescent at physiological values of 
intracellular pH but becomes activated in response to 
intracellular acidosis. Recent evidence suggests that a 
variety of receptor-mediated stimuli (e.g. adrenergic 
agonists, thrombin and endothelin) and other factors (e.g. 
oxidant stress, lipid metabolites) that are associated with 
ischaemia also modulate sarcolemmal NHE activity, by
altering its sensitivity to intracellular H+. Since sarco­
lemmal NHE activity is believed to be an important deter­
minant of the extent of myocardial injury during ischaemia 
and reperfusion, regulation of exchanger activity by 
endogenous factors that are associated with ischaemia is 
likely to be of pathophysiological importance.
(Eur Heart J Supplements 1999; 1 (Suppl K): K11-K17)
Key Words: Na‘t7H+ exchanger, ischaemia, acidosis, 
signal transduction, ion regulation.
Introduction
N a+/H + exchangers (NHEs) are membrane proteins 
which transport H+ in exchange for N a+ in an electro­
neutral manner, utilizing for their driving force the 
transmembrane N a+ gradient*1-31. Six mammalian iso- 
forms of NHE have so far been identified and these have 
been termed NHE-1 to NHE-6*4-71. NHE-1 to NHE-4 
are located in the plasma membrane, little is known 
about the localization and function of NHE-5, and 
NHE-6 appears to be the molecular homolog of the 
mitochondrial exchanger. NHE-1 and NHE-6 are 
ubiquitously distributed in tissue (the latter expressed 
abundantly in tissues with high mitochondrial con­
tent), whereas NHE-2 to NHE-5 show restricted 
expression*4-71. Only NHE-1 and NHE-6 transcripts 
have so far been detected in the heart*4,71 and it is 
believed that the sarcolemmal NHE of cardiac myocytes 
is comprised predominantly, if not exclusively, of the 
NHE-1 isoform*81.
Recently, the sarcolemmal NHE has received 
attention as a potential mediator of various physio­
logical and pathophysiological phenomena in the myo­
cardium, such as increased myofilament sensitivity to 
Ca2+ in response to stimulation of a variety o f G 
protein-coupled receptors*9-111 and the induction of 
hypertrophy by mechanical and neurohormonal 
stimuli*12-151. However, perhaps the strongest evidence
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for an important role for the sarcolemmal NHE in 
cardiac pathophysiology is that implicating the 
exchanger in the unfavourable sequelae of ischaemia 
and reperfusion, such as arrhythmias, contractile dys­
function and infarction. Such evidence was obtained 
initially with non-specific NHE inhibitors (NHEIs) such 
as amiloride and its 5-amino-substituted derivatives (for 
reviews, see Avkiran*161 and Frohlich and Karmazyn*171) 
and has been substantiated by more recent studies with 
novel benzoylguanidine derivatives, such as HOE- 
694*181, HOE-642 (cariporide)*191, and EMD-85131*201. 
These agents have proved to be of considerable 
investigative value since they are potent inhibitors of 
NHE*!8-20], do not appear to inhibit other ion transpor­
tation*18,191 or pH regulatory*211 systems, and exhibit 
marked selectivity for the NHE-1 isoform of the 
exchanger*19,20,221. Pre-clinical studies which have inves­
tigated the effects of these novel NHEIs on arrhythmias, 
contractile dysfunction and infarct size during myocar­
dial ischaemia and reperfusion have been reviewed 
recently*231 and are discussed elsewhere in this issue.
Cardiac sarcolem m al NHE activity 
during ischaem ia
The original hypothesis*241 that the sarcolemmal NHE 
may contribute to tissue injury and dysfunction during 
myocardial ischaemia and reperfusion, which is often 
referred to as the ‘Lazdunski Hypothesis’, proposed that 
sarcolemmal NHE activity was likely to be low during
1520-765X/99/OK0011+07 $18.00/0 ©  1999 The European Society o f  Cardiology
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ischaemia. However, upon reperfusion, an increase in 
exchanger activity would arise from the rapid normali­
zation of extracellular pH and the generation of an 
outwardly directed H+ gradient, and could mediate 
reperfusion injury. As noted in a recent review1235, al­
though this hypothesis is supported by studies which 
have shown a cardioprotective benefit with NHEIs when 
given shortly before or during reperfusion, it is not 
consistent with the majority of studies which have 
shown superior benefit when the NHEI is given prior to 
or early during ischaemia. The latter findings, alongside 
evidence that NHEIs attenuate intracellular Na+ [25_27] 
and Ca2+1261 accumulation during ischaemia in parallel 
with their cardioprotective effects, suggest that NHE 
activity is maintained during ischaemia and contributes 
substantially to the loss o f ionic homeostasis and to the 
extent of injury.
How does die sarcolemmal NHE retain its activity 
during ischaemia in the face of the significant extra­
cellular acidosis which is known to accompany intra­
cellular acidosis? First, it is important to note that, 
although the sarcolemmal NHE is undoubtedly 
inhibited by extracellular acidosis128,291, such inhibition 
is not absolute. Contrary to a common misconception, 
the primary regulator of NHE activity is not the trans- 
membrane H + gradient, but the intracellular pH, 
through the interaction of intracellular H+ with the 
so-called ‘H + sensor’ site of the exchanger protein121. 
Work from the Vaughan-Jones laboratory1291 has shown 
that the sarcolemmal NHE can remain active and 
extrude H+ against an inwardly directed H+ gradient, 
provided that the intracellular pH is sufficiently low. 
Second, certain processes associated with ischaemia, 
such as the release of neurohormonal mediators, the 
accumulation of lipid metabolites and the imposition of 
oxidant stress, may upregulate NHE activity by increas­
ing the sensitivity of the exchanger to intracellular H+ 
(this dual mechanism of regulation of sarcolemmal NHE 
activity is illustrated schematically in Fig. 1). This article 
will now outline the evidence supporting a potential role 
for such endogenous factors in maintaining sarcolemmal 
NHE activity during ischaemia.
NHE regulation by neurohorm onal 
m ediators
Catecholamines
It is well established that myocardial ischaemia results in 
activation of the sympathetic nervous system as well as 
the local release of norepinephrine within the ischaemic 
zone1301. Furthermore, there, is evidence that ax- 
adrenergic signalling is upregulated in ischaemic myo­
cardium1311. It is interesting to note that the majority of 
published work on catecholamine-induced changes in 
sarcolemmal NHE activity has concentrated on the role 
of a j-adrenoceptors (ar ARs). Thus, in isolated ventricu­










6-7 6-8 6-9 7-0 7-1 7-2
pHi
Figure 1 Dual regulation of sarcolemmal Na+/H + 
exchanger (NHE) activity in ventricular myocytes. NHE 
activity is regulated primarily by intracellular pH (pHj) 
and increases as pH| drops (open symbols). This relation­
ship can be shifted in an alkaline direction by a variety of 
endogenous stimuli such as neurohormonal mediators, 
oxidant stress and lipid metabolites, such that the sarco­
lemmal NHE has greater activity at any given pH| (solid 
symbols). See text for details.
shown that ar AR agonists (such as phenylephrine132,331 
and 6-fluoro-norepinephrine1341, usually in the presence 
of a ft-A R  antagonist) increase sarcolemmal NHE 
activity, while aj-AR antagonists (such as prazosin133,341) 
inhibit such NHE-stimulatory effects. In particular, 
a!-adrenergic stimulation appears to retain its ability to 
increase sarcolemmal NHE activity in the presence 
of extracellular acidosis1321, which has important impli­
cations for NHE regulation under ischaemic conditions.
Owing to the lack of selectivity of the pharmacologi­
cal agents used in previous studies, until recently it has 
not been possible to draw any conclusions about the 
identity of the a^AR subtype(s) that are involved in 
cij-adrenergic stimulation of sarcolemmal NHE activity. 
Prompted by (1) substantial evidence supporting a key 
role for sarcolemmal NHE activity in the pathogenesis 
of ischaemia and reperfusion-induced injury1161, (2) the 
reported ability of non-selective c^-adrenergic agonists 
to increase sarcolemmal NHE activity132-341 and (3) the 
observation1351 that the proarrhythmic effect of the non- 
selective a j-adrenergic agonist phenylephrine could be 
reversed not only by NHE inhibition but also by an 
a1A-AR-selective antagonist, the author’s laboratory has 
recently delineated the roles of a,-AR subtypes in regu­
lating sarcolemmal NHE activity in adult rat ventricular 
myocytes1361. The relevant data provide evidence, for the 
first time, that -adrenergic stimulation of sarcolemmal 
NHE activity is likely to be mediated selectively via the 
a1A-AR subtype1361. Since the a1A-AR is the dominant 
a^AR subtype expressed in human myocardium1371 and 
myocardial hypertrophy appears to be accompanied by 
its transcriptional induction1381, confirmation of a1A-AR- 
mediated regulation of sarcolemmal NHE activity may 
not only provide a potential target for therapeutic 
intervention but may also reveal a mechanism for the
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increased susceptibility of hypertrophied myocardium to 
the consequences of ischaemia and reperfusion (such as 
arrhythmias and contractile dysfunction).
In considering adrenergic regulation of the sarcolem­
mal NHE, it is important to note that ^-adrenergic 
stimulation also affects exchanger activity. Published 
studies agree that, in contrast to the effect of ar  
adrenergic stimulation, -adrenergic stimulation 
inhibits sarcolemmal NHE activity in a variety of 
species133’39,401, probably through a cAMP-mediated 
pathway139-411. Therefore, the effects of the endogenous 
catecholamines noradrenaline and adrenaline on sarco­
lemmal NHE activity may depend on the relative density 
or availability of aj- compared with /?,-ARs. These can 
be modulated by genetic factors (which may account for 
species-specific responses), accompanying disease (such 
as heart failure, which is associated with ft-AR down- 
regulation, or ischaemia, which enhances oq-AR signal­
ling) or pharmacological therapy (in particular, the use 
of adrenergic antagonists). It is noteworthy that, at least 
in rat ventricular myocytes, the a,-AR response appears 
to dominate, since noradrenaline produces a signifi­
cant increase in sarcolemmal NHE activity (author’s 
unpublished data).
Thrombin
The commonest cause of acute myocardial ischaemia in 
man is intracoronary thrombosis1421, and thrombosis 
is associated with elevated levels of thrombin in the 
vicinity of the evolving thrombus^431. Therefore, 
the biological actions of thrombin may be of patho­
physiological significance during myocardial ischaemia 
in the clinical setting. It is now well established that, in 
addition to its role in blood coagulation and thrombus 
formation, thrombin induces a variety of cellular 
responses through receptor-mediated pathways (for 
review, see Coughlin1441). Recently, the author’s labora­
tory has published the first evidence that both thrombin 
and the synthetic thrombin receptor activating hexa- 
peptide SFLLRN increase sarcolemmal NHE activity in 
adult rat ventricular myocytes1451. The common ability 
of thrombin and SFLLRN to stimulate sarcolemmal 
NHE activity is consistent with this action being 
mediated by the thrombin receptor that was first cloned 
by Vu et a/.1461 and is now known as protease-activated 
receptor 1 (PARI), the mRNA for which has been 
shown to be expressed in adult rat ventricular myo­
cytes1451. However, recent findings suggest that other 
protease-activated receptors may also be involved. Con­
nolly et a/.1471 have shown that in mice with targeted 
disruption of the PARI gene, responsiveness to 
thrombin is lost in some cell types (e.g. fibroblasts) but 
retained in others (e.g. platelets). This indicates the 
existence of additional thrombin receptor(s) and has led 
to the suggestion that different thrombin receptors may 
have tissue-specific roles[47]. Indeed, a second thrombin 
receptor (PAR3) has now been cloned and appears to be 
expressed in human myocardium1481. Furthermore, there
is preliminary evidence1491 for the expression of func­
tional PAR2, a trypsin-activated receptor that is respon­
sive also to the PARI-activating peptide SFLLRN1501, in 
neonatal rat ventricular myocytes. These developments 
necessitate verification of the hypothesis that cardiac 
sarcolemmal NHE is regulated by PARI and require 
determination of the roles, if any, of PAR2 and PAR3. 
Defining which of these receptors regulate sarco­
lemmal NHE activity clearly is critical to the potential 
therapeutic manipulation of this signalling pathway.
Endothelin
There is evidence that endothelin is released during 
myocardial ischaemia and reperfusion1511 and that this 
is accompanied by an upregulation of endothelin 
receptors1521. Therefore, the cellular actions o f endo­
thelin may also assume pathophysiological importance 
during myocardial ischaemia and reperfusion. Within 
the context o f the present article, it is notable that 
endothelin has been shown to stimulate sarcolemmal 
NHE activity, in isolated rat ventricular myocytes19,531 as 
well as in canine cardiac Purkinje fibres1401. It is of 
interest that recent evidence suggests that responsiveness 
o f the sarcolemmal NHE to stimulation by endothelin 
and angiotensin II (see below) may be altered in pressure 
overload-induced cardiac hypertrophy1531.
Angiotensin II
Several studies have shown that angiotensin-converting 
enzyme (ACE) inhibition can attenuate the detrimental 
consequences o f myocardial ischaemia and reperfusion, 
evidently through reduced bradykinin breakdown154-561. 
Nevertheless, data indicating that inhibition of angio­
tensin II action via type 1 receptors, through either 
molecular biological157,581 or pharmacological157-611 
means, can mimic at least some of the cardioprotective 
effects of ACE inhibition suggest that angiotensin II 
itself may be detrimental during ischaemia and reper­
fusion. This evidence, together with that suggesting a 
stimulation of sarcolemmal NHE activity in response 
angiotensin H111,62,631, implicates the exchanger in the 
potential detrimental effects of this peptide hormone in 
the setting of myocardial ischaemia and reperfusion. 
Consistent with this, recent studies in isolated myo­
cytes support a causal role for angiotensin II-mediated 
activation of the sarcolemmal NHE in cell injury 
during metabolic inhibition1641. Nevertheless, it may be 
noted that angiotensin II does not appear to be such a 
potent stimulus for the sarcolemmal NHE when com­
pared with the other mediators discussed above111,531. 
Furthermore, recent work in the author’s laboratory 
suggests that subtypes 1 and 2 of the angiotensin II 
receptor (ATt and AT2 receptors) may have opposing 
actions in the regulation of sarcolemmal NHE ac­
tivity1651. This dual regulation of the sarcolemmal NHE 
may have functional implications in disease conditions
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that are associated with an altered ATi:AT2 receptor 
ratio, such as heart failure166,675.
NHE regulation by other endogenous 
factors
Endogenous factors that have often been implicated in 
the pathogenesis of ischaemia and reperfusion-induced 
injury and dysfunction and particularly in the loss of 
ionic homeostasis, include the sarcolemmal accumu­
lation of lipid metabolites5685 and the generation of 
oxidant stress1695. In this context, it is interesting to note 
that exposure to exogenous lysophosphatidylcholine5705 
and hydrogen peroxide571,725 have both recently been 
shown recently to stimulate the sarcolemmal NHE in 
cultured neonatal5715 and freshly isolated adult570,725 rat 
ventricular myocytes. Although the mechanism(s) 
underlying lysophosphatidylcholine-induced stimulation 
of sarcolemmal NHE activity remain(s) unknown, there 
is evidence to suggest that the hydrogen peroxide effect 
may occur via activation of specific intracellular signal­
ing pathway(s), such as the extracellularly regulated 
kinase (ERK) cascade5715. Thus, it appears that factors 
other than classical receptor-mediated stimuli may also 
regulate sarcolemmal NHE activity.
Impact of NHE-stimulatory factors in 
ischaem ia and reperfusion
What is the potential impact, in the setting of myocar­
dial ischaemia and reperfusion, of stimulation of sarco­
lemmal NHE activity by the factors discussed above? 
Much of the evidence in this area has been obtained 
through the application of exogenous stimuli in in vitro 
models of ischaemia and reperfusion. Thus, work in 
Karmazyn’s laboratory has shown that both ar AR 
stimulation (in the presence of an adenosine antagon­
ist)5735 and endothelin5745 exacerbate post-ischaemic 
\ contractile dysfunction in isolated rat hearts. It is 
particularly relevant to the present article that the 
deleterious effects of both stimuli could be reversed by 
NHE inhibition573,745, thus implying a key role for the 
exchanger in the injurious mechanisms downstream of 
receptor activation. Consistent with this, Brunner and 
Opie5755 have recently shown that the deleterious effects 
of endothelin during ischaemia and reperfusion could be 
attenuated not only by ETA receptor antagonism but 
also by NHE inhibition. Furthermore, ar AR stimu­
lation selectively within the ischaemic zone has been 
shown by the author’s group5355 to exacerbate 
reperfusion-induced arrhythmias; this proarrhythmic 
effect is nullified by <z1A-AR antagonism or NHE inhi­
bition, implicating the exchanger in the downstream 
mechanisms.
Within the context of ischaemia and reperfusion, 
cij-AR stimulation has also been implicated in the induc­
tion of ischaemic pre-conditioning in rat myocar­
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dium5765. Since ischaemic pre-conditioning is associated 
with reduced intracellular acidosis during prolonged 
ischaemia5775, it is possible that %-adrenergic stimulation 
of sarcolemmal NHE activity may contribute to this 
phenomenon. However, Gabel et a/.5785 have shown 
recently that the H+ efflux during the prolonged 
ischaemic period is not increased in pre-conditioned 
hearts. Furthermore, any stimulation of sarcolemmal 
NHE activity is unlikely to contribute to the cardio­
protective mechanism(s) of ischaemic pre-conditioning, 
since such protection is retained (and indeed enhanced) 
in the presence of NHE inhibition5795.
In studying thrombin-induced effects during 
ischaemia and reperfusion, Goldstein et a/.5805 have 
shown that the incidence of malignant ventricular 
arrhythmias in the canine heart in vivo during acute 
ischaemia is greater following thrombotic coronary 
occlusion than non-thrombotic balloon occlusion. This 
implicates an arrhythmogenic role for factors (such as 
thrombin) that are associated with thrombus formation. 
Thrombin has now been shown to induce a potent 
arrhythmogenic effect during ischaemia and reperfusion 
in isolated rat hearts581,825 in a manner that appears to be 
reversible by NHE inhibition5825. A role for the sarco­
lemmal NHE in mediating the arrhythmogenic action of 
thrombin is supported by evidence that activation of 
the thrombin receptor exacerbates the intracellular 
accumulation of Na+ during ischaemia5835, an obser­
vation consistent with stimulation of exchanger activity.
. The role of increased sarcolemmal NHE activity in the 
potential detrimental effects of angiotensin II during 
myocardial ischaemia and reperfusion has not been 
characterized. However, the recent observation that ATj 
and AT2 receptors may mediate opposing actions in the 
regulation of sarcolemmal NHE activity5655 raises the 
possibility that selective antagonists of the ATi receptor 
may be o f benefit during ischaemia/reperfusion. They 
can inhibit NHE stimulation both by blocking 
AT,-mediated excitatory actions and by enhancing 
AT2-mediated inhibitory actions.
Finally, it is noteworthy that the cardiodepressant 
effects of low-dose lysophosphatidylcholine5705 and low- 
dose hydrogen peroxide in combination with myocardial 
ischaemia and reperfusion5845 could both be attenuated 
by pharmacological NHE inhibition. This suggests that 
the detrimental effects of these factors on myocardial 
integrity and function either may be mediated through 
increased sarcolemmal NHE activity or that they may 
require an active exchanger.
Conclusion
It is apparent from the evidence discussed above that 
sarcolemmal NHE activity is modulated by a variety of 
endogenous factors (e.g. catecholamines, thrombin, 
endothelin, angiotensin II, oxidant stress, lysophos­
phatidylcholine) and that stimulation of the exchanger 
by these factors may be of pathophysiological signifi­
cance during ischaemia and reperfbsion. Undoubtedly,
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there are other, currently unidentified, factors that also 
regulate sarcolemmal NHE activity in a positive or 
negative manner. The identification of such factors, 
characterization of their potential interplay, and 
delineation of the signalling mechanisms that underlie 
their effects on sarcolemmal NHE activity may identify 
common pathways. The latter might, in turn, represent 
fertile new targets for therapeutic manipulation of the 
exchanger, particularly in ischaemic heart disease.
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Sarcolemmal Na+/H + Exchanger Activity and 
Expression in Human Ventricular Myocardium
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OBJECTIVES To determine sarcolemmal Na+/H + exchanger (NHE) activity and expression in human 
ventricular myocardium.
BACKGROUND Although the sarcolemmal NHE has been implicated in various physiological and patho­
physiological phenomena in animal studies, its activity and expression in human myocardium 
have not been studied.
Ventricular myocardium was obtained from unused donor hearts with acute myocardial 
dysfunction (n = 5) and recipient hearts with chronic end stage heart failure (n =  11) through 
a transplantation program. Intracellular pH (pH;) was monitored in enzymatically isolated 
single ventricular myocytes by microepifluorescence. As the index of sarcolemmal NHE 
activity, the rate of H + efflux at a pHj of 6.90 (JH6.9) was determined after the induction of 
intracellular acidosis in bicarbonate-free medium. Na+/H + exchanger isoform 1 (NHE1) 
expression in ventricular myocardium was determined by immunoblot analysis.
Human ventricular myocytes exhibited readily detectable sarcolemmal N HE activity after the 
induction of intracellular acidosis, and this activity was suppressed by the NHEl-selective 
inhibitor HOE-642 (cariporide) at 1 funol/L. Sarcolemmal NHE activity of myocytes was 
significantly greater in recipient hearts (JH6.9 =  1-95 ±  0.18 mmol/L/min) than it was in 
unused donor hearts (JH6.9 =  1-06 ± 0.15 mmol/L/min). In contrast, NHE1 protein was 
expressed in similar abundance in ventricular myocardium from both recipient and unused 
donor hearts.
CONCLUSIONS Sarcolemmal NHE activity of human ventricular myocytes arises from the NHE1 isoform 
and is inhibited by HOE-642. Sarcolemmal NHE activity is significantly greater in recipient 
hearts with chronic end-stage heart failure than it is in unused donor hearts, and this 
difference is likely to arise from altered posttranslational regulation. (J Am Coll Cardiol 2000; 
36:534-40) © 2000 by the American College of Cardiology
METHODS
RESULTS
The sarcolemmal Na+/H + exchanger (NHE) of cardiac 
myocytes is believed to be the ubiquitous NHE isoform 1 
(N H El) of the multigene NHE family (1) and contributes 
significantly to the integrated control of intracellular pH 
(pHi) in this cell type (2). Na+/H + exchanger isoform 1 
activity is regulated primarily by pHj through the interaction 
of H + with a “H +-sensor” site on the exchanger’s mem­
brane domain in a manner that results in exchanger activa­
tion in response to intracellular acidosis (3,4). Consistent 
with this, the cardiac sarcolemmal NHE is relatively quies­
cent at physiological pH;, but its activity increases progres­
sively as pHj declines (2). Sarcolemmal NHE activity is also 
modulated by a variety of neurohormonal stimuli such as 
alphai-adrenergic agonists (5,6), endothelin (7), thrombin
(8) and angiotensin II (9) through receptor-mediated mech­
anisms. These agents appear to increase sarcolemmal NHE  
activity by increasing the pHi-sensitivity of the exchanger, 
which is the mechanism known to underlie growth factor- 
induced stimulation of N H E l (3,4).
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Recently, the sarcolemmal NHE has received attention as 
a potential mediator of various physiological and pathophys­
iological phenomena in myocardium such as inotropic 
responses to a variety of agonists (7,10-13) and muscle 
stretch (14) and the induction of hypertrophy by mechanical
(15) and neurohormonal (16) stimuli. In addition, work 
with the novel NHEl-selective inhibitors in our laboratory 
(17-20) and by others (for recent reviews, see Avkiran [21] 
and Karmazyn et al. [22]) has provided support for the 
hypothesis that sarcolemmal NHE activity is an important 
determinant of the severity of arrhythmias, contractile 
dysfunction and tissue necrosis during myocardial ischemia 
and reperfusion. Recent evidence suggests that NHE activ­
ity may also be involved in the induction of myocyte 
apoptosis during ischemia and reperfusion (23,24) and 
metabolic inhibition and recovery (25). These experimental 
findings have instigated trials with NHE inhibitors in 
clinical settings of myocardial ischemia and reperfusion, 
such as the recent GUARDIAN (Guard during Ischemia 
Against Necrosis) trial in patients with acute coronary 
syndromes (26).
Although significant advances have been made, as de­
scribed above, in understanding of the regulation and roles 
of the sarcolemmal NHE, these have been achieved exclu­
sively through the use of myocardial tissue and cells from a 
variety of animal species. As a consequence, the applicability 
to man of many of the findings is unconfirmed, and little is
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Abbreviations and Acronyms
beta; =  intrinsic buffeting power
dpHj/dt =  rate of recovery o f p H
Jh =  rate o f H + efflux
Jh6 .9  =  rate o f  H + efflux at pH; 6.90
N C E =  N a+/Ca2+ exchanger
N H E  =  N a+/H + exchanger
N H E l =  N a+/H + exchanger isoform 1 
pH ; =  intracellular pH
known regarding sarcolemmal NHE activity and expression 
in human myocardium. We have used a microepifluores- 
cence technique to determine, for the first time, sarcolem­
mal NHE activity in ventricular myocytes isolated from 
explanted human hearts. In addition, we determined NHE 
expression in ventricular myocardium of those hearts by 
immunoblot analysis.
METHODS
Human ventricular myocytes. Ventricular myocardium 
was obtained from explanted human hearts comprising 11 
recipient hearts with chronic end-stage heart failure (eight 
with ischemic heart disease and three with dilated cardio­
myopathy) and five donor hearts that were not used for 
transplantation due to a low ejection fraction, as described 
recendy (27). Table 1 shows the characteristics of the 
individuals from whom ventricular tissue was obtained over 
a period of 15 months and the number and ventricular 
origin o f the cells from each preparation that were used in 
the microepifluorescence studies. The mean age o f patients 
from whom recipient hearts were obtained was 49.3 ± 3.2 
years (n = 11), which was significantly greater (p <  0.05, 
unpaired t  test) than that of the individuals from whom the 
unused donor hearts originated (33.8 ±  6.2 years, n = 5).
Table 1. Origin of Human Ventricular Myocytes Used in 
the Study
Heart N o. Status




1 Recipient (IH D ) 55/M 4 (RV)
2 Unused donor 22/F 12 (RV)
3 Unused donor 19/F 16 (RV)
4 Recipient (DCM ) 20/M 10 (RV)
5 Recipient (DCM ) 50/M 7 (LV)
6 Recipient (IH D ) 48/M 11 (LV)
7 Unused donor 42/M 7 (LV)
8 Recipient (IH D ) 49/M 4 (RV)
9 Recipient (IH D ) 47/M 4 (RV)
10 Recipient (IH D ) 55/M . 5 (RV)
11 Unused donor 34/F 4 (LV)
12 Unused donor 52/F 4 (LV)
13 Recipient (IHD) 59/M 6 (RV)
14 Recipient (IH D ) 56/F 4 (LV)
15 Recipient (IH D ) 48/M 10 (RV)
16 Recipient (DCM ) 55/M 4 (LV)
D C M  =  dilated cardiomyopathy; IH D  =  ischemic heart disease; LV “= left 
ventricular, RV “  right ventricular.
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Myocytes were isolated by enzymatic digestion of left or 
right ventricular myocardium, as described in detail previ­
ously (28), and only rod shaped cells were used in the 
microepifluorescence studies. O f the 112 myocytes listed in 
Table 1, 87 (54 from recipient hearts and 33 from unused 
donor hearts) were used for determination of sarcolemmal 
NHE activity. The remainder were used for in situ calibra­
tion o f  the pH-sensitive fluorescent dye carboxy- 
seminaphthorhodafluor-1 (C-SNARF-1), estimation of in­
trinsic buffering power (beta;) and determination of the 
NHE-inhibitory efficacy of HOE-642 (cariporide), a potent 
NHEl-selective inhibitor (29), which we have shown to 
inhibit sarcolemmal NHE activity in rat ventricular myo­
cytes (19) and which was tested in the GUARDIAN trial 
(26).
Measurement o f pH; and beta;. The microepifluo- 
rescence-based approach that was used to monitor pH; in 
single cells has been described in detail previously (8) and 
used in our earlier studies with rat ventricular myocytes 
(5,6,8,9,19,30). In brief, cells loaded with C-SNARF-1 
were placed on a glass coverslip in a 100 /xL chamber and 
fluorescence recordings made using a dual-emission pho­
tometer system (D104C; Photon Technology International 
Inc.) during continuous superfusion (3.5 mL/min) with 
bicarbonate-free Tyrode’s solution (34*C). Calibration was 
with nigericin-containing solutions, and beta; was estimated 
during stepwise removal of extracellular N H 4C1, as de­
scribed (8). The calibration curve was obtained by nonlinear 
least squares fit o f normalized emission ratios; this gave 
best-fit values for pK and a of 7.08 and —1.46, respectively, 
which are similar to the values previously obtained in rat 
ventricular myocytes (8).
Determination o f sarcolemmal N H E activity. The rate of 
acid efflux (JH) was used as the index of sarcolemmal NHE  
activity, as in our previous work (5,6,8,9,19,30). After 5 to 
10 min of superfusion with Tyrode’s solution, myocytes 
were subjected to intracellular acidosis (in order to activate 
the sarcolemmal NHE) by transient (5 min) exposure to 30 
mmol/L N H 4C1 and its subsequent washout (14 min). 
Since pH; was lowered to ^6.90 upon N H 4C1 washout in 
all cells that were subjected to this protocol, JH was 
estimated at a pH; of 6.90 and termed Jh6 .9- 
In experiments in which the NHE inhibitor HOE-642 
was used, cells were subjected to two consecutive acid pulses 
(as described above) separated by 10 min. During the 
second acid pulse, HOE-642 (1 /xmol/L) was included in 
the superfusate during exposure to N H 4C1 and the first 
7 min o f N H 4C1 washout; HOE-642 was subsequently 
removed from the Tyrode’s solution to assess the reversibil­
ity o f drug action. With the same protocol, myocyte 
contraction was monitored using a video edge-detection 
system, as described before (31).
Determination o f N H E  and N a+/Ca2+ exchanger ex­
pression. Myocardial expression of N H E l was determined 
at protein level by immunoblot analysis. In order to avoid 
potential problems with differential recoveries of mem­
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branes from unused donor and recipient heart samples, 
immunoblot analysis was conducted using unfractionated 
tissue homogenates as described recendy (32). N a+/Ca2+ 
exchange (NCE) expression was also determined as a 
positive control for the presence of sarcolemmal protein in 
the samples. Ventricular tissue samples (approximately 
0.2 g) obtained from regions without overt signs of fibrosis 
or damage were rapidly thawed, weighed and homogenized 
for 3 to 4 min in lysis buffer (sorbitol [5%], histidine 
[pH 7.4; 25 mmol/L], Na2EDTA [50 mmol/L], KC1 
[50 mmol/L], leupeptin [1 jxg/ftL], PMSF [0.5 mmol/L] 
and benzamidine [1 mmol/L]). For NHE analysis, 0.5% 
SDS and 0.1% beta-mercaptoethanol were added to 25 /xL 
of sample containing 100 peg of protein. After boiling for 
5 min, 55 piL of lysis buffer and 5 /xL of polyoxyethylene-
8-lauryl ether (Sigma, Poole, United Kingdom) were added 
to the sample. After incubation at 37°C for 15 h, 50 p.L of 
3X SDS-sample buffer was added and the sample boiled for 
10 min. For NCE analysis, SDS-sample buffer (XI) was 
added directly to an aliquot of tissue homogenate to obtain 
a final protein concentration of 2 /xg//xL and the sample 
boiled for 10 min. After centrifugation, all samples (100 pig 
protein) were subjected to electrophoresis using a 7.5% 
SDS-polyacrylamide gel, and the separated proteins were 
transferred to polyvinylidene difluoride membranes. Immu­
noblot analysis was performed using mouse monoclonal 
antibody for N H E l (1:500 dilution; #MAB3140, Chemi- 
con International Inc., Harrow, United Kingdom) or NCE 
(1:500 dilution; #C2C12, Cambridge BioScience, United 
Kingdom) in conjunction with antimouse secondary anti­
body and enhanced chemiluminescence (Amersham Phar­
macia Biotech, Little Chalfont, United Kingdom). 
Statistical analysis. For each heart, Jh 6 .9  was determined 
in up to 11 cells of either left or right ventricular origin 
(Table 1), and an average value was obtained. Data for 
unused donor and recipient groups are expressed as mean ± 
SEM, with the n values representing the number of hearts 
in each group. The unpaired t test was used to compare JH6 9 
in recipient versus unused donor hearts, and p <  0.05 was 
considered significant.
RESULTS
The rate of recovery of pH ; (dpH/dt) after an intracellular 
acid load is determined not only by the JH but also by the 
beta; at the relevant pH; (33). Therefore, to obtain accurate 
estimates of JH (as the index of sarcolemmal N HE activity), 
it was necessary to determine betaj in both populations of 
myocytes. Our data revealed no difference in beta, between 
myocytes from recipient and unused donor hearts (Fig. 1). 
Linear least squares regression analysis of all data points 
gave the equation beta; = -33.7-pH ; + 260.1, which is very 
similar to the equation that describes the relationship 
between pH, and beta; in rat ventricular myocytes (8). Basal 
pH; values were not significantly different between myocytes 
from recipient (7.31 ±  0.02) and unused donor (7.29 ±
Figure 1. The relationship between pH; and f t  in human ventricular 
myocytes obtained from unused donor hearts (open symbols) and recipient 
hearts w ith end-stage heart failure (solid symbols). Linear least squares 
regression analysis o f all points gave the equation f t  =  — 33.7‘pH; +  260.1. 
f t =  intrinsic buffering power, pH; =  intracellular pH .
0.03) hearts, and both groups of cells acidified to a similar 
extent upon washout of NH 4C1, with minimal pH; values of 
6.70 ±  0.03 and 6.71 ± 0.03, respectively. Myocytes from 
recipient hearts exhibited faster recovery from acidosis, as 
illustrated by the representative recordings shown in Figure 
2A. Quantitative analysis of such data revealed that Jh 6 .9  
was significantly greater in myocytes from recipient hearts 
than it was in cells from unused donor hearts (Fig. 2B).
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Figure 2. (A) Representative single-cell pH ; recordings during acid pulses 
and (B) individual and mean J H6 9 values in ventricular myocytes obtained 
from unused donor hearts (open symbols) and recipient hearts with 
end-stage heart failure (solid symbols). In (B), n indicates the number of 
hearts in each group. p H s =  intracellular pH ; J H6 9 =  rate of H + efflux at 
pH; 6.90.
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Figure 3. Representative recordings o f (A) pH; and (B) cell contraction in 
human ventricular myocytes from recipient hearts with end-stage heart 
failure during two consecutive acid pulses. The first acid pulses (open 
symbols) were under control conditions whereas during the second acid 
pulses (solid symbols) H O E -642 (1 fimol/L) was present during exposure 
to NH<C1 and the first 7 min o f N H 4C1 washout, as indicated by the 
horizontal bars. The baseline changes in (B) reflect changes in resting cell 
length. pH; =  intracellular pH.
To confirm that, under the conditions used, recovery of 
pH; from acidosis in human ventricular myocytes occurred 
predominantly by H + efflux through the sarcolemmal 
NHE, we exposed myocytes to intracellular acidosis in the 
presence of HOE-642. As illustrated by the representative 
recordings shown in Figure 3A, although there was rapid 
recovery from acidosis under control conditions, such re­
covery was markedly suppressed in the presence of HOE- 
642. The effect of HOE-642 was rapidly reversible, such 
that when the inhibitor was removed from the superfusion 
solution, pH; recovered from acidosis at a rate comparable 
with that seen under control conditions (Fig. 3A). Figure 
3B illustrates that the changes in pH; were paralleled by 
changes in the amplitude of cell contraction. Thus, intra­
cellular alkalosis during NH4C1 exposure was associated 
with an increase in contraction amplitude, while intracellu­
lar acidosis after NH4C1 washout was accompanied by a 
reduction in contraction amplitude. Furthermore, HOE- 
642 depressed the recovery of cell contraction after NH4C1 
washout, in parallel with its inhibitory effect on pH; recov­
ery from acidosis.
Immunoblot analysis of a random selection of ventricular 
myocardium from unused donor and recipient hearts re­
vealed that the 110 kDa N H El protein was expressed in 
similar abundance in all samples (Fig. 4A). Na/Ca2+ ex­
changer expression was also readily detected in all samples as
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A. Na+/H+ exchanger expression
unused donor end-stage heart failure
Heart No. 2 3 7 4 16 8 10
B. Na+/Ca2+ exchanger expression
unused donor end-stage heart failure
120 kD»'
Heart No. 2 3  7  4 16 8  10 13
Figure 4. Autoradiograms illustrating protein expression of (A) the 
N a+/H + exchanger (N H E l isoform) and (B) the N a+/C a2+ exchanger in 
ventricular samples from unused donor hearts and recipient hearts with 
end-stage heart failure. H eart numbers relate to Table 1; in (B) the lane 
between heart numbers 10 and 13 contained size markers.
two proteins of 120 and 70 kDa; these have been shown 
previously to represent the intact NCE and a proteolytic 
fragment, respectively, in human myocardium (32). In 
contrast to N H E l, however, in three of the five recipient 
hearts that were studied (heart numbers, 4, 10 and 13 in 
Table 1), NCE protein was present in markedly greater 
abundance (Fig. 4B). This difference in NCE abundance, 
which is consistent with earlier reports (27,34), did not arise 
from differential protein loading since Coomassie blue 
staining (not shown) revealed comparable loading of sam­
ples.
DISCUSSION
Sarcolemmal NHE activity in human ventricular myo­
cytes. This study is the first to measure sarcolemmal NHE 
activity in ventricular myocytes from human hearts. Our 
data show that, after the induction of intracellular acidosis, 
sarcolemmal NHE activity is readily detectable in human 
myocytes, as has been shown to be the case in ventricular 
myocytes from other species (2,8,11). Interestingly, sar­
colemmal NHE activity in ventricular myocytes from un­
used donor hearts appeared to be lower than that in 
ventricular myocytes from normal rat hearts, measured using 
the same equipment and methodology. Thus, mean Jh6.9 
was 1.06 ±  0.15 mmol/L/min in five unused donor hearts 
(33 cells) in this study, but 2.76 ±  0.26 mmol/L/min in 37 
rat cells randomly selected from those studied during an 
overlapping period (5). This suggests the existence of 
species-specific differences in the expression or regulation of 
the sarcolemmal NHE.
Our finding that pH; recovery from acidosis in human 
ventricular myocytes was inhibited by 1 p.mol/L HOE-642 
confirms that such recovery arose from H + efflux through 
the sarcolemmal NHE. Furthermore, this finding indicates 
that the sarcolemmal NHE of human ventricular myocytes
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is indeed N H E l since at 1 /xmol/L HOE-642 is a selective 
inhibitor of this isoform (29). This is consistent with work 
by Fliegel and colleagues (35) who cloned N H E l from a 
human cardiac cDNA expression library. We also found 
that changes in pH,, induced by NH4C1 pulses in the 
absence or presence o f HOE-642, produced parallel 
changes in the amplitude o f myocyte shortening. This is in 
keeping with the established importance of pHi in regulat­
ing myocardial contractility (36) and consistent with the 
recent observations of Ito et al. (37) on the effects of N H 4C1 
pulses on cell shortening in rat ventricular myocytes. 
Unused donor versus recipient myocardium. An interest­
ing and potentially important finding of this study is the 
significantly greater sarcolemmal NHE activity of myocytes 
in recipient hearts with chronic end-stage heart failure 
relative to unused donor hearts with acute myocardial 
dysfunction. That the abundance Qf N H E l protein was 
similar in ventricular tissue from unused donor hearts and 
recipient hearts with end-stage heart failure suggests that 
posttranslational mechanisms are likely to be responsible for 
this difference in sarcolemmal NHE activity. Although 
these mechanisms cannot be identified on the basis of the 
present findings, it is interesting to note recent evidence that 
the activities of protein kinase C (38) and Ca2+/calmodulin 
dependent kinase (39) are increased in human myocardium 
with end-stage heart failure since both kinases have been 
proposed as stimulatory regulators of sarcolemmal NHE  
activity in rat ventricular myocytes (6-9,40).
In addition to a potential role for the kinase-mediated 
signaling pathways outlined above, it may be argued that an 
altered intracellular Na+ concentration, arising from an 
increased NCE activity (see below), could also contribute to 
the greater sarcolemmal NHE activity in recipient hearts 
with end-stage heart failure. This is unlikely, however, since 
recent work in sheep Purkinje fibers (41) has shown that 
variation in the intracellular Na+ concentration is not a 
physiologically important regulator of NHE activity in the 
heart.
Ventricular myocytes from human myocardium with 
end-stage heart failure exhibit varying degrees of hypertro­
phy (42). Therefore, the possibility that the observed dif­
ference in Jh6 .9 between recipient and unused donor hearts 
may simply reflect a difference in the myocyte membrane 
surface area to volume ratio needs to be considered. In this 
context, a recent paper (43) has reported the first direct 
measurements of membrane surface area (measured by cell 
capacitance) and cell volume (measured by confocal micros­
copy) in control versus hypertrophied ventricular myocytes. 
The findings of that study (43), which used rat ventricular 
myocytes, have revealed that the membrane surface area to 
volume ratio remains constant over a threefold increase in 
cell volume, with no significant difference in this ratio 
between control and hypertrophied cells. Therefore, the 
difference in Jh6 .9  observed in this study between unused 
donor versus recipient hearts is unlikely to be an artefact that 
arises from myocyte hypertrophy in the latter; instead, it is
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likely to reflect a true difference in sarcolemmal NHE  
activity.
It is notable that, although sarcolemmal NHE activity of 
myocytes was significantly greater in recipient hearts with 
end-stage heart failure under conditions of intracellular 
acidosis, basal pH; was not altered. This may indicate that, 
at physiological values of pH; (>7.10), the sarcolemmal 
NHE of myocytes was quiescent in both recipient and 
unused donor hearts, as is the case in ventricular myocytes 
from a variety of animal species (2,8,11). Maximum NHE  
activity could not be determined in this study because it was 
not possible to lower pH; below approximately 6.70 without 
compromising myocyte viability.
Potential clinical relevance of findings. The NHE phe­
notype of healthy human myocardium is unknown and may 
differ from that o f the unused donor hearts used in this 
study. However, if  it is assumed that our novel data reflect 
increased sarcolemmal NHE activity in end-stage heart 
failure, then this change could have important (pathophys­
iological consequences. In particular, the greater sarcolem­
mal NHE activity of failing myocardium may increase its 
susceptibility to injury and dysfunction during ischemia and 
reperfusion, in view of the proposed role of the exchanger in 
this setting (see introduction). Indeed, experimental studies 
have suggested that failing myocardium is more susceptible 
to contractile dysfunction (44) and ventricular fibrillation 
(45) during ischemia and reperfusion. In this context, it is 
important to note that: (1) the mechanisms that underlie the 
detrimental effects o f increased NHE activity during myo­
cardial ischemia and reperfusion are thought to involve 
Ca2+ influx through NCE, operating in reverse mode (46), 
and (2) expression o f NCE protein is increased in failing 
human myocardium (as shown in previous studies [27,34] 
and confirmed here), and this is accompanied by greater 
NCE activity (47). In the light of our findings, the question 
of whether increased NHE activity contributes to the 
development of heart failure also needs to be addressed, 
particularly in view o f the in vitro data that pharmacological 
NHE inhibition attenuates the development of hypertrophy 
in response to mechanical and neurohormonal stimuli in 
neonatal (15) and adult (16) rat ventricular myocytes.
Our data may also have wider clinical relevance because 
they represent the first direct evidence that human ventric­
ular myocytes express a functional N H E l protein whose 
activity is inhibited by HOE-642 in a readily reversible 
manner. This NHEl-selective inhibitor was used in the 
recent GUARDIAN trial, whose primary objective was to 
determine whether NHE inhibition decreases the combined 
incidence of mortality and myocardial infarction (both 
Q^wave and non-Q;wave) in patients with acute coronary 
syndromes (26). The preliminary results of this trial, as 
presented at the 48th Scientific Sessions of the American 
College o f Cardiology (48), have shown no significant 
reduction in the composite incidence of death and myocar­
dial infarction in response to drug treatment in the overall 
study population. Nevertheless, with the highest dose of
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HOE-642 (120 mg intravenously three times a day), there 
were significant reductions in the composite incidence of 
death and myocardial infarction in patients undergoing 
surgical revascularization and in the incidence of Q^wave 
myocardial infarction in the other patient populations (48). 
Although many factors may have contributed to these 
findings, including the presence or absence of timely reper­
fusion (without which NHE inhibition would not be 
expected to provide significant benefit [21]), it would be 
important to determine whether an NHE-inhibitory con­
centration ( s l  fimol/L) of HOE-642 was maintained in 
the circulation during the period of risk in the various study 
groups.
Concluding comments. Our present findings have shown 
that ventricular myocytes from explanted human hearts 
exhibit sarcolemmal NHE activity, which arises from the 
N H E l isoform and is inhibited by HOE-642 in a reversible 
manner. Such activity is significantly greater in recipient 
hearts with chronic end-stage heart failure than it is in 
unused donor hearts with acute myocardial dysfunction. 
This difference in sarcolemmal NHE activity occurs in the 
absence of a difference in N H E l protein expression in 
recipient versus donor myocardium, which suggests the 
involvement of posttranslational regulatory mechanisms. 
Identification of the relevant molecular mechanisms and 
determination of the functional significance of the observed 
difference in sarcolemmal NHE activity require further 
investigation.
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Na+/H + Exchange Inhibitors 
for Cardioprotective Therapy: 
Progress, Problems and Prospects
Metin Avkiran, PhD, FAHA, Michael S. Marber, MB, PhD, FACC, FAHA  
London, United Kingdom
Extensive pre-dinical work indicates that inhibition of the sarcolemmal Na+/H + exchanger 
(NHE) affords significant protection to myocardium subjected to ischemia and reperfusion, 
predominantly through reduced intracellular accumulation of Na+ and consequently Ca2+. In 
contrast, recent clinical studies with the NHE inhibitors cariporide and eniporide in patients 
with evolving myocardial infarction (MI) and those at risk of MI have provided mixed and 
somewhat contradictory data. The experimental evidence suggests that the key mechanism 
through which NHE inhibitors afford protection consists in slowing the progression of 
myocardial injury during ischemia and thereby enhancing myocardial salvage by reperfusion. 
It follows from this that, to obtain maximum cardioprotective benefit, 1) the NHE inhibitor 
must be present in jeopardized myocardium, at a concentration sufficient to inhibit NHE 
activity, before (or as soon as possible after) the onset of ischemia, and 2) ischemia must be 
terminated by timely reperfusion. Thus, in the GUARDIAN trial, the cardioprotective 
efficacy of cariporide was limited to the subset of high-risk patients who underwent coronary 
artery bypass graft surgery, in whom both prerequisites could be readily fulfilled. In contrast, 
no cardioprotective benefit was observed in the ESCAMI trial, in which eniporide was 
administered late as an adjunct to reperfusion therapy in patients with evolving MI. Ongoing 
clinical studies will determine whether NHE inhibition will find therapeutic application 
in the setting of cardiac surgery, while pre-dinical investigations continue to test the 
potential of NHE inhibitors in the treatment of other cardiovascular diseases such as 
heart failure. (J Am Coll Cardiol 2002;39:747-53) © 2002 by the American College of 
Cardiology Foundation
Since the latter part o f the 20th century, investigation of the 
mechanisms that contribute to myocardial injury and dys­
function during ischemia and reperfusion has been a major 
occupation of cardiovascular investigators. This effort has 
been based on the expectation that such an understanding 
may lead to the development of novel therapeutic ap­
proaches that can be used, in conjunction with reperfusion, 
to enhance the salvage and functional recovery of ischemic 
myocardium. Interest has variably focused on the roles and 
manipulation o f metabolic changes, inflammatory re­
sponses, oxidative stress and ionic perturbations (1). Most 
recently, the powerful adaptive response of the myocardium 
that is triggered by ischemic or pharmacologic precondi­
tioning has received widespread attention (2). Despite much 
investigative effort, however, no single therapy has been 
adopted clinically for protection of the ischemic/reperfused 
myocardium, a goal that is commonly referred to as “car- 
dioprotection”. The therapeutic arsenal that is currently 
available to physicians in combating ischemic heart disease 
targets the coronary vasculature and circulatory elements,
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and includes drugs that inhibit the development of athero­
sclerosis and stabilize existing lesions, drugs that suppress 
intracoronary thrombosis, and drugs and interventions that 
re-institute coronary perfusion. However, this arsenal is 
deficient in direct cardioprotective agents that specifically 
target the myocardial cells. A safe and effective new therapy 
that slows the progression of myocardial ischemic injury 
and/or attenuates the detrimental consequences of reperfu­
sion (“reperfusion injury”) would, therefore be expected to 
synergize with existing therapies and provide considerable 
benefit.
A NOVEL PHARMACOLOGIC 
APPROACH TO CARDI0PR0TECTI0N
Among the wide range of putative cardioprotective drugs 
that have been tested in experimental studies of myocardial 
ischemia and reperfusion, those that specifically target and 
inhibit the Na+/H + exchanger (NHE) isoform 1, a ubiq­
uitously expressed protein that is the molecular homolog of 
the cardiac sarcolemmal NHE, have shown particular 
promise. This growing family of NHE inhibitors, which 
include cariporide (3), eniporide (4) and zoniporide (5), 
have been found to afford substantial protection in animal 
models of myocardial ischemia and reperfusion, with an 
unusual degree of conformity between different investiga-
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Abbreviations and Acronyms
CABG =  coronary artery bypass graft
CK =  creatine kinase
CK-M B =  creatine kinase-MB isoform
ECG = electrocardiogram
ESCAM I = Evaluation o f the Safety and
Cardioprotective Effects o f  Eniporide 
in A cute Myocardial Infarction
EXPEDITION = N a+/H + Exchange Inhibition to 
Prevent Coronary Events in Acute 
Cardiac Conditions
GU A RD IAN =  Guard During Ischemia Against 
.Necrosis
M I =  myocardial infarction
NCX =  N a+/Ca2+ exchanger
N H E =  N a+/H + exchanger
PCI — percutaneous coronary intervention
tors, species and models (see recent reviews by Avkiran [6] 
and Karmazyn et al. [7]). Indeed, some laboratory findings 
suggest that NHE inhibition may provide cardioprotective 
benefit that is equivalent, or perhaps even superior, to that 
afforded by ischemic preconditioning (8-10).
The potential mechanisms that are likely to underlie the 
protection afforded by NHE inhibitors during myocardial 
ischemia and reperfusion have been reviewed recently (11). 
As illustrated in Figure 1 , the available experimental 
evidence suggests that such protection is likely to arise 
primarily from the attenuation of intracellular Na+ accu­
mulation during ischemia, which in turn would attenuate 
intracellular Ca2+ accumulation (through reduced Ca2+ 
efflux and/or increased Ca2+ influx via the sarcolemmal 
Na+/Ca2+ exchanger) during both ischemia and subsequent 
reperfusion (11). In some settings additional mechanisms, 
such as the attenuation of neutrophil accumulation (12,13) 
and coronary endothelial dysfunction (14) within the jeop­
ardized tissue, may also contribute to the protection afforded 
by NHE inhibitors, through the inhibition of NHE activity 
in non-myocardial cells (11).
The apparent therapeutic potential of NHE inhibitors, 
coupled with the perceived need for cardioprotective therapy 
in the management of ischemic heart disease, has led to the 
initiation of clinical studies with these agents within a 
remarkably short time. This is best illustrated by the 
observation that the first experimental data with cariporide 
were not published in peer-reviewed literature until 1995
(3), but by 1997 the drug was already being administered to 
patients with ischemic heart disease in the combined phase 
ll/phase III GUARDIAN (Guard During Ischemia 
Against Necrosis) trial (15). The recent publication of the 
results of the GUARDIAN trial (16) and other clinical 
studies with NHE inhibitors (17,18) provides an opportu­
nity to evaluate these results in relation to the pre-clinical 
knowledge base, to outline the likely prerequisites for 
effective utilization of NHE inhibitors in combating myo­
JACC Vol. 39, No. 5, 2002
March 6, 2002:747-53
cardial ischemia and to consider the prospective applications 
of these drugs.
CLINICAL STUDIES WITH NHE 
INHIBITORS: RESULTS AND REFLECTIONS
A  recent issue of the Journal of the American College of 
Cardiology includes a report of the main findings of a clinical 
study with eniporide (18), which follows the earlier publi­
cation of the results of two other clinical studies with 
cariporide (16,17). Two of these studies (17,18) involved 
patients with acute myocardial infarction (MI) in whom the 
NHE inhibitor was used as an adjunct to reperfusion 
therapy (by primary coronary angioplasty or thrombolysis), 
and the other study (16) tested the cardioprotective efficacy 
of NHE inhibition in a large number of patients at risk of 
MI during spontaneous or iatrogenic ischemia.
NHE inhibition in patients with MI. Rupprecht et al. 
(17) determined the effects of cariporide in patients with 
anterior MI who were expected to receive reperfusion 
therapy by primary coronary angioplasty within 6 h of the 
onset of symptoms. One hundred patients were randomized 
to receive placebo or 40 mg cariporide as an intravenous 
bolus 10 min before reperfusion, and placebo or drug 
administration was completed within approximately 4 h 
after the onset of symptoms. Cardiac enzymes (creatine 
kinase [CK], creatine kinase-MB isoform [CK-MB] and 
lactate dehydrogenase) were determined in blood samples 
obtained before and 4,12, 24, 36 and 72 h after reperfusion 
in 85 patients (placebo n =  43, cariporide n = 42). Left 
ventricular function was determined by contrast ventricu­
lography before treatment and at three-week follow-up in 
46 patients (placebo n = 21, cariporide n =  25). The main 
findings of the study were that, after reperfusion: 1) ejection 
fraction remained unchanged in the placebo group but 
increased in the cariporide group, such that the change from 
baseline to follow-up was greater in the latter group (p =  
0.045); 2) regional left ventricular wall-motion abnormali­
ties tended to resolve in both groups, but the change from 
baseline to follow-up was greater in the cariporide group 
(p = 0.045); and 3) the cumulative release of CK-MB (the 
area under the curve) was reduced in the cariporide group 
relative to the placebo group (p =  0.047). The authors 
concluded that these data were consistent with the notion 
that reperfusion injury contributed to MI in humans and 
should be a target for interventions such as NHE inhibition
(17). They further suggested that large-scale clinical trials 
were warranted to establish this therapeutic principle (17).
The results of such a trial, in the form of the ESCAMI 
(Evaluation of the Safety and Cardioprotective Effects of 
Eniporide in Acute Myocardial Infarction) trial, have been 
reported recently (18). This study employed a two-stage 
design and recruited patients with anterior or inferior MI 
who wei£ expected to receive reperfusion therapy, by pri­
mary coronary angioplasty or thrombolysis (at the physi­
cian’s discretion), within 6 h of the onset of symptoms.
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Figure 1. Potential mechanism through which N a+/H + exchanger (N H E) inhibition preserves intracellular ion homeostasis and thereby myocardial 
integrity and function after ischemia and reperfusion. (A) Under basal conditions, N H E  is relatively quiescent, the N a+/K + ATPase (Na* pump) utilizes 
A TP to extrude N a+, and the bidirectional N a+/C a2+ exchanger (NCX) works predominantly in forward (Ca2* efflux) mode. (B) During ischemia, N H E  
becomes activated in response to intracellular acidosis and possibly by other NHE-stimulatory factors (26). The resulting influx o f N a+, occurring in the 
presence of ischemia-induced attenuation o f N a+ pump activity, causes the intracellular accumulation o f N a+. Such a rise in the intracellular Na* 
concentration during ischemia alters the reversal potential of the N CX in a manner that inhibits its operation in forward mode but favors its operation in 
reverse (Ca2+ influx) mode, thus producing intracellular Ca2+ accumulation (Ca2+ overload) during both ischemia and subsequent reperfusion. (C) N H E  
inhibitors are likely to afford a cardioprotective effect during ischemia and reperfusion by inhibiting this sequence at an early stage, through the limitation 
of N a+ influx during ischemia. Note that the illustration has been simplified for clarity, and that mechanisms other than N H E  activity are also likely to 
contribute to the intracellular accumulation o f N a+ and consequently Ca2+ during ischemia and reperfusion.
Blood samples were collected before and 4, 8, 12,16,24, 36, 
48, 60 and 72 h after the start of reperfusion therapy for 
assessment of a-hydroxybutyrate dehydrogenase, CK and 
CK-MB content. Ejection fraction or regional wall motion 
were not assessed. In stage 1, patients (n = 430) were 
randomized to receive placebo (n = 88) or 50 mg (n = 86), 
100 mg (n = 91), 150 mg (n = 74) or 200 mg (n =  91) 
eniporide, as a 10-min intravenous infusion that had to be 
completed at least 10 min before the start of coronary 
angioplasty or within 15 min after the start of thrombolysis. 
Data from this stage indicated reductions in cumulative 
enzyme release of approximately 15% with 100 mg enipo­
ride and 30% with 150 mg eniporide, although no effect was
seen with the 200 mg dose. On the basis of these findings, 
the study was extended into stage 2, during which additional 
patients (n = 959) were randomized to receive placebo (n = 
322) or 100 mg (n =  321) or 150 mg (n = 316) eniporide 
in an identical manner to stage 1. However, the results of 
stage 2 of the trial, when considered alone or in combination 
with those of stage 1, revealed no effect of eniporide on 
cumulative enzyme release. Furthermore, this lack of effect 
of active treatment persisted across various predefined sub­
groups (e.g., reperfiision by thrombolysis [n = 590] vs. 
coronary angioplasty [n =  363]; anterior [n = 389] vs. inferior 
[n = 513] infarction; early [^4 h from the onset of symptoms, 
n = 696] vs. late [>4 h from the onset of symptoms, n = 229]
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reperfusion). Thus, the overall results of this study oppose the 
hypothesis that NHE inhibition, used as an adjunct to reper­
fusion, reduces MI by attenuating reperfusion injury.
Clearly, the outcome of the ESCAMI trial with enipo­
ride (18) contradicts the findings of the earlier study with 
cariporide (17) with respect to the effects of N HE inhibi­
tion, as an adjunct to reperfusion therapy, on cardiac 
enzyme release. This difference in outcome is unlikely to 
have a pharmacologic basis, because eniporide is a more 
potent N HE inhibitor than cariporide (19) and the doses of 
eniporide used in the ESCAMI trial (18) were up to five 
times greater than the dose of cariporide used by Rupprecht 
et al. (17). It might be argued that N HE inhibition during 
reperfusion reduces myocardial enzyme release only in a 
highly selected group of patients who have large anterior 
infarcts and receive reperfusion by primary coronary angio­
plasty (17). However, this is also unlikely because, in the 
ESCAMI study, cumulative enzyme release did not differ 
between placebo and eniporide treatment even in the 
subgroup of patients who had anterior infarcts and received 
reperfusion by primary coronary angioplasty (18). The most 
likely explanation for the apparent discrepancy appears to be 
a chance finding in the study by Rupprecht et al. (17), 
arising as a consequence of the small sample size. Indeed, 
such a finding is also likely to have been responsible for the 
ultimately misleading results of stage 1 of the ESCAMI trial
(18).
Is the lack of efficacy of N H E inhibition as an adjunct to 
reperfusion in patients with acute M I surprising, given what 
is known about the nature of reperfusion injury and the data 
from extensive pre-clinical work with NHE inhibitors? 
First, the existence of “lethal” reperfusion injury (defined as 
myocardial cell death arising from reperfusion rather than 
from the preceding period of ischemia) and its clinical 
relevance in the setting of acute MI are open to debate 
(20,21). Second, as reviewed in depth previously (6), the 
majority of available pre-clinical data show that NHE 
inhibitors limit infarct size dramatically when given before 
or soon after the onset of ischemia, but not when adminis­
tered shortly before or at the time of reperfusion, suggesting 
that N HE activity does not contribute significantly to any 
lethal reperfusion injury. Indeed, even in the early experi­
ments in pigs that demonstrated a limitation of infarct size 
with N HE inhibition from shortly before reperfusion, 
significantly greater benefit was observed when the NHE 
inhibitor was administered before the onset of ischemia
(22). A recent study by Klein et al. (23), in pigs that were 
instrumented to receive residual flow (through an extracor- 
poreal circuit) during a 60-min period of regional ischemia, 
has sought to determine definitively the key period during 
which N HE activity contributes to MI. As illustrated in 
Figure 2 , this study showed that infarct size measured after 
24 h of reperfusion was significantly reduced by the intra­
coronary infusion of cariporide during the first 30 min of 
ischemia or throughout the entire 60 min of ischemia plus 
the first 10 min of reperfusion, but not by such infusion
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Figure 2 . Effects on infarct size of intracoronaty infusion o f the N aV H *  
exchanger (N H E ) inhibitor cariporide during various periods, in pig hearts 
subjected to 60 min o f regional low-flow ischemia and 24 h of reperfusion. 
Infarct size was measured at the end o f 24 h o f reperfusion by both 
histochemical and histologic methods. The top panel illustrates the 
experimental protocol, w ith the vertically hatched bars indicating the 
periods o f cariporide infusion and the arrows showing the coronary sinus 
cariporide concentrations (in fi.mol/1) after 30 min o f ischemia, immedi­
ately before reperfusion and immediately after reperfusion, in the various 
study groups. Note that a minimum concentration of approximately 1 
fi.mol/1 cariporide is required for effective inhibition o f sarcolemmal N H E  
activity in cardiac ventricular myocytes (24). As shown, infarct size was 
significantly limited by the intracoronary infusion o f cariporide during the 
first 30 min o f ischemia or throughout the entire 60 min o f ischemia plus 
the first 10 min o f reperfusion. In contrast, infusion of cariporide during 
the last 15 min o f ischemia plus the first 10 min of reperfusion provided no 
benefit, even though the coronary sinus cariporide concentrations at the 
end o f ischemia and the beginning of reperfusion were sufficient to inhibit 
N H E  activity. Thus, N H E  activity during early ischemia, rather than that 
during late ischemia and early reperfusion, appears to be the principal 
determinant o f the extent o f myocardial infarction. 1 =  ischemia; R = 
reperfusion, * =  p <  0.05 versus control. The figure is based on data from 
Klein et al. (23).
during the last 15 min of ischemia plus the first 10 min of 
reperfusion (23). In the light of such data and with the 
benefit of hindsight, a strong case may be made that the 
negative overall outcome of the ESCAMI trial was in fact 
predictable and that the unexpected findings were the 
positive indications from the earlier, smaller clinical studies. 
Indeed, when considered together, the clinical and pre- 
clinical data reinforce the concept that NHE activity during 
early ischemia (rather than during reperfusion) is the prin­
cipal determinant of the extent of myocardial injury, such 
that early (ideally pre-ischemic) treatment is a prerequisite
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to obtain maximum cardioprotective benefit with NHE  
inhibitors (6,11).
NHE inhibition in patients at risk o f MI. The GUARD­
IAN trial (16) recruited three cohorts of patients who were 
defined as sharing a common risk of MI during hospital­
ization: these were patients with unstable angina or non-Qj 
wave MI (n =  5,233), patients undergoing high-risk per­
cutaneous coronary intervention (PCI) (n = 3,439), and 
patients undergoing high-risk coronary artery bypass graft 
(CABG) surgery (n =  2,918). The study was designed with 
the combined objectives of selecting an effective dose (the 
usual objective of a phase II trial) and determining clinical 
efficacy (the usual objective o f a phase III trial). As such, 
patients were randomized to receive placebo (n = 2,910) or 
20 mg (n = 2,909), 80 mg (n =  2,888) or 120 mg (n =  
2,883) cariporide every 8 h as an intravenous infusion for 
two to seven days after randomization. The results indicated 
no significant effect o f active treatment on the primary end 
point, which was all-cause mortality or MI (diagnosed by 
electrocardiogram and CK-MB criteria) between random­
ization and 36-day follow-up. Nevertheless, subgroup anal­
ysis revealed that in patients undergoing high-risk CABG 
surgery, there was a significant reduction in the combined 
incidence of death and MI with the 120 mg dose of 
cariporide (from 16.2% in the placebo group to 12.1%, p =  
0.03), and this benefit was maintained after six months (16). 
Intriguingly, the 120 mg dose of cariporide also tended to 
reduce the incidence of Qjwave MI in the other two entry 
diagnostic groups (16).
A laudable feature of the design of the GUARDIAN trial 
is the attempt to treat patients with the NHE inhibitor 
before the onset o f an episode of myocardial ischemia that 
might culminate in infarction, reflecting the knowledge 
gained from pre-clinical work. However, the pre-clinical 
work also indicates that the key mechanism through which 
NHE inhibitors afford protection is by delaying the pro­
gression of myocardial injury during ischemia and thereby 
enhancing myocardial salvage by reperfusion (6). It follows 
fiom this that a further prerequisite to obtain maximum 
cardioprotective benefit with NHE inhibitors is timely 
reperfusion, in whose absence severely ischemic myocar­
dium will eventually succumb to infarction regardless of 
treatment (6). It is probably not a coincidence therefore that 
the prerequisites of early treatment and timely reperfusion 
are both fulfilled in the setting of CABG surgery, where 
significant cardioprotective benefit was afforded by NHE  
inhibition in the GUARDIAN trial (16). As discussed by 
Theroux et al. (16), in the other entry diagnostic groups 
included in the GUARDIAN trial, evolving new infarcts 
would be reperfused only if  ST-segment elevation devel­
oped (in patients admitted with unstable angina or non-Q; 
wave MI) or abrupt vessel closure ensued (in patients 
undergoing high-risk PCI). It is reasonable to speculate that 
the tendency in these cohorts toward a reduced incidence of 
Qjwave MI in response to high-dose cariporide treatment
(16) may be a reflection of infarct size limitation by NHE
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inhibition in patients who exhibited such events and there­
fore received reperfusion therapy.
In addition to the presence or absence of timely reperfu­
sion, a further issue to consider in interpreting the data from 
the GUARDIAN trial is the lack of a discernible dose- 
response relationship, even among patients who underwent 
CABG surgery (16). This raises the possibility that the 
optimal dose of cariporide may be higher than the maxi­
mum dose used in the GUARDIAN trial, barring unac­
ceptable adverse effects. Indeed, pharmacokinetic modeling 
based on information from the GUARDIAN trial has 
indicated that, for therapeutic efficacy, a threshold plasma 
drug concentration of 550 ng/ml (approximately 1.4 p.mol/1) 
needs to be exceeded during the period of risk (16). The 
model has also predicted that this would have occurred in 
only 67% of patients who received the highest (120 mg) 
dose o f cariporide before CABG surgery (16). O f relevance 
to this issue, our recent studies in rat ventricular myocytes 
indicate that, in the presence of a physiologic Na+ concen­
tration, ^1 /xmol/1 cariporide is required for effective 
inhibition o f sarcolemmal NHE activity (24). Thus, future 
clinical studies will need to consider using higher doses or 
modified drug administration protocols to ensure that the 
myocardial drug concentration during the period of risk is 
sufficient for effective inhibition of sarcolemmal NHE  
activity.
NHE INHIBITORS FOR 
CARDIOPROTECTION IN ACUTE ISCHEMIA: WHAT NEXT?
The positive findings of the GUARDIAN trial in the 
setting of CABG surgery were revealed by retrospective 
analysis of subgroup data (16). Clearly, therefore, there is an 
important need for further trial(s) that are designed pro- 
spectively to determine whether NHE inhibition affords 
cardioprotective benefit in patients undergoing high-risk 
CABG surgery. In an effort to fulfill this need, the objective 
of the recently initiated EXPEDITION (Na+/H + Ex­
change Inhibition to Prevent Coronary Events in Acute 
Cardiac Conditions) trial is to test the hypothesis that NHE  
inhibition results in a reduction in myocardial injury in such 
patients, using a modified dosing regimen of cariporide. If 
the hypothesis is proven by the eventual, findings of the 
EXPEDITION trial, then it will be necessary to consider 
whether there are other clinical settings in which NHE  
inhibitors may be given to patients before the onset of 
myocardial ischemia, in order to preserve myocardial viabil­
ity during such ischemia and improve salvage by subsequent 
reperfusion. An immediate application may be in non- 
CABG cardiac surgery where the heart is also subjected to 
global ischemia and reperfusion. Additionally, consideration 
needs to be given to the possibility o f using NHE inhibitors 
for perioperative cardioprotection in patients who are at 
high risk o f cardiac events, such as MI, during non-cardiac 
surgery.
In the non-surgical sphere, it may be opportune to
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determine whether long-term NHE inhibition affords func­
tional and/or symptomatic benefit in patients with stable 
angina through direct myocardial protection. Recent data in 
conscious pigs subjected to repetitive cycles of sublethal 
regional ischemia (2 min) and reperfusion (8 min) have 
shown that the ensuing regional contractile dysfunction is 
attenuated by NHE inhibition (25). In addition to a 
potential benefit during the transient episodes of ischemia, 
NHE inhibition in patients with angina would be expected 
to provide further benefit if spontaneous coronary occlusion 
ensues, by delaying the progression of ischemic injury and 
thereby enhancing myocardial salvage by subsequent reper­
fusion, as discussed earlier.
NHE INHIBITORS FOR 
CARDIOPROTECTION BEYOND ACUTE ISCHEMIA?
Emerging experimental evidence suggests that sarcolemmal 
NHE activity may play an important pathophysiologic role 
beyond its contribution to the development of myocardial 
injury during acute ischemia and reperfusion. In this con­
text, it is notable that although sarcolemmal NHE activity is 
regulated primarily by intracellular pH, it is also subject to 
regulation by a variety o f neurohormonal mediators (26). 
Intriguingly, several myocardial G protein-coupled recep­
tors whose activation by their cognate ligands has been 
associated with the induction of a hypertrophic phenotype 
in vitro, such as oq-adrenergic (27), endothelin (28), angio­
tensin II (29) and thrombin (30) receptors, have also been 
shown to mediate increased sarcolemmal NHE activity 
(31-35). Furthermore, the induction of myocyte hypertro­
phy in vitro, in response to neurohormonal (36) or mechan­
ical (37) stimuli, has been shown to be attenuated by NHE  
inhibition. Importantly, recent in vivo evidence in the rat 
indicates that NHE inhibition with cariporide attenuates 
myocardial hypertrophy and the development of heart 
failure after infarction, independently of infarct size limita­
tion or afterload reduction (38,39). O f potential clinical 
relevance, our recent work has shown that ventricular 
myocytes from explanted human hearts with end-stage 
heart failure exhibit significantly greater sarcolemmal NHE  
activity than their counterparts from unused donor hearts, 
probably through altered posttranslational regulation of the 
exchanger (40). Thus, the available evidence points toward 
a causal or permissive role for sarcolemmal NHE activity in 
the development of cardiac hypertrophy and its progression 
to heart failure, suggesting that NHE inhibitors might find 
a novel therapeutic application in this setting.
Before the therapeutic potential of NHE inhibitors in the 
management of heart failure is tested in clinical trials, 
further experimental investigation may need to be per­
formed. At present, the distal mechanism(s) through which 
NHE regulates myocardial growth and remodeling are 
unclear, and there is some controversy regarding the relative 
contributions of Na+ influx versus H + efflux as mediators of 
such regulation. In addition, there is a paucity of informa­
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tion on the efficacy of NHE inhibition relative to, or in 
combination with, established therapies such as 
angiotensin-converting enzyme inhibition and beta- 
adrenergic receptor blockade in animal models of heart 
failure. In this context, a potential advantage of NHE  
inhibition over other therapies may be the direct attenuation 
of myocyte hypertrophy and remodeling in the absence of 
significant hemodynamic effects (39).
CONCLUSIONS
The mixed results of recent clinical studies with NHE  
inhibitors contrast with the highly encouraging data from 
pre-clinical investigations and serve to highlight the enor­
mous challenge of translating therapeutic potential into 
therapeutic reality. Nevertheless, a valid case may be made 
that the design of the clinical studies that have been 
completed to date did not reflect optimally the current 
knowledge from extensive pre-clinical work, particularly on 
the mechanism of action of NHE inhibitors. Indeed, with 
perfect hindsight, it is relatively straightforward to provide a 
scientific rationale for the disappointing outcomes of these 
clinical studies.
On the positive side, the clinical studies have shown that 
NHE inhibitors are well tolerated by patients (at least over 
a short period of treatment) and have provided a strong 
indication that, in the appropriate setting, they can indeed 
protect the human myocardium from injury during ischemia 
and reperfusion. Furthermore, animal experiments continue 
to support the cardioprotective potential of these agents in 
acute myocardial ischemia and have indicated that NHE  
inhibition may provide benefit beyond the preservation of 
acutely ischemic and reperfused myocardium. The very 
considerable challenge remains the translation o f this po­
tential into reality. This goal may be achieved only through 
pre-clinical work that improves our understanding of the 
pathophysiologic roles of the NHE system and the conse­
quences o f its inhibition, and complementary clinical trials 
that reflect such understanding.
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